FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Murphy, MK Nasir, K Truong, Q Ghoshhajra, B Abbara, S Hoffmann, U Brady, TJ Blankstein, R AF Murphy, Meagan K. Nasir, Khurram Quynh Truong Ghoshhajra, Brian Abbara, Suhny Hoffmann, Udo Brady, Thomas J. Blankstein, Ron TI Method of Risk Assessment has a Substantial Impact on Appropriateness Level Among Symtomatic Patients Referred for Cardiac CT SO CIRCULATION LA English DT Meeting Abstract DE Cardiac CT; CT angiography; Quality assessment C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Johns Hopkins Univ Hosp, Baltimore, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A19417 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231603140 ER PT J AU Murphy, RM Shah, RV Malhotra, R Pappagianopoulos, PP Hough, SS Bloch, KD Systrom, DM Semigran, MJ Lewis, GD AF Murphy, Ryan M. Shah, Ravi V. Malhotra, Rajeev Pappagianopoulos, Paul P. Hough, Stacyann S. Bloch, Kenneth D. Systrom, David M. Semigran, Marc J. Lewis, Gregory D. TI Pulmonary Vascular Response Patterns to Exercise Predict Exercise Capacity and Outcomes in Heart Failure SO CIRCULATION LA English DT Meeting Abstract DE Heart failure C1 [Murphy, Ryan M.; Shah, Ravi V.; Malhotra, Rajeev; Pappagianopoulos, Paul P.; Hough, Stacyann S.; Bloch, Kenneth D.; Systrom, David M.; Semigran, Marc J.; Lewis, Gregory D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A20229 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231603435 ER PT J AU Murphy, RM Shah, RV Pappagianopoulos, PP Hough, SS Systrom, DM Semigran, MJ Lewis, GD AF Murphy, Ryan M. Shah, Ravi V. Pappagianopoulos, Paul P. Hough, Stacyann S. Systrom, David M. Semigran, Marc J. Lewis, Gregory D. TI Exercise Oscillatory Ventilation is Associated with Abnormal Exercise Hemodynamics in Systolic Heart Failure SO CIRCULATION LA English DT Meeting Abstract DE Exercise tests; Ventilation; Heart failure C1 [Murphy, Ryan M.; Shah, Ravi V.; Pappagianopoulos, Paul P.; Hough, Stacyann S.; Systrom, David M.; Semigran, Marc J.; Lewis, Gregory D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A16785 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602262 ER PT J AU Nasir, K Budoff, MJ Post, WS Shaw, LJ Malik, S Polak, JF Hoffmann, U Bluemke, DA Sheuner, MT Wong, ND Kronmal, R Blumenthal, RS AF Nasir, Khurram Budoff, Matthew J. Post, Wendy S. Shaw, Leslee J. Malik, Shaista Polak, Joseph F. Hoffmann, Udo Bluemke, David A. Sheuner, Maren T. Wong, Nathan D. Kronmal, Richard Blumenthal, Roger S. TI Value of Coronary Artery Calcium and Carotid IMT in Predicting Cardiovascular Disease Events among Individuals with Family History of Heart Disease: The Multi-Ethnic Study of Atherosclerosis. SO CIRCULATION LA English DT Meeting Abstract DE Genetics; Prevention; Cardiac CT; Carotid arteries C1 Johns Hopkins Univ, Ciccarone Cntr Prevent, Baltimore, MD 21218 USA. Harbor UCLA Med Canter, Torrance, CA USA. Los Angeles Biomed Rsch Inst, Torrance, CA USA. Emory Univ, Atlanta, GA 30322 USA. Univ Calif Irvine, Irvine, CA 92717 USA. Tufts Univ, Sch Med, Medford, MA 02155 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Natl Inst Biomed Imaging & Bioengn, Bethesda, MD USA. Univ Calif Los Angeles, Cntr Hlth Policy Rsch, Los Angeles, CA USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A18549 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602874 ER PT J AU Qadir, S McEvoy, J Blaha, MJ Budoff, MJ Rivera, JJ Khan, A Shaw, LJ Min, J Berman, DS Raggi, P Rumberger, JA Blumenthal, RS Nasir, K AF Qadir, Sadia McEvoy, John Blaha, Michael J. Budoff, Matthew J. Rivera, Juan J. Khan, Atif Shaw, Leslee J. Min, James Berman, Daniel S. Raggi, Paolo Rumberger, John A. Blumenthal, Roger S. Nasir, Khurram TI Escalating Risk of All Cause Mortality in Asymptomatic Individuals with Very High Coronary Artery Calcium Scores: Is a Severely Elevated Coronary Artery Calcium Threshold of 1000 Severe Enough? SO CIRCULATION LA English DT Meeting Abstract DE Subclinical atherosclerosis; Calcium; Risk factors; Cardiac imaging C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Univ Miami, Miami, FL USA. Beth Israel Deconess Hosp, Boston, MA 02215 USA. Emory Univ, Sch Med, Atlanta, GA USA. Weill Cornell Med Coll, New York, NY USA. Univ Calif Los Angeles, Los Angeles, CA USA. Princeton Longev Cntr, Princeton, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A18513 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602862 ER PT J AU Rader, F Van Wagoner, DR Ellinor, PT Gillinov, MA Chung, MK Costantini, O Blackstone, EH AF Rader, Florian Van Wagoner, David R. Ellinor, Patrick T. Gillinov, Marc A. Chung, Mina K. Costantini, Otto Blackstone, Eugene H. TI Black Race is Linked to Lower Occurrence of Postoperative Atrial Fibrillation after Cardiac Surgery SO CIRCULATION LA English DT Meeting Abstract DE Atrial fibrillation; Cardiac surgery; Risk factors; Genetics C1 Metrohlth Med Ctr, Cleveland, OH USA. Cleveland Clin, Cleveland, OH 44106 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A16843 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602285 ER PT J AU Reust, DL Dixon, JA McKinney, RA Patel, RK Rivers, WT Mukherjee, R Stroud, RE Reeves, ST Abernathy, JH Spinale, FG AF Reust, Daryl L. Dixon, Jennifer A. McKinney, Richard A. Patel, Risha K. Rivers, William T. Mukherjee, Rupak Stroud, Robert E. Reeves, Scott T. Abernathy, James H. Spinale, Francis G. TI Continuous Localized Monitoring of Plasmin Activity Identifies Differential and Regional Effects of the Serine Protease Inhibitor Aprotinin: Relevance to Antifibrinolytic Therapy SO CIRCULATION LA English DT Meeting Abstract DE Cardiac surgery; Fibrinolytic agents C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12431 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600839 ER PT J AU Rodriguez, F Joynt, K Saldana, F Lopez, L Jha, A AF Rodriguez, Fatima Joynt, Karen Saldana, Fidencio Lopez, Lenny Jha, Ashish TI The Impact of Ethnicity and Hospital Ethnic Make-up on 30-Day Readmission Rates for Elderly Hispanic Patients With Heart Failure SO CIRCULATION LA English DT Meeting Abstract DE Quality assessment; Heart failure C1 Harvard Univ, Sch Med, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A17797 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602601 ER PT J AU Rogers, AM Hermann, LK Booher, AM Nienaber, CA Williams, DM Kazerooni, EA Froehlich, JB O' Gara, P Montgomery, DG Cooper, JV Harris, KM Hutchison, S Evangelista, A Isselbacher, EM Eagle, KA AF Rogers, Adam M. Hermann, Luke K. Booher, Anna M. Nienaber, Christoph A. Williams, David M. Kazerooni, Ella A. Froehlich, James B. O' Gara, Patrick Montgomery, Daniel G. Cooper, Jeanna V. Harris, Kevin M. Hutchison, Stuart Evangelista, Arturo Isselbacher, Eric M. Eagle, Kim A. CA IRAD Investigators TI Sensitivity of the National Thoracic Aortic Disease Guideline Diagnostic Algorithm for Identification of Acute Aortic Dissection at Initial Presentation: Results from the International Registry of Acute Aortic Dissection (IRAD) SO CIRCULATION LA English DT Meeting Abstract DE Aortic diseases; Aorta C1 Univ Michigan, Ann Arbor, MI 48109 USA. Mt Sinai Hosp, New York, NY 10029 USA. Univ Hosp Rostock, Rostock, Germany. Brigham & Womens Hosp, Boston, MA 02115 USA. Minneapolis Heart Inst, Minneapolis, MN USA. Univ Calgary, Calgary, AB, Canada. Hosp Gen Univ Vall dHebron, Barcelona, Spain. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12583 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600896 ER PT J AU Salomaa, V Noseworthy, PA Havulinna, AS Lahtinen, AM Jula, A Karhunen, PJ Perola, M Kontula, K Newton-Cheh, C AF Salomaa, Veikko Noseworthy, Peter A. Havulinna, Aki S. Lahtinen, Annukka M. Jula, Antti Karhunen, Pekka J. Perola, Markus Kontula, Kimmo Newton-Cheh, Christopher TI Common Single Nucleotide Polymorphisms Associated with Sudden Cardiac Death: The FinSCDgen Study SO CIRCULATION LA English DT Meeting Abstract DE Sudden cardiac death; Genetics; Epidemiology C1 THL Natl Inst Hlth & Welf, Helsinki, Finland. Massachusetts Gen Hosp, Cambridge, MA USA. Broad Inst, Cambridge, MA USA. Univ Helsinki, Helsinki, Finland. Tampere Univ Hosp, Tampere, Finland. Inst Mol Med FIMM, Helsinki, Finland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A17170 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602388 ER PT J AU Shah, RV Bhardwaj, A van Kimmenade, RD Januzzi, JL AF Shah, Ravi V. Bhardwaj, Anju van Kimmenade, Roland D. Januzzi, James L. TI Galectin-3 and Long-term Mortality in Patients with Acute Heart Failure SO CIRCULATION LA English DT Meeting Abstract DE Biomarkers; Heart failure; Prognosis C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Hosp Maastricht, Maastricht, Netherlands. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A9383 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600395 ER PT J AU Simon, T Bhatt, DL Bergougnan, L Vicaut, E Farenc, C Pearson, K Perrin, L LaCreta, F Dubar, M Hurbin, F AF Simon, Tabassome Bhatt, Deepak L. Bergougnan, Luc Vicaut, Eric Farenc, Christine Pearson, Kimberly Perrin, Laurent LaCreta, Frank Dubar, Michel Hurbin, Fabrice TI Genetic Polymorphism and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects SO CIRCULATION LA English DT Meeting Abstract C1 St Antoine Hosp, Paris, France. VA Boston Healthcare Syst, Boston, MA USA. Sanofi Aventis Rech Dev, Chilly Mazarin, France. Hop Fernand Vidal, Paris, France. Sanofi Aventis Rech Dev, Montpellier, France. Sanofi Aventis Rech Dev, Great Valley, PA USA. Bristol Myers Squibb, Plainsboro, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A17693 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602563 ER PT J AU Sips, PY Brouckaert, P Ichinose, F AF Sips, Patrick Y. Brouckaert, Peter Ichinose, Fumito TI The Alpha1 Isoform of Soluble Guanylate Cyclase Regulates Cardiac Contractility but is not Required for Cardioprotective Signaling SO CIRCULATION LA English DT Meeting Abstract DE Cardioprotection; Nitric oxide; Infarct size; Cardiac arrest; Transgenic models C1 Massachusetts Gen Hosp, Charlestown, MA USA. Univ Ghent VIB, Ghent, Belgium. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12267 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600793 ER PT J AU Sovari, AA Jiao, Z Dolmatova, E Kumar, V Wang, K Bonini, MG Duffy, H Dudley, SC AF Sovari, Ali A. Jiao, Zhe Dolmatova, Elena Kumar, Vibhash Wang, Kun Bonini, Marcelo G. Duffy, Heather Dudley, Samuel C. TI c-Src Tyrosine Kinase Is a Potential Therapeutic Target to Prevent Angiotensin-II Mediated Connexin43 Remodeling and Ventricular Arrhythmia SO CIRCULATION LA English DT Meeting Abstract DE Angiotensin II; Arrhythmias, treatment of; Connexin; Free radicals/Free-radical scavengers; Ventricular arrhythmia C1 Univ Illinois, Chicago, IL USA. Emory Univ, Atlanta, GA 30322 USA. Harvard Univ, Sch Med, BIDMC, Boston, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A17524 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602517 ER PT J AU Spinale, FG Toole, JM Yarbrough, WM Patel, RK O'Quinn, EC Gengler, I Gillis, JF Stroud, RE Ikonomidis, JS AF Spinale, Francis G. Toole, John M. Yarbrough, William M. Patel, Risha K. O'Quinn, Elizabeth C. Gengler, Isabelle Gillis, Jenna F. Stroud, Robert E. Ikonomidis, John S. TI The Unique Membrane Type-1 Matrix Metalloproteinase is Constitutively Active Within the Human Myocardial Interstitium and Dynamically Changes with Ischemia-Reperfusion SO CIRCULATION LA English DT Meeting Abstract DE Ischemia reperfusion; Proteolytic enzymes; Myocardium C1 [Spinale, Francis G.; Toole, John M.; Yarbrough, William M.; Patel, Risha K.; O'Quinn, Elizabeth C.; Gengler, Isabelle; Gillis, Jenna F.; Stroud, Robert E.; Ikonomidis, John S.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A15925 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602017 ER PT J AU Spinale, FG Zavadzkas, JA Stroud, RE Rivers, WT McKinney, RA Chang, EI Plyler, RA Bouges, S Mukherjee, R AF Spinale, Francis G. Zavadzkas, Juozas A. Stroud, Robert E. Rivers, William T. McKinney, Richard A. Chang, Eileen I. Plyler, Rebecca A. Bouges, Shenikqua Mukherjee, Rupak TI Myocardial Induction of Tissue Inhibitor of Matrix Metalloproteinase-4 Modifies Post Myocardial Infarction Left Ventricular Remodeling SO CIRCULATION LA English DT Meeting Abstract DE Myocardial infarction; Remodeling; Proteolytic enzymes C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A15791 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601942 ER PT J AU Spinale, FG Mukherjee, R Zavadzkas, JA Koval, CN Stroud, RE Rivers, WT McKinney, RA AF Spinale, Francis G. Mukherjee, Rupak Zavadzkas, Juozas A. Koval, Christine N. Stroud, Robert E. Rivers, William T. McKinney, Richard A. TI Altering Myocardial Membrane Type-1 Following Myocardial Infarction Directly Affects LV Remodeling and Function Through a Novel Fibrotic Signaling Cascade SO CIRCULATION LA English DT Meeting Abstract DE Myocardial infarction; Proteolytic enzymes; Remodeling C1 [Spinale, Francis G.; Mukherjee, Rupak; Zavadzkas, Juozas A.; Koval, Christine N.; Stroud, Robert E.; Rivers, William T.; McKinney, Richard A.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12801 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601075 ER PT J AU Spinale, FG Zavadzkas, JA Koval, CN Stroud, RE Plyler, RA Rivers, WT McKinney, RA Mukherjee, R AF Spinale, Francis G. Zavadzkas, Juozas A. Koval, Christine N. Stroud, Robert E. Plyler, Rebecca A. Rivers, William T. McKinney, Richard A. Mukherjee, Rupak TI Direct Regulation of Myocardial Membrane Type-1 Following Myocardial Infarction Causes Changes in Survival, Function and Remodeling SO CIRCULATION LA English DT Meeting Abstract DE Myocardial infarction; Proteolytic enzymes; Remodeling C1 [Spinale, Francis G.; Zavadzkas, Juozas A.; Koval, Christine N.; Stroud, Robert E.; Plyler, Rebecca A.; Rivers, William T.; McKinney, Richard A.; Mukherjee, Rupak] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12796 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601071 ER PT J AU Stewart, GC Gottumukkala, R Cornivelli, L Anello, MS Lipes, MA AF Stewart, Garrick C. Gottumukkala, Raju Cornivelli, Lizbeth Anello, Mary Susan Lipes, Myra A. TI Cardiac Autoantibody Production Defines Unique Heart Failure Phenotypes SO CIRCULATION LA English DT Meeting Abstract DE Heart failure; Antibodies; Immunologic factors C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Joslin Diabet Cntr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A17040 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602341 ER PT J AU Stroud, RE Ikonomidis, JS Yarbrough, WM Toole, JM O'Quinn, EC Gengler, I Spinale, FG AF Stroud, Robert E. Ikonomidis, John S. Yarbrough, William M. Toole, John M. O'Quinn, Elizabeth C. Gengler, Isabelle Spinale, Francis G. TI The Human Myocardial Interstitium Contains a Specific Portfolio of microRNAs which are Dynamically Regulated Following Ischemia-Reperfusion SO CIRCULATION LA English DT Meeting Abstract DE Ischemia reperfusion; Myocardium C1 [Stroud, Robert E.; Ikonomidis, John S.; Yarbrough, William M.; Toole, John M.; O'Quinn, Elizabeth C.; Gengler, Isabelle; Spinale, Francis G.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A13152 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601168 ER PT J AU Subramanian, S Qadir, S Fifer, KM Vijayakumar, J Fontanez, SI Sarfraz, N Figueroa, AL Abbara, S Brady, TJ Tawakol, A AF Subramanian, Sharath Qadir, Sadia Fifer, Kenneth M. Vijayakumar, Jayanthi Fontanez, Sara I. Sarfraz, Noeen Figueroa, Amparo L. Abbara, Suhny Brady, Thomas J. Tawakol, Ahmed TI F-18-FDG Uptake is Increased in Abdominal Aortic Aneurysms: Localization of Metabolic Activity within Aneurysmal Transition Zones SO CIRCULATION LA English DT Meeting Abstract DE Positron emission tomography; Abdominal aortic aneurysm; Inflammation C1 [Subramanian, Sharath; Qadir, Sadia; Fifer, Kenneth M.; Vijayakumar, Jayanthi; Fontanez, Sara I.; Sarfraz, Noeen; Figueroa, Amparo L.; Abbara, Suhny; Brady, Thomas J.; Tawakol, Ahmed] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A19820 PG 3 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231603276 ER PT J AU Tam, LM Fonarow, GC Bhatt, DL Grau-Sepulveda, MV Hernandez, AF Peterson, ED Schwamm, LH Giugliano, RP AF Tam, Lori M. Fonarow, Gregg C. Bhatt, Deepak L. Grau-Sepulveda, Maria V. Hernandez, Adrian F. Peterson, Eric D. Schwamm, Lee H. Giugliano, Robert P. TI Achievement of Secondary Prevention Performance Measures in Patients with Coronary Artery Disease in Teaching and Non-Teaching Hospitals: Results from the Get With The Guidelines CAD Program SO CIRCULATION LA English DT Meeting Abstract DE Acute coronary syndromes; Prevention; Quality assessment; Myocardial infarction C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Calif Los Angeles, Los Angeles, CA USA. VA Boston Healthcare Syst, Boston, MA USA. Duke Univ, Durham, NC USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A17495 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602510 ER PT J AU Terada, R Warren, S Wessels, A Chien, KR Kasahara, H AF Terada, Ryota Warren, Sonisha Wessels, Andy Chien, Kenneth R. Kasahara, Hideko TI Ablation of Nkx2-5 Beginning at Mid-Embryonic Stage Results in Premature Lethality and Cardiac Malformation SO CIRCULATION LA English DT Meeting Abstract DE Transgenic models; Congenital heart disease; Cardiac development; Gene expression; Molecular biology C1 Univ Florida, Gainesville, FL USA. Med Univ S Carolina, Charleston, SC 29425 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A15665 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601910 ER PT J AU Tsai, TT Messenger, JC Brennan, JM Patel, UD Dai, D Piana, R Anstrom, KJ Eisenstein, EL Dokholyan, RS Peterson, ED Douglas, PS AF Tsai, Thomas T. Messenger, John C. Brennan, J. Matthew Patel, Uptal D. Dai, David Piana, Robert Anstrom, Kevin J. Eisenstein, Eric L. Dokholyan, Rachel S. Peterson, Eric D. Douglas, Pamela S. TI Contemporary Risk of Follow-up Adverse Events in Older Patients with Chronic Kidney Disease and Dialysis Undergoing Percutaneous Coronary Interventions: A Report from the Merged NCDR CMS Registry SO CIRCULATION LA English DT Meeting Abstract DE Percutaneous coronary intervention; Renal function; Aging; Health services research C1 Denver VAMC, Denver, CO USA. Univ Colorado Denver, Denver, CO USA. Duke Univ, Med Cntr, Durham, NC USA. Vanderbilt Univ, Med Cntr, Nashville, TN USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A19884 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231603306 ER PT J AU Tsao, CW Gona, P Salton, CJ Hoffmann, U Fox, CS Danias, PG Blease, S Levy, D O'Donnell, CJ Manning, WJ Yeon, SB AF Tsao, Connie W. Gona, Philimon Salton, Carol J. Hoffmann, Udo Fox, Caroline S. Danias, Peter G. Blease, Susan Levy, Daniel O'Donnell, Christopher J. Manning, Warren J. Yeon, Susan B. TI Left Ventricular Wall Motion Abnormalities in a Community Population are Associated with Increased Coronary Artery Calcium SO CIRCULATION LA English DT Meeting Abstract DE Ventricular function; Cardiac MRI; Coronary artery disease; Cardiac CT C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NHLBIs Framingham Heart Study, Framingham, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A14814 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601682 ER PT J AU Velagaleti, RS Gona, P Salton, CJ Chuang, ML Blease, SJ Vasan, RS Levy, D Fox, CS Massaro, JM Hoffmann, U Mitchell, GF Manning, WJ O'Donnell, CJ AF Velagaleti, Raghava S. Gona, Philimon Salton, Carol J. Chuang, Michael L. Blease, Susan J. Vasan, Ramachandran S. Levy, Daniel Fox, Caroline S. Massaro, Joseph M. Hoffmann, Udo Mitchell, Gary F. Manning, Warren J. O'Donnell, Christopher J. TI Aortic Atherosclerosis and Left Ventricular Structure SO CIRCULATION LA English DT Meeting Abstract DE Arteriosclerosis; Magnetic resonance imaging; Remodeling C1 Boston VA Healthcare Syst, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Framingham Heart Dis Epidemiol Study, Framingham, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A20355 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231603478 ER PT J AU Weiner, RB Wang, F Hutter, AM Kim, J Picard, MH Wood, MJ Wang, TJ Baggish, AL AF Weiner, Rory B. Wang, Francis Hutter, Adolph M. Kim, Jonathan Picard, Michael H. Wood, Malissa J. Wang, Thomas J. Baggish, Aaron L. TI Participation in American-style Football is Associated with the Development of Hypertension and Concentric Left Ventricular Remodeling SO CIRCULATION LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A14596 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601623 ER PT J AU Yarbrough, WM Van Laer, A Rivers, WT McKinney, RA O'Quinn, EC Black, LE Stroud, RE Zile, MR Mukherjee, R Spinale, FG AF Yarbrough, William M. Van Laer, An Rivers, William T. McKinney, Richard A. O'Quinn, Elizabeth C. Black, Laurel E. Stroud, Robert E. Zile, Michael R. Mukherjee, Rupak Spinale, Francis G. TI Direct Modulation of Myocardial Tissue Inhibitor of Matrix Metalloproteinase-4 Alters the Course of Myocardial Growth and Matrix Remodeling with Pressure Overload SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophy; Remodeling C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A13228 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601200 ER PT J AU Yarbrough, WM Van Laer, A Rivers, WT McKinney, RA Black, LE Stroud, RE Zile, MR Mukherjee, R Spinale, FG AF Yarbrough, William M. Van Laer, An Rivers, William T. McKinney, Richard A. Black, Laurel E. Stroud, Robert E. Zile, Michael R. Mukherjee, Rupak Spinale, Francis G. TI Tissue Inhibitor of Matrix Metalloproteinase-4 Overexpression and Deletion- Effects on Survival and Collagen Accumulation with Pressure Overload Hypertrophy SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophy; Remodeling; Proteolytic enzymes C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12601 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600905 ER PT J AU Yeh, G McCarthy, E Wayne, P Stevenson, L Wood, M Forman, D Davis, R Phillips, R AF Yeh, Gloria McCarthy, Ellen Wayne, Peter Stevenson, Lynne Wood, Malissa Forman, Daniel Davis, Roger Phillips, Russell TI Selective Improvement of Quality of Life and Perceived Exercise Capacity Compared to Measured Exercise Capacity After Tai Chi Training: A Randomized Controlled Trial in Chronic Stable Heart Failure SO CIRCULATION LA English DT Meeting Abstract DE Heart failure; Quality of life; Physical activity; Intervention C1 Harvard Univ, Sch Med, Boston, MA USA. Beth Israel Deaconess Med Cntr, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A17099 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602366 ER PT J AU Yeh, RW Zelevinsky, K Normand, SLT Sakhuja, R Lovett, A Weiner, BH Rosenfield, KA AF Yeh, Robert W. Zelevinsky, Katya Normand, Sharon-Lise T. Sakhuja, Rahul Lovett, Ann Weiner, Bonnie H. Rosenfield, Kenneth A. TI 30-Day All-Cause Readmission After Percutaneous Coronary Intervention in Massachusetts: Clinical Predictors and Hospital-Variation of a New Quality Metric SO CIRCULATION LA English DT Meeting Abstract DE Percutaneous coronary intervention; Quality assessment; Epidemiology C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Massachusetts, Sch Med, Worcester, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A18716 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231602921 ER PT J AU Yu, LY Hales, CA AF Yu, Lunyin Hales, Charles A. TI Na+/H+ Exchanger 1 Gene Regulates Migration of Human Pulmonary Artery Smooth Muscle Cells Under Hypoxia SO CIRCULATION LA English DT Meeting Abstract DE Pulmonary hypertension; Smooth muscle; Sodium hydrogen exchange C1 [Yu, Lunyin; Hales, Charles A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A9065 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600354 ER PT J AU Zile, MR Baicu, CF Van Laer, A Patel, RK Black, LE Stroud, RE Mukherjee, R Spinale, FG AF Zile, Michael R. Baicu, Catalin F. Van Laer, An Patel, Risha K. Black, Laurel E. Stroud, Robert E. Mukherjee, Rupak Spinale, Francis G. TI Role of Membrane Type-1 Matrix Metalloproteinase Expression in Pressure-Overload Induced Left Ventricular Remodeling SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophy; Proteolytic enzymes; Remodeling C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A13207 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231601188 ER PT J AU Zile, MR DeSantis, SM Baicu, CF Prescott, CB Stroud, RE Thompson, SB McClure, CD Spinale, FG AF Zile, Michael R. DeSantis, Stacia M. Baicu, Catalin F. Prescott, Corey B. Stroud, Robert E. Thompson, Sheila B. McClure, Catherine D. Spinale, Francis G. TI Plasma Galectin-3 Levels in Patients with Structural and Clinical Manifestations of Hypertensive Heart Disease: Relationship to Determinants of Matrix Composition SO CIRCULATION LA English DT Meeting Abstract DE Hypertension; Heart disease C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12433 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600840 ER PT J AU Zile, MR Baicu, CF Stroud, RE Van Laer, A Mukherjee, R Spinale, FG AF Zile, Michael R. Baicu, Catalin F. Stroud, Robert E. Van Laer, An Mukherjee, Rupak Spinale, Francis G. TI Effects of Pressure-Overload Induced Left Ventricular Remodeling on Membrane Type-1 Matrix Metalloproteinase Promoter Activation and Expression SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophy; Proteolytic enzymes C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12438 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600842 ER PT J AU Zile, MR Mehurg, SM O'Quinn, EC Stroud, RE DeSantis, SM Spinale, FG AF Zile, Michael R. Mehurg, Shannon M. O'Quinn, Elizabeth C. Stroud, Robert E. DeSantis, Stacia M. Spinale, Francis G. TI Plasma microRNA in Patients with Hypertensive Heart Disease: Differential Expression in Left Ventricular Hypertrophy versus Diastolic Heart Failure SO CIRCULATION LA English DT Meeting Abstract DE Hypertension; Heart failure C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 23 PY 2010 VL 122 IS 21 SU S MA A12427 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V21UD UT WOS:000208231600837 ER PT J AU Gros, J Hu, JKH Vinegoni, C Feruglio, PF Weissleder, R Tabin, CJ AF Gros, Jerome Hu, Jimmy Kuang Hsien Vinegoni, Claudio Feruglio, Paolo Fumene Weissleder, Ralph Tabin, Clifford J. TI WNT5A/JNK and FGF/MAPK Pathways Regulate the Cellular Events Shaping the Vertebrate Limb Bud SO CURRENT BIOLOGY LA English DT Article ID RECEPTOR TYROSINE KINASE; SIGNALING PATHWAY; CHICK LIMB; MORPHOGENESIS; GASTRULATION; EXPRESSION; OUTGROWTH; MOTILITY; EMBRYO; MULTIPLE AB Background The vertebrate limb is a classical model for understanding patterning of three-dimensional structures during embryonic development Although decades of research have elucidated the tissue and molecular interactions within the limb bud required for patterning and morphogenesis of the limb, the cellular and molecular events that shape the limb bud itself have remained largely unknown Results We show that the mesenchymal cells of the early limb bud are not disorganized within the ectoderm as previously thought but are instead highly organized and polarized Using time-lapse video microscopy, we demonstrate that cells move and divide according to this orientation The combination of oriented cell divisions and movements drives the proximaldistal elongation of the limb bud necessary to set the stage for subsequent morphogenesis These cellular events are regulated by the combined activities of the WNT and FGF pathways We show that WNT5A/JNK is necessary for the proper orientation of cell movements and cell division In contrast, the FGF/MAPK signaling pathway, emanating from the apical ectodermal ridge, does not regulate cell orientation in the limb bud but instead establishes a gradient of cell velocity enabling continuous rearrangement of the cells at the distal tip of the limb Conclusions Together these data shed light on the cellular basis of vertebrate limb bud morphogenesis and uncover new layers to the sequential signaling pathways acting during vertebrate limb development C1 [Gros, Jerome; Hu, Jimmy Kuang Hsien; Tabin, Clifford J.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Vinegoni, Claudio; Feruglio, Paolo Fumene; Weissleder, Ralph] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Feruglio, Paolo Fumene] Univ Verona, Dept Neurol Neuropsychol Morphol & Movement Sci, I-37134 Verona, Italy. RP Tabin, CJ (reprint author), Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA. OI Gros, Jerome/0000-0002-2264-2851 FU National Institutes of Health (NIH) [UO1 HL080731, PO1 AI05490, RO1 EB006432, RO1 HD045499] FX We thank Carla Kim Andy McMahon Elaine Fuchs Rudolf Jaenisch and Andras Nagy for shanng mouse strains and Andrew Russell for assistance with statistical tests J G is a fellow of the Human Frontier Science Program C V is supported by National Institutes of Health (NIH) grants UO1 HL080731 PO1 AI05490 and RO1 EB006432 This work was supported by NIH grant RO1 HD045499 to C J T NR 25 TC 70 Z9 71 U1 0 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0960-9822 J9 CURR BIOL JI Curr. Biol. PD NOV 23 PY 2010 VL 20 IS 22 BP 1993 EP 2002 DI 10.1016/j.cub.2010.09.063 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 689JK UT WOS:000284923700022 PM 21055947 ER PT J AU Hung, CL Verma, A Uno, H Shin, SH Bourgoun, M Hassanein, AH McMurray, JJ Velazquez, EJ Kober, L Pfeffer, MA Solomon, SD AF Hung, Chung-Lieh Verma, Anil Uno, Hajime Shin, Sung-Hee Bourgoun, Mikhail Hassanein, Amira H. McMurray, John J. Velazquez, Eric J. Kober, Lars Pfeffer, Marc A. Solomon, Scott D. CA VALIANT Investigators TI Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE heart failure; mortality; myocardial infarction; remodeling; speckle-tracking imaging ID SPECKLE TRACKING ECHOCARDIOGRAPHY; DIASTOLIC HEART-FAILURE; END-SYSTOLIC VOLUME; 2-DIMENSIONAL STRAIN; CLINICAL-IMPLICATIONS; EJECTION FRACTION; INCREMENTAL VALUE; SIZE; DYSFUNCTION; VALIDATION AB Objectives We sought to investigate the clinical prognostic value of longitudinal and circumferential strain (S) and strain rate (SR) in patients after high-risk myocardial infarction (MI). Background Left ventricular (LV) contractile performance after MI is an important predictor of long-term outcome. Tissue deformation imaging might more closely reflect myocardial contractility than traditional measures of systolic functions. Methods The VALIANT (Valsartan in Acute Myocardial Infarction Trial) Echo study enrolled 603 patients with LV dysfunction, heart failure, or both 5 days after MI. We measured global peak longitudinal S and systolic SR (SRs) from apical 4- and 2-chamber views and global circumferential S and SRs from parasternal short-axis view with speckle tracking software (Velocity Vector Imaging, Siemens, Inc., Mountain View, California). We related global S and SRs to LV remodeling at 20-month follow-up and to clinical outcomes. Results Both longitudinal (mean: -5.1 +/- 1.6 100/ms) and circumferential SRs (mean: -8.0 +/- 2.8 100/ms) were predictive of death or hospital stay for heart failure (hazard ratio: 2.4, 95% confidence interval [CI]: 2.0 to 3.1, p < 0.001; hazard ratio: 1.3, 95% CI: 1.2 to 1.4, p < 0.001, respectively) after adjustment for clinical covariates by Cox proportional hazards, and longitudinal SRs further improved in predicting 18-month survivor on a model based on clinical and standard echocardiographic measures (increase in area under the receiver-operator characteristic curve: 0.13, p = 0.009). With multivariable logistic regression, circumferential SRs, but not longitudinal SRs, was strongly predictive of remodeling (odds ratio: 1.3, 95% CI: 1.1 to 1.4, p < 0.001). Conclusions Both longitudinal and circumferential SRs were independent predictors of outcomes after MI, whereas only circumferential SRs was predictive of remodeling, suggesting that preserved circumferential function might serve to restrain ventricular enlargement after MI. (J Am Coll Cardiol 2010;56:1812-22) (C) 2010 by the American College of Cardiology Foundation C1 [Hung, Chung-Lieh; Verma, Anil; Shin, Sung-Hee; Bourgoun, Mikhail; Hassanein, Amira H.; Pfeffer, Marc A.; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [McMurray, John J.] Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland. [Velazquez, Eric J.] Duke Univ, Med Ctr, Durham, NC USA. [Kober, Lars] Rigshosp, DK-2100 Copenhagen, Denmark. [Hung, Chung-Lieh] Mackay Mem Hosp, Div Cardiol, Dept Internal Med, Taipei, Taiwan. [Hung, Chung-Lieh] Mackay Med Coll, Taipei, Taiwan. [Hung, Chung-Lieh] Mackay Med Nursing & Management Coll, Taipei, Taiwan. [Uno, Hajime] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. RP Solomon, SD (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. EM ssolomon@rics.bwh.harvard.edu RI Solomon, Scott/I-5789-2013; OI mcmurray, john/0000-0002-6317-3975 FU Novartis; Boehringer Ingelheim; Amgen; Baxter; Bristol-Myers Squibb; Celladon; Sanofi-Aventis FX *From the Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts; dagger Western Infirmary, Glasgow, United Kingdom; double dagger Duke University Medical Center, Durham, North Carolina; Rigshospitalet, Copenhagen, Denmark; parallel to Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan; Mackay Medical College, Taipei, Taiwan; #Mackay Medicine, Nursing and Management College, Taipei, Taiwan; and the **Department of Biostatistics, Dana-Farber Cancer Institute, School of Public Health, Harvard University, Boston, Massachusetts. Dr. Velazquez has served as an advisory board member and received research grants from Novartis and Boehringer Ingelheim. Dr. Kober has received fees for presentations at meetings. Dr. Pfeffer has received grant/research support from Amgen, Baxter, Bristol-Myers Squibb, Celladon, Novartis, and Sanofi-Aventis; and has served as a consultant to Affectis Anthera, AstraZeneca, Biogen, Boehringer, Boston Scientific, Bristol-Myers Squibb, Celladon, Cytokinetics, Daiichi Sankyo, Genzyme, Gilead, GlaxoSmithKline, Medtronic, Mirabila, Nicox, Novartis, Roche, Salutria, Sanofi-Aventis, and Via Pharmaceuticals. Dr. Solomon has received research support from Novartis. All other authors have reported that they have no relationships to disclose. NR 39 TC 109 Z9 114 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 23 PY 2010 VL 56 IS 22 BP 1812 EP 1822 DI 10.1016/j.jacc.2010.06.044 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 681JQ UT WOS:000284308400006 PM 21087709 ER PT J AU Chatterjee, N Domoto-Reilly, K Fecci, PE Schwamm, LH Singhal, AB AF Chatterjee, N. Domoto-Reilly, K. Fecci, P. E. Schwamm, L. H. Singhal, A. B. TI LICORICE-ASSOCIATED REVERSIBLE CEREBRAL VASOCONSTRICTION WITH PRES SO NEUROLOGY LA English DT Editorial Material ID DEHYDROGENASE; INHIBITION C1 [Chatterjee, N.; Domoto-Reilly, K.; Schwamm, L. H.; Singhal, A. B.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Fecci, P. E.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Domoto-Reilly, K.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. RP Domoto-Reilly, K (reprint author), Massachusetts Gen Hosp, Dept Neurol, WACC 835,15 Parkman St, Boston, MA 02114 USA. EM KDomoto-Reilly@partners.org OI Schwamm, Lee/0000-0003-0592-9145 FU NCCDPHP CDC HHS [5U13 DP001176-02]; NCRR NIH HHS [1 UL1 RR025758-01, UL1 RR025758]; NINDS NIH HHS [P01 NS035611, P50 NS051343, P50 NS051343-01, R01 NS059775, R01NS051412, R01NS059775, R01NS38477, R21NS061119, U01 NS052220] NR 7 TC 10 Z9 10 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 23 PY 2010 VL 75 IS 21 BP 1939 EP 1941 DI 10.1212/WNL.0b013e3181feb299 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 684EY UT WOS:000284533900016 PM 21098410 ER PT J AU Higgins, JM Mahadevan, L AF Higgins, John M. Mahadevan, L. TI Physiological and pathological population dynamics of circulating human red blood cells SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE hematology; mathematical modeling; medical sciences; stochastic differential equations; systems biology ID IRON-DEFICIENCY; INDEXES; ANEMIA; ERYTHROCYTES; RETICULOCYTE; VOLUME; AREA AB The systems controlling the number, size, and hemoglobin concentrations of populations of human red blood cells (RBCs), and their dysregulation in anemia, are poorly understood. After release from the bone marrow, RBCs undergo reduction in both volume and total hemoglobin content by an unknown mechanism [Lew VL, et al. (1995) Blood 86:334-341; Waugh RE, et al. (1992) Blood 79:1351-1358]; after similar to 120 d, responding to an unknown trigger, they are removed. We used theory from statistical physics and data from the hospital clinical laboratory [d'Onofrio G, et al. (1995) Blood 85:818-823] to develop a master equation model for RBC maturation and clearance. The model accurately identifies patients with anemia and distinguishes thalassemia-trait anemia from iron-deficiency anemia. Strikingly, it also identifies many pre-anemic patients several weeks before anemia becomes clinically detectable. More generally we illustrate how clinical laboratory data can be used to develop and to test a dynamic model of human pathophysiology with potential clinical utility. C1 [Higgins, John M.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Higgins, John M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Higgins, John M.; Mahadevan, L.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. [Mahadevan, L.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. RP Higgins, JM (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. EM john_higgins@hms.harvard.edu; lm@seas.harvard.edu FU Harvard Medical School Research Information Technology Group; National Institute of Diabetes and Digestive and Kidney Diseases [DK083242]; National Heart, Lung, and Blood Institute [HL091331] FX We thank Alicia Soriano, Svetal Patel, Rosy Jaromin, Hasmukh Patel, David Dorfman, Paul Charest, the Harvard Crimson Tissue Bank, and the Partners Research Patient Data Repository for help acquiring samples and data. We thank Ricardo Paxson, Madhusudhan Venkadesan, and Shreyas Mandre for useful suggestions on the analysis; Frank Bunn, Carlo Brugnara, and Steve Sloan for helpful discussions regarding the findings; and Rebecca Ward for critical reading of the manuscript. The simulations in this paper were primarily run on the Orchestra cluster supported by the Harvard Medical School Research Information Technology Group. J.M.H. acknowledges support from National Institute of Diabetes and Digestive and Kidney Diseases Grant DK083242. L. M. acknowledges support from National Heart, Lung, and Blood Institute Grant HL091331. NR 21 TC 26 Z9 27 U1 1 U2 13 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 23 PY 2010 VL 107 IS 47 BP 20587 EP 20592 DI 10.1073/pnas.1012747107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 684DT UT WOS:000284529000080 PM 21059904 ER PT J AU Corcoran, RB Dias-Santagata, D Bergethon, K Iafrate, AJ Settleman, J Engelman, JA AF Corcoran, Ryan B. Dias-Santagata, Dora Bergethon, Kristin Iafrate, A. John Settleman, Jeffrey Engelman, Jeffrey A. TI BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation SO SCIENCE SIGNALING LA English DT Article ID LUNG-CANCER; KINASE INHIBITORS; BCR-ABL; EGFR; GEFITINIB; MELANOMA; ADENOCARCINOMAS; SENSITIVITY; CARCINOMA; GROWTH AB Oncogenic BRAF mutations are found in several tumor types, including melanomas and colorectal cancers. Tumors with BRAF mutations have increased mitogen-activated protein kinase pathway activity and heightened sensitivity to BRAF and MEK (mitogen-activated or extracellular signal-regulated protein kinase kinase) inhibitors. To identify potential mechanisms of acquired drug resistance, we generated clones resistant to the allosteric MEK inhibitor AZD6244 from two BRAF V600E mutant colorectal cancer cell lines that are highly sensitive to MEK or BRAF inhibition. These AZD6244-resistant (AR) clones, which exhibited cross-resistance to BRAF inhibitors, acquired resistance through amplification of the BRAF gene. A small percentage of treatment-naive parental cells showed preexisting BRAF amplification. We observed similar amplification in a subset of cells in a BRAF-mutant colorectal cancer. In cell lines, BRAF amplification increased the abundance of phosphorylated MEK and impaired the ability of AZD6244 to inhibit ERK (extracellular signal-regulated kinase) phosphorylation. The ability of AZD6244 to inhibit ERK phosphorylation in AR cells was restored by treatment with a BRAF inhibitor at low concentrations that reduced the abundance of phosphorylated MEK to amounts observed in parental cells. Combined MEK and BRAF inhibition fully overcame resistance to MEK or BRAF inhibitors alone and was also more effective in parental cells compared to treatment with either inhibitor alone. These findings implicate BRAF amplification as a mechanism of resistance to both MEK and BRAF inhibitors and suggest combined MEK and BRAF inhibition as a clinical strategy to overcome, or possibly prevent, this mechanism of resistance. C1 [Corcoran, Ryan B.; Settleman, Jeffrey; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA. [Corcoran, Ryan B.; Settleman, Jeffrey; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Dias-Santagata, Dora; Bergethon, Kristin; Iafrate, A. John] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA. RP Settleman, J (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA. EM Settleman.jeffrey@gene.com; jengelman@partners.org FU NIH [T32 CA071345, K08 CA120060-01, R01CA137008-01, R01CA140594, R01CA135257-01]; National Cancer Institute [P50CA090578]; Dana-Farber/Harvard Cancer Center [P50 CA127003]; American Association for Cancer Research; V Foundation; American Cancer Society [RSG-06-102-01-CCE]; Ellison Foundation FX R.B.C. was supported by NIH training grant T32 CA071345. This study was supported by NIH grants K08 CA120060-01 (to J.A.E.), R01CA137008-01 (to J.A.E.), R01CA140594 (to J.A.E.), and R01CA135257-01 (to J.A.E.); National Cancer Institute Lung Specialized Program of Research Excellence (SPORE) grant P50CA090578 (to J.A.E.); Dana-Farber/Harvard Cancer Center Gastrointestinal Cancer SPORE grant P50 CA127003 (to J.A.E.); the American Association for Cancer Research (to J.A.E.); the V Foundation (to J.A.E.); American Cancer Society grant RSG-06-102-01-CCE (to J.A.E.); and the Ellison Foundation Scholar (to J.A.E.). NR 29 TC 140 Z9 142 U1 2 U2 14 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1937-9145 J9 SCI SIGNAL JI Sci. Signal. PD NOV 23 PY 2010 VL 3 IS 149 AR ra84 DI 10.1126/scisignal.2001148 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 684CV UT WOS:000284525700001 PM 21098728 ER PT J AU Schnabel, RB Aspelund, T Li, G Sullivan, LM Suchy-Dicey, A Harris, TB Pencina, MJ D'Agostino, RB Levy, D Kannel, WB Wang, TJ Kronmal, RA Wolf, PA Burke, GL Launer, LJ Vasan, RS Psaty, BM Benjamin, EJ Gudnason, V Heckbert, SR AF Schnabel, Renate B. Aspelund, Thor Li, Guo Sullivan, Lisa M. Suchy-Dicey, Astrid Harris, Tamara B. Pencina, Michael J. D'Agostino, Ralph B., Sr. Levy, Daniel Kannel, William B. Wang, Thomas J. Kronmal, Richard A. Wolf, Philip A. Burke, Gregory L. Launer, Lenore J. Vasan, Ramachandran S. Psaty, Bruce M. Benjamin, Emelia J. Gudnason, Vilmundur Heckbert, Susan R. TI Validation of an Atrial Fibrillation Risk Algorithm in Whites and African Americans SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CONGESTIVE-HEART-FAILURE; ATHEROSCLEROSIS RISK; PREVALENCE; POPULATION; COHORT; ADULTS; PREVENTION; PROGNOSIS; STROKE; TRENDS AB Background: We sought to validate a recently published risk algorithm for incident atrial fibrillation (AF) in independent cohorts and other racial groups. Methods: We evaluated the performance of a Framing-ham Heart Study (FHS)-derived risk algorithm modified for 5-year incidence of AF in the FHS (n= 4764 participants) and 2 geographically and racially diverse cohorts in the age range 45 to 95 years: AGES (the Age, Gene/Environment Susceptibility-Reykjavik Study) (n= 4238) and CHS (the Cardiovascular Health Study) (n= 5410, of whom 874 [16.2%] were African Americans). The risk algorithm included age, sex, body mass index, systolic blood pressure, electrocardiographic PR interval, hypertension treatment, and heart failure. Results: We found 1359 incident AF events in 100 074 person-years of follow-up. Unadjusted 5-year event rates differed by cohort (AGES, 12.8 cases/1000 person-years; CHS whites, 22.7 cases/1000 person-years; and FHS, 4.5 cases/1000 person-years) and by race (CHS African Americans, 18.4 cases/1000 person-years). The strongest risk factors in all samples were age and heart failure. The relative risks for incident AF associated with risk factors were comparable across cohorts and race groups. After recalibration for baseline incidence and risk factor distribution, the Framingham algorithm, reported in C statistic, performed reasonably well in all samples: AGES, 0.67 (95% confidence interval [CI], 0.64-0.71); CHS whites, 0.68 (95% CI, 0.66-0.70); and CHS African Americans, 0.66 (95% CI, 0.61-0.71). Risk factors combined in the algorithm explained between 47.0% (AGES) and 63.6% (FHS) of the population-attributable risk. Conclusions: Risk of incident AF in community-dwelling whites and African Americans can be assessed reliably by routinely available and potentially modifiable clinical variables. Seven risk factors accounted for up to 64% of risk. C1 [Schnabel, Renate B.] Johannes Gutenberg Univ Mainz, Dept Med 2, Mainz, Germany. [Schnabel, Renate B.; Pencina, Michael J.; Levy, Daniel; Kannel, William B.; Wolf, Philip A.; Vasan, Ramachandran S.; Benjamin, Emelia J.] NHLBI, Framingham Study, Framingham, MA USA. [Aspelund, Thor; Gudnason, Vilmundur] Univ Iceland, Heart Prevent Clin & Res Inst, Iceland Heart Assoc, Reykjavik, Iceland. [Psaty, Bruce M.; Heckbert, Susan R.] Grp Hlth Res Inst, Grp Hlth Cooperat, Seattle, WA USA. [Burke, Gregory L.] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27109 USA. [Wang, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. [Levy, Daniel] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA. [Harris, Tamara B.; Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA. [Li, Guo; Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Suchy-Dicey, Astrid; Psaty, Bruce M.; Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Kronmal, Richard A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Sullivan, Lisa M.; Pencina, Michael J.; D'Agostino, Ralph B., Sr.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Kannel, William B.; Benjamin, Emelia J.] Boston Univ, Dept Epidemiol, Boston, MA USA. [D'Agostino, Ralph B., Sr.] Boston Univ, Dept Math & Stat, Boston, MA USA. [Wolf, Philip A.] Boston Univ, Dept Neurol, Boston, MA USA. [Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Whitaker Cardiovasc Inst, Evans Mem Med Dept, Cardiol Sect, Boston, MA USA. [Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Prevent Med, Boston, MA 02118 USA. RP Heckbert, SR (reprint author), Univ Washington, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Ste 1360, Seattle, WA 98101 USA. EM heckbert@u.washington.edu RI Aspelund, Thor/F-4826-2011; Aspelund, Thor/C-5983-2008; Li, Guo/E-5613-2012; Schnabel, Renate/F-6527-2014; Gudnason, Vilmundur/K-6885-2015; OI Benjamin, Emelia/0000-0003-4076-2336; Aspelund, Thor/0000-0002-7998-5433; Gudnason, Vilmundur/0000-0001-5696-0084; Ramachandran, Vasan/0000-0001-7357-5970 FU National Institutes of Health (NIH) [N01AG-12100, AG028321, AG029451, HL092577, RC1 HL101056, R01 NS 17950, 2K24 HL04334]; National Institute on Aging Intramural Research Program, Hjartavernd (the Icelandic Heart Association); Althingi; National Heart, Lung, and Blood Institute (NHLBI) [N01 HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, U01 HL080295, R01 HL068986, R01 HL087652]; NIH-NHLBI [N01-HC-25195]; Deutsche Forschungsgemeinschaft (German Research Foundation) [SCHN 1149/1-1] FX The AGES-Reykjavik study was funded by National Institutes of Health (NIH) contract N01-AG-12100, the National Institute on Aging Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The CHS research reported in this article was supported by National Heart, Lung, and Blood Institute (NHLBI) grants N01 HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, U01 HL080295, R01 HL068986, and R01 HL087652, with additional contribution from the National Institute of Neurological Disorders and Stroke. The FHS research was supported by NIH-NHLBI contract N01-HC-25195 and NIH grants AG028321, AG029451, HL092577, RC1 HL101056, and R01 NS 17950; NIH Research career award 2K24 HL04334; and Deutsche Forschungsgemeinschaft (German Research Foundation) Research Fellowship SCHN 1149/1-1. NR 24 TC 66 Z9 67 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 22 PY 2010 VL 170 IS 21 BP 1909 EP 1917 DI 10.1001/archinternmed.2010.434 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 683MN UT WOS:000284480000011 PM 21098350 ER PT J AU Kullgren, JT Galbraith, AA Hinrichsen, VL Miroshnik, I Penfold, RB Rosenthal, MB Landon, BE Lieu, TA AF Kullgren, Jeffrey T. Galbraith, Alison A. Hinrichsen, Virginia L. Miroshnik, Irina Penfold, Robert B. Rosenthal, Meredith B. Landon, Bruce E. Lieu, Tracy A. TI Health Care Use and Decision Making Among Lower-Income Families in High-Deductible Health Plans SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID BLUNT INSTRUMENT; INSURANCE; COMMUNICATION; AWARENESS; COSTS AB Background: Lower-income families may face unique challenges in high-deductible health plans (HDHPs). Methods: We administered a cross-sectional survey to a stratified random sample of families in a New England health plan's HDHP with at least $500 in annualized out-of-pocket expenditures. Lower-income families were defined as having incomes that were less than 300% of the federal poverty level. Primary outcomes were costrelated delayed or foregone care, difficulty understanding plans, unexpected costs, information-seeking, and likelihood of families asking their physician about hypothetical recommended services subject to the plan deductible. Multivariate logistic regression was used to control for potential confounders of associations between income group and primary outcomes. Results: Lower-income families (n= 141) were more likely than higher-income families (n= 273) to report costrelated delayed or foregone care (57% vs 42%; adjusted odds ratio [AOR], 1.81; 95% confidence interval [CI], 1.15-2.83]). There were no differences in plan understanding, unexpected costs, or information-seeking by income. Lower-income families were more likely than others to say they would ask their physician about a $100 blood test (79% vs 63%; AOR, 1.97; 95% CI, 1.18-3.28) or a $1000 screening colonoscopy (89% vs 80%; AOR, 2.04; 95% CI, 1.06-3.93) subject to the plan deductible. Conclusions: Lower-income families with out-of-pocket expenditures in an HDHP were more likely than higher-income families to report cost-related delayed or foregone care but did not report more difficulty understanding or using their plans, and might be more likely to question services requiring out-of-pocket expenditures. Policymakers and physicians should consider focused monitoring and benefit design modifications to support lower-income families in HDHPs. C1 [Kullgren, Jeffrey T.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA. [Kullgren, Jeffrey T.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Kullgren, Jeffrey T.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Lieu, Tracy A.] Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA. [Kullgren, Jeffrey T.] Brigham & Womens Hosp, Residency Program Primary Care & Populat Hlth, Boston, MA 02115 USA. [Kullgren, Jeffrey T.; Galbraith, Alison A.; Hinrichsen, Virginia L.; Miroshnik, Irina; Penfold, Robert B.; Lieu, Tracy A.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Galbraith, Alison A.; Hinrichsen, Virginia L.; Miroshnik, Irina; Penfold, Robert B.; Lieu, Tracy A.] Ctr Child Hlth Care Studies, Boston, MA USA. [Rosenthal, Meredith B.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Landon, Bruce E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. RP Kullgren, JT (reprint author), Univ Penn, Robert Wood Johnson Fdn Clin Scholars, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kullgren@mail.med.upenn.edu OI Rosenthal, Meredith/0000-0003-3410-0184 FU National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland [HD053440]; NICHD [HD047667, HD052742] FX This study was supported by an R21 grant (HD053440) from the National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland. Dr Lieu's effort was supported in part by a K24 Mid-Career Development Award from NICHD (HD047667). Dr Galbraith's effort was supported in part by a K23 Mentored Career Development Award from NICHD (HD052742). NR 28 TC 21 Z9 21 U1 0 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 22 PY 2010 VL 170 IS 21 BP 1918 EP 1925 DI 10.1001/archinternmed.2010.428 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 683MN UT WOS:000284480000012 PM 21098352 ER PT J AU Reiner, T Earley, S Turetsky, A Weissleder, R AF Reiner, Thomas Earley, Sarah Turetsky, Anna Weissleder, Ralph TI Bioorthogonal Small-Molecule Ligands for PARP1 Imaging in Living Cells SO CHEMBIOCHEM LA English DT Article DE bioorthogonal reactions; cycloadditions; imaging agents; PARP-1; tetrazines ID POLY(ADP-RIBOSE) POLYMERASE-1; DNA-DAMAGE; SITES C1 [Reiner, Thomas; Earley, Sarah; Turetsky, Anna; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Richard B Simches Res Ctr, Boston, MA 02114 USA. RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Richard B Simches Res Ctr, 185 Cambridge St,Suite 5-210, Boston, MA 02114 USA. EM rweissleder@mgh.harvard.edu OI Reiner, Thomas/0000-0002-7819-5480 FU National Cancer Institute (NCI, USA) [P50 CA86355, NIBI-B RO1 EB-010011]; National Institutes of Health (NIH, USA) [NIGMS T32 GM008313]; German National Academy of Sciences Leopoldina [LPDS-2009-24] FX We thank Drs. Ralph Mazitschek, Neal Devaraj, Scott Hilderbrand and Claudio Vinegoni for many helpful discussions, Dr. Yvonna Fisher-Jeffes for manuscript review and Joshua Dunham for image processing. This research was supported in part by the National Cancer Institute (NCI, USA) grants P50 CA86355 and NIBI-B RO1 EB-010011. A. T. was supported by a National Institutes of Health (NIH, USA) grant NIGMS T32 GM008313. T. R. was supported by a grant from the German National Academy of Sciences Leopoldina (LPDS-2009-24). NR 13 TC 34 Z9 34 U1 0 U2 11 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY SN 1439-4227 J9 CHEMBIOCHEM JI ChemBioChem PD NOV 22 PY 2010 VL 11 IS 17 BP 2374 EP 2377 DI 10.1002/cbic.201000477 PG 4 WC Biochemistry & Molecular Biology; Chemistry, Medicinal SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 686TH UT WOS:000284718100006 PM 20967817 ER PT J AU Vierling-Claassen, D Cardin, JA Moore, CI Jones, SR AF Vierling-Claassen, Dorea Cardin, Jessica A. Moore, Christopher I. Jones, Stephanie R. TI Computational modeling of distinct neocortical oscillations driven by cell-type selective optogenetic drive: separable resonant circuits controlled by low-threshold spiking and fast-spiking interneurons SO FRONTIERS IN HUMAN NEUROSCIENCE LA English DT Article DE gamma; GABA; channelrhodopsin; low-threshold spiking; fast-spiking; interneurons; somatosensory cortex ID RAT SOMATOSENSORY CORTEX; SHORT-TERM PLASTICITY; INHIBITORY INTERNEURONS; GAMMA-OSCILLATIONS; PYRAMIDAL NEURONS; QUANTITATIVE-ANALYSIS; NONPYRAMIDAL CELLS; EVOKED-POTENTIALS; VISUAL-CORTEX; NETWORKS AB Selective optogenetic drive of fast-spiking (FS) interneurons (INs) leads to enhanced local field potential (LFP) power across the traditional "gamma" frequency band (20-80 Hz; Cardin et al., 2009). In contrast, drive to regular-spiking (RS) pyramidal cells enhances power at lower frequencies, with a peak at 8 Hz. The first result is consistent with previous computational studies emphasizing the role of FS and the time constant of GABA(A) synaptic inhibition in gamma rhythmicity. However, the same theoretical models do not typically predict low-frequency LFP enhancement with RS drive. To develop hypotheses as to how the same network can support these contrasting behaviors, we constructed a biophysically principled network model of primary somatosensory neocortex containing FS, RS, and low-threshold spiking (LTS) INs. Cells were modeled with detailed cell anatomy and physiology, multiple dendritic compartments, and included active somatic and dendritic ionic currents. Consistent with prior studies, the model demonstrated gamma resonance during FS drive, dependent on the time constant of GABA(A) inhibition induced by synchronous FS activity. Lower-frequency enhancement during RS drive was replicated only on inclusion of an inhibitory LTS population, whose activation was critically dependent on RS synchrony and evoked longer-lasting inhibition. Our results predict that differential recruitment of FS and LTS inhibitory populations is essential to the observed cortical dynamics and may provide a means for amplifying the natural expression of distinct oscillations in normal cortical processing. C1 [Vierling-Claassen, Dorea; Jones, Stephanie R.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Vierling-Claassen, Dorea; Moore, Christopher I.] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA. [Cardin, Jessica A.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. RP Jones, SR (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St,Suite 2301, Charlestown, MA 02129 USA. EM srjones@nmr.mgh.harvard.edu FU NIH [K25MH07294, F32NS063694] FX We thank M. Kramer, U. Knoblich, and R. Haslinger for helpful conversations regarding data analysis, and M. Sikora for consultation on NEURON programming. Work supported by the MGH Claflin Award for Distinguished Scholarship, NIH grant K25MH07294, and NIH grant F32NS063694. NR 51 TC 30 Z9 30 U1 1 U2 7 PU FRONTIERS RES FOUND PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-5161 J9 FRONT HUM NEUROSCI JI Front. Hum. Neurosci. PD NOV 22 PY 2010 VL 4 AR 198 DI 10.3389/fnhum.2010.00198 PG 12 WC Neurosciences; Psychology SC Neurosciences & Neurology; Psychology GA 747JD UT WOS:000289315200001 PM 21152338 ER PT J AU Kerenyi, MA Orkin, SH AF Kerenyi, Marc A. Orkin, Stuart H. TI Networking erythropoiesis SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Review ID TRANSCRIPTION FACTOR GATA-1; PRIMARY ERYTHROID-CELLS; CHROMATIN OCCUPANCY; REPRESSOR COMPLEX; HUMAN GENOME; GLOBAL ROLE; CHIP-SEQ; GENE; PROTEINS; BINDING AB A relatively small cadre of lineage-restricted transcription factors largely orchestrates erythropoiesis, but how these nuclear factors interact to regulate this complex biology is still largely unknown. However, recent technological advances, such as chromatin immunoprecipitation (ChIP) paired with massively parallel sequencing (ChIP-seq), gene expression profiling, and comprehensive bioinformatic analyses, offer new insights into the intricacies of red cell molecular circuits. C1 [Kerenyi, Marc A.; Orkin, Stuart H.] Childrens Hosp Boston, Div Hematol Oncol, Boston, MA 02115 USA. [Kerenyi, Marc A.; Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Kerenyi, Marc A.; Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA. RP Orkin, SH (reprint author), Childrens Hosp Boston, Div Hematol Oncol, Boston, MA 02115 USA. EM stuart_orkin@dfci.harvard.edu RI cheng, yong/I-4270-2012 FU Howard Hughes Medical Institute; NHLBI NIH HHS [R01 HL032259] NR 37 TC 42 Z9 45 U1 1 U2 5 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0022-1007 J9 J EXP MED JI J. Exp. Med. PD NOV 22 PY 2010 VL 207 IS 12 BP 2537 EP 2541 DI 10.1084/jem.20102260 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 697HX UT WOS:000285505000001 PM 21098097 ER PT J AU Kriegl, L Horst, D Reiche, JA Engel, J Kirchner, T Jung, A AF Kriegl, Lydia Horst, David Reiche, Jana A. Engel, Jutta Kirchner, Thomas Jung, Andreas TI LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer SO JOURNAL OF TRANSLATIONAL MEDICINE LA English DT Article ID WNT SIGNALING PATHWAY; ENHANCER FACTOR-I; COLON-CANCER; BETA-CATENIN; TRANSCRIPTION FACTOR; ALPHA-ENHANCER; STEM-CELLS; HMG DOMAIN; GENE; PROGRESSION AB Background: Most colorectal carcinomas are driven by an activation of the canonical Wnt signalling pathway, which promotes the expression of multiple target genes mediating proliferation inavasion and invasion. Upon activation of the Wnt signalling pathway its key player beta-catenin translocates from the cytoplasm to the nucleus and binds to members of the T-cell factor (TCF)/lymphoid enhancer factor (LEF-1) family namely LEF-1 and TCF4 which are central mediators of transcription. In this study we investigated the expression of beta-Catenin, LEF1 and TCF4 in colorectal carcinomas and their prognostic significance. Methods: Immunohistochemical analyses of LEF-1, TCF4 and nuclear beta-Catenin were done using a tissue microarray with 214 colorectal cancer specimens. The expression patterns were compared with each other and the results were correlated with clinicopathologic variables and overall survival in univariate and multivariate analysis. Results: LEF-1 expression was found in 56 (26%) and TCF4 expression in 99 (46%) of colorectal carcinomas and both were heterogenously distributed throughout the tumours. Comparing LEF-1, TCF4 and b-catenin expression patterns we found no correlation. In univariate analysis, TCF4 expression turned out to be a negative prognostic factor being associated with shorter overall survival (p = 0.020), whereas LEF-1 expression as well as a LEF-1/TCF4 ratio were positive prognostic factors and correlated with longer overall survival (p = 0.015 respectively p = 0.001). In multivariate analysis, LEF-1 and TCF4 expression were confirmed to be independent predictors of longer respectively shorter overall survival, when considered together with tumour stage, gender and age (risk ratio for LEF-1: 2.66; p = 0.027 risk ratio for TCF4: 2.18; p = 0.014). Conclusions: This study demonstrates different prognostic values of LEF-1 and TCF4 expression in colorectal cancer patients indicating different regulation of these transcription mediators during tumour progression. Moreover both factors may serve as new potential predictive markers in low stage colon cancer cases in advance. C1 [Kriegl, Lydia; Horst, David; Reiche, Jana A.; Kirchner, Thomas; Jung, Andreas] Univ Munich, Dept Pathol, D-80337 Munich, Germany. [Engel, Jutta] Univ Munich, Univ Hosp Grosshadern, Dept Med Informat Biometry & Epidemiol, MCC,MCR, D-81377 Munich, Germany. [Horst, David] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Kriegl, L (reprint author), Univ Munich, Dept Pathol, Thalkirchnerstr 36, D-80337 Munich, Germany. EM Lydia.Kriegl@med.uni-muenchen.de FU K. L. Weigand'schen Stiftung, Germany; DFG [JU 368-4-1] FX We thank A Sendelhofert, A Heier, H Prelle, S. Liebmann and G Janssen for their expert support and experimental assistance. This study was supported in part by the K. L. Weigand'schen Stiftung, Germany (2005, support to LK and AJ) and DFG (JU 368-4-1 to AJ and TK). NR 31 TC 27 Z9 28 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1479-5876 J9 J TRANSL MED JI J. Transl. Med. PD NOV 22 PY 2010 VL 8 AR 123 DI 10.1186/1479-5876-8-123 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 689CT UT WOS:000284905600002 PM 21092222 ER PT J AU Lee, SR Kim, J Lee, S Jung, YM Kim, JK Oh, K AF Lee, Sung Rae Kim, Jongki Lee, Sejin Jung, Yongmin Kim, Jun Ki Oh, K. TI All-silica fiber Bessel-like beam generator and its applications in longitudinal optical trapping and transport of multiple dielectric particles SO OPTICS EXPRESS LA English DT Article ID LIGHT-BEAM; DIFFRACTION; AXICON AB A Bessel-like beam was generated in a novel all-fiber integrated structure. A concentric ring intensity pattern was achieved by the multimode interference along the coreless silica fiber, which was then focused by the integrated micro-lens to result in a Bessel-like beam. The average beam diameter of 7.5 mu m maintained over 500 mu m axial length for a continuous wave Yb-doped fiber laser input oscillating at the wavelength of 1.08 mu m. The generated beam was successfully applied to two-dimension optical trapping and longitudinal transport of multiple dielectric particles confirming its unique non-diffracting and self-reconstructing nature. Physical principle of operation, fabrication, and experimental results are discussed. (C) 2010 Optical Society of America C1 [Lee, Sung Rae; Kim, Jongki; Lee, Sejin; Oh, K.] Yonsei Univ, Inst Phys & Appl Phys, Seoul 120749, South Korea. [Jung, Yongmin] Univ Southampton Highfield, Optoelect Res Ctr, Southampton SO17 1BJ, Hants, England. [Kim, Jun Ki] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Lee, SR (reprint author), Yonsei Univ, Inst Phys & Appl Phys, 262 Seongsanno, Seoul 120749, South Korea. EM koh@yonsei.ac.kr RI Jung, Yongmin/I-3532-2012 FU NRF [ROA-2008-000-20054-0, R15-2004-024-00000-0, 2009-8-2175, 2010-8-0939, 2010-8-0037, 219299, 2009-8-1339, 2009-0093823]; KRF FX This work was supported in part by the NRF under Grant ROA-2008-000-20054-0, Grant R15-2004-024-00000-0, Grant 2009-8-2175, and Grant 2010-8-0939, Grant 2010-8-0037(the European Community's Seventh Framework Program [FP7/2007-2013] under Grant agreement no 219299, Gospel), Grant 2009-8-1339, Grant 2009-0093823, and in part by the Brain Korea 21 Project of the KRF. NR 16 TC 19 Z9 20 U1 0 U2 8 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 1094-4087 J9 OPT EXPRESS JI Opt. Express PD NOV 22 PY 2010 VL 18 IS 24 BP 25299 EP 25305 DI 10.1364/OE.18.025299 PG 7 WC Optics SC Optics GA 698IF UT WOS:000285586800078 PM 21164878 ER PT J AU Trott, CM Ouyang, J El Fakhri, G AF Trott, C. M. Ouyang, J. El Fakhri, G. TI Comparison of simultaneous and sequential SPECT imaging for discrimination tasks in assessment of cardiac defects SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article ID MYOCARDIAL-PERFUSION SPECT; BRAIN SPECT; DISEASE; REVASCULARIZATION; RECONSTRUCTION; FEASIBILITY; I-123-BMIPP; VIABILITY; EXTENT; PET AB Simultaneous rest perfusion/fatty-acid metabolism studies have the potential to replace sequential rest/stress perfusion studies for the assessment of cardiac function. Simultaneous acquisition has the benefits of increased signal and lack of need for patient stress, but is complicated by cross-talk between the two radionuclide signals. We consider a simultaneous rest (99m)Tc-sestamibi/(123)I-BMIPP imaging protocol in place of the commonly used sequential rest/stress (99m)Tc-sestamibi protocol. The theoretical precision with which the severity of a cardiac defect and the transmural extent of infarct can be measured is computed for simultaneous and sequential SPECT imaging, and their performance is compared for discriminating (1) degrees of defect severity and (2) sub-endocardial from transmural defects. We consider cardiac infarcts for which reduced perfusion and metabolism are observed. From an information perspective, simultaneous imaging is found to yield comparable or improved performance compared with sequential imaging for discriminating both severity of defect and transmural extent of infarct, for three defects of differing location and size. C1 [Trott, C. M.] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Trott, CM (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, 55 Fruit St, Boston, MA 02114 USA. EM ctrott@pet.mgh.harvard.edu RI Trott, Cathryn/B-5325-2013 OI Trott, Cathryn/0000-0001-6324-1766 FU NIBIB NIH HHS [R21 EB012326, R21 EB012326-01] NR 19 TC 1 Z9 1 U1 0 U2 4 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 J9 PHYS MED BIOL JI Phys. Med. Biol. PD NOV 21 PY 2010 VL 55 IS 22 BP 6897 EP 6910 DI 10.1088/0031-9155/55/22/019 PG 14 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA 674YT UT WOS:000283789700022 PM 21048290 ER PT J AU Ancha, HR Fajardo, NR Bauman, WA Rosman, AS Galea, M Creasey, G Korsten, MA AF Ancha, Hanumantha R. Fajardo, Noel R. Bauman, William A. Rosman, Alan S. Galea, Marinella Creasey, Graham Korsten, Mark A. TI Absence of high amplitude propagating contractions in subjects with chronic spinal cord injury SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Spinal cord injury; Neurogenic bowel; Bowel motility; High amplitude propagating contractions; Motility index ID COLONIC MOTOR-ACTIVITY; SLOW-TRANSIT CONSTIPATION; 24 HOUR; MOTILITY; MANOMETRY AB AIM: To investigate the presence or absence of high amplitude propagating contractions (HAPC), as well as the other measures of colonic motility, in persons with spinal cord injury (SCI). METHODS: Prolonged colonic ambulatory manometric studies were performed on 14 male volunteers: 8 with SCI (mean age, 59 +/- 13 years; mean duration of injury, 13 +/- 4 years) and 6 healthy able-bodied controls (mean age, 57 +/- 10 years). A solid-state manometry catheter was endoscopically clipped to the splenic flexure. Recording was performed for > 24 h after manometric catheter placement. RESULTS: HAPC were absent in individuals with SCI during pre-sleep, sleep, and post-sleep phases. HAPC were significantly increased after awakening in non-SCI controls (0.8 +/- 0.2 HAPC/h vs 10.5 +/- 2.0 HAPC/h, P < 0.005). The motility index was lower in those with SCI than in controls pre- and post-sleep (SCI vs non-SCI: Pre-sleep, 2.4 +/- 0.4 vs 8.8 +/- 1.9, P < 0.01; Post-sleep, 4.3 +/- 0.8 vs 16.5 +/- 4.5, P < 0.05). However; a sleep-induced depression of colonic motility was observed in both the SCI and non-SCI groups (Pre-sleep vs Sleep, non-SCI: 8.8 1.9 vs 2.1 +/- 0.9, P < 0.002; SCI: 2.4 +/- 0.4 vs 0.2 +/- 0.03, P < 0.001), with the motility index of those with SCI during sleep not significantly different than that of the controls. CONCLUSION: HAPC were not observed in individuals with SCI pre- or post-sleep. A sleep-induced depression in general colonic motility was evident in SCI and control subjects. (C) 2010 Baishideng. All rights reserved. C1 [Korsten, Mark A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Ancha, Hanumantha R.; Fajardo, Noel R.; Bauman, William A.; Rosman, Alan S.; Korsten, Mark A.] James J Peters VA Med Ctr, Rehabil Res & Dev Ctr Excellence Med Consequences, Bronx, NY 10468 USA. [Bauman, William A.; Rosman, Alan S.; Korsten, Mark A.] Mt Sinai Sch Med, Dept Med, Bronx, NY 10468 USA. [Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, Bronx, NY 10468 USA. [Galea, Marinella] James J Peters VA Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA. [Creasey, Graham] VA Med Ctr, Spinal Cord Injury Serv, Palo Alto, CA 94304 USA. RP Korsten, MA (reprint author), James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. EM mark.korsten@va.gov FU Department of Veterans Affairs Rehabilitation Research and Development Service Center of Excellence for the Medical Consequences of Spinal Cord Injury [B4162C] FX Supported by The Department of Veterans Affairs Rehabilitation Research and Development Service Center of Excellence for the Medical Consequences of Spinal Cord Injury (B4162C) NR 22 TC 1 Z9 2 U1 0 U2 0 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1007-9327 EI 2219-2840 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD NOV 21 PY 2010 VL 16 IS 43 BP 5435 EP 5439 DI 10.3748/wjg.v16.i43.5435 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 683SC UT WOS:000284494500006 PM 21086560 ER PT J AU Sequist, LV Gettinger, S Senzer, NN Martins, RG Janne, PA Lilenbaum, R Gray, JE Iafrate, AJ Katayama, R Hafeez, N Sweeney, J Walker, JR Fritz, C Ross, RW Grayzel, D Engelman, JA Borger, DR Paez, G Natale, R AF Sequist, Lecia V. Gettinger, Scott Senzer, Neil N. Martins, Renato G. Jaenne, Pasi A. Lilenbaum, Rogerio Gray, Jhanelle E. Iafrate, A. John Katayama, Ryohei Hafeez, Nafeeza Sweeney, Jennifer Walker, John R. Fritz, Christian Ross, Robert W. Grayzel, David Engelman, Jeffrey A. Borger, Darrell R. Paez, Guillermo Natale, Ronald TI Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID TYROSINE KINASE; HSP90; CHAPERONE; EML4-ALK; RECEPTOR; TUMORS; EGFR; EXPRESSION; PACLITAXEL; MUTATIONS AB Purpose IPI-504 is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90). Its potential anticancer activity has been validated in preclinical in vitro and in vivo models. We studied the activity of IPI-504 after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced, molecularly defined non-small-cell lung cancer (NSCLC). Patients and Methods Patients with advanced NSCLC, prior treatment with EGFR TKIs, and tumor tissue available for molecular genotyping were enrolled in this prospective, nonrandomized, multicenter, phase II study of IPI-504 monotherapy. The primary outcome was objective response rate (ORR). Secondary aims included safety, progression-free survival (PFS), and analysis of activity by molecular subtypes. Results Seventy-six patients were enrolled between December 2007 and May 2009 from 10 United States cancer centers. An ORR of 7% (five of 76) was observed in the overall study population, 10% (four of 40) in patients who were EGFR wild-type, and 4% (one of 28) in those with EGFR mutations. Although both EGFR groups were below the target ORR of 20%, among the three patients with an ALK gene rearrangement, two had partial responses and the third had prolonged stable disease (7.2 months, 24% reduction in tumor size). The most common adverse events included grades 1 and 2 fatigue, nausea, and diarrhea. Grade 3 or higher liver function abnormalities were observed in nine patients (11.8%). Conclusion IPI-504 has clinical activity in patients with NSCLC, particularly among patients with ALK rearrangements. J Clin Oncol 28:4953-4960. (c) 2010 by American Society of Clinical Oncology C1 [Sequist, Lecia V.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Infin Pharmaceut Inc, Cambridge, MA USA. Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA. Yale Univ, Sch Med, New Haven, CT USA. Yale Canc Ctr, New Haven, CT USA. Mary Crowley Canc Res Ctr, Dallas, TX USA. Univ Washington, Seattle, WA 98195 USA. Mt Sinai Canc Ctr, Miami Beach, FL USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Sequist, LV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, 55 Fruit St,POB 212, Boston, MA 02114 USA. EM LVSequist@partners.org FU Infinity Pharmaceuticals Inc. FX Supported by Infinity Pharmaceuticals Inc. NR 31 TC 192 Z9 197 U1 4 U2 13 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2010 VL 28 IS 33 BP 4953 EP 4960 DI 10.1200/JCO.2010.30.8338 PG 8 WC Oncology SC Oncology GA 681WC UT WOS:000284353000025 PM 20940188 ER PT J AU Shusterman, S London, WB Gillies, SD Hank, JA Voss, SD Seeger, RC Reynolds, CP Kimball, J Albertini, MR Wagner, B Gan, J Eickhoff, J DeSantes, KB Cohn, SL Hecht, T Gadbaw, B Reisfeld, RA Maris, JM Sondel, PM AF Shusterman, Suzanne London, Wendy B. Gillies, Stephen D. Hank, Jacquelyn A. Voss, Stephan D. Seeger, Robert C. Reynolds, C. Patrick Kimball, Jennifer Albertini, Mark R. Wagner, Barrett Gan, Jacek Eickhoff, Jens DeSantes, Kenneth B. Cohn, Susan L. Hecht, Toby Gadbaw, Brian Reisfeld, Ralph A. Maris, John M. Sondel, Paul M. TI Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID COLONY-STIMULATING FACTOR; TARGETED INTERLEUKIN-2 THERAPY; MONOCLONAL-ANTIBODY CH14.18; BONE-MARROW-TRANSPLANTATION; HIGH-RISK NEUROBLASTOMA; STAGE-IV NEUROBLASTOMA; PLUS INTERLEUKIN-2; CANCER GROUP; REFRACTORY NEUROBLASTOMA; CELLULAR CYTOTOXICITY AB Purpose The hu14.18-IL2 fusion protein consists of interleukin-2 molecularly linked to a humanized monoclonal antibody that recognizes the GD2 disialoganglioside expressed on neuroblastoma cells. This phase II study assessed the antitumor activity of hu14.18-IL2 in two strata of patients with recurrent or refractory neuroblastoma. Patients and Methods Hu14.18-IL2 was given intravenously (12 mg/m(2)/daily) for 3 days every 4 weeks for patients with disease measurable by standard radiographic criteria (stratum 1) and for patients with disease evaluable only by [(123)I] metaiodobenzylguanidine (MIBG) scintigraphy and/or bone marrow (BM) histology (stratum 2). Response was established by independent radiology review as well as BM histology and immunocytology, and durability was assessed by repeat evaluation after more than 3 weeks. Results Thirty-nine patients were enrolled (36 evaluable). No responses were seen in stratum 1 (n = 13). Of 23 evaluable patients in stratum 2, five patients (21.7%) responded; all had a complete response (CR) of 9, 13, 20, 30, and 35+ months duration. Grade 3 and 4 nonhematologic toxicities included capillary leak, hypoxia, pain, rash, allergic reaction, elevated transaminases, and hyper-bilirubinemia. Two patients required dopamine for hypotension, and one patient required ventilatory support for hypoxia. Most toxicities were reversible within a few days of completing a treatment course and were expected based on phase I results. Conclusion Patients with disease evaluable only by MIBG and/or BM histology had a 21.7% CR rate to hu14.8-IL2, whereas patients with bulky disease did not respond. Hu14.18-IL2 warrants further testing in children with nonbulky high-risk neuroblastoma. J Clin Oncol 28:4969-4975. (C) 2010 by American Society of Clinical Oncology C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp Boston, Boston, FL USA. Childrens Oncol Grp Stat & Data Ctr, Gainesville, FL USA. Provenance Biopharmaceut, Waltham, MA USA. Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. Scripps Res Inst, La Jolla, CA USA. Univ Texas, Lubbock, TX USA. Univ Chicago, Chicago, IL 60637 USA. NCI, Biol Resources Branch, Frederick, MD 21701 USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. RP Sondel, PM (reprint author), UW Madison, Wisconsin Inst Med Res, Dept Pediat, MACC Fund Childhood Canc Res Wing 4159, 1111 Highland Ave, Madison, WI 53792 USA. EM pmsondel@humonc.wisc.edu OI Reynolds, C. Patrick/0000-0002-2827-8536; Cohn, Susan/0000-0001-5749-7650 FU National Institutes of Health (NIH)/National Cancer Institute (NCI) [U10CA98543, U10 CA98413, R01-CA-32685-25, CA87025, CA81403, RR03186]; Midwest Athletes for Childhood Cancer Fund; Crawdaddy Foundation; Evan Dunbar Foundation; EMD Pharmaceuticals FX Supported by National Institutes of Health (NIH)/National Cancer Institute (NCI) Grant No. U10CA98543 (Children's Oncology Group [COG] Group Chair), NIH/NCI Grant No. U10 CA98413 (COG Statistics and Data Center), and NIH/NCI Grants No. R01-CA-32685-25, CA87025, CA81403, and RR03186, and grants from the Midwest Athletes for Childhood Cancer Fund, the Crawdaddy Foundation, and The Evan Dunbar Foundation. Hu14.18-IL2 (EMD 273063) was produced through a Material Cooperative Research and Development Agreement between the NCI and Merck KGaA.; Mark R. Albertini, EMD Pharmaceuticals NR 43 TC 83 Z9 86 U1 0 U2 11 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2010 VL 28 IS 33 BP 4969 EP 4975 DI 10.1200/JCO.2009.27.8861 PG 7 WC Oncology SC Oncology GA 681WC UT WOS:000284353000027 PM 20921469 ER PT J AU Dimopoulos, MA Terpos, E Chanan-Khan, A Leung, N Ludwig, H Jagannath, S Niesvizky, R Giralt, S Fermand, JP Blade, J Comenzo, RL Sezer, O Palumbo, A Harousseau, JL Richardson, PG Barlogie, B Anderson, KC Sonneveld, P Tosi, P Cavo, M Rajkumar, SV Durie, BGM San Miguel, J AF Dimopoulos, Meletios A. Terpos, Evangelos Chanan-Khan, Asher Leung, Nelson Ludwig, Heinz Jagannath, Sundar Niesvizky, Ruben Giralt, Sergio Fermand, Jean-Paul Blade, Joan Comenzo, Raymond L. Sezer, Orhan Palumbo, Antonio Harousseau, Jean-Luc Richardson, Paul G. Barlogie, Bart Anderson, Kenneth C. Sonneveld, Pieter Tosi, Patrizia Cavo, Michele Rajkumar, S. Vincent Durie, Brian G. M. San Miguel, Jesus TI Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Review ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; PROTEASOME INHIBITOR BORTEZOMIB; DOXORUBICIN-DEXAMETHASONE BDD; PROXIMAL TUBULE CELLS; NF-KAPPA-B; CYSTATIN-C; PRESENTING FEATURES; PROGNOSTIC FACTORS; IMPROVED SURVIVAL AB Renal impairment is a common complication of multiple myeloma (MM). The estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula is the recommended method for the assessment of renal function in patients with MM with stabilized serum creatinine. In acute renal injury, the RIFLE (risk, injury, failure, loss and end-stage kidney disease) and Acute Renal Injury Network criteria seem to be appropriate to define the severity of renal impairment. Novel criteria based on eGFR measurements are recommended for the definition of the reversibility of renal impairment. Rapid intervention to reverse renal dysfunction is critical for the management of these patients, especially for those with light chain cast nephropathy. Bortezomib with high-dose dexamethasone is considered as the treatment of choice for such patients. There is limited experience with thalidomide in patients with myeloma with renal impairment. Thus, thalidomide can be carefully administered, mainly in the context of well-designed clinical trials, to evaluate if it can improve the rapidity and probability of response that is produced by the combination with bortezomib and high-dose dexamethasone. Lenalidomide is effective in this setting and can reverse renal insufficiency in a significant subset of patients, when it is given at reduced doses, according to renal function. The role of plasma exchange in patients with suspected light chain cast nephropathy and renal impairment is controversial. High-dose melphalan (140 mg/m(2)) and autologous stem-cell transplantation should be limited to younger patients with chemosensitive disease. J Clin Oncol 28:4976-4984. (C) 2010 by American Society of Clinical Oncology C1 [Dimopoulos, Meletios A.] Univ Athens, Sch Med, Athens 11528, Greece. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. St Vincent Catholic Med Ctr, New York, NY USA. Cornell Univ, Weill Med Coll, New York, NY 10021 USA. Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplantat Serv, New York, NY 10021 USA. Mayo Clin, Rochester, MN USA. Wilhelminenspital Stadt Wien, Vienna, Austria. Hop St Louis, Serv Immunohematol, F-75475 Paris, France. Hosp Clin Barcelona, Barcelona, Spain. Univ Hosp Salamanca, Salamanca, Spain. Tufts Med Sch, Boston, MA USA. Univ Med Ctr Hamburg, Hamburg, Germany. Univ Turin, Turin, Italy. Italian Cooperat Grp, Bologna, Italy. Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy. Inst Biol, Hematol Lab, Nantes, France. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Arkansas Med Sci, Myeloma Inst Res Therapy, Little Rock, AR 72205 USA. Erasmus MC, Rotterdam, Netherlands. Cedars Sinai Samuel Oschin Canc Ctr, Los Angeles, CA USA. RP Dimopoulos, MA (reprint author), Univ Athens, Sch Med, 80 Vas Sofias Ave, Athens 11528, Greece. EM mdimop@med.uoa.gr RI IBSAL, Secretaria/H-3719-2011; OI SAN MIGUEL, JESUS/0000-0002-9183-4857; CAVO, MICHELE/0000-0003-4514-3227; Rajkumar, S. Vincent/0000-0002-5862-1833; Leung, Nelson/0000-0002-5651-1411 FU Celgene, Millennium, Onyx; Janssen Cilag, Celgene; Celgene, Genzyme; Ortho-Biotech; Celgene, Ortho-Biotech FX Ruben Niesvizky, Celgene, Millennium, Onyx; Joan Blade , Janssen Cilag, Celgene; Raymond L. Comenzo, Celgene, Genzyme; Orhan Sezer, Ortho-Biotech; Pieter Sonneveld, Celgene, Ortho-Biotech NR 83 TC 168 Z9 180 U1 0 U2 12 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2010 VL 28 IS 33 BP 4976 EP 4984 DI 10.1200/JCO.2010.30.8791 PG 9 WC Oncology SC Oncology GA 681WC UT WOS:000284353000028 PM 20956629 ER PT J AU Pappo, AS Krailo, M Chen, ZJ Rodriguez-Galindo, C Reaman, G AF Pappo, Alberto S. Krailo, Mark Chen, Zhengjia Rodriguez-Galindo, Carlos Reaman, Gregory TI Infrequent Tumor Initiative of the Children's Oncology Group: Initial Lessons Learned and Their Impact on Future Plans SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID PLEUROPULMONARY BLASTOMA; YOUNG-ADULTS; CLINICAL-TRIALS; TREP PROJECT; RARE TUMORS; ADOLESCENTS; CANCER; EPIDEMIOLOGY; CHILDHOOD; DIAGNOSIS AB The merger of the Pediatric Oncology Group, Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, and the National Wilms Tumor Study Group in 2000 offered the newly formed Children's Oncology Group ( COG), an opportunity to study rare cancers that had not been the subject of organized evaluation within the context of a cooperative group. In 2002, the COG formed the rare tumor committee which is comprised of four subcommittees. This article details the experience of the infrequent tumor subcommittee for the period of 2002 to 2007. During the initial implementation of this strategy, we have observed low rates of registration within the COG registry and low levels of participation in open banking, biology, and first-line therapeutic studies. This initial experience has allowed us to develop alternative strategies to increase registration rates and clinical trial enrollments. It is hoped that these new plans will allow us to increase our ability to better understand the biology and improve the treatment outcome of young patients with infrequent cancers. Furthermore, our initial experience has demonstrated to us the potential power of expanded cooperation and collaboration at a global level. J Clin Oncol 28:5011-5016. (C) 2010 by American Society of Clinical Oncology C1 [Pappo, Alberto S.] St Jude Childrens Hosp, Memphis, TN 38105 USA. Childrens Oncol Grp Arcadia, Arcadia, CA USA. Childrens Hlth Care Atlanta, Atlanta, GA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Oncol Grp, Bethesda, MD USA. RP Pappo, AS (reprint author), St Jude Childrens Hosp, 262 Danny Thomas Pl, Memphis, TN 38105 USA. EM alberto.pappo@stjude.org FU Children's Oncology Group [U10 CA98543, CA-098543] FX Supported in part by Chair's Grant No. U10 CA98543 of the Children's Oncology Group CA-098543. NR 21 TC 21 Z9 21 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2010 VL 28 IS 33 BP 5011 EP 5016 DI 10.1200/JCO.2010.31.2603 PG 6 WC Oncology SC Oncology GA 681WC UT WOS:000284353000031 PM 20956621 ER PT J AU Jankowska, A Ko, M Huang, Y Pape, UJ Szpurka, H Tahiliani, M Bandukwala, HS An, J Lamperti, ED Koh, KP Liu, XS Aravind, L Agarwal, S Rao, A Maciejewski, JP AF Jankowska, Anna Ko, Myunggon Huang, Yun Pape, Utz J. Szpurka, Hadrian Tahiliani, Mamta Bandukwala, Hozefa S. An, Jungeun Lamperti, Edward D. Koh, Kian Peng Liu, X. Shirley Aravind, L. Agarwal, Suneet Rao, Anjana Maciejewski, Jaroslaw P. TI Impaired Hydroxilation of 5-Methylcytosine In TET2 mutated Patients with Myeloid Malignancies SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jankowska, Anna; Szpurka, Hadrian; Maciejewski, Jaroslaw P.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Ko, Myunggon; Huang, Yun; Tahiliani, Mamta; Bandukwala, Hozefa S.; An, Jungeun; Lamperti, Edward D.; Koh, Kian Peng; Rao, Anjana] Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, Boston, MA 02115 USA. [Ko, Myunggon; Huang, Yun; Tahiliani, Mamta; Bandukwala, Hozefa S.; An, Jungeun; Lamperti, Edward D.; Koh, Kian Peng; Rao, Anjana] Program Cellular & Mol Med, Boston, MA USA. [Pape, Utz J.; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Pape, Utz J.; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Aravind, L.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA. [Agarwal, Suneet] Childrens Hosp, Div Pediat Hematol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 3 EP 3 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200002 ER PT J AU Yodai, A Tsai, A Lieber, M Weinstock, DM AF Yodai, Akinori Tsai, Albert Lieber, Michael Weinstock, David M. TI Differences In the Mechanism of CRLF2 Rearrangement In Precursor B-Cell Acute Lymphoblastic Leukemia Based on Extrasomy (21) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Yodai, Akinori; Weinstock, David M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tsai, Albert; Lieber, Michael] Univ So Calif, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 17 EP 17 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200028 ER PT J AU McCarthy, PL Owzar, K Anderson, KC Hofmeister, CC Hurd, DD Hassoun, H Giralt, S Stadtmauer, EA Richardson, PG Weisdorf, DJ Vij, R Moreb, JS Callander, NS Van Besien, K Gentile, T Isola, L Maziarz, RT Gabriel, DA Bashey, A Landau, H Martin, T Qazilbash, MH Levitan, D McClune, B Hars, V Postiglione, J Jiang, C Bennett, E Barry, SS Bressler, L Kelly, M Sexton, M Rosenbaum, C Parameswaran, H Pasquini, MC Horowitz, MM Shea, TC Devine, SM Linker, C AF McCarthy, Philip L. Owzar, Kouros Anderson, Kenneth C. Hofmeister, Craig C. Hurd, David Duane Hassoun, Hani Giralt, Sergio Stadtmauer, Edward A. Richardson, Paul G. Weisdorf, Daniel J. Vij, Ravi Moreb, Jan S. Callander, Natalie Scott Van Besien, Koen Gentile, Teresa Isola, Luis Maziarz, Richard T. Gabriel, Don A. Bashey, Asad Landau, Heather Martin, Thomas Qazilbash, Muzaffar H. Levitan, Denise McClune, Brian Hars, Vera Postiglione, John Jiang, Chen Bennett, Elizabeth Barry, Susan S. Bressler, Linda Kelly, Michael Sexton, Michele Rosenbaum, Cara Parameswaran, Hari Pasquini, Marcelo C. Horowitz, Mary M. Shea, Thomas C. Devine, Steven M. Linker, Charles TI Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [McCarthy, Philip L.] Roswell Pk Canc Inst, BMT Program, Buffalo, NY 14263 USA. [Owzar, Kouros; Hars, Vera; Postiglione, John; Jiang, Chen; Bennett, Elizabeth; Barry, Susan S.] Duke Univ, CALGB Stat Ctr, Durham, NC USA. [Anderson, Kenneth C.; Richardson, Paul G.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Hofmeister, Craig C.; Devine, Steven M.] Ohio State Univ, Med Ctr, Div Haematol, Columbus, OH 43210 USA. [Hurd, David Duane; Levitan, Denise] Wake Forest Univ, Winston Salem, NC 27109 USA. [Hassoun, Hani; Giralt, Sergio; Landau, Heather] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Stadtmauer, Edward A.] Univ Penn, Abramson Canc Ctr, Myeloma Program, Philadelphia, PA USA. [Weisdorf, Daniel J.; McClune, Brian] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Vij, Ravi] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Moreb, Jan S.] Univ Florida, Bone Marrow Transplant Program, Gainesville, FL USA. [Callander, Natalie Scott] Univ Wisconsin, Dept Hematol, Madison, WI USA. [Van Besien, Koen] Univ Chicago Hosp, Chicago, IL 60637 USA. [Gentile, Teresa] SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA. [Isola, Luis] Mt Sinai Med Ctr, New York, NY 10029 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Gabriel, Don A.; Shea, Thomas C.] Univ N Carolina, Chapel Hill, NC USA. [Bashey, Asad] BMT Grp Georgia, Atlanta, GA USA. [Martin, Thomas; Linker, Charles] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Qazilbash, Muzaffar H.] UT MD Anderson Canc Ctr, SCT CT Unit 423, Houston, TX USA. [Bressler, Linda; Kelly, Michael; Sexton, Michele] CALGB Univ Chicago, Chicago, IL USA. [Rosenbaum, Cara] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Parameswaran, Hari; Pasquini, Marcelo C.; Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. RI van Besien, Koen/G-4221-2012 OI van Besien, Koen/0000-0002-8164-6211 NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 21 EP 22 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200038 ER PT J AU Krishnan, A Pasquini, MC Ewell, M Stadtmauer, EA Alyea, EP Antin, JH Comenzo, RL Goodman, S Hari, P Negrin, R Qazilbash, MH Rowley, SD Sahebi, F Somlo, G Vesole, DH Vogl, DT Weisdorf, DJ Geller, N Horowitz, MM Giralt, S Maloney, DG AF Krishnan, Amrita Pasquini, Marcelo C. Ewell, Marian Stadtmauer, Edward A. Alyea, Edwin P., III Antin, Joseph H. Comenzo, Raymond L. Goodman, Stacey Hari, Parameswaran Negrin, Robert Qazilbash, Muzaffar H. Rowley, Scott D. Sahebi, Firoozeh Somlo, George Vesole, David H. Vogl, Dan T. Weisdorf, Daniel J. Geller, Nancy Horowitz, Mary M. Giralt, Sergio Maloney, David G. TI Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Krishnan, Amrita] City Hope Natl Med Ctr, Hematol & Stem Cell Transplantat, Duarte, CA USA. [Hari, Parameswaran] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Ewell, Marian] EMMES Corp, Rockville, MD USA. [Stadtmauer, Edward A.] Univ Penn, Myeloma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Comenzo, Raymond L.] Tufts Med Ctr, Boston, MA USA. [Goodman, Stacey; Horowitz, Mary M.] Vanderbilt Univ, Nashville, TN USA. [Negrin, Robert] Stanford Univ, Stanford, CA 94305 USA. [Qazilbash, Muzaffar H.] UT MD Anderson Canc Ctr, SCT CT Unit 423, Houston, TX USA. [Rowley, Scott D.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Div Blood & Marrow Transplantat, Hackensack, NJ USA. [Sahebi, Firoozeh] City Hope Natl Med Ctr, Kaiser Permanente Med Grp, Duarte, CA 91010 USA. [Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Geller, Nancy] NHLBI, Bethesda, MD 20892 USA. [Giralt, Sergio] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Maloney, David G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Maloney, David G.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 24 EP 25 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200042 ER PT J AU Furman, RR Byrd, JC Brown, JR Coutre, SE Benson, DM Wagner-Johnston, ND Flinn, IW Kahl, BS Spurgeon, SE Lannutti, B Giese, NA Webb, HK Ulrich, RG Peterman, S Holes, LM Yu, AS AF Furman, Richard R. Byrd, John C. Brown, Jennifer R. Coutre, Steven E. Benson, Don M., Jr. Wagner-Johnston, Nina D. Flinn, Ian W. Kahl, Brad S. Spurgeon, Stephen E. Lannutti, Brian Giese, Neil A. Webb, Heather K. Ulrich, Roger G. Peterman, Sissy Holes, Leanne M. Yu, Albert S. TI CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 delta, Demonstrates Clinical Activity and Pharmacodynamic Effects In patients with Relapsed or Refractory Chronic Lymphocytic Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Furman, Richard R.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Benson, Don M., Jr.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Coutre, Steven E.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Wagner-Johnston, Nina D.] Washington Univ, St Louis, MO USA. [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA. [Kahl, Brad S.] Univ Wisconsin, Madison, WI USA. [Spurgeon, Stephen E.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Webb, Heather K.] Calistoga Pharmaceut, Drug Safety, Seattle, WA USA. [Peterman, Sissy] Calistoga Pharmaceut, Clin, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 31 EP 31 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200056 ER PT J AU Lanasa, MC Andritsos, L Brown, JR Gabrilove, J Caligaris-Cappio, F Larson, R Kipps, TJ Leblond, V Milligan, D Janssens, A Heerema, NA Stilgenbauer, S Byrd, JC Grever, MR AF Lanasa, Mark C. Andritsos, Leslie Brown, Jennifer R. Gabrilove, Janice Caligaris-Cappio, Federico Larson, Richard Kipps, Thomas J. Leblond, Veronique Milligan, Donald Janssens, Ann Heerema, Nyla A. Stilgenbauer, Stephan Byrd, John C. Grever, Michael R. TI Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Lanasa, Mark C.] Duke Univ, Med Ctr, Durham, NC USA. [Andritsos, Leslie; Heerema, Nyla A.; Byrd, John C.; Grever, Michael R.] Ohio State Univ, Columbus, OH 43210 USA. [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gabrilove, Janice] Mt Sinai Sch Med, New York, NY USA. [Caligaris-Cappio, Federico] Univ Vita Salute San Raffaele, Milan, Italy. [Larson, Richard] Univ Chicago, Chicago, IL 60637 USA. [Kipps, Thomas J.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Leblond, Veronique] Hop La Pitie Salpetriere, Paris, France. [Milligan, Donald] Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England. [Janssens, Ann] Katholieke Univ Leuven Hosp, Louvain, Belgium. [Stilgenbauer, Stephan] Univ Ulm, Ulm, Germany. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 32 EP 33 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200059 ER PT J AU James, DF Brown, JR Werner, L Castro, JE Rai, KR Wierda, WG Greaves, A Rassenti, LZ Neuberg, D Kipps, TJ AF James, Danelle F. Brown, Jennifer R. Werner, Lillian Castro, Januario E. Rai, Kanti R. Wierda, William G. Greaves, Andrew Rassenti, Laura Z. Neuberg, Donna Kipps, Thomas J. TI Phenotypic Changes Associated with Acute Reductions In Leukemia Cell Counts In Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Lenalidomide as Initial Therapy SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kipps, Thomas J.] Univ Calif San Diego, UCSD Moores Canc Ctr, Moores Canc Ctr, La Jolla, CA 92093 USA. [Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Castro, Januario E.] UCSD, Ctr Canc, La Jolla, CA USA. [Rai, Kanti R.] N Shore Univ Hosp, N Shore LIJ Hlth Syst, Dept Med, Manhasset, NY USA. [Wierda, William G.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 33 EP 33 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200060 ER PT J AU Bernt, KM Zhu, N Faber, J Punt, N Pollock, RM Richon, VM Kung, AL Armstrong, S AF Bernt, Kathrin M. Zhu, Nan Faber, Joerg Punt, Natalie Pollock, Roy M. Richon, Victoria M. Kung, Andrew L. Armstrong, Scott TI Demonstration of a Role for Dot1l In MLL-Rearranged Leukemia Using a Conditional Loss of Function Model SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Bernt, Kathrin M.; Zhu, Nan; Punt, Natalie] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Armstrong, Scott] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Faber, Joerg] Johannes Gutenberg Univ Mainz, Childrens Hosp, D-6500 Mainz, Germany. [Pollock, Roy M.; Richon, Victoria M.] Epizyme Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 34 EP 34 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200063 ER PT J AU Neff, TA Heidel, FH Armstrong, S AF Neff, Tobias A. Heidel, Florian H. Armstrong, Scott TI Bmi-1 Is Dispensable for the Development of Acute Myeloid Leukemia Mediated by MLL-AF9 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Armstrong, Scott] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 34 EP 35 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200064 ER PT J AU Kuter, DJ Bussel, JB Newland, A Wasser, JS Lyons, RM George, JN Macik, G Nie, K Jun, S AF Kuter, David J. Bussel, James B. Newland, Adrian Wasser, Jeffrey S. Lyons, Roger M. George, James N. Macik, Gail Nie, Kun Jun, Susie TI Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bussel, James B.] New York Presbyterian Hosp, Dept Pediat, New York, NY USA. [Bussel, James B.] New York Presbyterian Hosp, Dept Med, Div Hematol, New York, NY USA. [Newland, Adrian] Royal London Hosp, Dept Hematol, London E1 1BB, England. [Wasser, Jeffrey S.] Manchester Mem Hosp, Manchester, CT USA. [Lyons, Roger M.] Canc Care Ctr S Texas US Oncol, San Antonio, TX USA. [George, James N.] OUHSC, Hematol Oncol Sect, Oklahoma City, OK USA. [Macik, Gail] Univ Virginia, Charlottesville, VA USA. [Nie, Kun; Jun, Susie] Amgen Inc, Thousand Oaks, CA 91320 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 36 EP 37 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200069 ER PT J AU Bussel, JB Zhang, J Tang, SD McIntosh, J Kater, DJ AF Bussel, James B. Zhang, Jenny Tang, Shande McIntosh, Joe Kater, David J. TI A Randomized, Double-Blind, Placebo-Controlled Phase II Trial on the Efficacy, Safety and Tolerability of E5501 (AKR501) In Subjects with Chronic Immune Thrombocytopenia (ITP) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Bussel, James B.] New York Presbyterian Hosp, Dept Pediat, New York, NY USA. [Bussel, James B.] New York Presbyterian Hosp, Dept Med, Div Hematol, New York, NY USA. [Zhang, Jenny; Tang, Shande; McIntosh, Joe] Eisai Corp N Amer, Woodcliff Lake, NJ USA. [Kater, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 38 EP 38 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200072 ER PT J AU Abou-Nassar, KE Vanderplas, A Friedberg, JW Abel, G Niland, J Rodriguez, MA Czuczman, MS Millenson, M Crosby, A Gordon, LI Zelenetz, AD LaCasce, A AF Abou-Nassar, Karim E. Vanderplas, Ann Friedberg, Jonathan W. Abel, Gregory Niland, Joyce Rodriguez, Maria A. Czuczman, Myron S. Millenson, Michael Crosby, Allison Gordon, Leo I. Zelenetz, Andrew D. LaCasce, Ann TI Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Abou-Nassar, Karim E.; Abel, Gregory; Crosby, Allison; LaCasce, Ann] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Niland, Joyce] City Hope Natl Med Ctr, Data Coordinating Ctr, Duarte, CA 91010 USA. [Friedberg, Jonathan W.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Rodriguez, Maria A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Millenson, Michael] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 42 EP 42 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200082 ER PT J AU Heidel, FH Neff, TA Feng, ZH Armstrong, SA AF Heidel, Florian H. Neff, Tobias A. Feng, Zhaohui Armstrong, Scott A. TI beta-Catenin Suppression Targets Imatinib Resistant Leukemia Stem Cells In Mice with BCR-ABL Induced Myeloproliferative Disease SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Armstrong, Scott A.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 47 EP 47 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200094 ER PT J AU Fulciniti, M Amin, SB Mohan, V Yang, G Nanjappa, P Tassone, PF Prabhala, RH Cheng, L Anderson, KC Treon, SP Munshi, NC AF Fulciniti, Mariateresa Amin, Samir B. Mohan, Varuna Yang, Guang Nanjappa, Puru Tassone, Pier-francesco Prabhala, Rao H. Cheng, Li Anderson, Kenneth C. Treon, Steven P. Munshi, Nikhil C. TI Targeting Sp1 Transactivation In Waldenstrom's Macroglobulinemia: a Novel Therapeutic Option SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Yang, Guang] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Tassone, Pier-francesco] Univ Catanzaro, Catanzaro, Italy. [Prabhala, Rao H.; Munshi, Nikhil C.] Va Boston Healthcare Syst, Dana Farber Canc Inst, W Roxbury, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 58 EP 59 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200121 ER PT J AU Bagby, GC Yates, J Anur, P Rathbuin, K Harrington, C Pasquini, R Pelz, C AF Bagby, Grover C., Jr. Yates, Jane Anur, Praveen Rathbuin, Keaney Harrington, Christina Pasquini, Ricardo Pelz, Carl TI Clonal Evolution In Fanconi Anemia; The Role of HOXA9 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Pelz, Carl] Oregon Hlth & Sci Univ, Mol & Med Genet & Stem Cell Ctr, Portland, OR 97201 USA. [Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR USA. [Yates, Jane; Rathbuin, Keaney] NW VA Canc Res Ctr, Portland, OR USA. [Harrington, Christina] Gene Microarray Shared Resource, Portland, OR USA. [Pasquini, Ricardo] Univ Fed Parana, Hosp Clin, BR-80060000 Curitiba, Parana, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 61 EP 61 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200127 ER PT J AU D'Souza, S Kurihara, N Shiozawa, Y Taichman, R Galson, D Roodman, D AF D'Souza, Sonia Kurihara, Noriyoshi Shiozawa, Yusuke Taichman, Russell Galson, Deborah Roodman, David TI Annexin II Interactions with the Annexin II Receptor Enhance Multiple Myeloma Cell Adhesion and Growth In the Bone Marrow Microenvironment SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [D'Souza, Sonia; Kurihara, Noriyoshi; Galson, Deborah; Roodman, David] Univ Pittsburgh, Bone Biol Ctr, UPMC, Pittsburgh, PA USA. [D'Souza, Sonia; Kurihara, Noriyoshi; Galson, Deborah; Roodman, David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Shiozawa, Yusuke; Taichman, Russell] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 62 EP 62 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200131 ER PT J AU Teramachi, J Windle, JJ Roodman, D Kurihara, N AF Teramachi, Jumpei Windle, Jolene J. Roodman, David Kurihara, Noriyoshi TI The ZZ Domain of Sequestosome-1/p62 Plays An Important Role In Stromal Cell Support of Myeloma Cell Growth and Osteoclast Formation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Teramachi, Jumpei; Roodman, David; Kurihara, Noriyoshi] Univ Pittsburgh, Pittsburgh, PA USA. [Teramachi, Jumpei; Roodman, David; Kurihara, Noriyoshi] UPMC, Ctr Bone Biol, Pittsburgh, PA USA. [Windle, Jolene J.] Virginia Commonwealth Univ, Richmond, VA USA. [Roodman, David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 62 EP 62 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200129 ER PT J AU Zhou, YS Liu, X Xu, L Hunter, Z Sun, J Yang, G Ciccarelli, B Patterson, C AF Zhou, Yandsheng Liu, Xia Xu, Lian Hunter, Zachary Sun, Jenny Yang, Guang Ciccarelli, Bryan Patterson, Christopher TI Involvement of Ets Factor Spi-B and Id2 In Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Zhou, Yandsheng; Liu, Xia; Xu, Lian; Sun, Jenny; Yang, Guang; Patterson, Christopher] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Hunter, Zachary] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ciccarelli, Bryan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 62 EP 62 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200130 ER PT J AU Fulciniti, M Amin, SB Nanjappa, P Rodig, SJ Hideshima, T Pal, J Mohan, V Lee, K Shammas, M Minvielle, S Prabhala, R Avet-Loiseau, H Cheng, L Anderson, KC Munshi, NC AF Fulciniti, Mariateresa Amin, Samir B. Nanjappa, Puru Rodig, Scott J. Hideshima, Teru Pal, Jagannath Mohan, Varuna Lee, Keeyun Shammas, Masood Minvielle, Stephane Prabhala, Rao Avet-Loiseau, Herve Cheng, Li Anderson, Kenneth C. Munshi, Nikhil C. TI Biology and Therapeutic Targeting of Sp1 Transactivation In Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Fulciniti, Mariateresa; Amin, Samir B.; Nanjappa, Puru; Hideshima, Teru; Pal, Jagannath; Mohan, Varuna; Lee, Keeyun; Shammas, Masood; Prabhala, Rao; Cheng, Li; Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rodig, Scott J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Pal, Jagannath; Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA. [Avet-Loiseau, Herve] Univ Hosp Nantes, Nantes, France. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA. RI Minvielle, Stephane/K-8251-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 64 EP 64 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200135 ER PT J AU Li, SR Pal, R Monaghan, S Schafer, P Ouyang, H Mapara, MY Lentzsch, S AF Li, Shirong Pal, Rekha Monaghan, Sara Schafer, Peter Ouyang, Hongjiao Mapara, Markus Y. Lentzsch, Suzanne TI C/EBPb Is a Critical Mediator of Resistance to IMiD (R) Immunomodulatory Compounds and Affected by IMiD Compounds Via Control of Protein Translation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Li, Shirong; Pal, Rekha; Mapara, Markus Y.; Lentzsch, Suzanne] Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Pittsburgh, PA USA. [Monaghan, Sara] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA USA. [Schafer, Peter] Celgene Corp, Translat Dev, Summit, NJ USA. [Ouyang, Hongjiao] VA Pittsburgh Healthcare Syst, Ctr Bone Biol, Pittsburgh, PA USA. RI mapara, markus/A-2134-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 64 EP 65 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200136 ER PT J AU Maiso, P Azab, A Liu, Y Zhang, Y Azab, F Sacco, A Ngo, HT Liu, Y Morgan, B Rommel, C Anderson, KC Roccaro, AM Ghobrial, IM AF Maiso, Patricia Azab, AbdelKareem Liu, Yang Zhang, Yong Azab, Feda Sacco, Antonio Ngo, Hai T. Liu, Yi Morgan, Brittany Rommel, Christian Anderson, Kenneth C. Roccaro, Aldo M. Ghobrial, Irene M. TI Dual Targeting of-TORC1 and-TORC2 as a New Strategy In the Treatment of Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Maiso, Patricia; Azab, AbdelKareem; Liu, Yang; Zhang, Yong; Azab, Feda; Sacco, Antonio; Ngo, Hai T.; Morgan, Brittany; Anderson, Kenneth C.; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Liu, Yi; Rommel, Christian] Intellikine, La Jolla, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 64 EP 64 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200134 ER PT J AU Azab, F Azab, AKA Maiso, P Quang, P Zhang, Y Morgan, B Ghobrial, IM AF Azab, Feda Azab, Abdel Kareem A. Maiso, Patricia Quang, Phong Zhang, Yong Morgan, Brittany Ghobrial, Irene M. TI Eph-B2/Ephrin-B2 Interaction Plays a Major Role In the Adhesion and Survival of WM Cells In the Context of the Bone Marrow Microenvironment SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 67 EP 67 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200143 ER PT J AU Shah, DI Takahasi-Makise, N Schultz, I Pierce, EL Li, LT Vogin, G Brigham, BS Zhou, Y Brugnara, C Campanella, M Danial, N Ward, DM Kaplan, J Paw, BH AF Shah, Dhvanit I. Takahasi-Makise, Naoko Schultz, Iman Pierce, Eric L. Li, Liangtao Vogin, Guillaume Brigham, Benjamin S. Zhou, Yi Brugnara, Carlo Campanella, Michelangelo Danial, Nika Ward, Diane M. Kaplan, Jerry Paw, Barry H. TI atpif1 regulates Mitochondrial Heme Synthesis In Developing Erythroid Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Shah, Dhvanit I.; Schultz, Iman; Pierce, Eric L.; Vogin, Guillaume; Brigham, Benjamin S.; Paw, Barry H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA 02115 USA. [Takahasi-Makise, Naoko; Li, Liangtao; Ward, Diane M.; Kaplan, Jerry] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA. [Zhou, Yi; Brugnara, Carlo] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Campanella, Michelangelo] Univ London Royal Vet Coll, London, England. [Danial, Nika] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 74 EP 75 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200164 ER PT J AU Adamia, S Avet-Loiseau, H Lode, L Bar-Natan, M Verselis, S Fox, E Galinsky, I Moreau, P Stone, R Griffin, JD AF Adamia, Sophia Avet-Loiseau, Herve Lode, Laurence Bar-Natan, Michal Verselis, Sigitas Fox, Edward Galinsky, Ilene Moreau, Philippe Stone, Richard Griffin, James D. TI Identification of Potential Therapeutic Targets Using Genome-Wide Analysis of Alternative Splicing (AS) In Patients with Acute Myeloid Leukemia (AML) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Verselis, Sigitas] Dana Farber Canc Inst, Mol Diagnost Lab, Boston, MA 02115 USA. [Adamia, Sophia; Bar-Natan, Michal] Harvard Univ, Sch Med, Boston, MA USA. [Moreau, Philippe] CHU Nantes, Dept Hematol, F-44035 Nantes 01, France. [Lode, Laurence] Hop Nantes, Nantes, France. [Galinsky, Ilene] Dana Farber Canc Inst, Adult Leukemia Program, Boston, MA 02115 USA. RI richard, chrystelle/K-8595-2015 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 81 EP 81 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200178 ER PT J AU Virgilio, M Payne, E Narla, A Sun, H Paw, B Look, AT Ebert, BL Berliner, N Khanna-Gupta, A AF Virgilio, Maria Payne, Elspeth Narla, Anupama Sun, Hong Paw, Barry Look, A. Thomas Ebert, Benjamin L. Berliner, Nancy Khanna-Gupta, Arati TI Treatment of Zebrafish Models of Ribosomopathies (Diamond Blackfan Anemia (DBA) and 5q-Syndrome) with L-Leucine Results In An Improvement of Anemia and Developmental Defects: Evidence for a Common Pathway? SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Payne, Elspeth; Narla, Anupama; Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. [Paw, Barry] Harvard Univ, Brigham & Womens Hosp, Div Hematol, Dept Med,Med Sch, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 89 EP 90 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200196 ER PT J AU Mueller, L Milsom, MD Brumme, K Harris, C Parmar, K Zhu, K Wendy, L Strait, K D'Andrea, AD Daley, GQ Williams, DA AF Mueller, Lars Milsom, Michael D. Brumme, Kristina Harris, Chad Parmar, Kalindi Zhu, Kaya Wendy, London Strait, Kelly D'Andrea, Alan D. Daley, George Q. Williams, David A. TI Mechanisms of Resistance to Reprogramming of Cells Defective In the Fanconi Anemia DNA Repair Pathway SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Mueller, Lars; Brumme, Kristina; Harris, Chad; Wendy, London; Strait, Kelly] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Parmar, Kalindi] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [D'Andrea, Alan D.] Dana Farber Canc Inst, Dept Rad Onc, Boston, MA 02115 USA. [Daley, George Q.] Childrens Hosp, Harvard Stem Cell Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 90 EP 90 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200197 ER PT J AU Jacobsohn, DA Arora, M Klein, JP Antin, JH Bolwell, BJ Boyiadzis, M Cahn, JY Cairo, M Cutler, CS Flowers, MED Gale, RP Hassebroek, A Herzig, RH Horowitz, MM Isola, L Klumpp, TR Lee, SJ Petersdorf, EW Santarone, S Schouten, HC Spellman, S Urbano, A Weisdorf, DJ Wingard, JR Pavletic, SZ AF Jacobsohn, David A. Arora, Mukta Klein, John P. Antin, Joseph H. Bolwell, Brian J. Boyiadzis, Michael Cahn, Jean-Yves Cairo, Mitchell S. Cutler, Corey S. Flowers, Mary E. D. Gale, Robert P. Hassebroek, Anna Herzig, Roger H. Horowitz, Mary M. Isola, Luis Klumpp, Thomas R. Lee, Stephanie J. Petersdorf, Effie W. Santarone, Stella Schouten, Harry C. Spellman, Stephen Urbano, Alvaro Weisdorf, Daniel J. Wingard, John R. Pavletic, Steven Z. TI Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jacobsohn, David A.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Klein, John P.] Med Coll Wisconsin, Dept Biostat, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Antin, Joseph H.; Cutler, Corey S.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Bolwell, Brian J.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Boyiadzis, Michael] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Cahn, Jean-Yves] CHU Grenoble, F-38043 Grenoble, France. [Cairo, Mitchell S.] Columbia Univ, New York Presbyterian Morgan Stanley Childrens Ho, New York, NY USA. [Flowers, Mary E. D.] Univ Washington, Seattle, WA 98195 USA. [Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Gale, Robert P.] Celgene Corp, Summit, NJ USA. [Hassebroek, Anna] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Herzig, Roger H.] Univ Louisville, James Graham Brown Canc Ctr, BMT, Louisville, KY 40292 USA. [Isola, Luis] Mt Sinai Med Ctr, BMT, New York, NY 10029 USA. [Klumpp, Thomas R.] Temple Univ, Wynnewood, PA USA. [Santarone, Stella] Osped Civile, BMT Ctr, Pescara, Italy. [Schouten, Harry C.] Acad Ziekenhuis Maastricht, Maastricht, Netherlands. [Urbano, Alvaro] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain. [Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Wingard, John R.] Univ Florida, Shands Canc Ctr, Gainesville, FL USA. [Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 97 EP 98 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200212 ER PT J AU Cutler, C Sun, LX Kim, H Sarantepoulos, S Bindra, B Chen, YB Rosenblatt, J Armand, P Koreth, J Ho, VT Alyea, EP Soiffer, RJ Ritz, J Antin, JH AF Cutler, Corey Sun, Lixian Kim, Haesook Sarantepoulos, Stefanie Bindra, Bhavjot Chen, Yi-Bin Rosenblatt, Jacalyn Armand, Philippe Koreth, John Ho, Vincent T. Alyea, Edwin P., III Soiffer, Robert J. Ritz, Jerome Antin, Joseph H. TI Prophylactic Rituximab After Allogeneic Stem Cell Transplantation Prevents Steroid-Requiring Chronic Graft-Vs.Host Disease SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Cutler, Corey; Bindra, Bhavjot; Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Sarantepoulos, Stefanie] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Chen, Yi-Bin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rosenblatt, Jacalyn] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA. [Koreth, John] Dana Farber Canc Inst, Dept Hem Onc, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 99 EP 99 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200215 ER PT J AU Armenian, S Sun, CL Kawashima, T Arora, M Leisenring, W Sklar, CA Baker, KS Francisco, L Teh, JB Mills, G Wong, FL Rosenthal, J Diller, L Hudson, MM Oeffinger, KC Robison, LL Bhatia, S AF Armenian, Saro Sun, Can-Lan Kawashima, Toana Arora, Mukta Leisenring, Wendy Sklar, Charles A. Baker, K. Scott Francisco, Liton Teh, Jennifer Berano Mills, George, III Wong, F. Lennie Rosenthal, Joseph Diller, Lisa Hudson, Melissa M. Oeffinger, Kevin C. Robison, Leslie L. Bhatia, Smita TI Long-Term Outcomes In Survivors of Childhood Cancer Treated with Hematopoietic Cell Transplantation (HCT) Versus Conventional Therapy: a Report From the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Armenian, Saro; Sun, Can-Lan; Francisco, Liton; Teh, Jennifer Berano; Mills, George, III; Wong, F. Lennie; Rosenthal, Joseph; Bhatia, Smita] City Hope Natl Med Ctr, Duarte, CA USA. [Kawashima, Toana; Leisenring, Wendy; Baker, K. Scott] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Arora, Mukta] Univ Minnesota, Minneapolis, MN USA. [Sklar, Charles A.; Oeffinger, Kevin C.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Diller, Lisa] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hudson, Melissa M.; Robison, Leslie L.] St Jude Childrens Hosp, Memphis, TN 38105 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 100 EP 101 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200218 ER PT J AU Wooten, J Nazmim, BS Richards, K Sharf, A Antin, JH Soiffer, RJ Ritz, J Shea, TC Serody, J Baldwin, AS Sarantopoulos, S AF Wooten, Jenna Nazmim, Bhuiya S. Richards, Kristy Sharf, Andrew Antin, Joseph H. Soiffer, Robert J. Ritz, Jerome Shea, Thomas C. Serody, Jonathan Baldwin, Albert S., Jr. Sarantopoulos, Stefanie TI B Cells Are Primed for Survival by BAFF-Driven Bim Degradation In Chronic Graft Versus Host Disease (cGVHD) Patients SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Wooten, Jenna; Sarantopoulos, Stefanie] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Richards, Kristy] UNC, Div Heme Onc, Chapel Hill, NC USA. [Sharf, Andrew] Univ N Carolina, Bone Marrow Transplant Unit, Chapel Hill, NC USA. [Serody, Jonathan] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med Microbiol & Immunol, Chapel Hill, NC USA. [Baldwin, Albert S., Jr.] Univ N Carolina, Lineberger Canc Ctr, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 100 EP 100 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200217 ER PT J AU Arai, S Jagasia, M Arora, M Miklos, D Chai, XY Storer, B Martin, PJ Cutler, C Weisdorf, DJ Pidala, J Palmer, J Flowers, M Jacobsohn, D Carpenter, PA Pavletic, SZ Vogelsang, GB Lee, SJ AF Arai, Sally Jagasia, Madan Arora, Mukta Miklos, David Chai, Xiaoyu Storer, Barry Martin, Paul J. Cutler, Corey Weisdorf, Daniel J. Pidala, Joseph Palmer, Jeanne Flowers, Mary Jacobsohn, David Carpenter, Paul A. Pavletic, Steven Z. Vogelsang, Georgia B. Lee, Stephanie J. TI Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Miklos, David] Stanford Univ, Sch Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Jagasia, Madan] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Chai, Xiaoyu; Storer, Barry; Flowers, Mary; Carpenter, Paul A.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Storer, Barry; Flowers, Mary; Carpenter, Paul A.] Univ Washington, Seattle, WA 98195 USA. [Martin, Paul J.] FRED HUTCHINSON CNCR RES CT, Seattle, WA USA. [Cutler, Corey] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Pidala, Joseph] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Palmer, Jeanne] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Jacobsohn, David] Childrens Mem Hosp, Stem Cell Transplant Program, Chicago, IL 60614 USA. [Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD USA. [Vogelsang, Georgia B.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 102 EP 103 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200221 ER PT J AU Abou-Nassar, KE Kim, HT Antin, JH Ho, VT Soiffer, RJ Cutler, C Alyea, EP Koreth, J Armand, P AF Abou-Nassar, Karim E. Kim, Haesook T. Antin, Joseph H. Ho, Vincent T. Soiffer, Robert J. Cutler, Corey Alyea, Edwin P., III Koreth, John Armand, Philippe TI The Impact of Geographic Proximity to Transplant Center on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Abou-Nassar, Karim E.; Antin, Joseph H.; Ho, Vincent T.; Soiffer, Robert J.; Cutler, Corey; Alyea, Edwin P., III; Koreth, John; Armand, Philippe] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 103 EP 104 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200223 ER PT J AU Ballen, KK Klein, JP Pedersen, TL Kurtzberg, J Lazarus, HM LeMaistre, CF Mehta, P Palmer, J Setterholm, M Wingard, JR Joffe, S Parsons, SK Switzer, GE Lee, SJ Rizzo, JD Majhail, NS AF Ballen, Karen K. Klein, John P. Pedersen, Tanya L. Kurtzberg, Joanne Lazarus, Hillard M. LeMaistre, Charles F. Mehta, Paulette Palmer, Jeanne Setterholm, Michelle Wingard, John R. Joffe, Steven Parsons, Susan K. Switzer, Galen E. Lee, Stephanie J. Rizzo, J. Douglas Majhail, Navneet S. CA Hlth Policy Working Comm CIBMTR TI Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Klein, John P.; Rizzo, J. Douglas] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Pedersen, Tanya L.] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Kurtzberg, Joanne] Duke Univ, Med Ctr, Durham, NC USA. [Lazarus, Hillard M.] Univ Hosp, Case Med Ctr, Cleveland, OH USA. [LeMaistre, Charles F.] Texas Transplant Inst, San Antonio, TX USA. [Mehta, Paulette] John L McClellan Mem Vet Adm Med Ctr, Little Rock, AR USA. [Palmer, Jeanne] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Setterholm, Michelle] Natl Marrow Donor Program, Minneapolis, MN USA. [Wingard, John R.] Univ Florida, Shands Canc Ctr, Gainesville, FL USA. [Parsons, Susan K.] Tufts Med Ctr, Boston, MA USA. [Joffe, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA. [Switzer, Galen E.] UPMC Hillman Canc Ctr, Pittsburgh, PA USA. [Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Majhail, Navneet S.] Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 104 EP 105 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200225 ER PT J AU Biernacki, MA Okam, M Shenoy, S Krishnamurti, L Horwitz, ME Neuberg, D Antin, JH Wu, CJ AF Biernacki, Melinda A. Okam, Maureen Shenoy, Shalini Krishnamurti, Lakshmanan Horwitz, Mitchell E. Neuberg, Donna Antin, Joseph H. Wu, Catherine J. TI Long-Term Follow-up of Adults with Severe Sickle Cell Disease After Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Biernacki, Melinda A.] Brown Univ, Dept Med, Providence, RI 02912 USA. [Okam, Maureen] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Shenoy, Shalini] Washington Univ, Sch Med, St Louis, MO USA. [Krishnamurti, Lakshmanan] UPMC, Childrens Hosp Pittsburgh, Div Hematol Oncol BMT, Pittsburgh, PA USA. [Horwitz, Mitchell E.] Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 120 EP 120 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200262 ER PT J AU Freedman, AS Kuruvilla, J Assouline, SE Engert, A Heo, D Solal-Celigny, P Corradini, P Verhoef, G Fanale, MA Bendiske, J Ewald, B Dey, J Baeck, J Younes, A AF Freedman, Arnold S. Kuruvilla, John Assouline, Sarit E. Engert, Andreas Heo, DaeSeog Solal-Celigny, Philippe Corradini, Paolo Verhoef, Gregor Fanale, Michelle A. Bendiske, Jennifer Ewald, Brett Dey, Jyotirmoy Baeck, Johan Younes, Anas TI Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Freedman, Arnold S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kuruvilla, John] Univ Toronto, Princess Space Margaret Hosp, Toronto, PQ, Canada. [Assouline, Sarit E.] McGill Univ, Jewish Gen Hosp, Div Hematol, Montreal, PQ H3T 1E2, Canada. [Assouline, Sarit E.] McGill Univ, Jewish Gen Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada. [Engert, Andreas] Univ Hosp Cologne, German Hodgkin Study Grp GHSG, Dept Internal Med 1, Cologne, Germany. [Heo, DaeSeog] Seoul Natl Univ, Seoul, South Korea. [Solal-Celigny, Philippe] Clin Victor Hugo, Ctr Jean Bernard, Le Mans, France. [Corradini, Paolo] Univ Milan, Fdn IRCCS, Ist Nazl Tumori, Milan, Italy. [Verhoef, Gregor] Univ Hosp Gasthuisberg, B-3000 Leuven, Belgium. [Fanale, Michelle A.; Younes, Anas] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Bendiske, Jennifer; Ewald, Brett; Dey, Jyotirmoy; Baeck, Johan] Novartis Pharmaceut Inc, Florham Pk, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 129 EP 129 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200285 ER PT J AU Bejar, R Stevenson, K Abdel-Wahab, O Marie, M Lin, K McAuley, JR Cheung, K Galili, N Garcia-Manero, G Kantarjian, H Raza, A Levine, R Neuberg, D Ebert, BL AF Bejar, Rafael Stevenson, Kristen Abdel-Wahab, Omar Marie, McConkey Lin, Katherine McAuley, James Randall Cheung, Kevin Galili, Naomi Garcia-Manero, Guillermo Kantarjian, Hagop Raza, Azra Levine, Ross Neuberg, Donna Ebert, Benjamin L. TI Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol (ASH) C1 [Bejar, Rafael; Marie, McConkey; Lin, Katherine] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Stevenson, Kristen] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Levine, Ross] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [McAuley, James Randall] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Galili, Naomi] Columbia Univ, Med Ctr, Irving Canc Res Ctr, New York, NY USA. [Garcia-Manero, Guillermo; Kantarjian, Hagop] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 136 EP 136 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200301 ER PT J AU Amin, SB Minvielle, S Hanlon, B Shah, PK Li, C Li, Y Swanson, D Moreau, P Magrangeas, F Anderson, KC Avet-Loiseau, H Munshi, NC AF Amin, Samir B. Minvielle, Stephane Hanlon, Bret Shah, Parantu K. Li, Cheng Li, Yi Swanson, David Moreau, Philippe Magrangeas, Florence Anderson, Kenneth C. Avet-Loiseau, Herve Munshi, Nikhil C. TI Gene Expression Profile Alone Is Inadequate In Predicting Complete Responses In Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Amin, Samir B.; Munshi, Nikhil C.] VA Boston Healthcare Syst, Dana Farber Canc Inst, Boston, MA USA. [Amin, Samir B.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA. [Minvielle, Stephane; Moreau, Philippe; Magrangeas, Florence; Avet-Loiseau, Herve] CHU Nantes, F-44035 Nantes 01, France. [Hanlon, Bret] Univ Wisconsin, Madison, WI USA. [Swanson, David] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015; richard, chrystelle/K-8595-2015 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 139 EP 139 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200307 ER PT J AU Gotlib, J DeAngelo, DJ George, TI Corless, CL Linder, A Langford, C Dutreix, C Gross, S Nikolova, Z Graubert, T AF Gotlib, Jason DeAngelo, Daniel J. George, Tracy I. Corless, Christopher L. Linder, Andrea Langford, Cheryl Dutreix, Catherine Gross, Stefan Nikolova, Zariana Graubert, Timothy TI KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Gotlib, Jason; George, Tracy I.; Linder, Andrea; Langford, Cheryl] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Corless, Christopher L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Dutreix, Catherine; Gross, Stefan; Nikolova, Zariana] Novartis Oncol, Basel, Switzerland. [Graubert, Timothy] Washington Univ, St Louis, MO USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 144 EP 144 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200317 ER PT J AU Racke, F Simpson, S Christian, B Blum, KA Hasserjian, R Zhao, WQ AF Racke, Frederick Simpson, Sabrina Christian, Beth Blum, Kristie A. Hasserjian, Robert Zhao, Weiqiang TI Evidence of Long Latency Periods Prior to Development of Mantle Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Racke, Frederick] Ohio State Univ, Dublin, OH USA. [Christian, Beth] Ohio State Univ, Dept Hematol & Oncol, Columbus, OH 43210 USA. [Hasserjian, Robert] Massachusetts Gen Hosp, Dept Pathol WRN 244, Boston, MA 02114 USA. RI Zhao, Weiqiang/E-4368-2011; Blum, Kristie/E-2768-2011 NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 147 EP 147 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200324 ER PT J AU Attar, EC Donohue, KA Amrein, PC Wadleigh, M DeAngelo, DJ Kolitz, JE Powell, BL Voorhees, PM Wang, ES Blum, W Booth, A Stone, RM Moser, BK Larson, R AF Attar, Eyal C. Donohue, Kathleen A. Amrein, Philip C. Wadleigh, Martha DeAngelo, Daniel J. Kolitz, Jonathan E. Powell, Bayard L. Voorhees, Peter M. Wang, Eunice S. Blum, William Booth, Allison Stone, Richard M. Moser, Barry K. Larson, Richard TI Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years: Cancer and Leukemia Group B (CALGB) Study 10502 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Attar, Eyal C.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. [Donohue, Kathleen A.; Moser, Barry K.] Duke Univ, CALGB Stat Ctr, Durham, NC USA. [Wadleigh, Martha; DeAngelo, Daniel J.; Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kolitz, Jonathan E.] N Shore Lond Isl Jewish Hlth Syst, Dept Med, Manhasset, NY USA. [Powell, Bayard L.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA. [Voorhees, Peter M.] Univ N Carolina, Chapel Hill, NC USA. [Wang, Eunice S.] New York State Dept Hlth, Roswell Pk Mem Inst, Buffalo, NY 14263 USA. [Blum, William] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Larson, Richard] Univ Chicago, Chicago, IL 60637 USA. RI Blum, William/E-2769-2011 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 150 EP 150 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200332 ER PT J AU Butler, MO Ansen, S Tanaka, M Imataki, O Berezovskaya, A Mooney, MM Metzler, G Milstein, MI Nadler, LM Hirano, N AF Butler, Marcus O. Ansen, Sascha Tanaka, Makito Imataki, Osamu Berezovskaya, Alla Mooney, Mary M. Metzler, Genita Milstein, Matthew I. Nadler, Lee. M. Hirano, Naoto TI A Series of Human Cell-Based Artificial APC Expands Long-lived, Th1-Biased, Viral Antigen-Specific CD4(+) T Cells with a Central/Effector Memory Phenotpype Restricted by Common HLA-DR Alleles SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Butler, Marcus O.; Ansen, Sascha; Tanaka, Makito; Imataki, Osamu; Berezovskaya, Alla; Mooney, Mary M.; Metzler, Genita; Milstein, Matthew I.; Nadler, Lee. M.; Hirano, Naoto] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 159 EP 160 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200355 ER PT J AU Pidala, J Kurland, B Chai, S Majhail, NS Weisdorf, DJ Cutler, C Jagasia, M Palmer, J Arora, M Martin, PJ Jacobsohn, D Vogelsang, GB Pavletic, SZ Lee, SJ AF Pidala, Joseph Kurland, Brenda Chai, Shawn Majhail, Navneet S. Weisdorf, Daniel J. Cutler, Corey Jagasia, Madan Palmer, Jeanne Arora, Mukta Martin, Paul J. Jacobsohn, David Vogelsang, Georgia B. Pavletic, Steven Z. Lee, Stephanie J. TI Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Pidala, Joseph] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Kurland, Brenda; Chai, Shawn; Martin, Paul J.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Cutler, Corey] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Jagasia, Madan] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Palmer, Jeanne] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Jacobsohn, David] Childrens Mem Hosp, Stem Cell Transplant Program, Chicago, IL 60614 USA. [Vogelsang, Georgia B.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 176 EP 176 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200394 ER PT J AU Sanchez-Aguilera, A Lee, YJ Lo Celso, C Ferraro, F Brumme, K Mondal, S Kim, C Adrienne, D Luo, HR Scadden, DT Williams, DA AF Sanchez-Aguilera, Abel Lee, Yun-Jung Lo Celso, Cristina Ferraro, Francesca Brumme, Kristina Mondal, Subhanjan Kim, Chaekyun Adrienne, Dorrance Luo, Hongbo R. Scadden, David T. Williams, David A. TI Vav1 Regulates Perivascular Homing, Bone Marrow Retention and Engraftment of Hematopoietic Stem Cells Via SDF1a Signaling SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sanchez-Aguilera, Abel; Brumme, Kristina; Kim, Chaekyun; Adrienne, Dorrance] Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA. [Lee, Yun-Jung] Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH USA. [Lo Celso, Cristina] Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, London, England. [Ferraro, Francesca] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Luo, Hongbo R.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Scadden, David T.] Harvard Stem Cell Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 179 EP 179 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200401 ER PT J AU Maloney, KW Loh, ML Raetz, E Borowitz, MJ Devidas, M Friedmann, AM Mattano, LA Wood, B Winick, N Hunger, S Carroll, WL AF Maloney, Kelly W. Loh, Mignon L. Raetz, Elizabeth Borowitz, Michael J. Devidas, Meenakshi Friedmann, Alison M. Mattano, Leonard A. Wood, Brent Winick, Naomi Hunger, Stephen Carroll, William L. TI Early Response Characteristics and Blast Cytogenetic FEatures In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Maloney, Kelly W.] Univ Colorado, Sch Med, Aurora, CO USA. [Loh, Mignon L.] Univ Calif San Francisco, Div Pediat Hematol Oncol, San Francisco, CA 94143 USA. [Raetz, Elizabeth] NYU, Langone Med Ctr, New York, NY USA. [Borowitz, Michael J.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA. [Devidas, Meenakshi] Univ Florida, Coll Med, Dept Biostat, Gainesville, FL USA. [Friedmann, Alison M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mattano, Leonard A.] Pfizer, Mystic, CT USA. [Wood, Brent] Seattle Canc Care Alliance, Seattle, WA USA. [Winick, Naomi] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Hunger, Stephen] Univ Colorado, Coll Med, Pediat Hem Onc BMT, Aurora, CO USA. [Carroll, William L.] NYU Med Ctr, NYU Canc Inst, New York, NY 10016 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 184 EP 184 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200415 ER PT J AU Gordon, LI Hong, FX Fisher, RI Bartlett, NL Connors, JM Gascoyne, RD Wagner, H Stiff, PJ Cheson, BD Gospodarowicz, M Advani, R Kahl, B Friedberg, JW Blum, KA Habermann, TM Tuscano, J Hoppe, R Horning, SJ AF Gordon, Leo I. Hong, Fanxing Fisher, Richard I. Bartlett, Nancy L. Connors, Joseph M. Gascoyne, Randy D. Wagner, Henry Stiff, Patrick J. Cheson, Bruce D. Gospodarowicz, Mary Advani, Ranjana Kahl, Brad Friedberg, Jonathan W. Blum, Kristie A. Habermann, Thomas M. Tuscano, Joseph Hoppe, Richard Horning, Sandra J. TI A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Hong, Fanxing] Dana Farber Canc Inst, Boston, MA 02115 USA. [Fisher, Richard I.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA. [Connors, Joseph M.] British Columbia Canc Agcy, Vancouver Clin, Vancouver, BC V5Z 4E6, Canada. [Wagner, Henry] Penn State Canc Inst, Hershey, PA USA. [Stiff, Patrick J.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Cheson, Bruce D.] Georgetown Univ Hosp, Div Hematol & Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Gospodarowicz, Mary] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Advani, Ranjana] Stanford Univ, Dept Med Onc, Stanford, CA 94305 USA. [Kahl, Brad] Univ Wisconsin, Madison, WI USA. [Friedberg, Jonathan W.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Blum, Kristie A.] Ohio State Univ, Columbus, OH 43210 USA. [Habermann, Thomas M.] Mayo Clin, Rochester, MN USA. [Tuscano, Joseph] UC Davis Canc Ctr, Sacramento, CA USA. [Hoppe, Richard] Stanford Univ, Palo Alto, CA 94304 USA. [Horning, Sandra J.] Genentech Inc, Clin Dev Hem Onc, San Francisco, CA 94080 USA. RI shaoping, liang/I-3447-2012; Blum, Kristie/E-2768-2011 NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 185 EP 185 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200416 ER PT J AU Katz, SG Labelle, JL Godes, M Fisher, J Bird, GH Walensky, LD AF Katz, Samuel G. Labelle, James L. Godes, Marina Fisher, Jill Bird, Gregory H. Walensky, Loren D. TI A Stapled BIM BH3 Helix Restores Apoptosis In Bim-Null Mantle Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA. Harvard Univ, Childrens Hosp Boston, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 196 EP 196 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200438 ER PT J AU Prabhala, RH Pelluru, D Fulciniti, M Nanjappa, P Pai, C Lee, S Prabhala, N Daley, J Treon, SP Munshi, NC AF Prabhala, Rao H. Pelluru, Dheeraj Fulciniti, Mariateresa Nanjappa, Puru Pai, Christine Lee, Saem Prabhala, Nithya Daley, John Treon, Steven P. Munshi, Nikhil C. TI Interleukin-17 and T(H)17 Pathway Supports Waldenstrom's Macroglobulinemia Cell-Growth: Potential Therapeutic Implications SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Prabhala, Rao H.] Va Boston Healthcare Syst, W Roxbury, MA USA. [Pelluru, Dheeraj; Fulciniti, Mariateresa; Nanjappa, Puru; Daley, John; Treon, Steven P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pai, Christine; Prabhala, Nithya] VA Boston Healthcare Syst, Res & Dev, W Roxbury, MA USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, Dana Farber Canc Inst, Boston, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 200 EP 200 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200447 ER PT J AU Calimeri, T Battista, E Conforti, F Neri, P Di Martino, MT Rossi, M Foresta, U Piro, E Ferrara, F Amorosi, A Bahlis, N Anderson, KC Munshi, NC Tagliaferri, P Causa, F Tassone, P AF Calimeri, Teresa Battista, Edmondo Conforti, Francesco Neri, Paola Di Martino, Maria Teresa Rossi, Marco Foresta, Umberto Piro, Eugenio Ferrara, Fiorenzo Amorosi, Andrea Bahlis, Nizar Anderson, Kenneth C. Munshi, Nikhil C. Tagliaferri, Pierosandro Causa, Filippo Tassone, Pierfrancesco TI SCID-Synth-Hu: a Novel Multiple Myeloma Model for In Vivo Expansion of Primary Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Calimeri, Teresa; Di Martino, Maria Teresa; Rossi, Marco; Foresta, Umberto; Tagliaferri, Pierosandro; Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Catanzaro, Italy. [Battista, Edmondo; Causa, Filippo] Italian Inst Technol, Ctr Adv Biomat Hlth Care ABC, Naples, Italy. [Conforti, Francesco; Amorosi, Andrea] Magna Graecia Univ Catanzaro, Sch Med, Dept Pathol, Catanzaro, Italy. [Neri, Paola; Bahlis, Nizar] Univ Calgary, Div Hematol, Calgary, AB, Canada. [Piro, Eugenio] AO Pugliese Ciaccio, Hematol Unit, Catanzaro, Italy. [Ferrara, Fiorenzo] Villa Serena Hosp, Orthoped Surg Unit, Catanzaro, Italy. [Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA. RI Battista, Edmondo/B-3104-2013 OI Battista, Edmondo/0000-0003-0915-9176 NR 0 TC 0 Z9 0 U1 1 U2 6 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 202 EP 203 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200453 ER PT J AU McMillin, DW Delmore, J Vanneman, MW Schlossman, RL Feather, J Munshi, NC Laubach, JP Richardson, PG Dranoff, G Anderson, KC Mitsiades, CS AF McMillin, Douglas W. Delmore, Jake Vanneman, Matthew W. Schlossman, Robert L. Feather, John Munshi, Nikhil C. Laubach, Jacob P. Richardson, Paul G. Dranoff, Glenn Anderson, Kenneth C. Mitsiades, Constantine S. TI Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [McMillin, Douglas W.; Delmore, Jake; Vanneman, Matthew W.; Schlossman, Robert L.; Feather, John; Munshi, Nikhil C.; Laubach, Jacob P.; Richardson, Paul G.; Dranoff, Glenn; Anderson, Kenneth C.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 202 EP 202 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200452 ER PT J AU Azab, AKA Quang, P Azab, F Magnani, J Patton, J Smith, T Sarkar, A Maiso, P Ngo, HT Roccaro, AM Sacco, A Liu, Y Zhang, Y Morgan, B Anderson, KC Kung, AL Carrasco, R Ghobrial, IM AF Azab, Abdel Kareem A. Quang, Phong Azab, Feda Magnani, John Patton, John Smith, Theodore Sarkar, Arun Maiso, Patricia Ngo, Hai T. Roccaro, Aldo M. Sacco, Antonio Liu, Yang Zhang, Yong Morgan, Brittany Anderson, Kenneth C. Kung, Andrew L. Carrasco, Ruben Ghobrial, Irene M. TI Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Carrasco, Ruben; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Magnani, John; Patton, John; Smith, Theodore; Sarkar, Arun] GlycoMimetics Inc, Gaithersburg, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 203 EP 203 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200454 ER PT J AU Prabhala, RH Fulciniti, M Pelluru, D Nanjappa, P Pai, C Lee, S Prabhala, N Song, WH Mitsiades, CS Lefkimmiatis, K Tai, YT Ghobrial, I Richardson, P Daley, J Anderson, KC Ettenberg, S Di Padova, F Munshi, NC AF Prabhala, Rao H. Fulciniti, Mariateresa Pelluru, Dheeraj Nanjappa, Puru Pai, Christine Lee, Saem Prabhala, Nithya Song, Weihua Mitsiades, Constantine S. Lefkimmiatis, Konstantinos Tai, Yu-Tzu Ghobrial, Irene Richardson, Paul Daley, John Anderson, Kenneth C. Ettenberg, Seth Di Padova, Franco Munshi, Nikhil C. TI Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Pai, Christine; Prabhala, Nithya; Lefkimmiatis, Konstantinos] VA Boston Healthcare Syst, Res & Dev, W Roxbury, MA USA. [Fulciniti, Mariateresa; Pelluru, Dheeraj; Nanjappa, Puru; Song, Weihua; Mitsiades, Constantine S.; Tai, Yu-Tzu; Ghobrial, Irene; Richardson, Paul; Daley, John; Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lee, Saem] VA Boston Healthcare Syst, Boston, MA USA. [Ettenberg, Seth; Di Padova, Franco] Novartis, Cambridge, MA USA. RI Lefkimmiatis, Konstantinos/I-1239-2016 OI Lefkimmiatis, Konstantinos/0000-0001-7137-7866 NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 204 EP 204 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200457 ER PT J AU Pardanani, A Gotlib, JR Jamieson, C Cortes, JE Talpaz, M Stone, RM Silverman, MH Shorr, J Gilliland, DG Tefferi, A AF Pardanani, Animesh Gotlib, Jason R. Jamieson, Catriona Cortes, Jorge E. Talpaz, Moshe Stone, Richard M. Silverman, Michael H. Shorr, Jolene Gilliland, D. Gary Tefferi, Ayalew TI Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly,, Disease-Related Symptoms, and JAK2V617F Allele Burden SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Pardanani, Animesh] Mayo Clin, Div Hematol, Rochester, MN USA. [Gotlib, Jason R.] Stanford U Sch Med, Stanford, CA USA. [Jamieson, Catriona] Univ Calif San Diego, La Jolla, CA 92093 USA. [Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Talpaz, Moshe] U Michigan, Ctr Canc, Ann Arbor, MI USA. [Talpaz, Moshe] U Michigan, Geriatr Ctr, Ann Arbor, MI USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Silverman, Michael H.] Biostrateg Consulting Ltd, Marblehead, MA USA. [Shorr, Jolene] TargeGen Inc, San Diego, CA USA. [Gilliland, D. Gary] Merck & Co Inc, N Wales, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 205 EP 206 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200460 ER PT J AU Yoda, A Haley, T Weigert, OB Kutok, J Maisonet, A Salois, M Fox, E Weinstock, DM AF Yoda, Akinori Haley, Terry Weigert, Oliver B. Kutok, Jeffery Maisonet, Adalis Salois, Maura Fox, Edward Weinstock, David M. TI Next Generation Sequencing Identifies Novel Oncogene Alterations In CRLF2-rearranged Precursor B-Cell Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Yoda, Akinori; Haley, Terry; Weigert, Oliver B.; Maisonet, Adalis; Salois, Maura; Fox, Edward; Weinstock, David M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kutok, Jeffery] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 210 EP 211 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200473 ER PT J AU Luptakova, K Glotzbecker, B Mills, H Stroopinsky, D Vasir, B Rosenblatt, J Kufe, D Avigan, D AF Luptakova, Katarina Glotzbecker, Brett Mills, Heidi Stroopinsky, Dina Vasir, Baldev Rosenblatt, Jacalyn Kufe, Donald Avigan, David TI Lenalidomide Decreases PD-1 Expression, Depletes Regulatory T-Cells and Improves Cellular Response to a Multiple Myeloma/Dendritic Cell Fusion Vaccine In Vitro SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Luptakova, Katarina; Glotzbecker, Brett; Mills, Heidi; Stroopinsky, Dina; Rosenblatt, Jacalyn; Avigan, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Vasir, Baldev; Kufe, Donald] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 218 EP 218 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200493 ER PT J AU Neviani, P Harb, JG Oaks, JJ Walker, C Santhanam, R Paisie, C Eiring, A Zhang, B Perazzona, B Ma, Y Mao, C Marcucci, G Holyoake, TL Volinia, S Cortes, JE Caligiuri, MA Huettner, C Bittman, R Chen, CS Arlinghaus, RB Hokland, P Roy, DC Bhatia, R Perrotti, D AF Neviani, Paolo Harb, Jason G. Oaks, Joshua J. Walker, Christopher Santhanam, Ramasamy Paisie, Carolyn Eiring, Anna Zhang, Bin Perazzona, Bastianella Ma, Y. Mao, Charlene Marcucci, Guido Holyoake, Tessa L. Volinia, Stefano Cortes, Jorge E. Caligiuri, Michael A. Huettner, Claudia Bittman, Robert Chen, Ching-Shih Arlinghaus, Ralph B. Hokland, Peter Roy, Denis-Claude Bhatia, Ravi Perrotti, Danilo TI BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph plus Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Neviani, Paolo; Harb, Jason G.; Oaks, Joshua J.; Walker, Christopher; Santhanam, Ramasamy; Paisie, Carolyn; Eiring, Anna; Mao, Charlene; Marcucci, Guido; Caligiuri, Michael A.; Perrotti, Danilo] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Zhang, Bin] City Hope Natl Med Ctr, HEM HCT, Duarte, CA 91010 USA. [Perazzona, Bastianella] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA. [Holyoake, Tessa L.] Univ Glasgow, Paul OGorman Leukaemia Res Ctr, Glasgow, Lanark, Scotland. [Volinia, Stefano] Univ Ferrara, Dept Morphol & Embryol, DAMA, I-44100 Ferrara, Italy. [Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA. [Huettner, Claudia] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bittman, Robert] CUNY, New York, NY 10021 USA. [Hokland, Peter] Arhus Sygehus, Immunhaematol Lab, Aarhus, Denmark. [Roy, Denis-Claude] Univ Montreal, Maisonneuve Rosemont Hosp, Montreal, PQ, Canada. [Bhatia, Ravi] City Hope Natl Med Ctr, Duarte, CA USA. RI Volinia, Stefano/A-3029-2010 OI Volinia, Stefano/0000-0003-0910-3893 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 227 EP 228 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200516 ER PT J AU Melanson, SE Stevenson, K Kim, HT Antin, JH Ho, VT Ritz, J Soiffer, RJ Court, M Kuo, F Longtine, J Jarolim, P AF Melanson, Stacy E. Stevenson, Kristen Kim, Haesook T. Antin, Joseph H. Ho, Vincent T. Ritz, Jerome Soiffer, Robert J. Court, Michael Kuo, Frank Longtine, Janina Jarolim, Petr TI Markedly Reduced Overall Survival of CYP2C19*2/*2 Homozygotes After Myeloablative Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Melanson, Stacy E.; Kuo, Frank; Longtine, Janina; Jarolim, Petr] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Stevenson, Kristen; Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Antin, Joseph H.; Ho, Vincent T.; Ritz, Jerome; Soiffer, Robert J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Court, Michael] Tufts Univ, Sch Med, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 230 EP 230 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200521 ER PT J AU Stadtmauer, EA Krishnan, A Pasquini, MC Ewell, M Alyea, EP Antin, JH Castro-Malaspina, H Kassim, AA Negrin, R Qazilbash, MH Rizzo, JD Rowley, SD Sahebi, F Somlo, G Vesole, DH Vogl, DT Weisdorf, DJ Geller, N Horowitz, MM Maloney, DG Giralt, S AF Stadtmauer, Edward A. Krishnan, Amrita Pasquini, Marcelo C. Ewell, Marian Alyea, Edwin P., III Antin, Joseph H. Castro-Malaspina, Hugo Kassim, Adetola A. Negrin, Robert Qazilbash, Muzaffar H. Rizzo, J. Douglas Rowley, Scott D. Sahebi, Firoozeh Somlo, George Vesole, David H. Vogl, Dan T. Weisdorf, Daniel J. Geller, Nancy Horowitz, Mary M. Maloney, David G. Giralt, Sergio TI Tandem Autologous Stem Cell Transplants (auto-auto) With or without Maintenance Therapy Versus Single Autologous Transplant Followed by HLA-Matched Sibling Non- Myeloablative Allogeneic Stem Cell Transplant (auto-allo) for Patients (pts) with High Risk (HR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Stadtmauer, Edward A.; Vogl, Dan T.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Sahebi, Firoozeh] Kaiser Permanente Med Grp, City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Rizzo, J. Douglas; Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Ewell, Marian] EMMES Corp, Rockville, MD USA. [Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Castro-Malaspina, Hugo] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Kassim, Adetola A.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Negrin, Robert] Stanford Univ, Stanford, CA 94305 USA. [Qazilbash, Muzaffar H.] Univ Texas MD Anderson Canc Ctr, SCT CT Unit 423, Houston, TX 77030 USA. [Rowley, Scott D.] Hackensack Univ, Med Ctr, Div Blood & Marrow Transplantat, John Theurer Canc Ctr, Hackensack, NJ USA. [Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Geller, Nancy] NHLBI, Bethesda, MD 20892 USA. [Maloney, David G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Maloney, David G.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 233 EP 234 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200527 ER PT J AU Eapen, M LeRademacher, J Deeg, HJ Antin, JH Champlin, R Carreras, J Fay, JW Passweg, JR Tolar, J Marsh, JCW Horowitz, MM AF Eapen, Mary LeRademacher, Jennifer Deeg, H. Joachim Antin, Joseph H. Champlin, Richard Carreras, Jeanette Fay, Joseph W. Passweg, Jakob R. Tolar, Jakub Marsh, Judith C. W. Horowitz, Mary M. TI Effect of Stem Cell Source From Unrelated Donors on Transplant Outcomes In Severe Aplastic Anemia (SAA): a Comparison of Unrelated Bone Marrow (BM) and Peripheral Blood Progenitor Cells (PBPC) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Carreras, Jeanette; Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Deeg, H. Joachim] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Deeg, H. Joachim] Univ Washington, Seattle, WA 98195 USA. [Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Champlin, Richard] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Fay, Joseph W.] Baylor Univ, Med Ctr, Dallas, TX USA. [Passweg, Jakob R.] Hop Cantonal Univ Geneva, Dept Med Interne, Geneva, Switzerland. [Tolar, Jakub] Univ Minnesota, Dept Pediat, Masonic Canc Ctr, Div Blood & Marrow Transplantat, Minneapolis, MN 55455 USA. [Marsh, Judith C. W.] Kings Coll London, London WC2R 2LS, England. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 236 EP 236 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200532 ER PT J AU Rummel, MJ Kuter, DJ Mandanas, R Giagounidis, A Wang, XN Mathias, SD Deuson, R AF Rummel, Mathias J. Kuter, David J. Mandanas, Romeo Giagounidis, Aristoteles Wang, Xuena Mathias, Susan D. Deuson, Robert TI Patient Quality of Life (QOL) In Nonsplenectomized Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim or Medical Standard of Care (SOC) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Rummel, Mathias J.] Univ Giessen Klinikum, D-6300 Giessen, Germany. [Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mandanas, Romeo] Integris Canc Inst Oklahoma, Oklahoma City, OK USA. [Giagounidis, Aristoteles] St Johannes Hosp, Med Klin 2, Duisburg, Germany. [Wang, Xuena; Deuson, Robert] Amgen Inc, Thousand Oaks, CA 91320 USA. [Mathias, Susan D.] Hlth Outcomes Solut, Winter Pk, FL USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 252 EP 252 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200570 ER PT J AU Lin, MI Carspecken, CW Uong, A Price, E Zon, LI AF Lin, Michelle I. Carspecken, Charles W. Uong, Audrey Price, Emily Zon, Leonard I. TI Genetic Interaction Between Angiopoietin-Like Proteins 1 and 2 and Notch Signaling During HSC Development SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Stem Cell Program, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Harvard Stem Cell Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 253 EP 254 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200574 ER PT J AU Strickland, SA Sun, ZX Ketterling, RP Cherry, AM Cripe, LD Dewald, G Higgins, RR Lazarus, HM Litzow, MR Luger, SM Paietta, E Rowe, JM Uno, H Vance, GH Tallman, MS AF Strickland, Stephen A. Sun, Zhuoxin Ketterling, Rhett P. Cherry, Athena M. Cripe, Larry D. Dewald, Gordon Higgins, Rodney R. Lazarus, Hillard M. Litzow, Mark R. Luger, Selina M. Paietta, Elisabeth Rowe, Jacob M. Uno, Hajime Vance, Gail H. Tallman, Martin S. TI Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not Monosomy SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Strickland, Stephen A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Sun, Zhuoxin; Uno, Hajime] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ketterling, Rhett P.; Dewald, Gordon; Litzow, Mark R.] Mayo Clin, Rochester, MN USA. [Cherry, Athena M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Cripe, Larry D.] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA. [Higgins, Rodney R.] Allina Hlth Abbott NW Hosp, Cytogenet Lab, Minneapolis, MN USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Luger, Selina M.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Paietta, Elisabeth] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA. [Rowe, Jacob M.] Rambam Med Ctr, Haifa, Israel. [Rowe, Jacob M.] Technion Israel Inst Technol, Haifa, Israel. [Vance, Gail H.] Indiana Univ Sch Med, Indianapolis, IN USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 256 EP 256 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200580 ER PT J AU Jankowska, A Makishima, H Tiu, RV Szpurka, H Huang, Y Sugimoto, Y Prince, C O'Keefe, CL Hsi, E List, AF Sekeres, MA Rao, A McDevitt, MA Maciejewski, JP AF Jankowska, Anna Makishima, Hideki Tiu, Ramon V. Szpurka, Hadrian Huang, Yun Sugimoto, Yuka Prince, Courtney O'Keefe, Christine L. Hsi, Eric List, Alan F. Sekeres, Mikkael A. Rao, Anjana McDevitt, Michael A. Maciejewski, Jaroslaw P. TI Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jankowska, Anna; Makishima, Hideki; Tiu, Ramon V.; Szpurka, Hadrian; Sugimoto, Yuka; Prince, Courtney; O'Keefe, Christine L.; Hsi, Eric; Sekeres, Mikkael A.; Maciejewski, Jaroslaw P.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Huang, Yun; Rao, Anjana] Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, Boston, MA 02115 USA. [Huang, Yun; Rao, Anjana] Program Cellular & Mol Med, Boston, MA USA. [List, Alan F.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [McDevitt, Michael A.] Johns Hopkins Univ, Sch Med, Dept Oncol, Div Hematol Malignancy, Baltimore, MD 21205 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 268 EP 269 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200612 ER PT J AU Kumar, S Flinn, IW Richardson, PG Hari, P Callander, NS Noga, SJ Stewart, AK Glass, J Rifkin, RM Wolf, JL Estevam, J Mulligan, G Shi, HL Webb, IJ Rajkumar, SV AF Kumar, Shaji Flinn, Ian W. Richardson, Paul G. Hari, Parameswaran Callander, Natalie Scott Noga, Stephen J. Stewart, A. Keith Glass, Jonathan Rifkin, Robert M. Wolf, Jeffrey L. Estevam, Jose Mulligan, George Shi, Hongliang Webb, Iain J. Rajkumar, S. Vincent TI Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kumar, Shaji; Rajkumar, S. Vincent] Mayo Clin, Div Hematol, Rochester, MN USA. [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hari, Parameswaran] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Callander, Natalie Scott] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA. [Noga, Stephen J.] Sinai Hosp, Baltimore, MD 21215 USA. [Stewart, A. Keith] Mayo Clin Arizona, Scottsdale, AZ USA. [Glass, Jonathan] LSU HC, Shreveport, LA USA. [Rifkin, Robert M.] Rocky Mt Canc Ctr, Denver, CO USA. [Wolf, Jeffrey L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Estevam, Jose; Mulligan, George; Shi, Hongliang; Webb, Iain J.] Millennium Pharmaceut Inc, Cambridge, MA USA. RI Kumar, Shaji/A-9853-2008 OI Kumar, Shaji/0000-0001-5392-9284 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 273 EP 273 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200622 ER PT J AU DeAngelo, DJ Tefferi, A Fiskus, W Mesa, RA Paley, CS Wadleigh, M Snyder, DS Begna, K Ondovik, MS Rine, J Bhalla, KN AF DeAngelo, Daniel J. Tefferi, Ayalew Fiskus, Warren Mesa, Ruben A. Paley, Carole S. Wadleigh, Martha Snyder, David S. Begna, Kebede Ondovik, Michael S. Rine, Jessica Bhalla, Kapil N. TI A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [DeAngelo, Daniel J.; Wadleigh, Martha] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tefferi, Ayalew] Mayo Clin, Div Hematol, Rochester, MN USA. [Fiskus, Warren] Univ Kansas, Med Ctr, Ctr Canc, Kansas City, KS 66103 USA. [Mesa, Ruben A.] Mayo Clin, Scottsdale, AZ USA. [Paley, Carole S.; Ondovik, Michael S.; Rine, Jessica] Novartis Pharmaceut, E Hanover, NJ USA. [Snyder, David S.] City Hope Canc Ctr, Duarte, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 276 EP 277 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200631 ER PT J AU Chapuy, B Monti, S Takeyama, K Getz, G Rodig, SJ Kutok, J Golub, TR Shipp, MA AF Chapuy, Bjoern Monti, Stefano Takeyama, Kunihiko Getz, Gad Rodig, Scott J. Kutok, Jeffery Golub, Todd R. Shipp, Margaret A. TI Integrative Analysis Reveals Multiple Alterations of p53 Signaling Pathway Components In Primary Diffuse Large B-Cell Lymphomas SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Chapuy, Bjoern; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Monti, Stefano; Golub, Todd R.] Broad Inst, Canc Program, Cambridge, MA USA. [Takeyama, Kunihiko] Bristol Myers KK, Tokyo, Japan. [Kutok, Jeffery] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 279 EP 279 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200636 ER PT J AU Xu, J Sankaran, VG Esrick, EB Ebert, BL Orkin, SH AF Xu, Jian Sankaran, Vijay G. Esrick, Erica B. Ebert, Benjamin L. Orkin, Stuart H. TI Reactivation of Silenced Human HbF In Adult Mice by Inactivation of BCL11A SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Xu, Jian; Sankaran, Vijay G.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp Boston,Harvard Stem Cell Inst,Div, Boston, MA 02115 USA. [Esrick, Erica B.; Ebert, Benjamin L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 282 EP 283 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200644 ER PT J AU Swords, RT Erba, HP DeAngelo, DJ Smith, PG Pickard, MD Dezube, BJ Giles, FJ Medeiros, BC AF Swords, Ronan T. Erba, Harry P. DeAngelo, Daniel J. Smith, Peter G. Pickard, Michael D. Dezube, Bruce J. Giles, Francis J. Medeiros, Bruno C. TI The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Swords, Ronan T.; Giles, Francis J.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA. [Erba, Harry P.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Smith, Peter G.] Millennium Pharmaceut Inc, Discovery, Cambridge, MA USA. [Pickard, Michael D.] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA. [Dezube, Bruce J.] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA. [Medeiros, Bruno C.] Stanford Comprehens Canc Ctr, Div Hematol, Stanford, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 288 EP 288 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200659 ER PT J AU Armand, P Perez, W Zhang, MJ Kim, H Klumpp, TR Dal Cin, P Waller, EK Litzow, MR Liesveld, JL Lazarus, HM Artz, A Gupta, V Savani, BN McCarthy, PL Cahn, JY Schouten, H Finke, J Ball, ED Aljurf, M Cutler, C Rowe, JM Antin, JH Isola, LM Di Bartolomeo, P Camitta, B Miller, AM Cairo, MS Stockerl-Goldstein, KE Sierra, J Savoie, ML Halter, J Stiff, PJ Nabhan, C Jakubowski, AA Bunjes, D Petersdorf, EW Devine, SM Maziarz, R Bornhauser, M Lewis, VA Marks, DI Bredeson, CN Soiffer, R Weisdorf, DJ AF Armand, Philippe Perez, Waleska Zhang, Mei-Jie Kim, Haesook Klumpp, Thomas R. Dal Cin, Paola Waller, Edmund K. Litzow, Mark R. Liesveld, Jane L. Lazarus, Hillard M. Artz, Andrew Gupta, Vikas Savani, Bipin N. McCarthy, Philip L. Cahn, Jean-Yves Schouten, Harry Finke, Jurgen Ball, Edward D. Aljurf, Mahmoud Cutler, Corey Rowe, Jacob M. Antin, Joseph H. Isola, Luis M. Di Bartolomeo, Paolo Camitta, Bruce Miller, Alan M. Cairo, Mitchell S. Stockerl-Goldstein, Keith E. Sierra, Jorge Savoie, Mary Lynn Halter, Joerg Stiff, Patrick J. Nabhan, Chadi Jakubowski, Ann A. Bunjes, Donald Petersdorf, Effie W. Devine, Steven M. Maziarz, Richard Bornhauser, Martin Lewis, Victor A. Marks, David I. Bredeson, Christopher N. Soiffer, Robert Weisdorf, Daniel J. TI Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Cutler, Corey; Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Perez, Waleska; Zhang, Mei-Jie] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Klumpp, Thomas R.] Temple Univ, Wynnewood, PA USA. [Dal Cin, Paola] Brigham & Womens Hosp, Boston, MA 02115 USA. [Waller, Edmund K.] Winship Canc Inst, Atlanta, GA USA. [Litzow, Mark R.] Mayo Clin, Rochester, MN USA. [Liesveld, Jane L.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Artz, Andrew] Univ Chicago Hosp, Chicago, IL 60637 USA. [Gupta, Vikas] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [McCarthy, Philip L.] Roswell Pk Canc Inst, BMT Program, Buffalo, NY 14263 USA. [Cahn, Jean-Yves] CHU Grenoble, F-38043 Grenoble 09, France. [Finke, Jurgen] Univ Freiburg Klinikum, Dept Med 1, Freiburg, Germany. [Ball, Edward D.] Univ Calif San Diego, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA. [Aljurf, Mahmoud] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia. [Rowe, Jacob M.] Technion Israel Inst Technol, Rambam Med Ctr, Haifa, Israel. [Isola, Luis M.] Mt Sinai Med Ctr, BMT, New York, NY 10029 USA. [Di Bartolomeo, Paolo] Osped Civile, Pescara, Italy. [Camitta, Bruce] Med Coll Wisconsin, Pediat Hematol Oncol BMT, Wauwatosa, WI USA. [Miller, Alan M.] Baylor Univ, Med Ctr, Dallas, TX USA. [Cairo, Mitchell S.] Columbia Univ, Med Ctr, Div Pediat Hematol & Blood & Marrow Transplantat, New York, NY USA. [Stockerl-Goldstein, Keith E.] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Sierra, Jorge] CETLAM Cooperat Grp, Barcelona, Spain. [Savoie, Mary Lynn] Foothills Med Ctr, Calgary, AB, Canada. [Halter, Joerg] Univ Basel Hosp, CH-4031 Basel, Switzerland. [Stiff, Patrick J.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Nabhan, Chadi] Advocate Lutheran Gen Hosp, Park Ridge, IL USA. [Jakubowski, Ann A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Bunjes, Donald] Univ Hosp Ulm, Ulm, Germany. [Petersdorf, Effie W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Devine, Steven M.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Maziarz, Richard] Oregon Hlth & Sci Univ, Ctr Clin Canc, Portland, WI USA. [Bornhauser, Martin] Univ Hosp, Dresden, Germany. [Lewis, Victor A.] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada. [Marks, David I.] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England. [Bredeson, Christopher N.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. RI Halter, Joerg/C-9487-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 299 EP 299 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200681 ER PT J AU Davids, MS Brown, JR Wiestner, A Letai, AG AF Davids, Matthew S. Brown, Jennifer R. Wiestner, Adrian Letai, Anthony G. TI BH3 Profiling Demonstrates Decreased Mitochondrial Priming for Apoptosis In Primary CLL Cells Exposed to Stroma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Davids, Matthew S.; Brown, Jennifer R.; Letai, Anthony G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wiestner, Adrian] NHLBI, Hematol Branch, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 305 EP 305 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200693 ER PT J AU Wang, L Pochet, N Cibulskis, K Zhang, WD Lawrence, M Sievers, QL Shefler, E Neuberg, D Gabriel, S Sougnez, C Regev, A Getz, G Hacohen, N Brown, JR Wu, CJ AF Wang, Lili Pochet, Nathalie Cibulskis, Kristian Zhang, Wandi Lawrence, Mike Sievers, Quinlan L. Shefler, Erica Neuberg, Donna Gabriel, Stacey Sougnez, Carrie Regev, Aviv Getz, Gad Hacohen, Nir Brown, Jennifer R. Wu, Catherine J. TI Whole Genome Sequencing Identifies Functional Mutations In the Wnt Pathway In CLL SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Wang, Lili] Dana Farber Canc Inst, Dept Med Oncol, Canc Vaccine Ctr, Boston, MA 02115 USA. [Pochet, Nathalie; Cibulskis, Kristian; Lawrence, Mike; Shefler, Erica; Gabriel, Stacey; Sougnez, Carrie; Regev, Aviv; Getz, Gad; Hacohen, Nir] Broad Inst, Cambridge, MA USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Dana Farber Canc Inst,Dept Med Oncol,Canc Vaccine, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 305 EP 306 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200694 ER PT J AU Loughran, TP Yao, XP Bennett, JM Litzow, MR Evens, AM Tallman, MS AF Loughran, Thomas P., Jr. Yao, Xiaopan Bennett, John M. Litzow, Mark R. Evens, Andrew M. Tallman, Martin S. TI Results of a Prospective: Multicenter Phase II Study of Initial Treatment with Methotrexate In LGL Leukemia (ECOG Protocol E5998) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Loughran, Thomas P., Jr.] Penn State Hershey Canc Inst CH72, Hershey, PA USA. [Yao, Xiaopan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bennett, John M.] Univ Rochester, Rochester, NY USA. [Litzow, Mark R.] Mayo Clin, Rochester, MN USA. [Evens, Andrew M.] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA. [Tallman, Martin S.] Mem Sloane Kettering Canc Ctr, Leukemia Serv, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 310 EP 310 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200703 ER PT J AU Toomey, CE Muzikanksy, A Lee, AI Barnes, JA Michaelson, JS Abramson, JS Hochberg, EP AF Toomey, Christina E. Muzikanksy, Alona Lee, Alfred Ian Barnes, Jeffrey A. Michaelson, James S. Abramson, Jeremy S. Hochberg, Ephraim P. TI Treatment Choice and Outcome In Diffuse Large B Cell Lymphoma (DLBCL) Patients 75 Years and Older SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Toomey, Christina E.; Barnes, Jeffrey A.; Abramson, Jeremy S.; Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [Muzikanksy, Alona] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Lee, Alfred Ian] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Michaelson, James S.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 323 EP 324 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200734 ER PT J AU Huang, H Waldon, Z Chan, G Zhu, H Steen, H Feng, GS Neel, B Cantor, A AF Huang, Hui Waldon, Zachary Chan, Gordon Zhu, Helen Steen, Hanno Feng, Gen-Sheng Neel, Benjamin Cantor, Alan TI Tyrosine Phosphorylation of Runx1 In Megakaryocytes by Src Family Kinases SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Waldon, Zachary; Steen, Hanno] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. [Huang, Hui; Cantor, Alan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chan, Gordon; Neel, Benjamin] Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada. [Chan, Gordon; Neel, Benjamin] Princess Margaret Hosp, Univ Hlth Network, Campbell Family Res Inst, Toronto, ON M4X 1K9, Canada. [Zhu, Helen; Feng, Gen-Sheng] UCSD Sch Med, Dept Pathol, La Jolla, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 327 EP 327 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200743 ER PT J AU Bai, XY Trowbridge, J Lee, J Orkin, SH Zon, LI AF Bai, Xiaoying Trowbridge, Jennifer Lee, Joseph Orkin, Stuart H. Zon, Leonard I. TI Analysis of TIF1gamma Conditional Knockout Establishes a Requirement for the Differentiation of Multiple Hematopoietic Lineages SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Bai, Xiaoying; Lee, Joseph] Childrens Hosp, Stem Cell Program, HHMI, Boston, MA 02115 USA. [Trowbridge, Jennifer; Orkin, Stuart H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Stem Cell Program & Hematol Oncol, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst,Harvard Stem Cell Inst, Boston, MA 02115 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 328 EP 328 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200745 ER PT J AU Chapuy, B Green, MR Lu, J Monti, S Hao, YS Yeda, KT Rodig, SJ Currie, T Takeyama, K Golub, TR Kutok, J Shipp, MA AF Chapuy, Bjoern Green, Michael R. Lu, Jun Monti, Stefano Hao, Yansheng Yeda, Kelly T. Rodig, Scott J. Currie, Treeve Takeyama, Kunihiko Golub, Todd R. Kutok, Jeffery Shipp, Margaret A. TI Mir-15a/16-1 Cluster Is Frequently Deleted In Primary Hodgkin Lymphoma and Modulates Multiple Survival Pathways Including AP-1 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Chapuy, Bjoern; Green, Michael R.; Hao, Yansheng; Yeda, Kelly T.; Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lu, Jun] Yale Univ, Genet Yale Stem Cell Ctr, New Haven, CT USA. [Monti, Stefano] Broad Inst, Canc Program, Comp Biol & Bioinf Progam, Cambridge, MA USA. [Currie, Treeve] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Takeyama, Kunihiko] Bristol Myers KK, Tokyo, Japan. [Golub, Todd R.] Broad Inst, Canc Program, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 328 EP 328 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200747 ER PT J AU Pollock, RM Daigle, SR Olhava, EJ Therkelsen, CA Majer, CR Songi, J Allain, CJ Sneeringer, CJ Johnston, LD Scott, MP Jin, L Kuntz, KW Chesworth, R Moyer, MP Bernt, KM Armstrong, S Copeland, RA Richon, VM AF Pollock, Roy M. Daigle, Scott R. Olhava, Edward J. Therkelsen, Carly A. Majer, Christina R. Songi, Jeffrey Allain, Christina J. Sneeringer, Christopher J. Johnston, L. Danielle Scott, Margaret Porter Jin, Lei Kuntz, Kevin W. Chesworth, Richard Moyer, Mikel P. Bernt, Kathrin M. Armstrong, Scott Copeland, Robert A. Richon, Victoria M. TI Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Pollock, Roy M.; Daigle, Scott R.; Olhava, Edward J.; Therkelsen, Carly A.; Majer, Christina R.; Songi, Jeffrey; Allain, Christina J.; Sneeringer, Christopher J.; Johnston, L. Danielle; Scott, Margaret Porter; Jin, Lei; Kuntz, Kevin W.; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.; Richon, Victoria M.] Epizyme Inc, Cambridge, MA USA. [Bernt, Kathrin M.] Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA. [Armstrong, Scott] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 342 EP 342 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200781 ER PT J AU Pal, J Wong, J Nanjappa, P Lee, S Shammas, M Munshi, NC AF Pal, Jagannath Wong, Jason Nanjappa, Puru Lee, Saem Shammas, Masood Munshi, Nikhil C. TI Inhibition of Homologous Recombination Pathway Promotes Telomere Shortening and Cell Survival without Affecting Telomerase Activity In Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Pal, Jagannath; Nanjappa, Puru; Shammas, Masood; Munshi, Nikhil C.] VA Boston Healthcare Syst, Dana Farber Canc Inst, Boston, MA USA. [Wong, Jason; Munshi, Nikhil C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 345 EP 345 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200787 ER PT J AU Reddy, MM Fernandes, M Griffin, JD Sattler, M AF Reddy, Mamatha M. Fernandes, Margret Griffin, James D. Sattler, Martin TI The JAK2V617F Oncogene, Associated with Myeloproliferative Neoplasms, Requires Expression of Inducible Phosphofructokinase/Fructose Bisphosphatase 3 for Cell Growth and Increased Metabolic Activity SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Reddy, Mamatha M.; Fernandes, Margret; Griffin, James D.; Sattler, Martin] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 347 EP 347 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200794 ER PT J AU Leen, AM Bollard, CM Mendizabal, AM Shpall, EJ Szabolcs, P Antin, JH Kapoor, N Heaton, C Grilley, BJ Gee, AP Brenner, MK Rooney, CM Heslop, HE AF Leen, Ann M. Bollard, Catherine M. Mendizabal, Adam M. Shpall, Elizabeth J. Szabolcs, Paul Antin, Joseph H. Kapoor, Neena Heaton, Callie Grilley, Bambi J. Gee, Adrian P. Brenner, Malcolm K. Rooney, Cliona M. Heslop, Helen E. TI Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Leen, Ann M.; Bollard, Catherine M.; Grilley, Bambi J.; Gee, Adrian P.; Brenner, Malcolm K.; Rooney, Cliona M.; Heslop, Helen E.] Baylor Coll Med, Methodist Hosp, Texas Childrens Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Mendizabal, Adam M.; Heaton, Callie] EMMES Corp, Rockville, MD USA. [Shpall, Elizabeth J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Szabolcs, Paul] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA. [Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Kapoor, Neena] Childrens Hosp Los Angeles, USC, Keck Sch Med, Los Angeles, CA 90027 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 361 EP 362 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200830 ER PT J AU Stroopinsky, D Rosenblatt, J Ito, K Yin, L Rajabi, H Vasir, B Kufe, T Glotzbecker, B Luptakova, K Mills, H Joyce, R Tzachanis, D Boussiotis, VA Levine, J Galinsky, I Stone, R Pandolfi, PP Kufe, D Avigan, D AF Stroopinsky, Dina Rosenblatt, Jacalyn Ito, Keisuke Yin, Li Rajabi, Hasan Vasir, Baldev Kufe, Turner Glotzbecker, Brett Luptakova, Katarina Mills, Heidi Joyce, Robin Tzachanis, Dimitrios Boussiotis, Vassiliki A. Levine, James Galinsky, Ilene Stone, Richard Pandolfi, Pier Paolo Kufe, Donald Avigan, David TI Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Stroopinsky, Dina; Rosenblatt, Jacalyn; Ito, Keisuke; Kufe, Turner; Glotzbecker, Brett; Luptakova, Katarina; Mills, Heidi; Joyce, Robin; Tzachanis, Dimitrios; Boussiotis, Vassiliki A.; Levine, James; Pandolfi, Pier Paolo; Avigan, David] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Yin, Li; Rajabi, Hasan; Vasir, Baldev; Galinsky, Ilene; Stone, Richard; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 369 EP 369 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200849 ER PT J AU Geng, HM Neuberg, D Paietta, E Deng, XT Li, YS Xin, Y Racevskis, J Ketterling, R Richards, SM Tallman, MS Rowe, JM Litzow, MR Elemento, O Melnick, AM AF Geng, Huimin Neuberg, Donna Paietta, Elisabeth Deng, Xutao Li, Yushan Xin, Yuan Racevskis, Janis Ketterling, Rhett Richards, Susan M. Tallman, Martin S. Rowe, Jacob M. Litzow, Mark R. Elemento, Olivier Melnick, Ari M. TI Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Geng, Huimin; Deng, Xutao; Elemento, Olivier] Weill Cornell Med Coll, Inst Computat Biomed, New York, NY USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [Paietta, Elisabeth; Racevskis, Janis] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA. [Li, Yushan; Xin, Yuan; Melnick, Ari M.] Weill Cornell Med Coll, Dept Med, Div Hematol Oncol, New York, NY USA. [Ketterling, Rhett; Litzow, Mark R.] Mayo Clin, Rochester, MN USA. [Richards, Susan M.] Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA. [Rowe, Jacob M.] Technion Israel Inst Technol, Rambam Med Ctr, Haifa, Israel. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 371 EP 371 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200853 ER PT J AU Richardson, PG Siegel, D Baz, R Kelley, SL Munshi, NC Sullivan, D Alsina, M Doss, D McBride, L Larkins, G Lizza, M Yu, X Zaki, M Jacques, CJ Anderson, KC AF Richardson, Paul G. Siegel, David Baz, Rachid Kelley, Susan L. Munshi, Nikhil C. Sullivan, Daniel Alsina, Melissa Doss, Deborah McBride, Laura Larkins, Gail Lizza, Maria Yu, Xin Zaki, Mohamed Jacques, Christian J. Anderson, Kenneth C. TI A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Richardson, Paul G.; Munshi, Nikhil C.; Doss, Deborah; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Siegel, David; McBride, Laura] Hackensack Univ Med Ctr, Ctr Canc, Hackensack, NJ USA. [Baz, Rachid; Sullivan, Daniel; Alsina, Melissa] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Kelley, Susan L.] Multiple Myeloma Res Consortium, Norwalk, CT USA. [Larkins, Gail; Lizza, Maria; Yu, Xin; Zaki, Mohamed; Jacques, Christian J.] Celgene Corp, Summit, NJ USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 377 EP 378 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200865 ER PT J AU Huiya, N Paul, JA Borowitz, MJ Thomson, B Isakoff, M Silverman, LB Steinherz, PG Kadota, R Pressey, JG Shen, V Chu, R Cooper, T Jeha, S Razzouk, BI Rytting, ME Barry, E Carroll, WL Gaynon, P AF Huiya, Nobuko Paul, Jo-Anne Borowitz, Michael J. Thomson, Blythe Isakoff, Michael Silverman, Lewis B. Steinherz, Peter G. Kadota, Richard Pressey, Joseph G. Shen, Violet Chu, Roland Cooper, Todd Jeha, Sima Razzouk, Bassem I. Rytting, Michael E. Barry, Elly Carroll, William L. Gaynon, Paul TI Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Huiya, Nobuko] Childrens Mem Hosp, Chicago, IL 60614 USA. [Paul, Jo-Anne] Genzyme Corp, San Antonio, TX USA. [Borowitz, Michael J.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA. [Thomson, Blythe] Seattle Childrens Hosp, Seattle, WA USA. [Isakoff, Michael] Connecticut Childrens Med Ctr, Hartford, CT USA. [Silverman, Lewis B.] Childrens Hosp Boston, Dana Farber Canc Inst, Boston, MA USA. [Steinherz, Peter G.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Kadota, Richard; Barry, Elly] Genzyme Corp, Cambridge, MA USA. [Pressey, Joseph G.] Univ Alabama Childrens Hosp, Birmingham, AL USA. [Shen, Violet] Childrens Hosp Orange Cty, Orange, CA 92668 USA. [Chu, Roland] Childrens Hosp Michigan, Detroit, MI 48201 USA. [Cooper, Todd] Emory Univ, Atlanta, GA 30322 USA. [Jeha, Sima] St Jude Childrens Hosp, Memphis, TN 38105 USA. [Razzouk, Bassem I.] St Vincent Childrens Hosp, Indianapolis, IN USA. [Rytting, Michael E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Carroll, William L.] NYU Canc Inst, NYU Med Ctr, New York, NY USA. [Gaynon, Paul] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 378 EP 379 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200867 ER PT J AU Parmar, K Vinciguerra, P Godinho, S Hamilton, A Pellman, D D'Andrea, AD AF Parmar, Kalindi Vinciguerra, Patrizia Godinho, Susana Hamilton, Abigail Pellman, David D'Andrea, Alan D. TI Cytokinesis Failure In Fanconi Anemia Pathway Deficient Hematopoietic Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Parmar, Kalindi; Vinciguerra, Patrizia; Hamilton, Abigail; D'Andrea, Alan D.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Godinho, Susana; Pellman, David] Childrens Hosp, Dana Farber Canc Inst, Howard Hughes Med Inst, Dept Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 385 EP 385 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200879 ER PT J AU Cai, A Keskin, D Alonso, A DeLuca, D Zhang, W Lokko, N Nardi, V Stone, RM Sidney, J Brusic, V Wu, CJ AF Cai, Ann Keskin, Derin Alonso, Anselmo DeLuca, David Zhang, Wandi Lokko, Nan Nardi, Valentina Stone, Richard M. Sidney, John Brusic, Vladimir Wu, Catherine J. TI Peptides Derived From Mutated BCR-ABL Elicit T Cell Immunity In CML Patients SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Cai, Ann] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol, Boston, MA USA. [Keskin, Derin; Alonso, Anselmo; DeLuca, David; Zhang, Wandi; Lokko, Nan; Brusic, Vladimir; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Nardi, Valentina] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Sidney, John] La Jolla Inst Allergy & Immunol, La Jolla, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 388 EP 388 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200888 ER PT J AU Matsuoka, KI Koreth, J Kim, HT Bascug, OG McDonough, S Antin, JH Soiffer, R Ritz, J AF Matsuoka, Ken-Ichi Koreth, John Kim, Haesook T. Bascug, O. Gregory McDonough, Sean Antin, Joseph H. Soiffer, Robert Ritz, Jerome TI Effects of Daily Low Dose IL-2 Therapy on Homeostatic Regulation of CD4+Foxp3+Regulatory T Cells In Patients with Chronic Graft-Versus-Host Disease SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Matsuoka, Ken-Ichi; Koreth, John; Bascug, O. Gregory; McDonough, Sean; Antin, Joseph H.; Soiffer, Robert; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 393 EP 393 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200896 ER PT J AU Jagasia, M Arora, M Flowers, M Chao, NJ McCarthy, PL Antin, JH Bolwell, BJ Bredeson, C Cahn, JY Cairo, MS Cutler, C Gale, RP Gupta, V Haagenson, MD Horowitz, MM Lee, SJ Litzow, MR Pavletic, SZ Urbano, A Weisdorf, DJ Zhang, MJ Hahn, T AF Jagasia, Madan Arora, Mukta Flowers, Mary Chao, Nelson J. McCarthy, Philip L. Antin, Joseph H. Bolwell, Brian J. Bredeson, Christopher Cahn, Jean-Yves Cairo, Mitchell S. Cutler, Corey Gale, Robert Peter Gupta, Vikas Haagenson, Michael D. Horowitz, Mary M. Lee, Stephanie J. Litzow, Mark R. Pavletic, Steven Z. Urbano, Alvaro Weisdorf, Daniel. J. Zhang, Mei-Jie Hahn, Theresa TI Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jagasia, Madan] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Weisdorf, Daniel. J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Flowers, Mary; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Flowers, Mary] Univ Washington, Seattle, WA 98195 USA. [Chao, Nelson J.] Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC USA. [McCarthy, Philip L.] Roswell Pk Canc Inst, BMT Program, Buffalo, NY 14263 USA. [Antin, Joseph H.; Cutler, Corey] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Bolwell, Brian J.] Cleveland Clin, Cleveland, OH 44106 USA. [Cahn, Jean-Yves] CHU Grenoble, F-38043 Grenoble 09, France. [Cairo, Mitchell S.] Columbia Univ, Med Ctr, Div Pediat Hematol & Blood & Marrow Transplantat, New York, NY USA. [Gale, Robert Peter] Ctr Adv Studies Leukemia, Los Angeles, CA USA. [Gupta, Vikas] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Haagenson, Michael D.] CIBMTR Minneapolis, Minneapolis, MN USA. [Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Litzow, Mark R.] Mayo Clin, Rochester, MN USA. [Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Urbano, Alvaro] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain. [Hahn, Theresa] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 394 EP 394 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200898 ER PT J AU Arora, M Klein, JP Antin, JH Bolwell, BJ Boyiadzis, M Cahn, JY Cairo, MS Cutler, CS Flowers, MED Gale, RP Hassebroek, A Herzig, RH Horowitz, MM Isola, L Jacobsohn, DA Klumpp, TR Lee, SJ Petersdorf, EW Santarone, S Schouten, HC Spellman, S Urbano, A Weisdorf, DJ Wingard, JR Pavletic, SZ AF Arora, Mukta Klein, John P. Antin, Joseph H. Bolwell, Brian J. Boyiadzis, Michael Cahn, Jean-Yves Cairo, Mitchell S. Cutler, Corey S. Flowers, Mary E. D. Gale, Robert P. Hassebroek, Anna Herzig, Roger H. Horowitz, Mary M. Isola, Luis Jacobsohn, David A. Klumpp, Thomas R. Lee, Stephanie J. Petersdorf, Effie W. Santarone, Stella Schouten, Harry C. Spellman, Stephen Urbano, Alvaro Weisdorf, Daniel J. Wingard, John R. Pavletic, Steven Z. TI Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Arora, Mukta] Univ Minnesota, Minneapolis, MN USA. [Klein, John P.] Med Coll Wisconsin, Dept Biostat, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Antin, Joseph H.; Cutler, Corey S.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Bolwell, Brian J.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Boyiadzis, Michael] Univ Pittsburgh Canc Inst, Pittsburgh, PA USA. [Cahn, Jean-Yves] CHU Grenoble, F-38043 Grenoble 09, France. [Cairo, Mitchell S.] Columbia Univ, NewYork Presbyterian Morgan Stanley Childrens Hos, New York, NY USA. [Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Flowers, Mary E. D.] Univ Washington, Seattle, WA 98195 USA. [Gale, Robert P.] Celgene Corp, Summit, NJ USA. [Herzig, Roger H.] Univ Louisville, James Graham Brown Canc Ctr, BMT, Louisville, KY 40292 USA. [Isola, Luis] Mt Sinai Med Ctr, BMT, New York, NY 10029 USA. [Jacobsohn, David A.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Klumpp, Thomas R.] Temple Univ, Wynnewood, PA USA. [Santarone, Stella] Osped Civile, BMT Ctr, Pescara, Italy. [Schouten, Harry C.] Acad Ziekenhuis, Maastricht, Netherlands. [Hassebroek, Anna; Spellman, Stephen] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Urbano, Alvaro] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain. [Weisdorf, Daniel J.] Univ Minnesota Med Ctr, Minneapolis, MN USA. Univ Florida, Shands Canc Ctr, Gainesville, FL USA. [Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, Canc Res Ctr, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 395 EP 396 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201001 ER PT J AU Lane, AA Armand, P Feng, Y Neuberg, D Abramson, JS Brown, JR Fisher, DC LaCasce, AS Jacobsen, ED McAfee, SL Spitzer, TR Freedman, AS Chen, YB AF Lane, Andrew A. Armand, Philippe Feng, Yang Neuberg, Donna Abramson, Jeremy S. Brown, Jennifer R. Fisher, David C. LaCasce, Ann S. Jacobsen, Eric D. McAfee, Steven L. Spitzer, Thomas R. Freedman, Arnold S. Chen, Yi-Bin TI Risk Factors Associated with the Development of Pneumonitis After High-Dose Chemotherapy with Cyclophosphamide, BCNU, and Etoposide (CBV) Followed by Autologous Stem Cell Transplant SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Lane, Andrew A.; Armand, Philippe; Brown, Jennifer R.; Fisher, David C.; LaCasce, Ann S.; Jacobsen, Eric D.; Freedman, Arnold S.] Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA 02114 USA. [Feng, Yang; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 398 EP 398 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201007 ER PT J AU Richardson, P Smith, A Arai, S Grupp, SA Kernan, NA Adams, R Martin, PL Abhyankar, S Gillio, A Grimley, M Lehmann, LE Haut, P Termuhlen, A Antin, JH Spitzer, T Avigan, D Massaro, J Hannah, AL Iacobelli, M Soiffer, RJ AF Richardson, Paul Smith, Angela Arai, Sally Grupp, Stephan A. Kernan, Nancy A. Adams, Roberta Martin, Paul L. Abhyankar, Sunil Gillio, Alfred, III Grimley, Michael Lehmann, Leslie E. Haut, Paul Termuhlen, Amanda Antin, Joseph H. Spitzer, Thomas Avigan, David Massaro, Joseph Hannah, Alison L. Iacobelli, Massimo Soiffer, Robert J. CA Defibrotide Study Grp TI Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Richardson, Paul] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA USA. [Smith, Angela] Univ Minnesota, Ped Hem Onc BMT, Minneapolis, MN USA. [Arai, Sally] Stanford Univ, Stanford, CA 94305 USA. [Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA USA. [Kernan, Nancy A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Adams, Roberta] Mayo Clin, Phoenix, AZ USA. [Martin, Paul L.] Duke Univ Med Ctr, Durham, NC USA. [Abhyankar, Sunil] Univ Kansas Med Ctr, Dept Hematol Oncol, Kansas City, KS USA. [Gillio, Alfred, III] Hackensack Univ Med Ctr, Tomorrows Childrens Inst, Hackensack, NJ USA. [Grimley, Michael] Texas Transplant Inst, San Antonio, TX USA. [Lehmann, Leslie E.] Dana Farber Canc Inst, Pediat Oncol HSCT, Boston, MA 02115 USA. [Haut, Paul] Indiana Univ Simon Canc Ctr, Indianapolis, IN USA. [Termuhlen, Amanda] Nationwide Childrens Hosp, Columbus, OH USA. [Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Spitzer, Thomas] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Avigan, David] BIDMC, Boston, MA USA. [Massaro, Joseph] Boston Univ, Dept Stat, Boston, MA 02215 USA. [Hannah, Alison L.] Gentium, Como, Italy. [Iacobelli, Massimo] Gentium SpA, Dept Med Sci, Villa Guardia, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 399 EP 400 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201009 ER PT J AU Brunstein, C Eapen, M Ahn, KW Appelbaum, FR Ballen, KK Champlin, R Kan, FY Laughlin, MJ Soiffer, RJ Weisdorf, DJ Woolfrey, A Horowitz, MM Wagner, JE AF Brunstein, Claudio Eapen, Mary Ahn, Kwang W. Appelbaum, Frederick R. Ballen, Karen K. Champlin, Richard Kan, Fangyu Laughlin, Mary J. Soiffer, Robert J. Weisdorf, Daniel J. Woolfrey, Ann Horowitz, Mary M. Wagner, John E. TI Reduced Intensity Conditioning (RIC) Transplantation In Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Brunstein, Claudio; Weisdorf, Daniel J.; Wagner, John E.] Univ Minnesota Med Ctr, Minneapolis, MN USA. [Ahn, Kwang W.; Kan, Fangyu; Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Champlin, Richard] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Laughlin, Mary J.] Univ Virginia, Hematopoiet Stem Cell Program, Charlottesville, VA USA. [Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 400 EP 401 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201011 ER PT J AU Smith, MR Neuberg, D Flinn, IW Grever, MR Bennett, JM Dewald, G Paietta, EM Litzow, MR Rowe, JM Lucas, D Kitada, S Jelinek, DF Gribben, JG Byrd, JC Reed, JC Hussein, MA Appelbaum, FR Larson, RA Moore, DF Tallman, MS AF Smith, Mitchell R. Neuberg, Donna Flinn, Ian W. Grever, Michael R. Bennett, John M. Dewald, Gordon Paietta, Elisabeth M. Litzow, Mark R. Rowe, Jacob M. Lucas, David Kitada, Shinichi Jelinek, Diane F. Gribben, John G. Byrd, John C. Reed, John C. Hussein, Mohamad A. Appelbaum, Frederick R. Larson, Richard A. Moore, Dennis F., Jr. Tallman, Martin S. TI Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Smith, Mitchell R.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA. [Grever, Michael R.; Lucas, David; Byrd, John C.] Ohio State Univ, Columbus, OH 43210 USA. [Bennett, John M.] Univ Rochester, Rochester, NY USA. [Dewald, Gordon] Mayo Clin, Rochester, MN USA. [Paietta, Elisabeth M.] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA. [Litzow, Mark R.; Jelinek, Diane F.] Mayo Clin, Rochester, MN USA. [Rowe, Jacob M.] Technion Israel Inst Technol, Rambam Med Ctr, Haifa, Israel. [Kitada, Shinichi; Reed, John C.] Sanford Burnham Med Res Inst, La Jolla, CA USA. [Gribben, John G.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Med Oncol, Inst Canc, London, England. [Hussein, Mohamad A.] Celgene Corp, Summit, NJ USA. [Appelbaum, Frederick R.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98195 USA. [Larson, Richard A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Moore, Dennis F., Jr.] Canc Ctr Kansas, Wichita, KS USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 408 EP 409 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201027 ER PT J AU Krause, DS Lezeau, S Hurley, M Schipani, E Scadden, DT AF Krause, Daniela S. Lezeau, Sanon Hurley, Michael Schipani, Ernestina Scadden, David T. TI Parathyroid Hormone-Induced Modulation of the Bone Marrow Microenvironment Inhibits the Development of Murine Chronic Myelogenous-Leukemia-Like Disease SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Krause, Daniela S.; Lezeau, Sanon; Hurley, Michael] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Schipani, Ernestina] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Scadden, David T.] Harvard Stem Cell Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 414 EP 414 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201040 ER PT J AU Richardson, PG Moreau, P Jakubowiak, AJ Facon, T Jagannath, S Vij, R Reece, DE White, DJ Raab, MS Benboubker, L Rossi, JF Tsao, C Fry, J Berman, D Singhal, AK Lonial, S AF Richardson, Paul G. Moreau, Philippe Jakubowiak, Andrzej J. Facon, Thierry Jagannath, Sundar Vij, Ravi Reece, Donna E. White, Darrell J. Raab, Marc S. Benboubker, Lotfi Rossi, Jean-Francois Tsao, Claire Fry, John Berman, David Singhal, Anil K. Lonial, Sagar TI Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Moreau, Philippe] Univ Hosp, Hotel Dieu, Nantes, France. [Jakubowiak, Andrzej J.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Facon, Thierry] Hop Claude Huriez, Serv Malad Sang, Lille, France. [Jagannath, Sundar] Mt Sinai Med Ctr, Multiple Myeloma Program, New York, NY 10029 USA. [Vij, Ravi] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Reece, Donna E.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [White, Darrell J.] Queen Elizabeth 2 Hlth Sci Ctr, Div Hematol, Halifax, NS, Canada. [Raab, Marc S.] Univ Klinikum Heildelberg, Heidelberg, Germany. [Benboubker, Lotfi] CHU Tours, Hop Bretonneau, Serv Hematol, Tours, France. [Rossi, Jean-Francois] Hop St Eloi, CHU Montpellier, Serv Hematol Clin & Biotherapies, Montpellier, France. [Tsao, Claire; Fry, John; Singhal, Anil K.] Facet Biotech, Redwood City, CA USA. [Berman, David] Bristol Myers Squibb Co, Princeton, NJ USA. [Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015 OI FACON, THIERRY/0000-0001-7705-8460; NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 434 EP 434 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201089 ER PT J AU Ghobrial, IM Weller, E Vij, R Munshi, NC Banwait, R Rourke, M Schlossman, RL Laubach, JP Jakubowiak, AJ Leduc, R Chuma, S Kunsman, J Dollard, AM Warren, D Harris, B Poon, T Sam, A Rodig, SJ Anderson, KC Richardson, PG AF Ghobrial, Irene M. Weller, Edie Vij, Ravi Munshi, Nikhil C. Banwait, Ranjit Rourke, Meghan Schlossman, Robert L. Laubach, Jacob P. Jakubowiak, Andrzej J. Leduc, Renee Chuma, Stacey Kunsman, Janet Dollard, Akari M. Warren, Diane Harris, Brianna Poon, Tiffany Sam, Amy Rodig, Scott J. Anderson, Kenneth C. Richardson, Paul G. TI Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ghobrial, Irene M.; Banwait, Ranjit; Rourke, Meghan; Kunsman, Janet; Warren, Diane; Sam, Amy] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Vij, Ravi] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA. [Jakubowiak, Andrzej J.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Rodig, Scott J.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 435 EP 436 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201093 ER PT J AU Kim, MK Suh, C Chi, HS Choi, HS Lee, KH Lee, GW Kim, IS Eom, HS Kong, SY Bae, SH Ryoo, HM Mun, YC Chung, H Hyun, MS AF Kim, Min Kyoung Suh, Cheolwon Chi, Hyun Sook Choi, Hee Soon Lee, Kyung Hee Lee, Gyeong-Won Kim, In-Suk Eom, Hyeon Seok Kong, Sun-Young Bae, Sung Hwa Ryoo, Hun-Mo Mun, Yeung-Chul Chung, Hwasoon Hyun, Myung Soo TI VEGFA and VEGFR2 Genetic Polymorphisms and Survival In Patients with Diffuse Large B Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Suh, Cheolwon] Asan Med Ctr, Dept Oncol, Seoul, South Korea. [Chi, Hyun Sook] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea. [Lee, Gyeong-Won] Gyeongsang Natl Univ, Gyeongsang Natl Hosp, Sch Med, Jinju, South Korea. [Kim, In-Suk] Gyeong Sang Natl Univ Hosp, Jinju, Gyeong Sang Do, South Korea. [Eom, Hyeon Seok] Natl Canc Ctr Korea, Dept Internal Med, Goyang, South Korea. [Kong, Sun-Young] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Kong, Sun-Young] Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Bae, Sung Hwa] Catholic Univ, Coll Med Daegu, Taegu, South Korea. [Ryoo, Hun-Mo] Daegu Catholic Univ Hosp, Dept Int Med, Div Hem Onc, Namgu, South Korea. [Mun, Yeung-Chul] Ewha Womans Univ Hosp, Seoul, South Korea. [Chung, Hwasoon] Ewha Womans Univ, Sch Med, Seoul, South Korea. [Hyun, Myung Soo] Yeungnam Univ, Med Ctr, Taegu, South Korea. [Kim, Min Kyoung; Choi, Hee Soon; Lee, Kyung Hee] Yeungnam Univ, Coll Med, Taegu, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 438 EP 438 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201097 ER PT J AU Banerji, V Ross, KN Li, LS Frumm, SM Schinzel, AC Hahn, CK Kakoza, RM Chow, KT Ross, L Inguilizian, H Galinsky, I Stone, RM DeAngelo, DJ Hahn, WC Kung, AL Stegmaier, K AF Banerji, Versha Ross, Kenneth N. Li, Loretta S. Frumm, Stacey M. Schinzel, Anna C. Hahn, Cynthia K. Kakoza, Rose M. Chow, Kwan T. Ross, Linda Inguilizian, Haig Galinsky, Ilene Stone, Richard M. DeAngelo, Daniel J. Hahn, William C. Kung, Andrew L. Stegmaier, Kimberly TI Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3 alpha (GSK-3 alpha) as a Modulator of Differentiation In Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Banerji, Versha; Li, Loretta S.; Frumm, Stacey M.; Schinzel, Anna C.; Hahn, Cynthia K.; Kakoza, Rose M.; Chow, Kwan T.; Ross, Linda; Inguilizian, Haig; Galinsky, Ilene; Stone, Richard M.; DeAngelo, Daniel J.; Hahn, William C.; Kung, Andrew L.; Stegmaier, Kimberly] Dana Farber Canc Inst, Boston, MA 02115 USA. [Banerji, Versha; Li, Loretta S.; Frumm, Stacey M.; Hahn, Cynthia K.; Kakoza, Rose M.; Chow, Kwan T.; Ross, Linda; Inguilizian, Haig; Kung, Andrew L.; Stegmaier, Kimberly] Childrens Hosp Boston, Boston, MA USA. [Ross, Kenneth N.] Broad Inst Harvard Univ & Massachusetts Inst Tech, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 440 EP 440 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201103 ER PT J AU Tyner, JW Sanda, T Gutierrez, A Glover, JM Chang, BH Willis, SG Ahn, Y Look, AT Druker, BJ AF Tyner, Jeffrey W. Sanda, Takaomi Gutierrez, Alejandro Glover, Jason M. Chang, Bill H. Willis, Stephanie G. Ahn, Yebin Look, A. Thomas Druker, Brian J. TI RNAi Screen Reveals TYK2 as a Novel Therapeutic Gene Target In T-Cell Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Tyner, Jeffrey W.; Glover, Jason M.; Chang, Bill H.; Willis, Stephanie G.; Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA. [Sanda, Takaomi; Gutierrez, Alejandro; Ahn, Yebin; Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 441 EP 441 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201104 ER PT J AU Ma, WX Gutierrez, A Goff, D Court-Recart, A Shih, A Jiang, QF Sadarangani, A Wu, C Jamieson, C Diccianni, M Wei, P Van Arsdale, T Look, T Jamieson, C AF Ma, Wenxue Gutierrez, Alejandro Goff, Daniel Court-Recart, Angela Shih, Alice Jiang, Qingfei Sadarangani, Anil Wu, Christina Jamieson, Christina Diccianni, Mitchell Wei, Ping Van Arsdale, Todd Look, Thomas Jamieson, Catriona TI A Notch Mutational Hierarchy Among Human T-ALL Leukemia Stem Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ma, Wenxue; Goff, Daniel; Court-Recart, Angela; Shih, Alice; Jiang, Qingfei; Sadarangani, Anil; Wu, Christina; Jamieson, Christina; Diccianni, Mitchell] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Gutierrez, Alejandro] Dana Farber Canc Inst, Somerville, MA USA. [Wei, Ping; Van Arsdale, Todd] Pfizer, San Diego, CA USA. [Look, Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 454 EP 455 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201137 ER PT J AU Kentsis, A Sanda, T Ngo, V Rodig, SJ Kutok, J Tholouli, E Byers, R Woude, GV Kung, AL Staudt, LM Look, AT AF Kentsis, Alex Sanda, Takaomi Ngo, Vu Rodig, Scott J. Kutok, Jeffery Tholouli, Eleni Byers, Richard Woude, George Vande Kung, Andrew L. Staudt, Louis M. Look, A. Thomas TI Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kentsis, Alex; Sanda, Takaomi; Kung, Andrew L.; Look, A. Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Childrens Hosp Boston, Boston, MA 02115 USA. [Ngo, Vu; Staudt, Louis M.] NCI, NIH, Bethesda, MD USA. [Rodig, Scott J.; Kutok, Jeffery] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA. [Tholouli, Eleni; Byers, Richard] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester, Lancs, England. [Woude, George Vande] Van Andel Res Inst, Grand Rapids, MI USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 458 EP 458 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201145 ER PT J AU Leblebjian, H McDonnell, A Skirvin, JA Wadleigh, M Yao, XP Neuberg, D Bartel, S DeAngelo, DJ Stone, RM AF Leblebjian, Houry McDonnell, Anne Skirvin, J. Andrew Wadleigh, Martha Yao, Xiaopan Neuberg, Donna Bartel, Sylvia DeAngelo, Daniel J. Stone, Richard M. TI Predictive Factors for All-Trans Retinoic Acid Related Differentiation Syndrome In Acute Promyelocytic Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Yao, Xiaopan] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Skirvin, J. Andrew] Northeastern Univ, Dana Farber Canc Ctr, Brigham & Womens Hosp, Boston, MA 02115 USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 462 EP 462 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201155 ER PT J AU Taylor, AM Humphries, JM White, RM Murphey, RD Burns, CE Zon, LI AF Taylor, Alison M. Humphries, Jessica M. White, Richard M. Murphey, Ryan D. Burns, Caroline E. Zon, Leonard I. TI p53 Dependent and Dose Dependent Effects of Rps29 Mutation In the Zebrafish Embryo SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Taylor, Alison M.; Humphries, Jessica M.; White, Richard M.; Murphey, Ryan D.; Zon, Leonard I.] Harvard Univ, Sch Med, Stem Cell Program & Hematol Oncol, Childrens Hosp, Boston, MA USA. [Taylor, Alison M.; Humphries, Jessica M.; White, Richard M.; Murphey, Ryan D.; Zon, Leonard I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst,Harvard Stem Cell Inst, Boston, MA USA. [Burns, Caroline E.] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 504 EP 504 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201273 ER PT J AU Jiang, YJ Leary, E Yavanian, G Anbazhagan, R Salerno, A Marasco, W Rodgerson, D AF Jiang, Yajuan Leary, Elizabeth Yavanian, Gregory Anbazhagan, Rajesh Salerno, Anthony Marasco, Wayne Rodgerson, Denis TI Isolation of G-CSF Mobilized Human Mesenchymal Stem Cells by Elutriation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jiang, Yajuan; Leary, Elizabeth; Yavanian, Gregory; Anbazhagan, Rajesh; Salerno, Anthony; Rodgerson, Denis] Neostem Inc, Cambridge, MA USA. [Marasco, Wayne] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 509 EP 509 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201286 ER PT J AU Rudner, LA Brown, KH Dobrinski, KP Bradley, DF Downie, J Meeker, ND Smith, A Garcia, MI Gutierrez, A Mullighan, C Look, AT Downing, JR Schiffman, JD Lee, C Trede, N Frazer, JK AF Rudner, Lynnie A. Brown, Kim H. Dobrinski, Kimberly P. Bradley, Diana F. Downie, Jonathan Meeker, Nathan D. Smith, Alexandra Garcia, Martha Iveth Gutierrez, Alejandro Mullighan, Charles Look, A. Thomas Downing, James R. Schiffman, Joshua D. Lee, Charles Trede, Nikolaus Frazer, J. Kimble TI Cross-Species Comparison of Acquired Genetic Changes In T tell Malignancy. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Rudner, Lynnie A.; Bradley, Diana F.; Downie, Jonathan; Smith, Alexandra] Univ Utah, Dept Oncol Sci, Salt Lake City, UT USA. [Brown, Kim H.; Dobrinski, Kimberly P.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Meeker, Nathan D.] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Garcia, Martha Iveth] Univ Texas Brownsville, Brownsville, TX 78520 USA. [Gutierrez, Alejandro] Dana Farber Canc Inst, Somerville, NJ USA. [Mullighan, Charles] St Jude Childrens Rsch Hosp, Dept Pathol, Memphis, TN USA. [Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. [Downing, James R.] St Jude Childrens Hosp, Memphis, TN 38105 USA. [Lee, Charles] Harvard Univ, Sch Med, BWH, Boston, MA USA. [Trede, Nikolaus] Univ Utah, Dept Pediat, Dept Oncol Sci, Salt Lake City, UT USA. [Frazer, J. Kimble] Univ Utah, Dept Pediat, Dept Oncol Sci, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 512 EP 512 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201295 ER PT J AU Kopinski, P Nieborowska-Skorska, M Hoser, G Ngaba, D Ray, R Koptyra, M Bolton, E Seferynska, I Storski, T Slupianek, A Reddy, MR Sattler, M Skorski, T AF Kopinski, Piotr Nieborowska-Skorska, Margaret Hoser, Grazyna Ngaba, Danielle Ray, Regina Koptyra, Mateusz Bolton, Elisabeth Seferynska, Ilona Storski, Tomasz Slupianek, Artur Reddy, Mamatha R. Sattler, Martin Skorski, Tomasz TI Mitochondrial Respiratory Chain Complex III Causes Genomic Instability In CML-CP. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kopinski, Piotr; Nieborowska-Skorska, Margaret; Ngaba, Danielle; Ray, Regina; Koptyra, Mateusz; Bolton, Elisabeth; Slupianek, Artur; Skorski, Tomasz] Temple Univ, Dept Microbiol & Immunol, Sch Med, Philadelphia, PA 19122 USA. [Hoser, Grazyna] Med Ctr Postgrad Educ, Warsaw, Poland. [Seferynska, Ilona] Inst Hematol & Blood Transfus, Warsaw, Poland. [Storski, Tomasz] Med Univ Warsaw, Warsaw, Poland. [Reddy, Mamatha R.; Sattler, Martin] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 519 EP 519 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201314 ER PT J AU Zhang, B Ho, YW Huang, Q Huettner, C Bhatia, R AF Zhang, Bin Ho, Yin Wei Huang, Qin Huettner, Claudia Bhatia, Ravi TI Altered Niche Interactions of Leukemia Stem Cells In a Chronic Phase Chronic Myelogenbus Leukemia (CML) Transgenic Mouse Model SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Zhang, Bin; Ho, Yin Wei; Bhatia, Ravi] City Hope Natl Med Ctr, HEM HCT, Duarte, CA 91010 USA. [Huang, Qin] City Hope Natl Canc Ctr, Dept Pathol, Duarte, CA USA. [Huettner, Claudia] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 519 EP 520 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201315 ER PT J AU Kawano, Y Kim, H Matsuoka, K Lazo-Kallanian, S Daley, J Antin, JH Soiffer, R Ritz, J AF Kawano, Yutaka Kim, Haesoak Matsuoka, Ken-ichi Lazo-Kallanian, Suzan Daley, John Antin, Joseph H. Soiffer, Robert Ritz, Jerome TI Decreased Telomerase Activity In CD4 Regulatory T Cells Is Associated with Severity of Chronic Graft-Versus-Host Disease (cGVHD) After Hematopoietic Stem Cell Transplantation (HSCT). SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kawano, Yutaka; Kim, Haesoak; Matsuoka, Ken-ichi; Lazo-Kallanian, Suzan; Daley, John; Antin, Joseph H.; Soiffer, Robert; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 538 EP 539 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201360 ER PT J AU Soriano, G Herrera, AF Hornick, JL Gilmore, E Ho, VT Ballen, KK Baden, LR Cutler, CS Antin, JH Soiffer, RJ Marty, FM AF Soriano, Gabriela Herrera, Alex F. Hornick, Jason L. Gilmore, Erin Ho, Vincent T. Ballen, Karen K. Baden, Lindsey R. Cutler, Corey S. Antin, Joseph H. Soiffer, Robert J. Marty, Francisco M. TI Cord Colitis: An Antibiotic-Responsive Colitis Syndrome Following Cord Blood Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Soriano, Gabriela; Herrera, Alex F.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Hornick, Jason L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Gilmore, Erin; Baden, Lindsey R.; Marty, Francisco M.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Ho, Vincent T.; Cutler, Corey S.; Antin, Joseph H.; Soiffer, Robert J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 543 EP 544 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201373 ER PT J AU Sorror, ML Storer, B Sandmaier, BM Franke, GN Laport, GG Chauncey, T Agura, E Maris, MT Wade, J Pulsipher, MA Maziarz, RT Sahebi, F McSweeney, P Bruno, B Vindelov, L Yeager, AM Rezvani, A Niederwieser, DW Blume, KG Storb, RF Maloney, DG AF Sorror, Mohamed L. Storer, Barry Sandmaier, Brenda M. Franke, Georg N. Laport, Ginna G. Chauncey, Thomas Agura, Edward Maris, Michael T. Wade, James Pulsipher, Michael A. Maziarz, Richard T. Sahebi, Firoozeh McSweeney, Peter Bruno, Benedetto Vindelov, Lars Yeager, Andrew M. Rezvani, Andrew Niederwieser, Dietger W. Blume, Karl G. Storb, Rainer F. Maloney, David G. TI Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sorror, Mohamed L.; Storer, Barry; Sandmaier, Brenda M.; Chauncey, Thomas; Rezvani, Andrew; Storb, Rainer F.; Maloney, David G.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Franke, Georg N.; Niederwieser, Dietger W.] Univ Leipzig, Leipzig, Germany. [Laport, Ginna G.; Blume, Karl G.] Stanford Univ, Stanford, CA 94305 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Agura, Edward] Baylor Univ, Dallas, TX USA. [Maris, Michael T.] Rocky Mt Canc Ctr, Denver, CO USA. [Wade, James] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [McSweeney, Peter] Univ Colorado, Boulder, CO 80309 USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Vindelov, Lars] Rigshosp, DK-2100 Copenhagen, Denmark. [Yeager, Andrew M.] Univ Arizona, Tucson, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 553 EP 553 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201395 ER PT J AU Duncan, C Apfelbaum, E Whitley, K Margossian, SP Lehmann, LE AF Duncan, Christine Apfelbaum, Erin Whitley, Katherine Margossian, Steven P. Lehmann, Leslie E. TI 25-OH Vitamin D Deficiency Following Pediatric Hematopoietic Stem Cell Transplant. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Lehmann, Leslie E.] Dana Farber Canc Inst, Pediat Oncol HSCT, Boston, MA 02115 USA. [Margossian, Steven P.] Childrens Hosp, DFCI, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 561 EP 561 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201413 ER PT J AU Varadarajan, P Toro, J Craig, RM Schneider, D Chao, JH Haile, D Freytes, CO AF Varadarajan, Prakash Toro, Juan Craig, Robert M. Schneider, Deanna Chao, Ju-Hsien Haile, David Freytes, Cesar O. TI Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude Intensive Chemotherapy? Oral and Infectious Toxicities Associated with Autotransplantation In Patients with BONJ SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Varadarajan, Prakash; Haile, David; Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Toro, Juan; Craig, Robert M.; Schneider, Deanna; Chao, Ju-Hsien] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 562 EP 563 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201417 ER PT J AU Koreth, J Biernacki, M Aldridge, J Kim, HT Alyea, EP Armand, P Cutler, C Ho, VT Wu, CJ Antin, JH Soiffer, RJ AF Koreth, John Biernacki, Melinda Aldridge, Julie Kim, Haesook T. Alyea, Edwin P., III Armand, Philippe Cutler, Corey Ho, Vincent T. Wu, Catherine J. Antin, Joseph H. Soiffer, Robert J. TI Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Koreth, John; Alyea, Edwin P., III; Armand, Philippe; Cutler, Corey; Ho, Vincent T.; Wu, Catherine J.; Antin, Joseph H.; Soiffer, Robert J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Biernacki, Melinda] Brown Univ, Dept Med, Providence, RI 02912 USA. [Aldridge, Julie; Kim, Haesook T.] Dana Farber Canc Inst, Div Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 567 EP 567 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201426 ER PT J AU Koreth, J Kim, HT Ho, VT Cutler, C Armand, P Soiffer, RJ Antin, JH Alyea, EP AF Koreth, John Kim, Haesook T. Ho, Vincent T. Cutler, Corey Armand, Philippe Soiffer, Robert J. Antin, Joseph H. Alyea, Edwin P., III TI Low Day 30 Total Donor Chimerism After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Poorer Overall Survival In Myeloid but Not Lymphoid Disorders SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Koreth, John; Ho, Vincent T.; Cutler, Corey; Armand, Philippe; Soiffer, Robert J.; Antin, Joseph H.; Alyea, Edwin P., III] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Div Biostat & Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 568 EP 568 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201428 ER PT J AU Brown, JR Messmer, B Werner, L Mikler, E Fisher, DC LaCasce, A Armand, P Jacobsen, ED Dalton, V Tesar, B Fernandes, SM McDonough, S Ritz, J Rassenti, LZ Kipps, TJ Neuberg, D Freedman, AS AF Brown, Jennifer R. Messmer, Bradley Werner, Lillian Mikler, Evgeny Fisher, David C. LaCasce, Ann Armand, Philippe Jacobsen, Eric D. Dalton, Virginia Tesar, Bethany Fernandes, Stacey M. McDonough, Sean Ritz, Jerome Rassenti, Laura Z. Kipps, Thomas J. Neuberg, Donna Freedman, Arnold S. TI A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Messmer, Bradley; Rassenti, Laura Z.] UCSD, Moores Canc Ctr, La Jolla, CA USA. [LaCasce, Ann] Dana Farber Canc Inst, Dept Med Onc, Boston, MA 02115 USA. [Kipps, Thomas J.] Univ Calif San Diego, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 594 EP 594 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201484 ER PT J AU Kim, H Eom, HS Kong, SY Park, SR Kim, SY Ro, J Park, SY AF Kim, Hyojeong Eom, Hyeon-Seok Kong, Sun-Young Park, Sook Ryun Kim, Sun Young Ro, Jungsil Park, Sang-Yoon TI Prognastic Significance of Immune Thrombocytopenic Purpura In Patients with Malignancy SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kim, Hyojeong] Natl Canc Ctr, Ctr Cilin Trials, Goyang Si, South Korea. [Eom, Hyeon-Seok] Natl Canc Ctr, Hematol Oncol Clin, Goyang Si, South Korea. [Kong, Sun-Young] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Kong, Sun-Young] Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Park, Sook Ryun] Natl Canc Ctr, Ctr Gastr Canc, Goyang Si, South Korea. [Kim, Sun Young] Natl Canc Ctr, Ctr Colorectal Canc, Goyang Si, South Korea. [Ro, Jungsil] Natl Canc Ctr, Ctr Breast Canc, Goyang Si, South Korea. [Park, Sang-Yoon] Natl Canc Ctr, Res Inst, Branch Uterine Canc, Goyang Si, South Korea. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 613 EP 613 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201530 ER PT J AU Fuchs, TA Hovinga, JAK Schatzberg, D Monestier, M Wagner, DD Lammle, B AF Fuchs, Tobias A. Hovinga, Johanna A. Kremer Schatzberg, Daphne Monestier, Marc Wagner, Denisa D. Laemmle, Bernhard TI Circulating Nucleosomes Reflect Disease Activity in Patients with Thrombotic Microangiopathies SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Fuchs, Tobias A.; Wagner, Denisa D.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Hovinga, Johanna A. Kremer; Laemmle, Bernhard] Univ Hosp Bern, CH-3010 Bern, Switzerland. [Hovinga, Johanna A. Kremer; Laemmle, Bernhard] Univ Bern, Bern, Switzerland. [Monestier, Marc] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 617 EP 617 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201539 ER PT J AU Desponts, C Robbins, D Le, T Chi, A Thies, S Armant, M Cutler, C Mendlein, J Grayson, P Multani, PS Shoemaker, D AF Desponts, Caroline Robbins, David Le, Thuy Chi, Annie Thies, Scott Armant, Myriam Cutler, Corey Mendlein, John Grayson, Paul Multani, Pratik S. Shoemaker, Daniel TI Use of Genome-Wide Expression Analysis to Optimize An Ex Vivo clinical Protocol for 16,16-Dimethyl Prostaglandin E2 Enhancement of Umbilical Cord Blood In Hematopoietic Stem Cell Transplantation. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Desponts, Caroline; Robbins, David; Le, Thuy; Chi, Annie; Thies, Scott; Mendlein, John; Grayson, Paul; Multani, Pratik S.; Shoemaker, Daniel] Fate Therapeut Inc, San Diego, CA USA. [Armant, Myriam] Ctr Human Cell Therapy, Immune Dis Inst, Boston, MA USA. [Cutler, Corey] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 621 EP 621 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201553 ER PT J AU Love, N Lonial, S Anderson, KC Fonseca, R Elder, M Paley, D Ziel, K AF Love, Neil Lonial, Sagar Anderson, Kenneth C. Fonseca, Rafael Elder, Melanie Paley, Douglas Ziel, Kathryn TI Tolerance and Response to Initial Systemic Therapy In Older Patients with Multiple Myeloma (MM): Observations From 276 Unselected Recent Cases In the Practices of US-Based Medical Oncologists (MOs). SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Love, Neil; Elder, Melanie; Paley, Douglas; Ziel, Kathryn] Res Practice, Miami, FL USA. [Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Fonseca, Rafael] Mayo Clin, Scottsdale, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 645 EP 645 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201618 ER PT J AU Zhao, JJ Lin, JH Chu, ZB Wang, Q Takada, K Mani, M Ciccarelli, B Hideshima, T Tai, YT Tao, JG Treon, SP Munshi, NC Anderson, KC Carrasco, R AF Zhao, Jian-Jun Lin, Jianhong Chu, Zhangbo Wang, Qi Takada, Kohichi Mani, Mala Ciccarelli, Bryan Hideshima, Teru Tai Yu-Tzu Tao, Jianguo Treon, Steven P. Munshi, Nikhil C. Anderson, Kenneth C. Carrasco, Ruben TI Bone Marrow Niche Down-Regulates Mir-30 In Multiple Myeloma Cells to Promote Cancer Progression and Cancer Initiation by Targeting BCL9/Wnt Pathway SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Zhao, Jian-Jun; Lin, Jianhong; Chu, Zhangbo; Wang, Qi; Takada, Kohichi; Mani, Mala; Ciccarelli, Bryan; Tai Yu-Tzu; Treon, Steven P.; Munshi, Nikhil C.; Carrasco, Ruben] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Hideshima, Teru; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA. [Tao, Jianguo] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 664 EP 665 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201671 ER PT J AU Kastritis, E Jakubikova, J Delmore, J Klippel, S McMillin, DW Ooi, M Jacobs, HM Laubach, JP Richardson, PG Anderson, KC Kung, AL Mitsiades, CS AF Kastritis, Efstathios Jakubikova, Jana Delmore, Jake Klippel, Steffen McMillin, Douglas W. Ooi, Melissa Jacobs, Hannah M. Laubach, Jacob P. Richardson, Paul G. Anderson, Kenneth C. Kung, Andrew L. Mitsiades, Constantine S. TI Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor - Microenvironment Interactions SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kastritis, Efstathios; Jakubikova, Jana; Delmore, Jake; Klippel, Steffen; McMillin, Douglas W.; Ooi, Melissa; Jacobs, Hannah M.; Laubach, Jacob P.; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 666 EP 666 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201676 ER PT J AU Chen, YY Con, S Hu, YG Kong, LH Peng, C Li, SG AF Chen, Yaoyu Con, Sullivan Hu, Yiguo Kong, Linghong Peng, Cong Li, Shaoguang TI Loss of P-Selectin Promotes the Function of Aged Hematopoietic and Leukemic Stem Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Chen, Yaoyu; Peng, Cong; Li, Shaoguang] Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA USA. [Con, Sullivan] Maine Inst Human Genet & Hlth, Bangor, ME USA. [Hu, Yiguo] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kong, Linghong] Jackson Lab, Bar Harbor, ME 04609 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 667 EP 667 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201679 ER PT J AU Jakubikova, J Klippel, S Kastritis, E Daley, J Ooi, M Delmore, J Laubach, JP Richardson, PG Sedlak, J Anderson, KC Mitsiades, CS AF Jakubikova, Jana Klippel, Steffen Kastritis, Efstathios Daley, John Ooi, Melissa Delmore, Jake Laubach, Jacob P. Richardson, Paul G. Sedlak, Jan Anderson, Kenneth C. Mitsiades, Constantine S. TI Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jakubikova, Jana; Klippel, Steffen; Kastritis, Efstathios; Ooi, Melissa; Delmore, Jake; Laubach, Jacob P.; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. [Daley, John] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Sedlak, Jan] Slovak Acad Sci, Canc Res Inst, Dept Tumor Immunol, Bratislava, Slovakia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 668 EP 668 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201683 ER PT J AU Huang, HT Kathrein, K Huang, YH Gitlin, Z Barton, A Song, AH Zhou, Y Zon, LI AF Huang, Hsuan-Ting Kathrein, Katie Huang, Yue-Hua Gitlin, Zachary Barton, Abby Song, Anhua Zhou, Yi Zon, Leonard I. TI Chd7 Is a Cell Autonomous Regulator of Chromatin In Hematopoietic Stem Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Huang, Hsuan-Ting; Kathrein, Katie; Huang, Yue-Hua; Gitlin, Zachary; Barton, Abby; Song, Anhua; Zhou, Yi; Zon, Leonard I.] Harvard Univ, Sch Med, Stem Cell Program & Hematol Oncol, Childrens Hosp, Boston, MA USA. [Huang, Hsuan-Ting; Kathrein, Katie; Huang, Yue-Hua; Gitlin, Zachary; Barton, Abby; Song, Anhua; Zhou, Yi; Zon, Leonard I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, HHMI,Harvard Stem Cell Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 673 EP 674 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201698 ER PT J AU Gutti, RK Sallmon, H Liu, ZJ Ferrer-Marin, F Cantor, A Bailey, M Sola-Visner, M AF Gutti, Ravi K. Sallmon, Hannes Liu, Zhi-Jian Ferrer-Marin, Francisca Cantor, Alan Bailey, Matthew Sola-Visner, Martha TI Developmental Differences In the Let-7b/IMP-1/IGF-II Axis contribute to the High Proliferative Rate of Neonatal Megakaryocyte progenitors SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Gutti, Ravi K.; Sallmon, Hannes; Liu, Zhi-Jian; Ferrer-Marin, Francisca; Bailey, Matthew; Sola-Visner, Martha] Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA. [Gutti, Ravi K.; Liu, Zhi-Jian; Ferrer-Marin, Francisca; Bailey, Matthew; Sola-Visner, Martha] Harvard Univ, Sch Med, Boston, MA USA. [Cantor, Alan] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 674 EP 674 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201700 ER PT J AU Bolli, N Payne, E Rhodes, J Johnston, A Guo, F Lee, JS Kanki, J Chen, AT Zhou, Y Zon, LI Look, AT AF Bolli, Niccolo Payne, Elspeth Rhodes, Jennifer Johnston, Adam Guo, Feng Lee, Jeong-Soo Kanki, John Chen, Aye T. Zhou, Yi Zon, Leonard I. Look, A. Thomas TI Cleavage and Polyadenylation Specificity Factor 1 Is Required for Definitive Hematopoietic Stem Cell Survival In Zebrafish SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Rhodes, Jennifer] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Chen, Aye T.] Childrenh Hosp, Div Hematol Oncol, Boston, MA USA. [Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Stem Cell Program & Hematol Oncol, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst,Harvard Stem Cell Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 676 EP 677 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201708 ER PT J AU Carroll, KJ Dovey, MC Cutting, CC Harris, JM Vedder, LM Goessling, W North, TE AF Carroll, Kelli J. Dovey, Michael C. Cutting, Claire C. Harris, James M. Vedder, Lea M. Goessling, Wolfram North, Trista E. TI Estrogen Receptors 1 and 2 Have Stage-Specific Effects on Hematopoietic Stem Cell Regulation In Zebrafish SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Carroll, Kelli J.; Dovey, Michael C.; Harris, James M.; Vedder, Lea M.; North, Trista E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA. [Cutting, Claire C.; Goessling, Wolfram] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Cutting, Claire C.; Goessling, Wolfram] Harvard Univ, Sch Med, Div Genet, Boston, MA 02115 USA. [Cutting, Claire C.; Goessling, Wolfram] Harvard Univ, Sch Med, Div Gastroenterol, Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 680 EP 680 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201718 ER PT J AU Goy, A Pro, B Savage, KJ Bartlett, NL Lechowicz, MJ Jacobsen, ED Young, F Crump, M Borghaei, H Link, B Fruchtman, SM O'Connor, OA AF Goy, Andre Pro, Barbara Savage, Kerry Joanne Bartlett, Nancy L. Lechowicz, Mary Jo Jacobsen, Eric D. Young, Faith Crump, Michael Borghaei, Hossein Link, Brian Fruchtman, Steven M. O'Connor, Owen A. TI Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Goy, Andre] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Pro, Barbara] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA. [Savage, Kerry Joanne] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. [Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA. [Lechowicz, Mary Jo] Emory Univ Hosp, Atlanta, GA 30322 USA. [Jacobsen, Eric D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Young, Faith] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Crump, Michael] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Borghaei, Hossein] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Link, Brian] Univ Iowa, Iowa City, IA USA. [Fruchtman, Steven M.] Allos Therapeut, Princeton, NJ USA. [O'Connor, Owen A.] NYU Langone Med Canter, NYU Canc Inst, Dept Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 731 EP 732 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201854 ER PT J AU Kumar, A Vanderplas, A LaCasce, AS Rodriguez, MA Crosby, AL Lepisto, E Czuczman, MS Nademanee, A Niland, J Gordon, LI Millenson, M Zelenetz, AD Friedberg, JW Abel, GA AF Kumar, Anita Vanderplas, Ann LaCasce, Ann S. Rodriguez, Maria A. Crosby, Allison L. Lepisto, Eva Czuczman, Myron S. Nademanee, Auayporn Niland, Joyce Gordon, Leo I. Millenson, Michael Zelenetz, Andrew D. Friedberg, Jonathan W. Abel, Gregory A. TI Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kumar, Anita] Brigham & Womens Hosp, Boston, MA 02115 USA. [Vanderplas, Ann; Nademanee, Auayporn; Niland, Joyce] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [LaCasce, Ann S.; Crosby, Allison L.; Abel, Gregory A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rodriguez, Maria A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Lepisto, Eva] Natl Comprehens Canc Network, Ft Washington, PA USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Gordon, Leo I.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA. [Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Millenson, Michael] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Friedberg, Jonathan W.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 732 EP 733 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662201857 ER PT J AU Abramson, JS Takvorian, T Jacobsen, ED Brown, JR Barnes, JA Feng, Y Neuberg, D Hochberg, EP AF Abramson, Jeremy S. Takvorian, Tak Jacobsen, Eric D. Brown, Jennifer R. Barnes, Jeffrey A. Feng, Yang Neuberg, Donna Hochberg, Ephraim P. TI A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Abramson, Jeremy S.; Takvorian, Tak; Barnes, Jeffrey A.; Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [Feng, Yang; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 740 EP 740 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662201876 ER PT J AU Chauhan, D Bandi, M Singh, AV Podar, K Richardson, PG Munshi, NC Viktorsson, K Lewensohn, R Spira, J Anderson, KC AF Chauhan, Dharminder Bandi, Madhavi Singh, Ajita V. Podar, Klaus Richardson, Paul G. Munshi, Nikhil C. Viktorsson, Kristina Lewensohn, Rolf Spira, Jack Anderson, Kenneth C. TI Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Chauhan, Dharminder; Bandi, Madhavi; Singh, Ajita V.; Podar, Klaus; Richardson, Paul G.; Munshi, Nikhil C.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Viktorsson, Kristina; Lewensohn, Rolf] Karolinska Univ Hosp, Div Hematol, Stockholm, Sweden. [Viktorsson, Kristina; Lewensohn, Rolf] Karolinska Inst, Stockholm, Sweden. [Spira, Jack] Oncopeptides AB, Solna, Sweden. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 767 EP 767 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202062 ER PT J AU Heinrichs, S Conover, L Bueso-Ramos, CE Kilpivaara, O Levine, R Stevenson, K Neuberg, D Bejar, R Ebert, BL Garcia-Manero, G Kantarjian, HM Look, AT AF Heinrichs, Stefan Conover, Lily Bueso-Ramos, Carlos E. Kilpivaara, Outi Levine, Ross Stevenson, Kristen Neuberg, Donna Bejar, Rafael Ebert, Benjamin L. Garcia-Manero, Guillermo Kantarjian, Hagop M. Look, A. Thomas TI MYBL2 Is a Candidate Tumor Suppressor Gene In MDS SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [Bueso-Ramos, Carlos E.; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kilpivaara, Outi; Levine, Ross] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Stevenson, Kristen] Childrens Hosp, Boston, MA 02115 USA. [Bejar, Rafael] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Garcia-Manero, Guillermo] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 777 EP 777 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202089 ER PT J AU Lewicki, M Ciccarelli, B Hunter, Z Brodsky, P Manning, R Hanzis, C Patterson, C Sheehy, P AF Lewicki, Megan Ciccarelli, Bryan Hunter, Zachary Brodsky, Philip Manning, Robert Hanzis, Christina Patterson, Christopher Sheehy, Patricia TI Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Lewicki, Megan; Brodsky, Philip; Manning, Robert; Hanzis, Christina; Patterson, Christopher; Sheehy, Patricia] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Ciccarelli, Bryan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Hunter, Zachary] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 797 EP 797 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202135 ER PT J AU Hunter, Z Cao, Y Lewicki, M Sun, J Tseng, H Hanzis, C Brodsky, P Manning, R Xu, L Yang, G Zhou, YS Liu, X Jiang, JR Patterson, C AF Hunter, Zachary Cao, Yang Lewicki, Megan Sun, Jenny Tseng, Hsiuyi Hanzis, Christina Brodsky, Philip Manning, Robert Xu, Lian Yang, Guang Zhou, Yangsheng Liu, Xia Jiang, Jingrui Patterson, Christopher TI Aberrant Expression of Regulatory miRNAs and Transcripts for IRS-PI3K Growth and Survival Signaling In Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Hunter, Zachary] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Cao, Yang; Lewicki, Megan; Sun, Jenny; Tseng, Hsiuyi; Hanzis, Christina; Brodsky, Philip; Manning, Robert; Xu, Lian; Yang, Guang; Zhou, Yangsheng; Liu, Xia; Jiang, Jingrui; Patterson, Christopher] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 798 EP 798 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202136 ER PT J AU Pal, J Sawyer, J Amin, SB Li, C Nanjappa, P Lee, S Minvielle, S Avet-Loiseau, H Shammas, M Munshi, NC AF Pal, Jagannath Sawyer, Jeffrey Amin, Samir B. Li, Cheng Nanjappa, Puru Lee, Saem Minvielle, Stephane Avet-Loiseau, Herve Shammas, Masood Munshi, Nikhil C. TI Elevated Homologous Recombination Induces Karyotypic Changes and Predicts Poor Clinical Outcome In Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Pal, Jagannath; Amin, Samir B.; Li, Cheng; Nanjappa, Puru; Shammas, Masood; Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pal, Jagannath; Nanjappa, Puru; Lee, Saem; Shammas, Masood; Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA. [Sawyer, Jeffrey] Arkansas Childrens Hosp, Boston, MA USA. RI Minvielle, Stephane/K-8251-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 801 EP 801 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202148 ER PT J AU Amin, SB Yan, ZY Shah, P Miguel, JFS Minvielle, S Avet-Loiseau, H Anderson, KC Munshi, NC Li, C AF Amin, Samir B. Yan, Zhenyu Shah, Parantu Miguel, Jesus F. San, Sr. Minvielle, Stephane Avet-Loiseau, Herve Anderson, Kenneth C. Munshi, Nikhil C. Li, Cheng TI An Integrative Analysis of Network Motifs and Gene Expression Data to Discover Experimentally Testable Transcription Factor-miRNA-Gene Regulatory Loops In Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Amin, Samir B.; Yan, Zhenyu; Shah, Parantu; Anderson, Kenneth C.; Munshi, Nikhil C.; Li, Cheng] Dana Farber Canc Inst, Boston, MA 02115 USA. [Amin, Samir B.; Li, Cheng] VA Boston Healthcare Syst, Boston, MA USA. [Amin, Samir B.; Li, Cheng] Harvard Univ, Sch Med, Boston, MA USA. [Miguel, Jesus F. San, Sr.] Hosp Clin Univ Salamanca, Serv Hematol, Salamanca, Spain. [Minvielle, Stephane; Avet-Loiseau, Herve] Univ Hosp Nantes, Nantes, France. RI Minvielle, Stephane/K-8251-2015 NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 802 EP 802 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202150 ER PT J AU Shah, PK Avet-Loiseau, H Minvielle, S Amin, SB Magrangeas, F Anderson, KC Li, C Munshi, NC AF Shah, Parantu K. Avet-Loiseau, Herve Minvielle, Stephane Amin, Samir B. Magrangeas, Florence Anderson, Kenneth C. Li, Cheng Munshi, Nikhil C. TI A Combined Survival Model Integrating Gene Expression and Alternative Splicing Events Provides Higher Predicative Power for Risk Stratification SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Shah, Parantu K.; Amin, Samir B.; Anderson, Kenneth C.; Li, Cheng; Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Magrangeas, Florence] Univ Nantes, INSERM, CHU Nantes, Hematol Lab,UMGC,U892, Nantes, France. [Avet-Loiseau, Herve] CHU, Nantes, France. [Minvielle, Stephane] U, Nantes, France. [Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA. RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 803 EP 803 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202153 ER PT J AU Jakubowiak, AJ Reece, DE Hofmeister, CC Lonial, S Zimmerman, TM Campagnaro, EL Schlossman, RL Laubach, JP Raje, N Anderson, TB Griffith, KA Hill, MA Harvey, CK Wear, S Barrickman, J Tendler, CL Esseltine, DL Kelley, SL Kaminski, MS Anderson, KC Richardson, PG AF Jakubowiak, Andrzej J. Reece, Donna E. Hofmeister, Craig C. Lonial, Sagar Zimmerman, Todd M. Campagnaro, Erica L. Schlossman, Robert L. Laubach, Jacob P. Raje, Noopur Anderson, Tara B. Griffith, Kent A. Hill, Melissa A. Harvey, Colleen K. Wear, Sandra Barrickman, Jennifer Tendler, Craig L. Esseltine, Dixie-Lee Kelley, Susan L. Kaminski, Mark S. Anderson, Kenneth C. Richardson, Paul G. TI Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jakubowiak, Andrzej J.; Anderson, Tara B.; Griffith, Kent A.; Hill, Melissa A.; Harvey, Colleen K.; Kaminski, Mark S.] Univ Michigan, Ann Arbor, MI 48109 USA. [Reece, Donna E.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Hofmeister, Craig C.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Lonial, Sagar] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. [Zimmerman, Todd M.] Univ Chicago, Chicago, IL 60637 USA. [Campagnaro, Erica L.] Univ Hosp Case Med Ctr, Div Hematol & Oncol, Cleveland, OH USA. [Schlossman, Robert L.; Laubach, Jacob P.; Anderson, Kenneth C.; Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wear, Sandra; Kelley, Susan L.] Multiple Myeloma Res Consortium, Norwalk, CT USA. [Barrickman, Jennifer] Celgene Inc, Summit, NJ USA. [Tendler, Craig L.] Centocor Ortho Biotech, Bridgewater, NJ USA. [Esseltine, Dixie-Lee] Takeda Oncol Co, Millennium Pharmacuet, Berlin, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 806 EP 806 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202161 ER PT J AU Ghobrial, I Azab, AKA Laubach, JP Banwait, R Rourke, M Quang, P Munshi, NC Schlossman, RL Chuma, S Kunsman, J Warren, D Sam, A Still, E Morgan, B Anderson, KC Richardson, PG AF Ghobrial, Irene Azab, Abdel Kareem A. Laubach, Jacob P. Banwait, Ranjit Rourke, Meghan Quang, Phong Munshi, Nikhil C. Schlossman, Robert L. Chuma, Stacey Kunsman, Janet Warren, Diane Sam, Amy Still, Eric Morgan, Brittany Anderson, Kenneth C. Richardson, Paul G. TI Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ghobrial, Irene; Banwait, Ranjit; Rourke, Meghan; Kunsman, Janet; Warren, Diane; Sam, Amy; Still, Eric] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 809 EP 810 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662202167 ER PT J AU Richardson, P Weber, D Mitsiades, CS Dimopoulos, MA Harousseau, JL Houp, J Graef, T Gause, CK Byrne, C Anderson, KC Siegel, D AF Richardson, Paul Weber, Donna Mitsiades, Constantine S. Dimopoulos, Meletios A. Harousseau, Jean-Luc Houp, Jennifer Graef, Thorsten Gause, Christine K. Byrne, Catriona Anderson, Kenneth C. Siegel, David TI A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Richardson, Paul; Mitsiades, Constantine S.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Weber, Donna] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Dimopoulos, Meletios A.] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Harousseau, Jean-Luc] Ctr Rene Gauducheau, F-44035 Nantes, France. [Houp, Jennifer; Graef, Thorsten; Gause, Christine K.] Merck Res Labs, Upper Gwynedd, PA USA. [Byrne, Catriona] Celgene Corp, Summit, NJ USA. [Siegel, David] Hackensack Univ Med Ctr, Hackensack, NJ USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 813 EP 813 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202175 ER PT J AU Siegel, DS Jagannath, S Hajek, R Dimopoulos, MA Yoon, SS Lonial, S Laubach, JP Graef, T Pietrangelo, D Lupinacci, L Reiser, D Anderson, KC AF Siegel, David S. Jagannath, Sundar Hajek, Roman Dimopoulos, Meletios A. Yoon, Sung-Soo Lonial, Sagar Laubach, Jacob P. Graef, Thorsten Pietrangelo, Dina Lupinacci, Lisa Reiser, David Anderson, Kenneth C. TI Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Siegel, David S.] Hackensack Univ Med Ctr, Hackensack, NJ USA. [Jagannath, Sundar] Mt Sinai Med Ctr, New York, NY 10029 USA. [Hajek, Roman] Fac Med MU, Brno, Czech Republic. [Hajek, Roman] Univ Hosp Brno, Brno, Czech Republic. [Dimopoulos, Meletios A.] Univ Athens, Dept Therapeut, Athens, Greece. [Yoon, Sung-Soo] Seoul Natl Univ Hosp, Seoul 110744, South Korea. [Lonial, Sagar] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. [Laubach, Jacob P.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Graef, Thorsten; Pietrangelo, Dina; Lupinacci, Lisa; Reiser, David] Merck Res Labs, Upper Gwynedd, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 813 EP 814 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662202176 ER PT J AU Yu, AP Bensimon, AG Marynchenko, M Wu, EQ Namjoshi, M Guo, A Ericson, SG Raje, N AF Yu, Andrew Peng Bensimon, Arielle G. Marynchenko, Maryna Wu, Eric Qiong Namjoshi, Madhav Guo, Amy Ericson, Solveig G. Raje, Noopur TI Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Yu, Andrew Peng; Bensimon, Arielle G.; Marynchenko, Maryna; Wu, Eric Qiong] Anal Grp Inc, Boston, MA USA. [Namjoshi, Madhav; Guo, Amy; Ericson, Solveig G.] Novartis Pharmaceut, E Hanover, NJ USA. [Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 816 EP 816 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202180 ER PT J AU Raibagkar, PS Richardson, PG Sonneveld, P Schuster, MW Irwin, D Stadtmauer, EA Facon, T Harousseau, JL Ben-Yehuda, D Lonial, S Goldschmidt, H Reece, DE San Miguel, JE Blade, J Boccadoro, M Neuwirth, R Esseltine, DL Anderson, KC Munshi, NC AF Raibagkar, Pooja S. Richardson, Paul G. Sonneveld, Pieter Schuster, Michael W. Irwin, David Stadtmauer, Edward A. Facon, Thierry Harousseau, Jean-Luc Ben-Yehuda, Dina Lonial, Sagar Goldschmidt, Hartmut Reece, Donna E. San Miguel, Jesus E. Blade, Joan Boccadoro, Mario Neuwirth, Rachel Esseltine, Dixie-Lee Anderson, Kenneth C. Munshi, Nikhil C. TI Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Raibagkar, Pooja S.; Richardson, Paul G.; Anderson, Kenneth C.; Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sonneveld, Pieter] Erasmus Med Ctr & Univ, Dept Hematol, Rotterdam, Netherlands. [Schuster, Michael W.] New York Presbyterian Hosp, New York, NY USA. [Irwin, David] Alta Bates Canc Ctr, Berkeley, CA USA. [Stadtmauer, Edward A.] Univ Penn, Abramson Canc Ctr, Myeloma Program, Philadelphia, PA 19104 USA. [Facon, Thierry] Hop Claude Huriez, Serv Malad Sang, Lille, France. [Harousseau, Jean-Luc] Hop Hotel Dieu, Nantes, France. [Ben-Yehuda, Dina] Hadassah Univ Med Ctr, Dept Hematol, Jerusalem, Israel. [Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Goldschmidt, Hartmut] Univ Klinikum Heidelberg, Heidelberg, Germany. [Goldschmidt, Hartmut] Natl Ctr Tumorerkrankungen, Heidelberg, Germany. [Reece, Donna E.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [San Miguel, Jesus E.] Hosp Clin Univ, Salamanca, Spain. [Blade, Joan] Inst Invest Biomed Agusti Pi & Sunyer, Barcelona, Spain. [Boccadoro, Mario] Univ Turin, Div Hematol, Myeloma Unit, AOUS Giovanni Battista, Turin, Italy. [Neuwirth, Rachel; Esseltine, Dixie-Lee] Millennium Pharmaceut Inc, Cambridge, MA USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA. RI FACON, THIERRY/M-9736-2014 OI FACON, THIERRY/0000-0001-7705-8460 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 819 EP 820 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662202187 ER PT J AU Jiang, JR Yang, G Liu, X Hunter, Z Manning, R Xu, L Patterson, C AF Jiang, Jingrui Yang, Guang Liu, Xia Hunter, Zachary Manning, Robert Xu, Lian Patterson, Christopher TI Microarray Analysis of the Peripheral Monocytes From Waldenstrom's Macroglobulinemia Patients Reveals a Distinct Gene Expression Profile SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jiang, Jingrui; Yang, Guang; Liu, Xia; Manning, Robert; Xu, Lian; Patterson, Christopher] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Hunter, Zachary] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 838 EP 838 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202233 ER PT J AU Steinbicker, AU Vonner, AJ Sachidanandan, C Lohmeyer, L Scadden, DT Peterson, RT Bloch, KD Yu, PB AF Steinbicker, Andrea U. Vonner, Ashley J. Sachidanandan, Chetana Lohmeyer, Lisa Scadden, David T. Peterson, Randall T. Bloch, Kenneth D. Yu, Paul B. TI Role of BMP Signaling In the Anemia of Chronic Disease SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Steinbicker, Andrea U.; Lohmeyer, Lisa] Massachusetts Gen Hosp, Anesthesia Ctr Crit Care Res, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Vonner, Ashley J.; Peterson, Randall T.; Bloch, Kenneth D.; Yu, Paul B.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Sachidanandan, Chetana] Inst Genom & Integrat Biol, Delhi, India. [Scadden, David T.] Harvard Stem Cell Inst, Boston, MA USA. RI Ganju, Shahji/F-3409-2012 NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 849 EP 849 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202266 ER PT J AU Woo, AJ Kim, J Xu, J Huang, H Cantor, A AF Woo, Andrew J. Kim, Jonghwan Xu, Jian Huang, Hui Cantor, Alan TI Role of the Kruppel-Type Zinc Finger Transcription Factor ZBP-89 In Human Globin Gene Regulation and Erythroid Development. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Woo, Andrew J.; Kim, Jonghwan; Xu, Jian; Huang, Hui; Cantor, Alan] Childrens Hosp Boston, Boston, MA USA. [Cantor, Alan] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 858 EP 858 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202290 ER PT J AU Imataki, O Ansen, S Tanaka, M Butler, MO Berezovskaya, A Kuzushima, K Nadler, LM Hirano, N AF Imataki, Osamu Ansen, Sascha Tanaka, Makito Butler, Marcus O. Berezovskaya, Alla Kuzushima, Kiyotaka Nadler, Lee M. Hirano, Naoto TI CD8 Coreceptor-Independent T Cell Stimulation Induces High Avidity CTL In the Presence of IL-21 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Imataki, Osamu; Ansen, Sascha; Tanaka, Makito; Butler, Marcus O.; Berezovskaya, Alla; Nadler, Lee M.; Hirano, Naoto] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kuzushima, Kiyotaka] Aichi Canc Ctr, Res Inst, Nagoya, Aichi 464, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 866 EP 866 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202309 ER PT J AU Ogasawara, M Yamakawa, T Katsura, Y Shima, K Matsukawa, T Kanaya, M Minauchi, K Nakata, M Ota, S Imai, K Hirano, T Kobayashi, N Kiyama, Y Hirano, N AF Ogasawara, Masahiro Yamakawa, Tomohiro Katsura, Yuki Shima, Kanako Matsukawa, Toshihiro Kanaya, Minoru Minauchi, Koichiro Nakata, Masanobu Ota, Shuichi Imai, Kiyotoshi Hirano, Teiichi Kobayashi, Naoki Kiyama, Yoshio Hirano, Naoto TI Efficient Generation of HLA-A24-Restricted WT1-Specific Cytotoxic T Lymphocytes Using Gene-Engineered Artificial Antigen-Presenting Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ogasawara, Masahiro; Yamakawa, Tomohiro; Katsura, Yuki; Shima, Kanako; Matsukawa, Toshihiro; Kanaya, Minoru; Minauchi, Koichiro; Nakata, Masanobu; Ota, Shuichi; Imai, Kiyotoshi; Hirano, Teiichi; Kobayashi, Naoki; Kiyama, Yoshio] Sapporo Hokuyu Hosp, Sapporo, Hokkaido, Japan. [Hirano, Naoto] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 871 EP 871 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202324 ER PT J AU Sudan, GL De Meyer, SF Brill, A Cifuni, SM Wagner, DD AF Sudan, Georgette L. De Meyer, Simon F. Brill, Alexander Cifuni, Stephen M. Wagner, Denisa D. TI The Role of VWF In BBB Permeability Associated with Hypoxia/Reoxygenation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sudan, Georgette L.; De Meyer, Simon F.; Brill, Alexander; Cifuni, Stephen M.; Wagner, Denisa D.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 871 EP 871 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202325 ER PT J AU Demers, M Ho-Tin-Noe, B Schatzberg, D Yang, JJ Wagner, DD AF Demers, Melanie Ho-Tin-Noe, Benoit Schatzberg, Daphne Yang, Janie J. Wagner, Denisa D. TI Thrombocytopenia Induced-Tumor Vascular Leakiness Increases Drug Efficacy. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Demers, Melanie; Ho-Tin-Noe, Benoit; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 872 EP 872 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202328 ER PT J AU Fuchs, TA Wagner, DD AF Fuchs, Tobias A. Wagner, Denisa D. TI Heparin Prevents Histone-Induced Thrombocytopenia and Mortality. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Fuchs, Tobias A.; Wagner, Denisa D.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 872 EP 872 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202329 ER PT J AU Salzer, W Asselin, B Supko, J Devidas, M Kaiser, N Plourde, PV Winick, N Reaman, G Raetz, E Carroll, WL Hunger, S AF Salzer, Wanda Asselin, Barbara Supko, Jeffrey Devidas, Meenakshi Kaiser, Nicole Plourde, Paul V. Winick, Naomi Reaman, Gregory Raetz, Elizabeth Carroll, William L. Hunger, Stephen TI Administration of Erwinia Asparaginase (Erwinase (R)) Following Allergy to PEG-Asparaginase In Children and Young Adults with Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG). SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Salzer, Wanda] NCI, Bethesda, MD 20892 USA. [Asselin, Barbara] Univ Rochester, Sch Med, Dept Pediat, Golisano Childrens Hosp URMC, Rochester, NY 14642 USA. [Supko, Jeffrey] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Devidas, Meenakshi] Univ Florida, Coll Med, Dept Biostat, Childrens Oncol Grp, Gainesville, FL USA. [Kaiser, Nicole] Childrens Hosp, Aurora, CO USA. [Plourde, Paul V.] EUSA Pharma, Langhorne, PA USA. [Winick, Naomi] Univ Texas SW Med Ctr Dallas, Div Pediat Hematol Oncol, Dallas, TX 75390 USA. [Reaman, Gregory] Childrens Natl Med Ctr, Dept Hematol Oncol, Washington, DC 20010 USA. [Raetz, Elizabeth] NYU, Langone Med Ctr, New York, NY USA. [Hunger, Stephen] Childrens Hosp, Aurora, CO USA. [Hunger, Stephen] Univ Colorado, Sch Med, Pediat Heme Onc BMT, Aurora, CO USA. [Carroll, William L.] NYU, Inst Canc, New York, NY USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 882 EP 882 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202357 ER PT J AU Mohan, SR Maciejewski, JP Tejura, B Erba, HP Stone, RM Sekeres, MA AF Mohan, Sanjay R. Maciejewski, Jaroslaw P. Tejura, Bindu Erba, Harry P. Stone, Richard M. Sekeres, Mikkael A. TI A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Maciejewski, Jaroslaw P.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Tejura, Bindu] Antisoma Inc, Cambridge, MA USA. [Erba, Harry P.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 883 EP 884 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662202362 ER PT J AU Blum, W Donohue, K Marcucci, G DeAngelo, DJ Uy, GL Powell, BL Stock, W Baer, M Kolitz, JE Wetzler, M Hoke, E Moser, BK Larson, RA AF Blum, William Donohue, Kate Marcucci, Guido DeAngelo, Daniel J. Uy, Geoffrey L. Powell, Bayard L. Stock, Wendy Baer, Maria Kolitz, Jonathan E. Wetzler, Meir Hoke, Eva Moser, Barry K. Larson, Richard A. TI Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Blum, William; Marcucci, Guido] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Donohue, Kate; Hoke, Eva; Moser, Barry K.] Duke Univ, Med Ctr, Canc & Leukemia Grp B Stat Ctr, Durham, NC USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Uy, Geoffrey L.] Washington Univ, St Louis, MO USA. [Powell, Bayard L.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA. [Stock, Wendy; Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA. [Baer, Maria] Univ Maryland, Baltimore, MD 21201 USA. [Kolitz, Jonathan E.] N Shore Univ Hosp, Manhasset, NY USA. [Wetzler, Meir] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. RI Blum, William/E-2769-2011 NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 898 EP 899 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662202399 ER PT J AU Miller, C Ailawadhi, S Jillella, AP Radich, JP DeAngelo, DJ Goldberg, SL Williams, D Lin, FP Akard, LP AF Miller, Carole Ailawadhi, Sikander Jillella, Anand P. Radich, Jerald P. DeAngelo, Daniel J. Goldberg, Stuart L. Williams, Denise Lin, Felice P. Akard, Luke Paul TI Patients (Pts) with Ph plus Chronic, Myeloid Leukemia In Chronic Phase (CML-CP) with a Suboptimal Molecular Response to Imatinib (IM) Can Achieve Deeper Responses When Switched to Nilotinib. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Miller, Carole] St Agnes Hosp, Baltimore, MD USA. [Jillella, Anand P.] Med Coll Georgia, Augusta, GA 30912 USA. [Ailawadhi, Sikander] Univ So Calif, Los Angeles, CA USA. [Radich, Jerald P.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Goldberg, Stuart L.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Williams, Denise; Lin, Felice P.] Novartis Pharmaeut Corp, E Hanover, NJ USA. [Akard, Luke Paul] Indiana Blood & Marrow Transplantat, Beech Grove, IN USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 950 EP 950 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202524 ER PT J AU Soiffer, RJ LeRademacher, J Ho, VT Kan, FY Artz, A Champlin, R Devine, S Lazarus, HM Marks, DI Porter, D Waller, EK Horowitz, MM Eapen, M AF Soiffer, Robert J. LeRademacher, Jennifer Ho, Vincent T. Kan, Fangyu Artz, Andrew Champlin, Richard Devine, Steven Lazarus, Hillard M. Marks, David I. Porter, David Waller, Edmund K. Horowitz, Mary M. Eapen, Mary TI Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignanciesimpact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Soiffer, Robert J.; Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02115 USA. [LeRademacher, Jennifer] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Kan, Fangyu] NMDP CIBMTR, Minneapolis, MN USA. [Artz, Andrew] Univ Chicago Hosp, Chicago, IL 60637 USA. [Champlin, Richard] UT MD Anderson Canc Ctr, Houston, TX USA. [Devine, Steven] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Marks, David I.] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England. [Porter, David] Univ Penn, Philadelphia, PA 19104 USA. [Waller, Edmund K.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. [Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 951 EP 952 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662202528 ER PT J AU Sorror, ML Storer, B Sandmaier, BM Braunert, L Laport, GG Chauncey, T Bredeson, C Maziarz, RT Pulsipher, MA Agura, E Mans, MT Vindelov, L Sahebi, F McSweeney, P Bruno, B Langston, A Storb, RF Maloney, DG AF Sorror, Mohamed L. Storer, Barry Sandmaier, Brenda M. Braunert, Leanthe Laport, Ginna G. Chauncey, Thomas Bredeson, Christopher Maziarz, Richard T. Pulsipher, Michael A. Agura, Edward Mans, Michael T. Vindelov, Lars Sahebi, Firoozeh McSweeney, Peter Bruno, Benedetto Langston, Amelia Storb, Rainer F. Maloney, David G. TI Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sorror, Mohamed L.; Storer, Barry; Sandmaier, Brenda M.; Chauncey, Thomas; Storb, Rainer F.; Maloney, David G.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Braunert, Leanthe] Univ Leipzig, Leipzig, Germany. [Laport, Ginna G.] Stanford Univ, Stanford, CA 94305 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Bredeson, Christopher] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA. [Agura, Edward] Baylor Univ, Dallas, TX USA. [Mans, Michael T.] Rocky Mt Canc Ctr, Denver, CO USA. [Vindelov, Lars] Rigshosp, DK-2100 Copenhagen, Denmark. [Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [McSweeney, Peter] Univ Colorado, Boulder, CO 80309 USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Langston, Amelia] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 978 EP 978 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202587 ER PT J AU Sorror, ML Storer, B Sandmaier, BM Chauncey, T Maris, MT Storb, RF Maloney, DG AF Sorror, Mohamed L. Storer, Bany Sandmaier, Brenda M. Chauncey, Thomas Maris, Michael T. Storb, Rainer F. Maloney, David G. TI Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sorror, Mohamed L.; Storer, Bany; Sandmaier, Brenda M.; Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Maris, Michael T.] Rocky Mt Canc Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 979 EP 979 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202588 ER PT J AU Chen, YB Aldridge, J Kim, H Ballen, KK Cutler, C Kao, G Liney, D Alyea, EP Armand, P Koreth, J Ritz, J Soiffer, RJ Spitzer, T Antin, JH Ho, VT AF Chen, Yi-Bin Aldridge, Julie Kim, Haesook Ballen, Karen K. Cutler, Corey Kao, Grace Liney, Deborah Alyea, Edwin P., III Armand, Philippe Koreth, John Ritz, Jerome Soiffer, Robert J. Spitzer, Thomas Antin, Joseph H. Ho, Vincent T. TI Reduced Intensity Conditioning (RIC) with Double Umbilical Cord Blood Transplantation Has Similar Outcomes Compared to RIC Transplantation From Related or Unrelated Adult Donors SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Chen, Yi-Bin; Ballen, Karen K.; Spitzer, Thomas] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cutler, Corey; Liney, Deborah; Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Koreth, John] Dana Farber Canc Inst, Dept Hem Onc, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 980 EP 981 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662202590 ER PT J AU McCarthy, PL Hahn, T Hassebroek, A Klein, JP Rizzo, JD Parsons, S Joffe, S Majhail, NS AF McCarthy, Philip L. Hahn, Theresa Hassebroek, Anna Klein, John P. Rizzo, J. Douglas Parsons, Susan Joffe, Steven Majhail, Navneet S. TI Significant Improvement In Overall Survival In Patients Who Underwent Autologous Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [McCarthy, Philip L.] Roswell Pk Canc Inst, BMT Program, Buffalo, NY 14263 USA. [Hahn, Theresa] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA. [Hassebroek, Anna] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Klein, John P.] Med Coll Wisconsin, Dept Biostat, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Parsons, Susan] Tufts Med Ctr, Boston, MA USA. [Joffe, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA. [Majhail, Navneet S.] Univ Minnesota, Hematol & Oncol IM Hematol, Minneapolis, MN USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 990 EP 990 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202612 ER PT J AU Hainz, U Sievers, QL Stevenson, K Goldstein, NR Dorfman, D Brown, JR Freeman, GJ Wu, CJ AF Hainz, Ursula Sievers, Quinlan L. Stevenson, Kristen Goldstein, Natalie R. Dorfman, David Brown, Jennifer R. Freeman, Gordon J. Wu, Catherine J. TI Marrow-Infiltrating T Cells In Patients with Chronic Lymphocytic Leukemia Display Markers of Functional Impairment and Express PD-1 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Stevenson, Kristen] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Dorfman, David] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1002 EP 1002 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202640 ER PT J AU Brown, JR Hanna, M Tesar, B Werner, L Reynolds, H Fernandes, SM Macconaill, L Wang, YY Correll, M Neuberg, D Freedman, AS AF Brown, Jennifer R. Hanna, Megan Tesar, Bethany Werner, Lillian Reynolds, Hazel Fernandes, Stacey M. Macconaill, Laura Wang, Yaoyu Correll, Mick Neuberg, Donna Freedman, Arnold S. TI High Resolution Genomic Analysis In CLL Demonstrates Genomic Stability In Untreated Patients and Novel Markers of Progression In Treated Patients SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Hanna, Megan; Macconaill, Laura] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Wang, Yaoyu; Correll, Mick] Dana Farber Canc Inst, Ctr Canc Computat Biol, Boston, MA 02115 USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1006 EP 1006 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202649 ER PT J AU Brown, JR Tesar, B Hanna, M Ash, M Fernandes, SM Macconaill, L Hainz, U Longtine, J Wu, CJ Werner, L Wang, YY Correll, M Neuberg, D Freedman, AS AF Brown, Jennifer R. Tesar, Bethany Hanna, Megan Ash, Megan Fernandes, Stacey M. Macconaill, Laura Hainz, Ursula Longtine, Janina Wu, Catherine J. Werner, Lillian Wang, Yaoyu Correll, Mick Neuberg, Donna Freedman, Arnold S. TI Amplification of 6p Associated with Familial CLL SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Brown, Jennifer R.; Tesar, Bethany; Ash, Megan; Longtine, Janina] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Hanna, Megan; Macconaill, Laura] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Hainz, Ursula] Dana Farber Canc Inst, Vienna, Austria. [Wang, Yaoyu] Dana Farber Canc Inst, Ctr Canc, Boston, MA 02115 USA. [Correll, Mick] Dana Farber Canc Inst, Ctr Canc Computat Biol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1009 EP 1009 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202655 ER PT J AU Kaufman, M Yan, XJ Ghia, EM Neuberg, D Rassenti, LZ Brown, JR Byrd, JC Kay, NE Rai, KR Kipps, TJ Chiorazzi, N AF Kaufman, Matthew Yan, Xiao-Jie Ghia, Emanuela M. Neuberg, Donna Rassenti, Laura Z. Brown, Jennifer R. Byrd, John C. Kay, Neil E. Rai, Kanti R. Kipps, Thomas J. Chiorazzi, Nicholas TI Improved Outcome of CLL Patients with Leukemic Clones Expressing Mutated IGHV May Not Be Due to An Inability to Bind (auto)Antigen In Vivo SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kaufman, Matthew; Rai, Kanti R.] N Shore Long Isl Jewish Hlth Syst, Dept Med, New Hyde Pk, NY USA. [Yan, Xiao-Jie; Chiorazzi, Nicholas] N Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA. [Ghia, Emanuela M.] Univ Calif San Diego, Rome, Italy. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [Rassenti, Laura Z.] UCSD, Moores Canc Ctr, La Jolla, CA USA. [Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Byrd, John C.] Ohio State Univ, Columbus, OH 43210 USA. [Kay, Neil E.] Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1013 EP 1013 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202664 ER PT J AU Amrein, PC Attar, EC Takvorian, T Hochberg, E Ballen, KK Leahy, KM Fisher, DC LaCasce, A Jacobsen, ED Armand, P Hasserjian, R Werner, L Neuberg, D Brown, JR AF Amrein, Philip C. Attar, Eyal C. Takvorian, Tak Hochberg, Ephraim Ballen, Karen K. Leahy, Kathleen M. Fisher, David C. LaCasce, Ann Jacobsen, Eric D. Armand, Philippe Hasserjian, Robert Werner, Lillian Neuberg, Donna Brown, Jennifer R. TI Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)-Correlates with p-Lyn and p-Syk SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Attar, Eyal C.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. [Takvorian, Tak] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA 02114 USA. [LaCasce, Ann] Dana Farber Canc Inst, Dept Med Onc D1B05, Boston, MA 02115 USA. [Hasserjian, Robert] Massachusetts Gen Hosp, Dept Pathol WRN 244, Boston, MA 02114 USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1020 EP 1020 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202680 ER PT J AU Cao, CX Tian, L Li, JL Griffin, JD Huang, SM Wu, L AF Cao, Chunxia Tian, Liang Li, Jian-Liang Griffin, James D. Huang, Suming Wu, Lizi TI Essential Role for the MAML1 Co-Activator In T-ALL. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Cao, Chunxia; Tian, Liang; Wu, Lizi] Univ Florida, Shands Canc Ctr, Gainesville, FL USA. [Li, Jian-Liang] Sanford Burnham Med Res Inst Lake Nona, Orlando, FL USA. [Griffin, James D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Huang, Suming] Univ Florida, Coll Med, Shands Canc Ctr Biochem & Mol Biol, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1036 EP 1036 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202724 ER PT J AU Grace, RF Neufeld, EJ Ritchey, AK Kumar, M Jeng, MR Blanchette, V Klaassen, R Buchanan, GR Kurth, MAH Nugent, DJ Thompson, AA Thornburg, C Lambert, MP Neier, MD Recht, M Stine, K Kalish, LA Bennett, CM AF Grace, Rachael F. Neufeld, Ellis J. Ritchey, A. Kim Kumar, Manjusha Jeng, Michael R. Blanchette, Victor Klaassen, Robert Buchanan, George R. Kurth, Margaret A. Heisel Nugent, Diane J. Thompson, Alexis A. Thornburg, Courtney Lambert, Michele P. Neier, Michelle D. Recht, Michael Stine, Kimo Kalish, Leslie A. Bennett, Carolyn M. TI The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Grace, Rachael F.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ritchey, A. Kim] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. [Kumar, Manjusha] Riley Childrens Hosp, Indianapolis, IN USA. [Jeng, Michael R.] Stanford Sch Med, Palo Alto, CA USA. [Blanchette, Victor] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Klaassen, Robert] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada. [Buchanan, George R.] Univ Texas Dallas, Dallas, TX 75230 USA. [Kurth, Margaret A. Heisel] Childrens Hosp & Clin, Minneapolis, MN USA. [Nugent, Diane J.] Childrens Hosp Orange Cty, Div Pediat Hematol, Dept Pediat, Orange, CA 92668 USA. [Thompson, Alexis A.] Childrens Mem Hosp, Chicago, IL 60614 USA. [Thornburg, Courtney] DUMC, Durham, NC USA. [Lambert, Michele P.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Neier, Michelle D.] Canc Inst New Jersey, New Brunswick, NJ USA. [Recht, Michael] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA. [Stine, Kimo] Arkansas Childrens Hosp, Little Rock, AR 72202 USA. [Kalish, Leslie A.] Childrens Hosp Boston, Clin Res Program, Boston, MA USA. [Bennett, Carolyn M.] Emory Univ, Sch Med, Atlanta, GA USA. RI Neufeld, Ellis/F-9331-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1039 EP 1040 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662202732 ER PT J AU Long, M Grace, RF Kalish, LA Neufeld, EJ AF Long, Michelle Grace, Rachael F. Kalish, Leslie A. Neufeld, Ellis J. TI Retrospective Review of 524 Cases of Pediatric ITP at An Academic Medical Center: Changes In Treatment of Childhood ITP Between 2003-2010. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Grace, Rachael F.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Kalish, Leslie A.] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA. RI Neufeld, Ellis/F-9331-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1040 EP 1040 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202733 ER PT J AU Gage, T Kazeroonian, MTA Pihan, GA AF Gage, Thomas Kazeroonian, Ali M. T. Pihan, German A. TI Genome Redux for Hematologists: a Graphical User Interface for Visualizing and Reducing Genome-Wide Data Sets Into Clinically Actionable Information SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Gage, Thomas; Kazeroonian, Ali M. T.; Pihan, German A.] BIDMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1059 EP 1059 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202781 ER PT J AU Singh, H Werner, L DeAngelo, DJ Amrein, PC Wadleigh, M Ballen, KK Fox, E Galinsky, I Neuberg, D Stone, RM Attar, EC AF Singh, Harshabad Werner, Lillian DeAngelo, Daniel J. Amrein, Philip C. Wadleigh, Martha Ballen, Karen K. Fox, Edward Galinsky, Ilene Neuberg, Donna Stone, Richard M. Attar, Eyal C. TI Clinical Outcomes of Acute Promyelocytic Leukemia (APL) Patients According to FLT3 Mutation Status. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ballen, Karen K.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. [Werner, Lillian; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [DeAngelo, Daniel J.; Wadleigh, Martha; Galinsky, Ilene; Stone, Richard M.] Dana Farber Canc Inst, Adult Leukemia Program, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1108 EP 1108 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203021 ER PT J AU Doolittle, ND Kraemer, DF Lacy, C Tyson, RM Neuwelt, EA AF Doolittle, Nancy D. Kraemer, Dale F. Lacy, Cynthia Tyson, Rose Marie Neuwelt, Edward A. TI Enhanced Delivery of Rituximab In Combination with Methotrexate-Based Blood-Brain Barrier Disruption for patients with Newly Diagnosed Primary CNS Lymphoma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Dept Neurosurg, Portland, OR 97201 USA. [Kraemer, Dale F.] Oregon State Univ, Dept Pharm Practice, Portland, OR USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 1 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1151 EP 1151 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203124 ER PT J AU Horwitz, SM Kim, YH Foss, FM Zain, JM Myskowski, P Lechowicz, MJ Fisher, DC Shustov, A Bartlett, NL Delioukina, ML Koutsoukos, T Fruchtman, SM O'Connor, OA Duvic, M AF Horwitz, Steven M. Kim, Youn H. Foss, Francine M. Zain, Jasmine M. Myskowski, Patricia Lechowicz, Mary Jo Fisher, David C. Shustov, Andrei Bartlett, Nancy L. Delioukina, Maria L. Koutsoukos, Tony Fruchtman, Steven M. O'Connor, Owen A. Duvic, Madeleine TI Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Horwitz, Steven M.; Myskowski, Patricia] Mem Sloan Kettering, New York, NY USA. [Kim, Youn H.] Stanford Sch Med, Stanford, CA USA. [Foss, Francine M.] Yale Med Oncol, New Haven, CT USA. [Zain, Jasmine M.] NYU Langone Med Ctr, New York, NY USA. [Lechowicz, Mary Jo] Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA. [Shustov, Andrei] Univ Washington, Seattle, WA 98195 USA. [Fisher, David C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA. [Delioukina, Maria L.] City Hope Natl Med Ctr, Duarte, CA USA. [Koutsoukos, Tony; Fruchtman, Steven M.] Allos Therapeut Inc, Princeton, NJ USA. [O'Connor, Owen A.] NYU Langone Med Canter, NYU Canc Inst, Dept Med, New York, NY USA. [Duvic, Madeleine] UT MD Anderson Canc Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1154 EP 1155 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203132 ER PT J AU Yang, G Xu, L Hunter, Z Liu, X Cao, Y Jiang, JR Tseng, H Zhou, YS Ioakimidis, L Hanzis, C Sheehy, P Patterson, C AF Yang, Guang Xu, Lian Hunter, Zachary Liu, Xia Cao, Yang Jiang, Jingrui Tseng, Hsiuyi Zhou, Yangsheng Ioakimidis, Leukothea Hanzis, Christina Sheehy, Patricia Patterson, Christopher TI The Rituximab and IVIG Related IgM Flare In Waldenstrom's Macroglobulinemia Is Associated with Monocytic Activation of Fcgriia Signaling, and Triggering of IL-6 Release by the PI3K/AKT and MAPK Pathways SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Yang, Guang; Xu, Lian; Liu, Xia; Cao, Yang; Jiang, Jingrui; Tseng, Hsiuyi; Zhou, Yangsheng; Ioakimidis, Leukothea; Hanzis, Christina; Sheehy, Patricia; Patterson, Christopher] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Hunter, Zachary] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1182 EP 1182 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203202 ER PT J AU Padmanabhan, S Kelly, KR Heaney, M Hodges, S Chanel, S Frattini, M Swords, R Bradley, R Teofilovici, F DeAngelo, DJ AF Padmanabhan, Swaminathan Kelly, Kevin R. Heaney, Mark Hodges, Stephanie Chanel, Suzanne Frattini, Mark Swords, Ronan Bradley, Robert Teofilovici, Florentina DeAngelo, Daniel J. TI A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Padmanabhan, Swaminathan; Kelly, Kevin R.; Hodges, Stephanie; Swords, Ronan] Univ Texas Hlth Sci Ctr San Antonio, CTRC, Inst Drug Dev, San Antonio, TX 78229 USA. [Heaney, Mark; Chanel, Suzanne; Frattini, Mark] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA. [Bradley, Robert; Teofilovici, Florentina] Synta Pharmaceut Corp, Lexington, MA USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1193 EP 1193 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203230 ER PT J AU Stubbs, MC Kim, WI Davis, T Qi, J Bradner, J Kung, AL Armstrong, SA AF Stubbs, Matthew C. Kim, Won-Il Davis, Tina Qi, Jun Bradner, James Kung, Andrew L. Armstrong, Scott A. TI Selective Inhibition of HDAC1 and HDAC2 Is a Potential Therapeutic Option for B-All SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Davis, Tina; Kung, Andrew L.] Dana Farber Canc Inst, Dept Pediat & Med Oncol, Boston, MA 02115 USA. [Armstrong, Scott A.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Harvard Stem Cell Inst, Childrens Hosp Boston,Div Hematol Oncol, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1194 EP 1194 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203232 ER PT J AU Ngo, HT Roccaro, AM Leontovich, A Liu, Y Zhang, Y Azab, AKA Sacco, A Still, E Morgan, B Anderson, KC Ghobrial, I AF Ngo, Hai T. Roccaro, Aldo M. Leontovich, Alexey Liu, Yang Zhang, Yong Azab, Abdel Kareem A. Sacco, Antonio Still, Eric Morgan, Brittany Anderson, Kenneth C. Ghobrial, Irene TI Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ghobrial, Irene] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Leontovich, Alexey] Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 2 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1220 EP 1220 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203290 ER PT J AU Magrangeas, F Avet-Loiseau, H Decaux, O Gouraud, W Harousseau, JL Anderson, KC Moreau, P Munshi, NC Minvielle, S AF Magrangeas, Florence Avet-Loiseau, Herve Decaux, Olivier Gouraud, Wilfried Harousseau, Jean Luc Anderson, Kenneth C. Moreau, Philippe Munshi, Nikhil C. Minvielle, Stephane TI High Resolution Genome-Wide Analyses Revealed That Bortezomib Selects a Prediagnosis Clone In Relapsed Patients with Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Magrangeas, Florence; Gouraud, Wilfried] Univ Nantes, CHU Nantes, UMGC, Lab Hematol,INSERM U892, Nantes, France. [Decaux, Olivier] CHU Rennes, Rennes, France. [Harousseau, Jean Luc] IFM, Nantes, France. [Moreau, Philippe] Univ Hosp, Nantes, France. [Munshi, Nikhil C.] VA Boston Healthcare System, Dana Farber Canc Inst, Boston, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA. [Minvielle, Stephane] U, Nantes, France. RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015; richard, chrystelle/K-8595-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1221 EP 1221 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203292 ER PT J AU Raje, N Vescio, R Montgomery, CW Parameswaran, R Tran, D Warsi, G Argonza-Aviles, E Ericson, SG Anderson, KC AF Raje, Noopur Vescio, Robert Montgomery, Charles W. Parameswaran, Ramakrishnan Tran, Diep Warsi, Ghulam Argonza-Aviles, Eliza Ericson, Solveig G. Anderson, Kenneth C. TI Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Raje, Noopur] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Vescio, Robert] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Montgomery, Charles W.] Hematol & Oncol Associates BridgePoint, Tupelo, MS USA. [Parameswaran, Ramakrishnan] Avera Canc Inst, Sioux Falls, SD USA. [Tran, Diep; Warsi, Ghulam; Argonza-Aviles, Eliza; Ericson, Solveig G.] Novartis Pharmaceut, E Hanover, NJ USA. [Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1225 EP 1225 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203303 ER PT J AU McMillin, DW Hunter, Z Delmore, J Monrose, V Smith, PG Birner, A Richardson, PG Anderson, KC Treon, SP Kung, AL Mitsiades, CS AF McMillin, Douglas W. Hunter, Zachary Delmore, Jake Monrose, Val Smith, Peter G. Birner, Ann Richardson, Paul G. Anderson, Kenneth C. Treon, Steven P. Kung, Andrew L. Mitsiades, Constantine S. TI MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenstrom's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [McMillin, Douglas W.; Hunter, Zachary; Delmore, Jake; Richardson, Paul G.; Anderson, Kenneth C.; Treon, Steven P.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Monrose, Val; Kung, Andrew L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Smith, Peter G.; Birner, Ann] Millenninm Pharmaceut Inc, Cambridge, MA USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1232 EP 1232 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203320 ER PT J AU Xu, L Patterson, C Sun, J Yang, G Zhou, YS Hunter, Z Ciccarelli, B Manning, R Liu, X Cao, Y Tseng, H Ioakimidis, L Hanzis, C AF Xu, Lian Patterson, Christopher Sun, Jenny Yang, Guang Zhou, Yangsheng Hunter, Zachary Ciccarelli, Bryan Manning, Robert Liu, Xia Cao, Yang Tseng, Hsiuyi Ioakimidis, Leukothea Hanzis, Christina TI Involvement of Lipogenic Pathway In 5-Azacytidine-Induced Cytotoxicity In Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Xu, Lian; Patterson, Christopher; Sun, Jenny; Yang, Guang; Zhou, Yangsheng; Manning, Robert; Liu, Xia; Cao, Yang; Tseng, Hsiuyi; Ioakimidis, Leukothea; Hanzis, Christina] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Hunter, Zachary] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ciccarelli, Bryan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1233 EP 1234 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203323 ER PT J AU Chauhan, D Tian, Z Hideshima, T Munshi, NC Richardson, PG Anderson, KC AF Chauhan, Dharminder Tian, Ze Hideshima, Teru Munshi, Nikhil C. Richardson, Paul G. Anderson, Kenneth C. TI An Investigational Novel Orally Bioavilable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21-and Caspase-8-Dependent Signaling Pathway SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Chauhan, Dharminder; Tian, Ze; Hideshima, Teru; Munshi, Nikhil C.; Richardson, Paul G.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1234 EP 1234 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203324 ER PT J AU Gorgun, G Hideshima, T Mimura, N Cirstea, D Santo, L Hu, YG Fabre, C Raje, N Munshi, NC Richardson, PG Anderson, KC AF Gorgun, Gullu Hideshima, Teru Mimura, Naoya Cirstea, Diana Santo, Loredana Hu, Yiguo Fabre, Claire Raje, Noopur Munshi, Nikhil C. Richardson, Paul G. Anderson, Kenneth C. TI Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Gorgun, Gullu; Hideshima, Teru; Mimura, Naoya; Cirstea, Diana; Santo, Loredana; Hu, Yiguo; Fabre, Claire; Munshi, Nikhil C.; Richardson, Paul G.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1235 EP 1235 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203328 ER PT J AU Chauhan, D Bandi, M Singh, AV Hideshima, T Munshi, NC Richardson, PG Anderson, KC AF Chauhan, Dharminder Bandi, Madhavi Singh, Ajita V. Hideshima, Teru Munshi, Nikhil C. Richardson, Paul G. Anderson, Kenneth C. TI A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Chauhan, Dharminder; Bandi, Madhavi; Singh, Ajita V.; Hideshima, Teru; Munshi, Nikhil C.; Richardson, Paul G.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1239 EP 1239 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203339 ER PT J AU Zuber, C Daelken, B Aigner, S Haeder, T Ab, O Whiteman, K Hideshima, T Lutz, RJ Osterroth, F Uherek, C AF Zuber, Chantal Daelken, Benjamin Aigner, Silke Haeder, Thomas Ab, Olga Whiteman, Kathleen Hideshima, Teru Lutz, Robert J. Osterroth, Frank Uherek, Christoph TI BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Zuber, Chantal; Daelken, Benjamin; Aigner, Silke; Osterroth, Frank] Biotest AG, GBU Biotherapeut, Dreieich, Germany. [Haeder, Thomas] Biotest AG, Corp Clin Res, Dreieich, Germany. [Lutz, Robert J.] ImmunoGen Inc, Translat Res & Dev, Waltham, MA USA. [Hideshima, Teru] Dana Farber Canc Inst, Boston, MA 02115 USA. [Uherek, Christoph] Biotest AG, Preclin Dev Biotherapeut, Dreieich, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1239 EP 1240 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203340 ER PT J AU Kong, SY Li, XF Nahar, S Song, WH de Weers, M Parren, PWHI Richardson, P Munshi, NC Anderson, KC Tai, YT AF Kong, Sun-Young Li, Xian-Feng Nahar, Sabikun Song, Weihua de Weers, Michel Parren, Paul W. H. I. Richardson, Paul Munshi, Nikhil C. Anderson, Kenneth C. Tai, Yu-Tzu TI Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kong, Sun-Young; Li, Xian-Feng; Nahar, Sabikun] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Kong, Sun-Young; Li, Xian-Feng; Nahar, Sabikun] Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [de Weers, Michel; Parren, Paul W. H. I.] Genmab BV, Utrecht, Netherlands. [Richardson, Paul] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1241 EP 1242 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203345 ER PT J AU Shacham, S Turner, JG Nir, R Draetta, G Sandanayaka, V Shechter, S Kauffman, M Sullivan, D AF Shacham, Sharon Turner, Joel G. Nir, Raphael Draetta, Giulio Sandanayaka, Vincent Shechter, Sharon Kauffman, Michael Sullivan, Daniel TI Preclinical Development of Small-Molecule CRM1 Inhibitors as Novel Therapy for the Treatment of Myeloma and Other Hematological Malignancies SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Shacham, Sharon; Sandanayaka, Vincent; Shechter, Sharon; Kauffman, Michael] Karyopharm Therapeut, Newton, MA USA. [Turner, Joel G.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Nir, Raphael] SBH Sci, Natick, MA USA. [Draetta, Giulio] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sullivan, Daniel] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1241 EP 1241 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203344 ER PT J AU Braunstein, MJ Scott, S Smith, ELP Joseph, DF Gonsky, J Carrasco, R Sukhdeo, K Protopopov, A Anderson, KC Batuman, O AF Braunstein, Marc J. Scott, Sadeaqua Smith, Eric L. P. Joseph, Danielle F. Gonsky, Jason Carrasco, Ruben Sukhdeo, Kumar Protopopov, Alexei Anderson, Kenneth C. Batuman, Olcay TI Genomic Analysis of Endothelial Progenitor Cells In Multiple Myeloma Reveals Aberrant Gene Pathways Common to Tumor Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Braunstein, Marc J.; Scott, Sadeaqua; Smith, Eric L. P.; Joseph, Danielle F.; Gonsky, Jason; Batuman, Olcay] Suny Downstate Med Ctr, Dept Med, Div Hematol Oncol, Brooklyn, NY 11203 USA. [Carrasco, Ruben; Sukhdeo, Kumar; Protopopov, Alexei; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1242 EP 1243 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203348 ER PT J AU Vesole, DH Oken, MM Heckler, C Greipp, PR Katz, MS Jacobus, S Morrow, GR AF Vesole, David H. Oken, Martin M. Heckler, Charles Greipp, Philip R. Katz, Michael S. Jacobus, Susanna Morrow, Gary R. CA Univ Rochester Canc Ctr & Eastern TI Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Vesole, David H.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Oken, Martin M.] Northwestern Hosp, Minneapolis, MN USA. [Heckler, Charles; Morrow, Gary R.] Univ Rochester, Rochester, NY USA. [Greipp, Philip R.] Mayo Clin, Rochester, MN USA. [Katz, Michael S.] Eastern Cooperat Oncol Grp, Boston, MA USA. [Jacobus, Susanna] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1243 EP 1243 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203349 ER PT J AU Jakubowiak, AJ Benson, DM Bensinger, W Siegel, DS Zimmerman, TM Mohrbacher, A Richardson, PG Afar, DEH Singhal, AK Anderson, KC AF Jakubowiak, Andrzej J. Benson, Don M., Jr. Bensinger, William Siegel, David S. Zimmerman, Todd M. Mohrbacher, Ann Richardson, Paul G. Afar, Daniel E. H. Singhal, Anil K. Anderson, Kenneth C. TI Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jakubowiak, Andrzej J.] Univ Michigan, Ann Arbor, MI 48109 USA. [Benson, Don M., Jr.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Bensinger, William] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Siegel, David S.] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Zimmerman, Todd M.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Mohrbacher, Ann] Univ So Calif, Div Hematol, Los Angeles, CA USA. [Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA. [Afar, Daniel E. H.; Singhal, Anil K.] Facet Biotech, Redwood City, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1245 EP 1245 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203355 ER PT J AU Kaufman, JL Shah, JJ Laubach, JP Heffner, L Francis, D Harvey, RD Lewis, C Tighiouart, M Richardson, P Orlowski, RZ Lonial, S AF Kaufman, Jonathan L. Shah, Jatin J. Laubach, Jacob P. Heffner, Leonard Francis, Dixil Harvey, R. Donald Lewis, Colleen Tighiouart, Mourad Richardson, Paul Orlowski, Robert Z. Lonial, Sagar TI Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kaufman, Jonathan L.; Heffner, Leonard; Francis, Dixil; Harvey, R. Donald; Lewis, Colleen; Tighiouart, Mourad; Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Shah, Jatin J.; Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Laubach, Jacob P.; Richardson, Paul] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1251 EP 1251 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203366 ER PT J AU Richardson, PG Jagannath, S Jakubowiak, AJ Lonial, S Raje, N Alsina, M Ghobrial, I Schlossman, RL Mazumder, A Munshi, NC Vesole, DH Colson, K McKenney, ML Lunde, LE Feather, J Hideshima, T Knight, RD Esseltine, DL Mitsiades, CS Anderson, KC AF Richardson, Paul G. Jagannath, Sundar Jakubowiak, Andrzej J. Lonial, Sagar Raje, Noopur Alsina, Melissa Ghobrial, Irene Schlossman, Robert L. Mazumder, Amitabha Munshi, Nikhil C. Vesole, David H. Colson, Kathleen McKenney, Mary L. Lunde, Laura E. Feather, John Hideshima, Teru Knight, Robert D. Esseltine, Dixie-Lee Mitsiades, Constantine S. Anderson, Kenneth C. TI Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After > 2 Years of Follow-up SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Richardson, Paul G.; Ghobrial, Irene; Schlossman, Robert L.; Munshi, Nikhil C.; Colson, Kathleen; McKenney, Mary L.; Lunde, Laura E.; Feather, John; Hideshima, Teru; Mitsiades, Constantine S.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jagannath, Sundar] Mt Sinai Med Ctr, New York, NY 10029 USA. [Jakubowiak, Andrzej J.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Lonial, Sagar] Emory Winship Canc Inst, Atlanta, GA USA. [Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Alsina, Melissa] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Mazumder, Amitabha] NYU, Ctr Comprehens Canc, New York, NY USA. [Vesole, David H.] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Knight, Robert D.] Celgene Inc, Summit, NJ USA. [Esseltine, Dixie-Lee] Millennium Pharmacuet Inc, Cambridge, MA USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1257 EP 1257 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203381 ER PT J AU Mahindra, A Richardson, PG Hari, P Sohani, AR Laubach, JP Burke, J Kaster, S Connolly, C Rivera, L Jacobs, P Saad, A Colson, K Ghobrial, I Schlossman, RL Adams, J Makrides, W Weller, E Munshi, NC Anderson, KC Raje, N AF Mahindra, Anuj Richardson, Paul G. Hari, Parameswaran Sohani, Aliyah R. Laubach, Jacob P. Burke, Jill Kaster, Sarah Connolly, Christine Rivera, Linda Jacobs, Paulette Saad, Ayman Colson, Kathleen Ghobrial, Irene Schlossman, Robert L. Adams, Jennifer Makrides, Wendy Weller, Edie Munshi, Nikhil C. Anderson, Kenneth C. Raje, Noopur TI Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sohani, Aliyah R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Hari, Parameswaran; Jacobs, Paulette] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Saad, Ayman] Froedtert & MCW Clin Canc Ctr, Neoplast Dis Related Disorders, Milwaukee, WI USA. [Ghobrial, Irene] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1258 EP 1258 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203383 ER PT J AU Jagannath, S Chanan-Khan, AA Heffner, LT Avigan, D Lutz, RJ Uherek, C Osterroth, F Ruehle, M Haeder, T Niemann, G Wartenberg-Demand, A Munshi, NC Anderson, KC AF Jagannath, Sundar Chanan-Khan, Asher A. Heffner, Leonard T. Avigan, David Lutz, Robert J. Uherek, Christoph Osterroth, Frank Ruehle, Markus Haeder, Thomas Niemann, Gabriele Wartenberg-Demand, Andrea Munshi, Nikhil C. Anderson, Kenneth C. TI BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jagannath, Sundar] Mt Sinai Med Ctr, Multiple Myeloma Program, New York, NY 10029 USA. [Chanan-Khan, Asher A.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Heffner, Leonard T.] Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA. [Avigan, David] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA. [Lutz, Robert J.] Immuno Gen Inc, Translational Res & Dev, Waltham, MA USA. [Uherek, Christoph] Biotest AG, Preclin Dev Biotherapeut, Dreieich, Germany. [Osterroth, Frank] Biotest AG, GBU Biotherapeut, Dreieich, Germany. [Ruehle, Markus] Biotest AG, Corp Drug Safety, Dreieich, Germany. [Haeder, Thomas; Niemann, Gabriele; Wartenberg-Demand, Andrea] Biotest AG, Corp Clin Res, Dreieich, Germany. [Munshi, Nikhil C.] Dana Farber Canc Inst, VA Boston Healthcare Syst, Boston, MA 02115 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1262 EP 1262 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203392 ER PT J AU Munshi, NC Lee, S Kambhampati, S Mohiuddin, A Rose, M Behler, C Han, A Efebera, Y Houranieh, A Brophy, MT Zimelman, A Prabhala, RH Saba, HI Klein, C Mehta, P Hayes, T Roodman, D Lichtenstein, AK AF Munshi, Nikhil C. Lee, Saem Kambhampati, Suman Mohiuddin, Abid Rose, Michal Behler, Caroline Han, Andrew Efebera, Yvonne Houranieh, Antoun Brophy, Mary T. Zimelman, Abraham Prabhala, Rao H. Saba, Hussain I. Klein, Catherine Mehta, Paulette Hayes, Teresa Roodman, David Lichtenstein, Alan K. TI Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Munshi, Nikhil C.; Lee, Saem; Han, Andrew; Efebera, Yvonne; Houranieh, Antoun; Brophy, Mary T.; Zimelman, Abraham; Prabhala, Rao H.] VA Boston Healthcare Syst, Boston, MA USA. [Kambhampati, Suman] Kansas City VA Med Ctr, Kansas City, MO USA. [Mohiuddin, Abid] Atlanta VA Med Ctr, Atlanta, GA USA. [Rose, Michal] VA Connecticut Healthcare Syst, West Haven, CT USA. [Behler, Caroline] San Francisco VA Med Ctr, San Francisco, CA USA. [Saba, Hussain I.] James A Haley VA Hosp, Tampa, FL USA. [Klein, Catherine] VA Eastern Colorado Hlth Care Syst, Aurora, CO USA. [Mehta, Paulette] John L McClellan Mem Vet Adm Med Ctr, Little Rock, AR USA. [Hayes, Teresa] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Roodman, David] Pittsburgh VA Med Ctr, Pittsburgh, PA USA. [Lichtenstein, Alan K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RI Efebera, Yvonne/E-3012-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1262 EP 1263 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203393 ER PT J AU Jakubowiak, AJ Richardson, PG Zimmerman, TM Alsina, M Kaufman, JL Kandarpa, M Harvey, CK Colson, K Mitchell, M Hideshima, T Sportelli, P Gardner, L Giusti, K Anderson, KC AF Jakubowiak, Andrzej J. Richardson, Paul G. Zimmerman, Todd M. Alsina, Melissa Kaufman, Jonathan L. Kandarpa, Malathi Harvey, Colleen K. Colson, Kathleen Mitchell, Monica Hideshima, Teru Sportelli, Peter Gardner, Lesa Giusti, Kathy Anderson, Kenneth C. TI Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jakubowiak, Andrzej J.; Kandarpa, Malathi; Harvey, Colleen K.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Richardson, Paul G.; Colson, Kathleen; Hideshima, Teru; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Zimmerman, Todd M.; Mitchell, Monica] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Alsina, Melissa] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Kaufman, Jonathan L.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Sportelli, Peter; Gardner, Lesa] Keryx Biopharmaceut Inc, New York, NY USA. [Giusti, Kathy] Multiple Myeloma Res Fdn Consortium, Norwalk, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1264 EP 1264 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203396 ER PT J AU Scott, BL Gooley, TA Linenberger, ML Sandmaier, BM Myerson, D Chauncey, T Appelbaum, FR Deeg, HJ AF Scott, Bart Lee Gooley, Ted A. Linenberger, Michael L. Sandmaier, Brenda M. Myerson, David Chauncey, Thomas Appelbaum, Frederick R. Deeg, H. Joachim TI International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Scott, Bart Lee; Gooley, Ted A.; Linenberger, Michael L.; Sandmaier, Brenda M.; Myerson, David; Chauncey, Thomas; Appelbaum, Frederick R.; Deeg, H. Joachim] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1272 EP 1272 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203417 ER PT J AU Sanda, T Tyner, JW Gutierrez, A Ngo, VN Moriggl, R Ahn, Y Glover, JM Chang, BH Willis, SG Staudt, LM Druker, BJ Look, AT AF Sanda, Takaomi Tyner, Jeffrey W. Gutierrez, Alejandro Ngo, Vu N. Moriggl, Richard Ahn, Yebin Glover, Jason M. Chang, Bill H. Willis, Stephanie G. Staudt, Louis M. Druker, Brian J. Look, A. Thomas TI Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Gutierrez, Alejandro; Look, A. Thomas] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Tyner, Jeffrey W.; Willis, Stephanie G.; Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Ngo, Vu N.; Staudt, Louis M.] NCI, Metab Branch, NIH, Bethesda, MD 20892 USA. [Moriggl, Richard] Ludwig Boltzmann Inst Canc Res, Vienna, Austria. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1298 EP 1298 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203486 ER PT J AU Hoare, K Hoare, S Zamora, B Flagg, T Ann, DT McClellan, S Shipp, MA Reinhard, M May, WS AF Hoare, Kishalay Hoare, Sarasija Zamora, Bernadette Flagg, Tammy Ann Dongtao McClellan, Steve Shipp, Margaret A. Reinhard, Mary May, W. Stratford TI Aberrant Ras Activation Associated with Functional Loss of Tnk1/Kos1 In Human B-Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Hoare, Kishalay; Hoare, Sarasija; Flagg, Tammy; May, W. Stratford] Univ Florida, Div Hematol Oncol, Gainesville, FL USA. [McClellan, Steve] Univ Florida, ICBR, Flow Cytometry Core Labs, Gainesville, FL USA. [Shipp, Margaret A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1299 EP 1300 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203490 ER PT J AU Blackburn, JS Liu, SL Langenau, DM AF Blackburn, Jessica S. Liu, Sali Langenau, David M. TI Notch Expression Expands the Pre-Malignant Pool of T-Cell Acute Lymphoblastic Leukemia Clones without Affecting Self-Renewal SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Blackburn, Jessica S.; Liu, Sali] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1300 EP 1300 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203492 ER PT J AU Fogerty, AE Colwell, A Austen, JW Kuter, DJ AF Fogerty, Annemarie E. Colwell, Amy Austen, Jay William, Jr. Kuter, David J. TI Thrombin Generation During Abdominal Surgical Procedures: Effect of Prophylactic Anticoagulation Therapy SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Fogerty, Annemarie E.; Colwell, Amy; Austen, Jay William, Jr.; Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1308 EP 1308 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203514 ER PT J AU Schlis, KD Stubbs, M DeAngelo, DJ Neuberg, D Dahlberg, SE Sallan, SE Armstrong, SA Silverman, LB AF Schlis, Krysta D. Stubbs, Matthew DeAngelo, Daniel J. Neuberg, Donna Dahlberg, Suzanne E. Sallan, Stephen E. Armstrong, Scott. A. Silverman, Lewis B. TI A Pilot Trial of Rapamycin with Glucocorticoids In Children and Adults with Relapsed ALL SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Schlis, Krysta D.; Sallan, Stephen E.; Armstrong, Scott. A.; Silverman, Lewis B.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Neuberg, Donna; Dahlberg, Suzanne E.] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1330 EP 1330 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203575 ER PT J AU Wayne, A Bhojwani, D Richards, K Stetler-Stevenson, M Silverman, LB Jeha, S Pui, CH McDevitt, J FitzGerald, DJ Kreitman, RJ Lechleider, RJ Pastan, I AF Wayne, Alan Bhojwani, Deepa Richards, Kelly Stetler-Stevenson, Maryalice Silverman, Lewis. B. Jeha, Sima Pui, Ching-Hon McDevitt, Jennifer FitzGerald, David J. Kreitman, Robert J. Lechleider, Robert J. Pastan, Ira TI Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Wayne, Alan; Richards, Kelly] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Bhojwani, Deepa; Jeha, Sima; Pui, Ching-Hon] St Jude Childrens Hosp, Memphis, TN 38105 USA. [Stetler-Stevenson, Maryalice] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Silverman, Lewis. B.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [FitzGerald, David J.; Kreitman, Robert J.; Pastan, Ira] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [McDevitt, Jennifer; Lechleider, Robert J.] Medimmune Inc, Gaithersburg, MD 20878 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1331 EP 1331 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203577 ER PT J AU Merryman, R Gostic, WJ Stevenson, KE Neuberg, D O'Brien, J Sallan, SE Silverman, LB AF Merryman, Reid Gostic, William J., II Stevenson, Kristen E. Neuberg, Donna O'Brien, Jane Sallan, Stephen E. Silverman, Lewis B. TI Asparaginase-Associated Myelosuppression and Effects on Dosing of Other Chemotherapeutic Agents In Children and Adolescents with Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Merryman, Reid; Gostic, William J., II] Harvard Univ, Sch Med, Boston, MA USA. [Stevenson, Kristen E.; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [O'Brien, Jane; Sallan, Stephen E.; Silverman, Lewis B.] Childrens Hosp, Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1332 EP 1333 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203580 ER PT J AU Ravandi, F Pigneux, A Smith, D Dombret, H Thomas, X Kantarjian, HM Cortes, JE DeAngelo, DJ Pratz, KW Asatiani, E Gianella-Borradori, A Longerey, B Harousseau, JL AF Ravandi, Farhad Pigneux, Arnaud Smith, Douglas Dombret, Herve Thomas, Xavier Kantarjian, Hagop M. Cortes, Jorge E. DeAngelo, Daniel J. Pratz, Keith W. Asatiani, Ekaterine Gianella-Borradori, Athos Longerey, Blandine Harousseau, Jean-Luc TI Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run In Part of a Phase II Trial of the Orally Available MEK-Inhibitor MSC1936369 In Patients with Advanced Hematological Malignancies SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ravandi, Farhad; Kantarjian, Hagop M.; Cortes, Jorge E.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Pigneux, Arnaud] Hop Haut Leveque, Pessac, France. [Smith, Douglas; Pratz, Keith W.] Sidney Kimmel Comprehens Canc Ctr John Hopkins, Baltimore, MD USA. [Dombret, Herve] Hop St Louis, Paris, France. [Thomas, Xavier] Hop Edouard Herriot, Lyon, France. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Asatiani, Ekaterine; Gianella-Borradori, Athos; Longerey, Blandine] Merck Serono SA, Geneva, Switzerland. [Harousseau, Jean-Luc] Hop Hotel Dieu, Nantes, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1350 EP 1350 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203627 ER PT J AU Luger, S Yao, XP Paietta, E Ketterling, R Rybka, W Litzow, MR Rowe, JM Larson, R Tallman, MS AF Luger, Selina Yao, Xiaopan Paietta, Elisabeth Ketterling, Rhett Rybka, Witold Litzow, Mark R. Rowe, Jacob M. Larson, Richard Tallman, Martin S. TI Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Luger, Selina] Univ Penn, Philadelphia, PA 19104 USA. [Yao, Xiaopan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Paietta, Elisabeth] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA. [Ketterling, Rhett; Litzow, Mark R.] Mayo Clin, Rochester, MN USA. [Rybka, Witold] Penn State Hershey Canc Inst, Div Hematol Oncol, Hershey, PA USA. [Rowe, Jacob M.] Technion Israel Inst Technol, Rambam Med Ctr, Haifa, Israel. [Larson, Richard] Univ Chicago, Chicago, IL 60637 USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1358 EP 1359 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203646 ER PT J AU Aster, JC Ashworth, TD Chiang, M Pear, WS Blacklow, S Kelliher, M Kastner, P Chan, S AF Aster, Jon C. Ashworth, Todd D. Chiang, Mark Pear, Warren S. Blacklow, Stephen Kelliher, Michelle Kastner, Philippe Chan, Susan TI Deletion-Based Mechanisms of Notch1 Activation In T-ALL: Key Roles for RAG Recombinase and A Conserved Internal Translational Start Site In Notch1. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Aster, Jon C.; Ashworth, Todd D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Chiang, Mark] Univ Michigan, Ann Arbor, MI 48109 USA. [Pear, Warren S.] Univ Penn, Philadelphia, PA 19104 USA. [Blacklow, Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Blacklow, Stephen] Harvard Univ, Sch Med, Boston, MA USA. [Kelliher, Michelle] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA USA. [Kelliher, Michelle] Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA USA. [Kastner, Philippe; Chan, Susan] Inst Genet & Biol Mol & Cellulaire, Strasbourg, France. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1378 EP 1379 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203698 ER PT J AU Troppito, L Muniandy, P Hedouin, S Silva, J Feldman, L Wu, C Yan, CT AF Troppito, Logan Muniandy, Parames Hedouin, Sabrine Silva, Joshua Feldman, Lauren Wu, Christine Yan, Catherine T. TI Hypomorphic Lig4 Impacts on Igh Class Switching and Translocations SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Troppito, Logan; Muniandy, Parames; Hedouin, Sabrine; Silva, Joshua; Feldman, Lauren; Wu, Christine; Yan, Catherine T.] Harvard Univ, Sch Med, BIDMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1381 EP 1381 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203704 ER PT J AU Guerin, A Bollu, V Guo, A Griffin, JD Yu, AP Wu, EQ AF Guerin, Annie Bollu, Vamsi Guo, Amy Griffin, James D. Yu, Andrew Peng Wu, Eric Qiong TI Comparison of Adherence Between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Guerin, Annie] Anal Grp Inc, Montreal, PQ, Canada. [Bollu, Vamsi; Guo, Amy] Novartis Pharmaceut, E Hanover, NJ USA. [Griffin, James D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Yu, Andrew Peng; Wu, Eric Qiong] Anal Grp Inc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1409 EP 1409 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203768 ER PT J AU Gyurkocza, B Storb, R Storer, BE Chauncey, T Lange, T Laport, GG Langston, A Pulsipher, MA Bredeson, C Maziarz, R Bruno, B Petersen, F Maris, M Agura, E Yeager, AM Bethge, WA Sahebi, F Appelbaum, FR Maloney, DG Estey, EH Sandmaier, BM AF Gyurkocza, Boglarka Storb, Rainer Storer, Barry E. Chauncey, Thomas Lange, Thoralf Laport, Ginna G. Langston, Amelia Pulsipher, Michael A. Bredeson, Christopher Maziarz, Richard Bruno, Benedetto Petersen, Finn Maris, Michael Agura, Edward Yeager, Andrew M. Bethge, Wolfgang A. Sahebi, Firoozeh Appelbaum, Frederick R. Maloney, David G. Estey, Elihu H. Sandmaier, Brenda M. TI A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Gyurkocza, Boglarka; Storb, Rainer; Storer, Barry E.; Appelbaum, Frederick R.; Maloney, David G.; Estey, Elihu H.; Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Gyurkocza, Boglarka; Storb, Rainer; Storer, Barry E.; Appelbaum, Frederick R.; Maloney, David G.; Estey, Elihu H.; Sandmaier, Brenda M.] Univ Washington, Seattle, WA 98195 USA. [Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lange, Thoralf] Univ Leipzig, Leipzig, Germany. [Laport, Ginna G.] Stanford Univ, Stanford, CA 94305 USA. [Langston, Amelia] Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA. [Pulsipher, Michael A.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Bredeson, Christopher] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Maziarz, Richard] Oregon Hlth & Sci Univ, Ctr Clin Canc, Portland, WI USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Petersen, Finn] LDS Hosp, Intermountain Blood & Marrow Trans Prog, Salt Lake City, UT USA. [Maris, Michael] Rocky Mt Blood & Marrow Trans, Denver, CO USA. [Agura, Edward] Baylor Univ, Med Ctr, BMT, Dallas, TX USA. [Yeager, Andrew M.] Univ Arizona, Tucson, AZ USA. [Bethge, Wolfgang A.] Univ Tubingen, Dept Med Hematol Oncol, Tubingen, Germany. [Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA 91010 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1415 EP 1416 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203781 ER PT J AU Blaser, BW Kim, H Plutzky, J Alyea, E Ho, V Cutler, C Armand, P Koreth, J Antin, JH Soiffer, R AF Blaser, Bradley W. Kim, Haesook Plutzky, Jorge Alyea, Edwin, III Ho, Vincent Cutler, Corey Armand, Philippe Koreth, John Antin, Joseph H. Soiffer, Robert TI Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Blaser, Bradley W.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Kim, Haesook] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Plutzky, Jorge] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA. [Alyea, Edwin, III; Ho, Vincent; Cutler, Corey; Armand, Philippe; Koreth, John; Antin, Joseph H.; Soiffer, Robert] Dana Farber Brigham & Womens Canc Ctr, Div Hematol Malignancies, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1419 EP 1419 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203788 ER PT J AU Hutchinson, CB Crow, JH Qin, H Lu, CM Sebastain, S Rehder, C Lagoo, AS Goodman, B Horwitz, ME Rizzieri, DA Datto, M Buckley, P Wang, E AF Hutchinson, Charles Blake Crow, Jennifer H. Qin Huang Lu, Chuanyi M. Sebastain, Siby Rehder, Catherine Lagoo, Anand S. Goodman, Barbara Horwitz, Mitchell E. Rizzieri, David A. Datto, Michael Buckley, Patrick Wang, Endi TI Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a Comprehensive Review of Literature SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Hutchinson, Charles Blake; Crow, Jennifer H.; Sebastain, Siby; Rehder, Catherine; Lagoo, Anand S.; Goodman, Barbara; Datto, Michael; Buckley, Patrick; Wang, Endi] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. [Qin Huang] City Hope Natl Canc Ctr, Dept Pathol, Duarte, CA USA. [Lu, Chuanyi M.] San Francisco VA Med Ctr, Lab Med Serv, San Francisco, CA USA. [Horwitz, Mitchell E.; Rizzieri, David A.] Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1423 EP 1424 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203797 ER PT J AU Richardson, PG Steinbach, G Kernan, N Guinan, EC Chen, AR Martin, PL Krishnan, A Arai, S Brochstein, JA Grupp, SA Mineishi, S Termuhlen, A Tomblyn, M Antin, JH Revta, C Hume, R Massaro, J Hannah, AL Iacobelli, M Soiffer, RJ AF Richardson, Paul G. Steinbach, Gideon Kernan, Nancy Guinan, Eva C. Chen, Allen R. Martin, Paul L. Krishnan, Amrita Arai, Sally Brochstein, Joel A. Grupp, Stephan A. Mineishi, Shin Termuhlen, Amanda Tomblyn, Marcie Antin, Joseph H. Revta, Carolyn Hume, Robin Massaro, Joseph Hannah, Alison L. Iacobelli, Massimo Soiffer, Robert J. CA Defibrotide Study Grp TI Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Steinbach, Gideon] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Kernan, Nancy] Mem Sloan Kettering Canc Ctr, Boston, MA USA. [Chen, Allen R.] Johns Hopkins Univ, Baltimore, MD USA. [Martin, Paul L.] Duke Univ, Med Ctr, Durham, NC USA. [Krishnan, Amrita] City Hope Natl Med Ctr, Hematol & Stem Cell Transplantat, Duarte, CA USA. [Arai, Sally] Stanford Univ, Stanford, CA 94305 USA. [Brochstein, Joel A.] Schneider Childrens Hosp, New Hyde Pk, NY USA. [Grupp, Stephan A.] Childrens Hosp Philadelphia, Philadelphia, PA USA. [Mineishi, Shin] Univ Michigan, Ann Arbor, MI 48109 USA. [Termuhlen, Amanda] Nationwide Childrens Hosp, Columbus, OH USA. [Tomblyn, Marcie] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA. [Hume, Robin; Hannah, Alison L.; Defibrotide Study Grp] Gentium, Como, Italy. [Massaro, Joseph] Boston Univ, Dept Stat, Boston, MA 02215 USA. [Iacobelli, Massimo] Gentium SpA, Dept Med Sci, Villa Guardia, Italy. OI Kernan, Nancy/0000-0003-1417-1823 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1430 EP 1431 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203812 ER PT J AU Corbacioglu, S Carreras, E Niederwieser, DW Sardella, M Hoyle, M Hume, R Massaro, J Hannah, AL Iacobelli, M Richardson, PG AF Corbacioglu, Selim Carreras, Enric Niederwieser, Dietger W. Sardella, Marco Hoyle, Margaret Hume, Robin Massaro, Joseph Hannah, Alison L. Iacobelli, Massimo Richardson, Paul G. CA Defibrotide Study Grp TI Safety of Defibrotide (DF) In Stem Cell Transplant (SCT) Patients (Pts) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 Univ Regensburg, Childrens Hosp Regensburg, Regensburg, Germany. [Carreras, Enric] Hosp Clin Barcelona, Barcelona, Spain. [Niederwieser, Dietger W.] Univ Leipzig, Leipzig, Germany. [Sardella, Marco; Hoyle, Margaret; Hume, Robin; Hannah, Alison L.; Defibrotide Study Grp] Gentium SpA, Como, Italy. [Massaro, Joseph] Boston Univ, Dept Stat, Boston, MA 02215 USA. [Iacobelli, Massimo] Gentium SpA, Dept Med Sci, Villa Guardia, Italy. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1431 EP 1431 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203813 ER PT J AU Akpek, G Pasquini, MC Agovi, MA Logan, B Cooke, KR Maziarz, RT Gupta, V Lazarus, HM Hale, GA Marks, DI Maharaj, D Popat, U Carabasi, M Bornhaeuser, M Bolwell, BJ Ringden, O Ballen, KK Rizzo, JD McCarthy, PL Ho, VT AF Akpek, Gorgun Pasquini, Marcelo C. Agovi, Manza-A Logan, Brent Cooke, Kenneth R. Maziarz, Richard T. Gupta, Vikas Lazarus, Hillard M. Hale, Gregory A. Marks, David I. Maharaj, Dipnarine Popat, Uday Carabasi, Matthew Bornhaeuser, Martin Bolwell, Brian J. Ringden, Olle Ballen, Karen K. Rizzo, J. Douglas McCarthy, Philip L. Ho, Vincent T. TI Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Akpek, Gorgun] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Rizzo, J. Douglas] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Cooke, Kenneth R.] Case Western Reserve Univ, Sch Med Pediat, Cleveland, OH 44106 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Gupta, Vikas] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Hale, Gregory A.] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA. [Marks, David I.] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England. [Maharaj, Dipnarine] Cell Transplant Inst, Boynton Beach, FL USA. [Popat, Uday] UT MD Anderson Canc Ctr, Houston, TX USA. [Carabasi, Matthew] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA. [Bornhaeuser, Martin] Univ Hosp, Med Clin 1, Dresden, Germany. [Bolwell, Brian J.] Cleveland Clin, Cleveland, OH 44106 USA. [Ringden, Olle] Karolinska Inst, Stokholm, Sweden. [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McCarthy, Philip L.] Roswell Pk Canc Inst, BMT Program, Buffalo, NY 14263 USA. [Ho, Vincent T.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1432 EP 1433 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203817 ER PT J AU Hahn, T McCarthy, PL Hassebroek, A Klein, JP Rizzo, JD Parsons, S Joffe, S Majhail, NS AF Hahn, Theresa McCarthy, Philip L. Hassebroek, Anna Klein, John P. Rizzo, J. Douglas Parsons, Susan Joffe, Steven Majhail, Navneet S. TI Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005 SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Hahn, Theresa] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA. [McCarthy, Philip L.] Roswell Pk Canc Inst, BMT Program, Buffalo, NY 14263 USA. [Hassebroek, Anna] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Klein, John P.] Med Coll Wisconsin, Dept Biostat, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Parsons, Susan] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. [Joffe, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA. [Majhail, Navneet S.] Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1442 EP 1442 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203840 ER PT J AU Ballen, KK Arora, M Zhu, XC Agovi, M Kalaycio, M Maziarz, RT Cortes, JE Woolfrey, A Horowitz, MM Saber, W AF Ballen, Karen K. Arora, Mukta Zhu, Xiaochun Agovi, Manza Kalaycio, Matt Maziarz, Richard T. Cortes, Jorge E. Woolfrey, Ann Horowitz, Mary M. Saber, Wael TI RESULTS of Allogeneic TRANSPLANTATION for Polycythemia VERA and Essential Thrombocythemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ballen, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Arora, Mukta] Univ Minnesota, Minneapolis, MN USA. [Horowitz, Mary M.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Agovi, Manza] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Kalaycio, Matt] Cleveland Clin, Cleveland, OH 44106 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Woolfrey, Ann] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Saber, Wael] Med Coll Wisconsin, Div Neoplast Dis, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1444 EP 1445 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203845 ER PT J AU Singh, H Werner, L DeAngelo, DJ Amrein, PC Wadleigh, M Ballen, KK Galinsky, I Neuberg, D Fox, E Stone, RM Attar, EC AF Singh, Harshabad Werner, Lillian DeAngelo, Daniel J. Amrein, Philip C. Wadleigh, Martha Ballen, Karen K. Galinsky, Ilene Neuberg, Donna Fox, Edward Stone, Richard M. Attar, Eyal C. TI Comparison of High Dose Chemotherapy with Autologous Stem Cell Rescue (ASCT) Versus Consolidation Chemotherapy for Patients < 60 with Cytogenetically Normal AML (CN-AML) and Flt3 ITD SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ballen, Karen K.; Attar, Eyal C.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. [Werner, Lillian; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [DeAngelo, Daniel J.; Wadleigh, Martha; Galinsky, Ilene; Stone, Richard M.] Dana Farber Canc Inst, Adult Leukemia Program, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1462 EP 1463 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203886 ER PT J AU Liu, Y Ni, M Roccaro, AM Leleu, X Zhang, Y Azab, AKA Azab, F Maiso, P Ngo, HT Sacco, A Morgan, B Brown, M Ghobrial, I AF Liu, Yang Ni, Min Roccaro, Aldo M. Leleu, Xavier Zhang, Yong Azab, Abdel Kareem A. Azab, Feda Maiso, Patricia Ngo, Hai T. Sacco, Antonio Morgan, Brittany Brown, Myles Ghobrial, Irene TI Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ghobrial, Irene] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Leleu, Xavier] CHRU, Hop Huriez, Serv Malad Sang, Lille, France. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1490 EP 1490 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204040 ER PT J AU Liu, Y Duan, SH Leleu, X Zhang, Y Azab, AKA Azab, F Maiso, P Ngo, HT Sacco, A Morgan, B Brown, M Anderson, KC Correll, M Roccaro, AM Ghobrial, IM AF Liu, Yang Duan, Shenghua Leleu, Xavier Zhang, Yong Azab, Abdel Kareem A. Azab, Feda Maiso, Patricia Ngo, Hai T. Sacco, Antonio Morgan, Brittany Brown, Myles Anderson, Kenneth C. Correll, Mick Roccaro, Aldo M. Ghobrial, Irene M. TI Genome Wide DNA Methylation Profiling In Patients with Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Duan, Shenghua; Correll, Mick] Dana Farber Canc Inst, Ctr Canc Computat Biol, Boston, MA 02115 USA. [Leleu, Xavier] CHRU, Hop Huriez, Serv Malad Sang, Lille, France. [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1491 EP 1491 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204042 ER PT J AU Heitmann, K Li, Z Klusmann, JH Thakur, BK Schoning, J Bourquin, JP Orkin, SH Reinhardt, D AF Heitmann, Kirsten Li, Zhe Klusmann, Jan-Henning Thakur, Basant Kumar Schoening, Jennifer Bourquin, Jean-Pierre Orkin, Stuart H. Reinhardt, Dirk TI Gene Expression-Based Chemical Genomics Identifies Valproic Acid to Revert the Oncogenic Effect of GATA1s In Down Syndrome Megakaryoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Heitmann, Kirsten; Klusmann, Jan-Henning; Schoening, Jennifer; Reinhardt, Dirk] Hannover Med Sch, D-3000 Hannover, Germany. [Li, Zhe] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA. [Bourquin, Jean-Pierre] Univ Kinderklin Zurich, Div Pediat Oncol, Zurich, Switzerland. [Orkin, Stuart H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RI Reinhardt, Dirk/D-3939-2011 OI Reinhardt, Dirk/0000-0003-4313-9056 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1499 EP 1499 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204066 ER PT J AU Liu, HD Chi, A Arnett, K Chiang, M Xu, LW Shestova, O Wang, HF Bhandoola, A Aster, JC Blacklow, SC Pear, WS AF Liu, Hudan Chi, Anthony Arnett, Kelly Chiang, Mark Xu, Lanwei Shestova, Olga Wang, Hongfang Bhandoola, Avinash Aster, Jon C. Blacklow, Stephen C. Pear, Warren S. TI Critical Functions for Notch Dimerization In T Cell Transformation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol ID TRANSCRIPTION; COMPLEX C1 [Liu, Hudan; Chi, Anthony; Xu, Lanwei; Shestova, Olga; Bhandoola, Avinash; Pear, Warren S.] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA. [Liu, Hudan; Xu, Lanwei; Shestova, Olga; Pear, Warren S.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA. [Arnett, Kelly; Blacklow, Stephen C.] Harvard Univ, Sch Med, Boston, MA USA. [Arnett, Kelly; Blacklow, Stephen C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chiang, Mark] Univ Michigan, Ann Arbor, MI 48109 USA. [Wang, Hongfang; Aster, Jon C.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 5 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1499 EP 1499 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204067 ER PT J AU Grace, RF Bennett, CM Ritchey, AK Jeng, MR Thornburg, C Lambert, M Neier, M Recht, M Kumar, M Blanchette, V Klaassen, R Buchanan, GR Kurth, MAH Nugent, DJ Thompson, AA Stine, K Kalish, LA Neufeld, EJ AF Grace, Rachael F. Bennett, Carolyn M. Ritchey, A. Kim Jeng, Michael R. Thornburg, Courtney Lambert, Michele Neier, Michelle Recht, Michael Kumar, Manjusha Blanchette, Victor Klaassen, Robert Buchanan, George R. Kurth, Margaret A. Heisel Nugent, Diane J. Thompson, Alexis A. Stine, Kimo Kalish, Leslie A. Neufeld, Ellis J. TI Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Grace, Rachael F.] Childrens Hosp Boston, Dana Farber Canc Inst, Boston, MA USA. [Bennett, Carolyn M.] Emory Univ, Sch Med, Childrens Healthcare Atlanta Scottish Rite Pediat, Atlanta, GA USA. [Ritchey, A. Kim] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. [Jeng, Michael R.] Stanford Sch Med, Palo Alto, CA USA. [Thornburg, Courtney] DUMC, Durham, NC USA. [Neier, Michelle] Canc Inst New Jersey, New Brunswick, NJ USA. [Recht, Michael] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA. [Kumar, Manjusha] Riley Childrens Hosp, Indianapolis, IN USA. [Blanchette, Victor] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Klaassen, Robert] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada. [Buchanan, George R.] Univ Texas Dallas, Dallas, TX 75230 USA. [Thompson, Alexis A.] Childrens Hosp & Clin, Minneapolis, MN USA. [Nugent, Diane J.] Childrens Hosp Orange Cty, Dept Pediat, Div Pediat Hematol, Orange, CA 92668 USA. [Thompson, Alexis A.] Childrens Mem Hosp, Chicago, IL 60614 USA. [Stine, Kimo] Arkansas Childrens Hosp, Little Rock, AR 72202 USA. [Kalish, Leslie A.] Childrens Hosp Boston, Clin Res Program, Boston, MA USA. RI Neufeld, Ellis/F-9331-2011 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1510 EP 1510 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204101 ER PT J AU Bussel, JB Zhang, J Tang, S McIntosh, J Kuter, DJ AF Bussel, James B. Zhang, Jenny Tang, Shande McIntosh, Joe Kuter, David J. TI Efficacy, Safety and Tolerability of E5501 (AKR501) In a 6-Month Extension Study In Subjects with Chronic Immune Thrombocytopenia (ITP) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Bussel, James B.] New York Presbyterian Hosp, Div Hematol, Dept Pediat, New York, NY USA. [Bussel, James B.] New York Presbyterian Hosp, Div Hematol, Dept Med, New York, NY USA. [Zhang, Jenny; Tang, Shande; McIntosh, Joe] Eisai Corp N America, Woodcliff Lake, NJ USA. [Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1516 EP 1516 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204115 ER PT J AU Gernsheimer, T Kuter, DJ Cines, DB Stasi, R Rummel, MJ Godeau, B Guo, M Franklin, J AF Gernsheimer, Terry Kuter, David J. Cines, Douglas B. Stasi, Roberto Rummel, Mathias J. Godeau, Bertrand Guo, Matthew Franklin, Janet TI Analysis of Mortality Rates During Romiplostim Clinical Studies of Patients (Pts) with Immune Thrombocytopenia (ITP) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Gernsheimer, Terry] Univ Washington, Seattle, WA 98195 USA. [Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cines, Douglas B.] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Stasi, Roberto] St George Hosp, London, England. [Rummel, Mathias J.] Klinikum Justus Liebig Univ, Giessen, Germany. [Godeau, Bertrand] Ctr Hosp Univ, Hop Henri Mondor, Creteil, France. [Guo, Matthew; Franklin, Janet] Amgen Inc, Thousand Oaks, CA 91320 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1518 EP 1519 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204121 ER PT J AU Boccia, R Kuter, DJ Rummel, MJ Macik, BG Pabinger, I Selleslag, D Rodeghiero, F Chong, B Wang, XN Lizambri, R AF Boccia, Ralph Kuter, David J. Rummel, Mathias J. Macik, B. Gail Pabinger, Ingrid Selleslag, Dominik Rodeghiero, Francesco Chong, Beng Wang, Xuena Lizambri, Richard TI The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Boccia, Ralph] Ctr Canc & Blood Disorders, Bethesda, MD USA. [Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rummel, Mathias J.] Klinikum Justus Liebig Univ, Giessen, Germany. [Macik, B. Gail] Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA. [Pabinger, Ingrid] Dept Med Hematol & Hemostaseol 1, Vienna, Austria. [Selleslag, Dominik] AZ St Jan Brugge AV, Brugge, Belgium. [Rodeghiero, Francesco] San Bortolo Hosp, Dept Hematol, Vicenza, Italy. [Chong, Beng] Univ New S Wale, Kogarah, NSW, Australia. [Chong, Beng] St George Hosp, Kogarah, NSW, Australia. [Wang, Xuena; Lizambri, Richard] Amgen Inc, Thousand Oaks, CA 91320 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1519 EP 1520 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204122 ER PT J AU Hu, Z Yang, YG AF Hu, Zheng Yang, Yong-Guang TI Macrophages Prevent Human Red Blood Cell Reconstitution In NOD/SCID and NOD/SCID/gamma c(-/-) Mice. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Hu, Zheng; Yang, Yong-Guang] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1528 EP 1528 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204143 ER PT J AU Very, GB Vergilio, JA Calicchio, M Fleming, MD Rollins, B AF Very, Gayane Badalian Vergilio, Jo-Anne Calicchio, Monica Fleming, Mark D. Rollins, Barrett TI Toll Receptors and Langerhans Cell Histiocytosis SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Very, Gayane Badalian; Rollins, Barrett] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA. [Vergilio, Jo-Anne; Fleming, Mark D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA 02115 USA. [Calicchio, Monica] Childrens Hosp Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1552 EP 1552 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204213 ER PT J AU Wear, S Richardson, PG Revta, C Vij, R Fiala, M Lonial, S Francis, D diCapua Siegel, DS Schramm, A Jakubowiak, AJ Harvey, CK Reece, DE Gul, E Jagannath, S La, L Hofmeister, CC Jansak, B Stewart, K Hagerty, R Wolf, JL Davis, B Krishnan, A Duarte, L Zimmerman, TM Cisneros, A Kumar, S Birgin, A Ott, R Tasca, L Kelley, SL Anderson, KC Giusti, K AF Wear, Sandra Richardson, Paul G. Revta, Carolyn Vij, Ravi Fiala, Mark Lonial, Sagar Francis, Dixil diCapua Siegel, David Samuel Schramm, Alex Jakubowiak, Andrzej J. Harvey, Colleen K. Reece, Donna E. Gul, Engin Jagannath, Sundar La, Lisa Hofmeister, Craig C. Jansak, Buffy Stewart, Keith Hagerty, Rachel Wolf, Jeffrey L. Davis, Beth Krishnan, Amrita Duarte, Lupe Zimmerman, Todd M. Cisneros, Angela Kumar, Shaji Birgin, Ann Ott, Robert Tasca, Leah Kelley, Susan L. Anderson, Kenneth C. Giusti, Kathy TI The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol ID CLINICAL-TRIALS C1 [Wear, Sandra; Ott, Robert; Tasca, Leah; Kelley, Susan L.] Multiple Myeloma Res Consortium, Norwalk, CT USA. [Richardson, Paul G.; Revta, Carolyn] Dana Farber Canc Inst, Boston, MA 02115 USA. [Vij, Ravi; Fiala, Mark] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Francis, Dixil] Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA. [diCapua Siegel, David Samuel; Schramm, Alex] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Jakubowiak, Andrzej J.; Harvey, Colleen K.] Univ Michigan, Ann Arbor, MI 48109 USA. [Reece, Donna E.; Gul, Engin] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Jagannath, Sundar; La, Lisa] Mt Sinai Med Ctr, New York, NY 10029 USA. [Hofmeister, Craig C.; Jansak, Buffy] Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA. [Stewart, Keith; Hagerty, Rachel] Mayo Clin, Scottsdale, AZ USA. [Wolf, Jeffrey L.; Davis, Beth] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Krishnan, Amrita; Duarte, Lupe] City Hope Natl Med Ctr, Duarte, CA USA. [Zimmerman, Todd M.; Cisneros, Angela] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Kumar, Shaji; Birgin, Ann] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA. [Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Giusti, Kathy] Multiple Myeloma Res Fdn, Norwalk, CT USA. RI Kumar, Shaji/A-9853-2008 OI Kumar, Shaji/0000-0001-5392-9284 NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1555 EP 1556 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204223 ER PT J AU Abel, GA Friese, CR Neville, BA Richardson, LC Wilson, KM Hastings, BT Earle, CC Soiffer, RJ AF Abel, Gregory A. Friese, Christopher R. Neville, Bridget A. Richardson, Lisa C. Wilson, Katherine M. Hastings, B. Taylor Earle, Craig C. Soiffer, Robert J. TI Primary Care Referrals for Suspected Hematologic Malignancies: Incidence, Factors Affecting Choice of Specialist, and Flow of Referral Information. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Abel, Gregory A.; Neville, Bridget A.; Hastings, B. Taylor; Soiffer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Friese, Christopher R.] Univ Michigan, Ann Arbor, MI 48109 USA. [Richardson, Lisa C.; Wilson, Katherine M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Earle, Craig C.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. RI Friese, Christopher/D-2097-2013 OI Friese, Christopher/0000-0002-2281-2056 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1567 EP 1567 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204250 ER PT J AU Lin, JH Lwin, T Tam, WN Zhao, JJ Crespo, L Choi, YS Znang, XW Tannenbaum, V Sotomayor, EM Moscinski, LC Dalton, WS Wright, K Tao, JG AF Lin, Jianhong Lwin, Tint Tam, Wayne Zhao, Jian-Jun Crespo, Luis Choi, Yong Sung Znang, Xinwei Tannenbaum, Victoria Sotomayor, Eduardo M. Moscinski, Lynn C. Dalton, William S. Wright, Ken Tao, Jianguo TI Microenvironment-Mediated Regulation of Micrornas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Lin, Jianhong; Lwin, Tint; Crespo, Luis; Znang, Xinwei; Tannenbaum, Victoria; Sotomayor, Eduardo M.; Moscinski, Lynn C.; Dalton, William S.; Tao, Jianguo] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol & Expt Therapeut Program, Tampa, FL USA. [Tam, Wayne] Cornell Univ, Dept Pathol, Weill Med Coll, Ithaca, NY 14853 USA. [Zhao, Jian-Jun] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Choi, Yong Sung] Alton Ochsner Med Fdn & Ochsner Clin, Lab Cellular Immunol, New Orleans, LA USA. [Wright, Ken] H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1576 EP 1576 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204273 ER PT J AU Yu, M Mazor, T Huang, H Huang, E Kathrein, K Woo, A Zon, LI Fraenkel, E Cantor, AB AF Yu, Ming Mazor, Tali Huang, Hui Huang, Emily Kathrein, Katie Woo, Andrew Zon, Leonard I. Fraenkel, Ernest Cantor, Alan B. TI Role of Polycomb Repressive Complex 1 (PRC1) In Runx1 Mediated Gene Regulation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Zon, Leonard I.] Harvard Univ, Childrens Hosp, Sch Med, Stem Cell Program, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst,Harvard Stem Cell Inst, Boston, MA 02115 USA. [Mazor, Tali; Fraenkel, Ernest] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. [Zon, Leonard I.] Harvard Univ, Childrens Hosp, Sch Med, Div Hematol Oncol,Stem Cell Program & Hematol Onc, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1580 EP 1580 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204283 ER PT J AU Trompouki, E Bowman, TV Lawton, LN Peng, Z DiBiase, A Cech, J Sessa, A LeBlanc, J Li, PL Heffner, G Daley, GQ Young, R Zon, LI AF Trompouki, Eirini Bowman, Teresa V. Lawton, Lee N. Peng, Zi DiBiase, Anthony Cech, Jennifer Sessa, Anna LeBlanc, Jocelyn Li, Pulin Heffner, Garrett Daley, George Q. Young, Richard Zon, Leonard I. TI BMP and WNT-Directed Transcription Factors TCF7L2/TCF4 and SMAD1 Bind to Distinct Hematopoietic-Specific Target Genes Depending on Cell Lineage SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Trompouki, Eirini; Bowman, Teresa V.; DiBiase, Anthony; Cech, Jennifer; Sessa, Anna; LeBlanc, Jocelyn; Li, Pulin; Heffner, Garrett; Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Trompouki, Eirini; Bowman, Teresa V.; DiBiase, Anthony; Cech, Jennifer; Sessa, Anna; LeBlanc, Jocelyn; Li, Pulin; Heffner, Garrett] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Lawton, Lee N.; Peng, Zi; Young, Richard] Whitehead Inst, Young Lab, Cambridge, MA 02142 USA. [Daley, George Q.] Childrens Hosp, Harvard Stem Cell Inst, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst,Harvard Stem Cell Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1582 EP 1582 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204290 ER PT J AU Song, WH Hideshima, T Tai, YT Prabhala, RH Anderson, KC Munshi, NC AF Song, Weihua Hideshima, Teru Tai, Yu-Tzu Prabhala, Rao H. Anderson, Kenneth C. Munshi, Nikhil C. TI Perifosine Affects Phenotype and Function of Human Myeloid Dendritic Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Song, Weihua; Hideshima, Teru; Tai, Yu-Tzu; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Prabhala, Rao H.; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, VA Boston Hlth Care Syst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1596 EP 1596 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204331 ER PT J AU Ghobrial, I Poon, T Rourke, M Chuma, S Kunsman, J Banwait, R Sam, A Warren, D Anderson, KC Richardson, P Treon, SP Matous, J AF Ghobrial, Irene Poon, Tiffany Rourke, Meghan Chuma, Stacey Kunsman, Janet Banwait, Ranjit Sam, Amy Warren, Diane Anderson, Kenneth C. Richardson, Paul Treon, Steven P. Matous, Jeffrey TI Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ghobrial, Irene; Rourke, Meghan; Kunsman, Janet; Banwait, Ranjit; Sam, Amy; Warren, Diane; Richardson, Paul] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Matous, Jeffrey] Rocky Mt Canc Ctr, Denver, CO USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1611 EP 1612 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204372 ER PT J AU Azab, AKA Quang, P Azab, F Thompson, B Maiso, P Roccaro, AM Sacco, A Ngo, HT Anderson, KC Kung, AL Lin, C Ghobrial, IM AF Azab, Abdel Kareem A. Quang, Phong Azab, Feda Thompson, Brian Maiso, Patricia Roccaro, Aldo M. Sacco, Antonio Ngo, Hai T. Anderson, Kenneth C. Kung, Andrew L. Lin, Charles Ghobrial, Irene M. TI Dynamic Regulation of the Level of Hypoxia In the Bone Marrow Regulates Cell Dissemination In Multiple Myeloma. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Thompson, Brian; Lin, Charles] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1645 EP 1645 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204455 ER PT J AU Sun, CY Hu, Y She, XM Chu, ZB Fang, J Chen, L AF Sun, Chunyan Hu, Yu She, Xiaomei Chu, Zhangbo Fang, Jun Chen, Lei TI MiR-15a and Mir-16-1 Affects the Angiogenesis of Multiple Myeloma by Targeting VEGF-A. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sun, Chunyan; Hu, Yu; She, Xiaomei; Chen, Lei] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, Wuhan 430074, Peoples R China. [Chu, Zhangbo] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Fang, Jun] Union Hosp, Dept Hematol, Wuhan, Hubei, Peoples R China. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1646 EP 1647 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204459 ER PT J AU Kong, SY Nahar, S Li, XF Song, WH Hu, YG Muchhal, U Desjarlais, J Richardson, P Munshi, NC Anderson, KC Tai, YT AF Kong, Sun-Young Nahar, Sabikun Li, Xian-Feng Song, Weihua Hu, Yiguo Muchhal, Umesh Desjarlais, John Richardson, Paul Munshi, Nikhil C. Anderson, Kenneth C. Tai, Yu-Tzu TI Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kong, Sun-Young; Nahar, Sabikun; Li, Xian-Feng; Hu, Yiguo] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Kong, Sun-Young; Nahar, Sabikun; Li, Xian-Feng; Hu, Yiguo] Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Muchhal, Umesh; Desjarlais, John] Xencor Inc, Monrovia, CA USA. [Richardson, Paul] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1655 EP 1656 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204483 ER PT J AU Mimura, N Hideshima, T Gorgun, G Cirstea, D Santo, L Hu, YG Fabre, C Blumenthal, M Tam, V Kertesz, NL Zeng, QP Patterson, JB Munshi, NC Richardson, P Anderson, KC AF Mimura, Naoya Hideshima, Teru Gorgun, Gullu Cirstea, Diana Santo, Loredana Hu, Yiguo Fabre, Claire Blumenthal, Martina Tam, Victor Kertesz, Nathalie L. Zeng, Qingping Patterson, John B. Munshi, Nikhil C. Richardson, Paul Anderson, Kenneth C. TI Targeting IRE1 alpha-XBP1 Pathway Is a Novel Therapeutic Strategy In Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Mimura, Naoya; Hideshima, Teru; Gorgun, Gullu; Hu, Yiguo; Fabre, Claire; Munshi, Nikhil C.; Richardson, Paul; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Cirstea, Diana; Santo, Loredana] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA USA. [Blumenthal, Martina; Tam, Victor; Kertesz, Nathalie L.; Zeng, Qingping; Patterson, John B.] MannKind Corp, Valencia, CA USA. NR 0 TC 2 Z9 2 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1659 EP 1659 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204493 ER PT J AU Malin, ES Toomey, CE Ono, J Sohani, AR Michaelson, JS Barnes, JA Abramson, JS Hochberg, EP AF Malin, Elisabeth S. Toomey, Christiana E. Ono, Jill Sohani, Aliyah R. Michaelson, James S. Barnes, Jeffrey A. Abramson, Jeremy S. Hochberg, Ephraim P. TI Primary Pancreatic Lymphoma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Ono, Jill; Sohani, Aliyah R.; Michaelson, James S.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Malin, Elisabeth S.; Toomey, Christiana E.; Barnes, Jeffrey A.; Abramson, Jeremy S.; Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1689 EP 1689 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204569 ER PT J AU Banwait, R Campigotto, F Weller, E Harris, B Yarar, D Roccaro, AM Rourke, M Leduc, R Leleu, X Ghobrial, IM AF Banwait, Ranjit Campigotto, Federico Weller, Edie Harris, Brianna Yarar, Dilek Roccaro, Aldo M. Rourke, Meghan Leduc, Renee Leleu, Xavier Ghobrial, Irene M. TI The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Banwait, Ranjit; Campigotto, Federico; Rourke, Meghan; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Leleu, Xavier] CHRU, Hop Huriez, Serv Malad Sang, Lille, France. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1690 EP 1691 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204572 ER PT J AU Hanzis, C Hunter, Z Manning, R Lewicki, M Brodsky, P Ioakimidis, L Tripsas, C Patterson, C Sheehy, P AF Hanzis, Christina Hunter, Zachary Manning, Robert Lewicki, Megan Brodsky, Philip Ioakimidis, Leukothea Tripsas, Christina Patterson, Christopher Sheehy, Patricia TI Associated Malignancies Among Patients and Kin with Waldenstrom's Macroglobulinemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Hanzis, Christina; Manning, Robert; Lewicki, Megan; Brodsky, Philip; Ioakimidis, Leukothea; Tripsas, Christina; Patterson, Christopher; Sheehy, Patricia] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Hunter, Zachary] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1692 EP 1693 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204578 ER PT J AU Gutierrez, A Kentsis, A Sanda, T Etchin, J Protopopov, A Zhang, JH Chin, L Silverman, LB Winter, S Hunger, S Sallan, SE Zha, S Alt, F Look, AT AF Gutierrez, Alejandro Kentsis, Alex Sanda, Takaomi Etchin, Julia Protopopov, Alexei Zhang, Jianhua Chin, Lynda Silverman, Lewis B. Winter, Stuart Hunger, Stephen Sallan, Stephen E. Zha, Shan Alt, Frederick Look, A. Thomas TI The BCL11B Tumor Suppressor Is Mutated In Human T-Cell Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Gutierrez, Alejandro; Kentsis, Alex; Sanda, Takaomi; Etchin, Julia; Silverman, Lewis B.; Sallan, Stephen E.; Look, A. Thomas] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Protopopov, Alexei; Zhang, Jianhua; Chin, Lynda] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02115 USA. [Winter, Stuart] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA. [Hunger, Stephen] Univ Colorado, Coll Med, Pediat Hem Onc BMT, Aurora, CO USA. [Zha, Shan] Columbia Univ, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1699 EP 1700 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204596 ER PT J AU Wang, JF Dayyani, F Brynzka, C Sweetser, D AF Wang, Jianfeng Dayyani, Farshid Brynzka, Christopher Sweetser, David TI TLEs Regulate Myeloid Proliferation and Differentiation In Association with Modulation of NF-kappa B and Wnt Signaling SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Wang, Jianfeng; Sweetser, David] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Dayyani, Farshid] Univ Texas MD Anderson Canc Ctr, Dept Hematol, Houston, TX 77030 USA. [Brynzka, Christopher] Toxikon Corp, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1699 EP 1699 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204595 ER PT J AU Thomas, GM Brill, A Schatzberg, D Wagner, DD AF Thomas, Grace M. Brill, Alexander Schatzberg, Daphne Wagner, Denisa D. TI Addressing the Issue of the Pathogenesis of Deep Vein Thrombosis In Cancer SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Thomas, Grace M.; Brill, Alexander; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pathol, Dis Inst, Boston, MA 02115 USA. [Schatzberg, Daphne] Immune Dis Inst, Boston, MA USA. RI Thomas, Grace/G-1020-2011 OI Thomas, Grace/0000-0003-4502-7154 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1715 EP 1715 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204639 ER PT J AU Butler, MO Imataki, O Yamashita, Y Tanaka, M Ansen, S Berezovskaya, A Milstein, MI Metzler, G Mooney, MM Murray, AP Mano, H Nadler, LM Hirano, N AF Butler, Marcus O. Imataki, Osamu Yamashita, Yoshihiro Tanaka, Makito Ansen, Sascha Berezovskaya, Alla Milstein, Matthew I. Metzler, Genita Mooney, Mary M. Murray, Andrew P. Mano, Hiroyuki Nadler, Lee M. Hirano, Naoto TI Human CD4(+) T Cells Help CD8(+) T Cells Proliferate Ex Vivo by Secreting Bath IL-2/IL-21 and Upregulating IL-21R SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Butler, Marcus O.; Imataki, Osamu; Tanaka, Makito; Ansen, Sascha; Berezovskaya, Alla; Milstein, Matthew I.; Metzler, Genita; Mooney, Mary M.; Murray, Andrew P.; Nadler, Lee M.; Hirano, Naoto] Dana Farber Canc Inst, Boston, MA 02115 USA. [Yamashita, Yoshihiro; Mano, Hiroyuki] Jichi Med Univ, Shimotsuke, Japan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1739 EP 1739 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204703 ER PT J AU Champlin, R Guinan, EC Nadler, LM McAdams, P Brennan, L Barbon, C Jiang, P Chwalisz, K Mattia-Goldberg, C Sajwani, K Boyd, R Thall, PF Parkman, R AF Champlin, Richard Guinan, Eva C. Nadler, Lee M. McAdams, Patricia Brennan, Lisa Barbon, Christine Jiang, Ping Chwalisz, Kristof Mattia-Goldberg, Cynthia Sajwani, Karim Boyd, Richard Thall, Peter F. Parkman, Robertson TI Leuprolide Acetate (GnRH Agonist) to Enhance Immune Function Post-Autologous Hematopoietic Stem Cell Transplantation (HSCT) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Champlin, Richard] UT MD Anderson Canc Ctr, Houston, TX USA. [Guinan, Eva C.; Nadler, Lee M.; Brennan, Lisa; Barbon, Christine] Dana Farber Canc Inst, Boston, MA 02115 USA. [Thall, Peter F.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. [Jiang, Ping; Chwalisz, Kristof; Mattia-Goldberg, Cynthia; Sajwani, Karim] Abbott Labs, Abbott Pk, IL 60064 USA. [Boyd, Richard] Monash Univ, Monash Immunol & Stem Cell Labs, Clayton, Vic 3800, Australia. [Parkman, Robertson] Childrens Hosp LA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1741 EP 1742 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204711 ER PT J AU Cohen, KS Cheng, S Larson, MG Cupples, LA McCabe, EL Wang, YA Martin, RP Klein, RJ Hashmi, B O'Donnell, CJ Ramachandran, VS Shaw, SY Wang, TJ AF Cohen, Kenneth S. Cheng, Susan Larson, Martin G. Cupples, L. Adrienne McCabe, Elizabeth L. Wang, Ying A. Martin, Roderick P. Klein, Rachael J. Hashmi, Basma O'Donnell, Christopher J. Ramachandran, Vasan S. Shaw, Stanley Y. Wang, Thomas J. TI CD34+Circulating Progenitor Cell Frequency Is Highly Heritable. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Cohen, Kenneth S.] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA. [Cheng, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA. [Larson, Martin G.; Cupples, L. Adrienne; Wang, Ying A.] Boston Univ, Dept Math & Biostat, Framingham Heart Study, Boston, MA 02215 USA. [McCabe, Elizabeth L.; Wang, Thomas J.] Massachusetts Gen Hosp, Div Cardiol, Framingham Heart Study, Boston, MA 02114 USA. [Martin, Roderick P.; Klein, Rachael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA USA. [Hashmi, Basma] Harvard Univ, Dept Bioengn, Boston, MA 02115 USA. [O'Donnell, Christopher J.] NHLBI, Ctr Populat Studies, Framingham Heart Study, Framingham, MA USA. [Shaw, Stanley Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1748 EP 1748 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204728 ER PT J AU Woelfel, M De Meyer, S Wagner, P McGinness, KE Wagner, DD Schaub, R AF Woelfel, Melissa De Meyer, Simon Wagner, Patricia McGinness, Kathleen E. Wagner, Denisa D. Schaub, Robert TI The Generation of An Aptamer Inhibitor of Murine Von Willebrand Factor (VWF) Mediated Platelet Aggregation. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Woelfel, Melissa; Wagner, Patricia; McGinness, Kathleen E.; Schaub, Robert] Archemix Corp, Cambridge, MA USA. [Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1749 EP 1749 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204731 ER PT J AU Nikova, DN Gilbert, GE AF Nikova, Dessislava N. Gilbert, Gary E. TI Focal Phosphatidylserine Exposure on Stressed Endothelial Cells In Relation to Membrane Topology: A Potential Basis for Compartmentalization of Procoagulant and Anticoagulant Activities SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Nikova, Dessislava N.; Gilbert, Gary E.] Harvard Univ, Sch Med, W Roxbury, MA USA. [Nikova, Dessislava N.; Gilbert, Gary E.] VA Boston Healthcare Syst, W Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1752 EP 1752 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204740 ER PT J AU Mitsiades, CS AF Mitsiades, Constantie S. TI How to Overcome Myeloma Stem Cell Resistance to Therapy - Targeting the Stem Cell Niche SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Mitsiades, Constantie S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1756 EP 1756 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204746 ER PT J AU Orkin, SH AF Orkin, Stuart H. TI New Strategies to Define Regulators of Fetal Hemoglobin. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Orkin, Stuart H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1758 EP 1759 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662204757 ER PT J AU Lieberman, J AF Lieberman, Judy TI Micromanipulating Hematological Malignancies and Other Cancers. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Lieberman, Judy] Harvard Univ, Childrens Hosp, Program Cellular & Mol Med, Immune Dis Inst,Med Sch, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1763 EP 1763 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204773 ER PT J AU Utz, K Neumon, B Frye, BL Chao, JH Toro, J Haile, D Freytes, C AF Utz, Kenneth Neumon, Bonita Frye, Brenda L. Chao, Ju-Hsien Toro, Juan Haile, David Freytes, Cesar TI Have Clinicians Adopted the International Uniform Response Criteria (IURC) for Multiple Myeloma (MM)? Adherence to the IURC for Posttransplant Evaluations In Patients with Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Utz, Kenneth] S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp, Dept Pharm, San Antonio, TX USA. [Frye, Brenda L.] Audie Murphy Vet Affairs BMT, San Antonio, TX USA. [Freytes, Cesar] Audie L Murphy Mem Vet Adm Med Ctr, Med Serv 111 BMT, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 43 EP 43 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662200085 ER PT J AU Dytfeld, D Kandarpa, M Strahler, JR Mellacheruvu, D Subramani, S Kraftson, SJ Ngoka, L Nesvizhskii, A Sreekumar, A Richardson, PG Jakubowiak, AJ AF Dytfeld, Dominik Kandarpa, Malathi Strahler, John R. Mellacheruvu, Dattatreya Subramani, Suchitra Kraftson, Stephanie J. Ngoka, Lambert Nesvizhskii, Alexey Sreekumar, Arun Richardson, Paul G. Jakubowiak, Andrzej J. TI Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and Dexamethasone SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Dytfeld, Dominik; Kandarpa, Malathi; Subramani, Suchitra; Kraftson, Stephanie J.; Jakubowiak, Andrzej J.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Strahler, John R.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA. [Mellacheruvu, Dattatreya; Nesvizhskii, Alexey] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. [Ngoka, Lambert; Sreekumar, Arun] Med Coll Georgia, Augusta, GA 30912 USA. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. RI Dytfeld, Dominik/H-5300-2011 NR 0 TC 0 Z9 1 U1 1 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 271 EP 272 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200619 ER PT J AU Cirstea, D Hideshima, T Santo, L Pozzi, S Vallet, S Patel, K Gorgun, G Hu, YG Guichard, SM Mahindra, A Anderson, KC Raje, N AF Cirstea, Diana Hideshima, Teru Santo, Loredana Pozzi, Samantha Vallet, Sonia Patel, Kishan Gorgun, Gullu Hu, Yiguo Guichard, Sylvie M. Mahindra, Anuj Anderson, Kenneth C. Raje, Noopur TI Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Cirstea, Diana; Santo, Loredana; Pozzi, Samantha; Vallet, Sonia; Patel, Kishan; Mahindra, Anuj; Raje, Noopur] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA USA. [Hideshima, Teru; Gorgun, Gullu; Hu, Yiguo; Anderson, Kenneth C.] Dana Farber Canc Inst, Leebow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Hideshima, Teru; Gorgun, Gullu; Hu, Yiguo; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Guichard, Sylvie M.] AstraZeneca, Macclesfield, Cheshire, England. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 346 EP 347 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200792 ER PT J AU Jakubowiak, AJ Dytfeld, D Jagannath, S Vesole, DH Anderson, TB Nordgren, BK Lebovic, D Stockerl-Goldstein, KE Griffith, KA Hill, MA Harvey, CK Dollard, AM Ott, R Kelley, SL Barrickman, J Kauffman, M Vij, R AF Jakubowiak, Andrzej J. Dytfeld, Dominik Jagannath, Sundar Vesole, David H. Anderson, Tara B. Nordgren, Brian K. Lebovic, Daniel Stockerl-Goldstein, Keith E. Griffith, Kent A. Hill, Melissa A. Harvey, Colleen K. Dollard, Akari M. Ott, Robert Kelley, Susan L. Barrickman, Jennifer Kauffman, Michael Vij, Ravi TI Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Jakubowiak, Andrzej J.; Dytfeld, Dominik; Anderson, Tara B.; Nordgren, Brian K.; Lebovic, Daniel; Griffith, Kent A.; Hill, Melissa A.; Harvey, Colleen K.] Univ Michigan, Ann Arbor, MI 48109 USA. [Jagannath, Sundar] Mt Sinai Med Ctr, New York, NY 10029 USA. [Vesole, David H.] Hackensack Univ Med Ctr, Hackensack, NJ USA. [Stockerl-Goldstein, Keith E.; Vij, Ravi] Washington Univ, Sch Med, St Louis, MO USA. [Dollard, Akari M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ott, Robert; Kelley, Susan L.] Multiple Myeloma Res Consortium, Norwalk, CT USA. [Barrickman, Jennifer] Celgene Inc, Summit, NJ USA. [Kauffman, Michael] Onyx Pharmaceut, Emeryville, CA USA. RI Dytfeld, Dominik/H-5300-2011 NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 376 EP 377 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662200863 ER PT J AU Kahl, B Byrd, JC Flinn, IW Wagner-Johnston, N Spurgeon, S Benson, DM Furman, RR Brown, JR Coutre, S Lannutti, B Giese, NA Ulrich, RG Webb, HK Peterman, S Holes, L Yu, AS AF Kahl, Brad Byrd, John C. Flinn, Ian W. Wagner-Johnston, Nina Spurgeon, Stephen Benson, Don M., Jr. Furman, Richard R. Brown, Jennifer R. Coutre, Steven Lannutti, Brian Giese, Neil A. Ulrich, Roger G. Webb, Heather K. Peterman, Sissy Holes, Leanne Yu, Albert S. TI Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 delta, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Kahl, Brad] Univ Wisconsin, Madison, WI USA. [Benson, Don M., Jr.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA. [Wagner-Johnston, Nina] Washington Univ, St Louis, MO USA. [Spurgeon, Stephen] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Furman, Richard R.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Coutre, Steven] Stanford Univ, Sch Med, Stanford, CA USA. [Webb, Heather K.] Calistoga Pharmaceut, Drug Safety, Seattle, WA USA. [Peterman, Sissy] Calistoga Pharmaceut, Clin, Seattle, WA USA. NR 0 TC 9 Z9 9 U1 1 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 741 EP 741 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662202001 ER PT J AU Santo, L Hideshima, T Cirstea, D Bandi, ML Nelson, EA Ikeda, H Vallet, S Pozzi, S Patel, K Gorgun, G Mimura, N Fabre, C Hu, YG Chauhan, D Squires, MS Munshi, NC Anderson, KC Raje, N AF Santo, Loredana Hideshima, Teru Cirstea, Diana Bandi, Madhavi L. Nelson, Erik A. Ikeda, Hiroshi Vallet, Sonia Pozzi, Samantha Patel, Kishan Gorgun, Gullu Mimura, Naoya Fabre, Claire Hu, Yiguo Chauhan, Dharminder Squires, Matthew S. Munshi, Nikhil C. Anderson, Kenneth C. Raje, Noopur TI AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Santo, Loredana; Cirstea, Diana; Vallet, Sonia; Pozzi, Samantha; Patel, Kishan; Raje, Noopur] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA USA. [Hideshima, Teru; Bandi, Madhavi L.; Nelson, Erik A.; Ikeda, Hiroshi; Gorgun, Gullu; Mimura, Naoya; Fabre, Claire; Hu, Yiguo; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA. [Squires, Matthew S.] Astex Therapeut Ltd, Cambridge, England. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1234 EP 1235 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203326 ER PT J AU Santo, L Hideshima, T Kung, AL Jarpe, M Cirstea, D Patel, K Pozzi, S Tseng, JC Rodig, SJ Bradner, J Anderson, KC Jones, S Raje, N AF Santo, Loredana Hideshima, Teru Kung, Andrew L. Jarpe, Matthew Cirstea, Diana Patel, Kishan Pozzi, Samantha Tseng, Jen C. Rodig, Scott J. Bradner, James Anderson, Kenneth C. Jones, Simon Raje, Noopur TI Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM) SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Santo, Loredana; Cirstea, Diana; Patel, Kishan; Pozzi, Samantha; Raje, Noopur] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA USA. [Hideshima, Teru; Kung, Andrew L.; Tseng, Jen C.; Bradner, James; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Jarpe, Matthew; Jones, Simon] Acetylon Pharmaceut Inc, Boston, MA USA. [Rodig, Scott J.] Brigham & Womens Hosp, Boston, MA 02115 USA. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 1 U2 8 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1235 EP 1236 PG 2 WC Hematology SC Hematology GA 752BH UT WOS:000289662203329 ER PT J AU Pozzi, S Cirstea, D Santo, L Nabikejje, DM Patel, K Luly, KM Gharti-Chhetry, G Vallet, S Eda, H Hideshima, T Green, SR Anderson, KC Scadden, DT Raje, N AF Pozzi, Samantha Cirstea, Diana Santo, Loredana Nabikejje, Doris M. Patel, Kishan Luly, Kathryn M. Gharti-Chhetry, Gaurav Vallet, Sonia Eda, Homare Hideshima, Teru Green, Simon R. Anderson, Kenneth C. Scadden, David T. Raje, Noopur TI CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Pozzi, Samantha; Cirstea, Diana; Santo, Loredana; Nabikejje, Doris M.; Patel, Kishan; Luly, Kathryn M.; Gharti-Chhetry, Gaurav; Vallet, Sonia; Eda, Homare; Raje, Noopur] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Hideshima, Teru; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Green, Simon R.] Cyclacel Pharmaceut Inc, Dundee DD1 5JJ, Scotland. [Scadden, David T.] Harvard Stem Cell Inst, Boston, MA USA. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1236 EP 1236 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203331 ER PT J AU Leleu, X Xie, WL Rourke, M Banwait, R Leduc, R Roper, N Weller, E Ghobrial, I AF Leleu, Xavier Xie, Wanling Rourke, Meghan Banwait, Ranjit Leduc, Renee Roper, Nitin Weller, Edie Ghobrial, Irene TI The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Leleu, Xavier] CHRU, Hop Huriez, Serv Malad Sang, Lille, France. [Rourke, Meghan; Banwait, Ranjit; Ghobrial, Irene] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1276 EP 1276 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662203427 ER PT J AU Mahindra, A Amin, SB Sohani, AR Motyckova, G Patel, K Vallet, S Pozzi, S Santo, L Cirstea, D Toomey, CE Michaelson, JS Hochberg, EP Dal Cin, P Rodig, SJ Hideshima, T Anderson, KC Munshi, NC Raje, N AF Mahindra, Anuj Amin, Samir B. Sohani, Aliyah R. Motyckova, Gabriela Patel, Kishan Vallet, Sonia Pozzi, Samantha Santo, Loredana Cirstea, Diana Toomey, Christiana E. Michaelson, Janes S. Hochberg, Ephraim P. Dal Cin, Paola Rodig, Scott J. Hideshima, Teru Anderson, Kenneth C. Munshi, Nikhil C. Raje, Noopur TI Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma. SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Sohani, Aliyah R.; Michaelson, Janes S.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Santo, Loredana; Cirstea, Diana] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA 02114 USA. [Toomey, Christiana E.; Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Lymphoma, Ctr Canc, Boston, MA 02114 USA. [Hideshima, Teru] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Dal Cin, Paola; Rodig, Scott J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Munshi, Nikhil C.] VA Boston Healthcare Syst, Dana Farber Canc Inst, Boston, MA USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Boston, MA USA. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1648 EP 1648 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204462 ER PT J AU Vallet, S Patel, K Cirstea, D Luly, K Pozzi, S Santo, L Eda, H Seehra, J Mahindra, A Scadden, DT Raje, N AF Vallet, Sonia Patel, Kishan Cirstea, Diana Luly, Katie Pozzi, Samantha Santo, Loredana Eda, Homare Seehra, Jasbir Mahindra, Anuj Scadden, David T. Raje, Noopur TI Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy SO BLOOD LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Hematology (ASH) CY DEC 04-07, 2010 CL Orlando, FL SP Amer Soc Hematol C1 [Vallet, Sonia; Patel, Kishan; Cirstea, Diana; Luly, Katie; Pozzi, Samantha; Santo, Loredana; Eda, Homare; Mahindra, Anuj; Scadden, David T.; Raje, Noopur] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Seehra, Jasbir] Acceleron Pharma Inc, Cambridge, MA USA. RI Pozzi, Samantha/A-7617-2012 OI Pozzi, Samantha/0000-0001-7917-1774 NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 19 PY 2010 VL 116 IS 21 BP 1659 EP 1659 PG 1 WC Hematology SC Hematology GA 752BH UT WOS:000289662204494 ER PT J AU Devine, EB Williams, EC Martin, DP Sittig, DF Tarczy-Hornoch, P Payne, TH Sullivan, SD AF Devine, Emily Beth Williams, Emily C. Martin, Diane P. Sittig, Dean F. Tarczy-Hornoch, Peter Payne, Thomas H. Sullivan, Sean D. TI Prescriber and staff perceptions of an electronic prescribing system in primary care: a qualitative assessment SO BMC MEDICAL INFORMATICS AND DECISION MAKING LA English DT Article ID PHYSICIAN ORDER ENTRY; CLINICAL DECISION-SUPPORT; ADVERSE DRUG EVENTS; MEDICATION ERRORS; INFORMATION-TECHNOLOGY; CROSS-SITE; HEALTH-CARE; IMPLEMENTATION; EXPERIENCES; HOSPITALS AB Background: The United States (US) Health Information Technology for Economic and Clinical Health Act of 2009 has spurred adoption of electronic health records. The corresponding meaningful use criteria proposed by the Centers for Medicare and Medicaid Services mandates use of computerized provider order entry (CPOE) systems. Yet, adoption in the US and other Western countries is low and descriptions of successful implementations are primarily from the inpatient setting; less frequently the ambulatory setting. We describe prescriber and staff perceptions of implementation of a CPOE system for medications (electronic-or e-prescribing system) in the ambulatory setting. Methods: Using a cross-sectional study design, we conducted eight focus groups at three primary care sites in an independent medical group. Each site represented a unique stage of e-prescribing implementation - pre/transition/post. We used a theoretically based, semi-structured questionnaire to elicit physician (n = 17) and staff (n = 53) perceptions of implementation of the e-prescribing system. We conducted a thematic analysis of focus group discussions using formal qualitative analytic techniques (i.e. deductive framework and grounded theory). Two coders independently coded to theoretical saturation and resolved discrepancies through discussions. Results: Ten themes emerged that describe perceptions of e-prescribing implementation: 1) improved availability of clinical information resulted in prescribing efficiencies and more coordinated care; 2) improved documentation resulted in safer care; 3) efficiencies were gained by using fewer paper charts; 4) organizational support facilitated adoption; 5) transition required time; resulted in workload shift to staff; 6) hardware configurations and network stability were important in facilitating workflow; 7) e-prescribing was time-neutral or time-saving; 8) changes in patient interactions enhanced patient care but required education; 9) pharmacy communications were enhanced but required education; 10) positive attitudes facilitated adoption. Conclusions: Prescribers and staff worked through the transition to successfully adopt e-prescribing, and noted the benefits. Overall impressions were favorable. No one wished to return to paper-based prescribing. C1 [Devine, Emily Beth; Sullivan, Sean D.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA. [Devine, Emily Beth; Tarczy-Hornoch, Peter] Univ Washington, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA. [Williams, Emily C.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Williams, Emily C.; Martin, Diane P.; Sullivan, Sean D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Sittig, Dean F.] Univ Texas Houston, Sch Hlth Informat Sci, UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX 77030 USA. [Payne, Thomas H.; Sullivan, Sean D.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Devine, EB (reprint author), Univ Washington, Pharmaceut Outcomes Res & Policy Program, Box 357630, Seattle, WA 98195 USA. EM bdevine@uw.edu OI Tarczy-Hornoch, Peter/0000-0003-1047-179X FU AHRQ Health Information Technology [5-UC1 HS015319]; AHRQ Mentored Clinical Scientist Training [5-K-08-HS014739] FX AHRQ Health Information Technology Grant #: 5-UC1 HS015319 (PI: Sullivan) AHRQ Mentored Clinical Scientist Training Grant #: 5-K-08-HS014739 (PI: Devine) NR 57 TC 9 Z9 9 U1 7 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6947 J9 BMC MED INFORM DECIS JI BMC Med. Inform. Decis. Mak. PD NOV 19 PY 2010 VL 10 AR 72 DI 10.1186/1472-6947-10-72 PG 12 WC Medical Informatics SC Medical Informatics GA 688VR UT WOS:000284883200001 PM 21087524 ER PT J AU Kelleher, RJ Shen, J AF Kelleher, Raymond J., III Shen, Jie TI gamma-Secretase and Human Disease SO SCIENCE LA English DT Editorial Material ID ALZHEIMERS-DISEASE; TUMOR-SUPPRESSOR; PRESENILIN-1; HYPOTHESIS; MUTATIONS; RELEASE; MOUSE; SKIN C1 [Kelleher, Raymond J., III] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Kelleher, Raymond J., III; Shen, Jie] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Shen, Jie] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA. RP Kelleher, RJ (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. EM kelleher@helix.mgh.harvard.edu FU NIA NIH HHS [RC2 AG036614]; NINDS NIH HHS [R01 NS041783, R01 NS042818, R01 NS075346] NR 13 TC 28 Z9 28 U1 0 U2 6 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD NOV 19 PY 2010 VL 330 IS 6007 BP 1055 EP 1056 DI 10.1126/science.1198668 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 682BU UT WOS:000284374700027 PM 21097925 ER PT J AU Lukina, E Watman, N Arreguin, EA Dragosky, M Iastrebner, M Rosenbaum, H Phillips, M Pastores, GM Kamath, RS Rosenthal, DI Kaper, M Singh, T Puga, AC Peterschmitt, MJ AF Lukina, Elena Watman, Nora Arreguin, Elsa Avila Dragosky, Marta Iastrebner, Marcelo Rosenbaum, Hanna Phillips, Mici Pastores, Gregory M. Kamath, Ravi S. Rosenthal, Daniel I. Kaper, Mathilde Singh, Tejdip Puga, Ana Cristina Peterschmitt, M. Judith TI Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study SO BLOOD LA English DT Article ID ENZYME THERAPY; GLUCOCEREBROSIDASE AB Eliglustat tartrate is an investigational oral substrate reduction therapy for Gaucher disease type 1 that is pharmacologically distinct from intravenous enzyme replacement therapy. Eliglustat tartrate improved clinical manifestations in patients who received 50 or 100 mg twice daily for 1 year during an open-label phase 2 study (Blood. 2010; 116(6): 893-899). We report further improvements after 2 years of treatment in 20 patients (11 females, 9 males; mean age, 33 years) with baseline splenomegaly and thrombocytopenia and/or anemia. Statistically significant P < .001) percentage improvements from baseline occurred in platelet count (mean +/- SD, 81% +/- 56%), hemoglobin level (20% +/- 15%), spleen volume (-52% +/- 11%), and liver volume (-24% +/- 13%). Mean platelet count increased similar to 50 000/mm(3). Mean hemoglobin level increased 2.1 g/dL overall and 3.1 g/dL in 10 patients with baseline anemia. Organ volume reductions were greatest in patients with severe baseline organomegaly. Seventeen (85%) patients met established therapeutic goals for >= 3 of the 4 parameters. Lumbar spine bone mineral density increased 7.8% +/- 10.6% (P = .01) and T-score 0.6 +/- 0.8 (P = .012), with major gains in osteoporotic and osteopenic patients. Magnetic resonance imaging assessment showed that bone marrow infiltration by Gaucher cells was decreased (8/18 patients) or stable (10/18 patients). No safety-related trends emerged during 2 years of treatment. This multisite, open-label, single-arm phase 2 study is registered at www.clinicaltrials.gov as NCT00358150. (Blood.2010;116(20):4095-4098) C1 [Kaper, Mathilde; Singh, Tejdip; Puga, Ana Cristina; Peterschmitt, M. Judith] Genzyme Corp, Cambridge, MA 02142 USA. [Lukina, Elena] Russian Acad Med Sci, Hematol Res Ctr, Moscow, Russia. [Watman, Nora] Hosp Ramos Mejia, Buenos Aires, DF, Argentina. [Arreguin, Elsa Avila] Hosp Especialidades Ctr Med La Raza, Inst Mexicano Seguro Social, Mexico City, DF, Mexico. [Dragosky, Marta; Iastrebner, Marcelo] Inst Argentino Diagnost & Tratamiento, Buenos Aires, DF, Argentina. [Rosenbaum, Hanna] Rambam Med Ctr, Haifa, Israel. [Phillips, Mici] Shaare Zedek Med Ctr, Jerusalem, Israel. [Pastores, Gregory M.] NYU, New York, NY USA. [Kamath, Ravi S.; Rosenthal, Daniel I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Peterschmitt, MJ (reprint author), Genzyme Corp, 500 Kendall St, Cambridge, MA 02142 USA. EM judith.peterschmitt@genzyme.com FU Genzyme Corporation; Amicus; Actelion; Biomarin; Shire HGT; Protalix FX The study was supported by research funding from Genzyme Corporation to E.L., N.W., E.A.A., M.D., M.I., H.R., M.P., G.P., R.S.K., and D.I.R.; M.J.P., M.K., A.C.P., and T.S. are employees and stockholders of Genzyme Corporation; E.L. received honoraria for travel and speaking from Genzyme Corporation; G.M.P. is the recipient of research grants from Amicus, Actelion, Biomarin, Genzyme, Shire HGT, and Protalix; and D.I.R. and R.S.K. were contracted by Genzyme to review bone images. N.W., E.A.A., M.D., M.I., H.R., and M.P. declare no competing financial interests. NR 14 TC 2 Z9 3 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2010 VL 116 IS 20 BP 4095 EP 4098 DI 10.1182/blood-2010-06-293902 PG 4 WC Hematology SC Hematology GA 681YC UT WOS:000284359400015 ER PT J AU Cripe, LD Uno, H Paietta, EM Litzow, MR Ketterling, RP Bennett, JM Rowe, JM Lazarus, HM Luger, S Tallman, MS AF Cripe, Larry D. Uno, Hajime Paietta, Elisabeth M. Litzow, Mark R. Ketterling, Rhett P. Bennett, John M. Rowe, Jacob M. Lazarus, Hillard M. Luger, Selina Tallman, Martin S. TI Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 SO BLOOD LA English DT Article ID MULTIDRUG-RESISTANCE MODULATOR; PHASE-I TRIAL; RISK MYELODYSPLASTIC SYNDROME; DE-NOVO; TRIHYDROCHLORIDE LY335979; CLINICAL-SIGNIFICANCE; ELDERLY-PATIENTS; EXPRESSION; PROTEIN; DAUNORUBICIN AB Zosuquidar, which modulates P-glycoprotein (P-gp) with minimal delay of anthracycline clearance, may reverse P-gp-mediated resistance in acute myeloid leukemia without increased toxicity. A total of 449 adults older than 60 years with acute myeloid leukemia or high-risk myelodysplastic syndrome enrolled in a randomized placebo-controlled double-blind trial (Eastern Cooperative Oncology Group 3999). Overall survival was compared between patients receiving conventional-dose cytarabine and daunorubicin and either zosuquidar (550 mg; 212 patients) or placebo (221 patients). Median and 2-year overall survival values were 7.2 months and 20% on zosuquidar and 9.4 months and 23% on placebo, respectively (P=.281). Remission rate was 51.9% on zosuquidar and 48.9% on placebo. All cause mortality to day 42 was not different (zosuquidar 22.2% vs placebo 16.3%; P=.158). In vitro modulation of P-gp activity by zosuquidar and expression of P-gp, multidrug resistance-related protein 1, lung resistance protein, and breast cancer resistance protein, were comparable in the 2 arms. Poor-risk cytogenetics were more common in P-gp(+) patients. P-gp expression and cytogenetics were correlated, though independent prognostic factors. We conclude that zosuquidar did not improve outcome in older acute myeloid leukemia, in part, because of the presence P-gp independent mechanisms of resistance. This trial is registered at www.clinicaltrials.gov as #NCT00046930. (Blood.2010;116(20):4077-4085) C1 [Cripe, Larry D.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46202 USA. [Uno, Hajime] Dana Farber Canc Inst, Boston, MA 02115 USA. [Paietta, Elisabeth M.; Ketterling, Rhett P.] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA. [Litzow, Mark R.] Mayo Clin, Rochester, MN USA. [Bennett, John M.] Univ Rochester, Rochester, NY USA. [Rowe, Jacob M.] Rambam Med Ctr, Haifa, Israel. [Lazarus, Hillard M.] Case Comprehens Canc Ctr, Cleveland, OH USA. [Luger, Selina] Univ Penn, Philadelphia, PA 19104 USA. [Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RP Cripe, LD (reprint author), Indiana Univ, Simon Canc Ctr, 535 Barnhill Dr, Indianapolis, IN 46202 USA. EM lcripe@iupui.edu FU US Public Health Service [CA23318, CA66636, CA21115, CA49883, CA13650, CA14958, CA11083, CA15488, CA17145]; National Cancer Institute, National Institutes of Health; Department of Health and Human Services FX This work was supported in part by the US Public Health Service (grants CA23318, CA66636, CA21115, CA49883, CA13650, CA14958, CA11083, CA15488, and CA17145) and the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. This study was conducted by the Eastern Cooperative Oncology Group (Dr Robert L. Comis, Chair). NR 36 TC 75 Z9 80 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2010 VL 116 IS 20 BP 4077 EP 4085 DI 10.1182/blood-2010-04-277269 PG 9 WC Hematology SC Hematology GA 681YC UT WOS:000284359400013 PM 20716770 ER PT J AU Jeanson, NT Scadden, DT AF Jeanson, Nathaniel T. Scadden, David T. TI Vitamin D receptor deletion leads to increased hematopoietic stem and progenitor cells residing in the spleen SO BLOOD LA English DT Article ID MINERAL ION HOMEOSTASIS; ABLATED MICE; BONE-MARROW; NICHE; OSTEOPONTIN; DEFICIENCY; COMPONENT; ALOPECIA; RICKETS; SIZE AB Bone components participate in the regulation of hematopoietic stem cells in the adult mammal. Vitamin D regulates bone mineralization and is associated with pleiotropic effects in many cell types, including putative roles in hematopoietic differentiation. We report that deletion of the vitamin D receptor (VDR) in hemato-poietic cells did not result in cell autonomous perturbation of hematopoietic stem cell or progenitor function. However, deletion of VDR in the microenvironment resulted in a marked accumulation of hematopoietic stem cells in the spleen that could be reversed by calcium dietary supplementation. These data suggest that VDR participates in restricting splenic hematopoiesis through maintenance of bone calcium homeostasis and are consistent with the concept that calcium regulation through VDR is a central participant in localizing adult hematopoiesis preferentially to bone marrow. (Blood.2010;116(20):4126-4129) C1 [Jeanson, Nathaniel T.; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Harvard Stem Cell Inst, Boston, MA 02114 USA. [Jeanson, Nathaniel T.] Harvard Grad Sch Arts & Sci, Biol & Biomed Sci Program, Cambridge, MA USA. RP Scadden, DT (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, Harvard Stem Cell Inst, Rm 4265A,185 Cambridge St, Boston, MA 02114 USA. EM scadden.david@mgh.harvard.edu FU National Institutes of Health; Massachusetts General Hospital FX D.T.S. was supported by the National Institutes of Health. N.T.J. was supported by the Massachusetts General Hospital. NR 16 TC 14 Z9 15 U1 1 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 18 PY 2010 VL 116 IS 20 BP 4126 EP 4129 DI 10.1182/blood-2010-04-280552 PG 4 WC Hematology SC Hematology GA 681YC UT WOS:000284359400019 PM 20664059 ER PT J AU Stamm, LM Heller, DM Goldberg, MB AF Stamm, Luisa M. Heller, Danielle M. Goldberg, Marcia B. TI Caging Targets for Destruction SO CELL HOST & MICROBE LA English DT Editorial Material ID AUTOPHAGY; GTPASES C1 [Stamm, Luisa M.; Goldberg, Marcia B.] Massachusetts Gen Hosp, Div Infect Dis, Dept Med, Cambridge, MA 02139 USA. [Stamm, Luisa M.; Heller, Danielle M.; Goldberg, Marcia B.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. RP Goldberg, MB (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Dept Med, Cambridge, MA 02139 USA. EM mgoldberg1@partners.org FU NIAID NIH HHS [T32 AI007061, R01 AI081724] NR 7 TC 0 Z9 0 U1 0 U2 1 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1931-3128 J9 CELL HOST MICROBE JI Cell Host Microbe PD NOV 18 PY 2010 VL 8 IS 5 BP 391 EP 393 DI 10.1016/j.chom.2010.10.010 PG 3 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 694DE UT WOS:000285274400002 PM 21075349 ER PT J AU Frank, T Rutherford, MA Strenzke, N Neef, A Pangrsic, T Khimich, D Fetjova, A Gundelfinger, ED Liberman, MC Harke, B Bryan, KE Lee, A Egner, A Riedel, D Moser, T AF Frank, Thomas Rutherford, Mark A. Strenzke, Nicola Neef, Andreas Pangrsic, Tina Khimich, Darina Fetjova, Anna Gundelfinger, Eckart D. Liberman, M. Charles Harke, Benjamin Bryan, Keith E. Lee, Amy Egner, Alexander Riedel, Dietmar Moser, Tobias TI Bassoon and the Synaptic Ribbon Organize Ca2+ Channels and Vesicles to Add Release Sites and Promote Refilling SO NEURON LA English DT Article ID CELL AFFERENT SYNAPSE; PRESYNAPTIC ACTIVE ZONE; AUDITORY-NERVE FIBERS; INNER HAIR-CELLS; FREQUENCY-SELECTIVITY; TRANSMITTER RELEASE; CALCIUM-DEPENDENCE; PROTEIN BASSOON; EXOCYTOSIS; MOUSE AB At the presynaptic active zone, Ca2+ influx triggers fusion of synaptic vesicles. It is not well understood how Ca2+ channel clustering and synaptic vesicle docking are organized. Here, we studied structure and function of hair cell ribbon synapses following genetic disruption of the presynaptic scaffold protein Bassoon. Mutant synapses-mostly lacking the ribbon-showed a reduction in membrane-proximal vesicles, with ribbonless synapses affected more than ribbon-occupied synapses. Ca2+ channels were also fewer at mutant synapses and appeared in abnormally shaped clusters. Ribbon absence reduced Ca2+ channel numbers at mutant and wildtype synapses. Fast and sustained exocytosis was reduced, notwithstanding normal coupling of the remaining Ca2+ channels to exocytosis. In vitro recordings revealed a slight impairment of vesicle replenishment. Mechanistic modeling of the in vivo data independently supported morphological and functional in vitro findings. We conclude that Bassoon and the ribbon (1) create a large number of release sites by organizing Ca2+ channels and vesicles, and (2) promote vesicle replenishment. C1 [Riedel, Dietmar] Max Planck Inst Biophys Chem, Electron Microscopy Lab, D-37077 Gottingen, Germany. [Frank, Thomas; Rutherford, Mark A.; Pangrsic, Tina; Khimich, Darina; Moser, Tobias] Univ Gottingen, Med Ctr, InnerEarLab, Dept Otolaryngol, D-37099 Gottingen, Germany. [Frank, Thomas; Rutherford, Mark A.; Strenzke, Nicola; Pangrsic, Tina; Khimich, Darina; Moser, Tobias] Univ Gottingen, Med Ctr, Ctr Mol Physiol Brain, D-37099 Gottingen, Germany. [Frank, Thomas; Moser, Tobias] Gottingen Grad Sch Neurosci & Mol Biosci, Int Max Planck Res Sch Neurosci, D-37077 Gottingen, Germany. [Frank, Thomas; Neef, Andreas; Moser, Tobias] Bernstein Ctr Computat Neurosci, D-37073 Gottingen, Germany. [Strenzke, Nicola] Univ Gottingen, Med Ctr, Dept Otolaryngol, Auditory Syst Physiol Grp, D-37099 Gottingen, Germany. [Strenzke, Nicola; Liberman, M. Charles] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Fetjova, Anna; Gundelfinger, Eckart D.] Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany. [Harke, Benjamin; Egner, Alexander] Max Planck Inst Biophys Chem, Dept Nanobiophoton, D-37077 Gottingen, Germany. [Bryan, Keith E.; Lee, Amy] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA. RP Riedel, D (reprint author), Max Planck Inst Biophys Chem, Electron Microscopy Lab, D-37077 Gottingen, Germany. EM driedel@gwdg.de; tmoser@gwdg.de RI Frank, Thomas/F-5273-2012; Moser, Tobias/L-5068-2014; Fejtova, Anna/E-6343-2015; OI Frank, Thomas/0000-0002-5113-176X; Moser, Tobias/0000-0001-7145-0533; Rutherford, Mark/0000-0002-2627-6254 FU Max Planck Society; German Research Foundation; Center for Molecular Physiology of the Brain [FZT-103]; German Federal Ministry of Education and Research [01GQ0810]; State of Saxony-Anhalt [EFRE-IfN C2/1]; National Institutes of Health [DC0188, DC009433, HL087120, T32 AI 07260]; Alexander von Humboldt Foundation FX We thank S. Blume, N. Dankenbrink-Werder, A. Gonzalez, M. Koppler, and B. Kracht for expert technical assistance. This work was supported by grants of the Max Planck Society (Tandem-Project grant to Nils Brose and T.M.), the German Research Foundation Fellowship to N.S., Center for Molecular Physiology of the Brain Grant FZT-103 to T.M. and A.E., the German Federal Ministry of Education and Research (01GQ0810, Bernstein Focus for Neurotechnology) to T.M. and A.E., the State of Saxony-Anhalt/European Structural Funds (EFRE-IfN C2/1) to E.D.G., and by the National Institutes of Health (Grants DC0188 to M.C.L., DC009433 and HL087120 to A.L., and T32 AI 07260 to K.E.B.). M.A.R. and T.P. were supported by fellowships of the Alexander von Humboldt Foundation. A.N. is a Fellow of the Bernstein Center for Computational Neuroscience Gottingen. The study was designed by TM., T.F., N.S., A.N., and D.R. The experimental work was performed by T.F. (Ca2+ imaging, Ca2+ current, and Cm recordings), M.A.R. (confocal and STED microscopy), N.S. (single-unit recordings under supervision of M.C.L.), T.P. (flash photolysis), D.K. (confocal microscopy), and D.R. (electron microscopy). A.E. and B.H. contributed to STED microscopy, and A.E. contributed to image analysis. AN. performed modeling and contributed to data analysis. A.F. and E.D.G. provided the mice (gene trap mutant in collaboration with Lexicon Pharmaceuticals) and discussion. K.E.B and A.L. performed protein-protein interaction experiments. T.M., T.F., N.S., A.N., and M.A.R. prepared the manuscript. NR 44 TC 113 Z9 114 U1 4 U2 15 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0896-6273 J9 NEURON JI Neuron PD NOV 18 PY 2010 VL 68 IS 4 BP 724 EP 738 DI 10.1016/j.neuron.2010.10.027 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 691KU UT WOS:000285079500011 PM 21092861 ER PT J AU Kormos, WA Wu, CC Branda, JA Piris, A AF Kormos, William A. Wu, Carol C. Branda, John A. Piris, Adriano TI A Man with Cough, Hypoxemia, and Rash Coccidioidomycosis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID GRANULOMATOUS DERMATITIS; PULMONARY COCCIDIOIDOMYCOSIS; BLOOD EOSINOPHILIA; PNEUMONIA; DIAGNOSIS C1 [Kormos, William A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Wu, Carol C.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Branda, John A.; Piris, Adriano] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kormos, William A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Wu, Carol C.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Branda, John A.; Piris, Adriano] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Kormos, WA (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. NR 29 TC 0 Z9 0 U1 0 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 18 PY 2010 VL 363 IS 21 BP 2046 EP 2054 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 681KC UT WOS:000284310000011 PM 21083390 ER PT J AU Stone, JH Specks, U AF Stone, John H. Specks, Ulrich TI Rituximab or Cyclophosphamide in ANCA-Associated Renal Vasculitis REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Specks, Ulrich] Mayo Clin, Rochester, MN USA. RP Stone, JH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM specks.ulrich@mayo.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 18 PY 2010 VL 363 IS 21 BP 2074 EP 2074 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 681KC UT WOS:000284310000024 ER PT J AU Stylianopoulos, T Diop-Frimpong, B Munn, LL Jain, RK AF Stylianopoulos, Triantafyllos Diop-Frimpong, Benjamin Munn, Lance L. Jain, Rakesh K. TI Diffusion Anisotropy in Collagen Gels and Tumors: The Effect of Fiber Network Orientation SO BIOPHYSICAL JOURNAL LA English DT Article ID HYDRODYNAMIC TRANSPORT-PROPERTIES; BRAIN EXTRACELLULAR-SPACE; HARD-SPHERE DISPERSIONS; REYNOLDS-NUMBER FLOW; NEOPLASTIC TISSUES; HINDERED DIFFUSION; IN-VIVO; MOBILITY FUNCTIONS; FIBROUS MEDIA; AGAROSE GELS AB The interstitial matrix is comprised of cross-linked collagen fibers, generally arranged in nonisotropic orientations. Spatial alignment of matrix components within the tissue can affect diffusion patterns of drugs. In this study, we developed a methodology for the calculation of diffusion coefficients of macromolecules and nanoparticles in collagenous tissues. The tissues are modeled as three-dimensional, stochastic, fiber networks with varying degrees of alignment. We employed a random walk approach to simulate diffusion and a Stokesian dynamics method to account for hydrodynamic hindrance. We performed our analysis for four different structures ranging from nearly isotropic to perfectly aligned. We showed that the overall diffusion coefficient is not affected by the orientation of the network. However, structural anisotropy results in diffusion anisotropy, which becomes more significant with increase in the degree of alignment, the size of the diffusing particle, and the fiber volume fraction. To test our model predictions we performed diffusion measurements in reconstituted collagen gels and tumor xenografts. We measured fiber alignment and diffusion with second harmonic generation and multiphoton fluorescent recovery after photo-bleaching techniques, respectively. The results showed for the first time in tumors that the structure and orientation of collagen fibers in the extracellular space leads to diffusion anisotropy. C1 [Stylianopoulos, Triantafyllos; Diop-Frimpong, Benjamin; Munn, Lance L.; Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA. [Stylianopoulos, Triantafyllos; Diop-Frimpong, Benjamin; Munn, Lance L.; Jain, Rakesh K.] Harvard Univ, Sch Med, Boston, MA USA. [Diop-Frimpong, Benjamin] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA. RP Jain, RK (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA. EM jain@steele.mgh.harvard.edu RI Munn, Lance/L-3950-2016; OI Munn, Lance/0000-0003-0698-7232; Stylianopoulos, Triantafyllos/0000-0002-3093-1696 FU National Institutes of Health [PO1-CA80124, RO1-CA126642, RO1-CA115767, RO1-CA85140]; Federal Share Income Grant; Department of Defense [BC095991, W91ZSQ7342N607]; Susan G. Komen Breast Cancer Foundation [KG091281] FX This work was supported by the National Institutes of Health (grant Nos. PO1-CA80124, RO1-CA126642, RO1-CA115767, and RO1-CA85140), the Federal Share Income Grant, and the Department of Defense Breast Cancer Research Innovator award (grant No. BC095991). T.S. was supported by a postdoctoral research fellowship from the Susan G. Komen Breast Cancer Foundation (grant No. KG091281). B.D.-F. was supported by an Era of Hope Predoctoral fellowship from the Department of Defense (grant No. W91ZSQ7342N607). NR 48 TC 60 Z9 60 U1 4 U2 37 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0006-3495 J9 BIOPHYS J JI Biophys. J. PD NOV 17 PY 2010 VL 99 IS 10 BP 3119 EP 3128 DI 10.1016/j.bpj.2010.08.065 PG 10 WC Biophysics SC Biophysics GA 682YK UT WOS:000284438700004 PM 21081058 ER PT J AU Masaki, K Ghaffari, R Gu, JW Richardson, GP Freeman, DM Aranyosi, AJ AF Masaki, Kinuko Ghaffari, Roozbeh Gu, Jianwen Wendy Richardson, Guy P. Freeman, Dennis M. Aranyosi, A. J. TI Tectorial Membrane Material Properties in TectaY1870Cl Heterozygous Mice SO BIOPHYSICAL JOURNAL LA English DT Article ID OUTER HAIR-CELLS; HEARING-LOSS; INNER-EAR; AMPLIFICATION; DELETION; REVEALS; COCHLEA; BUNDLES AB The solid component of the tectorial membrane (TM) is a porous matrix made up of the radial collagen fibers and the striated sheet matrix. The striated sheet matrix is believed to contribute to shear impedance in both the radial and longitudinal directions, but the molecular mechanisms involved have not been determined. A missense mutation in Tecta, a gene that encodes for the alpha-tectorin protein in the striated sheet matrix, causes a 60-dB threshold shift in mice with relatively little reduction in outer hair cell amplification. Here, we show that this threshold shift is coupled to changes in shear impedance, response to osmotic pressure, and concentration of fixed charge of the TM. In Tecta(Y1870Cl+) mice, the tectorin content of the TM was reduced, as was the content of glycoconjugates reacting with the lectin wheat germ agglutinin. Charge measurements showed a decrease in fixed charge concentration from -6.4 +/- 1.4 mmol/L in wild-types to -2.1 +/- 0.7 mmol/L in Tecta(Y187Cl+) TMs. TMs from Tecta(Y1870Cl+) mice showed little volume change in response to osmotic pressure compared to those of wild-type mice. The magnitude of both radial and longitudinal TM shear impedance was reduced by 10 +/- 1.6 dB in Tecta(Y1870Cl+) mice. However, the phase of shear impedance was unchanged. These changes are consistent with an increase in the porosity of the TM and a corresponding decrease of the solid fraction. Mechanisms by which these changes can affect the coupling between outer and inner hair cells are discussed. C1 [Masaki, Kinuko; Ghaffari, Roozbeh; Gu, Jianwen Wendy; Freeman, Dennis M.; Aranyosi, A. J.] MIT, Elect Res Lab, Cambridge, MA 02139 USA. [Masaki, Kinuko; Ghaffari, Roozbeh; Gu, Jianwen Wendy; Freeman, Dennis M.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Freeman, Dennis M.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [Masaki, Kinuko; Ghaffari, Roozbeh; Gu, Jianwen Wendy; Freeman, Dennis M.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab Auditory Physiol, Boston, MA 02114 USA. [Richardson, Guy P.] Univ Sussex, Sch Life Sci, Falmer, E Sussex, England. RP Aranyosi, AJ (reprint author), MIT, Elect Res Lab, Cambridge, MA 02139 USA. EM aaranyosi@partners.org FU National Institutes of Health (NIH) [R01-DC00238, R01-DC03544]; Wellcome Trust FX This work was supported by National Institutes of Health (NIH) grant R01-DC00238. W.G. and R.G. were supported in part by an NIH training grant to the Harvard-MIT Speech and Hearing Biosciences and Technology Program, and K.M. was supported in part by NIH grant R01-DC03544. G.R. was supported by the Wellcome Trust. NR 29 TC 8 Z9 8 U1 0 U2 2 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0006-3495 J9 BIOPHYS J JI Biophys. J. PD NOV 17 PY 2010 VL 99 IS 10 BP 3274 EP 3281 DI 10.1016/j.bpj.2010.09.033 PG 8 WC Biophysics SC Biophysics GA 682YK UT WOS:000284438700021 PM 21081075 ER PT J AU Coker, TR Chan, LS Newberry, SJ Limbos, MA Suttorp, MJ Shekelle, PG Takata, GS AF Coker, Tumaini R. Chan, Linda S. Newberry, Sydne J. Limbos, Mary Ann Suttorp, Marika J. Shekelle, Paul G. Takata, Glenn S. TI Diagnosis, Microbial Epidemiology, and Antibiotic Treatment of Acute Otitis Media in Children A Systematic Review SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID PNEUMOCOCCAL CONJUGATE VACCINE; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND TRIAL; PRESCRIBING STRATEGIES; CLINICAL-EFFICACY; GENERAL-PRACTICE; AMOXICILLIN; MANAGEMENT; CEFACLOR; PLACEBO AB Context Acute otitis media (AOM) is the most common condition for which antibiotics are prescribed for US children; however, wide variation exists in diagnosis and treatment. Objectives To perform a systematic review on AOM diagnosis, treatment, and the association of heptavalent pneumococcal conjugate vaccine (PCV7) use with AOM microbiology. Data Sources PubMed, Cochrane Databases, and Web of Science, searched to identify articles published from January 1999 through July 2010. Study Selection Diagnostic studies with a criterion standard, observational studies and randomized controlled trials comparing AOM microbiology with and without PCV7, and randomized controlled trials assessing antibiotic treatment. Data Extraction Independent article review and study quality assessment by 2 investigators with consensus resolution of discrepancies. Results Of 8945 citations screened, 135 were included. Meta-analysis was performed for comparisons with 3 or more trials. Few studies examined diagnosis; otoscopic findings of tympanic membrane bulging (positive likelihood ratio, 51[95% confidence interval {CI}, 36-73]) and redness (positive likelihood ratio, 8.4 [95% CI, 7-11]) were associated with accurate diagnosis. In the few available studies, prevalence of Streptococcus pneumoniae decreased (eg, 33%-48% vs 23%-31% of AOM isolates), while that of Haemophilus influenzae increased (41%-43% vs 56%-57%) pre-vs post-PCV7. Short-term clinical success was higher for immediate use of ampicillin or amoxicillin vs placebo(73% vs 60%; pooled rate difference, 12% [95% CI, 5%-18%]; number needed to treat, 9 [95% CI, 6-20]), while increasing the rate of rash or diarrhea by 3% to 5%. Two of 4 studies showed greater clinical success for immediate vs delayed antibiotics(95% vs 80%; rate difference, 15% [95% CI, 6%-24%] and 86% vs 70%; rate difference, 16% [95% CI, 6%-26%]). Data are absent on long-term effects on antimicrobial resistance. Meta-analyses in general showed no significant differences in antibiotic comparative effectiveness. Conclusions Otoscopic findings are critical to accurate AOM diagnosis. AOM microbiology has changed with use of PCV7. Antibiotics are modestly more effective than no treatment but cause adverse effects in 4% to 10% of children. Most antibiotics have comparable clinical success. JAMA. 2010; 304(19): 2161-2169 C1 [Coker, Tumaini R.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Pediat, Los Angeles, CA 90024 USA. [Coker, Tumaini R.] RAND, Santa Monica, CA USA. [Chan, Linda S.] Los Angeles Cty USC Med Ctr, Div Biostat & Outcomes Assessment, Los Angeles, CA USA. [Chan, Linda S.; Limbos, Mary Ann; Takata, Glenn S.] USC Keck Sch Med, Los Angeles, CA USA. [Newberry, Sydne J.; Suttorp, Marika J.; Shekelle, Paul G.] RAND Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA. [Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA. [Takata, Glenn S.] Childrens Hosp Los Angeles, Div Gen Pediat, Los Angeles, CA 90027 USA. RP Coker, TR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA RAND Ctr Adolescent Hlth Promot, 10960 Wilshire Blvd,Ste 1550, Los Angeles, CA 90024 USA. EM tcoker@mednet.ucla.edu FU Agency for Healthcare Research and Quality (AHRQ) [290-2007-10056]; EPC FX This article is based on research conducted by the Southern California Evidence-based Practice Center (EPC) under contract with the Agency for Healthcare Research and Quality (AHRQ) (contract 290-2007-10056). This work was commissioned by AHRQ as an update to an earlier report and in support of the update of practice guidelines.; AHRQ had a role, through its sponsorship of the EPC program, in the general methods of EPC systematic reviews and in development of the key questions for each review. However, AHRQ had no role in the specific conduct of the review; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. NR 70 TC 101 Z9 104 U1 1 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 17 PY 2010 VL 304 IS 19 BP 2161 EP 2169 DI 10.1001/jama.2010.1651 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 680XC UT WOS:000284269800027 PM 21081729 ER PT J AU Jarrett, BT Cofske, J Rosenberg, AE Oral, E Muratoglu, O Malchau, H AF Jarrett, Bryan T. Cofske, Jennifer Rosenberg, Andrew E. Oral, Ebru Muratoglu, Orhun Malchau, Henrik TI In Vivo Biological Response to Vitamin E and Vitamin-E-Doped Polyethylene SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID MOLECULAR-WEIGHT POLYETHYLENE; CROSS-LINKED POLYETHYLENE; TOTAL HIP-ARTHROPLASTY; ALPHA-TOCOPHEROL; ARTICULATING SURFACES; JOINT ENDOPROSTHESES; IRRADIATED UHMWPE; BONE INGROWTH; FOLLOW-UP; OSTEOLYSIS AB Background Cross linking has decreased the wear of ultra high molecular weight polyethylene, a cause of osteolysis leading to total joint replacement failure Compared with melting or annealing, doping cross linked ultra high molecular weight polyethylene with vitamin E stabilizes free radicals from irradiation while maintaining mechanical properties and wear resistance This study was done to determine the local tissue effects of free vitamin E and vitamin E eluted from ultra high molecular weight polyethylene implants in the joint space Methods Three studies were performed First, pure vitamin E and solubilized vitamin E were injected into rabbit knees to simulate vitamin-E elution from radiation cross linked ultra-high molecular weight polyethylene, second, vitamin-E-doped, irradiated ultra-high molecular weight polyethylene plugs were implanted into dorsal subcutaneous pouches of rabbits to determine the local effects of vitamin E elution from radiation cross-linked ultra high molecular weight polyethylene, and, third, two groups of vitamin-E-doped irradiated acetabular liners (high surface and uniform vitamin-E concentration profiles) were compared with undoped, control ultra high molecular weight polyethylene liners in a canine model of total hip replacement to determine the effect of possible vitamin E elution on bone ingrowth and the local tissue response to it in a load-bearing environment Results Injection of solubilized vitamin E resulted in histologically normal surrounding soft tissue at both two and twelve-week follow up intervals, while injection of pure vitamin E resulted in acute and chronic inflammation at the time of the two-week follow up Both control and vitamin E doped subcutaneous plugs showed inflammation associated with surgery at two weeks of follow up, but showed stable fibrous encapsulation without inflammation at twelve weeks of follow up In the canine total hip replacement model, there was no qualitative difference in local tissue appearance and no significant difference in the percent bone ingrowth and the percent bone density between the control and vitamin E groups Conclusions These investigations showed that vitamin E-doped ultra high molecular weight polyethylene plugs and total hip replacement components are well tolerated in both a small and a large animal model with no observed adverse effects on the surrounding tissues at twelve weeks of follow up C1 [Jarrett, Bryan T.; Cofske, Jennifer; Rosenberg, Andrew E.; Oral, Ebru; Muratoglu, Orhun; Malchau, Henrik] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02115 USA. RP Jarrett, BT (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Biomech & Biomat Lab, 1125 Gray Jackson,55 Fruit St, Boston, MA 02115 USA. NR 36 TC 9 Z9 13 U1 0 U2 5 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD NOV 17 PY 2010 VL 92A IS 16 BP 2672 EP 2681 DI 10.2106/JBJS.I.00068 PG 10 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 689HO UT WOS:000284918900006 PM 21084577 ER PT J AU Norstrom, EM Zhang, C Tanzi, R Sisodia, SS AF Norstrom, Eric M. Zhang, Can Tanzi, Rudolph Sisodia, Sangram S. TI Identification of NEEP21 as a beta-Amyloid Precursor Protein-Interacting Protein In Vivo That Modulates Amyloidogenic Processing In Vitro SO JOURNAL OF NEUROSCIENCE LA English DT Article ID ENRICHED ENDOSOMAL PROTEIN; APP FAMILY-MEMBERS; ALZHEIMERS-DISEASE; BIOCHEMICAL-ANALYSIS; ADAPTER PROTEIN; TRANSGENIC MICE; A-BETA; 21 KDA; FE65; HIPPOCAMPUS AB Alzheimer's disease (AD) is an age-related neurodegenerative disease and the most common form of dementia. AD is pathologically characterized by the deposition of pathogenic A beta peptides that are derived from larger integral membrane proteins, termed beta-amyloid precursor proteins (APPs). In an attempt to understand the function of APP, in vitro studies have focused on the identification of interacting proteins. To investigate the APP in vivo interactome in an unbiased manner, we generated mice that harbor a mouse prion protein promoter-driven cDNA encoding human APP-695 fused to a C-terminal affinity tag. Using this tag, we prepared mild detergent lysates from transgenic mouse brain cortical membrane preparations and isolated a number of previously identified APP-interacting proteins. In addition to these factors, mass spectrometric analysis revealed the presence of NEEP21 as a novel interacting protein. We now report that NEEP21 profoundly affects the processing of APP and A beta production. Thus, this study demonstrates that using proteomic methods on our transgenic model can uncover important in vivo APP-interacting proteins that will provide insights into the biology of APP. C1 [Norstrom, Eric M.; Sisodia, Sangram S.] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA. [Zhang, Can; Tanzi, Rudolph] Massachusetts Gen Hosp, Dept Neurol, Genet & Aging Res Unit, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA. [Zhang, Can; Tanzi, Rudolph] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Sisodia, SS (reprint author), Univ Chicago, Dept Neurobiol, 947 E 58th St,AB 327, Chicago, IL 60637 USA. EM ssisodia@bsd.uchicago.edu FU American Health Assistance Foundation; Chicago Biomedical Consortium FX This work was funded in part by the American Health Assistance Foundation (E.M.N.) and the Chicago Biomedical Consortium (S.S.S.). We thank Anna Shevchenko (Max Planck Institute, Dresden, Germany) for assistance on mass spectrometry. NR 53 TC 25 Z9 25 U1 0 U2 2 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 17 PY 2010 VL 30 IS 46 BP 15677 EP 15685 DI 10.1523/JNEUROSCI.4464-10.2010 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 681XU UT WOS:000284358500033 PM 21084623 ER PT J AU Nardone, DA AF Nardone, David A. TI Open Notes: Sharing Physician Notes With Patients SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 Portland VA Med Ctr, Portland, OR 97239 USA. RP Nardone, DA (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 16 PY 2010 VL 153 IS 10 BP 690 EP 690 DI 10.1059/0003-4819-153-10-201011160-00023 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 680ES UT WOS:000284215800031 PM 21079235 ER PT J AU Turner, EH AF Turner, Erick H. TI Reboxetine in depression All the relevant data? SO BRITISH MEDICAL JOURNAL LA English DT Letter ID TRIALS C1 [Turner, Erick H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Turner, Erick H.] Portland VA Med Ctr, P3MHDC, Portland, OR 97239 USA. RP Turner, EH (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA. EM turnere@ohsu.edu NR 6 TC 4 Z9 4 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BRIT MED J JI Br. Med. J. PD NOV 16 PY 2010 VL 341 AR c6487 DI 10.1136/bmj.c6487 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 684WJ UT WOS:000284585600004 PM 21081614 ER PT J AU Bernal, F Wade, M Godes, M Davis, TN Whitehead, DG Kung, AL Wahl, GM Walensky, LD AF Bernal, Federico Wade, Mark Godes, Marina Davis, Tina N. Whitehead, David G. Kung, Andrew L. Wahl, Geoffrey M. Walensky, Loren D. TI A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53 SO CANCER CELL LA English DT Article ID STABILIZED ALPHA-HELICES; CELL-CYCLE ARREST; WILD-TYPE P53; IN-VIVO; EMBRYONIC LETHALITY; BH3 HELIX; TRANSACTIVATION DOMAIN; MDM2-DEFICIENT MICE; MDM2 INHIBITOR; BCL-2 DOMAINS AB Cancer cells neutralize p53 by deletion, mutation, proteasomal degradation, or sequestration to achieve a pathologic survival advantage. Targeting the E3 ubiquitin ligase HDM2 can lead to a therapeutic surge in p53 levels. However, the efficacy of HDM2 inhibition can be compromised by overexpression of HDMX, an HDM2 homolog that binds and sequesters p53. Here, we report that a stapled p53 helix preferentially targets HDMX, blocks the formation of inhibitory p53-HDMX complexes, induces p53-dependent transcriptional upregulation, and thereby overcomes HDMX-mediated cancer resistance in vitro and in vivo. Importantly, our analysis of p53 interaction dynamics provides a blueprint for reactivating the p53 pathway in cancer by matching HDM2, HDMX, or dual inhibitors to the appropriate cellular context. C1 [Bernal, Federico; Godes, Marina; Davis, Tina N.; Whitehead, David G.; Kung, Andrew L.; Walensky, Loren D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Bernal, Federico; Godes, Marina; Davis, Tina N.; Whitehead, David G.; Kung, Andrew L.; Walensky, Loren D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA 02115 USA. [Bernal, Federico; Godes, Marina; Whitehead, David G.; Walensky, Loren D.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA. [Wade, Mark; Wahl, Geoffrey M.] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA. RP Walensky, LD (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA. EM loren_walensky@dfci.harvard.edu RI Wade, Mark /B-6719-2009; OI Wade, Mark /0000-0002-2688-5965; Kung, Andrew/0000-0002-9091-488X FU NCI [1K22CA128886]; NIH [5P01CA92625, CA61449, CA100845]; Todd J. Schwartz Pediatric Oncology Fund; Burroughs Wellcome Fund FX We thank Eric Smith for editorial and graphics assistance, Gregory Verdine for catalyzing the collaboration between L.D.W. and G.M.W., Bert Vogelstein for supplying HCT116 p53+/+ and HCT116 p53-/- cell lines, Lyubomir Vassilev for providing G.M.W. with enantiomeric Nutlin-3 for P-LISA experiments, and Ulf Landegren, Ola Soderberg, and Eric Nystrom for invaluable advice regarding P-LISA. This work was supported by NCI Career Transition Award 1K22CA128886 to F.B., NIH grant 5P01CA92625, the Todd J. Schwartz Pediatric Oncology Fund, and a Burroughs Wellcome Fund Career Award to L.D.W., and NIH grants CA61449 and CA100845 to G.M.W. NR 70 TC 127 Z9 129 U1 2 U2 44 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 J9 CANCER CELL JI Cancer Cell PD NOV 16 PY 2010 VL 18 IS 5 BP 411 EP 422 DI 10.1016/j.ccr.2010.10.024 PG 12 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 685WK UT WOS:000284658600007 PM 21075307 ER PT J AU Gan, BY Lim, C Chu, G Hua, SJ Ding, ZH Collins, M Hu, JA Jiang, S Fletcher-Sananikone, E Zhuang, L Chang, M Zheng, HW Wang, YA Kwiatkowski, DJ Kaelin, WG Signoretti, S DePinho, RA AF Gan, Boyi Lim, Carol Chu, Gerald Hua, Sujun Ding, Zhihu Collins, Michael Hu, Jian Jiang, Shan Fletcher-Sananikone, Eliot Zhuang, Li Chang, Michelle Zheng, Hongwu Wang, Y. Alan Kwiatkowski, David J. Kaelin, William G., Jr. Signoretti, Sabina DePinho, Ronald A. TI FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis SO CANCER CELL LA English DT Article ID MTOR SIGNALING PATHWAY; CLEAR-CELL CARCINOMA; C-MYC; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; TUMOR SUPPRESSION; GENE-EXPRESSION; HUMAN CANCERS; N-COR; METABOLISM AB mTORC1 is a validated therapeutic target for renal cell carcinoma (RCC). Here, analysis of Tsc1-deficient (mTORC1 hyperactivation) mice uncovered a FoxO-dependent negative feedback circuit constraining mTORC1-mediated renal tumorigenesis. We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and Fox Os; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes. Mechanistically, integrated analyses revealed that FoxO-mediated block operates via suppression of Myc through upregulation of the Myc antagonists, Mxi1-SR alpha and mir-145, establishing a FoxO-Mxi1-SR alpha/mir-145 axis as a major progression block in renal tumor development. C1 [Gan, Boyi; Lim, Carol; Chu, Gerald; Hua, Sujun; Ding, Zhihu; Hu, Jian; Jiang, Shan; Fletcher-Sananikone, Eliot; Zhuang, Li; Zheng, Hongwu; Wang, Y. Alan; DePinho, Ronald A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA. [Gan, Boyi; Lim, Carol; Hua, Sujun; Ding, Zhihu; Hu, Jian; Jiang, Shan; Fletcher-Sananikone, Eliot; Zhuang, Li; Zheng, Hongwu; Wang, Y. Alan; Kaelin, William G., Jr.; Signoretti, Sabina; DePinho, Ronald A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Gan, Boyi; Lim, Carol; Chu, Gerald; Hua, Sujun; Ding, Zhihu; Hu, Jian; Jiang, Shan; Fletcher-Sananikone, Eliot; Zhuang, Li; Zheng, Hongwu; Wang, Y. Alan; Kaelin, William G., Jr.; DePinho, Ronald A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Gan, Boyi; Lim, Carol; Chu, Gerald; Hua, Sujun; Ding, Zhihu; Hu, Jian; Jiang, Shan; Fletcher-Sananikone, Eliot; Zhuang, Li; Zheng, Hongwu; Wang, Y. Alan; DePinho, Ronald A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Chu, Gerald; Collins, Michael; Chang, Michelle; Signoretti, Sabina] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Kwiatkowski, David J.] Brigham & Womens Hosp, Div Translat Med, Boston, MA 02115 USA. [Kaelin, William G., Jr.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. RP DePinho, RA (reprint author), Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA. EM ron_depinho@dfci.harvard.edu OI Zheng, Hongwu/0000-0002-5823-4913 FU National Cancer Institute [R21CA135057, U01CA141508, 1P01CA120964]; DF/HCC [P50CA101942-06A1]; DOD [TS093049]; Damon Runyon Cancer Research Foundation; Multiple Myeloma Research Foundation; Robert A. and Renee E. Belfer Foundation Institute for Innovative Cancer Science FX We are grateful to Anton Berns for providing Rosa26-CreERT2 mouse strain. We are also grateful to Shan (Julia) Zhou for the assistance in the animal facility. This research is supported by National Cancer Institute grant R21CA135057 (R.A.D., B.G.), U01CA141508 (BAD.), 1P01CA120964 (D.J.K.), DF/HCC Kidney Cancer SPORE Career Development Grant (P50CA101942-06A1) and DOD TSCRP Career Transition Award (TS093049) (B.G.). B.G. is the Research Fellow of the Leukemia and Lymphoma Society. S.H. is supported by Damon Runyon Cancer Research Foundation Postdoctoral Fellowship. Y.A.W. is supported by Multiple Myeloma Research Foundation. R.A.D. was supported by an American Cancer Society Research Professorship and the Robert A. and Renee E. Belfer Foundation Institute for Innovative Cancer Science. NR 54 TC 58 Z9 62 U1 1 U2 4 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 J9 CANCER CELL JI Cancer Cell PD NOV 16 PY 2010 VL 18 IS 5 BP 472 EP 484 DI 10.1016/j.ccr.2010.10.019 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 685WK UT WOS:000284658600012 PM 21075312 ER PT J AU Marcus, GM Alonso, A Peralta, CA Lettre, G Vittinghoff, E Lubitz, SA Fox, ER Levitzky, YS Mehra, R Kerr, KF Deo, R Sotoodehnia, N Akylbekova, M Ellinor, PT Paltoo, DN Soliman, EZ Benjamin, EJ Heckbert, SR AF Marcus, Gregory M. Alonso, Alvaro Peralta, Carmen A. Lettre, Guillaume Vittinghoff, Eric Lubitz, Steven A. Fox, Ervin R. Levitzky, Yamini S. Mehra, Reena Kerr, Kathleen F. Deo, Rajat Sotoodehnia, Nona Akylbekova, Meggie Ellinor, Patrick T. Paltoo, Dina N. Soliman, Elsayed Z. Benjamin, Emelia J. Heckbert, Susan R. CA Candidate-Gene Assoc Resource CARe TI European Ancestry as a Risk Factor for Atrial Fibrillation in African Americans SO CIRCULATION LA English DT Article DE ancestry; African Americans; atrial fibrillation; genetics ID ATHEROSCLEROSIS RISK; HEART-FAILURE; UNITED-STATES; ADULTS; PREVALENCE; LOCUS; EPIDEMIOLOGY; HYPERTENSION; MANAGEMENT; INFERENCE AB Background-Despite a higher burden of standard atrial fibrillation (AF) risk factors, African Americans have a lower risk of AF than whites. It is unknown whether the higher risk is due to genetic or environmental factors. Because African Americans have varying degrees of European ancestry, we sought to test the hypothesis that European ancestry is an independent risk factor for AF. Methods and Results-We studied whites (n=4543) and African Americans (n=822) in the Cardiovascular Health Study (CHS) and whites (n=10 902) and African Americans (n=3517) in the Atherosclerosis Risk in Communities (ARIC) Study (n=3517). Percent European ancestry in African Americans was estimated with 1747 ancestry informative markers from the Illumina custom ITMAT-Broad-CARe array. Among African Americans without baseline AF, 120 of 804 CHS participants and 181 of 3517 ARIC participants developed incident AF. A meta-analysis from the 2 studies revealed that every 10% increase in European ancestry increased the risk of AF by 13% (hazard ratio, 1.13; 95% confidence interval, 1.03 to 1.23; P=0.007). After adjustment for potential confounders, European ancestry remained a predictor of incident AF in each cohort alone, with a combined estimated hazard ratio for each 10% increase in European ancestry of 1.17 (95% confidence interval, 1.07 to 1.29; P=0.001). A second analysis using 3192 ancestry informative markers from a genome-wide Affymetrix 6.0 array in ARIC African Americans yielded similar results. Conclusions-European ancestry predicted risk of incident AF. Our study suggests that investigating genetic variants contributing to differential AF risk in individuals of African versus European ancestry will be informative. (Circulation. 2010; 122: 2009-2015.) C1 [Marcus, Gregory M.] Univ Calif San Francisco, Div Cardiol, Electrophysiol Sect, San Francisco, CA 94143 USA. [Peralta, Carmen A.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Alonso, Alvaro] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Lettre, Guillaume] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada. [Lubitz, Steven A.; Ellinor, Patrick T.] Harvard Univ, Sch Med, Cardiovasc Res Ctr, Boston, MA USA. [Ellinor, Patrick T.] Harvard Univ, Sch Med, Cardiac Arrhythmia Serv, Boston, MA USA. [Lubitz, Steven A.] Harvard Univ, Brigham & Womens Hosp, Massachusetts Gen Hosp, Div Prevent Med,Med Sch, Boston, MA 02115 USA. [Fox, Ervin R.; Akylbekova, Meggie] Univ Mississippi, Med Ctr, Div Cardiol, Jackson, MS USA. [Levitzky, Yamini S.] Case Western Reserve Univ, Heart & Vasc Ctr, Div Cardiol, Cleveland, OH 44106 USA. [Mehra, Reena] Case Western Reserve Univ, Ctr Clin Invest, Cleveland, OH 44106 USA. [Mehra, Reena] Case Western Reserve Univ, Div Pulm Crit Care & Sleep Med, Cleveland, OH 44106 USA. [Kerr, Kathleen F.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Sotoodehnia, Nona] Univ Washington, Dept Med, Div Cardiol, Seattle, WA USA. [Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Deo, Rajat] Univ Penn, Electrophysiol Sect, Div Cardiovasc Med, Philadelphia, PA 19104 USA. [Paltoo, Dina N.] Natl Heart Blood & Lung Inst, NIH, DHHS, Bethesda, MD USA. [Soliman, Elsayed Z.] Wake Forest Univ, Bowman Gray Sch Med, Epidemiol Cardiol Res Ctr, Dept Epidemiol & Prevent, Winston Salem, NC USA. [Benjamin, Emelia J.] Boston Univ, Sch Med, Evans Dept Med, Div Cardiol & Prevent Med, Boston, MA 02118 USA. [Benjamin, Emelia J.] Boston Univ, Sch Med, Evans Dept Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA. [Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. RP Marcus, GM (reprint author), Univ Calif San Francisco, Div Cardiol, Electrophysiol Sect, 500 Parnassus Ave,MUE 434, San Francisco, CA 94143 USA. EM marcusg@medicine.ucsf.edu RI Alonso, Alvaro/A-4917-2010; Soliman, Elsayed/D-8124-2011; Kerr, Kathleen/A-2893-2013; OI Alonso, Alvaro/0000-0002-2225-8323; Soliman, Elsayed/0000-0001-5632-8150; Mehra, Reena/0000-0002-6222-2675; Benjamin, Emelia/0000-0003-4076-2336 FU National Heart, Lung, and Blood Institute (NHLBI) [K23 HL079114]; National Center for Research Resources (NCRR), National Institutes of Health (NIH). [KL2 RR024130]; CARe [N01-HC-65226]; University of North Carolina at Chapel Hill [N01-HC-55015]; Baylor Medical College [N01-HC55016]; University of Mississippi Medical Center [N01-HC-55021]; University of Minnesota [N01-HC-55019, N01-HC-48048, N01-HC-95163, U01 HL053934]; Johns Hopkins University [N01-HC-55020, N01-HC-85081, N01 HC-15103, N01-HC-95162, N01-HC-95168, U01 HL064360, U01 HL053937]; University of Texas, Houston [N01-HC-55022]; University of North Carolina, Forsyth County [N01-HC-55018]; National Human Genome Research Institute [U01HG004402]; NIH [UL1RR025005, RC1-HL01056, DA027021, R01 HL088456, T32HL007575, HHSN268200625226C]; NIH Roadmap for Medical Research [UL1RR025005]; NIH/NHLBI [RC1-HL099452]; American Heart Association [09SDG2280087, 0530188N]; Wake Forest University [N01-HC-85080, N01-HC-45205, N01-HC-95165]; University of Pittsburgh [N01-HC-85082, U01 HL077813]; University of California, Davis [N01-HC-85083]; University of California, Irvine [N01-HC85084, N01-HC-45134, N01-HC-95100, U01 HL053916]; New England Medical Center [N01-HC-85085, N01-HC-95167]; University of Vermont [N01-HC-85086, N01-HC-95166]; Georgetown University [N01-HC-35129]; University of Wisconsin [N01-HC-75150]; Geisinger Clinic [N01-HC-45133]; University of Washington [N01 HC-55222, U01 HL080295, N01-HC-95159, N01-HC-85079]; Case Western Reserve University [NIH HL 46380, M01RR00080]; University of Illinois [N01-HB-72982, N01-HB-97062]; Howard University [N01-HB-72991, N01-HB-97061]; University of Miami [N01-HB-72992, N01-HB-97064]; Duke University [N01-HB-72993]; George Washington University [N01-HB-72994]; University of Tennessee [N01-HB-72995, N01-HB-97070]; Yale University [N01-HB-72996, N01-HB-97072]; Children's Hospital-Philadelphia [N01-HB-72997, N01-HB-97056]; University of Chicago [N01-HB-72998, N01-HB-97053]; Medical College of Georgia [N01-HB-73000, N01-HB-97060]; Washington University [N01-HB-73001, N01-HB-97071]; Jewish Hospital and Medical Center of Brooklyn [N01-HB-73002]; Trustees of Health and Hospitals of the City of Boston, Inc [N01-HB-73003]; Children's Hospital-Oakland [N01-HB-73004, N01-HB-97054]; University of Mississippi [N01-HB-73005, N01-HC-95171]; St Luke's Hospital-New York [N01-HB-73006]; Alta Bates-Herrick Hospital [N01-HB-97051]; Columbia University [N01-HB-97058, N01-HC-95161]; St Jude's Children's Research Hospital [N01-HB-97066]; State University of New York-Albany [N01-HB-97068, N01-HB-97069]; New England Research Institute [N01-HB-97073]; Interfaith Medical Center-Brooklyn [N01-HB-97085]; University of Alabama at Birmingham [N01-HC-48047, N01-HC-95095]; Northwestern University [N01-HC-48049, N01-HC-95164]; Kaiser Foundation Research Institute [N01-HC-48050]; Tufts-New England Medical Center [N01-HC-45204]; Harbor-UCLA Research and Education Institute [N01-HC-05187, N01-HC-95169]; Boston University [N01-HC-25195, R01HL092577-01A1, RO1 HL076784, R01 AG028321, 6R01-NS 17950, U01 HL053941]; Jackson State University; Tougaloo College; Regents of the University of California; Cedars-Sinai Medical Center [R01-HL-071205]; University of Virginia [R01-HL-071205]; Case Western University [U01 HL063463]; University of Arizona [U01 HL053938]; MedStar Research Institute [U01 HL063429]; Central Society of Clinical Research Career Development Award; [N01-HC-95170]; [N01-HC-95172]; [N01-HC-95160] FX We wish to acknowledge the support of the National Heart, Lung, and Blood Institute (NHLBI) and the contributions of the research institutions, study investigators, field staff, and study participants in creating this resource for biomedical research. We would like to thank Drs Richard S. Cooper and Philip L. De Jager for providing the Nigerian and European American Affymetrix 6.0 genotype data sets, as well as Dr Nick Patterson and Arti Tandon for curating the list of AIMs on the Affymetrix 6.0 genotyping platform.; This work was made possible by grant KL2 RR024130 (G. M. M.) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). The CARe project (N01-HC-65226) involves 9 parent studies that contributed parent study data, ancillary study data, and DNA samples through the Massachusetts Institute of Technology-Broad Institute to create this genotype/phenotype database for wide dissemination to the biomedical research community. ARIC: University of North Carolina at Chapel Hill (N01-HC-55015), Baylor Medical College (N01-HC55016), University of Mississippi Medical Center (N01-HC-55021), University of Minnesota (N01-HC-55019), Johns Hopkins University (N01-HC-55020), University of Texas, Houston (N01-HC-55022), University of North Carolina, Forsyth County (N01-HC-55018); R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Infrastructure was partly supported by grant UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. This study was also supported by grant RC1-HL099452 from NIH/NHLBI and grant 09SDG2280087 from the American Heart Association. CHS: University of Washington (N01-HC-85079), Wake Forest University (N01-HC-85080), Johns Hopkins University (N01-HC-85081), University of Pittsburgh (N01-HC-85082), University of California, Davis (N01-HC-85083), University of California, Irvine (N01-HC85084), New England Medical Center (N01-HC-85085), University of Vermont (N01-HC-85086), Georgetown University (N01-HC-35129), Johns Hopkins University (N01 HC-15103), University of Wisconsin (N01-HC-75150), Geisinger Clinic (N01-HC-45133), University of Washington (N01 HC-55222, U01 HL080295). Cleveland Family Study: Case Western Reserve University (NIH HL 46380, M01RR00080). Cooperative Study of Sickle Cell Disease: University of Illinois (N01-HB-72982, N01-HB-97062), Howard University (N01-HB-72991, N01-HB-97061), University of Miami (N01-HB-72992, N01-HB-97064), Duke University (N01-HB-72993), George Washington University (N01-HB-72994), University of Tennessee (N01-HB-72995, N01-HB-97070), Yale University (N01-HB-72996, N01-HB-97072), Children's Hospital-Philadelphia (N01-HB-72997, N01-HB-97056), University of Chicago (N01-HB-72998, N01-HB-97053), Medical College of Georgia (N01-HB-73000, N01-HB-97060), Washington University (N01-HB-73001, N01-HB-97071), Jewish Hospital and Medical Center of Brooklyn (N01-HB-73002), Trustees of Health and Hospitals of the City of Boston, Inc, (N01-HB-73003), Children's Hospital-Oakland (N01-HB-73004, N01-HB-97054), University of Mississippi (N01-HB-73005), St Luke's Hospital-New York (N01-HB-73006), Alta Bates-Herrick Hospital (N01-HB-97051), Columbia University (N01-HB-97058), St Jude's Children's Research Hospital (N01-HB-97066), Research Foundation, State University of New York-Albany (N01-HB-97068, N01-HB-97069), New England Research Institute (N01-HB-97073), Interfaith Medical Center-Brooklyn (N01-HB-97085). Coronary Artery Risk in Young Adults: University of Alabama at Birmingham (N01-HC-48047), University of Minnesota (N01-HC-48048), Northwestern University (N01-HC-48049), Kaiser Foundation Research Institute (N01-HC-48050), University of Alabama at Birmingham (N01-HC-95095), Tufts-New England Medical Center (N01-HC-45204), Wake Forest University (N01-HC-45205), Harbor-UCLA Research and Education Institute (N01-HC-05187), University of California, Irvine (N01-HC-45134, N01-HC-95100).; Framingham Heart Study: Boston University (N0-HC-25195, R01HL092577-01A1, RO1 HL076784, R01 AG028321, 6R01-NS 17950). Jackson Heart Study: Jackson State University (N01-HC-95170), University of Mississippi (N01-HC-95171), Tougaloo College (N01-HC-95172). Multi-Ethnic Study of Atherosclerosis: University of Washington (N01-HC-95159), Regents of the University of California (N01-HC-95160), Columbia University (N01-HC-95161), Johns Hopkins University (N01-HC-95162, N01-HC-95168), University of Minnesota (N01-HC-95163), Northwestern University (N01-HC-95164), Wake Forest University (N01-HC-95165), University of Vermont (N01-HC-95166), New England Medical Center (N01-HC-95167), Harbor-UCLA Research and Education Institute (N01-HC-95169), Cedars-Sinai Medical Center (R01-HL-071205), University of Virginia (subcontract to R01-HL-071205). Sleep Heart Health Study: Johns Hopkins University (U01 HL064360), Case Western University (U01 HL063463), University of California, Davis (U01 HL053916), University of Arizona (U01 HL053938), University of Minnesota (relocating in 2006 to University of Arizona; U01 HL053934), University of Pittsburgh (U01 HL077813), Boston University (U01 HL053941), MedStar Research Institute (U01 HL063429), Johns Hopkins University (U01 HL053937). This work was also supported by grants from the NIH: RC1-HL01056 to Drs Benjamin and Alonso, DA027021 to Dr Ellinor, and R01 HL088456 to Dr Sotoodehnia. Dr Lubitz is supported by a training grant in the Epidemiology of Cardiovascular Disease from the NIH (T32HL007575). Dr Mehra is supported by the following: NHLBI K23 HL079114, American Heart Association National Scientist Development Award 0530188N, and Central Society of Clinical Research Career Development Award. NR 41 TC 77 Z9 80 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 16 PY 2010 VL 122 IS 20 BP 2009 EP 2015 DI 10.1161/CIRCULATIONAHA.110.958306 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 680DS UT WOS:000284213200010 PM 21098467 ER PT J AU Verzi, MP Shin, HJ He, HH Sulahian, R Meyer, CA Montgomery, RK Fleet, JC Brown, M Liu, XS Shivdasani, RA AF Verzi, Michael P. Shin, Hyunjin He, H. Hansen Sulahian, Rita Meyer, Clifford A. Montgomery, Robert K. Fleet, James C. Brown, Myles Liu, X. Shirley Shivdasani, Ramesh A. TI Differentiation-Specific Histone Modifications Reveal Dynamic Chromatin Interactions and Partners for the Intestinal Transcription Factor CDX2 SO DEVELOPMENTAL CELL LA English DT Article ID MODEL-BASED ANALYSIS; GENE-EXPRESSION; EPITHELIAL-CELLS; ENTEROCYTE DIFFERENTIATION; REGULATORY NETWORKS; GUT EPITHELIUM; HUMAN GENOME; STEM-CELLS; IN-VITRO; ENHANCERS AB Cell differentiation requires remodeling of tissue-specific gene loci and activities of key transcriptional regulators, which are recognized for their dominant control over cellular programs Using epigenomic methods, we characterized enhancer elements specifically modified in differentiating intestinal epithelial cells and found enrichment of transcription factor-binding motifs corresponding to CDX2, a critical regulator of the intestine Directed investigation revealed surprising lability in CDX2 occupancy of the genome, with redistribution from hundreds of sites occupied only in proliferating cells to thousands of new sites in differentiated cells Knockout mice confirmed distinct Cdx2 requirements in dividing and mature adult intestinal cells, including responsibility for the active enhancer configuration associated with maturity Dynamic CDX2 occupancy corresponds with condition-specific gene expression and, importantly, to differential co-occupancy with other tissue-restricted transcription factors, such as GATA6 and HNF4A These results reveal dynamic, context-specific functions and mechanisms of a prominent transcriptional regulator within a cell lineage C1 [Verzi, Michael P.; He, H. Hansen; Sulahian, Rita; Montgomery, Robert K.; Brown, Myles; Shivdasani, Ramesh A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Shin, Hyunjin; He, H. Hansen; Meyer, Clifford A.; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Verzi, Michael P.; Sulahian, Rita; Brown, Myles; Shivdasani, Ramesh A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Verzi, Michael P.; Sulahian, Rita; Brown, Myles; Shivdasani, Ramesh A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Montgomery, Robert K.] Childrens Hosp, Gastroenterol & Nutr Div, Boston, MA 02115 USA. [Fleet, James C.] Purdue Univ, Dept Foods & Nutr, W Lafayette, IN 47907 USA. RP Shivdasani, RA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RI He, Housheng/G-9614-2011; OI Brown, Myles/0000-0002-8213-1658; Fleet, James/0000-0002-0142-9517 FU National Institutes of Health (NIH) [RC2CA148222, R01DK08288, R01HG004069, R01DK054111, P50CA127003, T32DK07477]; Crohn s and Colitis Foundation of America [1987] FX Supported by National Institutes of Health (NIH) grants RC2CA148222 and R01DK082889 (R A S) R01HG004069 (X S L) R01DK054111 (J C F) and P50CA127003 (Dana Farber/Harvard Cancer Center) and a gift from the Caring for Carcinoid Foundation (R A S) MPV was supported by NIH training grant T32DK07477 and Fellowship No 1987 from the Crohn s and Colitis Foundation of America We thank S Krasinski for critical appraisal of the work M Lemieux and Andrew Kung for helpful discussions S Robine for permission to use and E Martin for providing Villin CreER(T2) transgenic mice and P Gruss for permission to use and G Gilliland and S Koo for providing Cdx1-/- mice M P V and R AS conceived the study analyzed data and wrote the manuscript MPV RS and R K M performed experiments MPV HS HHH CAM JCF and X S L developed the algo rithms and performed computational analyses HS JCF MB and X S L interpreted data and edited the report NR 56 TC 105 Z9 106 U1 0 U2 1 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1534-5807 J9 DEV CELL JI Dev. Cell PD NOV 16 PY 2010 VL 19 IS 5 BP 713 EP 726 DI 10.1016/j.devcel.2010.10.006 PG 14 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA 683ZH UT WOS:000284516300012 PM 21074721 ER PT J AU Gladden, AB Hebert, AM Schneeberger, EE McClatchey, AI AF Gladden, Andrew B. Hebert, Alan M. Schneeberger, Eveline E. McClatchey, Andrea I. TI The NF2 Tumor Suppressor, Merlin, Regulates Epidermal Development through the Establishment of a Junctional Polarity Complex SO DEVELOPMENTAL CELL LA English DT Article ID MEDIATES CONTACT INHIBITION; CELL-CELL ADHESION; APICAL-DOMAIN SIZE; TIGHT JUNCTIONS; EPITHELIAL POLARITY; ADHERENS JUNCTIONS; BARRIER FUNCTION; NEUROFIBROMATOSIS TYPE-2; ALPHA-CATENIN; BETA-CATENIN AB The neurofibromatosis type 2 (NF2) tumor suppressor, Merlin, is a FERM (Four point one, Ezrin, Radixin, Moesin) domain-containing protein whose loss results in defective morphogenesis and tumorigenesis in multiple tissues Like the closely related ERM proteins (Ezrin, Radixin, and Moesin), Merlin may organize the plasma membrane by assembling membrane protein complexes and linking them to the cortical actin cytoskeleton We previously found that Merlin is a critical mediator of contact-dependent inhibition of proliferation and is required for the establishment of stable adherens junctions (AJs) in cultured cells Here, we delineate the molecular function of Merlin in AJ establishment in epidermal keratinocytes in vitro and confirm that a role in AJ establishment is an essential function of Merlin in vivo Our studies reveal that Merlin can associate directly with alpha-catenin and link it to Par3, thereby providing an essential link between the AJ and the Par3 polarity complex during junctional maturation C1 [Gladden, Andrew B.; Hebert, Alan M.; McClatchey, Andrea I.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA. [Gladden, Andrew B.; Hebert, Alan M.; McClatchey, Andrea I.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Schneeberger, Eveline E.] Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA. RP McClatchey, AI (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02129 USA. FU NRSA [5F32CA124030]; NIH [R01 CA113733, W81XWH 05 1 0189]; O Brien Trust FX We thank members of the McClatchey laboratory for helpful discussions and B Morgan for comments on the manuscript Par3 expression plasmids were graciously provided by I Macara (University of Virginia) We thank M Giovannini (House Ear Institute) for the Nf2loxllox mice T Pawson (Mount Sinai Hospital Toronto) for the aPKC expression plasmid W Weis (Stanford University) for GST AJ constructs and R Fehon (University of Chicago) for Ez and EzDelta actln expression plasmids The work was supported by an NRSA fellowship (5F32CA124030) awarded to A B G and by grants from the NIH (R01 CA113733) DOD (W81XWH 05 1 0189) and O Brien Trust awarded to A I M NR 73 TC 76 Z9 79 U1 0 U2 9 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1534-5807 J9 DEV CELL JI Dev. Cell PD NOV 16 PY 2010 VL 19 IS 5 BP 727 EP 739 DI 10.1016/j.devcel.2010.10.008 PG 13 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA 683ZH UT WOS:000284516300013 PM 21074722 ER PT J AU Smith, JG Newton-Cheh, C Almgren, P Struck, J Morgenthaler, NG Bergmann, A Platonov, PG Hedblad, B Engstrom, G Wang, TJ Melander, O AF Smith, J. Gustav Newton-Cheh, Christopher Almgren, Peter Struck, Joachim Morgenthaler, Nils G. Bergmann, Andreas Platonov, Pyotr G. Hedblad, Bo Engstroem, Gunnar Wang, Thomas J. Melander, Olle TI Assessment of Conventional Cardiovascular Risk Factors and Multiple Biomarkers for the Prediction of Incident Heart Failure and Atrial Fibrillation SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE atrial fibrillation; epidemiology; heart failure; natriuretic peptides; prediction; risk factors ID VENTRICULAR SYSTOLIC DYSFUNCTION; NATRIURETIC PEPTIDE; MYOCARDIAL-INFARCTION; LIFETIME RISK; FOLLOW-UP; COMMUNITY; EPIDEMIOLOGY; POPULATION; SURVIVAL; EVENTS AB Objectives The purpose of this study was to assess the predictive accuracy of conventional cardiovascular risk factors for incident heart failure and atrial fibrillation, and the added benefit of multiple biomarkers reflecting diverse pathophysiological pathways. Background Heart failure and atrial fibrillation are interrelated cardiac diseases associated with substantial morbidity and mortality and increasing incidence. Data on prediction and prevention of these diseases in healthy individuals are limited. Methods In 5,187 individuals from the community-based MDCS (Malmo Diet and Cancer Study), we studied the performance of conventional risk factors and 6 biomarkers including midregional pro-atrial natriuretic peptide (MR-proANP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-adrenomedullin, cystatin C, C-reactive protein (CRP), and copeptin. Results During a mean follow-up of 14 years, 112 individuals were diagnosed with heart failure and 284 individuals with atrial fibrillation. NT-proBNP (hazard ratio [HR]: 1.63 per SD, 95% confidence interval [CI]: 1.29 to 2.06, p < 0.001), CRP (HR: 1.57 per SD, 95% CI: 1.28 to 1.94, p < 0.001), and MR-proANP (HR: 1.26 per SD, 95% CI: 1.02 to 1.56, p = 0.03) predicted incident heart failure independently of conventional risk factors and other biomarkers. MR-proANP (HR: 1.62, 95% CI: 1.42 to 1.84, p < 0.001) and CRP (HR: 1.18, 95% CI: 1.03 to 1.34, p = 0.01) independently predicted atrial fibrillation. Addition of biomarkers to conventional risk factors improved c-statistics from 0.815 to 0.842 for heart failure and from 0.732 to 0.753 for atrial fibrillation and the integrated discrimination improvement for both diseases (p < 0.001). Net reclassification improvement (NRI) with biomarkers was observed in 22% of individuals for heart failure (NRI, p < 0.001) and in 7% for atrial fibrillation (NRI, p = 0.06), mainly due to up-classification of individuals who developed disease (heart failure: 29%, atrial fibrillation: 19%). Addition of CRP to natriuretic peptides did not improve discrimination or reclassification. Conclusions Conventional cardiovascular risk factors predict incident heart failure and atrial fibrillation with reasonable accuracy in middle-age individuals free from disease. Natriuretic peptides, but not other biomarkers, improve discrimination modestly for both diseases above and beyond conventional risk factors and substantially improve risk classification for heart failure. (J Am Coll Cardiol 2010;56:1712-9) (C) 2010 by the American College of Cardiology Foundation C1 Lund Univ, Dept Clin Sci, Malmo, Sweden. Lund Univ, Dept Cardiol, S-22185 Lund, Sweden. Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA USA. MIT, Cambridge, MA 02139 USA. Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Brahms AG, Res Dept, Hennigsdorf, Germany. RP Smith, JG (reprint author), Lund Univ, Dept Clin Sci, S-22185 Lund, Sweden. EM gustav.smith@med.lu.se FU Malmo city council; BRAHMS AG; Siemens Diagnostics; Swedish Heart-Lung Foundation; National Institutes of Health (NIH) [K23-HL-080025, R01-HL-086875, R01-HL-083197, R01-DK-081572]; Doris Duke Charitable Foundation; Wellcome Fund; Swedish NHS; American Heart Association; Swedish Medical Research Council; AstraZeneca RD; Medical Faculty of Lund University; Malmo University Hospital; Albert Pahlsson Research Foundation; Crafoord Foundation; Region Skane; Hulda; Conrad Mossfelt Foundation; King Gustaf V and Queen Victoria Fund; Lennart Hanssons Memorial Fund; Wallenberg Foundation FX The Malmo Diet and Cancer study was made possible by grants from the Malmo city council. Biomarker measurements were performed and funded by BRAHMS AG and Siemens Diagnostics. Drs. Smith, Platonov, Hedblad, Engstrom, and Melander were supported by the Swedish Heart-Lung Foundation. Dr. Newton-Cheh was supported by National Institutes of Health (NIH) grant K23-HL-080025, a Doris Duke Charitable Foundation Clinical Scientist Development Award, a Burroughs Wellcome Fund Career Award for Medical Scientists, and served on the advisory board for Merck. Dr. Platonov was supported by the governmental funding of clinical research within the Swedish NHS. Dr. Wang was supported by NIH grants R01-HL-086875, R01-HL-083197, and R01-DK-081572 and by a grant from the American Heart Association. Drs. Hedblad and Melander were supported by the Swedish Medical Research Council. Dr. Engstrom is employed by AstraZeneca R&D. Dr. Melander was supported by grants from the Medical Faculty of Lund University, Malmo University Hospital, the Albert Pahlsson Research Foundation, the Crafoord Foundation, the Region Skane, the Hulda and Conrad Mossfelt Foundation, the King Gustaf V and Queen Victoria Fund, the Lennart Hanssons Memorial Fund, and the Wallenberg Foundation. Drs. Struck, Morgenthaler, and Bergmann are employees of Brahms AG, which holds patent rights on the assays used for MR-proADM, MR-proANP, and Copeptin. Drs. Wang and Melander contributed equally to this work. NR 39 TC 11 Z9 11 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 16 PY 2010 VL 56 IS 21 BP 1713 EP 1719 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 678GT UT WOS:000284062800006 ER PT J AU Elmariah, S Delaney, JAC O'Brien, KD Budoff, MJ Vogel-Claussen, J Fuster, V Kronmal, RA Halperin, JL AF Elmariah, Sammy Delaney, Joseph A. C. O'Brien, Kevin D. Budoff, Matthew J. Vogel-Claussen, Jens Fuster, Valentin Kronmal, Richard A. Halperin, Jonathan L. TI Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE bisphosphonate; calcification; coronary artery; valve; vascular ID DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-ARTERY CALCIUM; AORTIC-VALVE; POSTMENOPAUSAL OSTEOPOROSIS; ANNULAR CALCIFICATION; CARDIOVASCULAR EVENTS; COMPUTED-TOMOGRAPHY; BONE-DENSITY; DISEASE; ASSOCIATION AB Objectives The aim of this study was to determine whether nitrogen-containing bisphosphonate (NCBP) therapy is associated with the prevalence of cardiovascular calcification. Background Cardiovascular calcification correlates with atherosclerotic disease burden. Experimental data suggest that NCBP might limit cardiovascular calcification, which has implications for disease prevention. Methods The relationship of NCBP use to the prevalence of aortic valve, aortic valve ring, mitral annulus, thoracic aorta, and coronary artery calcification (AVC, AVRC, MAC, TAC, and CAC, respectively) detected by computed tomography was assessed in 3,710 women within the MESA (Multi-Ethnic Study of Atherosclerosis) with regression modeling. Results Analyses were age-stratified, because of a significant interaction between age and NCBP use (interaction p values: AVC p < 0.0001; AVRC p < 0.0001; MAC p = 0.002; TAC p < 0.0001; CAC p = 0.046). After adjusting for age; body mass index; demographic data; diabetes; smoking; blood pressure; cholesterol levels; and statin, hormone replacement, and renin-angiotensin inhibitor therapy, NCBP use was associated with a lower prevalence of cardiovascular calcification in women >= 65 years of age (prevalence ratio: AVC 0.68 [95% confidence interval (CI): 0.41 to 1.13]; AVRC 0.65 [95% CI: 0.51 to 0.84]; MAC 0.54 [95% CI: 0.33 to 0.93]; TAC 0.69 [95% CI: 0.54 to 0.88]; CAC 0.89 [95% CI: 0.78 to 1.02]), whereas calcification was more prevalent in NCBP users among the 2,181 women <65 years of age (AVC 4.00 [95% CI: 2.33 to 6.89]; AVRC 1.92 [95% CI: 1.42 to 2.61]; MAC 2.35 [95% CI: 1.12 to 4.84]; TAC 2.17 [95% CI: 1.49 to 3.15]; CAC 1.23 [95% CI: 0.97 to 1.57]). Conclusions Among women in the diverse MESA cohort, NCBPs were associated with decreased prevalence of cardiovascular calcification in older subjects but more prevalent cardiovascular calcification in younger ones. Further study is warranted to clarify these age-dependent NCBP effects. (J Am Coll Cardiol 2010;56:1752-9) (C) 2010 by the American College of Cardiology Foundation C1 [Elmariah, Sammy] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02114 USA. [Elmariah, Sammy; Fuster, Valentin; Halperin, Jonathan L.] Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA. [Delaney, Joseph A. C.] Univ Florida, Dept Pharmaceut Outcomes & Policy, Gainesville, FL USA. [O'Brien, Kevin D.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA. [Budoff, Matthew J.] Harbour UCLA, Div Cardiol, Los Angeles Biomed Res Inst, Torrance, CA USA. [Vogel-Claussen, Jens] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD USA. [Fuster, Valentin] CNIC, Madrid, Spain. [Kronmal, Richard A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Elmariah, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02114 USA. EM selmariah@partners.org RI Fuster, Valentin/H-4319-2015 OI Fuster, Valentin/0000-0002-9043-9986 FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169, T32 HL007824]; Glorney-Raisbeck Fellowship Program; Corlette Glorney Foundation; New York Academy of Medicine; Education Foundation for Cardiovascular Disease; GlaxoSmithKline; Abbott Laboratories; National Institute of Diabetes and Kidney Diseases; BG Medicine; Astellas Pharma; Bayer AG Healthcare; Bristol-Myers Squibb/Sanofi Partnership; Boehringer-Ingelheim; Daiichi Sankyo; Johnson Johnson; Sanofi-Aventis; Biotronik FX MESA was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute. Dr. Elmariah is supported by the Glorney-Raisbeck Fellowship Program, Corlette Glorney Foundation, the New York Academy of Medicine, GlaxoSmithKline Research, and Education Foundation for Cardiovascular Disease, and by a grant from the National Heart, Lung, and Blood Institute (T32 HL007824). Dr. Elmariah receives grant support from the New York Academy of Medicine, the National Heart, Lung, and Blood Institute, and GlaxoSmithKline. Dr. O'Brien has received grants from Abbott Laboratories, the National Heart, Lung, and Blood Institute, and the National Institute of Diabetes and Kidney Diseases; receives speaker honoraria from AstraZeneca, Merck, and Sanofi-Aventis; and is a consultant for Boehringer-Ingelheim, Merck, and Novartis. Dr. Budoff has a modest consulting agreement with the General Electric Company. Dr. Fuster receives grant support from the National Heart, Lung, and Blood Institute and chairs the HRP study, which is funded by BG Medicine. Dr. Halperin receives consulting fees from Astellas Pharma, Bayer AG Healthcare, the Bristol-Myers Squibb/Sanofi Partnership, Boehringer-Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Sanofi-Aventis; honoraria from Genzyme and Portola Pharmaceuticals; and is co-chairman of the IMPACT of BIOTRONIK Home Monitoring Guided Anticoagulation on Stroke Risk in Patients With Implanted ICD and CRT-D Devices, which is sponsored by Biotronik. All other authors have reported that they have no relationships to disclose. NR 41 TC 47 Z9 47 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 16 PY 2010 VL 56 IS 21 BP 1752 EP 1759 DI 10.1016/j.jacc.2010.05.050 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 678GT UT WOS:000284062800012 PM 21070928 ER PT J AU Zyloney, CE Jensen, K Polich, G Loiotile, RE Cheetham, A LaViolette, PS Tu, PC Kaptchuk, TJ Gollub, RL Kong, JA AF Zyloney, Carolyn E. Jensen, Karin Polich, Ginger Loiotile, Rita E. Cheetham, Alexandra LaViolette, Peter S. Tu, Peichi Kaptchuk, Ted J. Gollub, Randy L. Kong, Jian TI Imaging the functional connectivity of the Periaqueductal Gray during genuine and sham electroacupuncture treatment SO MOLECULAR PAIN LA English DT Article ID LOW-BACK-PAIN; RANDOMIZED CONTROLLED-TRIAL; RESTING HUMAN BRAIN; PLACEBO ANALGESIA; ELECTRICAL-STIMULATION; ACUPUNCTURE TREATMENT; SPONTANEOUS FLUCTUATIONS; ACUPOINT STIMULATION; IMPLICATED ACUPOINTS; DEFAULT MODE AB Background: Electroacupuncture (EA) is currently one of the most popular acupuncture modalities. However, the continuous stimulation characteristic of EA treatment presents challenges to the use of conventional functional Magnetic Resonance Imaging (fMRI) approaches for the investigation of neural mechanisms mediating treatment response because of the requirement for brief and intermittent stimuli in event related or block designed task paradigms. A relatively new analysis method, functional connectivity fMRI (fcMRI), has great potential for studying continuous treatment modalities such as EA. In a previous study, we found that, compared with sham acupuncture, EA can significantly reduce Periaqueductal Gray (PAG) activity when subsequently evoked by experimental pain. Given the PAG's important role in mediating acupuncture analgesia, in this study we investigated functional connectivity with the area of the PAG we previously identified and how that connectivity was affected by genuine and sham EA. Results: Forty-eight subjects, who were randomly assigned to receive either genuine or sham EA paired with either a high or low expectancy manipulation, completed the study. Direct comparison of each treatment mode's functional connectivity revealed: significantly greater connectivity between the PAG, left posterior cingulate cortex (PCC), and precuneus for the contrast of genuine minus sham; significantly greater connectivity between the PAG and right anterior insula for the contrast of sham minus genuine; no significant differences in connectivity between different contrasts of the two expectancy levels. Conclusions: Our findings indicate the intrinsic functional connectivity changes among key brain regions in the pain matrix and default mode network during genuine EA compared with sham EA. We speculate that continuous genuine EA stimulation can modify the coupling of spontaneous activity in brain regions that play a role in modulating pain perception. C1 [Zyloney, Carolyn E.; Jensen, Karin; Polich, Ginger; Loiotile, Rita E.; Cheetham, Alexandra; LaViolette, Peter S.; Gollub, Randy L.; Kong, Jian] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Tu, Peichi; Gollub, Randy L.; Kong, Jian] Harvard Univ, Sch Med, MIT, MGH,Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Kaptchuk, Ted J.] Harvard Univ, Osher Res Ctr, Sch Med, Charlestown, MA USA. RP Zyloney, CE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. EM czyloney@gmail.com; kongj@nmr.mgh.harvard.edu RI Jensen, Karin/G-6360-2012; OI Gollub, Randy L./0000-0002-9434-4044; Jensen, Karin/0000-0003-2521-3160 FU National Center for Complimentary and Alternative Medicine (NCCAM) [PO1-AT002048, R01 AT005280, R21 AT00949, KO1 AT003883, R21 AT004497, K24 AT004095]; National Center for Research Resources (NCRR) [M01-RR-01066, UL1 RR025758- 01, P41 RR14075] FX This work was supported by PO1-AT002048 to Bruce Rosen from National Center for Complimentary and Alternative Medicine (NCCAM), R01 AT005280 and R21 AT00949 to Randy Gollub from NCCAM, KO1 AT003883 and R21 AT004497 to Jian Kong from NCCAM, K24 AT004095 to Ted Kaptchuk from NCCAM, M01-RR-01066 and UL1 RR025758- 01 for Clinical Research Center Biomedical Imaging Core from National Center for Research Resources (NCRR), and P41 RR14075 for Center for Functional Neuroimaging Technologies from NCRR. NR 97 TC 29 Z9 37 U1 0 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1744-8069 J9 MOL PAIN JI Mol. Pain PD NOV 16 PY 2010 VL 6 AR 80 DI 10.1186/1744-8069-6-80 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 686NZ UT WOS:000284704300001 PM 21080967 ER PT J AU Kojima, Y Acar, A Eaton, EN Mellody, KT Scheel, C Ben-Porath, I Onder, TT Wang, ZC Richardson, AL Weinberg, RA Orimo, A AF Kojima, Yasushi Acar, Ahmet Eaton, Elinor Ng Mellody, Kieran T. Scheel, Christina Ben-Porath, Ittai Onder, Tamer T. Wang, Zhigang C. Richardson, Andrea L. Weinberg, Robert A. Orimo, Akira TI Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE CXCR4; Smad; tumor microenvironment; alpha-smooth muscle actin ID CARCINOMA-ASSOCIATED FIBROBLASTS; HUMAN-BREAST-CANCER; GROWTH-FACTOR-BETA; MESENCHYMAL STEM-CELLS; SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH-FACTOR-BETA-1; PROGRESSION; DIFFERENTIATION; ANGIOGENESIS; TRANSITION AB Much interest is currently focused on the emerging role of tumor-stroma interactions essential for supporting tumor progression. Carcinoma-associated fibroblasts (CAFs), frequently present in the stroma of human breast carcinomas, include a large number of myofibroblasts, a hallmark of activated fibroblasts. These fibroblasts have an ability to substantially promote tumorigenesis. However, the precise cellular origins of CAFs and the molecular mechanisms by which these cells evolve into tumor-promoting myofibroblasts remain unclear. Using a coimplantation breast tumor xenograft model, we show that resident human mammary fibroblasts progressively convert into CAF myofibroblasts during the course of tumor progression. These cells increasingly acquire two autocrine signaling loops, mediated by TGF-beta and SDF-1 cytokines, which both act in autostimulatory and cross-communicating fashions. These autocrine-signaling loops initiate and maintain the differentiation of fibroblasts into myofibroblasts and the concurrent tumor-promoting phenotype. Collectively, these findings indicate that the establishment of the self-sustaining TGF-beta and SDF-1 autocrine signaling gives rise to tumor-promoting CAF myofibroblasts during tumor progression. This autocrine-signaling mechanism may prove to be an attractive therapeutic target to block the evolution of tumor-promoting CAFs. C1 [Eaton, Elinor Ng; Scheel, Christina; Ben-Porath, Ittai; Onder, Tamer T.; Weinberg, Robert A.; Orimo, Akira] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Kojima, Yasushi; Acar, Ahmet; Mellody, Kieran T.; Orimo, Akira] Univ Manchester, Paterson Inst Canc Res, Canc Res UK Stromal Tumor Interact Grp, Manchester M20 4BX, Lancs, England. [Onder, Tamer T.; Weinberg, Robert A.] MIT, Dept Biol, Cambridge, MA 02139 USA. [Wang, Zhigang C.] Dana Farber Canc Inst, Dept Canc Biol, Cambridge, MA 02139 USA. [Richardson, Andrea L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Cambridge, MA 02139 USA. [Weinberg, Robert A.] MIT Ludwig Ctr Mol Oncol, Cambridge, MA 02139 USA. RP Weinberg, RA (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA. EM weinberg@wi.mit.edu; aorimo@picr.man.ac.uk RI Onder, Tamer /H-3330-2013; OI Onder, Tamer /0000-0002-2372-9158; Mellody, Kieran/0000-0002-8164-9148 FU National Institutes of Health/National Cancer Institute [R21CA87081-02]; German Academic Exchange Service; National Institutes of Health [P01 CA080111, R01 CA078461]; Breast Cancer Research Foundation; Massachusetts Institute of Technology; Cancer Research UK [C147/A6058] FX We thank Drs. Joseph Sodroski, Daniel Rifkin, Lalage Wakefield, and Luciano Zardi for reagents; Garry Ashton, Dr. Tsukasa Shibue, and Paul Chantry for technical assistance; Dr. David Sabatini for useful discussion; Dr. Nic Jones for critical reading of this manuscript; and members of R.A.W.'s and A.O.'s laboratories. This work was conducted using the core facility at the Paterson Institute of Cancer Research and the W. M. Keck Foundation Biological Imaging Facility at the Whitehead Institute. This work was supported by National Institutes of Health/National Cancer Institute Grant R21CA87081-02 (to R. A. W.), the German Academic Exchange Service (C. S.), National Institutes of Health Grants P01 CA080111 and R01 CA078461 (to R. A. W.), the Breast Cancer Research Foundation (R. A. W.), the Massachusetts Institute of Technology/Ludwig Fund for Cancer Research (to R. A. W.), and Cancer Research UK Grant C147/A6058 (to A.O.). R. A. W. is an American Cancer Society Research Professor and a Daniel K. Ludwig Cancer Research Professor. NR 57 TC 234 Z9 239 U1 5 U2 34 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 16 PY 2010 VL 107 IS 46 BP 20009 EP 20014 DI 10.1073/pnas.1013805107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 680UT UT WOS:000284261800074 PM 21041659 ER PT J AU Miao, BC Skidan, I Yang, JS Lugovskoy, A Reibarkh, M Long, K Brazell, T Durugkar, KA Maki, J Ramana, CV Schaffhausen, B Wagner, G Torchilin, V Yuan, JY Degterev, A AF Miao, Benchun Skidan, Igor Yang, Jinsheng Lugovskoy, Alexey Reibarkh, Mikhail Long, Kai Brazell, Tres Durugkar, Kulbhushan A. Maki, Jenny Ramana, C. V. Schaffhausen, Brian Wagner, Gerhard Torchilin, Vladimir Yuan, Junying Degterev, Alexei TI Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE PIP3 antagonist; anticancer ID APOPTOSIS-INDUCING LIGAND; PROTEIN-KINASE B/AKT; HUMAN CANCER; PLASMA-MEMBRANE; AKT; CELLS; PATHWAY; RECOGNITION; RECRUITMENT; AUTOPHAGY AB The PI3-kinase (PI3K) pathway regulates many cellular processes, especially cell metabolism, cell survival, and apoptosis. Phosphatidylinositol-3,4,5-trisphosphate (PIP3), the product of PI3K activity and a key signaling molecule, acts by recruiting pleckstrin-homology (PH) domain-containing proteins to cell membranes. Here, we describe a new structural class of nonphosphoinositide small molecule antagonists (PITenins, PITs) of PIP3-PH domain interactions (IC50 ranges from 13.4 to 31 mu M in PIP3/Akt PH domain binding assay). PITs inhibit interactions of a number of PIP3-binding PH domains, including those of Akt and PDK1, without affecting several PIP2-selective PH domains. As a result, PITs suppress the PI3K-PDK1-Akt pathway and trigger metabolic stress and apoptosis. A PIT-1 analog displayed significant antitumor activity in vivo, including inhibition of tumor growth and induction of apoptosis. Overall, our studies demonstrate the feasibility of developing specific small molecule antagonists of PIP3 signaling. C1 [Miao, Benchun; Brazell, Tres; Maki, Jenny; Schaffhausen, Brian; Degterev, Alexei] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA. [Skidan, Igor; Torchilin, Vladimir] Northeastern Univ, Dept Pharmaceut Sci, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA. [Yang, Jinsheng] Harvard Univ, Sch Med, Neurosci Ctr, Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Durugkar, Kulbhushan A.; Ramana, C. V.] Natl Chem Lab, Pune 411008, Maharashtra, India. [Lugovskoy, Alexey; Reibarkh, Mikhail; Wagner, Gerhard] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Long, Kai; Yuan, Junying] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. RP Degterev, A (reprint author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA. EM alexei.degterev@tufts.edu RI Venkata Ramana, Chepuri/F-9735-2010 OI Venkata Ramana, Chepuri/0000-0001-5801-311X FU Smith Family Award for Excellence in Biomedical Research; National Institute on Aging [R37 AG012859]; US Army [DAMD17-02-1-0403]; National Cancer Institute [RO1 CA34722, PO1-50661] FX We thank Dr. Joan Brugge (Harvard Medical School, Boston), Dr. Or Gozani (Stanford University, Stanford, CA), Dr. Tamas Balla (National Institutes of Health, Bethesda, MD), Dr. Stanley Korsmeyer (Dana Farber Cancer Center, Boston), Dr. Philip Tsichlis (Tufts Medical Center, Boston), and Dr. Aaron J. Marshall (University of Manitoba, Winnipeg, MB, Canada) for the gifts of plasmids and cells. We thank Albert Tai for help with SPR assay. This work was supported by a Smith Family Award for Excellence in Biomedical Research and National Institute on Aging Mentored Research Scientist Career Development Award (to A.D.), an Innovator Award from the US Army (DAMD17-02-1-0403), the National Cancer Institute (RO1 CA34722/PO1-50661) (to B.S.), and the National Institute on Aging (R37 AG012859) (to J.Y.). NR 31 TC 60 Z9 61 U1 1 U2 24 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 16 PY 2010 VL 107 IS 46 BP 20126 EP 20131 DI 10.1073/pnas.1004522107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 680UT UT WOS:000284261800094 PM 21041639 ER PT J AU Spiegel, BMR Bolus, R Agarwal, N Sayuk, G Harris, LA Lucak, S Esrailian, E Chey, WD Lembo, A Karsan, H Tillisch, K Talley, J Chang, L AF Spiegel, B. M. R. Bolus, R. Agarwal, N. Sayuk, G. Harris, L. A. Lucak, S. Esrailian, E. Chey, W. D. Lembo, A. Karsan, H. Tillisch, K. Talley, J. Chang, L. TI Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID QUALITY-OF-LIFE; INFORMATION-SYSTEM PROMIS; END-POINTS; GASTROINTESTINAL SYMPTOMS; OUTCOME MEASURES; WEEKLY PAIN; QUESTIONNAIRE; VALIDATION; DISORDERS; DISEASE AB P>Background There is uncertainty about how to measure patient-reported outcomes (PROs) in IBS. The Food and Drug Administration (FDA) emphasizes that PROs must be couched in a conceptual framework, yet existing IBS PROs were not based on such a framework. Aim To perform qualitative analyses to inform a new conceptual framework for IBS symptoms. Methods Following FDA guidance, we searched the literature for extant IBS questionnaires. We then performed interviews in IBS patients to learn about the illness experience in their own words. We cultivated vocabulary to inform a conceptual framework depicted with domains, sub-domains, and item categories, per FDA guidance. Results We identified 13 questionnaires with items encompassing 18 symptoms. We recruited 123 IBS patients for cognitive interviews. Major themes included: pain and discomfort are different - asking about discomfort is nonspecific and should be avoided in future PROs; bowel urgency is multifaceted - PROs should measure bowel immediacy, controllability, and predictability; and PROs should divide bloating into how it feels vs. how it looks. Symptom experience may be determined by 35-item categories within five domains: (i) pain; (ii) gas/bloat; (iii) diarrhoea; (iv) constipation; and (v) extraintestinal symptoms. Conclusions We applied FDA guidance to develop a framework that can serve as the foundation for developing a PRO for IBS clinical trials. C1 [Spiegel, B. M. R.; Talley, J.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Spiegel, B. M. R.; Bolus, R.; Esrailian, E.; Tillisch, K.; Chang, L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Spiegel, B. M. R.; Bolus, R.; Tillisch, K.; Chang, L.] UCLA Ctr Neurobiol Stress, Los Angeles, CA USA. [Spiegel, B. M. R.; Bolus, R.; Agarwal, N.; Esrailian, E.; Talley, J.] UCLA VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA USA. [Sayuk, G.; Chang, L.] Washington Univ, Dept Gastroenterol, St Louis, MO USA. [Harris, L. A.] Mayo Clin, Div Gastronenterol & Hepatol, Scottsdale, AZ USA. [Lucak, S.] Columbia Univ, Dept Gastroenterol, New York, NY USA. [Chey, W. D.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Lembo, A.] Harvard Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA. [Karsan, H.] Atlanta Gastroenterol Associates, Atlanta, GA USA. RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU Prometheus; Takeda North America; Rose Pharma A/G; Shire Pharmaceuticals; NIH [1K23DK084113]; Takeda; Rose Pharma and Prometheus; Danone Research; International Foundation for Functional Gastrointestinal Disorders (IFFGD) FX The authors wish to thank Bradley Snyder for his graphic design assistance in preparing the conceptual model image for this manuscript. Declaration of personal interests: Dr Spiegel has served as an advisor for Prometheus, Johnson and Johnson, Ironwood, Shire Pharmaceuticals, Salix Pharmaceuticals and AstraZeneca. He has received grants from Prometheus, Takeda North America, Rose Pharma A/G and Shire Pharmaceuticals. Dr Chey has served as a consultant for Albireo, AstraZeneca, Axcan, Ironwood, Movetis, Proctor & Gamble, Prometheus, Smartpill Corp, Salix, Santarus, Takeda and Xenoport. Dr Sayuk has received research funding from NIH 1K23DK084113. Dr Bolus has received grants from Prometheus, Takeda North America and Rose Pharma A/G via Dr. Spiegel's team. Dr Chang has received grant support from Takeda, Rose Pharma and Prometheus. She has served as a consultant for Prometheus Laboratories, Takeda, Forest, Albireo, McNeil, Rose Pharma, GlaxoSmithKline, Ironwood, Novartis, Salix, Ocera and Movetis. Dr Tillisch has received funding from Danone Research. Dr Esrailian has served as an advisory board member and speaker for Salix Pharmaceuticals. Dr Harris has served as a consultant for Salix, Prometheus, Proctor & Gamble, Ironwood & Takeda. Declaration of funding interests: This study was supported by an investigator-initiated research grant by Takeda Pharmaceuticals North America, Inc. It was also supported, in part, by a Junior Investigator Award from the International Foundation for Functional Gastrointestinal Disorders (IFFGD) to Dr Spiegel. NR 46 TC 25 Z9 25 U1 3 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD NOV 15 PY 2010 VL 32 IS 10 BP 1275 EP 1291 DI 10.1111/j.1365-2036.2010.04464.x PG 17 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 667AI UT WOS:000283164400008 PM 20955447 ER PT J AU Forman, DE Chen, AY Wiviott, SD Wang, TY Magid, DJ Alexander, KP AF Forman, Daniel E. Chen, Anita Y. Wiviott, Stephen D. Wang, Tracy Y. Magid, David J. Alexander, Karen P. TI Comparison of Outcomes in Patients Aged < 75, 75 to 84, and >= 85 Years With ST-Elevation Myocardial Infarction (from the ACTION Registry-GWTG) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE CORONARY SYNDROMES; HEART-ASSOCIATION COUNCIL; HEALTH-CARE PROFESSIONALS; IN-HOSPITAL MORTALITY; REPERFUSION THERAPY; THROMBOLYTIC THERAPY; QUALITY IMPROVEMENT; PRIMARY ANGIOPLASTY; SCIENTIFIC STATEMENT; GERIATRIC-CARDIOLOGY AB ST-segment elevation myocardial infarction (STEMI) is common in older adults and has high age-related mortality. We describe contemporary STEMI care using the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Network Registry Get With The Guidelines (ACTION-GWTG) database. Patients with STEMI (n = 30,188) from 285 ACTION-GWTG sites from January 1, 2007 to June 30, 2008 were grouped by age (<75, 75 to 84, and >= 85 years) to compare baseline characteristics, reperfusion, and in-hospital outcomes. In this population, 79.7% (24,070) were <75 years old, 14.2% (4,273) were 75 to 84 years old, and 6.1% (1,845) were >= 85 years old (the oldest old). Compared to younger patients, the oldest-old patients (median age 88 years, inter-quartile range 86 to 91) were more often women, had more hypertension, and end-organ co-morbidity (heart failure and stroke, p < 0.0001 for all). More than 42% of the oldest old were also cited as having contraindications to reperfusion, but with absolute or relative contraindications noted in only 10%, and patient preference was the most common reason indicated (45%). Even in reperfusion-eligible patients, the oldest old were less likely to receive it. Although patients who received reperfusion had better outcomes than those who did not, this was significant only for younger patients (<75 years old, odds ratio 0.58, confidence interval 0.40 to 0.84). In conclusion, >42% of the oldest old have reported contraindications to reperfusion, with neither mortality benefit nor harm in those who receive it. Disparities in process of care and co-morbidity may explain these observational findings. Whether efforts to optimize patient selection and initiate reperfusion therapy can improve outcomes in the oldest old with STEMI is unknown. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;106:1382-1388) C1 [Forman, Daniel E.; Wiviott, Stephen D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Forman, Daniel E.; Wang, Tracy Y.; Alexander, Karen P.] VA Boston Healthcare Syst, Boston, MA USA. [Chen, Anita Y.] Duke Clin Res Inst, Durham, NC USA. [Wang, Tracy Y.; Alexander, Karen P.] Duke Univ, Med Ctr, Durham, NC USA. [Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Magid, David J.] Univ Colorado Denver Hlth Sci, Denver, CO USA. RP Forman, DE (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM deforman@partners.org FU Schering-Plough Corporation, Whitehouse Station, New Jersey; Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership, New York, New York FX The ACTION Registry-GWTG is a program of the National Cardiovascular Data Registry with support from the American College of Cardiology and the American Heart Association that receives funding by the Schering-Plough Corporation, Whitehouse Station, New Jersey, and Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership, New York, New York. NR 30 TC 14 Z9 14 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD NOV 15 PY 2010 VL 106 IS 10 BP 1382 EP 1388 DI 10.1016/j.amjcard.2010.07.008 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 686DK UT WOS:000284676800003 PM 21059425 ER PT J AU Chen-Tournoux, A Khan, AM Baggish, AL Castro, VM Semigran, MJ McCabe, EL Moukarbel, G Reingold, J Durrani, S Lewis, GD Newton-Cheh, C Scherrer-Crosbie, M Kaplan, LM Wang, TJ AF Chen-Tournoux, Annabel Khan, Abigail May Baggish, Aaron L. Castro, Victor M. Semigran, Marc J. McCabe, Elizabeth L. Moukarbel, George Reingold, Jason Durrani, Sofia Lewis, Gregory D. Newton-Cheh, Christopher Scherrer-Crosbie, Marielle Kaplan, Lee M. Wang, Thomas J. TI Effect of Weight Loss After Weight Loss Surgery on Plasma N-Terminal Pro-B-Type Natriuretic Peptide Levels SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID BODY-MASS-INDEX; LEFT-VENTRICULAR FUNCTION; OBESE-PATIENTS; HEART-FAILURE; MORBIDLY OBESE; WALL THICKNESS; EXPRESSION; INTERVENTION; DYSFUNCTION; ADIPOSE AB Natriuretic peptides have multiple beneficial cardiovascular effects. Previous cross-sectional studies have indicated that obese subjects have lower natriuretic peptide concentrations than those of normal weight. It is not known whether this relative natriuretic peptide deficiency is reversible with weight loss. We studied 132 obese subjects undergoing weight loss surgery with serial measurement of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations at preoperative, early (1 to 2 months), and late postoperative (6 months) points. In addition, 20 subjects also underwent echocardiography at baseline and 6 months after surgery. Significant weight loss was observed after surgery (median body mass index 45.1, 41.0, and 32.9 kg/m(2) for the 3 corresponding points, analysis of variance p < 0.001). The median NT-proBNP levels increased substantially (31.6, 66.9, and 84.9 pg/ml; p < 0.001). The average intrasubject increase in NT-proBNP at the 2 postoperative points was 3.4 and 5.0 times the preoperative level (p < 0.001 for both points vs preoperatively). In the multivariate regression models adjusted for clinical characteristics and insulin resistance, the strongest predictor of the change in NT-proBNP level 6 months after weight loss surgery was the change in weight (p = 0.03). Echocardiography showed a mean intrasubject reduction in left ventricular mass index of 18% (p < 0.001) and mild improvements in diastolic function, with no change in ejection fraction. In conclusion, we have demonstrated that weight loss is associated with early and sustained increases in NT-proBNP concentrations, despite evidence of preserved systolic and improved diastolic function. These findings suggest a direct, reversible relation between obesity and reduced natriuretic peptide levels. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010; 106:1450-1455) C1 [Chen-Tournoux, Annabel; Khan, Abigail May; Baggish, Aaron L.; Semigran, Marc J.; McCabe, Elizabeth L.; Moukarbel, George; Reingold, Jason; Lewis, Gregory D.; Newton-Cheh, Christopher; Scherrer-Crosbie, Marielle; Wang, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Cardiol Div, Boston, MA 02115 USA. [Castro, Victor M.; Durrani, Sofia; Kaplan, Lee M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Weight Ctr, Boston, MA USA. RP Wang, TJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Cardiol Div, Boston, MA 02115 USA. EM tjwang@partners.org FU National Institutes of Health, Bethesda, Maryland [R01-HL-086875]; National Heart, Lung, and Blood Institute (Bethesda, Maryland); Doris Duke Charitable Foundation (New York, New York); Burroughs Wellcome Fund Career Award for Medical Scientists (Research Triangle Park, North Carolina) FX This study was supported in part by grant R01-HL-086875 from the National Institutes of Health, Bethesda, Maryland. Dr. Newton-Cheh was supported by a K23 grant from the National Heart, Lung, and Blood Institute (Bethesda, Maryland), Doris Duke Charitable Foundation Clinical Scientist Development Award (New York, New York) and Burroughs Wellcome Fund Career Award for Medical Scientists (Research Triangle Park, North Carolina). NR 30 TC 25 Z9 25 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD NOV 15 PY 2010 VL 106 IS 10 BP 1450 EP 1455 DI 10.1016/j.amjcard.2010.06.076 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 686DK UT WOS:000284676800013 PM 21059435 ER PT J AU Seetharaman, SV Taylor, AB Holloway, S Hart, PJ AF Seetharaman, Sai V. Taylor, Alexander B. Holloway, Stephen Hart, P. John TI Structures of mouse SOD1 and human/mouse SOD1 chimeras SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE Copper-zinc superoxide dismutase; Amyotrophic lateral sclerosis; X-ray crystallography; Protein aggregation ID AMYOTROPHIC-LATERAL-SCLEROSIS; ZINC SUPEROXIDE-DISMUTASE; MOTOR-NEURON DISEASE; WILD-TYPE; TRANSGENIC MICE; POSTTRANSLATIONAL MODIFICATIONS; ATOMIC STRUCTURES; CRYSTAL-STRUCTURE; COPPER CHAPERONE; FAMILIAL ALS AB Mutations in human copper-zinc superoxide dismutase (SOD1) cause an inherited form of amyotrophic lateral sclerosis (ALS). Inclusions enriched in pathogenic SOD1 accumulate in the spinal cords of transgenic mice expressing these proteins, but endogenous mouse SOD1 is not found as a component of these aggregates. In the accompanying paper, Karch and colleagues analyze aggregation propensities of human/mouse SOD1 chimeras in cell culture and identify two sequence elements in the human enzyme that seem to enhance its aggregation relative to the mouse enzyme. Here, we report the first structure of mouse SOD1 along with those of SOD1 chimeras in which residues 1-80 come from human SOD1 and residues 81-153 come from mouse SOD1 and vice versa. Taken together, the structural and cell-based data suggest a model in which residues Q42 and Q123 in mouse SOD1 modulate non-native SOD1-SOD1 intermolecular interactions at edge strands in the SOD1 Greek key beta-barrel. (C) 2010 Elsevier Inc. All rights reserved. C1 [Seetharaman, Sai V.; Taylor, Alexander B.; Holloway, Stephen; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, XRay Crystallog Core Lab, San Antonio, TX 78229 USA. [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM pjhart@biochem.uthscsa.edu FU NIH-NINDS [R01-NS39112, P01-NS04913]; William and Ella Owens Medical Research Foundation; Judith and Jean Pape Adams Charitable Foundation; X-ray Crystallography Core Laboratory; UTHSCSA FX This work was supported by Grants from the NIH-NINDS R01-NS39112 (to PJH), P01-NS04913 (to JSV, DRB, and PJH). SVS was supported in part by the William and Ella Owens Medical Research Foundation and the Judith and Jean Pape Adams Charitable Foundation. Support for the X-ray Crystallography Core Laboratory by the UTHSCSA Executive Research Committee and the San Antonio Cancer Institute is also gratefully acknowledged. We thank Celeste Karch, Mercedes Prudencio, and David Borchelt for continued collaboration and invaluable insight into the biological aspects of aggregation of SOD1 and the SOD1 chimera structures described in this paper. NR 62 TC 7 Z9 10 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD NOV 15 PY 2010 VL 503 IS 2 BP 183 EP 190 DI 10.1016/j.abb.2010.08.014 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 662JU UT WOS:000282804400003 PM 20727846 ER PT J AU Grimmer, T Tholen, S Yousefi, BH Alexopoulos, P Forschler, A Forstl, H Henriksen, G Klunk, WE Mathis, CA Perneczky, R Sorg, C Kurz, A Drzezga, A AF Grimmer, Timo Tholen, Susanne Yousefi, Behrooz H. Alexopoulos, Panagiotis Forschler, Annette Forstl, Hans Henriksen, Gjermund Klunk, William E. Mathis, Chester A. Perneczky, Robert Sorg, Christian Kurz, Alexander Drzezga, Alexander TI Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E epsilon 4 Genotype in Alzheimer's Disease SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Alzheimer's disease; apolipoprotein E; Pittsburgh Compound B; positron emission tomography; prospective study ID CLINICAL-DIAGNOSIS; HUMAN BRAIN; PET; DEMENTIA; PIB; DEPOSITION; CRITERIA; DECLINE; ALLELE; MEMORY AB Background Pittsburgh Compound B ([(11)C]PiB) is a specific positron emission tomography (PET) marker of cerebral amyloid deposits Only few data have been published on in vivo longitudinal changes of amyloid load in Alzheimer's disease (AD) patients with conflicting results Therefore, little is known about the factors that influence these changes Methods A group of 24 patients with probable AD diagnosed by combining established clinical criteria with an AD typical pattern in [(18)F] fluoro deoxy glucose PET underwent [(11)C] PiB PET examinations at baseline and after 24 months The difference of amyloid load between the two examinations and the association with clinical and neurobiological variables was examined with a regions of interest approach and voxel based analyses Results Cerebral [(11)C] PiB uptake ratio increased significantly by an annual rate of 3 92% Although the increase occurred in all parts of the neocortex no increase was detected in the archipallium The increase was gene-dose dependent (analysis of variance p = 012) to the number of apolipoprotein E epsilon 4 alleles Progression of dementia symptoms was correlated to the [(11)C] PiB increase in numerous regions associated with cognition Conclusions The results of this study indicate that a significant increase of amyloid deposition occurs in patients with AD during a relatively short interval of its clinical course The rate of amyloid aggregation rate is closely associated with the apolipoprotein E genotype which might be important for the evaluation of antiamyloid drug treatment effects The present study further emphasizes the value of amyloid plaque imaging as a marker of disease progression and as a potential surrogate marker to be used in antiamyloid drug trials C1 [Grimmer, Timo; Tholen, Susanne; Alexopoulos, Panagiotis; Forstl, Hans; Perneczky, Robert; Sorg, Christian; Kurz, Alexander] Tech Univ Munich, Dept Psychiat & Psychotherapy, Klinikum Rechts Isar, D-81675 Munich, Germany. [Yousefi, Behrooz H.; Henriksen, Gjermund; Drzezga, Alexander] Tech Univ Munich, Dept Nucl Med, Klinikum Rechts Isar, D-81675 Munich, Germany. [Forschler, Annette] Tech Univ Munich, Dept Neuroradiol, Klinikum Rechts Isar, D-81675 Munich, Germany. [Mathis, Chester A.] Univ Pittsburgh, Dept Radiol, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. [Klunk, William E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. [Drzezga, Alexander] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA USA. RP Grimmer, T (reprint author), Tech Univ Munich, Dept Psychiat & Psychotherapy, Klinikum Rechts Isar, Mohlstr 26, D-81675 Munich, Germany. RI Yousefi, Behrooz/A-2076-2011 FU German research foundation (Deutsche Forschungsgemeinschaft) [HL 45604-2, HJW DR 445/3-1, AK DR 445/4-1]; Technische Universitat Munchen; National Institutes of Health [R01 AG018402, R37 AG025516, P01 AG025204] FX This work was supported in part by the German research foundation (Deutsche Forschungsgemeinschaft) (HL 45604-2 to GH AD and HJW DR 445/3-1 to AD GH, and AK DR 445/4-1 to AD, GH AK), by a KKI-grant for clinical research of the Technische Universitat Munchen (to AD and TG) and by the National Institutes of Health (R01 AG018402 to CAM R37 AG025516 to WEK P01 AG025204 to WEK) NR 38 TC 51 Z9 51 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD NOV 15 PY 2010 VL 68 IS 10 BP 879 EP 884 DI 10.1016/j.biopsych.2010.05.013 PG 6 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 679BH UT WOS:000284133900002 PM 20598287 ER PT J AU Spencer, TJ Madras, BK Bonab, AA Dougherty, DD Clarke, A Mirto, T Martin, J Fischman, AJ AF Spencer, Thomas J. Madras, Bertha K. Bonab, Ali A. Dougherty, Darin D. Clarke, Allison Mirto, Tara Martin, Jessica Fischman, Alan J. TI A Positron Emission Tomography Study Examining The Dopaminergic Activity of Armodafinil in Adults Using [C-11]Altropane and [C-11]Raclopride SO BIOLOGICAL PSYCHIATRY LA English DT Article DE ADHD; neurochemical imaging; PET imaging pharmacokinetics stimulants; substance abuse ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; FILM-COATED TABLETS; ORAL METHYLPHENIDATE; DOUBLE-BLIND; HUMAN BRAIN; EXTRACELLULAR DOPAMINE; RECEPTOR OCCUPANCY; MODAFINIL; TRANSPORTERS; CHILDREN AB Background Armodafinil prescribed principally to treat narcolepsy is undergoing assessment of therapeutic potential for other neuropsychiatric disorders and medical conditions The neurochemical substrates and mechanisms of armodafinil are unresolved We investigated the hypothesis that armodafinil enhances wakefulness by modulating the activities of the dopamine transporter (DAT) With positron emission tomography imaging we determined DAT occupancy and changes in extracellular dopamine by armodafinil in vivo Methods Twelve subjects were enrolled Plasma armodafinil levels were obtained In vivo armodafinil occupancy of the DAT in striatum was detected by [C-11]altropane and changes in extracellular dopamine were detected by indirect displacement of [C-11]raclopride in human subjects at different times after drug administration Results Armodafinil (100 mg by mouth [PO]) occupied striatal DAT (34 0 +/- 90% at 1 hour 404 +/- 95% at 25 hours n = 6) and 250 mg occupied striatal DAT (60 5 +/- 74% at 1 hour, 652 +/- 61% at 25 hours n = 6) In addition armodafinil was associated with changes in extracellular dopamine (17 8 +/- 30 1% [100 mg PO] and 70 +/- 86% [250 mg PO] at 2 5 hours n = 6) Conclusions Occupancy of the DAT and changes in extracellular dopamine in vivo further implicates the actions of armodafinil on DAT as a potential candidate for its therapeutic improvement of wakefulness and other conditions C1 [Spencer, Thomas J.; Clarke, Allison; Mirto, Tara; Martin, Jessica] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Boston, MA 02114 USA. [Spencer, Thomas J.; Dougherty, Darin D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Psychiat Serv, Boston, MA 02114 USA. [Spencer, Thomas J.; Dougherty, Darin D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Bonab, Ali A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Nucl Med, Boston, MA 02114 USA. [Madras, Bertha K.] New England Primate Res Ctr, Div Neurochem, Boston, MA USA. [Bonab, Ali A.; Fischman, Alan J.] Shriners Hosp Children, Boston, MA USA. RP Spencer, TJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pediat Psychopharmacol Unit, Fruit St, Boston, MA 02114 USA. FU Cephalon Pharmaceuticals; Shire Laboratories Inc; Eli Lilly Company; GlaxoSmithKline; Janssen Pharmaceutical; McNeil Pharmaceutical; Novartis Pharmaceuticals; Cephalon; Pfizer; National Institute of Mental Health; Wyeth; Jazz Pharmaceuticals; Bristol Myers Squibb; Brand Ideas; Reed Elsevier; Medtronic; Cyberonics; Eli Lilly; McNeil; Northstar FX This study was supported by funding from Cephalon Pharmaceuticals; Dr Thomas Spencer has received research support from has been a speaker for or on a speaker bureau or has been an advisor or on an Advisory Board of the following sources Shire Laboratories Inc Eli Lilly & Company GlaxoSmithKline Janssen Pharmaceutical McNeil Pharmaceutical Novartis Pharmaceuticals Cephalon Pfizer, and the National Institute of Mental Health Dr Darin Dougherty's research has been funded by the National Institute of Mental Health National All, once for Research on Schizophrenia and Depression Tourette Syndrome Association and Obsessive Compulsive Foundation He has received honoraria, consultation fees and/or royalties from Wyeth Jazz Pharmaceuticals Bristol Myers Squibb Brand Ideas and Reed Elsevier He has also participated in research funded by Medtronic Cyberonics Eli Lilly McNeil and Northstar All other authors report no biomedical financial interests or potential conflicts of interest NR 25 TC 12 Z9 12 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD NOV 15 PY 2010 VL 68 IS 10 BP 964 EP 970 DI 10.1016/j.biopsych.2010.08.026 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 679BH UT WOS:000284133900012 PM 21035624 ER PT J AU Hooker, JM Kim, SW Reibel, AT Alexoff, D Xu, YW Shea, C AF Hooker, Jacob M. Kim, Sung Won Reibel, Achim T. Alexoff, David Xu, Youwen Shea, Colleen TI Evaluation of [C-11]metergoline as a PET radiotracer for 5HTR in nonhuman primates SO BIOORGANIC & MEDICINAL CHEMISTRY LA English DT Article DE Metergoline; Carbon-11; PET; Serotonin; Altanserin ID 5-HT2A RECEPTORS; PHARMACOLOGICAL CHARACTERIZATION; SEROTONIN TRANSPORTER; METERGOLINE; RADIOLIGAND; VOLUNTEERS; BINDING; ANTAGONIST; DISORDER; LIGAND AB Metergoline, a serotonin receptor antagonist, was labeled with carbon-11 in order to evaluate its pharmacokinetics and distribution in non-human primates using positron emission tomography. [C-11]Metergoline had moderate brain uptake and exhibited heterogeneous specific binding, which was blocked by pretreatment with metergoline and altanserin throughout the cortex. Non-specific binding and insensitivity to changes in synaptic serotonin limit its potential as a PET radiotracer. However, the characterization of [C-11]metergoline pharmacokinetics and binding in the brain and peripheral organs using PET improves our understanding of metergoline drug pharmacology. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Hooker, Jacob M.; Kim, Sung Won; Reibel, Achim T.; Alexoff, David; Xu, Youwen; Shea, Colleen] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA. [Hooker, Jacob M.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Hooker, Jacob M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. [Kim, Sung Won] NIAAA, Rockville, MD 20892 USA. [Reibel, Achim T.] Johannes Gutenberg Univ Mainz, Mainz, Germany. RP Hooker, JM (reprint author), Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA. EM hooker@nmr.mgh.harvard.edu OI Hooker, Jacob/0000-0002-9394-7708 FU U.S. Department of Energy, Office of Biological and Environmental Research [DE-AC02-98CH10886]; NIH [1F32EB008320]; NIMH PDSP [HHSN-271-2008-00025-C] FX This work was carried out at Brookhaven National Laboratory under contract DE-AC02-98CH10886 with the U.S. Department of Energy, supported by its Office of Biological and Environmental Research. J.M.H. was supported by an NIH Postdoctoral Fellowship (1F32EB008320) and through the Goldhaber Distinguished Fellowship program at BNL. The authors are grateful to Dr. Michael Schueller for cyclotron operation and the PET imaging team at BNL (Pauline Carter, Payton King, and Don Warner) for carrying out primate imaging experiments and to Dr. Joanna Fowler for scientific input. The receptor binding profile for metergoline was generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract # HHSN-271-2008-00025-C (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda MD, USA. NR 37 TC 5 Z9 5 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0968-0896 J9 BIOORGAN MED CHEM JI Bioorg. Med. Chem. PD NOV 15 PY 2010 VL 18 IS 22 BP 7739 EP 7745 DI 10.1016/j.bmc.2010.04.039 PG 7 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry GA 673HK UT WOS:000283649900005 PM 20451398 ER PT J AU Porter, MP AF Porter, Michael P. TI Examining the Association Between Delay in Diagnosis and Decreased Survival in Bladder Cancer SO CANCER LA English DT Editorial Material ID RADICAL CYSTECTOMY; GENDER C1 [Porter, Michael P.] Univ Washington, Dept Urol, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Porter, MP (reprint author), 1660 S Columbian Way S-112-GU, Seattle, WA 98108 USA. EM mporter@u.washington.edu NR 9 TC 4 Z9 4 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD NOV 15 PY 2010 VL 116 IS 22 BP 5122 EP 5125 DI 10.1002/cncr.25290 PG 4 WC Oncology SC Oncology GA 678CP UT WOS:000284047400003 PM 20665888 ER PT J AU Choueiri, TK Lim, ZD Hirsch, MS Tamboli, P Jonasch, E McDermott, DF Dal Cin, P Corn, P Vaishampayan, U Heng, DYC Tannir, NM AF Choueiri, Toni K. Lim, Zita Dubauskas Hirsch, Michelle S. Tamboli, Pheroze Jonasch, Eric McDermott, David F. Dal Cin, Paola Corn, Paul Vaishampayan, Ulka Heng, Daniel Y. C. Tannir, Nizar M. TI Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Adult Metastatic Xp11.2 Translocation Renal Cell Carcinoma SO CANCER LA English DT Article DE vascular endothelial growth factor (VEGF); sunitinib; adult translocation renal cell carcinoma (RCC); targeted therapy; kidney cancer ID SUNITINIB; NEOPLASMS; EFFICACY; ALVEOLAR; FUSIONS; TUMORS; TFE3 AB BACKGROUND: Adult "translocation'' renal cell carcinoma (RCC), bearing transcription factor E3 (TFE3) gene fusions at Xp11.2, is a recently recognized, unique entity for which prognosis and therapy remain poorly understood. In the current study, the authors investigated the effect of vascular endothelial growth factor (VEGF)-targeted therapy in this distinct subtype of RCC. METHODS: A retrospective review was conducted to describe the clinical characteristics and outcome of adult patients with metastatic Xp11.2 RCC who had strong TFE3 nuclear immunostaining and received anti-VEGF therapy. Tumor response to anti-VEGF therapy was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS) distributions. RESULTS: Fifteen patients were identified, of whom 10, 3, and 2 received sunitinib, sorafenib, and monoclonal anti-VEGF antibodies, respectively. The median follow-up was 19.1 months, the median age of the patients was 41 years, and the female: male ratio was 4:1. Initial histologic description included clear cell (n = 8 patients), papillary (n 1 patient), or mixed clear cell/papillary RCC (n = 6 patients). Five patients had received prior systemic therapy. Five patients had undergone fluorescent in situ hybridization analysis and all demonstrated a translocation involving chromosome Xp11.2. When treated with VEGF-targeted therapy, 3 patients achieved a partial response, 7 patients had stable disease, and 5 patients developed progressive disease. The median PFS and OS of the entire cohort were 7.1 months and 14.3 months, respectively. CONCLUSIONS: Adult-onset, translocation-associated metastatic RCC is an aggressive disease that affects a younger population of patients with a female predominance. In the current study, VEGF-targeted agents appeared to demonstrate some efficacy. Cancer 2010;116:5219-25. (c) 2010 American Cancer Society. C1 [Choueiri, Toni K.] Brigham & Womens Hosp, Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA. [Lim, Zita Dubauskas; Tamboli, Pheroze; Jonasch, Eric; Corn, Paul; Tannir, Nizar M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [McDermott, David F.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Vaishampayan, Ulka] Karmanos Canc Inst, Detroit, MI USA. [Heng, Daniel Y. C.] Tom Baker Canc Clin, Calgary, AB, Canada. RP Choueiri, TK (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Kidney Canc Ctr, 44 Binney St, Boston, MA 02115 USA. EM Toni_Choueiri@dfci.harvard.edu FU NCI NIH HHS [P50 CA101942, P30 CA016672] NR 28 TC 42 Z9 49 U1 0 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD NOV 15 PY 2010 VL 116 IS 22 BP 5219 EP 5225 DI 10.1002/cncr.25512 PG 7 WC Oncology SC Oncology GA 678CP UT WOS:000284047400013 PM 20665500 ER PT J AU Rahmanzadeh, R Rai, P Celli, JP Rizvi, I Baron-Luhr, B Gerdes, J Hasan, T AF Rahmanzadeh, Ramtin Rai, Prakash Celli, Jonathan P. Rizvi, Imran Baron-Luehr, Bettina Gerdes, Johannes Hasan, Tayyaba TI Ki-67 as a Molecular Target for Therapy in an In vitro Three-Dimensional Model for Ovarian Cancer SO CANCER RESEARCH LA English DT Article ID ASSISTED LIGHT INACTIVATION; MONOCLONAL-ANTIBODY; PHOTODYNAMIC THERAPY; PROLIFERATING CELLS; CATIONIC LIPOSOMES; DELIVERY-SYSTEM; SINGLET-OXYGEN; TUMOR-GROWTH; PROTEINS; ORGANIZATION AB Targeting molecular markers and pathways implicated in cancer cell growth is a promising avenue for developing effective therapies. Although the Ki-67 protein (pKi-67) is a key marker associated with aggressively proliferating cancer cells and poor prognosis, its full potential as a therapeutic target has never before been successfully shown. In this regard, its nuclear localization presents a major hurdle because of the need for intracellular and intranuclear delivery of targeting and therapeutic moieties. Using a liposomally encapsulated construct, we show for the first time the specific delivery of a Ki-67-directed antibody and subsequent light-triggered death in the human ovarian cancer cell line OVCAR-5. Photoimmunoconjugate-encapsulating liposomes (PICEL) were constructed from anti-pKi-67 antibodies conjugated to fluorescein 5(6)-isothiocyanate, as a photoactivatable agent, followed by encapsulation in noncationic liposomes. Nucleolar localization of the PICELs was confirmed by confocal imaging. Photodynamic activation with PICELs specifically killed pKi-67-positive cancer cells both in monolayer and in three-dimensional (3D) cultures of OVCAR-5 cells, with the antibody TuBB-9 targeting a physiologically active form of pKi-67 but not with MIB-1, directed to a different epitope. This is the first demonstration of (a) the exploitation of Ki-67 as a molecular target for therapy and (b) specific delivery of an antibody to the nucleolus in monolayer cancer cells and in an in vitro 3D model system. In view of the ubiquity of pKi-67 in proliferating cells in cancer and the specificity of targeting in 3D multicellular acini, these findings are promising and the approach merits further investigation. Cancer Res; 70(22); 9234-42. (C) 2010 AACR. C1 [Rahmanzadeh, Ramtin; Rai, Prakash; Celli, Jonathan P.; Rizvi, Imran; Hasan, Tayyaba] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Rizvi, Imran] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. [Baron-Luehr, Bettina; Gerdes, Johannes] Res Ctr Borstel, Dept Immunol & Cell Biol, Borstel, Germany. RP Hasan, T (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA. EM thasan@mgh.harvard.edu RI Rahmanzadeh, Ramtin/L-7941-2016; OI Rizvi, Imran/0000-0001-9673-4700 FU NIH [5R01 CA119388-03]; American Recovery and Reinvestment Act [RC1CA146337]; Deutsche Forschungsgemeinschaft [Ra1771/1-1] FX NIH grant 5R01 CA119388-03 and American Recovery and Reinvestment Act grant RC1CA146337. R. Rahmanzadeh acknowledges support from Deutsche Forschungsgemeinschaft grant Ra1771/1-1. NR 38 TC 35 Z9 36 U1 3 U2 15 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD NOV 15 PY 2010 VL 70 IS 22 BP 9234 EP 9242 DI 10.1158/0008-5472.CAN-10-1190 PG 9 WC Oncology SC Oncology GA 680DT UT WOS:000284213300029 PM 21045152 ER PT J AU Rizvi, I Celli, JP Evans, CL Abu-Yousif, AO Muzikansky, A Pogue, BW Finkelstein, D Hasan, T AF Rizvi, Imran Celli, Jonathan P. Evans, Conor L. Abu-Yousif, Adnan O. Muzikansky, Alona Pogue, Brian W. Finkelstein, Dianne Hasan, Tayyaba TI Synergistic Enhancement of Carboplatin Efficacy with Photodynamic Therapy in a Three-Dimensional Model for Micrometastatic Ovarian Cancer SO CANCER RESEARCH LA English DT Article ID DISSEMINATED INTRAPERITONEAL TUMORS; PHASE-II TRIAL; ANTICANCER AGENTS; DEBULKING SURGERY; CARCINOMA CELLS; SOLID TUMORS; IN-VITRO; GROWTH; CHEMOTHERAPY; COMBINATION AB Metastatic ovarian cancer (OvCa) frequently recurs due to chemoresistance, highlighting the need for non-overlapping combination therapies that mechanistically synergize to eradicate residual disease. Photodynamic therapy (PDT), a photochemistry-based cytotoxic modality, sensitizes ovarian tumors to platinum agents and biologics and has shown clinical promise against ovarian carcinomatosis. We introduce a three-dimensional (3D) model representing adherent ovarian micrometastases and high-throughput quantitative imaging methods to rapidly screen the order-dependent effects of combining benzoporphyrin-derivative (BPD) monoacid A-based PDT with low-dose carboplatin. 3D ovarian micronodules grown on Matrigel were subjected to BPD-PDT either before or after carboplatin treatment. We developed custom fluorescence image analysis routines to quantify residual tumor volume and viability. Carboplatin alone did not eradicate ovarian micrometastases at a dose of 400 mg/m(2), leaving surviving cores that were nonsensitive or impermeable to chemotherapy. BPD-PDT (1.25 mu mol/L.J/cm(2)) created punctate cytotoxic regions within tumors and disrupted micronodular structure. Treatment with BPD-PDT prior to low-dose carboplatin (40 mg/m(2)) produced a significant synergistic reduction [P < 0.0001, analysis of covariance (ANCOVA)] in residual tumor volume [0.26; 95% confidence interval (95% CI), 0.19-0.36] compared with PDT alone (0.76; 95% CI, 0.63-0.92) or carboplatin alone (0.95; 95% CI, 0.83-1.09), relative to controls. This synergism was not observed with the reverse treatment order. Here, we demonstrate for the first time the use of a 3D model for micrometastatic OvCa as a rapid and quantitative reporter to optimize sequence and dosing regimens of clinically relevant combination strategies. This approach combining biological modeling with high-content imaging provides a platform to rapidly screen therapeutic strategies for a broad array of metastatic tumors. Cancer Res; 70(22); 9319-28. (C) 2010 AACR. C1 [Rizvi, Imran; Celli, Jonathan P.; Evans, Conor L.; Abu-Yousif, Adnan O.; Hasan, Tayyaba] Harvard Univ, Wellman Ctr Photomed, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Muzikansky, Alona; Finkelstein, Dianne] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Rizvi, Imran; Pogue, Brian W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. RP Hasan, T (reprint author), Harvard Univ, Wellman Ctr Photomed, Massachusetts Gen Hosp, Sch Med, 40 Blossom St, Boston, MA 02114 USA. EM thasan@partners.org OI Rizvi, Imran/0000-0001-9673-4700 FU NIH [RO1CA119388, RO1CA146337, RO1AR040532]; WCP; National Cancer Institute [F32CA138153]; MBRC FX NIH grants RO1CA119388, RO1CA146337, and RO1AR040532 (T. Hasan); WCP Graduate Student Fellowship (I. Rizvi); MBRC Tosteson Fellowship; and National Cancer Institute grant F32CA138153 (C. L. Evans). NR 50 TC 62 Z9 62 U1 3 U2 22 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD NOV 15 PY 2010 VL 70 IS 22 BP 9319 EP 9328 DI 10.1158/0008-5472.CAN-10-1783 PG 10 WC Oncology SC Oncology GA 680DT UT WOS:000284213300037 PM 21062986 ER PT J AU Cao, HJ Florez, S Amen, M Huynh, T Skobe, Z Baldini, A Amendt, BA AF Cao, Huojun Florez, Sergio Amen, Melanie Huynh, Tuong Skobe, Ziedonis Baldini, Antonio Amendt, Brad A. TI Tbx1 regulates progenitor cell proliferation in the dental epithelium by modulating Pitx2 activation of p21 SO DEVELOPMENTAL BIOLOGY LA English DT Article DE Tbx1; PITX2; p21; DiGeorge syndrome; Tooth development ID AXENFELD-RIEGER-SYNDROME; DIGEORGE-SYNDROME REGION; CARDIO-FACIAL SYNDROME; TOOTH DEVELOPMENT; GENE-EXPRESSION; FUNCTIONAL INTERACTIONS; HOMEODOMAIN PROTEIN; OUTFLOW TRACT; BETA-CATENIN; ENAMEL KNOT AB Tbx1(-/-) mice present with phenotypic effects observed in DiGeorge syndrome patients however, the molecular mechanisms of Tbx1 regulating craniofacial and tooth development are unclear. Analyses of the Tbx1 null mice reveal incisor microdontia, small cervical loops and BrdU labeling reveals a defect in epithelial cell proliferation. Furthermore, Tbx1 null mice molars are lacking normal cusp morphology. Interestingly, p21 (associated with cell cycle arrest) is up regulated in the dental epithelium of Tbx1(-/-) embryos. These data suggest that Tbx1 inhibits p21 expression to allow for cell proliferation in the dental epithelial cervical loop, however Tbx1 does not directly regulate p21 expression. A new molecular mechanism has been identified where Tbx1 inhibits Pitx2 transcriptional activity and decreases the expression of Pibc2 target genes, p21, Lef-1 and Pitx2c. p21 protein is increased in PITX2C transgenic mouse embryo fibroblasts (MEF) and chromatin immunoprecipitation assays demonstrate endogenous Pitx2 binding to the p21 promoter. Tbx1 attenuates PITX2 activation of endogenous p21 expression and Tbx1 null MEFs reveal increased Pibc2a and activation of Pitx2c isoform expression. Tbx1 physically interacts with the PITX2 C-terminus and represses PITX2 transcriptional activation of the p21, LEF-1, and Pitac promoters. Tbx1(-/+)Pitx2(-/+) double heterozygous mice present with an extra premolar-like tooth revealing a genetic interaction between these factors. The ability of Tbx1 to repress PITX2 activation of p21 may promote cell proliferation. In addition, PIDC2 regulation of p21 reveals a new role for PITX2 in repressing cell proliferation. These data demonstrate new functional mechanisms for Tbx1 in tooth morphogenesis and provide a molecular basis for craniofacial defects in DiGeorge syndrome patients. (C) 2010 Elsevier Inc. All rights reserved. C1 [Cao, Huojun; Florez, Sergio; Amen, Melanie; Huynh, Tuong; Baldini, Antonio; Amendt, Brad A.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA. [Skobe, Ziedonis] Forsyth Inst, Dept Biomineralizat, Boston, MA USA. [Baldini, Antonio] Inst Genet & Biophys CNR, Naples, Italy. RP Amendt, BA (reprint author), Texas A&M Hlth Sci Ctr, Inst Biosci & Genet Med, 2121 W Holcombe Blvd, Houston, TX 77030 USA. EM bamendt@ibt.tainhsc.edu RI genes, anthony/F-2541-2012 FU EU; National Institute of Dental and Craniofacial Research [DE 13941, DE 18885]; [HL064832] FX We thank Dr. Tord A. Hjalt (University of Lund, Lund, Sweden) for reagents, Dr. James Martin (Texas A&M HSC-IBT) for technical advice and members of the Amendt laboratory for helpful discussions. Support for this research was provided from grants HL064832 and EU grant AnEUploidy to Antonio Baldini and DE 13941 and DE 18885 from the National Institute of Dental and Craniofacial Research to Brad A. Amendt. NR 54 TC 20 Z9 22 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0012-1606 J9 DEV BIOL JI Dev. Biol. PD NOV 15 PY 2010 VL 347 IS 2 BP 289 EP 300 DI 10.1016/j.ydbio.2010.08.031 PG 12 WC Developmental Biology SC Developmental Biology GA 675LT UT WOS:000283832900005 PM 20816801 ER PT J AU Dollard, SC Butler, LM Jones, AMG Mermin, JH Chidzonga, M Chipato, T Shiboski, CH Brander, C Mosam, A Kiepiela, P Hladik, W Martin, JN AF Dollard, Sheila C. Butler, Lisa M. Jones, Alison M. Graves Mermin, Jonathan H. Chidzonga, Midion Chipato, Tsungai Shiboski, Caroline H. Brander, Christian Mosam, Anisa Kiepiela, Photini Hladik, Wolfgang Martin, Jeffrey N. TI Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the "Kaposi's sarcoma Belt" SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE KSHV; HHV-8; Africa; adults ID IMMUNODEFICIENCY-VIRUS TYPE-1; TO-CHILD TRANSMISSION; RISK-FACTORS; SEXUAL TRANSMISSION; BLOOD-TRANSFUSION; HOMOSEXUAL-MEN; HERPESVIRUS KSHV/HHV-8; SEROLOGIC ASSAYS; UNITED-STATES; INFECTION AB Equatorial Africa has among the highest incidences of Kaposi's sarcoma (KS) in the world, thus earning the name "KS Belt." This was the case even before the HIV epidemic. To date, there is no clear evidence that HHV-8 seroprevalence is higher in this region but interpretation of the available literature is tempered by differences in serologic assays used across studies. We examined representatively sampled ambulatory adults in Uganda, which is in the "KS Belt," and in Zimbabwe and South Africa which are outside the Belt, for HHV-8 antibodies. All serologic assays were uniformly performed in the same reference laboratory by the same personnel. In the base-case serologic algorithm, seropositivity was defined by reactivity in an immunofluorescence assay or in 2 enzyme immunoassays. A total of 2,375 participants were examined. In Uganda, HHV-8 seroprevalence was high early in adulthood (35.5% by age 21) without significant change thereafter. In contrast, HHV-8 seroprevalence early in adulthood was lower in Zimbabwe and South Africa (13.7 and 10.8%, respectively) but increased with age. After age adjustment, Ugandans had 3.24-fold greater odds of being HHV-8 infected than South Africans (p < 0.001) and 2.22-fold greater odds than Zimbabweans (p < 0.001). Inferences were unchanged using all other serologic algorithms evaluated. In conclusion, HHV-8 infection is substantially more common in Uganda than in Zimbabwe and South Africa. These findings help to explain the high KS incidence in the "KS Belt" and underscore the importance of a uniform approach to HHV-8 antibody testing. C1 [Butler, Lisa M.; Jones, Alison M. Graves; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA. [Dollard, Sheila C.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Mermin, Jonathan H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, CDC, Atlanta, GA USA. [Chidzonga, Midion; Chipato, Tsungai] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe. [Shiboski, Caroline H.] Univ Calif San Francisco, Dept Orofacial Sci, Div Oral Med Oral Pathol & Oral Radiol, San Francisco, CA 94143 USA. [Brander, Christian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr, Boston, MA USA. [Brander, Christian] ICREA, Barcelona, Spain. [Brander, Christian] Hosp Badalona Germans Trias & Pujol, Irsicaixa AIDS Res Inst, Badalona, Catalonia, Spain. [Mosam, Anisa] Univ KwaZulu Natal, Dept Dermatol, Durban, South Africa. [Kiepiela, Photini] MRC, HIV Prevent & Res Unit, Durban, South Africa. [Hladik, Wolfgang] Ctr Dis Control & Prevent, Epidemiol Unit, Entebbe, Uganda. RP Martin, JN (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 185 Berry St,Suite 5700, San Francisco, CA 94107 USA. EM martin@psg.ucsf.edu RI Mermin, Jonathan/J-9847-2012; OI Brander, Christian/0000-0002-0548-5778 FU National Institutes of Health [U01 CA078124, R01 CA119903, P30 MH062246, D43 TW000003, R03 TW006054, P01 DE007946, K01 HD052020, P30 AI027763]; AIDS Malignancy Consortium [U01 CA071375]; University of California [CC99-SF-001]; South Africa National Research Foundation [2054349]; AIDS Care Research in Africa Program FX Grant sponsor: National Institutes of Health; Grant numbers: U01 CA078124, R01 CA119903, P30 MH062246, D43 TW000003, R03 TW006054, P01 DE007946, K01 HD052020, and P30 AI027763; Grant sponsor: AIDS Malignancy Consortium; Grant number: U01 CA071375; Grant sponsor: University of California Universitywide AIDS Research Program; Grant number: CC99-SF-001; Grant sponsor: South Africa National Research Foundation (Thuthuka Programme); Grant number: 2054349; Grant sponsor: AIDS Care Research in Africa Program NR 42 TC 25 Z9 25 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD NOV 15 PY 2010 VL 127 IS 10 BP 2395 EP 2401 DI 10.1002/ijc.25235 PG 7 WC Oncology SC Oncology GA 672DT UT WOS:000283563900016 PM 20143397 ER PT J AU Ozsahin, M Gruber, G Olszyk, O Karakoyun-Celik, O Pehlivan, B Azria, D Roelandts, M Kaanders, JHAM Cengiz, M Krengli, M Matzinger, O Zouhair, A AF Ozsahin, Mahmut Gruber, Guenther Olszyk, Olimpia Karakoyun-Celik, Omur Pehlivan, Berrin Azria, David Roelandts, Martine Kaanders, Johannes H. A. M. Cengiz, Mustafa Krengli, Marco Matzinger, Oscar Zouhair, Abderrahim TI OUTCOME AND PROGNOSTIC FACTORS IN OLFACTORY NEUROBLASTOMA: A RARE CANCER NETWORK STUDY SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Olfactory neuroblastoma; Esthesioneuroblastoma; Radiotherapy; Surgery; Chemotherapy ID INTENSITY-MODULATED RADIOTHERAPY; RADIATION-THERAPY; NASAL CAVITY; PARANASAL SINUSES; ESTHESIONEUROBLASTOMA; CHEMOTHERAPY; EXPERIENCE; MALIGNANCIES; IRRADIATION; SURGERY AB Purpose: To assess the outcome in patients with olfactory neuroblastoma (ONB). Methods and Materials: Seventy-seven patients treated for nonmetastatic ONB between 1971 and 2004 were included. According to Kadish classification, there were 11 patients with Stage A, 29 with Stage B, and 37 with Stage C. T-classification included 9 patients with T1, 26 with T2, 16 with T3, 15 with T4a, and 11 with T4b tumors. Sixty-eight patients presented with N0 (88%) disease. Results: Most of the patients (n = 56, 73 %) benefited from surgery (S), and total excision was possible in 44 patients (R0 in 32, R1 in 13, R2 in 11). All but five patients benefited from RT, and chemotherapy was given in 21(27%). Median follow-up period was 72 months (range, 6-315). The 5-year overall survival (OS), disease-free survival (DES), locoregional control, and local control were 64%, 57%, 62%, and 70%, respectively. In univariate analyses, favorable factors were Kadish A or B disease, T1 T3 tumors, no nodal involvement, curative surgery, R0/R1 resection, and RT-dose 54 Gy or higher. Multivariate analysis revealed that the best independent factors predicting the outcome were T1 T3, N0, R0/R1 resection, and total RT dose (54 Gy or higher). Conclusion: In this multicenter retrospective study, patients with ONB treated with R0 or R1 surgical resection followed by at least 54-Gy postoperative RT had the best outcome. Novel strategies including concomitant chemotherapy and/or higher dose RT should be prospectively investigated in this rare disease for which local failure remains a problem. (C) 2010 Elsevier Inc. C1 [Ozsahin, Mahmut; Matzinger, Oscar; Zouhair, Abderrahim] CHU Vaudois, Dept Radiat Oncol, CH-1011 Lausanne, Switzerland. [Ozsahin, Mahmut; Matzinger, Oscar; Zouhair, Abderrahim] Univ Lausanne, Lausanne, Switzerland. [Gruber, Guenther; Matzinger, Oscar] Univ Bern, Inselspital, CH-3010 Bern, Switzerland. [Olszyk, Olimpia] Ctr Oscar Lambret, F-59020 Lille, France. [Karakoyun-Celik, Omur] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pehlivan, Berrin] Inst Gustave Roussy, Villejuif, France. [Azria, David] Ctr Reg Lutte Canc Paul Lamarque Val dAurelle, Inst Natl Sante & Recerche Med U896, Montpellier, France. [Roelandts, Martine] Inst Jules Bordet, B-1000 Brussels, Belgium. [Kaanders, Johannes H. A. M.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. [Cengiz, Mustafa] Hacettepe Univ, Sch Med, Ankara, Turkey. [Krengli, Marco] Univ Piemonte Orientale, Novara, Italy. RP Ozsahin, M (reprint author), CHU Vaudois, Dept Radiat Oncol, Bugnon 46, CH-1011 Lausanne, Switzerland. EM mahmut.ozsahin@chuv.ch RI Kaanders, Hans/A-7432-2014; OI Matzinger, Oscar/0000-0002-5054-1564 FU Rare Cancer Network FX This study was supported by the Rare Cancer Network. NR 35 TC 28 Z9 30 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD NOV 15 PY 2010 VL 78 IS 4 BP 992 EP 997 DI 10.1016/j.ijrobp.2009.09.019 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 677BC UT WOS:000283963100004 PM 20231062 ER PT J AU Nguyen, PL Chen, RC Hoffman, KE Trofimov, A Efstathiou, JA Coen, JJ Shipley, WU Zetman, AL Talcott, JA AF Nguyen, Paul L. Chen, Ronald C. Hoffman, Karen E. Trofimov, Alexei Efstathiou, Jason A. Coen, John J. Shipley, William U. Zetman, Anthony L. Talcott, James A. TI RECTAL DOSE-VOLUME HISTOGRAM PARAMETERS ARE ASSOCIATED WITH LONG-TERM PATIENT-REPORTED GASTROINTESTINAL QUALITY OF LIFE AFTER CONVENTIONAL AND HIGH-DOSE RADIATION FOR PROSTATE CANCER: A SUBGROUP ANALYSIS OF A RANDOMIZED TRIAL SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Prostate cancer; DVH; Quality of life; Radiation; Randomized trial ID CONFORMAL RADIOTHERAPY; 3-DIMENSIONAL RADIOTHERAPY; TOXICITY; CARCINOMA; THERAPY; ADENOCARCINOMA; IRRADIATION; ESCALATION AB Purpose: We examined whether rectal dose volume histogram (DVH) parameters were associated with long-term patient-reported gastrointestinal (GI) quality of life (QOL) after conventional (70.2 GyE) or high-dose (79.2 GyE) radiation for prostate cancer. Methods and Materials: Of 64 men with localized prostate cancer alive with a minimum 7-year follow-up after treatment as part of a randomized trial with either 70.2 GyE or 79.2 GyE of external beam radiation at Massachusetts General Hospital, 56 men (88%) returned a QOL questionnaire, and 50 of those men had DVH information. The DVH parameters of the anterior rectal wall were correlated with patient-reported long-term GI QOL using Pearson correlation and t tests. Results: There was a trend toward an association between increased long-term GI dysfunction and higher V60 (p = 0.07), V65 (p = 0.06), V70 (p = 0.09), and V75 (p = 0.09). When dichotomized by their medians, a V60 > 54% (p = 0.04), V70 > 44% (p = 0.06), and V75 > 39% (p = 0.06) were associated with increased long-term GI dysfunction. There was no difference in long-term GI dysfunction between men on the conventional vs. high-dose arms (p = 0.49). Conclusions: Dose volume histogram parameters of the anterior rectal wall were associated with long-term patient-reported GI QOL after prostate radiation, whereas the dose prescribed to the prostate was not, suggesting that DVH constraints, rather than total prescribed dose, may have the greatest impact on long-term bowel dysfunction, and therefore that continued dose escalation may be feasible if appropriate dose-volume constraints are met. (C) 2010 Elsevier Inc. C1 [Nguyen, Paul L.; Chen, Ronald C.; Hoffman, Karen E.; Trofimov, Alexei; Efstathiou, Jason A.; Coen, John J.; Shipley, William U.; Zetman, Anthony L.; Talcott, James A.] Harvard Univ, Sch Med, Boston, MA USA. [Talcott, James A.] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA. [Trofimov, Alexei; Efstathiou, Jason A.; Coen, John J.; Shipley, William U.; Zetman, Anthony L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Nguyen, Paul L.; Chen, Ronald C.; Hoffman, Karen E.] Harvard Radiat Oncol Program, Boston, MA USA. RP Nguyen, PL (reprint author), Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM pnguyen@LROC.harvard.edu NR 24 TC 19 Z9 19 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD NOV 15 PY 2010 VL 78 IS 4 BP 1081 EP 1085 DI 10.1016/j.ijrobp.2009.09.015 PG 5 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 677BC UT WOS:000283963100016 PM 20207497 ER PT J AU Zhang, M Coen, JJ Suzuki, Y Siedow, MR Niemierko, A Khor, LY Pollack, A Zhang, YF Zietman, AL Shipley, WU Chakravarti, A AF Zhang, Min Coen, John J. Suzuki, Yoshiyuki Siedow, Michael R. Niemierko, Andrzej Khor, Li-Yan Pollack, Alan Zhang, Yifen Zietman, Anthony L. Shipley, William U. Chakravarti, Arnab TI SURVIVIN IS A POTENTIAL MEDIATOR OF PROSTATE CANCER METASTASIS SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Survivin; Prostate cancer; Metastasis ID MOLECULAR MARKERS; CELL-DEATH; MECHANISMS; EXPRESSION; APOPTOSIS; REGULATOR; RADIATION; GENE; PERSPECTIVE; SUPPRESSION AB Purpose: We examined whether Survivin expression is associated with an increased risk of metastasis in prostate cancer. Methods and Materials: A total of 205 patients with T1 (23%) and T2 (77%) prostate cancer were treated with conventional external beam radiation therapy from 1991 to 1993 at the Massachusetts General Hospital. Of the patients, 62 had adequate and suitable-stained tumor material for Survivin analysis. Median follow-up was 102 months (range, 5-127 months). Distant failure was determined on the basis of clinical criteria. In preclinical studies, replication-deficient adenovirus encoding phosphorylation-defective Survivin Thr34 -> Ala dominant-negative mutant pAd-S(T34A) or short hairpin RNA (shRNA) was used to inhibit Survivin in prostate cancer models, and the cell motility, morphology, and metastasis were investigated. Results: Our correlative data on men with early-stage (T1/T2) prostate cancers treated at Massachusetts General Hospital by definitive radiotherapy indicated that overexpression of Survivin (positive staining in >= 10% cells) was associated with a significantly increased risk for the subsequent development of distant metastasis (p = 0.016) in the univariaite analysis. In the multivariate analysis, overexpression of Survivin remained an independent predictor of distant metastasis (p = 0.008). The inhibition of Survivin dramatically inhibited invasiveness of prostate cancer cells in the in vitro invasion assay and spontaneous metastasis in the Dunning prostate cancer in vivo model. Furthermore, attenuation of Survivin resulted in changes in the microtubule cytoskeleton, loss of cellular polarity, and loss of motility. Conclusions: This study suggests that Survivin may be a potentially important prognostic marker and promising therapeutic target in metastatic prostate cancer. (C) 2010 Elsevier Inc. C1 [Zhang, Min; Suzuki, Yoshiyuki; Siedow, Michael R.; Niemierko, Andrzej; Chakravarti, Arnab] Ohio State Univ, Sch Med, Dept Radiat Oncol, Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA. [Zhang, Min; Suzuki, Yoshiyuki; Siedow, Michael R.; Niemierko, Andrzej; Chakravarti, Arnab] Ohio State Univ, Sch Med, Richard L Solove Res Inst, Columbus, OH 43210 USA. [Coen, John J.; Zhang, Yifen; Zietman, Anthony L.; Shipley, William U.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Pollack, Alan] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Khor, Li-Yan] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. RP Chakravarti, A (reprint author), Ohio State Univ, Sch Med, Dept Radiat Oncol, Arthur G James Comprehens Canc Ctr, 300 W 10th Ave,Room 080B, Columbus, OH 43210 USA. EM arnab.chakravarti@osumc.edu FU Ohio State University/Arthur G. James Comprehensive Cancer Center; National Institutes of Health/National Cancer Institute [RO1CA108633] FX Support for this work was provided by The Ohio State University/Arthur G. James Comprehensive Cancer Center and National Institutes of Health/National Cancer Institute RO1CA108633 (both to A.C.). NR 43 TC 25 Z9 27 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD NOV 15 PY 2010 VL 78 IS 4 BP 1095 EP 1103 DI 10.1016/j.ijrobp.2009.09.007 PG 9 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 677BC UT WOS:000283963100018 PM 20231071 ER PT J AU McCarl, CA Khalil, S Ma, JA Oh-Hora, M Yamashita, M Roether, J Kawasaki, T Jairaman, A Sasaki, Y Prakriya, M Feske, S AF McCarl, Christie-Ann Khalil, Sara Ma, Jian Oh-Hora, Masatsugu Yamashita, Megumi Roether, Jens Kawasaki, Takumi Jairaman, Amit Sasaki, Yoshiteru Prakriya, Murali Feske, Stefan TI Store-Operated Ca2+ Entry through ORAI1 Is Critical for T Cell-Mediated Autoimmunity and Allograft Rejection SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ACTIVATED CALCIUM-CHANNELS; INTESTINAL INFLAMMATION; MICE LACKING; LYMPHOCYTES; IMMUNODEFICIENCY; STIM1; SKIN; DEFICIENCY; INHIBITION; MUTATION AB ORAI1 is the pore-forming subunit of the Ca2+ release-activated Ca2+ (CRAC) channel, which is responsible for store-operated Ca2+ entry in lymphocytes. A role for ORAI1 in T cell function in vivo has been inferred from in vitro studies of T cells from human immunodeficient patients with mutations in ORAI1 and Orai1(-/-) mice, but a detailed analysis of T cell-mediated immune responses in vivo in mice lacking functional ORAI1 has been missing. We therefore generated Orai1 knock-in mice (Orai1(KI/KI)) expressing a nonfunctional ORAI1-R93W protein. Homozygosity for the equivalent ORAI1-R91W mutation abolishes CRAC channel function in human T cells resulting in severe immunodeficiency. Homozygous Orai1(KI/KI) mice die neonatally, but Orai1(KI/KI) fetal liver chimeric mice are viable and show normal lymphocyte development. T and B cells from Orai1(KI/KI) mice display severely impaired store-operated Ca2+ entry and CRAC channel function resulting in a strongly reduced expression of several key cytokines including IL-2, IL-4, IL-17, IFN-gamma, and TNF-alpha in CD4(+) and CD8(+) T cells. Cell-mediated immune responses in vivo that depend on Th1, Th2, and Th17 cell function were severely attenuated in ORAI1-deficient mice. Orai1(KI/KI) mice lacked detectable contact hypersensitivity responses and tolerated skin allografts significantly longer than wild-type mice. In addition, T cells from Orai1(KI/KI) mice failed to induce colitis in an adoptive transfer model of inflammatory bowel disease. These findings reaffirm the critical role of ORAI1 for T cell function and provide important insights into the in vivo functions of CRAC channels for T cell-mediated immunity. The Journal of Immunology, 2010, 185: 5845-5858. C1 [McCarl, Christie-Ann; Khalil, Sara; Ma, Jian; Kawasaki, Takumi; Feske, Stefan] New York Univ, Dept Pathol, Langone Med Ctr, New York, NY 10016 USA. [McCarl, Christie-Ann; Oh-Hora, Masatsugu; Roether, Jens; Sasaki, Yoshiteru; Feske, Stefan] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Yamashita, Megumi; Jairaman, Amit; Prakriya, Murali] Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Feinberg Sch Med, Chicago, IL 60611 USA. RP Feske, S (reprint author), New York Univ, Dept Pathol, Langone Med Ctr, 550 1st Ave, New York, NY 10016 USA. EM feskes01@nyumc.org RI Ma, Jian/K-5260-2012; OI Feske, Stefan/0000-0001-5431-8178 FU March of Dimes Foundation; National Institutes of Health [AI066128, AI054636, NS057499] FX This work was supported by a March of Dimes Foundation grant (to S. F.) and by National Institutes of Health Grants AI066128 (to S. F.), AI054636 (to Klaus Rajewsky, whose laboratory helped with this work), and NS057499 (to M.P.). NR 47 TC 57 Z9 57 U1 0 U2 5 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD NOV 15 PY 2010 VL 185 IS 10 BP 5845 EP 5858 DI 10.4049/jimmunol.1001796 PG 14 WC Immunology SC Immunology GA 675RJ UT WOS:000283848000022 PM 20956344 ER PT J AU Henrich, TJ Li, JZ Felsenstein, D Kotton, CN Plenge, RM Pereyra, F Marty, FM Lin, NH Grazioso, P Crochiere, DM Eggers, D Kuritzkes, DR Tsibris, AMN AF Henrich, Timothy J. Li, Jonathan Z. Felsenstein, Donna Kotton, Camille N. Plenge, Robert M. Pereyra, Florencia Marty, Francisco M. Lin, Nina H. Grazioso, Paul Crochiere, Danielle M. Eggers, Daniel Kuritzkes, Daniel R. Tsibris, Athe M. N. TI Xenotropic Murine Leukemia Virus-Related Virus Prevalence in Patients with Chronic Fatigue Syndrome or Chronic Immunomodulatory Conditions SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID PROSTATE-CANCER; XMRV; RETROVIRUS; INFECTION; ABSENCE; BLOOD AB We investigated the prevalence of xenotropic murine leukemia virus-related virus (XMRV) among 293 participants seen at academic hospitals in Boston, Massachusetts. Participants were recruited from the following 5 groups of patients: chronic fatigue syndrome (n = 32), human immunodeficiency virus infection (n = 43), rheumatoid arthritis (n = 97), hematopoietic stem-cell or solid organ transplant (n = 26), or a general cohort of patients presenting for medical care (n = 95). XMRV DNA was not detected in any participant samples. We found no association between XMRV and patients with chronic fatigue syndrome or chronic immunomodulatory conditions. C1 [Henrich, Timothy J.; Li, Jonathan Z.; Felsenstein, Donna; Kotton, Camille N.; Lin, Nina H.; Grazioso, Paul; Crochiere, Danielle M.; Eggers, Daniel; Kuritzkes, Daniel R.; Tsibris, Athe M. N.] Massachusetts Gen Hosp, Div Infect Dis, Cambridge, MA 02139 USA. [Henrich, Timothy J.; Li, Jonathan Z.; Pereyra, Florencia; Marty, Francisco M.; Kuritzkes, Daniel R.; Tsibris, Athe M. N.] Brigham & Womens Hosp, Div Infect Dis, Cambridge, MA USA. [Plenge, Robert M.] Brigham & Womens Hosp, Div Allergy, Cambridge, MA USA. [Plenge, Robert M.] Brigham & Womens Hosp, Div Immunol, Cambridge, MA USA. [Henrich, Timothy J.; Li, Jonathan Z.; Felsenstein, Donna; Kotton, Camille N.; Plenge, Robert M.; Pereyra, Florencia; Marty, Francisco M.; Lin, Nina H.; Kuritzkes, Daniel R.; Tsibris, Athe M. N.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Pereyra, Florencia] Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA 02139 USA. [Marty, Francisco M.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Tsibris, AMN (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 65 Landsdowne St,Rm 422, Cambridge, MA 02139 USA. EM atsibris@partners.org FU National Institutes of Health [T32 AI07387]; Harvard Catalyst, The Harvard Clinical and Translational Science Center [UL1 RR025758, K24 RR016482, K08 AI081547]; Dana Farber Cancer Institute Brigham and Women's Hospital; Massachusetts General Hospital FX National Institutes of Health grants T32 AI07387 (to J.L.), KL2 Medical Research Investigator Training (MeRIT) program of Harvard Catalyst, The Harvard Clinical and Translational Science Center UL1 RR025758 (to T.J.H.), K24 RR016482 (to D. R. K.), and K08 AI081547 (to A.M.N.T.).; We thank the study participants for their participation. We thank Robert Silverman for his kind gift of the XMRV VP62 plasmid. We also thank the clinic staff of the Dana Farber Cancer Institute Brigham and Women's Hospital and Massachusetts General Hospital Infectious Diseases clinics and the Massachusetts General Hospital transplant clinic for their efforts in support of this study. We are grateful to Hongying Wang for her statistical analysis advice. NR 16 TC 52 Z9 54 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 15 PY 2010 VL 202 IS 10 BP 1478 EP 1481 DI 10.1086/657168 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 665SY UT WOS:000283057000004 PM 20936980 ER PT J AU Yukl, SA Gianella, S Sinclair, E Epling, L Li, QS Duan, LJ Choi, ALM Girling, V Ho, T Li, PL Fujimoto, K Lampiris, H Hare, CB Pandori, M Haase, AT Gunthard, HF Fischer, M Shergill, AK McQuaid, K Havlir, DV Wong, JK AF Yukl, Steven A. Gianella, Sara Sinclair, Elizabeth Epling, Lorrie Li, Qingsheng Duan, Lijie Choi, Alex L. M. Girling, Valerie Ho, Terence Li, Peilin Fujimoto, Katsuya Lampiris, Harry Hare, C. Bradley Pandori, Mark Haase, Ashley T. Guenthard, Huldrych F. Fischer, Marek Shergill, Amandeep K. McQuaid, Kenneth Havlir, Diane V. Wong, Joseph K. TI Differences in HIV Burden and Immune Activation within the Gut of HIV-Positive Patients Receiving Suppressive Antiretroviral Therapy SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CD38 ANTIGEN-EXPRESSION; DNA CPG METHYLATION; T-CELL-ACTIVATION; LYMPHOID-TISSUE; HISTONE ACETYLATION; VIRAL SUPPRESSION; TYPE-1 INFECTION; PROGNOSTIC VALUE; RECTAL MUCOSA AB Background. The gut is a major reservoir for human immunodeficiency virus (HIV) in patients receiving antiretroviral therapy (ART). We hypothesized that distinct immune environments within the gut may support varying levels of HIV. Methods. In 8 HIV-1-positive adults who were receiving ART and had CD4(+) T cell counts of >200 cells/mu L and plasma viral loads of <40 copies/mu L, levels of HIV and T cell activation were measured in blood samples and endoscopic biopsy specimens from the duodenum, ileum, ascending colon, and rectum. Results. HIV DNA and RNA levels per CD4(+) T cell were higher in all 4 gut sites compared with those in the blood. HIV DNA levels increased from the duodenum to the rectum, whereas the median HIV RNA level peaked in the ileum. HIV DNA levels correlated positively with T cell activation markers in peripheral blood mononuclear cells (PBMCs) but negatively with T cell activation markers in the gut. Multiply spliced RNA was infrequently detected in gut, and ratios of unspliced RNA to DNA were lower in the colon and rectum than in PBMCs, which reflects paradoxically low HIV transcription, given the higher level of T cell activation in the gut. Conclusions. HIV DNA and RNA are both concentrated in the gut, but the inverse relationship between HIV DNA levels and T cell activation in the gut and the paradoxically low levels of HIV expression in the large bowel suggest that different processes drive HIV persistence in the blood and gut. C1 [Yukl, Steven A.; Choi, Alex L. M.; Li, Peilin; Fujimoto, Katsuya; Lampiris, Harry; Shergill, Amandeep K.; McQuaid, Kenneth; Wong, Joseph K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Yukl, Steven A.; Sinclair, Elizabeth; Epling, Lorrie; Choi, Alex L. M.; Girling, Valerie; Ho, Terence; Li, Peilin; Fujimoto, Katsuya; Lampiris, Harry; Hare, C. Bradley; Shergill, Amandeep K.; McQuaid, Kenneth; Havlir, Diane V.; Wong, Joseph K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sinclair, Elizabeth; Epling, Lorrie; Girling, Valerie; Ho, Terence; Hare, C. Bradley; Havlir, Diane V.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Pandori, Mark] Dept Publ Hlth, San Francisco, CA USA. [Li, Qingsheng; Duan, Lijie; Haase, Ashley T.] Univ Minnesota, Minneapolis, MN USA. [Gianella, Sara; Guenthard, Huldrych F.; Fischer, Marek] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland. RP Yukl, SA (reprint author), 4150 Clement St,111W3, San Francisco, CA 94121 USA. EM steven.yukl@ucsf.edu RI gunthard, huldrych/F-1724-2011; Fujimoto, Katsuya/G-2835-2012; Infektiologie, USZ/A-6921-2011 OI gunthard, huldrych/0000-0002-1142-6723; FU US Department of Veterans Affairs; National Institutes of Health [P30-AI027763, NS051145, T32 AI60530]; Swiss National Science Foundation [324730-130865, 3100A0-112670] FX US Department of Veterans Affairs (Merit Award to J.K.W. and S.Y.); National Institutes of Health (grant P30-AI027763 to S.Y., grant NS051145 to J.K.W. and S.Y., and grant T32 AI60530 to D. V. H. and S.Y.); Swiss National Science Foundation (grant to S. G., grant 324730-130865 to H. F. G., and grant 3100A0-112670 to M.F.). NR 47 TC 134 Z9 134 U1 2 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 15 PY 2010 VL 202 IS 10 BP 1553 EP 1561 DI 10.1086/656722 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 665SY UT WOS:000283057000014 PM 20939732 ER PT J AU Chou, KL Amick, MM Brandt, J Camicioli, R Frei, K Gitelman, D Goldman, J Growdon, J Hurtig, HI Levin, B Litvan, I Marsh, L Simuni, T Troster, AI Uc, EY AF Chou, Kelvin L. Amick, Melissa M. Brandt, Jason Camicioli, Richard Frei, Karen Gitelman, Darren Goldman, Jennifer Growdon, John Hurtig, Howard I. Levin, Bonnie Litvan, Irene Marsh, Laura Simuni, Tanya Troester, Alexander I. Uc, Ergun Y. CA Parkinston Study Grp Cognitive Psychiat Working Grp TI A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; cognitive impairment; cognitive screening ID MINI-MENTAL-STATE; DEMENTIA RATING-SCALE; COMMUNITY POPULATION; IMPAIRMENT; VALIDATION; DONEPEZIL; DEFICITS; SCORE; MOCA; TOOL AB Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. (C) 2010 Movement Disorder Society C1 [Chou, Kelvin L.] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI 48109 USA. [Chou, Kelvin L.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA. [Amick, Melissa M.] Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02118 USA. [Amick, Melissa M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Brandt, Jason] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA. [Brandt, Jason] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Camicioli, Richard] Univ Alberta, Dept Med, Div Neurol, Edmonton, AB, Canada. [Frei, Karen] Parkinsons & Movement Disorders Inst, Fountain Valley, CA USA. [Gitelman, Darren; Simuni, Tanya] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA. [Gitelman, Darren] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Chicago, IL 60611 USA. [Goldman, Jennifer] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Growdon, John] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Hurtig, Howard I.] Univ Penn Hlth Syst, Dept Neurol, Philadelphia, PA USA. [Levin, Bonnie] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA. [Litvan, Irene] Univ Louisville, Sch Med, Dept Neurol, Louisville, KY 40292 USA. [Marsh, Laura] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Simuni, Tanya] Northwestern Univ, Feinberg Sch Med, Parkinsons Dis & Movement Disorders Ctr, Chicago, IL 60611 USA. [Troester, Alexander I.] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA. [Uc, Ergun Y.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA. [Uc, Ergun Y.] Vet Affairs Med Ctr, Iowa City, IA 52242 USA. RP Chou, KL (reprint author), Univ Michigan, Sch Med, Dept Neurol, 1500 E Med Ctr Dr,SPC 5316, Ann Arbor, MI 48109 USA. EM klchou@med.umich.edu OI Brandt, Jason/0000-0001-7381-6244; Chou, Kelvin/0000-0002-2597-7315; Camicioli, Richard/0000-0003-2977-8660; Litvan, Irene/0000-0002-3485-3445 FU NIH [NS44504-08, K23060949, R01 NS36711-05A2, MH069666, P50NS38377, HD39822 M032413, NS037167, NS36630-08]; HSG; Michael J. Fox Foundation; Boehringer Ingelheim; NIH via the Parkinson Study Group; Canadian Institute for Health Research; Novartis; National Parkinson Foundation; Parkinson's Disease Foundation; Teva; Solvay; GlaxoSmithKline; Chiltern; Eli Lilly; Forest Research Institute; Takeda; Medtronic Inc; Department of Veterans Affairs; Parkinson Study Group; Ortho-McNeil Pharmaceutical, Inc FX Dr. Chou receives research support from the NIH (NS44504-08), participates as a site-PI in clinical trials sponsored by the HSG (PHAROS, 2CARE, and CREST-HD), receives royalties from UpToDate, has received honoraria for lectures from Teva Neurosciences, Medtronic, Inc., and Allergan, and has served as a consultant to Medtronic Inc., and Teva Neurosciences. Dr. Amick receives research support from the Michael J. Fox Foundation. She has received funds from Boehringer Ingelheim and Ortho-McNeil Pharmaceutical, Inc for coordination of clinical trials. Dr. Brandt receives royalties from Psychological Assessment Resources, Inc. and occasionally gives expert witness testimony related to clinical cases. Dr. Camicioli has received research support from the NIH via the Parkinson Study Group, operating grant support from the Canadian Institute for Health Research, and a one time unrestricted clinical grant and clinical trials payment from Novartis. Dr. Frei has no financial disclosures to make. Dr. Gitelman is consultant for Abiant Inc. and has received research support from the National Parkinson Foundation and the Michael J. Fox Foundation. Dr. Goldman has received research support from NIH K23060949 and the Parkinson's Disease Foundation and has participated as site-PI in clinical trials by Merz (blepharospasm) and Parkinson's Study Group/Boehringer-Ingelheim (PRAMI-BID). Dr. Growdon serves on the editorial board for Archives of Neurology and Neurodegenerative Diseases. He has received royalties from Elsevier for a book, "The Dementias 2'', and serves as an advisor for Neurimmune. Dr. Hurtig has received research support from Teva, Solvay, Boehringer-Ingelheim, Novartis, and GlaxoSmithKline, receives royalties from UpToDate, and has received honoraria from Teva (visiting lecturer Brown University 6/3/09). Dr. Levin has no financial disclosures to report. Dr. Litvan has received research support from Chiltern, NIH R01 NS36711-05A2, Parkinson Study Group and National Parkinson Foundation, and has served as a consultant for Noscira. Dr. Marsh has received research support from the NIH (Grants #MH069666, P50NS38377, HD39822 M032413, NS037167, NS36630-08), the Michael J. Fox Foundation, Eli Lilly, Forest Research Institute, and Boehringer-Ingelheim, and received honoraria from serving as a consultant to Boehringer-Ingelheim, Ovation Pharmaceuticals, Acadia Pharmaceuticals, and Merck Serono. Dr. Simuni has received research grant support from the NIH, Teva, Boehringer-Ingelheim, GlaxoSmithKline, Novartis and Takeda, and has served as a consultant for Boehringer-Ingelheim, Allergan, Teva, GlaxoSmithKline, Novartis, UCB, Valeant and Vernalis. Dr. Troster has received research support from the National Parkinson Foundation, GlaxoSmithKline, and Medtronic Inc,, performs neuropsychological testing in his clinical practice (75% effort), and serves as a consultant to Medtronic, Inc. and St. Jude Neuromodulation. Dr. Uc receives research support from the National Institutes of Health, Department of Veterans Affairs, Parkinson's Disease Foundation, and has received compensation from the NIH and the Parkinson Study Group as a grant reviewer. NR 33 TC 54 Z9 57 U1 2 U2 11 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV 15 PY 2010 VL 25 IS 15 BP 2501 EP 2507 DI 10.1002/mds.23362 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 678FX UT WOS:000284060600004 PM 20878991 ER PT J AU Gao, XA Schwarzschild, MA O'Reilly, EJ Wang, H Ascherio, A AF Gao, Xiang Schwarzschild, Michael A. O'Reilly, Eilis J. Wang, Hao Ascherio, Alberto TI Restless Legs Syndrome and Parkinson's Disease in Men SO MOVEMENT DISORDERS LA English DT Article DE restless legs syndrome; Parkinson's disease; men ID CORONARY-HEART-DISEASE; PHOBIC ANXIETY; RISK; DIAGNOSIS; WOMEN; PATHOPHYSIOLOGY; PREVALENCE; QUALITY AB We examined whether men with restless legs syndrome (RLS) have a higher prevalence of Parkinson's disease (PD) among 23,119 US participants of the Health Professional Follow-up Study who were free of diabetes and arthritis. RLS was assessed using a set of standardized questions recommended by the International RLS Study Group. PD cases were identified by self-reported questionnaires and confirmed by review of medical records. Compared to men without RLS, multivariate-adjusted odds ratios for PD were 1.1 (95% confidence interval: 0.4, 3.0) for men with RLS symptoms 5-14 times per month and 3.09 (95% confidence interval: 1.5, 6.2; P trend = 0.003) for those with symptoms 15 times or more per month, after adjusting for age, smoking, use of antidepressant, and other covariates. In conclusion, men with RLS are more likely to have concurrent PD. Prospective studies are warranted to clarify the temporal relationship between RLS and PD. (C) 2010 Movement Disorder Society C1 [Gao, Xiang; Ascherio, Alberto] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA. [Gao, Xiang; Ascherio, Alberto] Harvard Univ, Sch Med, Boston, MA USA. [Gao, Xiang; O'Reilly, Eilis J.; Wang, Hao; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Schwarzschild, Michael A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [O'Reilly, Eilis J.; Ascherio, Alberto] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Gao, XA (reprint author), Brigham & Womens Hosp, Dept Med, Channing Lab, 181 Longwood Ave, Boston, MA USA. EM ludger.schoels@uni-tuebingen.de FU NIH/NINDS [R01 NS048517, R01 NS062879-01A2, K24 NS060991, R01 NS 054978, R21 NS058324]; US Department of Defense [W81XHW-04-1-0881, W81XWH-05-1-0117]; Michael J Fox Foundation; Parkinson Disease Foundation; RJG Parkinson's disease Foundation; American Federation for Aging Research; NIH [R01 NS045893, R01 NS047467, R01NS48517, R01 NS042194, R01 NS046635] FX The study was supported by NIH/NINDS grant R01 NS048517 and NIH/NINDS grant R01 NS062879-01A2. None of the sponsors participated in the design of study or in the collection, analysis, or interpretation of the data.; Gao: Advisory Boards: Dr. Gao serves on the Monitoring Committee of the Parkinson Study Group; Employment: Instructor in Medicine at Harvard Medical School; Research Scientist at Harvard School of Public Health; Associate Epidemiologist, Brigham and Women's Hospital; Grants: PI for NIH/NINDS grant "Prospective study of restless legs syndrome'' (R01 NS062879-01A2). Schwarzschild: Employment: Associate Professor in Medicine at Harvard Medical School and Mass General Hospital; Honoraria: Non-industry-sponsored speaker honoraria; Grants: PI for NIH/NINDS grant (K24 NS060991, R01 NS 054978, R21 NS058324), the US Department of Defense (W81XHW-04-1-0881) and the Michael J Fox Foundation, the Parkinson Disease Foundation, the RJG Parkinson's disease Foundation, and the American Federation for Aging Research. O'Reilly: Employment: Research fellow at Harvard School of Public Health. Wang: Employment: Research fellow at Harvard School of Public Health. Ascherio: Advisory Boards: Dr. Ascherio serves on the scientific advisory board of the Michael J Fox Foundation. Employment: Professor in Nutrition and Epidemiology at Harvard School of Public Health and Professor in Medicine at Harvard Medical School; Grants: PI for NIH (R01 NS045893, R01 NS047467, R01NS48517, R01 NS042194, and R01 NS046635) and the US department of Defense (W81XWH-05-1-0117). NR 24 TC 14 Z9 15 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV 15 PY 2010 VL 25 IS 15 BP 2654 EP 2657 DI 10.1002/mds.23256 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 678FX UT WOS:000284060600025 PM 20737545 ER PT J AU Montine, TJ Shi, M Quinn, JF Peskind, ER Craft, S Ginghina, C Chung, KA Kim, H Galasko, DR Jankovic, J Zabetian, CP Leverenz, JB Zhang, J AF Montine, Thomas J. Shi, Min Quinn, Joseph F. Peskind, Elaine R. Craft, Suzanne Ginghina, Carmen Chung, Kathryn A. Kim, Hojoong Galasko, Douglas R. Jankovic, Joseph Zabetian, Cyrus P. Leverenz, James B. Zhang, Jing TI CSF A beta(42) and tau in Parkinson's Disease with Cognitive Impairment SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; cognitive impairment; CSF biomarkers; A beta(42); tau ID CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; BIOMARKERS; DEMENTIA; RATIO; BETA AB We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF A beta(42), total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls <= 50 years (35), Controls > 50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Ab42 was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Ab42 may be a common feature of PD-CIND and PD-D. (c) 2010 Movement Disorder Society C1 [Montine, Thomas J.; Shi, Min; Ginghina, Carmen; Zhang, Jing] Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98104 USA. [Quinn, Joseph F.; Chung, Kathryn A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Peskind, Elaine R.; Craft, Suzanne] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98104 USA. [Peskind, Elaine R.; Leverenz, James B.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, VA NW Network Mental Illness Res, Seattle, WA USA. [Craft, Suzanne; Kim, Hojoong; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Kim, Hojoong; Zabetian, Cyrus P.; Leverenz, James B.] Univ Washington, Dept Neurol, Sch Med, Seattle, WA 98104 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Jankovic, Joseph] Baylor Coll Med, Parkinsons Dis Ctr, Houston, TX 77030 USA. [Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA. RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, Sch Med, 300 9th Ave,Room 713B, Seattle, WA 98104 USA. EM tmontine@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558 FU NIH [ES004696, NS057567, AG025327, AG033398, NS060252, NS062684, AG05136, AG08017] FX This work was supported by grants from the NIH (ES004696, NS057567, AG025327, AG033398, NS060252, NS062684, AG05136, and AG08017), the Michael J. Fox Foundation, the VA, and the Nancy and Buster Alvord Endowment. This support had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. We thank Dr. Kathleen Montine for editorial assistance. NR 19 TC 86 Z9 89 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV 15 PY 2010 VL 25 IS 15 BP 2682 EP 2685 DI 10.1002/mds.23287 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 678FX UT WOS:000284060600032 PM 20818673 ER PT J AU Ehrlich, S Morrow, EM Roffman, JL Wallace, SR Naylor, M Bockholt, HJ Lundquist, A Yendiki, A Ho, BC White, T Manoach, DS Clark, VP Calhoun, VD Gollub, RL Holt, DJ AF Ehrlich, Stefan Morrow, Eric M. Roffman, Joshua L. Wallace, Stuart R. Naylor, Melissa Bockholt, H. Jeremy Lundquist, Antonia Yendiki, Anastasia Ho, Beng-Choon White, Tonya Manoach, Dara S. Clark, Vincent P. Calhoun, Vince D. Gollub, Randy L. Holt, Daphne J. TI The COMT Val108/158Met polymorphism and medial temporal lobe volumetry in patients with schizophrenia and healthy adults SO NEUROIMAGE LA English DT Article DE COMT Val108/158Met Polymorphism; Amygdala; Hippocampus; Structural MRI; Schizophrenia; Dopamine ID CATECHOL-O-METHYLTRANSFERASE; VAL(158)MET GENOTYPE; BRAIN STRUCTURE; FUNCTIONAL POLYMORPHISM; HIPPOCAMPAL VOLUME; PREFRONTAL CORTEX; GENE POLYMORPHISM; WORKING-MEMORY; HIGH-RISK; ASSOCIATION AB Abnormalities of the medial temporal lobe have been consistently demonstrated in schizophrenia. A common functional polymorphism, Val108/158Met, in the putative schizophrenia susceptibility gene, catechol-O-methyltransferase (COMT), has been shown to influence medial temporal lobe function. However, the effects of this polymorphism on volumes of medial temporal lobe structures, particularly in patients with schizophrenia, are less clear. Here we measured the effects of COMT Val108/158Met genotype on the volume of two regions within the medial temporal lobe, the amygdala and hippocampus, in patients with schizophrenia and healthy control subjects. We obtained MRI and genotype data for 98 schizophrenic patients and 114 matched controls. An automated atlas-based segmentation algorithm was used to generate volumetric measures of the amygdala and hippocampus. Regression analyses included COMT met allele load as an additive effect, and also controlled for age, intracranial volume, gender and acquisition site. Across patients and controls, each copy of the COMT met allele was associated on average with a 2.6% increase in right amygdala volume, a 3.8% increase in left amygdala volume and a 2.2% increase in right hippocampus volume. There were no effects of COMT genotype on volumes of the whole brain and prefrontal regions. Thus, the COMT Val108/158Met polymorphism was shown to influence medial temporal lobe volumes in a linear-additive manner, mirroring its effect on dopamine catabolism. Taken together with previous work, our data support a model in which lower COMT activity, and a resulting elevation in extracellular dopamine levels, stimulates growth of medial temporal lobe structures. (C) 2009 Elsevier Inc. All rights reserved. C1 [Ehrlich, Stefan; Roffman, Joshua L.; Wallace, Stuart R.; Lundquist, Antonia; Yendiki, Anastasia; Manoach, Dara S.; Gollub, Randy L.; Holt, Daphne J.] Massachusetts Gen Hosp, MGH MIT HMS Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Ehrlich, Stefan; Morrow, Eric M.; Roffman, Joshua L.; Wallace, Stuart R.; Manoach, Dara S.; Gollub, Randy L.; Holt, Daphne J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Ehrlich, Stefan] Charite Univ Med Berlin, Dept Psychiat, Berlin, Germany. [Morrow, Eric M.] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA. [Naylor, Melissa] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Bockholt, H. Jeremy; Clark, Vincent P.; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA. [Ho, Beng-Choon] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA. [White, Tonya] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [White, Tonya] Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN USA. [Clark, Vincent P.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA. [Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA. RP Ehrlich, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St, Charlestown, MA 02129 USA. EM stefan@nmr.mgh.harvard.edu RI Ho, Beng-Choon/D-6959-2011; Calhoun, Vince/H-7146-2013; Morrow, Eric/J-2767-2013; Clark, Vincent/B-3343-2010; OI Ho, Beng-Choon/0000-0003-3976-1555; Calhoun, Vince/0000-0001-9058-0747; Clark, Vincent/0000-0002-9151-2102; Ehrlich, Stefan/0000-0003-2132-4445; Gollub, Randy L./0000-0002-9434-4044 FU Janssen-Cilag; Solvay Pharmaceuticals; NIH/NCRR [P41RR14075]; Department of Energy, Mental Illness and Neuroscience Discovery (MIND) Research Network; Morphometry Biomedical Informatics Research Network (mBIRN) [1U24, RR021382A, BIRN U24RR021992, NIMH K23 MH076054, NIMH K23 MH080954]; National Alliance for Research in Schizophrenia and Depression; Sidney R. Baer, Jr Foundation; Burroughs Wellcome Fund; Nellie Ball Research Trust; Deutsche Forschungsgemeinschaft; Harvard Clinical and Translational Science Center, National Center for Research Resources [M01-RR-01066] FX During the preceding 5 years, Dr. Ho has received research funding from Janssen-Cilag, and consulting fees from Solvay Pharmaceuticals. All other authors declare no biomedical financial interests or potential conflicts of interest.; This work was supported by NIH/NCRR P41RR14075, Department of Energy, Mental Illness and Neuroscience Discovery (MIND) Research Network, Morphometry Biomedical Informatics Research Network (mBIRN) 1U24, RR021382A, Function BIRN U24RR021992, NIMH K23 MH076054 (D.J.H.), NIMH K23 MH080954 (E.M.M.), National Alliance for Research in Schizophrenia and Depression (D.J.H., B.C.H., E.M.M.) with the Sidney R. Baer, Jr Foundation (D.J.H.), Burroughs Wellcome Fund (E.M.M.), the Nellie Ball Research Trust (B.C.H.) and the Deutsche Forschungsgemeinschaft (SE.). The project was also supported by M01-RR-01066, Harvard Clinical and Translational Science Center, from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Research Resources or the National Institutes of Health. NR 62 TC 46 Z9 47 U1 3 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD NOV 15 PY 2010 VL 53 IS 3 BP 992 EP 1000 DI 10.1016/j.neuroimage.2009.12.046 PG 9 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 652VQ UT WOS:000282039300023 PM 20026221 ER PT J AU Kremen, WS O'Brien, RC Panizzon, MS Prom-Wormley, E Eaves, LJ Eisen, SA Eyler, LT Hauger, RL Fennema-Notestine, C Fischl, B Grant, MD Hellhammer, DH Jak, AJ Jacobson, KC Jernigan, TL Lupien, SJ Lyons, MJ Mendoza, SP Neale, MC Seidman, LJ Thermenos, HW Tsuang, MT Dale, AM Franz, CE AF Kremen, William S. O'Brien, Robert C. Panizzon, Matthew S. Prom-Wormley, Elizabeth Eaves, Lindon J. Eisen, Seth A. Eyler, Lisa T. Hauger, Richard L. Fennema-Notestine, Christine Fischl, Bruce Grant, Michael D. Hellhammer, Dirk H. Jak, Amy J. Jacobson, Kristen C. Jernigan, Terry L. Lupien, Sonia J. Lyons, Michael J. Mendoza, Sally P. Neale, Michael C. Seidman, Larry J. Thermenos, Heidi W. Tsuang, Ming T. Dale, Anders M. Franz, Carol E. TI Salivary cortisol and prefrontal cortical thickness in middle-aged men: A twin study SO NEUROIMAGE LA English DT Article DE Heritability; Magnetic resonance imaging (MRI); Hippocampus; HPA axis structure; Genetic correlation ID PITUITARY-ADRENAL AXIS; HUMAN CEREBRAL-CORTEX; SURFACE-BASED ANALYSIS; HEALTHY ELDERLY-MEN; PLASMA-CORTISOL; HIPPOCAMPAL ATROPHY; CINGULATE CORTEX; STRESS; BRAIN; VOLUME AB Although glucocorticoid receptors are highly expressed in the prefrontal cortex, the hippocampus remains the predominant focus in the literature examining relationships between cortisol and brain. We examined phenotypic and genetic associations of cortisol levels with the thickness of prefrontal and anterior cingulate cortex regions, and with hippocampal volume in a sample of 388 middle-aged male twins who were 5159 years old. Small but significant negative phenotypic associations were found between cortisol levels and the thickness of left dorsolateral (superior frontal gyrus, left rostral middle frontal gyrus) and ventrolateral (pars opercularis, pars triangularis, pars orbitalis) prefrontal regions, and right dorsolateral (superior frontal gyrus) and medial orbital frontal cortex. Most of the associations remained significant after adjusting for general cognitive ability, cardiovascular risk factors, and depression. Bivariate genetic analyses suggested that some of the associations were primarily accounted for by shared genetic influences; that is, some of the genes that tend to result in increased cortisol levels also tend to result in reduced prefrontal cortical thickness. Aging has been associated with reduced efficiency of hypothalamic-pituitary-adrenal function, frontal lobe shrinkage, and increases in health problems, but our present data do not allow us to determine the direction of effects. Moreover, the degree or the direction of the observed associations and the extent of their shared genetic underpinnings may well change as these individuals age. Longitudinal assessments are underway to elucidate the direction of the associations and the genetic underpinnings of longitudinal phenotypes for changes in cortisol and brain morphology. (c) 2010 Published by Elsevier Inc. C1 [Kremen, William S.; O'Brien, Robert C.; Panizzon, Matthew S.; Eyler, Lisa T.; Hauger, Richard L.; Fennema-Notestine, Christine; Jak, Amy J.; Jernigan, Terry L.; Tsuang, Ming T.; Franz, Carol E.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Kremen, William S.; Tsuang, Ming T.] Univ Calif San Diego, Ctr Behav Genom, La Jolla, CA 92093 USA. [Kremen, William S.; Eyler, Lisa T.; Hauger, Richard L.; Jak, Amy J.; Tsuang, Ming T.] VA San Diego Healthcare Syst, La Jolla, CA USA. [Prom-Wormley, Elizabeth; Eaves, Lindon J.; Neale, Michael C.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA. [Prom-Wormley, Elizabeth; Eaves, Lindon J.; Neale, Michael C.] Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA USA. [Eisen, Seth A.] Dept Vet Affairs, Washington, DC USA. [Eisen, Seth A.] Washington Univ, Dept Med, St Louis, MO USA. [Eisen, Seth A.] Washington Univ, Dept Psychiat, St Louis, MO USA. [Fennema-Notestine, Christine] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA. [Fischl, Bruce; Dale, Anders M.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Fischl, Bruce; Dale, Anders M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Grant, Michael D.; Lyons, Michael J.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Hellhammer, Dirk H.] Univ Trier, Dept Clin & Physiol Psychol, Trier, Germany. [Jacobson, Kristen C.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA. [Lupien, Sonia J.] Univ Montreal, Hop Louis H Lafontaine, Mental Hlth Res Ctr Fernand Seguin, Montreal, PQ H3C 3J7, Canada. [Mendoza, Sally P.] Univ Calif Davis, Davis Primate Ctr, Davis, CA 95616 USA. [Seidman, Larry J.; Thermenos, Heidi W.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Dale, Anders M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. RP Kremen, WS (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr MC 0738, La Jolla, CA 92093 USA. EM wkremen@ucsd.edu RI Lyons, Michael/B-6119-2011; Jacobson, Kristen/D-2064-2009; Hellhammer, Dirk/F-1888-2013; OI Lyons, Michael/0000-0001-6516-9219; Fennema-Notestine, Christine/0000-0002-6527-6361; Prom-Wormley, Elizabeth/0000-0001-9230-9723 FU National Institute on Aging [AG022982, AG018384, AG018386]; National Center for Research Resources [P41-RR14075, BIRN002]; National Institute for Biomedical Imaging and Bioengineering [R01 EB006758]; National Institute for Neurological Disorders and Stroke [R01 NS052585-01]; Mental Illness and Neuroscience Discovery (MIND) Institute; National Alliance for Medical Image Computing (NAMIC); National Institutes of Health through the NIH Roadmap for Medical Research [U54 EB005149]; Ellison Medical Foundation; U.S. Department of Veterans Affairs FX Funded by National Institute on Aging (AG022982, AG022381, AG018384, AG018386); National Center for Research Resources (P41-RR14075; NCRR BIRN Morphometric Project BIRN002); National Institute for Biomedical Imaging and Bioengineering (R01 EB006758); National Institute for Neurological Disorders and Stroke (R01 NS052585-01); Mental Illness and Neuroscience Discovery (MIND) Institute, part of the National Alliance for Medical Image Computing (NAMIC), funded by the National Institutes of Health through the NIH Roadmap for Medical Research, Grant U54 EB005149. Additional support was provided by The Autism & Dyslexia Project funded by the Ellison Medical Foundation. The U.S. Department of Veterans Affairs has provided financial support for the development and maintenance of the Vietnam Era Twin (VET) Registry. Numerous organizations have provided invaluable assistance in the conduct of this study, including: Department of Defense; National Personnel Records Center, National Archives and Records Administration; Internal Revenue Service; National Opinion Research Center; National Research Council, National Academy of Sciences; the Institute for Survey Research, Temple University. Most importantly, the authors gratefully acknowledge the continued cooperation and participation of the members of the VET Registry and their families. Without their contribution this research would not have been possible. NR 82 TC 34 Z9 34 U1 1 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD NOV 15 PY 2010 VL 53 IS 3 BP 1093 EP 1102 DI 10.1016/j.neuroimage.2010.02.026 PG 10 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 652VQ UT WOS:000282039300035 PM 20156572 ER PT J AU Kamat, A Ancuta, P Blumberg, RS Gabuzda, D AF Kamat, Anupa Ancuta, Petronela Blumberg, Richard S. Gabuzda, Dana TI Serological Markers for Inflammatory Bowel Disease in AIDS Patients with Evidence of Microbial Translocation SO PLOS ONE LA English DT Article ID ANTI-SACCHAROMYCES-CEREVISIAE; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL DEPLETION; ACTIVE ANTIRETROVIRAL THERAPY; ULCERATIVE-COLITIS PATIENTS; POUCH-ANAL ANASTOMOSIS; MEMBRANE PORIN-C; CROHNS-DISEASE; HIV-INFECTION AB Background: Breakdown of the gut mucosal barrier during chronic HIV infection allows translocation of bacterial products such as lipopolysaccharides (LPS) from the gut into the circulation. Microbial translocation also occurs in inflammatory bowel disease (IBD). IBD serological markers are useful in the diagnosis of IBD and to differentiate between Crohn's disease (CD) and ulcerative colitis (UC). Here, we evaluate detection of IBD serological markers in HIV-infected patients with advanced disease and their relationship to HIV disease markers. Methods: IBD serological markers (ASCA, pANCA, anti-OmpC, and anti-CBir1) were measured by ELISA in plasma from AIDS patients (n = 26) with low CD4 counts (<300 cells/mu l) and high plasma LPS levels, and results correlated with clinical data. For meta-analysis, relevant data were abstracted from 20 articles. Results: IBD serological markers were detected in approximately 65% of AIDS patients with evidence of microbial translocation. An antibody pattern consistent with IBD was detected in 46%; of these, 75% had a CD-like pattern. Meta-analysis of data from 20 published studies on IBD serological markers in CD, UC, and non-IBD control subjects indicated that IBD serological markers are detected more frequently in AIDS patients than in non-IBD disease controls and healthy controls, but less frequently than in CD patients. There was no association between IBD serological markers and HIV disease markers (plasma viral load and CD4 counts) in the study cohort. Conclusions: IBD serological markers may provide a non-invasive approach to monitor HIV-related inflammatory gut disease. Further studies to investigate their clinical significance in HIV-infected individuals are warranted. C1 [Kamat, Anupa; Gabuzda, Dana] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Blumberg, Richard S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Ancuta, Petronela] INSERM, U743, Montreal, PQ, Canada. [Ancuta, Petronela] Univ Montreal, Dept Microbiol & Immunol, Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Montreal, PQ H3C 3J7, Canada. RP Kamat, A (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM dana_gabuzda@dfci.harvard.edu FU NIH [DA26322, MH083588, DK44319, DK51362, DK53056]; Harvard Digestive Diseases Center for AIDS Research and DFCI/Harvard Center for Cancer Research; Fonds de la Recherche en Sante Quebec (FRSQ); INSERM; [MH59745]; [NS38841]; [MH59656]; [NS54591]; [MH59724] FX This work was supported by NIH DA26322 and MH083588. R. B. was supported by NIH DK44319, DK51362, DK53056, and the Harvard Digestive Diseases Center. P.A. was supported by New Investigator Awards from Fonds de la Recherche en Sante Quebec (FRSQ) and INSERM. Core facilities were supported by the Harvard Center for AIDS Research and DFCI/Harvard Center for Cancer Research grants. NNTC sites were supported by MH59745, NS38841, MH59656, NS54591, and MH59724. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 85 TC 19 Z9 21 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 15 PY 2010 VL 5 IS 11 AR e15533 DI 10.1371/journal.pone.0015533 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 680KW UT WOS:000284231800040 PM 21125014 ER PT J AU Perlot, T Pawlitzky, I Manis, JP Zarrin, AA Brodeur, PH Alt, FW AF Perlot, Thomas Pawlitzky, Inka Manis, John P. Zarrin, Ali A. Brodeur, Peter H. Alt, Frederick W. TI Analysis of Mice Lacking DNaseI Hypersensitive Sites at the 5 ' End of the IgH Locus SO PLOS ONE LA English DT Article ID HEAVY-CHAIN LOCUS; LYMPHOCYTE DEVELOPMENT; IMMUNOGLOBULIN LOCI; V(D)J RECOMBINATION; ENHANCER; REGION; GENE; COMPARTMENTALIZATION; REARRANGEMENTS; MECHANISM AB The 5' end of the IgH locus contains a cluster of DNaseI hypersensitive sites, one of which (HS1) was shown to be pro-B cell specific and to contain binding sites for the transcription factors PU. 1, E2A, and Pax5. These data as well as the location of the hypersensitive sites at the 5' border of the IgH locus suggested a possible regulatory function for these elements with respect to the IgH locus. To test this notion, we generated mice carrying targeted deletions of either the pro-B cell specific site HS1 or the whole cluster of DNaseI hypersensitive sites. Lymphocytes carrying these deletions appear to undergo normal development, and mutant B cells do not exhibit any obvious defects in V(D)J recombination, allelic exclusion, or class switch recombination. We conclude that deletion of these DNaseI hypersensitive sites does not have an obvious impact on the IgH locus or B cell development. C1 [Perlot, Thomas; Zarrin, Ali A.; Alt, Frederick W.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Immune Dis Inst, Boston, MA 02115 USA. [Perlot, Thomas; Zarrin, Ali A.; Alt, Frederick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Pawlitzky, Inka; Brodeur, Peter H.] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Program Immunol, Boston, MA 02111 USA. [Manis, John P.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Manis, John P.] Harvard Univ, Sch Med, Joint Program Transfus Med, Boston, MA USA. RP Perlot, T (reprint author), Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1010 Vienna, Austria. EM alt@enders.tch.harvard.edu FU National Institutes of Health [R01 AI020047, GM36064] FX This work was funded by National Institutes of Health R01 AI020047 (to FWA) and GM36064 (to PHB). FWA is an Investigator of the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 20 TC 7 Z9 7 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 15 PY 2010 VL 5 IS 11 AR e13992 DI 10.1371/journal.pone.0013992 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 680KW UT WOS:000284231800022 PM 21085586 ER PT J AU Yin, MT Shi, QH Hoover, DR Anastos, K Sharma, A Young, M Levine, A Cohen, MH Shane, E Golub, ET Tien, PC AF Yin, Michael T. Shi, Qiuhu Hoover, Donald R. Anastos, Kathryn Sharma, Anjali Young, Mary Levine, Alexandra Cohen, Mardge H. Shane, Elizabeth Golub, Elizabeth T. Tien, Phyllis C. TI Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study SO AIDS LA English DT Article DE fracture; fragility fracture; HIV-infected women; premenopausal ID BONE-MINERAL DENSITY; ANTIRETROVIRAL THERAPY; AIDS PATIENTS; MEN; OSTEOPOROSIS; PREVALENCE; OSTEOPENIA; INITIATION; DECREASES; EFAVIRENZ AB Background: The clinical importance of the association of HIV infection and antiretroviral therapy (ART) with low bone mineral density (BMD) in premenopausal women is uncertain because BMD stabilizes on established ART and fracture data are limited. Methods: We measured time to first new fracture at any site with median follow-up of 5.4 years in 2391 (1728 HIV-infected, 663 HIV-uninfected) participants in the Women's Interagency HIV Study (WIHS). Self-report of fracture was recorded at semiannual visits. Proportional hazard models assessed predictors of incident fracture. Results: At baseline, HIV-infected women were older (40 +/- 9 vs. 36 +/- 10 years, P<0.0001), more likely to report postmenopausal status and be hepatitis C virus-infected, and weighed less than HIV-uninfected women. Among HIV-infected women, mean CD4(+) cell count was 482 cells/mu l; 66% were taking ART. Unadjusted incidence of fracture did not differ between HIV-infected and uninfected women (1.8 vs. 1.4/100 person-years, respectively, P - 0.18). In multivariate models, white (vs. African-American) race, hepatitis C virus infection, and higher serum creatinine, but not HIV serostatus, were statistically significant predictors of incident fracture. Among HIV-infected women, older age, white race, current cigarette use, and history of AIDS-defining illness were associated with incidence of new fracture. Conclusion: Among predominantly premenopausal women, there was little difference in fracture incidence rates by HIV status, rather traditional risk factors were important predictors. Further research is necessary to characterize fracture risk in HIV-infected women during and after the menopausal transition. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Yin, Michael T.] Columbia Univ, Div Infect Dis, Med Ctr, New York, NY 10032 USA. [Shi, Qiuhu] New York Med Coll, Valhalla, NY 10595 USA. [Hoover, Donald R.] Rutgers State Univ, Piscataway, NJ USA. [Anastos, Kathryn] Montefiore Med Ctr, Bronx, NY 10467 USA. [Sharma, Anjali] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA. [Young, Mary] Georgetown Sch Med, Washington, DC USA. [Levine, Alexandra] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Golub, Elizabeth T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Tien, Phyllis C.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Dept Med, Chicago, IL 60612 USA. RP Yin, MT (reprint author), Columbia Univ, Div Infect Dis, Med Ctr, 630 W168th St,PH8-876, New York, NY 10032 USA. EM Mty4@columbia.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590, K23 AI 059884, K23 AI 066943]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI) [UL1 RR024131] FX The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Drs. Yin and Tien are supported by the National Institute of Allergy and Infectious Diseases through K23 AI 059884 and K23 AI 066943, respectively. NR 36 TC 46 Z9 46 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD NOV 13 PY 2010 VL 24 IS 17 BP 2679 EP 2686 DI 10.1097/QAD.0b013e32833f6294 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 672KV UT WOS:000283582800010 PM 20859192 ER PT J AU Yamada, M Kida, K Amutuhaire, W Ichinose, F Kaneki, M AF Yamada, Marina Kida, Kotaro Amutuhaire, Willington Ichinose, Fumito Kaneki, Masao TI Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Parkinson's disease; MPTP; Caspase-3; Apoptosis; Substantia nigra; Striatum ID 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MOUSE MODEL; SUBSTANTIA-NIGRA; CELL-DEATH; DOPAMINERGIC-NEURONS; APOPTOTIC NUCLEI; PARS COMPACTA; C57BL/6 MICE; ACTIVATION; MECHANISMS; NEURODEGENERATION AB The development of Parkinson's disease is accompanied by concurrent activation of caspase-3 and apoptosis of dopaminergic neurons of human patients and rodent models. The role of caspase-3, a final executioner of apoptosis, in the pathogenesis of Parkinson's disease, however, remains to be determined. Here, we show that gene disruption of caspase-3 protects mice from 1-methyle-4-phenyl-1,2,3,6-tetrahmydropyridine (MPTP)-induced Parkinsonian syndrome, as reflected by reversal of MPTP-induced bradykinesia and decreased tyrosine hydroxylase expression in the nigra-striatum. MPTP treatment resulted in increased caspase-3 activation and apoptosis in the substantia nigra of wild-type mice at 24 h after the inception of MPTP treatment, as compared with vehicle-treated control animals. Gene disruption of caspase-3 prevented MPTP-induced apoptosis in the substantia nigra. At 7 days after MPTP treatment, tyrosine hydroxylase expression was suppressed and infiltration of activated microglia and astrocytes was markedly increased in the nigra-striatum of wild-type mice. All of these alterations following MPTP treatment were blocked by disruption of caspase-3 in mice. These results clearly indicate that caspase-3 activation is required for the development of MPTP-induced Parkinson's disease in mice. These findings suggest that activation of caspase-3-mediated apoptosis of dopaminergic neurons in the early stage may play an important role in the pathogenesis of Parkinson's disease. (C) 2010 Elsevier Inc. All rights reserved. C1 [Yamada, Marina; Kida, Kotaro; Amutuhaire, Willington; Ichinose, Fumito; Kaneki, Masao] Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Sch Med, Charlestown, MA 02129 USA. [Yamada, Marina; Kaneki, Masao] Shriners Hosp Children, Boston, MA 02114 USA. RP Kaneki, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Sch Med, 149 13th St,Rm 6604, Charlestown, MA 02129 USA. EM mkaneki@helix.mgh.harvard.edu FU Microscopy and Image Analysis Core of Massachusetts General Hospital, National Institutes of Health [P30 NS045776]; [R01 DK05827]; [R01 HL101930] FX We are grateful to Dr. T.W. Mak for providing caspase-3 knock-out mice. We thank Dr. C. Waeber for helpful technical assistance. This work was partly supported by research Grants to M.K. (R01 DK05827), F.I. (R01 HL101930), and the Microscopy and Image Analysis Core of Massachusetts General Hospital (P30 NS045776) from the National Institutes of Health. NR 40 TC 19 Z9 24 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 12 PY 2010 VL 402 IS 2 BP 312 EP 318 DI 10.1016/j.bbrc.2010.10.023 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 688PA UT WOS:000284862300027 PM 20937256 ER PT J AU Larson, JL Yuan, GC AF Larson, Jessica L. Yuan, Guo-Cheng TI Epigenetic domains found in mouse embryonic stem cells via a hidden Markov model SO BMC BIOINFORMATICS LA English DT Article ID CHIP-SEQ DATA; HUMAN GENOME; CHROMATIN-STRUCTURE; GENE-EXPRESSION; NONCODING RNAS; PLURIPOTENT; METHYLATION; DROSOPHILA; POLYCOMB; HETEROCHROMATIN AB Background: Epigenetics is an important layer of transcriptional control necessary for cell-type specific gene regulation. Recent studies have shown significant epigenetic patterns associated with developmental stages and diseases. However, previous studies have been mostly limited to focal epigenetic patterns, whereas methods for analyzing large-scale organizations are still lacking. Results: We developed a hidden Markov model (HMM) approach for detecting the types and locations of epigenetic domains from multiple histone modifications. We used this method to analyze a published ChIP-seq dataset of five histone modification marks (H3K4me2, H3K4me3, H3K27me3, H3K9me3, and H3K36me3) in mouse embryonic stem (ES) cells. We identified three types of domains, corresponding to active, non-active, and null states. In total, our three-state HMM identified 258 domains in the mouse genome containing 9.6 genes on average. These domains were validated by a number of criteria. The largest domains correspond to olfactory receptor (OR) gene clusters. Each Hox gene cluster also forms a separate epigenetic domain. We found that each type of domain is associated with distinct biological functions and structural changes during early cell differentiation. Conclusions: The HMM approach successfully detects domains of consistent epigenetic patterns from ChIP-seq data, providing new insights into the role of epigenetics in long-range gene regulation. C1 [Larson, Jessica L.; Yuan, Guo-Cheng] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Yuan, Guo-Cheng] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Yuan, GC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. EM gcyuan@jimmy.harvard.edu FU NIH [T32 GM074897] FX This research was supported by an NIH training grant (T32 GM074897) awarded to J. Larson and a Claudia Adams Barr Award (to GY). NR 39 TC 12 Z9 12 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2105 J9 BMC BIOINFORMATICS JI BMC Bioinformatics PD NOV 12 PY 2010 VL 11 AR 557 DI 10.1186/1471-2105-11-557 PG 12 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Mathematical & Computational Biology GA 685CA UT WOS:000284600800001 PM 21073706 ER PT J AU Walsh, RM Hochedlinger, K AF Walsh, Ryan M. Hochedlinger, Konrad TI Modeling Rett Syndrome with Stem Cells SO CELL LA English DT Editorial Material ID CPG-BINDING PROTEIN-2; MECP2; SYMPTOMS; REVERSAL; MICE C1 [Walsh, Ryan M.; Hochedlinger, Konrad] Massachusetts Gen Hosp, Howard Hughes Med Inst, Ctr Regenerat Med, Boston, MA 02114 USA. [Walsh, Ryan M.; Hochedlinger, Konrad] Massachusetts Gen Hosp, Howard Hughes Med Inst, Ctr Canc, Boston, MA 02114 USA. [Walsh, Ryan M.; Hochedlinger, Konrad] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Walsh, Ryan M.; Hochedlinger, Konrad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Walsh, Ryan M.; Hochedlinger, Konrad] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Hochedlinger, K (reprint author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Ctr Regenerat Med, Boston, MA 02114 USA. EM khochedlinger@helix.mgh.harvard.edu FU NICHD NIH HHS [R01 HD058013]; NIH HHS [DP2 OD003266] NR 10 TC 13 Z9 13 U1 0 U2 2 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 J9 CELL JI Cell PD NOV 12 PY 2010 VL 143 IS 4 BP 499 EP 500 DI 10.1016/j.cell.2010.10.037 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 679GF UT WOS:000284149100006 PM 21074040 ER PT J AU Neely, GG Hess, A Costigan, M Keene, AC Goulas, S Langeslag, M Griffin, RS Belfer, I Dai, F Smith, SB Diatchenko, L Gupta, V Xia, CP Amann, S Kreitz, S Heindl-Erdmann, C Wolz, S Ly, CV Arora, S Sarangi, R Dan, D Novatchkova, M Rosenzweig, M Gibson, DG Truong, D Schramek, D Zoranovic, T Cronin, SJF Angjeli, B Brune, K Dietzl, G Maixner, W Meixner, A Thomas, W Pospisilik, JA Alenius, M Kress, M Subramaniam, S Garrity, PA Bellen, HJ Woolf, CJ Penninger, JM AF Neely, G. Gregory Hess, Andreas Costigan, Michael Keene, Alex C. Goulas, Spyros Langeslag, Michiel Griffin, Robert S. Belfer, Inna Dai, Feng Smith, Shad B. Diatchenko, Luda Gupta, Vaijayanti Xia, Cui-Ping Amann, Sabina Kreitz, Silke Heindl-Erdmann, Cornelia Wolz, Susanne Ly, Cindy V. Arora, Suchir Sarangi, Rinku Dan, Debasis Novatchkova, Maria Rosenzweig, Mark Gibson, Dustin G. Truong, Darwin Schramek, Daniel Zoranovic, Tamara Cronin, Shane J. F. Angjeli, Belinda Brune, Kay Dietzl, Georg Maixner, William Meixner, Arabella Thomas, Winston Pospisilik, J. Andrew Alenius, Mattias Kress, Michaela Subramaniam, Sai Garrity, Paul A. Bellen, Hugo J. Woolf, Clifford J. Penninger, Josef M. TI A Genome-wide Drosophila Screen for Heat Nociception Identifies alpha 2 delta 3 as an Evolutionarily Conserved Pain Gene SO CELL LA English DT Article ID BLOOD OXYGENATION; NEUROPATHIC PAIN; BARREL CORTEX; MECHANISMS; SYNESTHESIA; MORPHOGENESIS; TRANSDUCTION; STIMULATION; PERCEPTION; MANAGEMENT AB Worldwide, acute, and chronic pain affects 20% of the adult population and represents an enormous financial and emotional burden. Using genome-wide neuronal-specific RNAi knockdown in Drosophila, we report a global screen for an innate behavior and identify hundreds of genes implicated in heat nociception, including the alpha 2 delta family calcium channel subunit straightjacket (stj). Mice mutant for the stj ortholog CACNA2D3 (alpha 2 delta 3) also exhibit impaired behavioral heat pain sensitivity. In addition, in humans, alpha 2 delta 3 SNP variants associate with reduced sensitivity to acute noxious heat and chronic back pain. Functional imaging in alpha 2 delta 3 mutant mice revealed impaired transmission of thermal pain-evoked signals from the thalamus to higher-order pain centers. Intriguingly, in alpha 2 delta 3 mutant mice, thermal pain and tactile stimulation triggered strong cross-activation, or synesthesia, of brain regions involved in vision, olfaction, and hearing. C1 [Costigan, Michael; Woolf, Clifford J.] Harvard Univ, Sch Med, Childrens Hosp Boston, Program Neurobiol, Boston, MA 02115 USA. [Costigan, Michael; Woolf, Clifford J.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. [Neely, G. Gregory; Goulas, Spyros; Xia, Cui-Ping; Amann, Sabina; Novatchkova, Maria; Truong, Darwin; Schramek, Daniel; Zoranovic, Tamara; Cronin, Shane J. F.; Angjeli, Belinda; Meixner, Arabella; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria. [Neely, G. Gregory] Garvan Inst Med Res, Neurosci Program, Sydney, NSW 2010, Australia. [Hess, Andreas; Kreitz, Silke; Heindl-Erdmann, Cornelia; Wolz, Susanne; Brune, Kay] Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany. [Keene, Alex C.] NYU, Dept Biol, New York, NY 10003 USA. [Langeslag, Michiel; Kress, Michaela] Innsbruck Med Univ, Dept Physiol, Div Physiol & Med Phys, A-6020 Innsbruck, Austria. [Griffin, Robert S.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02129 USA. [Belfer, Inna; Dai, Feng] Univ Pittsburgh, Dept Anesthesiol, Mol Epidemiol Pain Program, Pittsburgh, PA USA. [Smith, Shad B.; Diatchenko, Luda; Gibson, Dustin G.; Maixner, William] Univ N Carolina, Ctr Neurosensory Disorders, Chapel Hill, NC 27599 USA. [Gupta, Vaijayanti; Arora, Suchir; Sarangi, Rinku; Dan, Debasis; Subramaniam, Sai] Strand Life Sci Pvt Ltd, Bangalore, Karnataka, India. [Bellen, Hugo J.] Baylor Coll Med, Dept Neurosci, Dept Mol & Human Genet, HHMI, Houston, TX 77030 USA. [Rosenzweig, Mark; Garrity, Paul A.] Brandeis Univ, Dept Biol, Natl Ctr Behav Genom, Waltham, MA 02458 USA. [Dietzl, Georg] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA. [Thomas, Winston] Deltagen Inc, San Mateo, CA 94403 USA. [Pospisilik, J. Andrew] Max Planck Inst Immunobiol, D-79108 Freiburg, Germany. [Alenius, Mattias] Linkoping Univ, Dept Clin & Expt Med, SE-58185 Linkoping, Sweden. RP Woolf, CJ (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Program Neurobiol, Boston, MA 02115 USA. EM clifford.woolf@childrens.harvard.edu; josef.penninger@imba.oeaw.ac.at RI neely, graham/A-6511-2011; Penninger, Josef/I-6860-2013; Schramek, Daniel/J-5792-2014; OI Penninger, Josef/0000-0002-8194-3777; zoranovic, tamara/0000-0002-5369-6385 FU National Institute of Health NRSA [1 F32GM086207-01]; NIH [NS039518, NS038253, NS044232]; Mary Curie IIF; EuroThymaide; DFG [661/TP4]; BMBF [01EM0514, 01GQ0731, 0314102]; Doerenkamp Foundation for Innovations in Animal and Consumer Protection FX We thank all members of our laboratories and the VDRC for helpful discussions and excellent technical support. We thank Ricardo de Matos Simoes for support with statistical analysis. We thank B.J. Dickson for elav/UAS Dicer 2 stocks. alpha 2 delta 3 mutant mice were generated by Deltagen (San Mateo, CA). J.M.P. is supported by grants from IMBA, the Austrian Ministry of Sciences, the Austrian Academy of Sciences, GEN-AU (AustroMouse), ApoSys, and an EU ERC Advanced Grant. A.C.K. is supported by National Institute of Health NRSA 1 F32GM086207-01. C.J.W. is supported by NIH NS039518 and NS038253. G.G.N. was supported by a Mary Curie IIF Fellowship and EuroThymaide. A.H. is supported by DFG 661/TP4 and BMBF (01EM0514, 01GQ0731, 0314102) and K.B. by the Doerenkamp Foundation for Innovations in Animal and Consumer Protection. P.A.G. is supported by NIH NS044232. NR 44 TC 100 Z9 103 U1 1 U2 30 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 J9 CELL JI Cell PD NOV 12 PY 2010 VL 143 IS 4 BP 628 EP 638 DI 10.1016/j.cell.2010.09.047 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 679GF UT WOS:000284149100019 PM 21074052 ER PT J AU Jiang, SX Zagozdzon, R Jorda, MA Parmar, K Fu, YG Williams, JS Wood, JAT Makriyannis, A Banu, N Avraham, S Groopman, JE Avraham, HK AF Jiang, Shuxian Zagozdzon, Radoslaw Jorda, Meritxell Alberich Parmar, Kalindi Fu, Yigong Williams, John S. Wood, Jodi Anne T. Makriyannis, Alexandros Banu, Naheed Avraham, Shalom Groopman, Jerome E. Avraham, Hava Karsenty TI Endocannabinoids Are Expressed in Bone Marrow Stromal Niches and Play a Role in Interactions of Hematopoietic Stem and Progenitor Cells with the Bone Marrow Microenvironment SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID CANNABINOID RECEPTORS; SELF-RENEWAL; MICE; MIGRATION; DIFFERENTIATION; TRANSPLANTATION; OPPORTUNITIES; MURINE; SYSTEM AB Endocannabinoids are lipid signaling molecules that act via G-coupled receptors, CB1 and CB2. The endocannabinoid system is capable of activation of distinct signaling pathways on demand in response to pathogenic events or stimuli, hereby enhancing cell survival and promoting tissue repair. However, the role of endocannabinoids in hematopoietic stem and progenitor cells (HSPCs) and their interaction with hematopoietic stem cells (HSC) niches is not known. HSPCs are maintained in the quiescent state in bone marrow (BM) niches by intrinsic and extrinsic signaling. We report that HSPCs express the CB1 receptors and that BM stromal cells secrete endocannabinoids, anandamide (AEA) (35 pg/10(7) cells), and 2-AG (75.2 ng/10(7) cells). In response to the endotoxin lipopolysaccharide (LPS), elevated levels of AEA (75.6 pg/10(7) cells) and 2-AG (98.8 ng/10(7) cells) were secreted from BM stromal cells, resulting in migration and trafficking of HSPCs from the BM niches to the peripheral blood. Furthermore, administration of exogenous cannabinoid CB1 agonists in vivo induced chemotaxis, migration, and mobilization of human and murine HSPCs. Cannabinoid receptor knock-out mice Cnr1(-/-) showed a decrease in side population (SP) cells, whereas fatty acid amide hydrolase (FAAH)(-/-) mice, which have elevated levels of AEA, yielded increased colony formation as compared with WT mice. In addition, G-CSF-induced mobilization in vivo was modulated by endocannabinoids and was inhibited by specific cannabinoid antagonists as well as impaired in cannabinoid receptor knock-out mice Cnr1(-/-), as compared with WT mice. Thus, we propose a novel function of the endocannabinoid system, as a regulator of HSPC interactions with their BM niches, where endocannabinoids are expressed in HSC niches and under stress conditions, endocannabinoid expression levels are enhanced to induce HSPC migration for proper hematopoiesis. C1 [Jiang, Shuxian; Zagozdzon, Radoslaw; Fu, Yigong; Banu, Naheed; Avraham, Shalom; Groopman, Jerome E.; Avraham, Hava Karsenty] Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02215 USA. [Jiang, Shuxian; Zagozdzon, Radoslaw; Fu, Yigong; Banu, Naheed; Avraham, Shalom; Groopman, Jerome E.; Avraham, Hava Karsenty] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Parmar, Kalindi] Northeastern Univ, Dana Farber Canc Inst, Boston, MA 02215 USA. [Jorda, Meritxell Alberich] Northeastern Univ, Harvard Stem Cell Inst, Boston, MA 02215 USA. [Williams, John S.; Wood, Jodi Anne T.; Makriyannis, Alexandros] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02215 USA. [Williams, John S.; Wood, Jodi Anne T.; Makriyannis, Alexandros] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02215 USA. RP Avraham, HK (reprint author), 99 Brookline Ave,3rd Floor, Boston, MA 02115 USA. EM havraham@bidmc.harvard.edu FU National Institutes of Health [CA 096805, CA 135226]; Career Enhancement Award [K18 PAR-02-069]; National Blood Foundation; European Hematology Association; Department of Defense [BC086398] FX This work was supported, in whole or in part, by National Institutes of Health Grants CA 096805 (to H. A.) and CA 135226 (to H. A.), Career Enhancement Award K18 PAR-02-069 (to H. A.), the National Blood Foundation (to H. A.), an EHA research fellowship from The European Hematology Association (to M. A. J.), and Department of Defense Concept Award BC086398 (to S. J.). NR 44 TC 10 Z9 10 U1 1 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 12 PY 2010 VL 285 IS 46 BP 35471 EP 35478 DI 10.1074/jbc.M110.144758 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 675QK UT WOS:000283845300025 PM 20826813 ER PT J AU Bowman, BR Lee, S Wang, SY Verdine, GL AF Bowman, Brian R. Lee, Seongmin Wang, Shuyu Verdine, Gregory L. TI Structure of Escherichia coli AlkA in Complex with Undamaged DNA SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID 3-METHYLADENINE DNA; SACCHAROMYCES-CEREVISIAE; BASE-EXCISION; REPAIR ENZYME; GLYCOSYLASE-I; ACTIVE-SITE; INTRAHELICAL LESION; POLYMERASE-BETA; DAMAGED DNA; DUPLEX DNA AB Because DNA damage is so rare, DNA glycosylases interact for the most part with undamaged DNA. Whereas the structural basis for recognition of DNA lesions by glycosylases has been studied extensively, less is known about the nature of the interaction between these proteins and undamaged DNA. Here we report the crystal structures of the DNA glycosylase AlkA in complex with undamaged DNA. The structures revealed a recognition mode in which the DNA is nearly straight, with no amino acid side chains inserted into the duplex, and the target base pair is fully intrahelical. A comparison of the present structures with that of AlkA recognizing an extrahelical lesion revealed conformational changes in both the DNA and protein as the glycosylase transitions from the interrogation of undamaged DNA to catalysis of nucleobase excision. Modeling studies with the cytotoxic lesion 3-methyladenine and accompanying biochemical experiments suggested that AlkA actively interrogates the minor groove of the DNA while probing for the presence of lesions. C1 [Verdine, Gregory L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Bowman, Brian R.; Lee, Seongmin; Wang, Shuyu; Verdine, Gregory L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. [Verdine, Gregory L.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. [Verdine, Gregory L.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA. RP Verdine, GL (reprint author), 12 Oxford St, Cambridge, MA 02138 USA. EM Gregory_verdine@harvard.edu FU National Institutes of Health [GM044853]; U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357] FX This work was supported, in whole or in part, by National Institutes of Health Grant GM044853 (to G.L.V.).; We thank Frank Murphy, Narayanasami Sukumar, and all of the staff of the Northeastern Collaborative Access Team (NE-CAT) at the Advanced Photon Source for assistance during data collection. We also thank Yevgeny Brudno for help with the melting temperature studies and Hariharan Jayaram, Danaya Pakotiprapha, Marie Spong, Rou-Jia Sung, Yan Qi, and members of the Verdine laboratory for useful discussions. Use of the Advanced Photon Source was supported by the U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract DE-AC02-06CH11357. NR 54 TC 14 Z9 14 U1 2 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 12 PY 2010 VL 285 IS 46 BP 35783 EP 35791 DI 10.1074/jbc.M110.155663 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 675QK UT WOS:000283845300056 PM 20843803 ER PT J AU Gavathiotis, E Reyna, DE Davis, ML Bird, GH Walensky, LD AF Gavathiotis, Evripidis Reyna, Denis E. Davis, Marguerite L. Bird, Gregory H. Walensky, Loren D. TI BH3-Triggered Structural Reorganization Drives the Activation of Proapoptotic BAX SO MOLECULAR CELL LA English DT Article ID MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; STABILIZED ALPHA-HELICES; PROGRAMMED CELL-DEATH; BH3-ONLY PROTEINS; CONFORMATIONAL-CHANGE; BH3 DOMAINS; INTRACELLULAR-LOCALIZATION; APOPTOTIC ACTIVITY; BCL-2 DOMAINS; CYTOCHROME-C AB BAX is a proapoptotic BCL-2 family member that lies dormant in the cytosol until converted into a killer protein in response to cellular stress. Having recently identified the elusive trigger site for direct BAX activation, we now delineate by NMR and biochemical methods the essential allosteric conformational changes that transform ligand-triggered BAX into a fully activated monomer capable of propagating its own activation. Upon BAX engagement by a triggering BH3 helix, the unstructured loop between a helices 1 and 2 is displaced, the carboxy-terminal helix 9 is mobilized for membrane translocation, and the exposed BAX BH3 domain propagates the death signal through an auto activating interaction with the trigger site of inactive BAX monomers. Our structure-activity analysis of this seminal apoptotic process reveals pharmacologic opportunities to modulate cell death by interceding at key steps of the BAX activation pathway. C1 [Gavathiotis, Evripidis; Reyna, Denis E.; Davis, Marguerite L.; Bird, Gregory H.; Walensky, Loren D.] Harvard Univ, Sch Med, Dept Pediat Oncol, Boston, MA 02115 USA. [Gavathiotis, Evripidis; Reyna, Denis E.; Davis, Marguerite L.; Bird, Gregory H.; Walensky, Loren D.] Harvard Univ, Sch Med, Program Canc Chem Biol, Dana Farber Canc Inst, Boston, MA 02115 USA. [Gavathiotis, Evripidis; Reyna, Denis E.; Davis, Marguerite L.; Bird, Gregory H.; Walensky, Loren D.] Harvard Univ, Sch Med, Div Hematol Oncol, Childrens Hosp Boston, Boston, MA 02115 USA. [Gavathiotis, Evripidis; Reyna, Denis E.; Davis, Marguerite L.; Bird, Gregory H.; Walensky, Loren D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Walensky, LD (reprint author), Harvard Univ, Sch Med, Dept Pediat Oncol, Boston, MA 02115 USA. EM loren_walensky@dfci.harvard.edu FU National institutes of Health (NIH) [2R01CA050239]; American Society of Hematology; William Lawrence Children's Foundation; American Heart Association FX We thank E. Smith for editorial and graphics assistance, N. Tjandra and M. Suzuki for BAX NMR assignments and helpful discussions, C. Turner of the MIT/Harvard Center for Magnetic Resonance and S. Pochapsky of the Brandeis University Nuclear Magnetic Resonance Facility for technical advice, and S. Gygi and J. Mintseris of Harvard Medical School for mass spectrometry analysis. This work was supported by National institutes of Health (NIH) grant 2R01CA050239, an American Society of Hematology Junior Faculty Scholar Award, and a grant from the William Lawrence Children's Foundation to L.D.W.; and an American Heart Association Founders Affiliate Scientist Development Grant to E.G. We also thank the LaTorre family for their generous support of D.E.R. NR 64 TC 131 Z9 135 U1 1 U2 14 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1097-2765 J9 MOL CELL JI Mol. Cell PD NOV 12 PY 2010 VL 40 IS 3 BP 481 EP 492 DI 10.1016/j.molcel.2010.10.019 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 684NJ UT WOS:000284556300016 PM 21070973 ER PT J AU Blaya, C Salurn, GA Moorjani, P Seganfredo, AC Heldt, E Leistner-Segal, S Smoller, JW Manfro, GG AF Blaya, Carolina Salurn, Giovanni A. Moorjani, Priya Seganfredo, Ana Carolina Heldt, Elizeth Leistner-Segal, Sandra Smoller, Jordan W. Manfro, Gisele Gus TI Panic disorder and serotonergic genes (SLC6A4, HTR1A and HTR2A): Association and interaction with childhood trauma and parenting SO NEUROSCIENCE LETTERS LA English DT Article DE Gene-environment interaction; Panic disorder; HTR1A; HTR2A; 5-HTTLPR; SLC6A4 ID PROMOTER POLYMORPHISM 5-HTTLPR; BEHAVIORAL-INHIBITION; SEXUAL-ABUSE; RECEPTOR; ANXIETY; METAANALYSIS; MICE; ENVIRONMENTS; RESPONSIVITY; AGORAPHOBIA AB Objective: The aim of this study is to evaluate the association between HTR1A, HTR2A and the 5-HTTLPR in panic disorder (PD) patients and controls. In addition, this study also aims to evaluate the interaction between these genes and two environmental factors previously associated with PD: childhood trauma and parental bonding. Methods: This is a case-control candidate gene association study (107 PD patients and 125 controls). Genes were analyzed using a gene-based test in PLINK followed by single marker association tests and haplotype test only for genes that reached experiment-wide significance in the gene-based test in order to minimize multiple testing. Logistic regression was used to test the relationships between genotype in the additive model, trauma, optimal paternal parenting and optimal maternal parenting and their interactions. Results: Only HTR1A was associated with PD in gene-based test after correction for multiple tests (p(corrected) = 0.027) and one HTR1A haplotype comprising four SNPs was associated with PD (p(corrected) = 0.032). In the interaction analysis, no significant gene-environment interaction was found with the genes evaluated. Conclusion: This study reinforces the association between HTR1A and PD. No major evidence of gene-environment interaction in PD with parenting or trauma was found. Further studies are necessary in order to confirm these findings. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Blaya, Carolina; Salurn, Giovanni A.; Seganfredo, Ana Carolina; Heldt, Elizeth; Leistner-Segal, Sandra; Manfro, Gisele Gus] Univ Fed Rio Grande do Sul, Postgrad Program Med Sci, Hosp Clin Porto Alegre, Anxiety Disorders Program, BR-90470280 Porto Alegre, RS, Brazil. [Blaya, Carolina] Univ Fed Ciencias Sauae Porto Alegre, Anxiety Program, Porto Alegre, RS, Brazil. [Moorjani, Priya] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Smoller, Jordan W.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat Genet Program Mood & Anxiety Disorders, Dept Psychiat, Boston, MA 02114 USA. [Smoller, Jordan W.] Massachusetts Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. RP Manfro, GG (reprint author), Univ Fed Rio Grande do Sul, Postgrad Program Med Sci, Hosp Clin Porto Alegre, Anxiety Disorders Program, Luiz Manoel Gonzaga 630-11, BR-90470280 Porto Alegre, RS, Brazil. EM gmanfro@portoweb.com.br RI Leistner-Segal, Sandra/B-2858-2008; Salum, Giovanni/A-7849-2010 OI Leistner-Segal, Sandra/0000-0003-3792-6168; Salum, Giovanni/0000-0002-7537-7289 FU Fundacao de Incentivo a Pesquisa (FIPE-HCPA) [04-272]; CAPES; CNPq [301533/2006-7, 504838/2009-1, 505066/2007-6]; Rose and Eugene Kleiner Family Foundation FX This research was supported by Fundacao de Incentivo a Pesquisa (FIPE-HCPA) grant 04-272 (CB and GGM), CAPES (CB, GAS), CNPq grants 301533/2006-7, 504838/2009-1, 505066/2007-6 (GGM, CB and GAS), Rose and Eugene Kleiner Family Foundation (JWS). NR 45 TC 20 Z9 20 U1 0 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD NOV 12 PY 2010 VL 485 IS 1 BP 11 EP 15 DI 10.1016/j.neulet.2010.08.042 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 668KF UT WOS:000283266700003 PM 20817074 ER PT J AU Harousseau, JL Palumbo, A Richardson, PG Schlag, R Dimopoulos, MA Shpilberg, O Kropff, M Kentos, A Cavo, M Golenkov, A Komarnicki, M Mateos, MV Esseltine, DL Cakana, A Liu, K Deraedt, W van de Velde, H San Miguel, JF AF Harousseau, Jean-Luc Palumbo, Antonio Richardson, Paul G. Schlag, Rudolf Dimopoulos, Meletios A. Shpilberg, Ofer Kropff, Martin Kentos, Alain Cavo, Michele Golenkov, Anatoly Komarnicki, Mieczyslaw Mateos, Maria-Victoria Esseltine, Dixie-Lee Cakana, Andrew Liu, Kevin Deraedt, William van de Velde, Helgi San Miguel, Jesus F. TI Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone SO BLOOD LA English DT Article ID STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; POLYMERASE-CHAIN-REACTION; PEGYLATED LIPOSOMAL DOXORUBICIN; LONG-TERM SURVIVAL; HIGH-DOSE THERAPY; PROLONGED THERAPY; BONE-MARROW; APEX TRIAL; III VISTA AB The phase 3 Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone study in newly diagnosed multiple myeloma patients ineligible for high-dose therapy demonstrated that bortezomib-melphalan-prednisone (VMP) was superior to melphalan-prednisone across all efficacy end points. We assessed the prognostic impact of response on time-to-event parameters in the intent-to-treat population. Patients received nine 6-week cycles of treatment. Time to progression, time to next therapy, and treatment-free interval were associated with quality of response. When European Group for Blood and Marrow Transplantation criteria were used, complete response (CR) was associated with significantly longer time to progression (hazard ratio [HR] = 0.45, P = .004), time to next therapy (HR = 0.46, P = .0004), and treatment-free interval (HR = 0.38, P < .0001) versus partial response, but there was no significant difference in overall survival (HR = 0.87, P = .54); similar differences were seen with CR versus very good partial response by uniform criteria. Quality of response improved with prolonged VMP treatment, with 28% of CRs achieved during cycles 5-9. CR duration appeared similar among patients with "early" (cycles 1-4) and "late" CRs (cycles 5-9) and among patients receiving 9 versus < 9 cycles of bortezomib within VMP. These results highlight that CR is an important treatment goal and support prolonged VMP therapy to achieve maximal response. This study is registered at http://www.clinicaltrials.gov as NCT00111319. (Blood. 2010;116(19):3743-3750) C1 [Harousseau, Jean-Luc] Ctr Rene Gauducheau, F-44805 Nantes, France. [Palumbo, Antonio] Univ Turin, Turin, Italy. [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Schlag, Rudolf] Praxisklin Dr Schlag, Wurzburg, Germany. [Dimopoulos, Meletios A.] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Shpilberg, Ofer] Rabin Med Ctr, Petah Tiqwa, Israel. [Kropff, Martin] Univ Munster, Munster, Germany. [Kentos, Alain] Belgian Myeloma Study Grp, Brussels, Belgium. [Cavo, Michele] Univ Bologna, Inst Hematol & Med Oncol Seragnoli, Bologna, Italy. [Golenkov, Anatoly] Moscow Reg Clin Inst, Moscow, Russia. [Komarnicki, Mieczyslaw] Univ Med Sci, Dept Hematol, Poznan, Poland. [Mateos, Maria-Victoria; San Miguel, Jesus F.] Hosp Univ Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain. [Esseltine, Dixie-Lee] Millennium Pharmaceut Inc, Cambridge, MA USA. [Cakana, Andrew] Johnson & Johnson Pharmaceut Res & Dev, High Wycombe, Bucks, England. [Liu, Kevin] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA. [Deraedt, William; van de Velde, Helgi] Johnson & Johnson Pharmaceut Res & Dev, Beerse, Belgium. RP Harousseau, JL (reprint author), Ctr Rene Gauducheau, Bd Jacques Monod, F-44805 Nantes, France. EM jl-harousseau@nantes.fnclcc.fr RI IBSAL, Secretaria/H-3719-2011; OI SAN MIGUEL, JESUS/0000-0002-9183-4857; CAVO, MICHELE/0000-0003-4514-3227 FU Millennium Pharmaceuticals Inc.; Millennium Pharmaceuticals; Janssen-Cilag; Celgene FX We thank Mark Simmonds, Steve Hill, and Jane Saunders of FireKite for writing and editorial assistance in the development of this manuscript, which was supported by funding from Millennium Pharmaceuticals Inc.; J.-L.H.: membership of advisory board and honoraria, Janssen-Cilag and Celgene. A. P.: honoraria, Janssen-Cilag and Celgene. P. G. R.: research funding, Millennium Pharmaceuticals; membership of advisory board, Janssen-Cilag and Celgene. M. A. D.: consultancy and honoraria, Millennium Pharmaceuticals and Ortho Biotech. O.S.: membership of advisory board, Janssen-Cilag. M. K.: honoraria, Ortho Biotech. M. C.: honoraria, Millennium Pharmaceuticals. M.-V.M.: honoraria, Millennium Pharmaceuticals; honoraria and membership of advisory board, Janssen-Cilag. D.-L. E.: employee of Millennium Pharmaceuticals Inc. A. C., K. L., W. D., H.v.d.V.: employee of, and ownership interest in, Johnson & Johnson. K. L.: ownership interest in Merck. J.F.S.M.: consultancy, honoraria, paid expert testimony, and membership of advisory board, Janssen-Cilag, Celgene, and Novartis. NR 39 TC 55 Z9 58 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 11 PY 2010 VL 116 IS 19 BP 3743 EP 3750 DI 10.1182/blood-2010-03-275800 PG 8 WC Hematology SC Hematology GA 678VM UT WOS:000284110400013 PM 20628153 ER PT J AU Lee-Lewandrowski, E Gregory, K Lewandrowski, K AF Lee-Lewandrowski, Elizabeth Gregory, Kimberly Lewandrowski, Kent TI Point of care testing in a large urban academic medical center: Evolving test menu and clinical applications SO CLINICA CHIMICA ACTA LA English DT Article DE Point of care testing; Near patient testing; Outcomes; Emergency department ID LENGTH-OF-STAY; EMERGENCY-DEPARTMENT; IMPLEMENTATION; IMPACT; PROGRAM; FUTURE AB Introduction There have been many reports describing individual POCT technologies but there are no recent studies describing the organizational scope and impact of a POCT program Methods Our menu of POCT tests has increased to 26 and the test volume to 664.287 tests/year equivalent to 14 5% of the volume of the central core laboratory POCT is performed in nearly all inpatient units and in a variety of outpatient settings. Results Cumulatively 84 6% of the test volume and most testing sites can be accounted for by 4 traditional tests (bedside glucose testing. fecal occult blood, dipstick urinalysis and activated clotting time) Most FOCI tests are not performed because of a true medical necessity but rather to improve the efficiency of clinical operations. Conclusion We ale experiencing a significant increase in requests for new POCT tests Unlike established high volume conventional POC tests, these new requests originate from specialized services seeking to improve the efficiency of clinical operations (C) 2010 Elsevier B V All rights reserved C1 [Lee-Lewandrowski, Elizabeth; Gregory, Kimberly; Lewandrowski, Kent] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Lee-Lewandrowski, Elizabeth; Lewandrowski, Kent] Harvard Univ, Sch Med, Boston, MA USA. RP Lewandrowski, K (reprint author), Massachusetts Gen Hosp, Dept Pathol, Gray 5 Chem,55 Fruit St, Boston, MA 02114 USA. NR 12 TC 7 Z9 9 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD NOV 11 PY 2010 VL 411 IS 21-22 BP 1799 EP 1805 DI 10.1016/j.cca.2010.08.002 PG 7 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 659JG UT WOS:000282562200043 PM 20699093 ER PT J AU Ragas, X Sanchez-Garcia, D Ruiz-Gonzalez, R Dai, TH Agut, M Hamblin, MR Nonell, S AF Ragas, Xavier Sanchez-Garcia, David Ruiz-Gonzalez, Ruben Dai, Tianhong Agut, Montserrat Hamblin, Michael R. Nonell, Santi TI Cationic Porphycenes as Potential Photosensitizers for Antimicrobial Photodynamic Therapy SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID GRAM-NEGATIVE BACTERIA; LIPID-SOLUBLE PHTHALOCYANINES; SINGLET OXYGEN; ESCHERICHIA-COLI; EFFICIENT PHOTOSENSITIZERS; MOLECULAR-OXYGEN; PORPHYRINS; INACTIVATION; PHOTOINACTIVATION; INFECTIONS AB Structures of typical photosensitizers used in antimicrobial photodynamic therapy are based on porphyrins, phthalocyanines, and phenothiazinium salts, with cationic charges at physiological pH values. However, derivatives of the porphycene macrocycle (a structural isomer of porphyrin) have barely been investigated as antimicrobial agents. Therefore, we report the synthesis of the first tricationic water-soluble porphycene and its basic photochemical properties. We successfully tested it for in vitro photoinactivation of different Gram-positive and Gram-negative bacteria, as well as a fungal species (Candida) in a drug-dose and light-dose dependent manner. We also used the cationic porphycene in vivo to treat an infection model comprising mouse third degree burns infected with a bioluminescent methicillin-resistant Staphylococcus aureus strain. There was a 2.6-log(10) reduction (p < 0.001) of the bacterial bioluminescence for the PDT-treated group after irradiation with 180 J.cm(-2) of red light. C1 [Ragas, Xavier; Sanchez-Garcia, David; Ruiz-Gonzalez, Ruben; Agut, Montserrat; Nonell, Santi] Univ Ramon Llull, Inst Quim Sarria, Barcelona 08017, Spain. [Ragas, Xavier; Dai, Tianhong; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Dai, Tianhong; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Nonell, S (reprint author), Univ Ramon Llull, Inst Quim Sarria, Barcelona 08017, Spain. EM santi.nonell@iqs.url.edu RI dong, guofa/D-5248-2011; Nonell, Santi/L-2561-2013; Sanchez-Garcia, David/L-5892-2013; Agut, Montserrat/L-5905-2013; Ruiz-Gonzalez, Ruben/K-6384-2013; OI Nonell, Santi/0000-0002-8900-5291; Sanchez-Garcia, David/0000-0002-3936-9329; Agut, Montserrat/0000-0001-9173-9684; Ruiz-Gonzalez, Ruben/0000-0002-9837-411X; Hamblin, Michael/0000-0001-6431-4605 FU Spanish Ministerio de Ciencia e Innovacion [CTQ2007-67763-C03-01/BQU]; U.S. NIH [R01A1050875]; Generalitat de Catalunya (DURSI); Fons Social Europeu; Bullock-Wellman Postdoctoral Fellowship; Obra Social "la Caixa" FX This work was supported by a grant of the Spanish Ministerio de Ciencia e Innovacion (CTQ2007-67763-C03-01/BQU) and by U.S. NIH grant R01A1050875 to M RH. X.R. and R.R. were supported by the Generalitat de Catalunya (DURSI) and Fons Social Europeu with a pre-doctoral fellowship. R.R. also thanks Obra Social "la Caixa" for its Master's grant. T. D. was supported by the Bullock-Wellman Postdoctoral Fellowship Award. We thank Sorisa for providing us with the Sorisa Photocare LED source and Xenogen Corp for the gift of XEN31. NR 42 TC 37 Z9 39 U1 0 U2 31 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD NOV 11 PY 2010 VL 53 IS 21 BP 7796 EP 7803 DI 10.1021/jm1009555 PG 8 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 673ZP UT WOS:000283703000026 PM 20936792 ER PT J AU Staley, K AF Staley, Kevin TI STROKE Recovery inhibitors under attack SO NATURE LA English DT Editorial Material ID ISCHEMIC-STROKE; POTENTIATION; MECHANISMS C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Staley, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. EM kstaley@partners.org NR 11 TC 1 Z9 1 U1 1 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD NOV 11 PY 2010 VL 468 IS 7321 BP 176 EP 177 DI 10.1038/468176a PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 678DG UT WOS:000284051000027 PM 21068818 ER PT J AU Kuter, DJ Rummel, M Boccia, R Macik, BG Pabinger, I Selleslag, D Rodeghiero, F Chong, BH Wang, XN Berger, DP AF Kuter, David J. Rummel, Mathias Boccia, Ralph Macik, B. Gail Pabinger, Ingrid Selleslag, Dominik Rodeghiero, Francesco Chong, Beng H. Wang, Xuena Berger, Dietmar P. TI Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CONTROLLED-TRIAL; DOUBLE-BLIND; PURPURA; SPLENECTOMY; TERM; EFFICACY; ITP; COMPLICATIONS; MANAGEMENT; MORTALITY AB Background: Romiplostim, a thrombopoietin mimetic, increases platelet counts in patients with immune thrombocytopenia, with few adverse effects. Methods: In this open-label, 52-week study, we randomly assigned 234 adult patients with immune thrombocytopenia, who had not undergone splenectomy, to receive the standard of care (77 patients) or weekly subcutaneous injections of romiplostim (157 patients). Primary end points were incidences of treatment failure and splenectomy. Secondary end points included the rate of a platelet response (a platelet count >50 x 10(sup 9) per liter at any scheduled visit), safety outcomes, and the quality of life. Results: The rate of a platelet response in the romiplostim group was 2.3 times that in the standard-of-care group (95% confidence interval [CI], 2.0 to 2.6; P<0.001). Patients receiving romiplostim had a significantly lower incidence of treatment failure (18 of 157 patients [11%]) than those receiving the standard of care (23 of 77 patients [30%], P<0.001) (odds ratio with romiplostim, 0.31; 95% CI, 0.15 to 0.61). Splenectomy also was performed less frequently in patients receiving romiplostim (14 of 157 patients [9%]) than in those receiving the standard of care (28 of 77 patients [36%], P<0.001) (odds ratio, 0.17; 95% CI, 0.08 to 0.35). The romiplostim group had a lower rate of bleeding events, fewer blood transfusions, and greater improvements in the quality of life than the standard-of-care group. Serious adverse events occurred in 23% of patients (35 of 154) receiving romiplostim and 37% of patients (28 of 75) receiving the standard of care. Conclusions: Patients treated with romiplostim had a higher rate of a platelet response, lower incidence of treatment failure and splenectomy, less bleeding and fewer blood transfusions, and a higher quality of life than patients treated with the standard of care. (Funded by Amgen; ClinicalTrials.gov number, NCT00415532.) N Engl J Med 2010;363:1889-99. C1 [Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rummel, Mathias] Klinikum Justus Liebig Univ, Giessen, Germany. [Pabinger, Ingrid] Med Univ Wien, Vienna, Austria. [Boccia, Ralph] Ctr Canc & Blood Disorders, Bethesda, MD USA. [Macik, B. Gail] Univ Virginia, Charlottesville, VA USA. [Selleslag, Dominik] Algemeen Ziekenhuis St Jan, Brugge, Belgium. [Rodeghiero, Francesco] San Bortolo Hosp, Vicenza, Italy. [Chong, Beng H.] Univ New S Wales, St George Clin Sch, Kogarah, NSW, Australia. [Wang, Xuena; Berger, Dietmar P.] Amgen Inc, Thousand Oaks, CA USA. RP Kuter, DJ (reprint author), Massachusetts Gen Hosp, Yawkey 7940,55 Fruit St, Boston, MA 02114 USA. EM kuter.david@mgh.harvard.edu FU Amgen; GlaxoSmithKline; Ligand; Pfizer; Eisai; MGI Pharma; Shionogi; Commonwealth Serum Lab FX Supported by Amgen.; Dr. Kuter reports receiving consulting fees from Amgen, GlaxoSmithKline, Ligand, Pfizer, Eisai, MGI Pharma, Shionogi, and Ono Pharmaceutical and research support from Amgen, GlaxoSmithKline, Eisai, and Shionogi; Dr. Boccia reports receiving speaker's fees, consulting fees, and research support from Amgen; speaker's fees from GlaxoSmithKline; and holding equity in Amgen and Johnson and Johnson; Dr. Pabinger reports receiving consulting fees from Amgen and GlaxoSmithKline and helping to develop speakers' bureau programs for Amgen; Dr. Selleslag reports receiving consulting fees and speaker's fees from Amgen; Dr. Rodeghiero reports receiving research support from and serving on the boards of Amgen, GlaxoSmithKline, and Shionogi, as well as receiving speaker's fees from Amgen and GlaxoSmithKline; Dr. Chong reports serving on the board, receiving honoraria, and receiving research support from Amgen, GlaxoSmithKline, and Commonwealth Serum Lab; and Drs. Wang and Berger report being employees of, and holding equity in, Amgen. No other potential conflict of interest relevant to this article was reported. NR 28 TC 137 Z9 141 U1 0 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 11 PY 2010 VL 363 IS 20 BP 1889 EP 1899 DI 10.1056/NEJMoa1002625 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 678CR UT WOS:000284047600004 PM 21067381 ER PT J AU Bhatt, DL Cryer, BL Contant, CF Cohen, M Lanas, A Schnitzer, TJ Shook, TL Lapuerta, P Goldsmith, MA Laine, L Scirica, BM Murphy, SA Cannon, CP AF Bhatt, Deepak L. Cryer, Byron L. Contant, Charles F. Cohen, Marc Lanas, Angel Schnitzer, Thomas J. Shook, Thomas L. Lapuerta, Pablo Goldsmith, Mark A. Laine, Loren Scirica, Benjamin M. Murphy, Sabina A. Cannon, Christopher P. CA COGENT Investigators TI Clopidogrel with or without Omeprazole in Coronary Artery Disease. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID LOW-DOSE ASPIRIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROTON PUMP INHIBITORS; ST-SEGMENT ELEVATION; ANTIPLATELET-THERAPY; MYOCARDIAL-INFARCTION; STATIN-INTERACTION; CONTROLLED TRIAL; RISK; INTERVENTION AB Background: Gastrointestinal complications are an important problem of antithrombotic therapy. Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy. Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel. Methods: We randomly assigned patients with an indication for dual antiplatelet therapy to receive clopidogrel in combination with either omeprazole or placebo, in addition to aspirin. The primary gastrointestinal end point was a composite of overt or occult bleeding, symptomatic gastroduodenal ulcers or erosions, obstruction, or perforation. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, revascularization, or stroke. The trial was terminated prematurely when the sponsor lost financing. Results: We planned to enroll about 5000 patients; a total of 3873 were randomly assigned and 3761 were included in analyses. In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001). The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P=0.001). A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P=0.96); high-risk subgroups did not show significant heterogeneity. The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole. Conclusions: Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding. There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI. (Funded by Cogentus Pharmaceuticals; ClinicalTrials.gov number, NCT00557921.) N Engl J Med 2010;363:1909-17. C1 [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA 02132 USA. [Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA. [Bhatt, Deepak L.; Contant, Charles F.; Scirica, Benjamin M.; Murphy, Sabina A.; Cannon, Christopher P.] Brigham & Womens Hosp, Thrombolysis Myocardial Infarct TIMI Study Grp, Boston, MA 02115 USA. [Cryer, Byron L.] Univ Texas SW, Dallas, TX USA. [Cryer, Byron L.] VA N Texas Hlth Care Syst, Dallas, TX USA. [Cohen, Marc] Newark Beth Israel Med Ctr, Newark, NJ USA. [Lanas, Angel] Univ Zaragoza, Inst Aragones Ciencias Salud, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Zaragoza, Spain. [Schnitzer, Thomas J.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. [Schnitzer, Thomas J.] Northwestern Univ, Feinberg Sch Med, Dept Internal Med Rheumatol, Chicago, IL 60611 USA. [Shook, Thomas L.] Parexel Int, Waltham, MA USA. [Lapuerta, Pablo] Cogentus Pharmaceut, Menlo Pk, CA USA. [Laine, Loren] Univ So Calif, Los Angeles, CA USA. RP Bhatt, DL (reprint author), VA Boston Healthcare Syst, 1400 VFW Pkwy, Boston, MA 02132 USA. EM dlbhattmd@post.harvard.edu RI Stegeman, Dick/E-4952-2012 FU Cogentus Pharmaceuticals FX Supported by Cogentus Pharmaceuticals. NR 46 TC 503 Z9 541 U1 2 U2 39 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 11 PY 2010 VL 363 IS 20 BP 1909 EP 1917 DI 10.1056/NEJMoa1007964 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 678CR UT WOS:000284047600006 PM 20925534 ER PT J AU Ring, DC Herndon, JH Meyer, GS AF Ring, David C. Herndon, James H. Meyer, Gregg S. TI Case 34-2010: A 65-Year-Old Woman with an Incorrect Operation on the Left Hand. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID WRONG-SITE SURGERY; MEDICAL ERRORS; ORTHOPEDICS; PREVENTION; DISCLOSURE; BEHAVIOR C1 [Ring, David C.; Herndon, James H.] Massachusetts Gen Hosp, Dept Orthoped, Boston, MA 02114 USA. [Meyer, Gregg S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Meyer, Gregg S.] Massachusetts Gen Hosp, Massachusetts Gen Phys Org, Boston, MA 02114 USA. [Ring, David C.; Herndon, James H.] Harvard Univ, Sch Med, Dept Orthopaed Surg, Boston, MA USA. [Meyer, Gregg S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Ring, DC (reprint author), Massachusetts Gen Hosp, Dept Orthoped, Boston, MA 02114 USA. FU Wright Medical; Biomet; Skeletal Dynamics; Acumed; Tornier; Joint Active Systems; Stryker; AO North America; AO International; board of trustees of the Journal of Bone and Joint Surgery; Boston Consulting Group; CRICO Risk Management Foundation FX Dr. Ring reports receiving consulting fees from Wright Medical, Biomet, Skeletal Dynamics, Acumed, and Tornier; payment for expert testimony from motor vehicle insurance companies, corporations, and legal firms regarding personal injury and malpractice lawsuits; grant support from Joint Active Systems, Stryker, and Biomet; lecture fees from AO North America and AO International; and royalties from Hand Innovations, Wright Medical, Skeletal Dynamics, and Biomet; and owning stock in Illuminos and Mimedex. Dr. Herndon reports receiving payment for serving on the board of trustees of the Journal of Bone and Joint Surgery. Dr. Meyer reports receiving consulting fees from Boston Consulting Group, honoraria from the Agency for Healthcare Research and Quality, and grant support to his institution from CRICO Risk Management Foundation. No other potential conflict of interest relevant to this article was reported. NR 26 TC 3 Z9 3 U1 1 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 11 PY 2010 VL 363 IS 20 BP 1951 EP 1958 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 678CR UT WOS:000284047600012 ER PT J AU Kantoff, PW Frohlich, MW Schellhammer, PF AF Kantoff, Philip W. Frohlich, Mark W. Schellhammer, Paul F. CA IMPACT Authors TI Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Kantoff, Philip W.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Frohlich, Mark W.] Dendreon Corp, Seattle, WA USA. [Schellhammer, Paul F.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. RP Kantoff, PW (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 3 TC 0 Z9 0 U1 1 U2 6 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 11 PY 2010 VL 363 IS 20 BP 1967 EP 1968 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 678CR UT WOS:000284047600018 ER PT J AU Biffi, A Plourde, A Shen, YP Onofrio, R Smith, EE Frosch, M Prada, CM Gusella, J Greenberg, SM Rosand, J AF Biffi, Alessandro Plourde, Anna Shen, Yiping Onofrio, Robert Smith, Eric E. Frosch, Matthew Prada, Claudia M. Gusella, James Greenberg, Steven M. Rosand, Jonathan TI Screening for Familial APP Mutations in Sporadic Cerebral Amyloid Angiopathy SO PLOS ONE LA English DT Article ID WHITE-MATTER LESIONS; INTRACEREBRAL HEMORRHAGE; DIAGNOSIS; SUBSTITUTIONS; HEREDITARY; COGNITION; DEMENTIA; GENE AB Background: Advances in genetic technology have revealed that variation in the same gene can cause both rare familial and common sporadic forms of the same disease. Cerebral amyloid angiopathy (CAA), a common cause of symptomatic intracerebral hemorrhage (ICH) in the elderly, can also occur in families in an autosomal dominant pattern. The majority of affected families harbor mutations in the Beta amyloid Peptide (Ab) coding region of the gene for amyloid precursor protein (APP) or have duplications of chromosomal segments containing APP. Methodology/Principal Findings: A total of 58 subjects with a diagnosis of probable or definite CAA according to validated criteria were included in the present study. We sequenced the Ab coding region of APP in 58 individuals and performed multiplex ligation-dependent probe amplification to determine APP gene dosage in 60. No patient harbored a known or novel APP mutation or gene duplication. The frequency of mutations investigated in the present study is estimated to range from 0% to 8% in individuals with probable CAA in the general population, based on the ascertained sample size. Conclusions/Significance: We found no evidence that variants at loci associated with familial CAA play a role in sporadic CAA. Based on our findings, these rare highly-penetrant mutations are unlikely to be seen in sporadic CAA patients. Therefore, our results do not support systematic genetic screening of CAA patients who lack a strong family history of hemorrhage or dementia. C1 [Biffi, Alessandro; Plourde, Anna; Shen, Yiping; Gusella, James; Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Biffi, Alessandro; Plourde, Anna; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Hemorrhag Stroke Res Grp, Boston, MA 02114 USA. [Biffi, Alessandro; Plourde, Anna; Onofrio, Robert; Gusella, James; Rosand, Jonathan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA. [Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada. [Frosch, Matthew; Prada, Claudia M.] Massachusetts Gen Hosp, Inst Neurodegenerat Dis, Boston, MA 02114 USA. RP Biffi, A (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. EM jrosand@partners.org RI Smith, Eric/C-5443-2012 OI Smith, Eric/0000-0003-3956-1668 FU National Institute of Neurological Disorders and Stroke (NINDS) [K23NS042695]; Massachusetts General Hospital Deane Institute for Integrative Research in Atrial Fibrillation and Stroke; American Heart Association/Bugher Foundation for Stroke Prevention Research FX This work was funded by National Institute of Neurological Disorders and Stroke (NINDS) grant K23NS042695 awarded to Dr. Rosand and by the Massachusetts General Hospital Deane Institute for Integrative Research in Atrial Fibrillation and Stroke. Dr Biffi receives support from the American Heart Association/Bugher Foundation for Stroke Prevention Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 3 Z9 3 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 11 PY 2010 VL 5 IS 11 AR e13949 DI 10.1371/journal.pone.0013949 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 678OA UT WOS:000284087800015 PM 21085603 ER PT J AU Ramos-Casals, M Tzioufas, AG Stone, JH AF Ramos-Casals, Manuel Tzioufas, Athanasios G. Stone, John H. TI Treatment Approaches in Primary Sjogren Syndrome Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID RITUXIMAB TREATMENT; SINGLE-BLIND; TRIAL C1 [Ramos-Casals, Manuel] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Spain. [Tzioufas, Athanasios G.] Univ Athens, Sch Med, Dept Pathophysiol, GR-11527 Athens, Greece. [Stone, John H.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. RP Ramos-Casals, M (reprint author), Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Spain. EM mramos@clinic.ub.es NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 10 PY 2010 VL 304 IS 18 BP 2016 EP 2016 DI 10.1001/jama.2010.1583 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 677OB UT WOS:000284000600016 ER PT J AU Ducharme, N Banks, WA Morley, JE Robinson, SM Niehoff, ML Mattern, C Farr, SA AF Ducharme, Nicole Banks, William A. Morley, John E. Robinson, Sandra M. Niehoff, Michael L. Mattern, Claudia Farr, Susan A. TI Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration (vol 641, pg 128, 2010) SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Correction C1 [Ducharme, Nicole; Banks, William A.; Morley, John E.; Robinson, Sandra M.; Niehoff, Michael L.; Farr, Susan A.] St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63103 USA. [Ducharme, Nicole; Morley, John E.; Robinson, Sandra M.; Niehoff, Michael L.; Farr, Susan A.] Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, St Louis, MO USA. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Mattern, Claudia] M&P Pharma AG, CH-6370 Stans, Switzerland. RP Banks, WA (reprint author), St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO 63103 USA. EM wabanks1@uw.edu RI morley, john/F-9177-2011 OI morley, john/0000-0001-6444-2965 NR 1 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD NOV 10 PY 2010 VL 646 IS 1-3 BP 46 EP 46 DI 10.1016/j.ejphar.2010.07.021 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 662YY UT WOS:000282851400006 ER PT J AU Kieran, MW Walker, D Frappaz, D Prados, M AF Kieran, Mark W. Walker, David Frappaz, Didier Prados, Michael TI Brain Tumors: From Childhood Through Adolescence Into Adulthood SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Review ID LOW-GRADE GLIOMAS; GERM-CELL TUMORS; CENTRAL-NERVOUS-SYSTEM; PEDIATRIC OLIGODENDROGLIOMAS; MAPK PATHWAY; YOUNG-ADULTS; FOLLOW-UP; MEDULLOBLASTOMA; CHEMOTHERAPY; CHILDREN AB The transition from childhood to adulthood through adolescence has been clearly identified as a time of great physical, psychological, emotional, social, and sexual change. Clinical care is currently divided into adult or pediatric care; adolescent patients require specific expertise that most clinical practices do not have. When illness coincides with the adolescent transition, the health system is severely challenged. Health systems historically have varied widely in the age they choose for allocating an individual to the adult model of health care. Tumors of the CNS complicate the difficult adjustments required in adolescents and young adults by virtue of their morbidity, complex treatment, and prognosis. Some brain tumors are unique to children, some occur predominantly in adults, and others peak in adolescence. Delays in the diagnosis of brain tumors can occur at any age but are particularly common in adolescence because of difficulties of accessing health systems, the difficulties of discriminating pathologic from typical adolescent behavioral characteristics, and changing endocrine function. Coming to terms with the cancer diagnosis; coping personally, socially, and financially with cancer treatments; accepting the risk of a shortened life span; confronting acquired disability; and coping with complex rehabilitation and adjusted plans for life are challenges for which there are no established specialist health models. This article will discuss the changing brain tumor profile of children, adolescents, and adults, with a focus on our limited understanding of the adolescent/young adult transition period. C1 [Kieran, Mark W.] Dana Farber Canc Inst, Boston, MA 02115 USA. Queens Med Ctr, Sch Human Dev, Nottingham NG7 2UH, England. Inst Hematooncol Pediat, Lyon, France. Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA. RP Kieran, MW (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM Mark_kieran@dfci.harvard.edu OI Kieran, Mark/0000-0003-2184-7692 FU TransMolecular; Merck AG; Novartis; Schering-Plough; Celtic Pharma FX Employment or Leadership Position: None Consultant or Advisory Role: Mark W. Kieran, Celgene (C), Infinity Pharmaceuticals (C), AstraZeneca (C) Stock Ownership: None Honoraria: David Walker, International Conference Speaker Honorarium Research Funding: Mark W. Kieran, TransMolecular, Merck AG, Novartis, Schering-Plough, Celtic Pharma Expert Testimony: David Walker, MedicoLegal Consults (multiple) (C) Other Remuneration: None NR 42 TC 37 Z9 40 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 10 PY 2010 VL 28 IS 32 BP 4783 EP 4789 DI 10.1200/JCO.2010.28.3481 PG 7 WC Oncology SC Oncology GA 676RS UT WOS:000283935500013 PM 20458039 ER PT J AU Canellos, GP AF Canellos, George P. TI Early-Stage Favorable Hodgkin's Lymphoma: Is Chemotherapy Alone Sufficient? Reply SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Letter ID DISEASE; SURVIVAL; THERAPY; TRIAL C1 Dana Farber Canc Inst, Boston, MA 02115 USA. RP Canellos, GP (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 10 PY 2010 VL 28 IS 32 BP E670 EP E670 DI 10.1200/JCO.2010.31.6224 PG 1 WC Oncology SC Oncology GA 676RS UT WOS:000283935500009 ER PT J AU Roberts, LE Eggermont, JJ Caspary, DM Shore, SE Melcher, JR Kaltenbach, JA AF Roberts, Larry E. Eggermont, Jos J. Caspary, Donald M. Shore, Susan E. Melcher, Jennifer R. Kaltenbach, James A. TI Ringing Ears: The Neuroscience of Tinnitus SO JOURNAL OF NEUROSCIENCE LA English DT Article ID DORSAL COCHLEAR NUCLEUS; PRIMARY AUDITORY-CORTEX; ENRICHED ACOUSTIC ENVIRONMENT; INDUCED HEARING-LOSS; TIMING-DEPENDENT PLASTICITY; SPONTANEOUS NEURAL ACTIVITY; AGE-RELATED-CHANGES; AWAKE GUINEA-PIGS; INFERIOR COLLICULUS; NOISE EXPOSURE AB Tinnitus is a phantom sound (ringing of the ears) that affects quality of life for millions around the world and is associated in most cases with hearing impairment. This symposium will consider evidence that deafferentation of tonotopically organized central auditory structures leads to increased neuron spontaneous firing rates and neural synchrony in the hearing loss region. This region covers the frequency spectrum of tinnitus sounds, which are optimally suppressed following exposure to band-limited noise covering the same frequencies. Cross-modal compensations in subcortical structures may contribute to tinnitus and its modulation by jaw-clenching and eye movements. Yet many older individuals with impaired hearing do not have tinnitus, possibly because age-related changes in inhibitory circuits are better preserved. A brain network involving limbic and other nonauditory regions is active in tinnitus and may be driven when spectrotemporal information conveyed by the damaged ear does not match that predicted by central auditory processing. C1 [Roberts, Larry E.] McMaster Univ, Dept Psychol Neurosci & Behav, Hamilton, ON L8S 4K1, Canada. [Eggermont, Jos J.] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada. [Eggermont, Jos J.] Univ Calgary, Dept Psychol, Calgary, AB T2N 4N1, Canada. [Caspary, Donald M.] So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA. [Shore, Susan E.] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA. [Shore, Susan E.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA. [Melcher, Jennifer R.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. [Kaltenbach, James A.] Cleveland Clin, Head & Neck Inst, Dept Neurosci, Cleveland, OH 44195 USA. RP Roberts, LE (reprint author), McMaster Univ, Dept Psychol Neurosci & Behav, 1280 Main St W, Hamilton, ON L8S 4K1, Canada. EM roberts@mcmaster.ca FU Canadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council (NSERC) of Canada; American Tinnitus Association; Tinnitus Research Initiative; NSERC; Alberta Heritage Foundation for Medical Research; National Institutes of Health (NIH) [DC000151-28, DC008532-03, R01DC004825, P3005188, R01 DC009097]; Tinnitus Research Consortium; NIH/NIDCD (National Institute on Deafness and Other Communication Disorders) [RC1DC010645] FX The research was supported by Canadian Institutes of Health Research (CIHR) and Natural Sciences and Engineering Research Council (NSERC) of Canada, the American Tinnitus Association, and the Tinnitus Research Initiative (L.E.R.); CIHR, NSERC, and the Alberta Heritage Foundation for Medical Research (J.J.E.); National Institutes of Health (NIH) Grants DC000151-28 and DC008532-03 (D.M.C.); NIH Grants R01DC004825 and P3005188, the Tinnitus Research Consortium, and Tinnitus Research Initiative (S.E.S.); NIH/NIDCD (National Institute on Deafness and Other Communication Disorders) Grant RC1DC010645, the Tinnitus Research Initiative, Tinnitus Research Consortium, and American Tinnitus Association (J.R.M.); and NIH Grant R01 DC009097 (J.A.K.). NR 106 TC 195 Z9 199 U1 9 U2 42 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 10 PY 2010 VL 30 IS 45 BP 14972 EP 14979 DI 10.1523/JNEUROSCI.4028-10.2010 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 678QY UT WOS:000284096300010 PM 21068300 ER PT J AU del Camino, D Murphy, S Heiry, M Barrett, LB Earley, TJ Cook, CA Petrus, MJ Zhao, M D'Amours, M Deering, N Brenner, GJ Costigan, M Hayward, NJ Chong, JHA Fanger, CM Woolf, CJ Patapoutian, A Moran, MM AF del Camino, Donato Murphy, Sarah Heiry, Melissa Barrett, Lee B. Earley, Taryn J. Cook, Colby A. Petrus, Matt J. Zhao, Michael D'Amours, Marc Deering, Nate Brenner, Gary J. Costigan, Michael Hayward, Neil J. Chong, Jayhong A. Fanger, Christopher M. Woolf, Clifford J. Patapoutian, Ardem Moran, Magdalene M. TI TRPA1 Contributes to Cold Hypersensitivity SO JOURNAL OF NEUROSCIENCE LA English DT Article ID RECEPTOR POTENTIAL A1; ION-CHANNEL TRPA1; SENSORY NEURONS; COVALENT MODIFICATION; NOCICEPTIVE NEURONS; NERVE INJURY; CALCIUM-IONS; PAIN; ACTIVATION; TRPM8 AB TRPA1 is a nonselective cation channel expressed by nociceptors. Although it is widely accepted that TRPA1 serves as a broad irritancy receptor for a variety of reactive chemicals, its role in cold sensation remains controversial. Here, we demonstrate that mild cooling markedly increases agonist-evoked rat TRPA1 currents. In the absence of an agonist, even noxious cold only increases current amplitude slightly. These results suggest that TRPA1 is a key mediator of cold hypersensitivity in pathological conditions in which reactive oxygen species and proinflammatory activators of the channel are present, but likely plays a comparatively minor role in acute cold sensation. Supporting this, cold hypersensitivity can be induced in wild-type but not Trpa1(-/-) mice by subcutaneous administration of a TRPA1 agonist. Furthermore, the selective TRPA1 antagonist HC-030031 [2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide] reduces cold hypersensitivity in rodent models of inflammatory and neuropathic pain. C1 [del Camino, Donato; Murphy, Sarah; Heiry, Melissa; Cook, Colby A.; Zhao, Michael; D'Amours, Marc; Deering, Nate; Hayward, Neil J.; Chong, Jayhong A.; Fanger, Christopher M.; Moran, Magdalene M.] Hydra Biosci Inc, Cambridge, MA 02139 USA. [Petrus, Matt J.; Patapoutian, Ardem] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA. [Earley, Taryn J.; Patapoutian, Ardem] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA. [Barrett, Lee B.; Costigan, Michael; Woolf, Clifford J.] Childrens Hosp Boston, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA. [Barrett, Lee B.; Costigan, Michael; Woolf, Clifford J.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. [Brenner, Gary J.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neuronal Plast Res Grp, Charlestown, MA 02129 USA. [Brenner, Gary J.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP del Camino, D (reprint author), Hydra Biosci Inc, 790 Mem Dr, Cambridge, MA 02139 USA. EM ddelcamino@hydrabiosciences.com FU National Institutes of Health [NS039518] FX This work was supported in part by National Institutes of Health Grant NS039518 (C.J.W.). We thank JoAnn Witek for tissue culture support and Jennifer Monsen for formulation work. We are grateful to Timothy Strassmaier, Xiaoguang Zhen, David Kimball, and David Clapham for helpful comments on this manuscript. D.d.C. performed electrophysiological experiments, designed experiments, analyzed data, wrote the paper, and supervised the project. S.M. performed electrophysiological experiments and analyzed data. M.H. performed electrophysiological experiments, analyzed data, and wrote the paper. L.B.B. designed and performed SNI experiments. T.J.E. and M.J.P. performed mouse in vivo experiments. C.A.C. performed rat in vivo experiments. M.Z. performed rat in vivo experiments. M.D. performed analytical work. N.D. performed electrophysiological experiments and wrote the paper. G.J.B. performed SNI experiments. M.C. performed SNI experiments. N.J.H. wrote the paper. J.A.C. analyzed data and wrote the paper. C.M.F. analyzed data and wrote the paper. C.J.W. designed experiments, analyzed data, and wrote the paper. A.P. designed experiments, analyzed data, and wrote the paper. M.M.M. designed experiments, analyzed data, wrote the paper, and supervised the project. NR 39 TC 107 Z9 107 U1 1 U2 6 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 10 PY 2010 VL 30 IS 45 BP 15165 EP 15174 DI 10.1523/JNEUROSCI.2580-10.2010 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 678QY UT WOS:000284096300032 PM 21068322 ER PT J AU Nambiar, PR Gupta, RR Misra, V AF Nambiar, Prashant R. Gupta, Rishi R. Misra, Vikas TI An "Omics" based survey of human colon cancer SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS LA English DT Review DE Colon cancer; Transcriptomics; Metabolomics; Proteomics; Systems biology; Colorectal cancer ID GENE-EXPRESSION PROFILES; FECAL-OCCULT-BLOOD; HUMAN COLORECTAL-CANCER; MAS NMR-SPECTROSCOPY; SYSTEMS BIOLOGY; HUMAN BREAST; 2-DIMENSIONAL ELECTROPHORESIS; OLIGONUCLEOTIDE ARRAYS; PROGNOSIS PREDICTION; NONNEOPLASTIC MUCOSA AB Despite an increased understanding of the molecular pathogenesis of colorectal cancer (CRC) during the past two decades, reliable and robust biomarkers to enable screening, surveillance, and primary prevention of this disease are lacking. CRC diagnosis and therapy remain dependent upon descriptive classification and staging systems, based primarily on morphology and histology. The traditional approach of understanding complex biological systems by studying smaller, discrete units of the whole system has been less fruitful for understanding complex diseases. The implicit assumption of traditional methods, that a single or even only a few factors, play a dominant role in a complex disease might be inadequate when studying multifactorial diseases such as cancer. The burgeoning field of systems biology adopts a holistic approach, wherein the integration of individual parts of the system is sought. The cornerstone of a systems biology approach has been the development of a variety of high-throughput "omics" sciences, including genomics, transcriptomics, proteomics, and metabolomics. This review will focus on the "omics" literature in the field of sporadic human CRC and present examples of how a systems approach has been extremely useful in understanding concepts that would have been difficult to develop using traditional methods. (C) 2010 Elsevier B.V. All rights reserved. C1 [Nambiar, Prashant R.] Pfizer Inc, Toxicol Pathol Drug Safety Res & Dev, Groton, CT 06340 USA. [Gupta, Rishi R.] Pfizer PharmaTx Res & Dev, Groton Struct Biol, Antibacterial Chem Discovery Technol, Groton, CT 06340 USA. [Misra, Vikas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol, Boston, MA 02115 USA. [Misra, Vikas] Harvard Univ, Sch Med, Dana Farber Canc Inst, AIDS, Boston, MA 02115 USA. RP Nambiar, PR (reprint author), Pfizer Inc, Toxicol Pathol Drug Safety Res & Dev, Eastern Point Rd, Groton, CT 06340 USA. EM prashant.nambiar@pfizer.com FU Dana-Farber Cancer Institute FX The authors acknowledge the analytic input provided by Dennis Pelletier in Drug Safety Research Development at Pfizer Inc. VM is supported by the Claudia Adams Barr Program in Innovative Basic Cancer Research (PI: Dana H Gabuzda) at Dana-Farber Cancer Institute. We would also like to acknowledge scientists at GeneGo Inc. specifically Dr. Lellean JeBailey for helping us with MetaCore (R) analysis. NR 91 TC 35 Z9 36 U1 0 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0027-5107 J9 MUTAT RES-FUND MOL M JI Mutat. Res.-Fundam. Mol. Mech. Mutagen. PD NOV 10 PY 2010 VL 693 IS 1-2 SI SI BP 3 EP 18 DI 10.1016/j.mrfmmm.2010.07.008 PG 16 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology GA 687OX UT WOS:000284788900002 PM 20691711 ER PT J AU Cantuti-Castelvetri, I Hernandez, LF Keller-McGandy, CE Kett, LR Landy, A Hollingsworth, ZR Saka, E Crittenden, JR Nillni, EA Young, AB Standaert, DG Graybiel, AM AF Cantuti-Castelvetri, Ippolita Hernandez, Ledia F. Keller-McGandy, Christine E. Kett, Lauren R. Landy, Alex Hollingsworth, Zane R. Saka, Esen Crittenden, Jill R. Nillni, Eduardo A. Young, Anne B. Standaert, David G. Graybiel, Ann M. TI Levodopa-Induced Dyskinesia Is Associated with Increased Thyrotropin Releasing Hormone in the Dorsal Striatum of Hemi-Parkinsonian Rats SO PLOS ONE LA English DT Article ID DOPA-INDUCED DYSKINESIA; MEDIUM SPINY NEURONS; BASAL GANGLIA; NUCLEUS-ACCUMBENS; IMMUNOHISTOCHEMICAL LOCALIZATION; ANTITHYROID TREATMENT; DEPLETED STRIATUM; INDUCED BEHAVIOR; GENE-EXPRESSION; DISEASE AB Background: Dyskinesias associated with involuntary movements and painful muscle contractions are a common and severe complication of standard levodopa (L-DOPA, L-3,4-dihydroxyphenylalanine) therapy for Parkinson's disease. Pathologic neuroplasticity leading to hyper-responsive dopamine receptor signaling in the sensorimotor striatum is thought to underlie this currently untreatable condition. Methodology/Principal Findings: Quantitative real-time polymerase chain reaction (PCR) was employed to evaluate the molecular changes associated with L-DOPA-induced dyskinesias in Parkinson's disease. With this technique, we determined that thyrotropin releasing hormone (TRH) was greatly increased in the dopamine-depleted striatum of hemi-parkinsonian rats that developed abnormal movements in response to L-DOPA therapy, relative to the levels measured in the contralateral non-dopamine-depleted striatum, and in the striatum of non-dyskinetic control rats. ProTRH immunostaining suggested that TRH peptide levels were almost absent in the dopamine-depleted striatum of control rats that did not develop dyskinesias, but in the dyskinetic rats, proTRH immunostaining was dramatically up-regulated in the striatum, particularly in the sensorimotor striatum. This up-regulation of TRH peptide affected striatal medium spiny neurons of both the direct and indirect pathways, as well as neurons in striosomes. Conclusions/Significance: TRH is not known to be a key striatal neuromodulator, but intrastriatal injection of TRH in experimental animals can induce abnormal movements, apparently through increasing dopamine release. Our finding of a dramatic and selective up-regulation of TRH expression in the sensorimotor striatum of dyskinetic rat models suggests a TRH-mediated regulatory mechanism that may underlie the pathologic neuroplasticity driving dopamine hyper-responsivity in Parkinson's disease. C1 [Cantuti-Castelvetri, Ippolita; Kett, Lauren R.; Landy, Alex; Hollingsworth, Zane R.; Young, Anne B.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Dept Neurol, Charlestown, MA USA. [Hernandez, Ledia F.; Keller-McGandy, Christine E.; Crittenden, Jill R.; Graybiel, Ann M.] MIT, Dept Brain & Cognit Sci, McGovern Inst Brain Res, Cambridge, MA 02139 USA. [Saka, Esen] Hacettepe Univ, Fac Med, Dept Neurol, TR-06100 Ankara, Turkey. [Standaert, David G.] Univ Alabama, Ctr Neurodegenerat & Expt Therapeut, Birmingham, AL USA. [Nillni, Eduardo A.] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Med,Div Endocrinol, Providence, RI 02903 USA. RP Cantuti-Castelvetri, I (reprint author), Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Dept Neurol, Charlestown, MA USA. EM can-cas@helix.mgh.harvard.edu RI F. Hernandez, Ledia/J-3077-2012; OI F. Hernandez, Ledia/0000-0002-5293-3748; Standaert, David/0000-0003-2921-8348 FU MGH/MIT Morris Udall Center of Excellence [NIH NS38372]; American Parkinson Disease Association Advanced Centers for Parkinson Research at Massachusetts General Hospital; University of Alabama Birmingham; NIDDK/NIH [R01 DK58148, NS045231]; Stanley H. and Sheila G. Sydney Fund; Parkinson's Disease Foundation; Fulbright Fellowship; Michael J. Fox Foundation FX This study was supported in part by the MGH/MIT Morris Udall Center of Excellence in PD Research (NIH NS38372) (ICC, LRK, ZRH, ABY, LFH, AMG, CEKMcG, JRC), and the American Parkinson Disease Association Advanced Centers for Parkinson Research at Massachusetts General Hospital (ICC, ABY) and University of Alabama Birmingham (DGS); NIDDK/NIH grant R01 DK58148 and R01 NINDS/NIH grant NS045231 (EAN); Stanley H. and Sheila G. Sydney Fund (AMG); Parkinson's Disease Foundation Fellowship and Fulbright Fellowship (LFH); Michael J. Fox Foundation (AMG, JRC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 67 TC 5 Z9 5 U1 2 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 10 PY 2010 VL 5 IS 11 AR e13861 DI 10.1371/journal.pone.0013861 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 677ZN UT WOS:000284036800007 PM 21085660 ER PT J AU Xiong, JH Liu, JA Rayner, S Tian, Z Li, YH Chen, SG AF Xiong, Jianghui Liu, Juan Rayner, Simon Tian, Ze Li, Yinghui Chen, Shanguang TI Pre-Clinical Drug Prioritization via Prognosis-Guided Genetic Interaction Networks SO PLOS ONE LA English DT Article ID CELL LUNG-CANCER; BREAST-CANCER; TARGETED THERAPIES; IDENTIFICATION; PHARMACOLOGY; GEMCITABINE; ROBUSTNESS; MODULARITY; INHIBITORS; SIGNATURES AB The high rates of failure in oncology drug clinical trials highlight the problems of using pre-clinical data to predict the clinical effects of drugs. Patient population heterogeneity and unpredictable physiology complicate pre-clinical cancer modeling efforts. We hypothesize that gene networks associated with cancer outcome in heterogeneous patient populations could serve as a reference for identifying drug effects. Here we propose a novel in vivo genetic interaction which we call 'synergistic outcome determination' (SOD), a concept similar to 'Synthetic Lethality'. SOD is defined as the synergy of a gene pair with respect to cancer patients' outcome, whose correlation with outcome is due to cooperative, rather than independent, contributions of genes. The method combines microarray gene expression data with cancer prognostic information to identify synergistic gene-gene interactions that are then used to construct interaction networks based on gene modules (a group of genes which share similar function). In this way, we identified a cluster of important epigenetically regulated gene modules. By projecting drug sensitivity-associated genes on to the cancer-specific intermodule network, we defined a perturbation index for each drug based upon its characteristic perturbation pattern on the inter-module network. Finally, by calculating this index for compounds in the NCI Standard Agent Database, we significantly discriminated successful drugs from a broad set of test compounds, and further revealed the mechanisms of drug combinations. Thus, prognosis-guided synergistic gene-gene interaction networks could serve as an efficient in silico tool for pre-clinical drug prioritization and rational design of combinatorial therapies. C1 [Xiong, Jianghui; Liu, Juan] Wuhan Univ, Sch Comp Sci, Wuhan 430072, Peoples R China. [Xiong, Jianghui; Li, Yinghui; Chen, Shanguang] China Astronaut Res & Training Ctr, State Key Lab Space Med Fundamentals & Applicat, Bioinformat Syst Biol & Translat Med Grp, Beijing, Peoples R China. [Rayner, Simon] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Bioinformat Grp, Wuhan, Peoples R China. [Tian, Ze] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Xiong, JH (reprint author), Wuhan Univ, Sch Comp Sci, Wuhan 430072, Peoples R China. EM laserxiong@gmail.com; liujuan@whu.edu.cn OI rayner, simon/0000-0001-8703-9140 FU National Natural Science Foundation of China [30600759, 60773010, 60970063]; State Key Lab of Space Medicine Fundamentals and Application [SMFA09A07]; Advanced Space Medico-Engineering Research Project of China [01105015, 01104099] FX This work was partly supported by the National Natural Science Foundation of China to J.X. (30600759) and J.L. (60773010 and 60970063), grant from State Key Lab of Space Medicine Fundamentals and Application to J.X. (SMFA09A07), and Advanced Space Medico-Engineering Research Project of China to J.X. (01105015, 01104099). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 5 Z9 8 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 10 PY 2010 VL 5 IS 11 AR e13937 DI 10.1371/journal.pone.0013937 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 677ZN UT WOS:000284036800024 PM 21085674 ER PT J AU Crum-Cianflone, NF Roediger, M Hullsiek, KH Ganesan, A Landrum, M Weintrob, A Agan, B Medina, S Rahkola, J Hale, B Janoff, EN AF Crum-Cianflone, Nancy F. Roediger, Mollie Hullsiek, Kathy Huppler Ganesan, Anuradha Landrum, Michael Weintrob, Amy Agan, Brian Medina, Sheila Rahkola, Jeremy Hale, Braden Janoff, Edward N. CA Infect Dis Clinical Res Program HI TI The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection SO VACCINE LA English DT Article DE Ethnicity; Antibodies; Pneumococcal vaccination; HIV ID IMMUNODEFICIENCY-VIRUS-INFECTION; HIV-1-INFECTED UGANDAN ADULTS; POLYSACCHARIDE VACCINE; RISK-FACTORS; RESISTANCE PATTERNS; CLINICAL-FEATURES; CHARLESTON COUNTY; CONJUGATE VACCINE; SOUTH-CAROLINA; DISEASE AB Ethnicity may be associated with the incidence of pneumococcal infections and the frequency of protective vaccine responses. Earlier studies have suggested that HIV-infected persons of black ethnicity develop less robust immune responses to pneumococcal vaccination that may relate to their higher incidence of invasive disease. We evaluated the association of ethnicity with capsule-specific antibody responses to pneumococcal revaccination, with either the pneumococcal conjugate (PCV) or polysaccharide (PPV) vaccines among 188 HIV-infected adults. The proportion of the 77 African Americans (AA) and 111 Caucasians with comparable virologic and immunologic parameters who achieved a positive immune response (>= 2-fold rise in capsule-specific IgG from baseline with post-vaccination value >= 1 mu g/mL for >= 2 of 4 serotypes) at day 60 after revaccination was similar (43% vs. 49%, respectively, p = 0.65). Results were also similar when vaccine types (PPV and PCV) were examined separately. Mean changes in log(10) transformed IgG levels from baseline to days 60 and 180 post-vaccination were also not significantly different between AA and Caucasians. In summary, in this ethnically diverse cohort with equal access to care, we did not observe differential antibody responses between AA and Caucasian HIV-infected adults after pneumococcal revaccination. Published by Elsevier Ltd. C1 [Crum-Cianflone, Nancy F.] USN, San Diego Med Ctr, Clin Invest Dept KCA, San Diego, CA 92134 USA. [Crum-Cianflone, Nancy F.; Roediger, Mollie; Hullsiek, Kathy Huppler; Ganesan, Anuradha; Landrum, Michael; Weintrob, Amy; Agan, Brian; Medina, Sheila; Hale, Braden] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA. [Roediger, Mollie; Hullsiek, Kathy Huppler] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Ganesan, Anuradha] Natl Naval Med Ctr, Bethesda, MD USA. [Landrum, Michael] San Antonio Mil Med Ctr, San Antonio, TX USA. [Weintrob, Amy] Walter Reed Army Med Ctr, Washington, DC 20307 USA. [Rahkola, Jeremy; Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, Denver, CO 80202 USA. [Hale, Braden] USN, Hlth Res Ctr, San Diego, CA 92134 USA. [Rahkola, Jeremy; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Crum-Cianflone, NF (reprint author), USN, San Diego Med Ctr, Clin Invest Dept KCA, 34800 Bob Wilson Dr,Ste 5, San Diego, CA 92134 USA. EM nancy.crum@med.navy.mil OI Agan, Brian/0000-0002-5114-1669 FU Department of Defense (DoD) through the Uniformed Services University of the Health Sciences [IDCRP RV-150]; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) [Y1-AI-5072]; Veterans Affairs Research Service FX Support for this work (IDCRP RV-150) was provided by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072. Additional support was obtained from the Veterans Affairs Research Service. NR 27 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD NOV 10 PY 2010 VL 28 IS 48 BP 7583 EP 7588 DI 10.1016/j.vaccine.2010.09.056 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 696HN UT WOS:000285432600002 PM 20887830 ER PT J AU Lovoll, M Wiik-Nielsen, J Grove, S Wiik-Nielsen, CR Kristoffersen, AB Faller, R Poppe, T Jung, J Pedamallu, CS Nederbragt, AJ Meyerson, M Rimstad, E Tengs, T AF Lovoll, Marie Wiik-Nielsen, Jannicke Grove, Soren Wiik-Nielsen, Christer R. Kristoffersen, Anja B. Faller, Randi Poppe, Trygve Jung, Joonil Pedamallu, Chandra S. Nederbragt, Alexander J. Meyerson, Matthew Rimstad, Espen Tengs, Torstein TI A novel totivirus and piscine reovirus (PRV) in Atlantic salmon (Salmo salar) with cardiomyopathy syndrome (CMS) SO VIROLOGY JOURNAL LA English DT Article ID SKELETAL-MUSCLE INFLAMMATION; INFECTIOUS MYONECROSIS VIRUS; HEART AB Background: Cardiomyopathy syndrome (CMS) is a severe disease affecting large farmed Atlantic salmon. Mortality often appears without prior clinical signs, typically shortly prior to slaughter. We recently reported the finding and the complete genomic sequence of a novel piscine reovirus (PRV), which is associated with another cardiac disease in Atlantic salmon; heart and skeletal muscle inflammation (HSMI). In the present work we have studied whether PRV or other infectious agents may be involved in the etiology of CMS. Results: Using high throughput sequencing on heart samples from natural outbreaks of CMS and from fish experimentally challenged with material from fish diagnosed with CMS a high number of sequence reads identical to the PRV genome were identified. In addition, a sequence contig from a novel totivirus could also be constructed. Using RT-qPCR, levels of PRV in tissue samples were quantified and the totivirus was detected in all samples tested from CMS fish but not in controls. In situ hybridization supported this pattern indicating a possible association between CMS and the novel piscine totivirus. Conclusions: Although causality for CMS in Atlantic salmon could not be proven for either of the two viruses, our results are compatible with a hypothesis where, in the experimental challenge studied, PRV behaves as an opportunist whereas the totivirus might be more directly linked with the development of CMS. C1 [Tengs, Torstein] Natl Vet Inst, Sect Virol & Serol, N-0106 Oslo, Norway. [Lovoll, Marie; Grove, Soren; Wiik-Nielsen, Christer R.; Faller, Randi] Natl Vet Inst, Sect Immunoprophylaxis, N-0106 Oslo, Norway. [Wiik-Nielsen, Jannicke] Natl Vet Inst, Sect Fish Hlth, N-0106 Oslo, Norway. [Kristoffersen, Anja B.] Natl Vet Inst, Epidemiol Sect, N-0106 Oslo, Norway. [Poppe, Trygve] Norwegian Sch Vet Sci, Dept Basic Sci & Aquat Med, N-0033 Oslo, Norway. [Jung, Joonil; Pedamallu, Chandra S.] MIT, Broad Inst, Cambridge, MA 02142 USA. [Nederbragt, Alexander J.] Univ Oslo, CEES, N-0316 Oslo, Norway. [Meyerson, Matthew] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Rimstad, Espen] Norwegian Sch Vet Sci, Dept Food Safety & Infect Biol, N-0033 Oslo, Norway. RP Tengs, T (reprint author), Natl Vet Inst, Sect Virol & Serol, POB 750 Sentrum, N-0106 Oslo, Norway. EM torstein.tengs@vetinst.no RI Meyerson, Matthew/E-7123-2012; Nederbragt, Alexander/B-8013-2010 OI Nederbragt, Alexander/0000-0001-5539-0999 FU Research Council of Norway [183196/S40, 1869072, 1869073] FX We thank Elisabeth Dahl Nybo and Karen Baekken Soleim for technical assistance. This work was supported by grants from the Research Council of Norway (183196/S40, 1869072 and 1869073). NR 27 TC 43 Z9 43 U1 1 U2 26 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-422X J9 VIROL J JI Virol. J. PD NOV 10 PY 2010 VL 7 AR 309 DI 10.1186/1743-422X-7-309 PG 7 WC Virology SC Virology GA 685UH UT WOS:000284653100002 PM 21067578 ER PT J AU Zhou, QQ Kee, YS Poirier, CC Jelinek, C Osborne, J Divi, S Surcel, A Will, ME Eggert, US Muller-Taubenberger, A Iglesias, PA Cotter, RJ Robinson, DN AF Zhou, Qiongqiong Kee, Yee-Seir Poirier, Christopher C. Jelinek, Christine Osborne, Jonathan Divi, Srikanth Surcel, Alexandra Will, Marie E. Eggert, Ulrike S. Mueller-Taubenberger, Annette Iglesias, Pablo A. Cotter, Robert J. Robinson, Douglas N. TI 14-3-3 Coordinates Microtubules, Rac, and Myosin II to Control Cell Mechanics and Cytokinesis SO CURRENT BIOLOGY LA English DT Article ID CHAIN PHOSPHORYLATION; MUTATIONAL ANALYSIS; DICTYOSTELIUM RACE; CLEAVAGE FURROW; ACTIN-FILAMENTS; PROTEIN; LOCALIZATION; DYNAMICS; KINASE; CONTRACTILITY AB Background: During cytokinesis, regulatory signals are presumed to emanate from the mitotic spindle. However, what these signals are and how they lead to the spatiotemporal changes in the cortex structure, mechanics, and regional contractility are not well understood in any system. Results: To investigate pathways that link the microtubule network to the cortical changes that promote cytokinesis, we used chemical genetics in Dictyostelium to identify genetic suppressors of nocodazole, a microtubule depolymerizer. We identified 14-3-3 and found that it is enriched in the cortex, helps maintain steady-state microtubule length, contributes to normal cortical tension, modulates actin wave formation, and controls the symmetry and kinetics of cleavage furrow contractility during cytokinesis. Furthermore, 14-3-3 acts downstream of a Rac small GTPase (RacE), associates with myosin II heavy chain, and is needed to promote myosin II bipolar thick filament remodeling. Conclusions: 14-3-3 connects microtubules, Rac, and myosin II to control several aspects of cortical dynamics, mechanics, and cytokinesis cell shape change. Furthermore, 14-3-3 interacts directly with myosin II heavy chain to promote bipolar thick filament remodeling and distribution. Overall, 14-3-3 appears to integrate several critical cytoskeletal elements that drive two important processes-cytokinesis cell shape change and cell mechanics. C1 [Zhou, Qiongqiong; Kee, Yee-Seir; Osborne, Jonathan; Divi, Srikanth; Surcel, Alexandra; Will, Marie E.; Robinson, Douglas N.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA. [Jelinek, Christine; Cotter, Robert J.; Robinson, Douglas N.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA. [Poirier, Christopher C.; Iglesias, Pablo A.] Johns Hopkins Univ, Dept Elect & Comp Engn, Baltimore, MD 21218 USA. [Robinson, Douglas N.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA. [Eggert, Ulrike S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Eggert, Ulrike S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Mueller-Taubenberger, Annette] Univ Munich, Inst Anat & Cell Biol, D-80336 Munich, Germany. RP Robinson, DN (reprint author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA. EM dnr@jhmi.edu RI Iglesias, Pablo/A-5202-2008 OI Iglesias, Pablo/0000-0002-0840-155X FU American Heart Fellowship; National Institutes of Health (NIH) [GM066817, GM86704, GM082834]; American Cancer Society [RSG CCG-114122]; National Science Foundation [CCF 0621740] FX We thank the members of the Robinson laboratory for helpful comments on the manuscript and Cathy Kabacoff in particular for assistance with generating cell lines. This work was supported by an American Heart Fellowship (to Q.Z.), National Institutes of Health (NIH) grant GM066817 (to D.N.R.), American Cancer Society grant RSG CCG-114122 (to D.N.R.), National Science Foundation grant CCF 0621740 (to P.A.I. and D.N.R.), NIH grant GM86704 (to P.A.I. and D.N.R.), and NIH grant GM082834 (to U.S.E). NR 34 TC 31 Z9 32 U1 0 U2 10 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0960-9822 J9 CURR BIOL JI Curr. Biol. PD NOV 9 PY 2010 VL 20 IS 21 BP 1881 EP 1889 DI 10.1016/j.cub.2010.09.048 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 679XK UT WOS:000284193900020 PM 20951045 ER PT J AU Wiviott, SD Mega, JL AF Wiviott, Stephen D. Mega, Jessica L. TI Another Step on the Road to Tailored Antiplatelet Therapy SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material ID ACUTE CORONARY SYNDROMES; MYOCARDIAL-INFARCTION; CLOPIDOGREL; THROMBOSIS; EVENTS C1 [Wiviott, Stephen D.; Mega, Jessica L.] Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp,Dept Med,Med Sch, Boston, MA 02115 USA. RP Wiviott, SD (reprint author), Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp,Dept Med,Med Sch, 75 Francis St, Boston, MA 02115 USA. EM swiviott@partners.org NR 12 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 9 PY 2010 VL 56 IS 20 BP 1637 EP 1638 DI 10.1016/j.jacc.2010.08.610 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 674JQ UT WOS:000283737600005 PM 21050972 ER PT J AU Rost, NS Rahman, RM Biffi, A Smith, EE Kanakis, A Fitzpatrick, K Lima, F Worrall, BB Meschia, JF Brown, RD Brott, TG Sorensen, AG Greenberg, SM Furie, KL Rosand, J AF Rost, N. S. Rahman, R. M. Biffi, A. Smith, E. E. Kanakis, A. Fitzpatrick, K. Lima, F. Worrall, B. B. Meschia, J. F. Brown, R. D., Jr. Brott, T. G. Sorensen, A. G. Greenberg, S. M. Furie, K. L. Rosand, J. TI White matter hyperintensity volume is increased in small vessel stroke subtypes SO NEUROLOGY LA English DT Article ID CEREBRAL AMYLOID ANGIOPATHY; ACUTE ISCHEMIC-STROKE; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL VOLUME; NORTHERN MANHATTAN; ELDERLY-PEOPLE; LESIONS; LEUKOARAIOSIS; RISK; SEVERITY AB Objective: White matter hyperintensity (WMH) may be a marker of an underlying cerebral microangiopathy. Therefore, we hypothesized that WMH would be most severe in patients with lacunar stroke and intracerebral hemorrhage (ICH), 2 types of stroke in which cerebral small vessel (SV) changes are pathophysiologically relevant. Methods: We determined WMH volume (WMHV) in cohorts of prospectively ascertained patients with acute ischemic stroke (AIS) (Massachusetts General Hospital [MGH], n = 628, and the Ischemic Stroke Genetics Study [ISGS], n = 263) and ICH (MGH, n = 122). Results: Median WMHV was 7.5 cm(3) (interquartile range 3.4-14.7 cm(3)) in the MGH AIS cohort (mean age 65 +/- 15 years). MGH patients with larger WMHV were more likely to have lacunar stroke compared with cardioembolic (odds ratio [OR] = 1.87 per SD normally transformed WMHV), large artery (OR = 2.25), undetermined (OR = 1.87), or other (OR = 1.85) stroke sub-types (p < 0.03). These associations were replicated in the ISGS cohort (p = 0.03). In a separate analysis, greater WMHV was seen in ICH compared with lacunar stroke (OR = 1.2, p < 0.02) and in ICH compared with all ischemic stroke subtypes combined (OR = 1.34, p < 0.007). Conclusions: Greater WMH burden was associated with SV stroke compared with other ischemic stroke subtypes and, even more strongly, with ICH. These data, from 2 independent samples, support the model that increasing WMHV is a marker of more severe cerebral SV disease and provide further evidence for links between the biology of WMH and SV stroke. Neurology(R) 2010;75:1670-1677 C1 [Rost, N. S.] Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Ctr Human Genet Res, Boston, MA 02114 USA. [Rost, N. S.; Rahman, R. M.; Biffi, A.; Kanakis, A.; Fitzpatrick, K.; Lima, F.; Greenberg, S. M.; Furie, K. L.; Rosand, J.] Massachusetts Gen Hosp, Stroke Serv, Dept Neurol, Boston, MA 02114 USA. [Rost, N. S.; Rahman, R. M.; Biffi, A.; Rosand, J.] MIT & Harvard, Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Sorensen, A. G.] Massachusetts Gen Hosp, Ctr Biomed Imaging, Dept Radiol, Boston, MA 02114 USA. [Meschia, J. F.; Brott, T. G.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Brown, R. D., Jr.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Worrall, B. B.] Univ Virginia Hlth Syst, Dept Neurol & Publ Hlth Sci, Charlottesville, VA USA. [Smith, E. E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 1N4, Canada. RP Rost, NS (reprint author), Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Ctr Human Genet Res, 175 Cambridge St,Suite 300, Boston, MA 02114 USA. EM nrost@partners.org OI Smith, Eric/0000-0003-3956-1668 FU American Heart Association Bugher Foundation; Massachusetts General Hospital Deane Institute for Integrative Research in Atrial Fibrillation and Stroke; NIH/NINDS [5P50NS051343, 5K23NS064052, R01NS059727, R01 NS42733, 5K23NS064052-01A1, 1R01NS059727, 5R01NS062028, K23NS046327, 5R01NS039987-10, 5R01NS028492-14, R01 NS039987-10, R01 NS039512Z-07, RC1 NS068092-01, U01 NS069208-01, NS063925, NS061119, R01-HS011392, P50-NS051343]; National Stroke Association; American Stroke Association-Bugher Foundation; Fulbright Foundation; American Association of University Women; CIHR; Canadian Stroke Network; Hotchkiss Brain Institute; NIH (NHGRI/NIH) [U01 NS069208-01, U-01 HG005160]; NIH (NHLBI) [K08-NS45802, R01-NS42733]; NIH (NINDS) [R25 NS065733, R01 NS42147, R01 NS 39987, R01 NS039512]; University of Virginia-CTSA; Genentech, Inc.; Siemens Medical Solutions; Millennium Pharmaceuticals, Inc.; AstraZeneca; Genentech Inc.; Novartis; Merck Serono; Schering Plough Corp.; NIH (NCI) [CA137254]; NIH [R01AG026484, K24NS056207, R01AG021084, R01NS042147, U54NS057405]; Alzheimer's Association; American Heart Association; Deane Institute; MGH Deane Institute for Integrative Research in Atrial Fibrillation and Stroke FX Supported by the American Heart Association Bugher Foundation, the Massachusetts General Hospital Deane Institute for Integrative Research in Atrial Fibrillation and Stroke, and the NIH/NINDS (5P50NS051343, 5K23NS064052, and R01NS059727). The Ischemic Stroke Genetics Study was supported by the NIH/NINDS (R01 NS42733).; Dr. Rost serves as an Associate Editor for Frontiers in Hospitalist Neurology and as an Assistant Editor for Stroke; and receives research support from the NIH (NINDS 5K23NS064052-01A1 [PI]), the National Stroke Association, and the American Stroke Association-Bugher Foundation. Dr. Rahman receives support from the Fulbright Foundation (MoRST Scholarship) and the American Association of University Women (Postdoctoral Fellowship Grant). Dr. Biffi has received research support from the NIH (1R01NS059727 [Research Fellow]) and the American Stroke Association-Bugher Foundation. Dr. Smith has received speaker honoraria from the Canadian Consortium on Dementia; serves on speakers' bureaus for QuantiaMD and BMJ Best Practice; and has received/receives research support from the NIH (5R01NS062028 [PI] and K23NS046327 [PI]), the CIHR, the Canadian Stroke Network, and the Hotchkiss Brain Institute. Ms. Kanakis, Ms. Fitzpatrick, and Dr. Lima report no disclosures. Dr. Worrall serves as an Associate Editor of Neurology and on the editorial board of Seminars in Neurology; receives royalties from the publication of Merritt's Neurology, 10th, 11th, and 12th editions (chapter author); receives/has received research support from the NIH (NHGRI/NIH U-01 HG005160 [Co-PI], U01 NS069208-01[Co-PI], NHLBI contract [PI], NINDS R25 NS065733 [Mentor], NINDS R01 NS42147 [Site PI], NINDS R01 NS 39987 [Executive committee, Site PI], NINDS R01 NS039512 [Executive committee, Co-I], NHLBI contract [Physician investigator], K08-NS45802 [PI], and R01-NS42733 [Site PI]), and from the University of Virginia-CTSA Pilot Project. Dr. Meschia serves on the editorial boards of Stroke and the Journal of Stroke and Cerebrovascular Diseases; and receives research support from the NIH (NINDS 5R01NS039987-10 [PI]). Dr. Brown receives royalties from the publication of Handbook of Stroke (Lippincott Williams & Wilkins, 2005) and Mayo Clinic Internal Medicine Board Review (Mayo Clinic Press); serves on the Board of Directors of the Neilsen Foundation; and receives research support from the NIH (NINDS 5R01NS028492-14 [PI], R01 NS039987-10 [coinvestigator], R01 NS039512Z-07 [coinvestigator], RC1 NS068092-01 [coinvestigator], and U01 NS069208-01 [coinvestigator]). Dr. Brott reports no disclosures. Dr. Sorensen has served on scientific advisory boards for Olea Medical and Breakaway Imaging; has received funding for travel from the Genentech, Inc., Siemens Medical Solutions, Millennium Pharmaceuticals, Inc., and AstraZeneca; serves as a Section Editor of Stroke and on the editorial boards of The Oncologist and the Journal of Clinical Oncology; holds patents re: Method for evaluating novel, stroke treatments using a tissue risk map, Imaging system for obtaining quantative perfusion indices, Delay-compensated calculation of tissue blood flow, High-flow oxygen delivery system and methods of use thereof, and Magnetic resonance spatial risk map for tissue outcome prediction; receives royalties from the publication of Cerebral MR Perfusion Imaging (Thieme, 2000); has received speaker honoraria from Siemens Medical Solutions, Novartis, and GE Healthcare; has served as a consultant to Mitsubishi Tanabe Pharma Corporation, AstraZeneca, and Genentech, Inc.; receives research support from Millennium Pharmaceuticals, Inc., Siemens Medical Solutions, AstraZeneca, Genentech Inc., Novartis, Merck Serono, Schering Plough Corp., the NIH (NINDS NS38477 [PI], NCI CA137254 [PI], NINDS NS063925 [PI], and NINDS NS061119 [PI]); and holds stock and stock options in Epix Pharmaceuticals. Dr.; Greenberg serves on sientific advisory boards for Roche and Alzheimer's Immunotherapy; serves on the editorial boards of Neurology, Stroke, Cerebrovascular Disease, and the Journal of Alzheimer's Disease and Other Dementias; has received speaker honoraria from Merck Serono, Esteve, Medtronics, Inc., and Pfizer Inc; and has received/receives research support from the NIH (R01AG026484 [PI], K24NS056207 [PI], R01AG021084 [coinvestigator], R01NS042147 [PI], and U54NS057405, 2007-2012 [coinvestigator]), and from the Alzheimer's Association. Dr. Furie receives research support from the NIH/NINDS (R01-HS011392 [PI] and NINDS P50-NS051343 [PI]), the American Heart Association, and the Deane Institute. Dr. Rosand has received research support from the NIH (NINDS R01-NS059727 [PI] and NINDS P50NS051343 [PI]), the American Heart Association Bugher Foundation, and the MGH Deane Institute for Integrative Research in Atrial Fibrillation and Stroke. NR 40 TC 63 Z9 64 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 9 PY 2010 VL 75 IS 19 BP 1670 EP 1677 DI 10.1212/WNL.0b013e3181fc279a PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 683JV UT WOS:000284473000006 PM 21060091 ER PT J AU Andersson, KL Friedman, LS AF Andersson, Karin L. Friedman, Lawrence S. TI Hepatitis A A Traveling Target SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material ID UNITED-STATES; IMMUNIZATION; EPIDEMIOLOGY; VACCINATION C1 [Friedman, Lawrence S.] Newton Wellesley Hosp, Dept Med, Newton, MA 02462 USA. [Friedman, Lawrence S.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Andersson, Karin L.; Friedman, Lawrence S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Andersson, Karin L.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Andersson, Karin L.; Friedman, Lawrence S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Friedman, LS (reprint author), Newton Wellesley Hosp, Dept Med, 2014 Washington St, Newton, MA 02462 USA. EM lfriedman@partners.org NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 8 PY 2010 VL 170 IS 20 BP 1818 EP 1819 DI 10.1001/archinternmed.2010.412 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 676SC UT WOS:000283937600015 PM 21059975 ER PT J AU Campbell, EG Rao, SR DesRoches, CM Iezzoni, LI Vogeli, C Bolcic-Jankovic, D Miralles, PD AF Campbell, Eric G. Rao, Sowmya R. DesRoches, Catherine M. Iezzoni, Lisa I. Vogeli, Christine Bolcic-Jankovic, Dragana Miralles, Paola D. TI Physician Professionalism and Changes in Physician-Industry Relationships From 2004 to 2009 SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CONFLICTS-OF-INTEREST; HEALTH-CARE; PROPOSAL; COST; US AB Background: One tenet of medical professionalism is managing conflicts of interest related to physician-industry relationships (PIRs). Since 2004 much has been done at the institutional, state, and national levels to limit PIRs. This study estimates the nature, extent, consequences, and changes in PIRs nationally. Methods: We performed a national survey of a stratified random sample of 2938 primary care physicians (internal medicine, family practice, and pediatrics) and specialists (cardiology, general surgery, psychiatry, and anesthesiology). A total of 1891 physicians completed the survey, yielding an overall response rate of 64.4%. The main outcome measure was prevalence of several types of PIRs and comparison with PIRs in 2004. Results: Overall, 83.8% of all respondents reported some type of relationship with industry during the previous year. Approximately two-thirds (63.8%) received drug samples, 70.6% food and beverages, 18.3% reimbursements, and 14.1% payments for professional services. Since 2004 the percentage of each of these benefits has decreased significantly. Higher rates of PIRs are significantly and inversely associated with low levels of Medicare spending. Conclusion: Among a random sample of physicians, the prevalence of self-reported PIRs in 2009 was 83.8%, which was lower than in 2004. C1 [Campbell, Eric G.; Rao, Sowmya R.; DesRoches, Catherine M.; Iezzoni, Lisa I.; Vogeli, Christine; Miralles, Paola D.] Univ Massachusetts, Mongan Inst Hlth Policy, Massachusetts Gen Hosp, Boston, MA 02125 USA. [Bolcic-Jankovic, Dragana] Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA. [Campbell, Eric G.; Rao, Sowmya R.; DesRoches, Catherine M.; Iezzoni, Lisa I.; Vogeli, Christine] Harvard Univ, Sch Med, Boston, MA USA. RP Campbell, EG (reprint author), Mongan Inst Hlth Policy, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM ecampbell@partners.org FU Institute on Medicine FX This study, the second in a series, was supported by a grant from the Institute on Medicine as a Profession. NR 22 TC 56 Z9 56 U1 0 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 8 PY 2010 VL 170 IS 20 BP 1820 EP 1826 DI 10.1001/archinternmed.2010.383 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 676SC UT WOS:000283937600016 PM 21059976 ER PT J AU De Sousa, M Smith, D Corcoran, A Bailey, FA Furman, C Ritchie, C Rosenfeld, K Shreve, S Casarett, D AF De Sousa, Maysa Smith, Dawn Corcoran, Amy Bailey, F. Amos Furman, Christian Ritchie, Christine Rosenfeld, Kenneth Shreve, Scott Casarett, David TI Families' Perceptions of Inpatient and Home Hospice Care at End-of-Life SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID TERMINALLY-ILL C1 [De Sousa, Maysa; Smith, Dawn; Casarett, David] Ctr Hlth Equ Res & Promot, Dept Vet Affairs Med Ctr, Philadelphia, PA USA. [Corcoran, Amy; Casarett, David] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Bailey, F. Amos] Safe Harbor Palliat Care, Dept Vet Affairs Med Ctr, Birmingham, AL USA. [Furman, Christian] Univ Louisville, Div Geriatr Med, Louisville, KY 40292 USA. [Ritchie, Christine] Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs Med Ctr, Birmingham, AL USA. [Rosenfeld, Kenneth] Dept Vet Affairs Med Ctr, Greater Los Angeles, CA USA. [Shreve, Scott] Hosp & Palliat Care, Dept Vet Affairs, Washington, DC USA. RP Casarett, D (reprint author), Philadelphia VA Ctr Hlth Equ Res & Promot, Inst Aging, Ctr Bioeth, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM Casarett@mail.med.upenn.edu FU PHS HHS [K01 HP00084-02] NR 6 TC 4 Z9 4 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 8 PY 2010 VL 170 IS 20 BP 1856 EP 1857 DI 10.1001/archinternmed.2010.392 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 676SC UT WOS:000283937600023 PM 21059980 ER PT J AU Shackleford, JA Kandasamy, N Sharp, GC AF Shackleford, J. A. Kandasamy, N. Sharp, G. C. TI On developing B-spline registration algorithms for multi-core processors SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article ID NONRIGID IMAGE REGISTRATION; ADAPTIVE RADIOTHERAPY; DEFORMATION; RECONSTRUCTION; OPTIMIZATION; MODEL AB Spline-based deformable registration methods are quite popular within the medical-imaging community due to their flexibility and robustness. However, they require a large amount of computing time to obtain adequate results. This paper makes two contributions towards accelerating B-spline-based registration. First, we propose a grid-alignment scheme and associated data structures that greatly reduce the complexity of the registration algorithm. Based on this grid-alignment scheme, we then develop highly data parallel designs for B-spline registration within the stream-processing model, suitable for implementation on multi-core processors such as graphics processing units (GPUs). Particular attention is focused on an optimal method for performing analytic gradient computations in a data parallel fashion. CPU and GPU versions are validated for execution time and registration quality. Performance results on large images show that our GPU algorithm achieves a speedup of 15 times over the single-threaded CPU implementation whereas our multi-core CPU algorithm achieves a speedup of 8 times over the single-threaded implementation. The CPU and GPU versions achieve near-identical registration quality in terms of RMS differences between the generated vector fields. C1 [Shackleford, J. A.; Kandasamy, N.] Drexel Univ, Dept Elect & Comp Engn, Philadelphia, PA 19104 USA. [Sharp, G. C.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Shackleford, JA (reprint author), Drexel Univ, Dept Elect & Comp Engn, Philadelphia, PA 19104 USA. OI Shackleford, James/0000-0002-7987-651X FU Federal [C06CA059267] FX Funding for this project has been provided by the Federal share of program income earned by MGH on C06CA059267. NR 32 TC 53 Z9 53 U1 0 U2 8 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 J9 PHYS MED BIOL JI Phys. Med. Biol. PD NOV 7 PY 2010 VL 55 IS 21 BP 6329 EP 6351 DI 10.1088/0031-9155/55/21/001 PG 23 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA 665SO UT WOS:000283056000004 PM 20938071 ER PT J AU Ngwa, W Makrigiorgos, GM Berbeco, RI AF Ngwa, Wilfred Makrigiorgos, G. Mike Berbeco, Ross I. TI Applying gold nanoparticles as tumor-vascular disrupting agents during brachytherapy: estimation of endothelial dose enhancement SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article ID RADIATION-THERAPY; MONTE-CARLO; IN-VIVO; CELLULAR-LEVEL; DRUG-DELIVERY; RADIOTHERAPY; ANGIOGENESIS; DOSIMETRY; CANCER; PROLIFERATION AB Tumor vascular disrupting agents (VDAs) represent a promising approach to the treatment of cancer, in view of the tumor vasculature's pivotal role in tumor survival, growth and metastasis. VDAs targeting the tumor's dysmorphic endothelial cells can cause selective and rapid occlusion of the tumor vasculature, leading to tumor cell death from ischemia and extensive hemorrhagic necrosis. In this study, the potential for applying gold nanoparticles (AuNPs) as VDAs, during brachytherapy, is examined. Analytic calculations based on the electron energy loss formula of Cole were carried out to estimate the endothelial dose enhancement caused by radiationinduced photo/Auger electrons originating from AuNPs targeting the tumor endothelium. The endothelial dose enhancement factor (EDEF), representing the ratio of the dose to the endothelium with and without gold nanoparticles was calculated for different AuNP local concentrations, and endothelial cell thicknesses. Four brachytherapy sources were investigated, I-125, Pd-103, Yb-169, as well as 50 kVp x-rays. The results reveal that, even at relatively low intra-vascular AuNP concentrations, ablative dose enhancement to tumor endothelial cells due to photo/Auger electrons from theAuNPs can be achieved. Pd-103 registered the highest EDEF values of 7.4-271.5 for local AuNP concentrations ranging from 7 to 350 mg g(-1), respectively. Over the same concentration range, I-125, 50 kVp and Yb-169 yielded values of 6.4-219.9, 6.3-214.5 and 4.0-99.7, respectively. Calculations of the EDEF as a function of endothelial cell thickness showed that lower energy sources like Pd-103 reach the maximum EDEF at smaller thicknesses. The results also reveal that the highest contribution to the EDEF comes from Auger electrons, apparently due to their shorter range. Overall, the data suggest that ablative dose enhancement to tumor endothelial cells can be achieved by applying tumor vasculaturetargeted AuNPs as adjuvants to brachytherapy, with lower energy sources. Such ablative magnitude dose enhancement in a relatively small endothelial volume may rapidly disrupt or cause severe biological damage to tumor endothelial cells, without increased toxicity to healthy tissues not containing AuNPs. The findings provide significant impetus for considering the application of AuNPs as VDAs during brachytherapy. C1 [Ngwa, Wilfred] Brigham & Womens Hosp, Dana Farber Canc Inst, Div Med Phys & Biophys, Dept Radiat Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Ngwa, W (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Div Med Phys & Biophys, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM mmakrigiorgos@lroc.harvard.edu NR 48 TC 34 Z9 36 U1 2 U2 9 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 J9 PHYS MED BIOL JI Phys. Med. Biol. PD NOV 7 PY 2010 VL 55 IS 21 BP 6533 EP 6548 DI 10.1088/0031-9155/55/21/013 PG 16 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA 666WO UT WOS:000283153600007 PM 20959684 ER PT J AU Pierce, A Wei, R Halade, D Yoo, SE Ran, QT Richardson, A AF Pierce, Anson Wei, Rochelle Halade, Dipti Yoo, Si-Eun Ran, Qitao Richardson, Arlan TI A Novel mouse model of enhanced proteostasis: Full-length human heat shock factor 1 transgenic mice SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Aggresome; Chaperones; Heat shock proteins; Heat shock response; Polyglutamine; Heat shock transcription factor 1 ID TRANSCRIPTION FACTOR; OXIDATIVE STRESS; PROTEINS; DISEASE; HSF1; ACTIVATION; AGGRESOMES; ASSOCIATION; DEGRADATION; REPRESSION AB The heat shock response (HSR) is controlled by the master transcriptional regulator heat shock factor 1 (HSF1). HSF1 maintains proteostasis and resistance to stress through production of heat shock proteins (HSPs). No transgenic model exists that overexpresses HSF1 in tissues of the central nervous system (CNS). We generated a transgenic mouse overexpressing full-length non-mutant HSF1 and observed a 2-4-fold increase in HSF1 mRNA and protein expression in all tissues studied of HSF1 transgenic (HSF1(+/0)) mice compared to wild type (WT) littermates, including several regions of the CNS. Basal expression of HSP70 and 90 showed only mild tissue-specific changes: however, in response to forced exercise, the skeletal muscle HSR was more elevated in HSF1(+/0) mice compared to WT littermates and in fibroblasts following heat shock, as indicated by levels of inducible HSP70 mRNA and protein. HSF1(+/0) cells elicited a significantly more robust HSR in response to expression of the 82 repeat polyglutamine-YFP fusion construct (Q82YFP) and maintained proteasome-dependent processing of Q82YFP compared to WT fibroblasts. Overexpression of HSF1 was associated with fewer, but larger Q82YFP aggregates resembling aggresomes in HSF1(+/0) cells, and increased viability. Therefore, our data demonstrate that tissues and cells from mice overexpressing full-length non-mutant HSF1 exhibit enhanced proteostasis. Published by Elsevier Inc. C1 [Pierce, Anson; Yoo, Si-Eun; Ran, Qitao; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Pierce, Anson; Wei, Rochelle; Halade, Dipti; Yoo, Si-Eun; Ran, Qitao; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Pierce, Anson; Ran, Qitao; Richardson, Arlan] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78284 USA. RP Pierce, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM piercea2@uthscsa.edu RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 FU VA career development award [VISN17]; Semp Russ Foundation of the San Antonio Area Foundation FX This work was supported by a VA career development award, VISN17 grant, and by the Semp Russ Foundation of the San Antonio Area Foundation to A.P. NR 28 TC 11 Z9 11 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 5 PY 2010 VL 402 IS 1 BP 59 EP 65 DI 10.1016/j.bbrc.2010.09.111 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 679TB UT WOS:000284182600011 PM 20920476 ER PT J AU Yang, L Hu, HM Zielinska-Kwiatkowska, A Chansky, HA AF Yang, Liu Hu, Hsien-Ming Zielinska-Kwiatkowska, Anna Chansky, Howard A. TI FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Ewing's sarcoma; EWS-Fli1; Oncogenic fusion protein; FOXO1; RNA interference; Inducible siRNA; Tumor suppressor gene ID FORKHEAD TRANSCRIPTION FACTORS; RNA INTERFERENCE; DNA-BINDING; EXPRESSION; CANCER; RECEPTOR; GROWTH; TUMORS; TRANSLOCATION; REPRESSION AB Ewing's family tumors are characterized by a specific t(11;22) chromosomal translocation that results in the formation of EWS-Fli1 oncogenic fusion protein. To investigate the effects of EWS-Fli1 on gene expression, we carried out DNA microarray analysis after specific knockdown of EWS-Fli1 through transfection of synthetic siRNAs. EWS-Fli1 knockdown increased expression of genes such as DKK1 and p57 that are known to be repressed by EWS-Fli1 fusion protein. Among other potential EWS-Fli1 targets identified by our microarray analysis, we have focused on the FOXO1 gene since it encodes a potential tumor suppressor and has not been previously reported in Ewing's cells. To better understand how EWS-Fli1 affects FOXO1 expression, we have established a doxycycline-inducible siRNA system to achieve stable and reversible knockdown of EWS-Fli1 in Ewing's sarcoma cells. Here we show that FOXO1 expression in Ewing's cells has an inverse relationship with EWS-Fli1 protein level, and FOXO1 promoter activity is increased after doxycycline-induced EWS-Fli1 knockdown. In addition, we have found that direct binding of EWS-Fli1 to FOXO1 promoter is attenuated after doxycycline-induced siRNA knockdown of the fusion protein. Together, these results suggest that suppression of FOXO1 function by EWS-Fli1 fusion protein may contribute to cellular transformation in Ewing's family tumors. (C) 2010 Elsevier Inc. All rights reserved. C1 [Yang, Liu] Univ Washington, Sch Med, Dept Orthoped, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA. RP Yang, L (reprint author), Univ Washington, Sch Med, Dept Orthoped, 1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA. EM lyang@u.washington.edu FU Veterans Affairs Merit Review Award; Public Health Service Grant [RO1 AR051455] FX This work was supported by Public Health Service Grant RO1 AR051455 (to L.Y.) and by a Veterans Affairs Merit Review Award (to H.A.C.). NR 27 TC 9 Z9 10 U1 3 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 5 PY 2010 VL 402 IS 1 BP 129 EP 134 DI 10.1016/j.bbrc.2010.09.129 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 679TB UT WOS:000284182600023 PM 20933505 ER PT J AU Buecker, C Geijsen, N AF Buecker, Christa Geijsen, Niels TI Different Flavors of Pluripotency, Molecular Mechanisms, and Practical Implications SO CELL STEM CELL LA English DT Article ID EMBRYONIC STEM-CELLS; GROUND-STATE PLURIPOTENCY; GENE-EXPRESSION; MOUSE EPIBLAST; HOMOLOGOUS RECOMBINATION; MAINTAINS PLURIPOTENCY; SELF-RENEWAL; ES CELLS; NANOG; LINES AB Pluripotent stem cells (PSCs) have been classified into two distinct states: a primitive, naive LIF-dependent state represented by murine ESCs, and a primed bFGF-dependent state observed in murine and rat epiblast stem cells (EpiSCs). The vast similarities between EpiSCs and human ESCs suggest that, despite their blastocyst origin, human ESCs exist in a primed pluripotent state. Recent findings demonstrate that the naive and primed pluripotent states are interconvertible, even in human cells, and hint that growth factor-mediated Nanog expression may be an important factor regulating the balance between them. C1 [Buecker, Christa; Geijsen, Niels] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA 02114 USA. [Buecker, Christa; Geijsen, Niels] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Geijsen, Niels] Hubrecht Inst Dev Biol & Stem Cell Res, NL-3584 CT Utrecht, Netherlands. [Geijsen, Niels] Univ Utrecht, Sch Vet Med, Dept Clin Sci Compan Anim, NL-3584 CM Utrecht, Netherlands. RP Geijsen, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, CPZN 4256,185 Cambridge St, Boston, MA 02114 USA. EM n.geijsen@hubrecht.eu OI Buecker, Christa/0000-0003-3055-2642 FU NICHD NIH HHS [R01 HD048769] NR 50 TC 23 Z9 23 U1 0 U2 7 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1934-5909 J9 CELL STEM CELL JI Cell Stem Cell PD NOV 5 PY 2010 VL 7 IS 5 BP 559 EP 564 DI 10.1016/j.stem.2010.10.007 PG 6 WC Cell & Tissue Engineering; Cell Biology SC Cell Biology GA 682GX UT WOS:000284390500007 PM 21040897 ER PT J AU Warren, L Manos, PD Ahfeldt, T Loh, YH Li, H Lau, F Ebina, W Mandal, PK Smith, ZD Meissner, A Daley, GQ Brack, AS Collins, JJ Cowan, C Schlaeger, TM Rossi, DJ AF Warren, Luigi Manos, Philip D. Ahfeldt, Tim Loh, Yuin-Han Li, Hu Lau, Frank Ebina, Wataru Mandal, Pankaj K. Smith, Zachary D. Meissner, Alexander Daley, George Q. Brack, Andrew S. Collins, James J. Cowan, Chad Schlaeger, Thorsten M. Rossi, Derrick J. TI Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA SO CELL STEM CELL LA English DT Article ID EMBRYONIC STEM-CELLS; HUMAN SOMATIC-CELLS; TOLL-LIKE RECEPTORS; HUMAN IPS CELLS; DENDRITIC CELLS; DEFINED FACTORS; ANTIVIRAL RESPONSES; IN-VITRO; RIG-I; FIBROBLASTS AB Clinical application of induced pluripotent stem cells (iPSCs) is limited by the low efficiency of iPSC derivation and the fact that most protocols modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPSCs toward clinically useful cell types are lacking. Here we describe a simple, nonintegrating strategy for reprogramming cell fate based on administration of synthetic mRNA modified to overcome innate antiviral responses. We show that this approach can reprogram multiple human cell types to pluripotency with efficiencies that greatly surpass established protocols. We further show that the same technology can be used to efficiently direct the differentiation of RNA-induced pluripotent stem cells (RiPSCs) into terminally differentiated myogenic cells. This technology represents a safe, efficient strategy for somatic cell reprogramming and directing cell fate that has broad applicability for basic research, disease modeling, and regenerative medicine. C1 [Warren, Luigi; Ebina, Wataru; Mandal, Pankaj K.; Rossi, Derrick J.] Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, Boston, MA 02115 USA. [Manos, Philip D.; Daley, George Q.; Schlaeger, Thorsten M.; Rossi, Derrick J.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Daley, George Q.] Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA. [Manos, Philip D.; Ahfeldt, Tim; Lau, Frank; Meissner, Alexander; Daley, George Q.; Cowan, Chad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Meissner, Alexander; Daley, George Q.; Brack, Andrew S.; Cowan, Chad; Rossi, Derrick J.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Ahfeldt, Tim; Brack, Andrew S.; Cowan, Chad] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Ahfeldt, Tim] Univ Med Ctr Hamburg Eppendorf, Dept Biochem & Mol Biol Mol Cell Biol 2, D-20246 Hamburg, Germany. [Loh, Yuin-Han; Daley, George Q.; Schlaeger, Thorsten M.] Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA. [Loh, Yuin-Han; Daley, George Q.; Schlaeger, Thorsten M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Loh, Yuin-Han] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Rossi, Derrick J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Li, Hu; Collins, James J.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. [Li, Hu; Collins, James J.] Boston Univ, Ctr BioDynam, Boston, MA 02215 USA. [Li, Hu; Collins, James J.] Harvard Univ, Wyss Inst Biologically Inspired Engn, Boston, MA 02115 USA. [Lau, Frank; Cowan, Chad] Stowers Med Inst, Boston, MA 02114 USA. [Smith, Zachary D.; Meissner, Alexander] MIT & Harvard, Broad Inst, Cambridge, MA 02142 USA. [Daley, George Q.; Collins, James J.] Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA. [Daley, George Q.] Brigham & Womens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. RP Rossi, DJ (reprint author), Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, 300 Longwood Ave, Boston, MA 02115 USA. EM rossi@idi.harvard.edu RI Loh, Yuin-Han/E-1096-2014; mandal, pankaj/B-4885-2016; Ahfeldt, Tim/E-2935-2017 OI Loh, Yuin-Han/0000-0002-4715-6454; FU Harvard Stem Cell Institute; A*Star Institute of Medical Biology and Singapore stem cell consortium; Roberto and Allison Mignone Fund for Stem Cell Research; Howard Hughes Medical Institute; NIH [RL1DE019021]; SysCODE (Systems-based Consortium for Organ Design Engineering) FX The authors wish to thank Sun Hur, Victor Li, Laurence Daheron, Odelya Hartung, Alys Peisley, Sutheera Ratanasirintrawoot, Brad Hamilton, Chenmei Luo, Jonathan Kagan, Julie Sahalie, Alejandro De Los Angeles, and Lior Zangi for help, insight, and suggestions. D.J.R., A.M., GOD, A.S.B, C.C., and T.M.S. were supported by grants from the Harvard Stem Cell Institute. Y.-H.L. is supported by the A*Star Institute of Medical Biology and Singapore stem cell consortium. T.A. was supported by the Roberto and Allison Mignone Fund for Stem Cell Research. J.J.C. is supported by Howard Hughes Medical Institute, SysCODE (Systems-based Consortium for Organ Design & Engineering), and NIH grant # RL1DE019021. D.J.R. recently founded a company, Mod-eRNA Therapeutics, dedicated to the clinical translation of this technology. G.Q.D. is a member of the scientific advisory boards and holds equity in the following companies: Epizyme, iPierian, Solasia KK, and MPM Capital, LLP. C.C. is on the SAB of lpierian. L.W. is a consultant for Stemgent. NR 53 TC 1017 Z9 1094 U1 51 U2 265 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1934-5909 J9 CELL STEM CELL JI Cell Stem Cell PD NOV 5 PY 2010 VL 7 IS 5 BP 618 EP 630 DI 10.1016/j.stem.2010.08.012 PG 13 WC Cell & Tissue Engineering; Cell Biology SC Cell Biology GA 682GX UT WOS:000284390500013 PM 20888316 ER PT J AU Li, WS Li, G Chen, ZQ Wood, KB AF Li Wei-shi Li Gang Chen Zhong-qiang Wood, Kirkham B. TI Sagittal plane analysis of the spine and pelvis in adult idiopathic scoliosis SO CHINESE MEDICAL JOURNAL LA English DT Article DE adult; idiopathic scoliosis; sagittal balance; radiographic measures; pelvic morphology ID RADIOGRAPHIC PARAMETERS; ALIGNMENT; SPONDYLOLISTHESIS; BALANCE; INSTRUMENTATION; THORACOLUMBAR; DEFORMITY; LORDOSIS; FUSION AB Background There has been an increasing recognition of the importance of sagittal spinopelvic alignment in patients with scoliosis as it relates to clinical outcomes. However, the changes seen in sagittal spinopelvic alignment in adult idiopathic scoliosis patients is poorly defined. This study was conducted to evaluate the sagittal alignment of pelvis, and spine in adult idiopathic scoliosis patients. Methods The sagittal parameters of the spine and pelvis were analyzed in lateral standing radiographs of 124 patients (mean age 47.4 years) with adult idiopathic scoliosis, including thoracic kyphosis (TK), thoracolumbar junction kyphosis (TLJ), lumbar lordosis (LL), pelvic incidence (PI), sacrum slope (SS), pelvic tilt (PT) and C7 plumb line (C7PL). The patients were divided into three groups according to the age: 20-40 years, 41-64 years, and 65 years. The parameters were compared with those in normal adults and adolescent idiopathic scoliosis (AIS) patients. The relationship between all parameters as well as age and sagittal parameters were analyzed. Results The PI in patients with adult idiopathic scoliosis was 58.1 degrees+/-13.0 degrees, which was significantly higher than that in normal adults. The PT (19.9 degrees+/-10.6 degrees) was also higher than that in both normal adults and AIS patients, while the SS (38.1 degrees+/-12.0 degrees) was similar or smaller. As age increased, C7PL, PT and TJL increased while LL decreased. There was no relationship between age and both PI and TK. PT had the strongest statistical association with the C7PL. Conclusions PI is higher in adult idiopathic scoliosis than normal subjects. The PT is the most relevant pelvic parameter to the global sagittal alignment of the spine. Age significantly influences sagittal parameters of the spine and pelvis except the PI and TK. Chin Med, J 2010;123(21):2978-2982 C1 [Li Wei-shi; Li Gang; Wood, Kirkham B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA. [Li Wei-shi; Chen Zhong-qiang] Peking Univ, Hosp 3, Dept Orthopaed, Beijing 100191, Peoples R China. RP Wood, KB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA. EM kbwood@partners.org NR 24 TC 6 Z9 17 U1 0 U2 3 PU CHINESE MEDICAL ASSOC PI BEIJING PA 42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA SN 0366-6999 J9 CHINESE MED J-PEKING JI Chin. Med. J. PD NOV 5 PY 2010 VL 123 IS 21 BP 2978 EP 2982 DI 10.3760/cma.j.issn.0366-6999.2010.21.005 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 682FQ UT WOS:000284387200005 PM 21162941 ER PT J AU Mehrhof, F Loffler, M Gelbrich, G Ozcelik, C Posch, M Hense, HW Keil, U Scheffold, T Schunkert, H Angermann, C Ertl, G Jahns, R Pieske, B Wachter, R Edelmann, F Wollert, KC Maisch, B Pankuweit, S Erbel, R Neumann, T Herzog, W Katus, H Muller-Tasch, T Zugck, C Dungen, HD Regitz-Zagrosek, V Lehmkuhl, E Stork, S Siebert, U Wasem, J Neumann, A Gohler, A Anker, SD Kohler, F Mockel, M Osterziel, KJ Dietz, R Rauchhaus, M AF Mehrhof, Felix Loeffler, Markus Gelbrich, Goetz Oezcelik, Cemil Posch, Maximilian Hense, Hans-Werner Keil, Ulrich Scheffold, Thomas Schunkert, Heribert Angermann, Christiane Ertl, Georg Jahns, Roland Pieske, Burkert Wachter, Rolf Edelmann, Frank Wollert, Kai C. Maisch, Bernhard Pankuweit, Sabine Erbel, Raimund Neumann, Till Herzog, Wolfgang Katus, Hugo Mueller-Tasch, Thomas Zugck, Christian Duengen, Hans-Dirk Regitz-Zagrosek, Vera Lehmkuhl, Elke Stoerk, Stefan Siebert, Uwe Wasem, Juergen Neumann, Anja Goehler, Alexander Anker, Stefan D. Koehler, Friedrich Moeckel, Martin Osterziel, Karl-Josef Dietz, Rainer Rauchhaus, Mathias CA Competence Network Heart Failure TI A network against failing hearts-Introducing the German "Competence Network Heart Failure" SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Letter DE Heart failure; Epidemiology of heart failure; Molecular mechanisms of heart failure; Pharmacological therapy of heart failure; Management of heart failure; Biomaterial banking ID RATIONALE; DESIGN; MORTALITY; TRIAL C1 [Mehrhof, Felix; Oezcelik, Cemil; Posch, Maximilian; Duengen, Hans-Dirk; Anker, Stefan D.; Koehler, Friedrich; Moeckel, Martin; Dietz, Rainer; Rauchhaus, Mathias] Charite, Dept Cardiol, D-13353 Berlin, Germany. [Loeffler, Markus; Gelbrich, Goetz] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany. [Hense, Hans-Werner; Keil, Ulrich] Univ Munster, Inst Epidemiol & Social Med, Munster, Germany. [Scheffold, Thomas] Univ Witten Herdecke, Inst Heart & Circulat Res, Dortmund, Germany. [Schunkert, Heribert] Univ Klinikum Schleswig Holstein, Cardiovasc & Pulm Med Ctr, D-23538 Lubeck, Germany. [Angermann, Christiane; Ertl, Georg; Jahns, Roland; Stoerk, Stefan] Univ Wurzburg, Dept Internal Med, Wurzburg, Germany. [Pieske, Burkert] Graz Univ, Dept Cardiol, Graz, Austria. [Wachter, Rolf; Edelmann, Frank] Univ Gottingen, Dept Cardiol & Pneumol, Gottingen, Germany. [Wollert, Kai C.] Hannover Med Sch, Dept Cardiol & Angiol, D-3000 Hannover, Germany. [Maisch, Bernhard; Pankuweit, Sabine] Univ Hosp Giessen & Marburg, Dept Cardiol, Marburg, Germany. [Erbel, Raimund; Neumann, Till] Univ Essen Gesamthsch, W German Heart Ctr, Essen, Germany. [Katus, Hugo; Zugck, Christian] Univ Heidelberg Hosp, Dept Cardiol, Heidelberg, Germany. [Regitz-Zagrosek, Vera; Lehmkuhl, Elke] Charite, Cardiovasc Res Ctr, D-13353 Berlin, Germany. [Osterziel, Karl-Josef] Cardiopraxis Amberg, Amberg, Germany. [Wasem, Juergen; Neumann, Anja] Univ Duisburg Essen, Inst Hlth Care Management, Essen, Germany. [Siebert, Uwe; Goehler, Alexander] Harvard Univ, Sch Med, Cardiovasc Res Program, Inst Technol Assessment, Boston, MA USA. [Siebert, Uwe; Goehler, Alexander] Massachsetts Gen Hosp, Dept Radiol, Boston, MA USA. [Siebert, Uwe; Goehler, Alexander] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA. [Siebert, Uwe; Goehler, Alexander] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Informat Syst & Hlth Technol Asses, Hall In Tirol, Austria. RP Mehrhof, F (reprint author), Charite, Dept Cardiol, Campus Virchow Klinikum, D-13353 Berlin, Germany. EM felix.mehrhof@charite.de RI Katus, Hugo/P-1712-2016; OI Wasem, Juergen/0000-0001-9653-168X; Wachter, Rolf/0000-0003-2231-2200 NR 12 TC 13 Z9 13 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 J9 INT J CARDIOL JI Int. J. Cardiol. PD NOV 5 PY 2010 VL 145 IS 1 BP 135 EP 138 DI 10.1016/j.ijcard.2009.06.061 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 674HA UT WOS:000283727000076 PM 19679361 ER PT J AU Weisbart, RH Chan, G Heinze, E Mory, R Nishimura, RN Colburn, K AF Weisbart, Richard H. Chan, Grace Heinze, Emil Mory, Rachel Nishimura, Robert N. Colburn, Keith TI BRAF Drives Synovial Fibroblast Transformation in Rheumatoid Arthritis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID B-RAF; SIGNALING PATHWAY; JOINT DESTRUCTION; MUTATIONS; CANCER; GENE; ACTIVATION; MECHANISM; MELANOMA AB Synovial fibroblasts destroy articular cartilage and bone in rheumatoid arthritis, but the mechanism of fibroblast transformation remains elusive. Because gain-of-function mutations of BRAF can transform fibroblasts, we examined BRAF in rheumatoid synovial fibroblasts. The strong gain-of-function mutation, V600R, of BRAF found in melanomas and other cancers was identified in first passage synovial fibroblasts from two of nine rheumatoid arthritis patients and confirmed by restriction site mapping. BRAF-specific siRNA inhibited proliferation of synovial fibroblasts with V600R mutations. A BRAF aberrant splice variant with an intact kinase domain and partial loss of the N-terminal autoinhibitory domain was identified in fibroblasts from an additional patient, and fibroblast proliferation was inhibited by BRAF-specific siRNA. Our finding is the first to establish mechanisms for fibroblast transformation responsible for destruction of articular cartilage and bone in rheumatoid arthritis and establishes a new target for therapeutic intervention. C1 [Weisbart, Richard H.; Chan, Grace] Vet Affairs Greater Los Angeles Hlth Care Syst, Dept Res, Sepulveda, CA 91343 USA. [Heinze, Emil; Mory, Rachel] Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA. [Nishimura, Robert N.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Colburn, Keith] Vet Affairs Med Ctr, Dept Med, Loma Linda, CA 92357 USA. [Colburn, Keith] Loma Linda Univ, Dept Med, Loma Linda, CA 92354 USA. RP Weisbart, RH (reprint author), 16111 Plummer St, North Hills, CA 91343 USA. EM rweisbar@ucla.edu NR 22 TC 4 Z9 8 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 5 PY 2010 VL 285 IS 45 BP 34299 EP 34303 DI 10.1074/jbc.C110.168195 PG 5 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 673KL UT WOS:000283659100002 PM 20843808 ER PT J AU Eichelsdoerfer, JL Evans, JA Slaugenhaupt, SA Cuajungco, MP AF Eichelsdoerfer, Jonathan L. Evans, Jeffrey A. Slaugenhaupt, Susan A. Cuajungco, Math P. TI Zinc Dyshomeostasis Is Linked with the Loss of Mucolipidosis IV-associated TRPML1 Ion Channel SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID LYSOSOMAL MEMBRANE PERMEABILIZATION; ENDOGENOUS ZINC; ENHANCED ZINC; CELL-CULTURE; BRAIN; AUTOPHAGY; MUTATION; RELEASE; NEURONS; INJURY AB Chelatable zinc is important in brain function, and its homeostasis is maintained to prevent cytotoxic overload. However, certain pathologic events result in intracellular zinc accumulation in lysosomes and mitochondria. Abnormal lysosomes and mitochondria are common features of the human lysosomal storage disorder known as mucolipidosis IV (MLIV). MLIV is caused by the loss of TRPML1 ion channel function. MLIV cells develop large hyperacidic lysosomes, membranous vacuoles, mitochondrial fragmentation, and autophagic dysfunction. Here, we observed that RNA interference of mucolipin-1 gene (TRPML1) in HEK-293 cells mimics the MLIV cell phenotype consisting of large lysosomes and membranous vacuoles that accumulate chelatable zinc. To show that abnormal chelatable zinc levels are indeed correlated with MLIV pathology, we quantified its concentration in cultured MLIV patient fibroblast and control cells with a spectrofluorometer using N-(6-methoxy-8-quinolyl)-p-toluene sulfonamide fluorochrome. We found a significant increase of chelatable zinc levels in MLIV cells but not in control cells. Furthermore, we quantified various metal isotopes in whole brain tissue of TRPML1(-/-) null mice and wild-type littermates using inductively coupled plasma mass spectrometry and observed that the zinc-66 isotope is markedly elevated in the brain of TRPML1(-/-) mice when compared with controls. In conclusion, we show for the first time that the loss of TRPML1 function results in intracellular chelatable zinc dyshomeostasis. We propose that chelatable zinc accumulation in large lysosomes and membranous vacuoles may contribute to the pathogenesis of the disease and progressive cell degeneration in MLIV patients. C1 [Eichelsdoerfer, Jonathan L.; Evans, Jeffrey A.; Cuajungco, Math P.] Calif State Univ Fullerton, Dept Biol Sci, Fullerton, CA 92831 USA. [Eichelsdoerfer, Jonathan L.; Evans, Jeffrey A.; Cuajungco, Math P.] Calif State Univ Fullerton, Ctr Appl Biotechnol Studies, Fullerton, CA 92831 USA. [Slaugenhaupt, Susan A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. [Slaugenhaupt, Susan A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Cuajungco, Math P.] Mental Hlth Res Inst, Parkville, Vic 3052, Australia. RP Cuajungco, MP (reprint author), Calif State Univ Fullerton, Dept Biol Sci, 800 N State Coll Blvd, Fullerton, CA 92831 USA. EM mcuajungco@fullerton.edu RI Cuajungco, Math/B-2647-2008 OI Cuajungco, Math/0000-0003-0749-9564 FU National Institutes of Health [R01 NS39995]; Doris Howell-CSUPERB research scholarships; Howard Hughes Medical Institute; National Science Foundation [MCB 920127] FX This work was supported, in whole or in part, by National Institutes of Health Grant R01 NS39995 (to S. A. S.). This work was also partially supported by Doris Howell-CSUPERB research scholarships (to J.L.E. and J.A.E.), the Howard Hughes Medical Institute undergraduate research program, and National Science Foundation Grant MCB 920127 (to M. P. C.). A preliminary account of this work was presented in the Experimental Biology 2010 meeting on April 26, 2010 in Anaheim, CA. NR 34 TC 40 Z9 40 U1 1 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 5 PY 2010 VL 285 IS 45 BP 34304 EP 34308 DI 10.1074/jbc.C110.165480 PG 5 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 673KL UT WOS:000283659100003 PM 20864526 ER PT J AU Park, J Kang, SI Lee, SY Zhang, XF Kim, MS Beers, LF Lim, DS Avruch, J Kim, HS Lee, SB AF Park, Jikyoung Kang, Soo Im Lee, Sun-Young Zhang, Xian F. Kim, Myoung Shin Beers, Lisa F. Lim, Dae-Sik Avruch, Joseph Kim, Ho-Shik Lee, Sean Bong TI Tumor Suppressor Ras Association Domain Family 5 (RASSF5/NORE1) Mediates Death Receptor Ligand-induced Apoptosis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID CHROMATIN CONDENSATION; NUCLEAR TRANSLOCATION; HIPPO PATHWAY; KINASE MST1; RASSF1A; ACTIVATION; PROTEIN; IDENTIFICATION; NORE1; PHOSPHORYLATION AB Epigenetic silencing of RASSF (Ras association domain family) genes RASSF1 and RASSF5 (also called NORE1) by CpG hypermethylation is found frequently in many cancers. Although the physiological roles of RASSF1 have been studied in some detail, the exact functions of RASSF5 are not well understood. Here, we show that RASSF5 plays an important role in mediating apoptosis in response to death receptor ligands, TNF-alpha and TNF-related apoptosis-inducing ligand. Depletion of RASSF5 by siRNA significantly reduced TNF-alpha-mediated apoptosis, likely through its interaction with proapoptotic kinase MST1, a mammalian homolog of Hippo. Consistent with this, siRNA knockdown of MST1 also resulted in resistance to TNF-alpha-induced apoptosis. To further study the role of Rassf5 in vivo, we generated Rassf5-deficient mouse. Inactivation of Rassf5 in mouse embryonic fibroblasts (MEFs) resulted in resistance to TNF-alpha- and TNF-related apoptosis-inducing ligand-mediated apoptosis. Importantly, Rassf5-null mice were significantly more resistant to TNF-alpha-induced apoptosis and failed to activate Mst1. Loss of Rassf5 also resulted in spontaneous immortalization of MEFs at earlier passages than the control MEFs, and Rassf5-null immortalized MEFs, but not the immortalized wild type MEFs, were fully transformed by K-RasG12V. Together, our results demonstrate a direct role for RASSF5 in death receptor ligand-mediated apoptosis and provide further evidence for RASSF5 as a tumor suppressor. C1 [Park, Jikyoung; Kang, Soo Im; Kim, Myoung Shin; Beers, Lisa F.; Lee, Sean Bong] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA. [Lee, Sun-Young; Kim, Ho-Shik] Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea. [Zhang, Xian F.; Avruch, Joseph] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Lim, Dae-Sik] Korea Adv Inst Sci & Technol, Biomed Res Ctr, Dept Biol Sci, Natl Res Lab Mol Genet, Taejon 305701, South Korea. RP Lee, SB (reprint author), NIDDK, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10,9D11, Bethesda, MD 20892 USA. EM seanL@intra.niddk.nih.gov RI Lim, Dae-Sik/C-1599-2011 OI Lim, Dae-Sik/0000-0003-2356-7555 FU National Institutes of Health NIDDK FX This work was supported, in whole or in part, by a grant the National Institutes of Health NIDDK Intramural Research Program (to S. B. L.). NR 43 TC 35 Z9 37 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 5 PY 2010 VL 285 IS 45 BP 35029 EP 35038 DI 10.1074/jbc.M110.165506 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 673KL UT WOS:000283659100077 PM 20810663 ER PT J AU Horst, D Gu, XS Bhasin, M Yang, QL Verzi, M Lin, DX Joseph, M Zhang, XB Chen, W Li, YP Shivdasani, RA Libermann, TA AF Horst, David Gu, Xuesong Bhasin, Manoj Yang, Quanli Verzi, Michael Lin, Dongxu Joseph, Marie Zhang, Xiaobo Chen, Wei Li, Yi-Ping Shivdasani, Ramesh A. Libermann, Towia A. TI Requirement of the Epithelium-specific Ets Transcription Factor Spdef for Mucous Gland Cell Function in the Gastric Antrum SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MUCIN GENE-EXPRESSION; PROSTATE-CANCER; PDEF EXPRESSION; BINDING DOMAIN; NECK CELLS; FAMILY; MEMBER; MICE; RAT; TRANSLOCATION AB Mucus-secreting cells of the stomach epithelium provide a protective barrier against damage that might result from bacterial colonization or other stimuli. Impaired barrier function contributes to chronic inflammation and cancer. Knock-out mice for the epithelium-specific transcription factor Spdef (also called Pdef) have defects in terminal differentiation of intestinal and bronchial secretory cells. We sought to determine the physiologic function of Spdef in the stomach, another site of significant levels of Spdef expression. We used in situ hybridization and immunohistochemistry to localize Spdef-expressing cells in the mouse stomach; targeted gene disruption to generate mice lacking Spdef; and histologic, immunologic, and transcriptional profiling approaches to determine the requirements of Spdef in stomach epithelial homeostasis. In wild-type mice, Spdef RNA and protein are expressed predominantly in mucous gland cells of the antrum and in mucous neck cells of the glandular corpus. Within 1.5 years, nearly half of homozygous mutant mice developed profound mucosal hyperplasia of the gastric antrum. Submucosal infiltration of inflammatory cells preceded antral hyperplasia by several weeks. The absence of Spdef impaired terminal maturation of antral mucous gland cells, as reflected in reduced expression of Muc6 and Tff2 and reduced numbers of secretory granules. Antral gene expression abnormalities overlapped significantly with those in Spdef(-/-) colon, including genes implicated in secretory granule traffic and functions. Spdef is required for terminal maturation of antral mucous gland cells to protect animals from gastric inflammation and resulting hyperplasia. These requirements parallel Spdef functions in secretory intestinal cells and suggest a common molecular mechanism for maturation of gastrointestinal secretory lineages. C1 [Shivdasani, Ramesh A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Gu, Xuesong; Bhasin, Manoj; Yang, Quanli; Lin, Dongxu; Joseph, Marie; Shivdasani, Ramesh A.; Libermann, Towia A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Gu, Xuesong; Bhasin, Manoj; Yang, Quanli; Lin, Dongxu; Joseph, Marie; Libermann, Towia A.] Harvard Univ, Sch Med, BIDMC Genom & Prote Ctr, Boston, MA 02115 USA. [Gu, Xuesong; Bhasin, Manoj; Yang, Quanli; Lin, Dongxu; Joseph, Marie; Libermann, Towia A.] Harvard Univ, Sch Med, Div Interdisciplinary Med & Biotechnol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [Zhang, Xiaobo] Massachusetts Gen Hosp, Gastrointestinal Unit, Charlestown, MA 02114 USA. [Zhang, Xiaobo] Massachusetts Gen Hosp, MGH Weight Ctr, Charlestown, MA 02114 USA. [Chen, Wei; Li, Yi-Ping] Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA. [Chen, Wei; Li, Yi-Ping] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. RP Shivdasani, RA (reprint author), 44 Binney St, Boston, MA 02215 USA. EM ramesh_shivdasani@dfci.harvard.edu; tliberma@bidmc.harvard.edu OI Libermann, Towia/0000-0002-4006-8179 FU National Institutes of Health [CA85467, DK081113, AR44741]; Prostate Cancer Foundation; Deutsche Forschungsgemeinschaft FX This work was supported, in whole or in part, by National Institutes of Health Grants CA85467 (to T. A. L.), DK081113 (to R. A. S.), and AR44741 (to Y. P. L.). This work was also supported by a Prostate Cancer Foundation award (to X. G.), and a fellowship from the Deutsche Forschungsgemeinschaft (to D. H.). NR 45 TC 14 Z9 14 U1 1 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 5 PY 2010 VL 285 IS 45 BP 35047 EP 35055 DI 10.1074/jbc.M110.164541 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 673KL UT WOS:000283659100079 PM 20801882 ER PT J AU Abdallah, RT Keum, JS Lee, MH Wang, B Gooz, M Luttrell, DK Luttrell, LM Jaffa, AA AF Abdallah, Rany T. Keum, Joo-Seob Lee, Mi-Hye Wang, Bing Gooz, Monika Luttrell, Deirdre K. Luttrell, Louis M. Jaffa, Ayad A. TI Plasma Kallikrein Promotes Epidermal Growth Factor Receptor Transactivation and Signaling in Vascular Smooth Muscle through Direct Activation of Protease-activated Receptors SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID OXIDE-GENERATING VASODILATORS; MOLECULAR-WEIGHT KININOGEN; RAT CAROTID-ARTERY; NITRIC-OXIDE; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; SUBSTRATE-SPECIFICITY; THROMBIN RECEPTORS; CORONARY-ARTERIES; GENE-EXPRESSION AB The kallikrein-kinin system, along with the interlocking reninangiotensin system, is a key regulator of vascular contractility and injury response. The principal effectors of the kallikrein-kinin system are plasma and tissue kallikreins, proteases that cleave high molecular weight kininogen to produce bradykinin. Most of the cellular actions of kallikrein (KK) are thought to be mediated by bradykinin, which acts via G protein-coupled B1 and B2 bradykinin receptors on VSMCs and endothelial cells. Here, we find that primary aortic vascular smooth muscle but not endothelial cells possess the ability to activate plasma prekallikrein. Surprisingly, exposing VSMCs to prekallikrein leads to activation of the ERK1/2 mitogen-activated protein kinase cascade via a mechanism that requires kallikrein activity but does not involve bradykinin receptors. In transfected HEK293 cells, we find that plasma kallikrein directly activates G protein-coupled protease-activated receptors (PARs) 1 and 2, which possess consensus kallikrein cleavage sites, but not PAR4. In vascular smooth muscles, KK stimulates ADAM (a disintegrin and metalloprotease) 17 activity via a PAR1/2 receptor-dependent mechanism, leading sequentially to release of the endogenous ADAM17 substrates, amphiregulin and tumor necrosis factor-alpha, metalloprotease-dependent transactivation of epidermal growth factor receptors, and metalloprotease and epidermal growth factor receptor-dependent ERK1/2 activation. These results suggest a novel mechanism of bradykinin-independent kallikrein action that may contribute to the regulation of vascular responses in pathophysiologic states, such as diabetes mellitus. C1 [Abdallah, Rany T.; Keum, Joo-Seob; Lee, Mi-Hye; Wang, Bing; Gooz, Monika; Luttrell, Deirdre K.; Luttrell, Louis M.; Jaffa, Ayad A.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Jaffa, AA (reprint author), Amer Univ Beirut, Fac Med, Dept Biochem, Beirut, Lebanon. EM aj24@aub.edu.lb FU National Institutes of Health [HL087986, HL077192, DK55524]; South Carolina Center for Biomedical Research Excellence in Cardiovascular Diseases; Department of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grants HL087986 and HL077192 (to A. A. J.), and DK55524 (to L. M. L.). This work was also supported by the South Carolina Center for Biomedical Research Excellence in Cardiovascular Diseases (to D. K. L.) and Department of Veterans Affairs Research Enhancement Award Program awards. NR 66 TC 23 Z9 24 U1 0 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 5 PY 2010 VL 285 IS 45 BP 35206 EP 35215 DI 10.1074/jbc.M110.171769 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 673KL UT WOS:000283659100094 PM 20826789 ER PT J AU Wong, KK Muller, MLTM Kuwabara, H Studenski, SA Bohnen, NI AF Wong, Ka Kit Muller, Martijn L. T. M. Kuwabara, Hiroto Studenski, Stephanie A. Bohnen, Nicolaas I. TI Olfactory loss and nigrostriatal dopaminergic denervation in the elderly SO NEUROSCIENCE LETTERS LA English DT Article DE Aging; Basal ganglia; Dopamine; Nigrostriatal; Olfaction; positron emission tomography ID C-11 METHYL TRIFLATE; LEWY BODY DISEASE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; PET RADIOLIGANDS; IN-VIVO; DEMENTIA; AGE; DYSFUNCTION AB Olfactory dysfunction may precede common neurodegenerative disorders in the elderly, such as Alzheimer (AD) or Parkinson disease (PD). However, pathobiological mechanisms of olfactory loss in the elderly are poorly understood. Although nigrostriatal dopaminergic denervation is a key patholobiological feature of PD, age-associated nigrostriatal denervation (AASDD) occurs also with normal aging and can be more prominent in some elderly. We investigated the relationship between AASDD and olfactory performance in community-dwelling subjects. Community-dwelling subjects (n = 73, 44 F/29 M, mean age 64.0 +/- 16.4, range 20-85) underwent brain dopamine transporter (DAT)[C-11]2-beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (beta-CFT) positron emission tomography (PET) imaging and olfactory assessment using the 40-odor University of Pennsylvania Smell Identification Test (UPSIT). Subjects with clinical or DAT PET evidence of Parkinson disease (PD) were not eligible for the study. AASDD was defined based on normative data in young and middle-aged subjects. Compared to a mild and general linear decline in odor identification observed in most subjects (R-2 = 0.18, P = 0.0002), there were 13 subjects who deviated below the 5% confidence interval level in age-predicted UPSIT scores. Analysis limited to elderly subjects 60 years and over demonstrated a significant association between poor smell (n = 10 out of 49, 20.4%) and AASDD (chi(2) = 4.4, P<0.05). There is a significant association between olfactory dysfunction and more prominent nigrostriatal denervation in the elderly. Olfactory assessment may have potential as a screening tool to detect age-accelerated neurodegeneration in the elderly. Published by Elsevier Ireland Ltd. C1 [Muller, Martijn L. T. M.; Bohnen, Nicolaas I.] Univ Michigan, Dept Radiol, Funct Neuroimaging Cognit & Mobil Lab, Ann Arbor, MI 48105 USA. [Wong, Ka Kit; Bohnen, Nicolaas I.] GRECC, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Muller, Martijn L. T. M.; Bohnen, Nicolaas I.] Univ Michigan, Dept Radiol, Dept Neurol, Ann Arbor, MI 48105 USA. [Kuwabara, Hiroto] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA. [Studenski, Stephanie A.] GRECC, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Studenski, Stephanie A.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. RP Bohnen, NI (reprint author), Univ Michigan, Dept Radiol, Funct Neuroimaging Cognit & Mobil Lab, 24 Frank Lloyd Wright Dr,Box 362, Ann Arbor, MI 48105 USA. EM nbohnen@umich.edu FU Department of Veterans Affairs FX This study was funded by the Department of Veterans Affairs. NR 32 TC 20 Z9 21 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD NOV 5 PY 2010 VL 484 IS 3 BP 163 EP 167 DI 10.1016/j.neulet.2010.08.037 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 664XX UT WOS:000282998400001 PM 20727944 ER PT J AU Sykes, DB Attar, EC Bazari, H AF Sykes, David B. Attar, Eyal C. Bazari, Hasan TI Case 23-2010: Unusual Paraprotein Effects in MGUS - Treat or Not? REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Sykes, David B.; Attar, Eyal C.; Bazari, Hasan] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Sykes, DB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 4 PY 2010 VL 363 IS 19 BP 1875 EP 1875 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 674YK UT WOS:000283787800034 ER PT J AU Uy, GL Lane, AA Welch, JS Grieselhuber, NR Payton, JE Ley, TJ AF Uy, Geoffrey L. Lane, Andrew A. Welch, John S. Grieselhuber, Nicole R. Payton, Jacqueline E. Ley, Timothy J. TI A protease-resistant PML-RAR alpha has increased leukemogenic potential in a murine model of acute promyelocytic leukemia SO BLOOD LA English DT Article ID ACID RECEPTOR-ALPHA; NEUTROPHIL ELASTASE; TRANSGENIC MICE; PML/RAR-ALPHA; MOUSE MODEL; CELLS; DIFFERENTIATION; PROLIFERATION; PENETRANCE; EXPRESSION AB Previous studies in our laboratory demonstrated that the azurophil granule protease neutrophil elastase (NE) cleaves promyelocytic leukemia-retinoic acid receptor (PML-RAR)alpha(PR), the fusion protein that initiates acute promyelocytic leukemia (APL). Further, NE deficiency reduces the penetrance of APL in a murine model of this disease. We therefore predicted that NE-mediated PR cleavage might be important for its ability to initiate APL. To test this hypothesis, we generated a mouse expressing NE-resistant PR. These mice developed APL indistinguishable from wild-type PR, but with significantly reduced latency (median leukemia-free survival of 274 days vs 473 days for wild-type PR, P < .001). Resistance to proteolysis may increase the abundance of full-length PR protein in early myeloid cells, and our previous data suggested that noncleaved PR may be less toxic to early myeloid cells. Together, these effects appear to increase the leukemogenicity of NE-resistant PR, contrary to our previous prediction. We conclude that NE deficiency may reduce APL penetrance via indirect mechanisms that are still NE dependent. (Blood. 2010;116(18):3604-3610) C1 [Uy, Geoffrey L.; Lane, Andrew A.; Welch, John S.; Grieselhuber, Nicole R.; Ley, Timothy J.] Washington Univ, Sch Med, Div Oncol, Sect Stem Cell Biol, St Louis, MO 63110 USA. [Payton, Jacqueline E.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA. [Lane, Andrew A.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Ley, TJ (reprint author), Washington Univ, Sch Med, Div Oncol, Sect Stem Cell Biol, 660 S Euclid Ave,Campus Box 8007, St Louis, MO 63110 USA. EM tley@dom.wustl.edu OI Uy, Geoffrey/0000-0002-7809-0996 FU National Institutes of Health [T32 HL007088, K23 CA140707, CA083962]; Barnes-Jewish Hospital Foundation; National Cancer Institute Cancer Center [P30 CA91842] FX This work was supported by National Institutes of Health grants T32 HL007088 and K23 CA140707 to G.L.U. and CA083962 to T.J.L and by the Barnes-Jewish Hospital Foundation to T.J.L. G.L.U is an American Society of Hematology Scholar in Clinical/Translational Research. J.S.W. is a Leukemia & Lymphoma Society Fellow. The Siteman Cancer Center and High Speed Cell Sorter Core is supported in part by a National Cancer Institute Cancer Center Support Grant P30 CA91842. NR 23 TC 5 Z9 8 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 4 PY 2010 VL 116 IS 18 BP 3604 EP 3610 DI 10.1182/blood-2008-11-189282 PG 7 WC Hematology SC Hematology GA 675SM UT WOS:000283853200030 PM 20647568 ER PT J AU Whitman, SP Maharry, K Radmacher, MD Becker, H Mrozek, K Margeson, D Holland, KB Wu, YZ Schwind, S Metzeler, KH Wen, J Baer, MR Powell, BL Carter, TH Kolitz, JE Wetzler, M Moore, JO Stone, RM Carroll, AJ Larson, RA Caligiuri, MA Marcucci, G Bloomfield, CD AF Whitman, Susan P. Maharry, Kati Radmacher, Michael D. Becker, Heiko Mrozek, Krzysztof Margeson, Dean Holland, Kelsi B. Wu, Yue-Zhong Schwind, Sebastian Metzeler, Klaus H. Wen, Jing Baer, Maria R. Powell, Bayard L. Carter, Thomas H. Kolitz, Jonathan E. Wetzler, Meir Moore, Joseph O. Stone, Richard M. Carroll, Andrew J. Larson, Richard A. Caligiuri, Michael A. Marcucci, Guido Bloomfield, Clara D. TI FLT3 internal tandem duplication associates with adverse outcome and gene-and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study SO BLOOD LA English DT Article ID NORMAL KARYOTYPE; PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS; MUTATIONS; STEM; AML; ACTIVATION; IMPACT; ADULTS; CELLS AB The clinical impact of FLT3-internal tandem duplications (ITDs), an adverse prognostic marker in adults aged < 60 years with primary cytogenetically normal acute myeloid leukemia (CN-AML), requires further investigation in older patients. In CN-AML patients aged >= 60 years treated on Cancer and Leukemia Group B frontline trials, we found that FLT3-ITD remained associated with shorter disease-free survival (P < .001; hazard ratio = 2.10) and overall survival (P < .001; hazard ratio = 1.97) in multivariable analyses. This impact on shorter disease-free survival and overall survival was in patients aged 60-69 (P < .001, each) rather than in those aged >= 70 years. An FLT3-ITD-associated gene-expression signature revealed overexpression of FLT3, homeobox genes (MEIS1, PBX3, HOXB3), and immunotherapeutic targets (WT1, CD33) and underexpression of leukemia-associated (MLLT3, TAL1) and erythropoiesis-associated (GATA3, EPOR, ANK1, HEMGN) genes. An FLT3-ITD-associated microRNA-expression signature included overexpressed miR-155 and underexpressed miR-144 and miR-451. FLT3-ITD identifies older CN-AML patients with molecular high risk and is associated with gene-and microRNA-expression signatures that provide biologic insights for novel therapeutic approaches. (Blood. 2010;116(18):3622-3626) C1 [Whitman, Susan P.; Maharry, Kati; Radmacher, Michael D.; Becker, Heiko; Mrozek, Krzysztof; Margeson, Dean; Holland, Kelsi B.; Wu, Yue-Zhong; Schwind, Sebastian; Metzeler, Klaus H.; Wen, Jing; Caligiuri, Michael A.; Marcucci, Guido; Bloomfield, Clara D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Baer, Maria R.] Duke Univ, Med Ctr, Canc & Leukemia Grp B CALGB Stat Ctr, Durham, NC USA. [Baer, Maria R.] Univ Maryland, Baltimore, MD 21201 USA. [Powell, Bayard L.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA. [Carter, Thomas H.] Univ Iowa, Iowa City, IA USA. [Kolitz, Jonathan E.] N Shore Univ Hosp, Manhasset, NY USA. [Wetzler, Meir] Roswell Pk Canc Inst, Buffalo, NY USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Carroll, Andrew J.] Univ Alabama Birmingham, Birmingham, AL USA. [Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA. RP Caligiuri, MA (reprint author), Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Suite 519,300 W 10th Ave, Columbus, OH 43210 USA. EM michael.caligiuri@osumc.edu; guido.marcucci@osumc.edu; clara.bloomfield@osumc.edu RI Metzeler, Klaus/C-2118-2009; Mrozek, Krzysztof/A-3142-2008; OI Metzeler, Klaus/0000-0003-3920-7490; Carter, Thomas/0000-0001-7796-2986; Larson, Richard/0000-0001-9168-3203 FU National Cancer Institute (Bethesda, MD) [CA140158, CA101140, CA114725, CA16058, CA77658, CA089341, CA129657]; Coleman Leukemia Research Foundation; Deutsche Krebshilfe-Dr Mildred Scheel Cancer Foundation; CALGB [9665, 8461, 10201, 9720, 9420, 8923, 8525, 20202]; National Cancer Institute [CA31946, CA33601] FX This work was supported in part by National Cancer Institute (Bethesda, MD) grants CA140158, CA101140, CA114725, CA16058, CA77658, CA089341, and CA129657, The Coleman Leukemia Research Foundation (to C. D. B.) and the Deutsche Krebshilfe-Dr Mildred Scheel Cancer Foundation (to H. B.). The research for CALGB 9665, 8461, 10201, 9720, 9420, 8923, 8525, and 20202 was supported, in part, by grants from the National Cancer Institute (CA31946) to the Cancer and Leukemia Group B (Monica M. Bertagnolli, MD, Chairman) and to the CALGB Statistical Center (Stephen George, PhD; CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. NR 25 TC 98 Z9 105 U1 0 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 4 PY 2010 VL 116 IS 18 BP 3622 EP 3626 DI 10.1182/blood-2010-05-283648 PG 5 WC Hematology SC Hematology GA 675SM UT WOS:000283853200032 PM 20656931 ER PT J AU Maes, K Nemeth, E Roodman, GD Huston, A Esteve, F Freytes, C Callander, N Katodritou, E Tussing-Humphreys, L Rivera, S Vanderkerken, K Lichtenstein, A Ganz, T AF Maes, Ken Nemeth, Elizabeta Roodman, G. David Huston, Alissa Esteve, Flavia Freytes, Cesar Callander, Natalie Katodritou, Eirini Tussing-Humphreys, Lisa Rivera, Seth Vanderkerken, Karin Lichtenstein, Alan Ganz, Tomas TI In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2 SO BLOOD LA English DT Article ID EXPRESSION; IL-6; PROMOTER; CELLS; RECEPTORS; CYTOKINES; BMP; INFLAMMATION; INDUCTION; SURVIVAL AB Hepcidin is the principal iron-regulatory hormone and a pathogenic factor in anemia of inflammation. Patients with multiple myeloma (MM) frequently present with anemia. We showed that MM patients had increased serum hepcidin, which inversely correlated with hemoglobin, suggesting that hepcidin contributes to MM-related anemia. Searching for hepcidin-inducing cytokines in MM, we quantified the stimulation of hepcidin promoter-luciferase activity in HuH7 cells by MM sera. MM sera activated the hepcidin promoter significantly more than did normal sera. We then examined the role of bone morphogenetic proteins (BMPs) and interleukin-6 (IL-6), the major transcriptional regulators of hepcidin. Mutations in both BMP-responsive elements abrogated the activation dramatically, while mutations in the IL-6-responsive signal transducer and activator of transcription 3-binding site (STAT3-BS) had only a minor effect. Cotreatment with anti-BMP-2/4 or noggin-Fc blocked the promoter induction with all MM sera, anti-IL-6 blocked it with a minority of sera, whereas anti-BMP-4, -6, or -9 antibodies had no effect. BMP-2-immunodepleted MM sera had decreased promoter stimulatory capacity, and BMP-2 concentrations in MM sera were significantly higher than in normal sera. Our results demonstrate that BMP-2 is a major mediator of the hepcidin stimulatory activity of MM sera. (Blood. 2010;116(18):3635-3644) C1 [Nemeth, Elizabeta; Rivera, Seth; Ganz, Tomas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Nemeth, Elizabeta; Rivera, Seth; Ganz, Tomas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Maes, Ken; Vanderkerken, Karin] Vrije Univ Brussel VUB, Dept Hematol & Immunol, Brussels, Belgium. [Roodman, G. David; Huston, Alissa; Esteve, Flavia] Univ Pittsburgh, Sch Med & Pittsburgh, VA Med Ctr, Pittsburgh, PA USA. [Freytes, Cesar] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78229 USA. [Callander, Natalie] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Hematol, Madison, WI USA. [Katodritou, Eirini] Theagen Canc Ctr, Dept Hematol, Thessaloniki, Greece. [Tussing-Humphreys, Lisa] USDA ARS, Baton Rouge, LA USA. [Lichtenstein, Alan] W Los Angeles VA Univ Calif Los Angeles Med Ctr, Los Angeles, CA USA. RP Ganz, T (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 10833 Le Conte Ave,CHS 37-055, Los Angeles, CA 90095 USA. EM tganz@mednet.ucla.edu RI Vanderkerken, Karin/I-3513-2013 FU National Institutes of Health [RO1 DK 065029]; UCLA-Jonsson Comprehensive Cancer Center; VA, Los Angeles, CA FX This work was funded by National Institutes of Health grant RO1 DK 065029 (T.G. and E.N.), an Interdisciplinary Seed Grant from the UCLA-Jonsson Comprehensive Cancer Center (E.N., A.L., and T.G.), and by research support from the VA, Los Angeles, CA (A.L.). NR 33 TC 67 Z9 72 U1 1 U2 8 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 4 PY 2010 VL 116 IS 18 BP 3635 EP 3644 DI 10.1182/blood-2010-03274571 PG 10 WC Hematology SC Hematology GA 675SM UT WOS:000283853200034 PM 20679527 ER PT J AU Rask-Madsen, C King, GL AF Rask-Madsen, Christian King, George L. TI DIABETES Podocytes lose their footing SO NATURE LA English DT Editorial Material ID ENDOTHELIAL GROWTH-FACTOR; INSULIN; EXPRESSION; SURVIVAL C1 [Rask-Madsen, Christian; King, George L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. RP Rask-Madsen, C (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. EM george.king@joslin.harvard.edu NR 11 TC 3 Z9 4 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD NOV 4 PY 2010 VL 468 IS 7320 BP 42 EP 44 PG 3 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 674YF UT WOS:000283786900028 PM 21048754 ER PT J AU Liu, Y Samad, OA Zhang, L Duan, B Tong, QC Lopes, C Ji, RR Lowell, BB Ma, QF AF Liu, Yang Samad, Omar Abdel Zhang, Ling Duan, Bo Tong, Qingchun Lopes, Claudia Ji, Ru-Rong Lowell, Bradford B. Ma, Qiufu TI VGLUT2-Dependent Glutamate Release from Nociceptors Is Required to Sense Pain and Suppress Itch SO NEURON LA English DT Article ID DORSAL-ROOT GANGLIA; MECHANICALLY EVOKED DYSESTHESIAE; C-FIBER AFFERENTS; SPINAL-CORD; NEUROPATHIC PAIN; TRANSMITTER PHENOTYPES; EXPERIMENTAL PRURITUS; CENTRAL SENSITIZATION; SCRATCHING BEHAVIOR; ATOPIC-DERMATITIS AB Itch can be suppressed by painful stimuli, but the underlying neural basis is unknown. We generated conditional null mice in which vesicular glutamate transporter type 2 (VGLUT2)-dependent synaptic glutamate release from mainly Nav1.8-expressing nociceptors was abolished. These mice showed deficits in pain behaviors, including mechanical pain, heat pain, capsaicin-evoked pain, inflammatory pain, and neuropathic pain. The pain deficits were accompanied by greatly enhanced itching, as suggested by (1) sensitization of both histamine-dependent and histamine-independent itch pathways and (2) development of spontaneous scratching and skin lesions. Strikingly, intradermal capsaicin injection promotes itch responses in these mutant mice, as opposed to pain responses in control litter-mates. Consequently, coinjection of capsaicin was no longer able to mask itch evoked by pruritogenic compounds. Our studies suggest that synaptic glutamate release from a group of peripheral nociceptors is required to sense pain and suppress itch. Elimination of VGLUT2 in these nociceptors creates a mouse model of chronic neurogenic itch. C1 [Liu, Yang; Samad, Omar Abdel; Duan, Bo; Lopes, Claudia; Ma, Qiufu] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Liu, Yang; Samad, Omar Abdel; Duan, Bo; Lopes, Claudia; Ma, Qiufu] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. [Tong, Qingchun; Lowell, Bradford B.] Beth Israel Deaconess Med Ctr, Div Endocrinol, Dept Med, Boston, MA 02215 USA. [Tong, Qingchun; Lowell, Bradford B.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Zhang, Ling; Ji, Ru-Rong] Brigham & Womens Hosp, Dept Anesthesiol, Pain Res Ctr, Boston, MA 02115 USA. RP Ma, QF (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 1 Jimmy Fund Way, Boston, MA 02115 USA. EM qiufu_ma@dfci.harvard.edu RI samad, omar/K-1921-2012; OI Tong, Qingchun/0000-0002-4561-2540; Ji, Ru-Rong/0000-0002-9355-3688 FU National Institutes of Health National Institute of Dental and Craniofacial Research [R01DE018025]; National Institute of Neurological Disorders and Stroke [R01NS047710, P01NS047572] FX We thank Dr. Rohini Kuner for the Nav1.8Cre mice, Dr. Silvia Arber for the TauGFP reporter mice, and Dr. Zhou-Feng Chen for the GRPR probe. We thank Drs. Clifford Woolf, Sang-Kyou Han, Charles Stiles, and Fu-chia Yang for critical comments on the manuscript. The work is supported by the National Institutes of Health National Institute of Dental and Craniofacial Research (Grant R01DE018025) and National Institute of Neurological Disorders and Stroke (Grants R01NS047710 and P01NS047572). NR 63 TC 117 Z9 120 U1 2 U2 19 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0896-6273 J9 NEURON JI Neuron PD NOV 4 PY 2010 VL 68 IS 3 BP 543 EP 556 DI 10.1016/j.neuron.2010.09.008 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 680SX UT WOS:000284255800020 PM 21040853 ER PT J AU Van de Velde, SK Gill, TJ AF Van de Velde, Samuel K. Gill, Thomas J. TI Treatment for Acute Anterior Cruciate Ligament Tear SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Van de Velde, Samuel K.; Gill, Thomas J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Van de Velde, SK (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM svandevelde@partners.org NR 3 TC 2 Z9 2 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 4 PY 2010 VL 363 IS 19 BP 1871 EP 1872 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 674YK UT WOS:000283787800028 PM 21047244 ER PT J AU Chen, CC Zinn, PO Kasper, EM Ogilvy, CS AF Chen, Clark C. Zinn, Pascal O. Kasper, Ekkehard M. Ogilvy, Christopher S. TI Cranio-spinal migration of a metallic clip placed during arteriovenous malformation resection - A case report, review of the literature, and management strategies SO BMC NEUROLOGY LA English DT Article ID FOREIGN-BODY; BULLET AB Background: Microclip placement during AVM resection is generally accepted to be a safe practice in neurosurgery. Here, we describe an unusual complication involving cranio-spinal clip migration discovered five years after the initial AVM surgery. Case Presentation: A 53-year-old man underwent resection of a superior vermian AVM that required the placement of two microclips during the procedure. Five years after surgery, the patient suffered from descending sensory radiculopathy that resolved spontaneously. The workup revealed cranio-spinal migration of one of the previously placed microclips. Conclusions: AVM clip migration is a rare phenomenon; however, the diagnosis should be entertained in patients with posterior fossa instrumentation who suffer from unusual neurologic symptoms. C1 [Chen, Clark C.; Zinn, Pascal O.; Kasper, Ekkehard M.] Harvard Univ, Sch Med, Dept Neurosurg, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [Chen, Clark C.; Zinn, Pascal O.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Ogilvy, Christopher S.] Harvard Univ, Sch Med, Dept Neurosurg, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Chen, CC (reprint author), Harvard Univ, Sch Med, Dept Neurosurg, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. EM cchen10@bidmc.harvard.edu RI Chen, Clark/C-8714-2013 OI Chen, Clark/0000-0001-6258-9277 NR 13 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2377 J9 BMC NEUROL JI BMC Neurol. PD NOV 3 PY 2010 VL 10 AR 109 DI 10.1186/1471-2377-10-109 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 682SL UT WOS:000284423200001 PM 21047415 ER PT J AU Gu, C Yaddanapudi, S Weins, A Osborn, T Reiser, J Pollak, M Hartwig, J Sever, S AF Gu, Changkyu Yaddanapudi, Suma Weins, Astrid Osborn, Teresia Reiser, Jochen Pollak, Martin Hartwig, John Sever, Sanja TI Direct dynamin-actin interactions regulate the actin cytoskeleton SO EMBO JOURNAL LA English DT Article DE actin; cytoskeleton; dynamin ID BARBED ENDS; MEDIATED ENDOCYTOSIS; GTPASE ACTIVITY; CELL-MIGRATION; LEADING-EDGE; GELSOLIN; FILAMENTS; PURIFICATION; PROTEINS; NUCLEATION AB The large GTPase dynamin assembles into higher order structures that are thought to promote endocytosis. Dynamin also regulates the actin cytoskeleton through an unknown, GTPase-dependent mechanism. Here, we identify a highly conserved site in dynamin that binds directly to actin filaments and aligns them into bundles. Point mutations in the actin-binding domain cause aberrant membrane ruffling and defective actin stress fibre formation in cells. Short actin filaments promote dynamin assembly into higher order structures, which in turn efficiently release the actin-capping protein (CP) gelsolin from barbed actin ends in vitro, allowing for elongation of actin filaments. Together, our results support a model in which assembled dynamin, generated through interactions with short actin filaments, promotes actin polymerization via displacement of actin-CPs. The EMBO Journal (2010) 29, 3593-3606. doi:10.1038/emboj.2010.249; Published online 8 October 2010 C1 [Gu, Changkyu; Yaddanapudi, Suma; Sever, Sanja] Harvard Univ, Sch Med, Div Nephrol, Dept Med, Charlestown, MA 02129 USA. [Gu, Changkyu; Yaddanapudi, Suma; Sever, Sanja] Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Weins, Astrid; Pollak, Martin] Beth Israel Deaconess Med Ctr, Div Nephrol, Boston, MA 02215 USA. [Osborn, Teresia; Hartwig, John] Brigham & Womens Hosp, Translat Med Div, Boston, MA 02115 USA. [Reiser, Jochen] Univ Miami, Div Nephrol & Hypertens, Coral Gables, FL 33124 USA. RP Sever, S (reprint author), Harvard Univ, Sch Med, Div Nephrol, Dept Med, 149 13th St, Charlestown, MA 02129 USA. EM ssever@partners.org FU National Institute of Health [R01 DK64787]; NephCure Foundation FX We are indebted to Fujiwara Ikuko and John A Hammer III for providing recombinant CP as well as pyrine-labelled actin. This work was supported by the National Institute of Health (R01 DK64787 to SS) and the NephCure Foundation. NR 55 TC 92 Z9 95 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0261-4189 J9 EMBO J JI Embo J. PD NOV 3 PY 2010 VL 29 IS 21 BP 3593 EP 3606 DI 10.1038/emboj.2010.249 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 695QD UT WOS:000285386700002 PM 20935625 ER PT J AU DesRoches, CM Campbell, EG AF DesRoches, Catherine M. Campbell, Eric G. TI Physicians' Experiences With Impaired Colleagues Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [DesRoches, Catherine M.; Campbell, Eric G.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. RP DesRoches, CM (reprint author), Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. EM cdesroches@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 3 PY 2010 VL 304 IS 17 BP 1896 EP 1897 DI 10.1001/jama.2010.1560 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 674GT UT WOS:000283725900014 ER PT J AU Dykes, PC Carroll, DL Hurley, A Lipsitz, S Benoit, A Chang, F Meltzer, S Tsurikova, R Zuyov, L Middleton, B AF Dykes, Patricia C. Carroll, Diane L. Hurley, Ann Lipsitz, Stuart Benoit, Angela Chang, Frank Meltzer, Seth Tsurikova, Ruslana Zuyov, Lyubov Middleton, Blackford TI Fall Prevention in Acute Care Hospitals A Randomized Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID CONSEQUENT INJURIES; ELDERLY-PEOPLE; PATIENT FALLS; RISK; PROGRAM; CIRCUMSTANCES; INTERVENTIONS; SETTINGS AB Context Falls cause injury and death for persons of all ages, but risk of falls increases markedly with age. Hospitalization further increases risk, yet no evidence exists to support short-stay hospital-based fall prevention strategies to reduce patient falls. Objective To investigate whether a fall prevention tool kit (FPTK) using health information technology (HIT) decreases patient falls in hospitals. Design, Setting, and Patients Cluster randomized study conducted January 1, 2009, through June 30, 2009, comparing patient fall rates in 4 urban US hospitals in units that received usual care (4 units and 5104 patients) or the intervention (4 units and 5160 patients). Intervention The FPTK integrated existing communication and workflow patterns into the HIT application. Based on a valid fall risk assessment scale completed by a nurse, the FPTK software tailored fall prevention interventions to address patients' specific determinants of fall risk. The FPTK produced bed posters composed of brief text with an accompanying icon, patient education handouts, and plans of care, all communicating patient-specific alerts to key stakeholders. Main Outcome Measures The primary outcome was patient falls per 1000 patient-days adjusted for site and patient care unit. A secondary outcome was fall-related injuries. Results During the 6-month intervention period, the number of patients with falls differed between control (n=87) and intervention (n=67) units (P=.02). Site-adjusted fall rates were significantly higher in control units (4.18 [95% confidence interval {CI}, 3.45-5.06] per 1000 patient-days) than in intervention units (3.15 [95% CI, 2.54-3.90] per 1000 patient-days; P=.04). The FPTK was found to be particularly effective with patients aged 65 years or older (adjusted rate difference, 2.08 [95% CI, 0.61-3.56] per 1000 patient-days; P=.003). No significant effect was noted in fall-related injuries. Conclusion The use of a fall prevention tool kit in hospital units compared with usual care significantly reduced rate of falls. C1 [Dykes, Patricia C.; Benoit, Angela; Chang, Frank; Meltzer, Seth; Middleton, Blackford] Partners HealthCare Syst, Boston, MA USA. [Dykes, Patricia C.; Hurley, Ann; Lipsitz, Stuart; Tsurikova, Ruslana; Middleton, Blackford] Brigham & Womens Hosp, Boston, MA 02115 USA. [Dykes, Patricia C.; Lipsitz, Stuart; Middleton, Blackford] Harvard Univ, Sch Med, Boston, MA USA. [Carroll, Diane L.; Zuyov, Lyubov] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Dykes, PC (reprint author), Partners HealthCare Syst, Brigham & Womens Hosp, 93 Worcester St, Wellesley, MA 02481 USA. EM pdykes@partners.org FU Robert Wood Johnson Foundation Interdisciplinary Nursing Quality Research Initiative FX This work was supported by a grant from the Robert Wood Johnson Foundation Interdisciplinary Nursing Quality Research Initiative (Translating Fall Risk Status Into Interventions to Prevent Patient Falls). NR 36 TC 88 Z9 91 U1 0 U2 21 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 3 PY 2010 VL 304 IS 17 BP 1912 EP 1918 DI 10.1001/jama.2010.1567 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 674GT UT WOS:000283725900021 PM 21045097 ER PT J AU Nordstrand, LM Svard, J Larsen, E Nilsen, A Ougland, R Furu, K Lien, GF Rognes, T Namekawa, SH Lee, JT Klungland, A AF Nordstrand, Line M. Svard, Jessica Larsen, Elisabeth Nilsen, Anja Ougland, Rune Furu, Kari Lien, Guro F. Rognes, Torbjorn Namekawa, Satoshi H. Lee, Jeannie T. Klungland, Arne TI Mice Lacking Alkbh1 Display Sex-Ratio Distortion and Unilateral Eye Defects SO PLOS ONE LA English DT Article ID BONE MORPHOGENETIC PROTEINS; GERM-CELL APOPTOSIS; OXIDATIVE DEMETHYLATION; ALKYLATION DAMAGE; MOUSE DEVELOPMENT; ESCHERICHIA-COLI; PHOSPHATIDYLSERINE RECEPTOR; METHYLATION DAMAGE; GENE ENCODES; DNA-DAMAGE AB Background: Eschericia coli AlkB is a 2-oxoglutarate- and iron-dependent dioxygenase that reverses alkylated DNA damage by oxidative demethylation. Mouse AlkB homolog 1 (Alkbh1) is one of eight members of the newly discovered family of mammalian dioxygenases. Methods and Findings: In the present study we show non-Mendelian inheritance of the Alkbh1 targeted allele in mice. Both Alkbh1(-/-) and heterozygous Alkbh1(+/-) offspring are born at a greatly reduced frequency. Additionally, the sex-ratio is considerably skewed against female offspring, with one female born for every three to four males. Most mechanisms that cause segregation distortion, act in the male gametes and affect male fertility. The skewing of the sexes appears to be of paternal origin, and might be set in the pachythene stage of meiosis during spermatogenesis, in which Alkbh1 is upregulated more than 10-fold. In testes, apoptotic spermatids were revealed in 5-10% of the tubules in Alkbh1(-/-) adults. The deficiency of Alkbh1 also causes misexpression of Bmp2, 4 and 7 at E11.5 during embryonic development. This is consistent with the incompletely penetrant phenotypes observed, particularly recurrent unilateral eye defects and craniofacial malformations. Conclusions: Genetic and phenotypic assessment suggests that Alkbh1 mediates gene regulation in spermatogenesis, and that Alkbh1 is essential for normal sex-ratio distribution and embryonic development in mice. C1 [Nordstrand, Line M.; Svard, Jessica; Larsen, Elisabeth; Nilsen, Anja; Ougland, Rune; Furu, Kari; Lien, Guro F.; Rognes, Torbjorn; Klungland, Arne] Oslo Univ Hosp, Inst Med Microbiol, Ctr Mol Biol & Neurosci, Oslo, Norway. [Rognes, Torbjorn] Univ Oslo, Dept Informat, N-0316 Oslo, Norway. [Larsen, Elisabeth; Ougland, Rune; Namekawa, Satoshi H.; Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Klungland, Arne] Univ Oslo, Inst Basic Med Sci, Oslo, Norway. [Lee, Jeannie T.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA. RP Nordstrand, LM (reprint author), Oslo Univ Hosp, Inst Med Microbiol, Ctr Mol Biol & Neurosci, Oslo, Norway. EM arne.klungland@rr-research.no RI Rognes, Torbjorn/A-9692-2008; OI Rognes, Torbjorn/0000-0002-9329-9974 FU Norwegian Research Council; Norwegian Cancer Society; European Union FX This work was supported by the National Program in Functional Genomics (FUGE) sponsored by the Norwegian Research Council, the Norwegian Cancer Society and the European Union program 'DNA repair'. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 62 TC 22 Z9 24 U1 1 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 3 PY 2010 VL 5 IS 11 AR e13827 DI 10.1371/journal.pone.0013827 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 674WJ UT WOS:000283780800024 PM 21072209 ER PT J AU Allen, KD Oddone, EZ Coffman, CJ Datta, SK Juntilla, KA Lindquist, JH Walker, TA Weinberger, M Bosworth, HB AF Allen, Kelli D. Oddone, Eugene Z. Coffman, Cynthia J. Datta, Santanu K. Juntilla, Karen A. Lindquist, Jennifer H. Walker, Tessa A. Weinberger, Morris Bosworth, Hayden B. TI Telephone-Based Self-management of Osteoarthritis A Randomized Trial SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID PHYSICAL-ACTIVITY; HEALTH-STATUS; KNEE OSTEOARTHRITIS; EDUCATION-PROGRAMS; CLINICAL-TRIALS; CHRONIC DISEASE; ARTHRITIS; VETERANS; INTERVENTIONS; OUTCOMES AB Background: Osteoarthritis is a leading cause of pain and disability, and self-management behaviors for osteoarthritis are underutilized. Objective: To examine the effectiveness of a telephone-based self-management intervention for hip or knee osteoarthritis in a primary care setting. Design: Randomized clinical trial with equal assignment to osteoarthritis self-management, health education (attention control), and usual care control groups. (ClinicalTrials.gov registration number: NCT00288912) Setting: Primary care clinics in a Veterans Affairs Medical Center. Patients: 515 patients with symptomatic hip or knee osteoarthritis. Intervention: The osteoarthritis self-management intervention involved educational materials and 12 monthly telephone calls to support individualized goals and action plans. The health education intervention involved nonosteoarthritis educational materials and 12 monthly telephone calls related to general health screening topics. Measurements: The primary outcome was score on the Arthritis Impact Measurement Scales-2 pain subscale (range, 0 to 10). Pain was also assessed with a 10-cm visual analog scale. Measurements were collected at baseline and 12 months. Results: 461 participants (90%) completed the 12-month assessment. The mean Arthritis Impact Measurement Scales-2 pain score in the osteoarthritis self-management group was 0.4 point lower (95% CI, -0.8 to 0.1 point; P = 0.105) than in the usual care group and 0.6 point lower (CI, -1.0 to -0.2 point; P = 0.007) than in the health education group at 12 months. The mean visual analog scale pain score in the osteoarthritis self-management group was 1.1 points lower (CI, -1.6 to -0.6 point; P < 0.001) than in the usual care group and 1.0 point lower (CI, -1.5 to -0.5 point; P < 0.001) than in the health education group. Health care use did not differ across the groups. Limitation: The study was conducted at 1 Veterans Affairs Medical Center, and the sample consisted primarily of men. Conclusion: A telephone-based osteoarthritis self-management program produced moderate improvements in pain, particularly compared with a health education control group. C1 Duke Univ, Med Ctr, Durham Vet Affairs Med Ctr, Durham, NC 27706 USA. Univ N Carolina, Chapel Hill, NC USA. RP Allen, KD (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv 152, Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA. EM kelli.allen@duke.edu FU U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 04-016, 08-027, 91-408] FX By the U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (IIR 04-016 and Career Scientist Awards 08-027 [Dr. Bosworth] and 91-408 [Dr. Weinberger]). NR 42 TC 40 Z9 41 U1 1 U2 8 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 2 PY 2010 VL 153 IS 9 BP 570 EP 579 DI 10.7326/0003-4819-153-9-201011020-00006 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 673MH UT WOS:000283667000003 PM 21041576 ER PT J AU Flaherty, KT AF Flaherty, Keith T. TI Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID METASTATIC MALIGNANT-MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; PHASE-III; IMATINIB MESYLATE; TUMOR PROGRESSION; B-RAF; DACARBAZINE; INHIBITION; MUTATIONS; KINASE AB Patients with metastatic melanoma have a poor prognosis and limited treatment options. In about one half of analyzed patients with metastatic melanoma, a mutated signal transduction molecule has been identified: v-raf murine sarcoma viral oncogene homolog B1 (BRAF). This molecule is part of an intracellular signaling cascade and may play a role in many different types of cancer. This article provides an overview of the current treatment options for metastatic melanoma and describes the pathophysiology underlying the development of therapies based on inhibition of BRAF. It summarizes findings of phase 1 and phase 2 studies of BRAF inhibitor therapy primarily in patients with metastatic melanoma, who have shown objective response rates of 70% to 80%. However, initial responses have not been sustained, with a median time to relapse of approximately 9 months. Clinicians should be aware of phase 3 trials of these agents and trials combining these therapies with other novel therapies because, at a minimum, BRAF inhibitors seem to be valuable as palliative therapy for metastatic melanoma. C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Flaherty, KT (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM kflaherty@partners.org FU Plexxikon [PLX4032] FX The phase 1 and phase 2 trials of PLX4032 were supported by Plexxikon. NR 23 TC 21 Z9 23 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 2 PY 2010 VL 153 IS 9 BP 587 EP 591 DI 10.7326/0003-4819-153-9-201011020-00008 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 673MH UT WOS:000283667000005 PM 21041578 ER PT J AU Sander, JD Reyon, D Maeder, ML Foley, JE Thibodeau-Beganny, S Li, XH Regan, MR Dahlborg, EJ Goodwin, MJ Fu, FL Voytas, DF Joung, JK Dobbs, D AF Sander, Jeffry D. Reyon, Deepak Maeder, Morgan L. Foley, Jonathan E. Thibodeau-Beganny, Stacey Li, Xiaohong Regan, Maureen R. Dahlborg, Elizabeth J. Goodwin, Mathew J. Fu, Fengli Voytas, Daniel F. Joung, J. Keith Dobbs, Drena TI Predicting success of oligomerized pool engineering (OPEN) for zinc finger target site sequences SO BMC BIOINFORMATICS LA English DT Article ID DNA-BINDING; TRANSCRIPTION-FACTOR; GENE-THERAPY; NUCLEASES; PROTEINS; CELLS; RECOGNITION; MICROARRAYS; SELECTION; DESIGN AB Background: Precise and efficient methods for gene targeting are critical for detailed functional analysis of genomes and regulatory networks and for potentially improving the efficacy and safety of gene therapies. Oligomerized Pool ENgineering (OPEN) is a recently developed method for engineering C2H2 zinc finger proteins (ZFPs) designed to bind specific DNA sequences with high affinity and specificity in vivo. Because generation of ZFPs using OPEN requires considerable effort, a computational method for identifying the sites in any given gene that are most likely to be successfully targeted by this method is desirable. Results: Analysis of the base composition of experimentally validated ZFP target sites identified important constraints on the DNA sequence space that can be effectively targeted using OPEN. Using alternate encodings to represent ZFP target sites, we implemented Naive Bayes and Support Vector Machine classifiers capable of distinguishing "active" targets, i.e., ZFP binding sites that can be targeted with a high rate of success, from those that are "inactive" or poor targets for ZFPs generated using current OPEN technologies. When evaluated using leave-one-out cross-validation on a dataset of 135 experimentally validated ZFP target sites, the best Naive Bayes classifier, designated ZiFOpT, achieved overall accuracy of 87% and specificity(+) of 90%, with an ROC AUC of 0.89. When challenged with a completely independent test set of 140 newly validated ZFP target sites, ZiFOpT performance was comparable in terms of overall accuracy (88%) and specificity(+) (92%), but with reduced ROC AUC (0.77). Users can rank potentially active ZFP target sites using a confidence score derived from the posterior probability returned by ZiFOpT. Conclusion: ZiFOpT, a machine learning classifier trained to identify DNA sequences amenable for targeting by OPEN-generated zinc finger arrays, can guide users to target sites that are most likely to function successfully in vivo, substantially reducing the experimental effort required. ZiFOpT is freely available and incorporated in the Zinc Finger Targeter web server (http://bindr.gdcb.iastate.edu/ZiFiT). C1 [Sander, Jeffry D.; Maeder, Morgan L.; Foley, Jonathan E.; Thibodeau-Beganny, Stacey; Regan, Maureen R.; Dahlborg, Elizabeth J.; Goodwin, Mathew J.; Joung, J. Keith] Massachusetts Gen Hosp, Mol Pathol Unit, Ctr Canc Res, Charlestown, MA 02129 USA. [Sander, Jeffry D.; Maeder, Morgan L.; Foley, Jonathan E.; Thibodeau-Beganny, Stacey; Regan, Maureen R.; Dahlborg, Elizabeth J.; Goodwin, Mathew J.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA 02129 USA. [Sander, Jeffry D.; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Sander, Jeffry D.; Reyon, Deepak; Fu, Fengli; Dobbs, Drena] Iowa State Univ, Dept Genet Dev & Cell Biol, Interdept Grad Program Bioinformat & Computat Bio, Ames, IA 50011 USA. [Maeder, Morgan L.; Joung, J. Keith] Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02115 USA. [Li, Xiaohong; Voytas, Daniel F.] Univ Minnesota, Ctr Genome Engn, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA. RP Sander, JD (reprint author), Massachusetts Gen Hosp, Mol Pathol Unit, Ctr Canc Res, Charlestown, MA 02129 USA. EM jsander@partners.org FU NIH [T32CA009216, GM066387, GM069906, GM078369]; NSF [DBI 0501678, IGERT0504304]; ISU's Center for Integrated Animal Genomics (CIAG); Department of Genetics, Development and Cell Biology FX This work was supported in part by the following grants: NIH T32CA009216 (J.D.S); NIH GM066387 (D. D.); NIH GM069906 and GM078369 (J.K.J.); NSF DBI 0501678 (D. F. V.) and graduate research assistantships provided by USDA MGET 2001-52100-11506, NSF IGERT0504304, and ISU's Center for Integrated Animal Genomics (CIAG) and Department of Genetics, Development and Cell Biology. We thank members of our groups, especially M. Terribilini, B. Lewis, and P. Zaback for valuable comments. NR 50 TC 14 Z9 15 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2105 J9 BMC BIOINFORMATICS JI BMC Bioinformatics PD NOV 2 PY 2010 VL 11 AR 543 DI 10.1186/1471-2105-11-543 PG 11 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Mathematical & Computational Biology GA 682JZ UT WOS:000284400400001 PM 21044337 ER PT J AU Assimes, TL Holm, H Kathiresan, S Reilly, MP Thorleifsson, G Voight, BF Erdmann, J Willenborg, C Vaidya, D Xie, CC Patterson, CC Morgan, TM Burnett, MS Li, MY Hlatky, MA Knowles, JW Thompson, JR Absher, D Iribarren, C Go, A Fortmann, SP Sidney, S Risch, N Tang, H Myers, RM Berger, K Stoll, M Shah, SH Thorgeirsson, G Andersen, K Havulinna, AS Herrera, JE Faraday, N Kim, Y Kral, BG Mathias, RA Ruczinski, I Suktitipat, B Wilson, AF Yanek, LR Becker, LC Linsel-Nitschke, P Lieb, W Konig, IR Hengstenberg, C Fischer, M Stark, K Reinhard, W Winogradow, J Grassl, M Grosshennig, A Preuss, M Schreiber, S Wichmann, HE Meisinger, C Yee, J Friedlander, Y Do, R Meigs, JB Williams, G Nathan, DM MacRae, CA Qu, LM Wilensky, RL Matthai, WH Qasim, AN Hakonarson, H Pichard, AD Kent, KM Satler, L Lindsay, JM Waksman, R Knouff, CW Waterworth, DM Walker, MC Mooser, VE Marrugat, J Lucas, G Subirana, I Sala, J Ramos, R Martinelli, N Olivieri, O Trabetti, E Malerba, G Pignatti, PF Guiducci, C Mirel, D Parkin, M Hirschhorn, JN Asselta, R Duga, S Musunuru, K Daly, MJ Purcell, S Eifert, S Braund, PS Wright, BJ Balmforth, AJ Ball, SG Ouwehand, WH Deloukas, P Scholz, M Cambien, F Huge, A Scheffold, T Salomaa, V Girelli, D Granger, CB Peltonen, L McKeown, PP Altshuler, D Melander, O Devaney, JM Epstein, SE Rader, DJ Elosua, R Engert, JC Anand, SS Hall, AS Ziegler, A O'Donnell, CJ Spertus, JA Siscovick, D Schwartz, SM Becker, D Thorsteinsdottir, U Stefansson, K Schunkert, H Samani, NJ Quertermous, T AF Assimes, Themistocles L. Holm, Hilma Kathiresan, Sekar Reilly, Muredach P. Thorleifsson, Gudmar Voight, Benjamin F. Erdmann, Jeanette Willenborg, Christina Vaidya, Dhananjay Xie, Changchun Patterson, Chris C. Morgan, Thomas M. Burnett, Mary Susan Li, Mingyao Hlatky, Mark A. Knowles, Joshua W. Thompson, John R. Absher, Devin Iribarren, Carlos Go, Alan Fortmann, Stephen P. Sidney, Stephen Risch, Neil Tang, Hua Myers, Richard M. Berger, Klaus Stoll, Monika Shah, Svati H. Thorgeirsson, Gudmundur Andersen, Karl Havulinna, Aki S. Herrera, J. Enrique Faraday, Nauder Kim, Yoonhee Kral, Brian G. Mathias, Rasika A. Ruczinski, Ingo Suktitipat, Bhoom Wilson, Alexander F. Yanek, Lisa R. Becker, Lewis C. Linsel-Nitschke, Patrick Lieb, Wolfgang Koenig, Inke R. Hengstenberg, Christian Fischer, Marcus Stark, Klaus Reinhard, Wibke Winogradow, Janina Grassl, Martina Grosshennig, Anika Preuss, Michael Schreiber, Stefan Wichmann, H-Erich Meisinger, Christa Yee, Jean Friedlander, Yechiel Do, Ron Meigs, James B. Williams, Gordon Nathan, David M. MacRae, Calum A. Qu, Liming Wilensky, Robert L. Matthai, William H., Jr. Qasim, Atif N. Hakonarson, Hakon Pichard, Augusto D. Kent, Kenneth M. Satler, Lowell Lindsay, Joseph M. Waksman, Ron Knouff, Christopher W. Waterworth, Dawn M. Walker, Max C. Mooser, Vincent E. Marrugat, Jaume Lucas, Gavin Subirana, Isaac Sala, Joan Ramos, Rafael Martinelli, Nicola Olivieri, Oliviero Trabetti, Elisabetta Malerba, Giovanni Pignatti, Pier Franco Guiducci, Candace Mirel, Daniel Parkin, Melissa Hirschhorn, Joel N. Asselta, Rosanna Duga, Stefano Musunuru, Kiran Daly, Mark J. Purcell, Shaun Eifert, Sandra Braund, Peter S. Wright, Benjamin J. Balmforth, Anthony J. Ball, Stephen G. Ouwehand, Willem H. Deloukas, Panos Scholz, Michael Cambien, Francois Huge, Andreas Scheffold, Thomas Salomaa, Veikko Girelli, Domenico Granger, Christopher B. Peltonen, Leena McKeown, Pascal P. Altshuler, David Melander, Olle Devaney, Joseph M. Epstein, Stephen E. Rader, Daniel J. Elosua, Roberto Engert, James C. Anand, Sonia S. Hall, Alistair S. Ziegler, Andreas O'Donnell, Christopher J. Spertus, John A. Siscovick, David Schwartz, Stephen M. Becker, Diane Thorsteinsdottir, Unnur Stefansson, Kari Schunkert, Heribert Samani, Nilesh J. Quertermous, Thomas CA Myocardial Infarction Genet Wellcome Trust Case Control Cardiogenics TI Lack of Association Between the Trp719Arg Polymorphism in Kinesin-Like Protein-6 and Coronary Artery Disease in 19 Case-Control Studies SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE coronary artery disease; KIF6; kinesin-like protein 6; myocardial infarction; polymorphism ID NONFATAL MYOCARDIAL-INFARCTION; HEART-DISEASE; CARDIOVASCULAR-DISEASE; GENE VARIANTS; RISK-FACTORS; GENOMEWIDE ASSOCIATION; CHROMOSOME 9P21.3; GENOTYPE DATA; POPULATION; HEALTH AB Objectives We sought to replicate the association between the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism (rs20455), and clinical coronary artery disease (CAD). Background Recent prospective studies suggest that carriers of the 719Arg allele in KIF6 are at increased risk of clinical CAD compared with noncarriers. Methods The KIF6 Trp719Arg polymorphism (rs20455) was genotyped in 19 case-control studies of nonfatal CAD either as part of a genome-wide association study or in a formal attempt to replicate the initial positive reports. Results A total of 17,000 cases and 39,369 controls of European descent as well as a modest number of South Asians, African Americans, Hispanics, East Asians, and admixed cases and controls were successfully genotyped. None of the 19 studies demonstrated an increased risk of CAD in carriers of the 719Arg allele compared with noncarriers. Regression analyses and fixed-effects meta-analyses ruled out with high degree of confidence an increase of >= 2% in the risk of CAD among European 719Arg carriers. We also observed no increase in the risk of CAD among 719Arg carriers in the subset of Europeans with early-onset disease (younger than 50 years of age for men and younger than 60 years of age for women) compared with similarly aged controls as well as all non-European subgroups. Conclusions The KIF6 Trp719Arg polymorphism was not associated with the risk of clinical CAD in this large replication study. (J Am Coll Cardiol 2010;56:1552-63) (C) 2010 by the American College of Cardiology Foundation C1 [Assimes, Themistocles L.; Hlatky, Mark A.; Knowles, Joshua W.; Fortmann, Stephen P.; Waksman, Ron; Quertermous, Thomas] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94304 USA. [Holm, Hilma; Thorleifsson, Gudmar; Thorsteinsdottir, Unnur; Stefansson, Kari] deCODE Genet, Reykjavik, Iceland. [Kathiresan, Sekar; MacRae, Calum A.; Musunuru, Kiran; O'Donnell, Christopher J.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Kathiresan, Sekar; MacRae, Calum A.; Musunuru, Kiran; O'Donnell, Christopher J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Kathiresan, Sekar; Voight, Benjamin F.; Musunuru, Kiran; Daly, Mark J.; Purcell, Shaun; Altshuler, David] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Kathiresan, Sekar; Voight, Benjamin F.; Guiducci, Candace; Mirel, Daniel; Parkin, Melissa; Hirschhorn, Joel N.; Musunuru, Kiran; Daly, Mark J.; Purcell, Shaun; Peltonen, Leena; Altshuler, David] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA. [Kathiresan, Sekar; Meigs, James B.; Williams, Gordon; Nathan, David M.; MacRae, Calum A.; Waksman, Ron; Musunuru, Kiran; Daly, Mark J.; Altshuler, David; O'Donnell, Christopher J.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Reilly, Muredach P.; Wilensky, Robert L.; Matthai, William H., Jr.] Univ Penn, Cardiovasc Inst, Philadelphia, PA 19104 USA. [Reilly, Muredach P.; Wilensky, Robert L.; Qasim, Atif N.; Rader, Daniel J.] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA. [Voight, Benjamin F.; Altshuler, David; Rader, Daniel J.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Erdmann, Jeanette; Willenborg, Christina; Linsel-Nitschke, Patrick; Lieb, Wolfgang; Grosshennig, Anika; Preuss, Michael; Schunkert, Heribert] Univ Lubeck, Med Klin 2, Lubeck, Germany. [Willenborg, Christina; Koenig, Inke R.; Grosshennig, Anika; Preuss, Michael; Ziegler, Andreas] Univ Lubeck, Inst Med Biometrie & Stat, Lubeck, Germany. [Vaidya, Dhananjay; Herrera, J. Enrique; Kral, Brian G.; Mathias, Rasika A.; Yanek, Lisa R.; Becker, Lewis C.; Becker, Diane] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Xie, Changchun; Anand, Sonia S.] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada. [Xie, Changchun; Anand, Sonia S.] McMaster Univ, Dept Med, Hamilton, ON, Canada. [Xie, Changchun; Anand, Sonia S.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. [Patterson, Chris C.; McKeown, Pascal P.] Queens Univ Belfast, Ctr Publ Hlth, Inst Clin Sci, Belfast, Antrim, North Ireland. [Morgan, Thomas M.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. [Burnett, Mary Susan; Pichard, Augusto D.; Kent, Kenneth M.; Satler, Lowell; Lindsay, Joseph M.; Devaney, Joseph M.; Epstein, Stephen E.] Washington Hosp Ctr, Cardiovasc Res Inst, MedStar Hlth Res Inst, Washington, DC 20010 USA. [Thompson, John R.; Wright, Benjamin J.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England. [Absher, Devin; Myers, Richard M.] HudsonAlpha Inst Biotechnol, Huntsville, AL USA. [Iribarren, Carlos; Go, Alan; Sidney, Stephen] Kaiser Permanente, Div Res, Oakland, CA USA. [Risch, Neil] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA. [Tang, Hua] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA. [Berger, Klaus] Univ Munster, Inst Epidemiol & Social Med, Munster, Germany. [Stoll, Monika; Huge, Andreas] Univ Munster, Leibniz Inst Arteriosclerosis Res, Munster, Germany. [Shah, Svati H.; Granger, Christopher B.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Shah, Svati H.] Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA. [Thorgeirsson, Gudmundur; Andersen, Karl; Thorsteinsdottir, Unnur; Stefansson, Kari] Univ Iceland, Fac Med, Reykjavik, Iceland. [Thorgeirsson, Gudmundur; Andersen, Karl] Landspitali Univ Hosp, Dept Med, Reykjavik, Iceland. [Havulinna, Aki S.; Salomaa, Veikko] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland. [Faraday, Nauder] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA. [Kim, Yoonhee; Wilson, Alexander F.] NHGRI, Genometr Sect, Inherited Dis Res Branch, NIH, Baltimore, MD USA. [Ruczinski, Ingo] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA. [Suktitipat, Bhoom] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Hengstenberg, Christian; Fischer, Marcus; Stark, Klaus; Reinhard, Wibke; Winogradow, Janina; Grassl, Martina] Univ Regensburg, Klin & Poliklin Innere Med 2, Regensburg, Germany. [Schreiber, Stefan] Univ Kiel, Inst Klin Mol Biol, Kiel, Germany. [Wichmann, H-Erich; Meisinger, Christa] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany. [Wichmann, H-Erich] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany. [Wichmann, H-Erich] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany. [Meisinger, Christa] Klinikum Augsburg, KORA Myocardial Infarct Registry, Augsburg, Germany. [Yee, Jean; Siscovick, David; Schwartz, Stephen M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Yee, Jean; Siscovick, David; Schwartz, Stephen M.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Yee, Jean; Schwartz, Stephen M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Friedlander, Yechiel] Hebrew Univ Jerusalem, Epidemiol Unit, Hadassah Sch Publ Hlth, Jerusalem, Israel. [Do, Ron; Engert, James C.] McGill Univ, Dept Human Genet, Montreal, PQ, Canada. [Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Dept Med, Boston, MD USA. [Williams, Gordon] Brigham & Womens Hosp, Cardiovasc Endocrinol Sect, Div Endocrinol Diabet & Hypertens, Boston, MD USA. [Nathan, David M.] Massachusetts Gen Hosp, Ctr Diabet, Boston, MD USA. [Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA. [Knouff, Christopher W.; Waterworth, Dawn M.; Walker, Max C.; Mooser, Vincent E.] GlaxoSmithKline Inc, Genet Div & Drug Discovery, King Of Prussia, PA USA. [Marrugat, Jaume; Lucas, Gavin; Subirana, Isaac; Elosua, Roberto] IMIM, Barcelona, Spain. [Marrugat, Jaume; Lucas, Gavin; Subirana, Isaac; Elosua, Roberto] CIBER Epidemiol & Salud Publ, Barcelona, Spain. [Sala, Joan] Hosp Girona Josep Trueta, Serv Cardiol, Girona, Spain. [Sala, Joan] Hosp Girona Josep Trueta, Unitat Coronaria, Girona, Spain. [Sala, Joan] Inst Invest Biomed Girona, Girona, Spain. [Ramos, Rafael] Family Med, Res Unit, Girona, Spain. [Ramos, Rafael] Jordi Gol Inst Primary Care Res IDIAP Jordi Gol &, Girona, Spain. [Ramos, Rafael] Catalan Inst Hlth ICS, Catalunya, Spain. [Ramos, Rafael] Univ Girona, Dept Med Sci, Sch Med, Girona, Spain. [Martinelli, Nicola; Olivieri, Oliviero; Girelli, Domenico] Univ Verona, Dept Med, I-37100 Verona, Italy. [Trabetti, Elisabetta; Malerba, Giovanni; Pignatti, Pier Franco] Univ Verona, Dept Life & Reprod Sci, Sect Biol & Genet, I-37100 Verona, Italy. [Hirschhorn, Joel N.; Altshuler, David] Harvard Univ, Sch Med, Dept Genet, Boston, MD USA. [Asselta, Rosanna; Duga, Stefano] Univ Milan, Dipartimento Biol & Genet Sci Med, Milan, Italy. [Purcell, Shaun] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MD USA. [Eifert, Sandra] Univ Munich, Herzchirurg Klin & Poliklin, Munich, Germany. [Braund, Peter S.; Samani, Nilesh J.] Univ Leicester, Dept Cardiovasc Sci, Glenfield Hosp, Leicester, Leics, England. [Balmforth, Anthony J.; Ball, Stephen G.; Hall, Alistair S.] Univ Leeds, MCRC, LIGHT, Leeds, W Yorkshire, England. [Ouwehand, Willem H.] Univ Cambridge, Dept Haematol, Cambridge, England. [Ouwehand, Willem H.] NHS Blood & Transplant, Cambridge, England. [Ouwehand, Willem H.; Deloukas, Panos; Peltonen, Leena] Wellcome Trust Sanger Inst, Cambridge, England. [Scholz, Michael] Trium Anal Online GmbH, Munich, Germany. [Cambien, Francois] Univ Paris 06, INSERM, UMRS 936, Paris, France. [Scheffold, Thomas] Univ Witten Herdecke, Inst Heart & Circulat Res, Dortmund, Germany. [Granger, Christopher B.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Peltonen, Leena] Univ Helsinki, Inst Mol Med, Helsinki, Finland. [Melander, Olle] Lund Univ, Dept Clin Sci Hypertens & Cardiovasc Dis, Malmo Univ Hosp, Malmo, Sweden. [Engert, James C.] McGill Univ, Dept Med, Montreal, PQ, Canada. [O'Donnell, Christopher J.] NHLBI, Framingham, MA USA. [O'Donnell, Christopher J.] Framingham Heart Dis Epidemiol Study, Framingham, MA USA. [Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Spertus, John A.] Univ Missouri, Kansas City, MO 64110 USA. RP Assimes, TL (reprint author), Stanford Univ, Sch Med, Dept Med, Hlth Sci Bldg, Stanford, CA 94304 USA. EM tassimes@stanford.edu RI Ramos , Rafel/D-9627-2016; Martinelli, Nicola/J-5622-2016; Konig, Inke/A-4544-2009; Erdmann, Jeanette/A-4417-2009; Erdmann, Jeanette/P-7513-2014; Altshuler, David/A-4476-2009; Schreiber, Stefan/B-6748-2008; Willenborg, Christina/D-2668-2012; Lucas, Gavin/D-4346-2012; Deloukas, Panos/B-2922-2013; Meisinger, Christine/B-5358-2014; Granger, Christopher/D-3458-2014; Duga, Stefano/F-8173-2014; Voight, Benjamin/F-1775-2011; Stark, Klaus/D-3813-2009; Wilson, Alexander/C-2320-2009; Lieb, Wolfgang/C-1990-2012; Morgan, Tom/C-3478-2012 OI Ziegler, Andreas/0000-0002-8386-5397; Duga, Stefano/0000-0003-3457-1410; Suktitipat, Bhoom/0000-0001-8034-7757; Marrugat, Jaume/0000-0003-3320-554X; Vaidya, Dhananjay/0000-0002-7164-1601; Ouwehand, Willem/0000-0002-7744-1790; Ramos , Rafel/0000-0001-8146-5288; Martinelli, Nicola/0000-0001-6465-5119; Malerba, Giovanni/0000-0001-8705-8560; Ramos , Rafel/0000-0001-7970-5537; Asselta, Rosanna/0000-0001-5351-0619; Meisinger, Christa/0000-0002-9026-6544; ELOSUA, ROBERTO/0000-0001-8235-0095; Erdmann, Jeanette/0000-0002-4486-6231; Altshuler, David/0000-0002-7250-4107; Schreiber, Stefan/0000-0003-2254-7771; Willenborg, Christina/0000-0001-5217-6882; Deloukas, Panos/0000-0001-9251-070X; Granger, Christopher/0000-0002-0045-3291; Stark, Klaus/0000-0002-7832-1942; FU German Migraine & Headache Society (DMKG); AstraZeneca; Berlin Chemie; Boots Healthcare; GlaxoSmithKline; McNeil Pharma (former Woelm Pharma); MSD Sharp Dohme; Pfizer; Alnylam; Merck; Daiichi Sankyo; Novartis; Medtronic FX The collection of clinical and sociodemographic data in the Dortmund Health Study was supported by the German Migraine & Headache Society (DMKG) and by unrestricted grants of equal share from AstraZeneca, Berlin Chemie, Boots Healthcare, GlaxoSmithKline, McNeil Pharma (former Woelm Pharma), MSD Sharp & Dohme and Pfizer to the University of Muenster. Recruitment of the Medstar sample was supported by a research grant from GlaxoSmithKline and genotyping of the PennCATH and Medstar samples was supported by GlaxoSmithKline. Drs. Holm, Thorleifsson, Thorsteinsdottir, and Stefansson are employees of deCODE genetics, a for-profit company that develops SNP based diagnostic tests for various diseases including coronary artery disease. Drs. Mooser, Walker, and Waterworth are employees of GlaxoSmithKline. Dr. Knouff was employed at GlaxoSmithKline at the time data were generated for this manuscript. Dr. Altshuler has received research funds from Pfizer. Dr. Kathiresan has received consulting fees from Pfizer, Alnylam, Merck, Daiichi Sankyo, and Novartis. Dr. Reilly has received research funds from Merck. Dr. Shah has received research funds from Medtronic. All other authors have reported that they have no relationships to disclose. NR 48 TC 51 Z9 53 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 2 PY 2010 VL 56 IS 19 BP 1552 EP 1563 DI 10.1016/j.jacc.2010.06.022 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 671UX UT WOS:000283538000005 PM 20933357 ER PT J AU Arciniegas, DB Beresford, TP AF Arciniegas, David B. Beresford, Thomas P. TI Managing difficult interactions with patients in neurology practices A practical approach SO NEUROLOGY LA English DT Article ID PRIMARY-CARE; DEMENTIA; PSYCHOPATHOLOGY; PREVALENCE; OUTCOMES C1 [Arciniegas, David B.; Beresford, Thomas P.] Univ Colorado, Sch Med, Neurobehav Disorders Program, Dept Psychiat, Aurora, CO 80045 USA. [Arciniegas, David B.] Univ Colorado, Sch Med, Behav Neurol Sect, Dept Neurol, Aurora, CO 80045 USA. [Beresford, Thomas P.] Denver Vet Affairs Med Ctr, Psychiat Serv, Denver, CO USA. RP Arciniegas, DB (reprint author), Univ Colorado, Sch Med, Neurobehav Disorders Program, Dept Psychiat, 13001 E 17th Pl,Campus Box F546, Aurora, CO 80045 USA. EM David.Arciniegas@UCDenver.edu FU Neuropsychiatry; American Psychiatric Publishing, Inc.; Demos Medical Publishing; Orasi Medical, Inc.; National Institute of Mental Health (NIMH) [R01 MH081920-01A1]; National Institute of Child Health and Human Development (NICHD) [R01 HD047242-04, R01 HD047242-04S1]; Department of Defense [W81XWH-08-2-0652, A-15306]; National Institute on Aging (NIA) [R21 AG028609-01]; Henry M. Jackson Foundation; National Institute on Alcohol Abuse and Alcoholism [5R21AA016294] FX Dr. Arciniegas serves as an Associate Editor for Journal of Neuropsychiatry and Clinical Neurosciences and Neuropsychiatric Disease and Treatment, serves as an Editorial Board Member for The Open Psychiatry Journal, Brain Injury, Neurotrauma Letter, serves as Guest Editor for NeuroRehabilitation, and serves as International Editorial Board Member for Archivos de Neurociencias; receives publishing royalties from Neuropsychiatry: An Introductory Approach (Cambridge University Press, 2001), Clinical Manual for the Management of Adults with Traumatic Brain Injuries (American Psychiatric Publishing, Inc., 2010-prepublication royalties), and Brain Injury Medicine, 2nd edition (Demos Medical Publishing, 2010-prepublication royalties); receives research support from Orasi Medical, Inc.; receives research support from National Institute of Mental Health (NIMH R01 MH081920-01A1 [Coinvestigator]), National Institute of Child Health and Human Development (NICHD R01 HD047242-04 [Site Principal Investigator], NICHD R01 HD047242-04S1 [Site Principal Investigator]), Department of Defense (W81XWH-08-2-0652 [Consultant]), National Institute on Aging (NIA R21 AG028609-01 [Coinvestigator]); and receives research support from Henry M. Jackson Foundation. Dr. Beresford served as editorial board member for Alcohol & Alcoholism; received royalties from publishing Neuropsychiatry: An Introductory Approach, Cambridge University Press; received honoraria from speaking engagements or educational activities from Bristol Meyers Squibb; and receives research support from Department of Defense [A-15306 (Principal Investigator)] and National Institute on Alcohol Abuse and Alcoholism [5R21AA016294 (Principal Investigator)]. NR 21 TC 4 Z9 4 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 2 PY 2010 VL 75 IS 18 SU 1 BP S39 EP S44 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 690KH UT WOS:000285003200008 PM 21041770 ER PT J AU Corboy, JR Gross, RA AF Corboy, John R. Gross, Robert A. TI Clinical perspective for the practicing neurologist A new journal? SO NEUROLOGY LA English DT Editorial Material C1 [Corboy, John R.] Univ Colorado, Dept Neurol, Denver, CO 80202 USA. [Corboy, John R.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Gross, Robert A.] Univ Rochester, Med Ctr, Strong Epilepsy Ctr, Rochester, NY 14642 USA. RP Corboy, JR (reprint author), Univ Colorado, 12631 E 17th Ave,B185, Aurora, CO 80045 USA. EM john.corboy@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 2 PY 2010 VL 75 IS 18 SU 1 BP S1 EP S1 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 690KH UT WOS:000285003200001 ER PT J AU Miravalle, A Corboy, JR AF Miravalle, Augusto Corboy, John R. TI Therapeutic options in multiple sclerosis Five new things SO NEUROLOGY LA English DT Article ID CEREBROSPINAL VENOUS INSUFFICIENCY; STEM-CELL TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; AUTOIMMUNE ENCEPHALOMYELITIS; ORAL FINGOLIMOD; JC VIRUS; INTERFERON; DISEASE; FLUID; REMYELINATION C1 [Miravalle, Augusto; Corboy, John R.] Univ Colorado, Dept Neurol, Denver, CO 80202 USA. [Corboy, John R.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Miravalle, A (reprint author), 12631 E 17th Ave,B185, Aurora, CO 80045 USA. EM augusto.miravalle@ucdenver.edu FU Novartis; BioMS Medical; Orasi Medical Inc.; NIH/NINDS [1UO1NS4571901A1]; National MS Society FX Dr. Miravalle serves as a consultant for Bayer Schering Pharma, EMD Serono, Inc., Advanced Studies in Medicine (ASiM), and Novartis. Dr. Corboy serves as Editor for Neurology (R) Clinical Practice and as Section Editor for Neurology Today; serves as a consultant for Bayer Schering Pharma, EMD Serono, Inc., Advanced Studies in Medicine (ASiM), and Novartis; has received research support from Novartis, BioMS Medical, Orasi Medical Inc., the NIH/NINDS (1UO1NS4571901A1 [PI]), and the National MS Society; and has reviewed files and given expert testimony in medico-legal cases. He is a part-time employee of the Denver Veterans Medical Center. NR 35 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 2 PY 2010 VL 75 IS 18 SU 1 BP S22 EP S26 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 690KH UT WOS:000285003200005 PM 21041767 ER PT J AU Wei, XL Dombkowski, D Meirelles, K Pieretti-Vanmarcke, R Szotek, PP Chang, HL Preffer, FI Mueller, PR Teixeira, J MacLaughlin, DT Donahoe, PK AF Wei, Xiaolong Dombkowski, David Meirelles, Katia Pieretti-Vanmarcke, Rafael Szotek, Paul P. Chang, Henry L. Preffer, Frederic I. Mueller, Peter R. Teixeira, Jose MacLaughlin, David T. Donahoe, Patricia K. TI Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE anthrapyrazolone; chemotherapy resistance; stem/progenitor cell-enriched populations ID DRUG EFFLUX CAPACITY; STEM-CELLS; SIDE POPULATION; COLORECTAL-CANCER; II RECEPTOR; PROGNOSTIC-SIGNIFICANCE; BORDERLINE TUMORS; FALLOPIAN-TUBE; MARKERS CD133; IN-VIVO AB Cancer stem cells are proposed to be tumor-initiating cells capable of tumorigenesis, recurrence, metastasis, and drug resistance, and, like somatic stem cells, are thought to be capable of unlimited self-renewal and, when stimulated, proliferation and differentiation. Here we select cells by expression of a panel of markers to enrich for a population with stem cell-like characteristics. A panel of eight was initially selected from 95 human cell surface antigens as each was shared among human ovarian primary cancers, ovarian cancer cell lines, and normal fimbria. A total of 150 combinations of markers were reduced to a panel of three-CD44, CD24, and Epcam-which selected, in three ovarian cancer cell lines, those cells which best formed colonies. Cells expressing CD44, CD24, and Epcam exhibited stem cell characteristics of shorter tumor-free intervals in vivo after limiting dilution, and enhanced migration in invasion assays in vitro. Also, doxorubicin, cisplatin, and paclitaxel increased this enriched population which, conversely, was significantly inhibited by Mullerian inhibiting substance (MIS) or the MIS mimetic SP600125. These findings demonstrate that flow cytometry can be used to detect a population which shows differential drug sensitivity, and imply that treatment of patients can be individualized to target both stem/progenitor cell enriched and nonenriched subpopulations. The findings also suggest that this population, amenable to isolation by flow cytometry, can be used to screen for novel treatment paradigms, including biologic agents such as MIS, which will improve outcomes for patients with ovarian cancer. C1 [Wei, Xiaolong; Meirelles, Katia; Pieretti-Vanmarcke, Rafael; Szotek, Paul P.; Chang, Henry L.; MacLaughlin, David T.; Donahoe, Patricia K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Surg Res Labs, Boston, MA 02114 USA. [Dombkowski, David; Preffer, Frederic I.] Massachusetts Gen Hosp, Dept Pathol, Flow Cytometry Lab, Boston, MA 02114 USA. [Dombkowski, David; Preffer, Frederic I.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Mueller, Peter R.] Massachusetts Gen Hosp, Abdominal Imaging & Intervent Div, Boston, MA 02114 USA. [Teixeira, Jose] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA. RP Wei, XL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Surg Res Labs, Boston, MA 02114 USA. EM xwei2@partners.org; pdonahoe@partners.org OI Teixeira, Jose/0000-0002-6438-5064 FU Massachusetts General Hospital Executive Committee; National Institutes of Health [R01 CA17393]; Harvard Stem Cell Institute; Ovarian Cancer Foundation FX We thank Caroline Coletti for excellent editorial support. This work was supported by a Massachusetts General Hospital Executive Committee on Research Award for Medical Discovery (to X.W.), National Institutes of Health Grant R01 CA17393 (to P.K.D. and D.T.M.), Harvard Stem Cell Institute (P.K.D.), Ovarian Cancer Foundation (D.T.M.), and gifts from Commons Development, the McBride Family Foundation, the Austen Foundation, and the Surdna-Gar Foundation. NR 62 TC 46 Z9 48 U1 2 U2 7 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 2 PY 2010 VL 107 IS 44 BP 18874 EP 18879 DI 10.1073/pnas.1012667107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 674MJ UT WOS:000283749000028 PM 20952655 ER PT J AU Gao, YJ Xiao, QA Ma, HM Li, L Liu, J Feng, Y Fang, ZY Wu, J Han, XK Zhang, JH Sun, YH Wu, GW Padera, R Chen, HQ Wong, KK Ge, GX Ji, HB AF Gao, Yijun Xiao, Qian Ma, HuiMin Li, Li Liu, Jun Feng, Yan Fang, Zhaoyuan Wu, Jing Han, Xiangkun Zhang, Junhua Sun, Yihua Wu, Gongwei Padera, Robert Chen, Haiquan Wong, Kwok-kin Ge, Gaoxiang Ji, Hongbin TI LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID PEUTZ-JEGHERS-SYNDROME; TARGETED THERAPIES; TUMOR-SUPPRESSOR; BREAST-CANCER; MUTATIONS; METASTASIS; ADENOCARCINOMA; SPECIFICITY; PHENOTYPE; PATHWAYS AB LKB1 loss-of-function mutations, observed in similar to 30% of human lung adenocarcinomas, contribute significantly to lung cancer malignancy progression. We show that lysyl oxidase ( LOX), negatively regulated by LKB1 through mTOR-HIF-1 alpha signaling axis, mediates lung cancer progression. Inhibition of LOX activity dramatically alleviates lung cancer malignancy progression. Up-regulated LOX expression triggers excess collagen deposition in Lkb1-deficient lung tumors, and thereafter results in enhanced cancer cell proliferation and invasiveness through activation of beta 1 integrin signaling. High LOX level and activity correlate with poor prognosis and metastasis. Our findings provide evidence of how LKB1 loss of function promotes lung cancer malignancy through remodeling of extracellular matrix microenvironment, and identify LOX as a potential target for disease treatment in lung cancer patients. C1 [Xiao, Qian; Ma, HuiMin; Liu, Jun; Wu, Jing; Ge, Gaoxiang] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China. [Gao, Yijun; Li, Li; Feng, Yan; Fang, Zhaoyuan; Han, Xiangkun; Wu, Gongwei; Ji, Hongbin] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China. [Zhang, Junhua; Sun, Yihua; Chen, Haiquan] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Dept Thorac Surg, Shanghai 200032, Peoples R China. [Zhang, Junhua; Sun, Yihua; Chen, Haiquan] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China. [Padera, Robert] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Wong, Kwok-kin] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Ge, GX (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China. EM gxge@sibs.ac.cn; hbji@sibs.ac.cn OI wong, kwok kin/0000-0001-6323-235X FU National Basic Research Program of China [2010CB912102, 2010CB529703]; National Natural Science Foundation of China [30740084, 30871284, 30971495]; Chinese Academy of Sciences [2008KIP101, 2008KIP102]; Science and Technology Commission of Shanghai Municipality [08PJ14105] FX The authors acknowledge Drs. William Kaelin (Boston), Celeste Simon (Philadelphia), Caroline Damsky (San Francisco), Charles Shanley (Royal Oak, MI), Jianfeng Chen (Shanghai, China), Jun-Lin Guan (Ann Arbor, MI), Jing Fang (Shanghai, China), Larry Fisher (Bethesda), and Liang Chen (Boston) for sharing reagents; Dr. Tyler Jacks (Cambridge, MA) for providing the KrasG12D mice; Drs. Dangsheng Li, Lei Zhang, Jun-Lin Guan, Xiaofan Wang, and Steve Weiss for invaluable comments on the manuscript; and Ye Wang, Feng Liu, Wei Bian, Xiaoyan Wang, and Fei Li for technical support. This work was supported by National Basic Research Program of China Grants 2010CB912102 and 2010CB529703, National Natural Science Foundation of China Grants 30740084, 30871284, and 30971495, Chinese Academy of Sciences Grants 2008KIP101 and 2008KIP102, and Science and Technology Commission of Shanghai Municipality Grant 08PJ14105. H.J. and G.G. are scholars of the Hundred Talents Program of the Chinese Academy of Sciences. NR 30 TC 65 Z9 76 U1 1 U2 11 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 2 PY 2010 VL 107 IS 44 BP 18892 EP 18897 DI 10.1073/pnas.1004952107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 674MJ UT WOS:000283749000031 PM 20956321 ER PT J AU Serwold, T Hochedlinger, K Swindle, J Hedgpeth, J Jaenisch, R Weissman, IL AF Serwold, Thomas Hochedlinger, Konrad Swindle, John Hedgpeth, Joe Jaenisch, Rudolf Weissman, Irving L. TI T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE induced pluripotent stem cells; lymphoma; notch; receptor-mediated leukemogenesis; T cell receptor ID PLURIPOTENT STEM-CELLS; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN PERIPHERAL-BLOOD; LYMPHOCYTE-ACTIVATION; NUCLEAR TRANSFER; CLONED MICE; LEUKEMOGENESIS; CALCINEURIN; EXPRESSION; BINDING AB The conversion of mature somatic cells into pluripotent stem cells, both by nuclear transfer and transduction with specific "reprogramming" genes, represents a major advance in regenerative medicine. Pluripotent stem cell lines can now be generated from an individual's own cells, facilitating the generation of immunologically acceptable stem cell-based therapeutics. Many cell types can undergo nuclear reprogramming, leading to the question of whether the identity of the reprogrammed cell of origin has a biological consequence. Peripheral blood, containing a mixture of T, B, NK, and myeloid cell types, represents one potential source of reprogrammable cells. In this study, we describe the unique case of mice derived from a reprogrammed T cell. These mice have prerearranged T-cell receptor (TCR) genes in all cells. Surprisingly, approximate to 50% of mice with prerearranged TCR genes develop spontaneous T cell lymphomas, which originate in the thymus. The lymphomas arise from developing T cells, and contain activated Notch1, similar to most human and mouse T-cell acute lymphoblastic lymphomas. Furthermore, lymphomagenesis requires the expression of both prerearranged TCR alpha and TCR beta genes, indicating a critical role for TCR signaling. Furthermore, inhibitors of multiple branches of TCR signaling suppress lymphoma growth, implicating TCR signaling as an essential component in lymphoma proliferation. The lymphomagenesis in mice derived from a reprogrammed T cell demonstrates the deleterious consequences of misregulation of the TCR rearrangement and signaling pathways and illustrates one case of cellular reprogramming where the identity of the cell of origin has profound consequences. C1 [Serwold, Thomas] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. [Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Canc, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Boston, MA 02114 USA. [Swindle, John; Hedgpeth, Joe] Complegen Inc, Seattle, WA 98104 USA. [Jaenisch, Rudolf] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Weissman, Irving L.] Stanford Univ, Stanford Inst Stem Cell Biol & Regenerat Med, Ctr Canc, Stanford, CA 94305 USA. RP Serwold, T (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. EM thomas.serwold@joslin.harvard.edu; irv@stanford.edu FU California Institute of Regenerative Medicine; Leukemia and Lymphoma Research Foundation; Smith Family FX We acknowledge Christina Muscat for antibody conjugations, Libuse Jerabek for managing the laboratory, Andrew T. Girvin (Stanford University, CA) for the NFAT-eGFP retroviral construct, and Matthew Inlay for comments on the manuscript. The research in this manuscript was supported by funds from the California Institute of Regenerative Medicine, by the de Villiers award of the Leukemia and Lymphoma Research Foundation, and by the Smith Family Fund (all to I.L.W.). NR 43 TC 22 Z9 22 U1 0 U2 6 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 2 PY 2010 VL 107 IS 44 BP 18939 EP 18943 DI 10.1073/pnas.1013230107 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 674MJ UT WOS:000283749000039 PM 20956329 ER PT J AU Hagmann, P Sporns, O Madan, N Cammoun, L Pienaar, R Wedeen, VJ Meuli, R Thiran, JP Grant, PE AF Hagmann, P. Sporns, O. Madan, N. Cammoun, L. Pienaar, R. Wedeen, V. J. Meuli, R. Thiran, J-P Grant, P. E. TI White matter maturation reshapes structural connectivity in the late developing human brain SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE connectome; development; graph; network dynamics; tractography ID STATE FUNCTIONAL CONNECTIVITY; HUMAN CEREBRAL-CORTEX; WATER DIFFUSION; NERVOUS-SYSTEM; RANDOM NETWORKS; DEFAULT MODE; MYELINATION; MR; PLASTICITY; ANISOTROPY AB From toddler to late teenager, the macroscopic pattern of axonal projections in the human brain remains largely unchanged while undergoing dramatic functional modifications that lead to network refinement. These functional modifications are mediated by increasing myelination and changes in axonal diameter and synaptic density, as well as changes in neurochemical mediators. Here we explore the contribution of white matter maturation to the development of connectivity between ages 2 and 18 y using high b-value diffusion MRI tractography and connectivity analysis. We measured changes in connection efficacy as the inverse of the average diffusivity along a fiber tract. We observed significant refinement in specific metrics of network topology, including a significant increase in node strength and efficiency along with a decrease in clustering. Major structural modules and hubs were in place by 2 y of age, and they continued to strengthen their profile during subsequent development. Recording resting-state functional MRI from a subset of subjects, we confirmed a positive correlation between structural and functional connectivity, and in addition observed that this relationship strengthened with age. Continuously increasing integration and decreasing segregation of structural connectivity with age suggests that network refinement mediated by white matter maturation promotes increased global efficiency. In addition, the strengthening of the correlation between structural and functional connectivity with age suggests that white matter connectivity in combination with other factors, such as differential modulation of axonal diameter and myelin thickness, that are partially captured by inverse average diffusivity, play an increasingly important role in creating brain-wide coherence and synchrony. C1 [Hagmann, P.; Meuli, R.] Univ Hosp Ctr, Dept Radiol, CH-1011 Lausanne, Switzerland. [Hagmann, P.; Meuli, R.] Univ Lausanne, CH-1011 Lausanne, Switzerland. [Hagmann, P.; Cammoun, L.; Thiran, J-P] Ecole Polytech Fed Lausanne, Signal Proc Lab 5, CH-1015 Lausanne, Switzerland. [Sporns, O.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA. [Madan, N.] Tufts Med Ctr, Dept Radiol, Boston, MA 02111 USA. [Pienaar, R.; Grant, P. E.] Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA. [Pienaar, R.; Grant, P. E.] Childrens Hosp, Dept Radiol, Boston, MA 02115 USA. [Wedeen, V. J.; Grant, P. E.] Massachusetts Gen Hosp Harvard, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA. RP Hagmann, P (reprint author), Univ Hosp Ctr, Dept Radiol, CH-1011 Lausanne, Switzerland. EM patric.hagmann@epfl.ch RI Sporns, Olaf/A-1667-2010; Bullmore, Edward/C-1706-2012; OI Sporns, Olaf/0000-0001-7265-4036; Bullmore, Edward/0000-0002-8955-8283; Thiran, Jean-Philippe/0000-0003-2938-9657 FU Swiss National Science Foundation; Department of Radiology of University Hospital Center and University of Lausanne; National Institutes of Health; J. S. McDonnell Foundation FX We thank Randy Buckner and Thomas Benner for helpful advice on planning the resting-state protocol and the diffusion scans, respectively. This work was financially supported by the Swiss National Science Foundation, the Department of Radiology of University Hospital Center and University of Lausanne, the National Institutes of Health, and the J. S. McDonnell Foundation. NR 58 TC 206 Z9 208 U1 6 U2 43 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 2 PY 2010 VL 107 IS 44 BP 19067 EP 19072 DI 10.1073/pnas.1009073107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 674MJ UT WOS:000283749000060 PM 20956328 ER PT J AU Miraoui, H Marie, PJ AF Miraoui, Hichem Marie, Pierre J. TI Fibroblast Growth Factor Receptor Signaling Crosstalk in Skeletogenesis SO SCIENCE SIGNALING LA English DT Review ID LIGAND-BINDING SPECIFICITY; APERT-SYNDROME; OSTEOBLAST DIFFERENTIATION; BONE-FORMATION; TYROSINE KINASES; STRUCTURAL BASIS; MOUSE MODEL; CRANIOSYNOSTOSIS; FGF; MUTATIONS AB Fibroblast growth factors (FGFs) play important roles in the control of embryonic and postnatal skeletal development by activating signaling through FGF receptors (FGFRs). Germline gain-of-function mutations in FGFR constitutively activate FGFR signaling, causing chondrocyte and osteoblast dysfunctions that result in skeletal dysplasias. Crosstalk between the FGFR pathway and other signaling cascades controls skeletal precursor cell differentiation. Genetic analyses revealed that the interplay of WNT and FGFR1 determines the fate and differentiation of mesenchymal stem cells during mouse craniofacial skeletogenesis. Additionally, interactions between FGFR signaling and other receptor tyrosine kinase networks, such as those mediated by the epidermal growth factor receptor and platelet-derived growth factor receptor, were associated with excessive osteoblast differentiation and bone formation in the human skeletal dysplasia called craniosynostosis, which is a disorder of skull development. We review the roles of FGFR signaling and its crosstalk with other pathways in controlling skeletal cell fate and discuss how this crosstalk could be pharmacologically targeted to correct the abnormal cell phenotype in skeletal dysplasias caused by aberrant FGFR signaling. C1 [Marie, Pierre J.] Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol,UMR606, F-75475 Paris 10, France. [Miraoui, Hichem; Marie, Pierre J.] Univ Paris Diderot, F-75475 Paris 10, France. [Miraoui, Hichem] Massachusetts Gen Hosp, Dept Internal Med, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA. [Miraoui, Hichem] Massachusetts Gen Hosp, Dept Internal Med, Reprod Endocrine Unit, Boston, MA 02114 USA. RP Marie, PJ (reprint author), Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol,UMR606, 2 Rue Ambroise Pare, F-75475 Paris 10, France. EM pierre.marie@inserm.fr NR 60 TC 41 Z9 41 U1 2 U2 7 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1937-9145 J9 SCI SIGNAL JI Sci. Signal. PD NOV 2 PY 2010 VL 3 IS 146 AR re9 DI 10.1126/scisignal.3146re9 PG 5 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 674IT UT WOS:000283734500001 PM 21045207 ER PT J AU Nugent, N Amstadter, A Yang, BZ Knopik, V Saxe, G Smoller, J Moorjan, P Haddad, S Basu, A Siburian, R Fagerness, J Koenen, K AF Nugent, Nicole Amstadter, Ananda Yang, Bao-Zhu Knopik, Valerie Saxe, Glenn Smoller, Jordan Moorjan, Priya Haddad, Stephan Basu, Aditi Siburian, Richie Fagerness, Jessen Koenen, Karestan TI Gene-environment interactions in response to trauma: HTR1a, parent posttraumatic stress symptoms, and trajectories of posttraumatic stress symptoms in pediatric injury patients SO BEHAVIOR GENETICS LA English DT Meeting Abstract CT 40th Annual Meeting of Behavior-Genetics-Association CY MAY, 2009 CL State Coll, Pennsylvania, PA SP Behavior Genet Assoc HO State Coll C1 [Nugent, Nicole] Alpert Brown Univ, Providence, RI USA. [Amstadter, Ananda] Med Univ S Carolina, Charleston, SC USA. [Saxe, Glenn] Boston Childrens Hosp, Boston, MA USA. [Smoller, Jordan; Koenen, Karestan] Harvard Univ, Cambridge, MA 02138 USA. [Yang, Bao-Zhu] Yale Univ, New Haven, CT 06520 USA. [Moorjan, Priya; Haddad, Stephan; Basu, Aditi; Siburian, Richie; Fagerness, Jessen] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-8244 J9 BEHAV GENET JI Behav. Genet. PD NOV PY 2010 VL 40 IS 6 SI SI BP 807 EP 808 PG 2 WC Behavioral Sciences; Genetics & Heredity; Psychology, Multidisciplinary SC Behavioral Sciences; Genetics & Heredity; Psychology GA 686KW UT WOS:000284696200087 ER PT J AU Balakrishnan, A Stearns, AT Rhoads, DB Ashley, SW Tavakkolizadeh, A AF Balakrishnan, Anita Stearns, Adam T. Rhoads, David B. Ashley, Stanley W. Tavakkolizadeh, Ali TI Microrna mir-125a modulates post-resection intestinal apoptosis via downregulation of pro-survival Bcl2 family member MCL1 SO BRITISH JOURNAL OF SURGERY LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Academic-and-Research-Surgeons CY JAN 06-07, 2010 CL Royal Free Hosp, London, ENGLAND SP Soc Acad Res Surg HO Royal Free Hosp C1 [Balakrishnan, Anita; Stearns, Adam T.; Ashley, Stanley W.; Tavakkolizadeh, Ali] Brigham & Womens Hosp, Boston, MA 02115 USA. [Balakrishnan, Anita; Stearns, Adam T.; Rhoads, David B.; Ashley, Stanley W.; Tavakkolizadeh, Ali] Harvard Univ, Sch Med, Boston, MA USA. [Rhoads, David B.] MassGen Hosp Children, Boston, MA USA. OI Stearns, Adam/0000-0003-4327-7360 NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0007-1323 J9 BRIT J SURG JI Br. J. Surg. PD NOV PY 2010 VL 97 SU 6 BP 29 EP 29 PG 1 WC Surgery SC Surgery GA 686TI UT WOS:000284718200080 ER PT J AU Stearns, AT Balakrishnan, A Radmanesh, A Rhoads, DB Ashley, SW Tavakkolizadeh, A AF Stearns, Adam T. Balakrishnan, Anita Radmanesh, Alireza Rhoads, David B. Ashley, Stanley W. Tavakkolizadeh, Ali TI Contribution of afferent and efferent vagal fibers to diet-induced obesity SO BRITISH JOURNAL OF SURGERY LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Academic-and-Research-Surgeons CY JAN 06-07, 2010 CL Royal Free Hosp, London, ENGLAND SP Soc Acad Res Surg HO Royal Free Hosp C1 [Stearns, Adam T.; Balakrishnan, Anita; Radmanesh, Alireza; Ashley, Stanley W.; Tavakkolizadeh, Ali] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA. [Stearns, Adam T.] Univ Oxford, Dept Physiol, Oxford, England. [Balakrishnan, Anita] Univ Liverpool, Sch Clin Sci, Liverpool L69 3BX, Merseyside, England. [Rhoads, David B.] Harvard Univ, Sch Med, MassGen Hosp Children, Pediat Endocrine Unit, Boston, MA USA. OI Stearns, Adam/0000-0003-4327-7360 NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0007-1323 J9 BRIT J SURG JI Br. J. Surg. PD NOV PY 2010 VL 97 SU 6 BP 29 EP 29 PG 1 WC Surgery SC Surgery GA 686TI UT WOS:000284718200082 ER PT J AU Chen, L Janne, PA Jackman, DM Ortiz, T Johnson, BE Joshi, VA Lindeman, NI AF Chen, L. Janne, P. A. Jackman, D. M. Ortiz, T. Johnson, B. E. Joshi, V. A. Lindeman, N. I. TI Dideoxyterminator Sanger Sequence Analysis of EGFR KRAS BRAF PIK3CA and ERBB2 in Consecutive Advanced Stage Non Small Cell Lung Carcinomas (NSCLC) SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Molecular-Pathology CY NOV 18-20, 2010 CL San Jose, CA SP Assoc Mol Pathol C1 [Chen, L.; Lindeman, N. I.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Janne, P. A.; Jackman, D. M.; Ortiz, T.; Johnson, B. E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Joshi, V. A.] Partners Ctr Personalized Genet Med, Cambridge, MA USA. [Lindeman, N. I.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 1525-1578 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2010 VL 12 IS 6 BP 904 EP 904 PG 1 WC Pathology SC Pathology GA 677FE UT WOS:000283973700225 ER PT J AU Freeman, EW Anderson, GL Caan, BJ Caldwell, SA Carpenter, JS Cohen, LS Ensrud, K Guthrie, KA Joffe, H LaCroix, AZ Newton, KM Parrott, E Reed, SD Sherman, S Sternfeld, B AF Freeman, Ellen W. Anderson, Garnet L. Caan, Bette J. Caldwell, Sheila A. Carpenter, Janet S. Cohen, Lee S. Ensrud, Kristine Guthrie, Katherine A. Joffe, Hadine LaCroix, Andrea Z. Newton, Katherine M. Parrott, Estella Reed, Susan D. Sherman, Sheryl Sternfeld, Barbara CA MsFLASH Investigator Grp TI Efficacy of Escitalopram for Menopausal Hot Flashes: A Randomized Controlled Trial in the MsFlash Network SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Meeting Abstract CT 21st Annual Meeting of the North-American-Menopause-Society CY OCT 06-09, 2010 CL Chicago, IL SP N Amer Menopause Soc C1 [Freeman, Ellen W.] Univ Penn, Philadelphia, PA 19104 USA. [Cohen, Lee S.; Joffe, Hadine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Anderson, Garnet L.; Guthrie, Katherine A.; LaCroix, Andrea Z.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Sherman, Sheryl; MsFLASH Investigator Grp] NIA, Bethesda, MD 20892 USA. [Ensrud, Kristine] Univ Minnesota, Minneapolis, MN USA. [Caan, Bette J.; Sternfeld, Barbara] Kaiser Permanente No Calif, Oakland, CA USA. [Carpenter, Janet S.] Indiana Univ, Indianapolis, IN 46204 USA. [Newton, Katherine M.; Reed, Susan D.] Grp Hlth Res Inst, Seattle, WA USA. [Reed, Susan D.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Parrott, Estella] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Caldwell, Sheila A.] Natl Ctr Complementary & Alternat Med, Bethesda, MD USA. [Ensrud, Kristine] Minneapolis VAMC, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD NOV-DEC PY 2010 VL 17 IS 6 BP 1217 EP 1217 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 677LK UT WOS:000283993700056 ER PT J AU Janne, P AF Jaenne, P. TI Resistance to targeted therapy: mechanisms and therapeutic implications SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Jaenne, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 9 EP 9 DI 10.1016/S1359-6349(10)71705-5 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100009 ER PT J AU Piccart, M Dinh, P Bedard, P Sotiriou, C Baselga, J Fumagalli, D Bradbury, I Gelber, R Loi, S AF Piccart, M. Dinh, P. Bedard, P. Sotiriou, C. Baselga, J. Fumagalli, D. Bradbury, I. Gelber, R. Loi, S. TI The Neo BIG programme SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Dinh, P.; Fumagalli, D.] Inst Jules Bordet, BIG, B-1000 Brussels, Belgium. [Bedard, P.] Princess Margaret Hosp, Div Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada. [Baselga, J.] Vall dHebron Univ Hosp, Barcelona, Spain. [Bradbury, I.] Frontier Sci Ltd UK, Inverness, Scotland. [Gelber, R.] Dana Farber Canc Inst, Div Biostatist & Epidemiol, Boston, MA 02115 USA. RI Loi, Sherene/H-1979-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 16 EP 16 DI 10.1016/S1359-6349(10)71721-3 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100023 ER PT J AU Patnaik, A Courtney, K Signoretti, S Loda, M Grant, A Pedrosa, I Lunsford, E Frangioni, J Pandolfi, P Cantley, L AF Patnaik, A. Courtney, K. Signoretti, S. Loda, M. Grant, A. Pedrosa, I. Lunsford, E. Frangioni, J. Pandolfi, P. Cantley, L. TI Targeting the PI3K/mTOR pathway in genetically engineered mouse models of advanced prostate cancer SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Patnaik, A.; Grant, A.; Pedrosa, I.; Lunsford, E.; Frangioni, J.; Pandolfi, P.; Cantley, L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Courtney, K.; Signoretti, S.; Loda, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Patnaik, A.; Courtney, K.; Signoretti, S.; Loda, M.; Grant, A.; Pedrosa, I.; Frangioni, J.; Pandolfi, P.; Cantley, L.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 18 EP 19 DI 10.1016/S1359-6349(10)71731-6 PG 2 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100031 ER PT J AU Matulonis, U Hirsch, M Liu, J Hahn, W AF Matulonis, U. Hirsch, M. Liu, J. Hahn, W. TI Mutational analysis of epithelial ovarian cancer using OncoMap SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Matulonis, U.; Liu, J.; Hahn, W.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hirsch, M.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 21 EP 21 DI 10.1016/S1359-6349(10)71740-7 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100036 ER PT J AU Moellering, RE Shen, Y Wiest, OG Bradner, JE Verdine, GL AF Moellering, R. E. Shen, Y. Wiest, O. G. Bradner, J. E. Verdine, G. L. TI Computational modeling and molecular optimization of stabilized alpha-helical peptides targeting NOTCH-CSL transcriptional complexes SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Moellering, R. E.; Verdine, G. L.] Harvard Univ, Cambridge, MA 02138 USA. [Shen, Y.; Wiest, O. G.] Univ Notre Dame, South Bend, IN USA. [Bradner, J. E.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 30 EP 30 DI 10.1016/S1359-6349(10)71774-2 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100069 ER PT J AU Fairbrother, W Wong, H Budha, N Blackwood, B Gould, S Erickson, R LoRusso, P Eckhardt, SG Wagner, A Chan, I AF Fairbrother, W. Wong, H. Budha, N. Blackwood, B. Gould, S. Erickson, R. LoRusso, P. Eckhardt, S. G. Wagner, A. Chan, I. TI Pharmacokinetic-pharmacodynamic modeling of the effect of GDC-0152, a selective antagonist of the inhibitor of apoptosis (IAP) proteins, on monocyte chemotactic protein-1 (MCP-1) indicates species differences in MCP-1 response SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Fairbrother, W.] Genentech Inc, Prot Engn, San Francisco, CA 94080 USA. [Wong, H.] Genentech Inc, Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA. [Budha, N.] Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA. [Blackwood, B.; Gould, S.] Genentech Inc, Canc Signaling & Translat Oncol, San Francisco, CA 94080 USA. [Erickson, R.] Genentech Inc, Safety Assessment, San Francisco, CA 94080 USA. [LoRusso, P.] Karmanos Canc Inst, Dept Med, Detroit, MI USA. [LoRusso, P.] Karmanos Canc Inst, Dept Pharmacol, Detroit, MI USA. [Eckhardt, S. G.] Univ Colorado, Div Med Oncol, Denver, CO 80202 USA. [Wagner, A.] Dana Farber Canc Inst, Ludwig Ctr Canc Res, Boston, MA 02115 USA. [Chan, I.] Genentech Inc, Clin Sci, San Francisco, CA 94080 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 34 EP 34 DI 10.1016/S1359-6349(10)71787-0 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100082 ER PT J AU Fritz, C Lim, A Slocum, K Tunkey, C Paez, G West, K Ross, R Normant, E Sequist, L Palombella, V AF Fritz, C. Lim, A. Slocum, K. Tunkey, C. Paez, G. West, K. Ross, R. Normant, E. Sequist, L. Palombella, V. TI EML4-ALK is a sensitive client protein of Hsp90, and rearrangements of the ALK locus are associated with clinical response to IPI-504 (retaspimycin hydrochloride), a novel Hsp90 chaperone inhibitor, in patients with non-small cell lung cancer SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Fritz, C.; Lim, A.; Tunkey, C.; Paez, G.; Normant, E.] Infin Pharmaceut, Canc Biol, Cambridge, MA USA. [Slocum, K.; West, K.] Infin Pharmaceut, Pharmacol, Cambridge, MA USA. [Ross, R.] Infin Pharmaceut, Clin Oncol, Cambridge, MA USA. [Palombella, V.] Infin Pharmaceut, Drug Discovery, Cambridge, MA USA. [Sequist, L.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 69 EP 69 DI 10.1016/S1359-6349(10)71915-7 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100210 ER PT J AU Fletcher, J Rege, T Liang, C Raut, C Foley, K Flynn, D Corless, C Heinrich, M Demetri, G Wang, Y AF Fletcher, J. Rege, T. Liang, C. Raut, C. Foley, K. Flynn, D. Corless, C. Heinrich, M. Demetri, G. Wang, Y. TI Polyclonal resistance to kinase inhibition in GIST: Mechanisms and therapeutic strategies SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Fletcher, J.; Rege, T.; Liang, C.; Raut, C.; Corless, C.; Wang, Y.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Foley, K.] Synta Pharmaceut Corp, Vivo Pharmacol, Lexington, MA USA. [Flynn, D.] Deciphera Pharmaceut, Drug Dev, Lawrence, KS USA. [Heinrich, M.] Oregon Hlth & Sci Univ, Div Hematol & Oncol, Portland, OR 97201 USA. [Demetri, G.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 83 EP 83 DI 10.1016/S1359-6349(10)71958-3 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100248 ER PT J AU Solomon, B Bang, YJ Camidge, DR Iafrate, AJ Kwak, EL Maki, RG Ou, SI Salgia, R Shaw, A Clark, J AF Solomon, B. Bang, Y. J. Camidge, D. R. Iafrate, A. J. Kwak, E. L. Maki, R. G. Ou, S. I. Salgia, R. Shaw, A. Clark, J. TI Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC) SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Solomon, B.] Peter MacCallum Canc Ctr, Melbourne, Australia. [Bang, Y. J.] Seoul Natl Univ, Dept Internal Med, Seoul, South Korea. [Camidge, D. R.] Univ Colorado, Ctr Canc, Div Med Oncol, Aurora, CO USA. [Iafrate, A. J.] Massachusetts Gen Hosp, Translat Res Lab, Boston, MA 02114 USA. [Maki, R. G.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [Ou, S. I.] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA. [Salgia, R.] Univ Chicago, Ctr Canc, Hematol Oncol Sect, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 117 EP 117 DI 10.1016/S1359-6349(10)72076-0 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100363 ER PT J AU Shapiro, GI Molina, J Bendell, J Brana, I Spicer, J Kwak, E Pandya, S Millham, R Houk, B Bell-McGuinn, K AF Shapiro, G. I. Molina, J. Bendell, J. Brana, I. Spicer, J. Kwak, E. Pandya, S. Millham, R. Houk, B. Bell-McGuinn, K. TI First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Shapiro, G. I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Molina, J.] Mayo Clin, Rochester, MN USA. [Bendell, J.] Sarah Cannon Canc Res Inst, Nashville, TN USA. [Brana, I.] Val dHebron Hosp, Barcelona, Spain. [Spicer, J.] Guys Hosp, London SE1 9RT, England. [Kwak, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pandya, S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Millham, R.] Pfizer Oncol, NIA, New London, CT USA. [Houk, B.] Pfizer Oncol, NIA, La Jolla, CA USA. [Bell-McGuinn, K.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 123 EP 123 DI 10.1016/S1359-6349(10)72094-2 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100381 ER PT J AU Wagner, AJ Jayson, GC Gomez-Roca, C Zee, YK Morgan, JA Yan, Y Ware, J Mazina, KE Lauchle, J Soria, JC AF Wagner, A. J. Jayson, G. C. Gomez-Roca, C. Zee, Y. K. Morgan, J. A. Yan, Y. Ware, J. Mazina, K. E. Lauchle, J. Soria, J. C. TI A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTor inhibitor GDC-0980 administered QW SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Wagner, A. J.; Morgan, J. A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jayson, G. C.; Zee, Y. K.] Christie NHS Fdn Trust, Manchester, Lancs, England. [Gomez-Roca, C.; Soria, J. C.] Inst Cancerol Gustave Roussy, Villejuif, France. [Yan, Y.; Ware, J.; Mazina, K. E.; Lauchle, J.] Genentech Inc, GRED, San Francisco, CA 94080 USA. RI Jayson, Gordon/O-8224-2015 OI Jayson, Gordon/0000-0002-8515-8944 NR 0 TC 2 Z9 2 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 123 EP 124 DI 10.1016/S1359-6349(10)72096-6 PG 2 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100383 ER PT J AU Fairbrother, W LoRusso, P Wagner, A Budha, N Darbonne, W Shin, Y Wong, H Chan, I Ware, J Eckhardt, SG AF Fairbrother, W. LoRusso, P. Wagner, A. Budha, N. Darbonne, W. Shin, Y. Wong, H. Chan, I. Ware, J. Eckhardt, S. G. TI Phase I pharmacokinetics and pharmacodynamics of GDC-0152, a novel IAP protein antagonist, administered to patients with locally advanced or metastatic malignancies SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Fairbrother, W.] Genentech Inc, Prot Engn, San Francisco, CA 94080 USA. [LoRusso, P.] Karmanos Canc Inst, Dept Med, Detroit, MI USA. [LoRusso, P.] Karmanos Canc Inst, Dept Pharmacol, Detroit, MI USA. [Wagner, A.] Dana Farber Canc Inst, Ludwig Ctr Canc Res, Boston, MA 02115 USA. [Budha, N.; Ware, J.] Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA. [Darbonne, W.] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA. [Shin, Y.; Wong, H.] Genentech Inc, Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA. [Chan, I.] Genentech Inc, Clin Sci, San Francisco, CA 94080 USA. [Eckhardt, S. G.] Univ Colorado, Div Med Oncol, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 125 EP 125 DI 10.1016/S1359-6349(10)72100-5 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100387 ER PT J AU Vergote, I Sella, A Bedell, C Ramondetta, L Shapiro, GI Balic, K Prokopczuk, E Sauer, L Tseng, L Berger, R AF Vergote, I. Sella, A. Bedell, C. Ramondetta, L. Shapiro, G. I. Balic, K. Prokopczuk, E. Sauer, L. Tseng, L. Berger, R. TI Phase 2 study of XL184 in a cohort of ovarian cancer patients (pts) with measurable soft tissue disease SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Vergote, I.] Univ Hosp Leuven, Louvain, Belgium. [Sella, A.] Assaf Harofeh Med Ctr, Dept Oncol, IL-70300 Zerifin, Israel. [Bedell, C.] Mary Crowley Med Res Ctr, Dallas, TX USA. [Ramondetta, L.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Shapiro, G. I.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Balic, K.; Prokopczuk, E.; Sauer, L.; Tseng, L.] Exelixis Inc, San Francisco, CA USA. [Berger, R.] Chaim Sheba Med Ctr, Inst Oncol & Radiotherapy, IL-52621 Tel Hashomer, Israel. NR 0 TC 1 Z9 1 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 129 EP 129 DI 10.1016/S1359-6349(10)72114-5 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100401 ER PT J AU Aisner, J Manola, J Dakhil, S Stella, P Schiller, J AF Aisner, J. Manola, J. Dakhil, S. Stella, P. Schiller, J. TI Vandetanib, docetaxel and carboplatin followed by maintenance vandetanib or placebo in patients with stage IIIB, IV or recurrent non-small cell lung cancer (NSCLC): a randomized phase II study (PrE0502) by PrECOG, LLC (NCT006872970) SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Aisner, J.] Canc Inst New Jersey, New Brunswick, NJ USA. [Manola, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Dakhil, S.] Canc Ctr Kansas PA, Wichita, KS USA. [Stella, P.] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA. [Schiller, J.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 130 EP 130 DI 10.1016/S1359-6349(10)72117-0 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100404 ER PT J AU Bentink, S Sultana, R Rubio, R Matulonis, U Quackenbush, J AF Bentink, S. Sultana, R. Rubio, R. Matulonis, U. Quackenbush, J. TI Whole-genome sequencing and analysis of an ovarian cancer patient SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Bentink, S.; Sultana, R.; Rubio, R.; Matulonis, U.; Quackenbush, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 179 EP 180 DI 10.1016/S1359-6349(10)72276-X PG 2 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100561 ER PT J AU Clancy, MS Cleary, JM Mani, S Choy, E Wolf, MA Silverman, MH Gad, SC Cuasay, LC Dezube, BJ Shapiro, GI AF Clancy, M. S. Cleary, J. M. Mani, S. Choy, E. Wolf, M. A. Silverman, M. H. Gad, S. C. Cuasay, L. C. Dezube, B. J. Shapiro, G. I. TI ALB 109564(a), a novel tubulin inhibitor: phase 1 trial in patients with solid tumours SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Cleary, J. M.; Dezube, B. J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Cleary, J. M.; Shapiro, G. I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mani, S.] Montefiore Med Ctr, Bronx, NY 10467 USA. [Choy, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wolf, M. A.] Albany Mol Res Inc, Albany, NY USA. [Silverman, M. H.] BioStrateg Consulting Ltd, Marblehead, MA USA. [Gad, S. C.] Gad Consulting Serv Inc, Cary, NC USA. [Cuasay, L. C.] Westat Corp, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 181 EP 181 DI 10.1016/S1359-6349(10)72282-5 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100567 ER PT J AU Lyons, J Squires, M Lock, V Graham, B Smyth, T Ong, E Mahadevan, D Kwak, E Shapiro, G AF Lyons, J. Squires, M. Lock, V. Graham, B. Smyth, T. Ong, E. Mahadevan, D. Kwak, E. Shapiro, G. TI Design and validation of pharmacodynamic assays to measure the activity of the HSP90 inhibitor, AT13387 in surrogate tissue and tumor in a phase I study SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Lyons, J.; Squires, M.; Lock, V.; Graham, B.; Smyth, T.] Astex Therapeut Ltd, Translat Res, Cambridge, England. [Ong, E.; Mahadevan, D.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA. [Kwak, E.; Shapiro, G.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 187 EP 187 DI 10.1016/S1359-6349(10)72303-X PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100588 ER PT J AU Cheng, JD Tibes, R Schellens, JH Shapiro, GI Pavlick, AC Oza, AM Xu, Y Song, Y Lam, RLH Demuth, T AF Cheng, J. D. Tibes, R. Schellens, J. H. Shapiro, G. I. Pavlick, A. C. Oza, A. M. Xu, Y. Song, Y. Lam, R. L. H. Demuth, T. TI Pharmacodynamic evaluation of pCDC2 and Wee1 signature as biomarkers of target engagement for the Wee1 tyrosine kinase inhibitor MK-1775 SO EJC SUPPLEMENTS LA English DT Meeting Abstract CT 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 16-19, 2010 CL Berlin, GERMANY C1 [Cheng, J. D.; Demuth, T.] Merck & Co Inc, Clin Oncol, N Wales, PA USA. [Tibes, R.] Translat Genom Res Inst, Scottsdale, AZ USA. [Schellens, J. H.] Netherlands Canc Inst, Amsterdam, Netherlands. [Shapiro, G. I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pavlick, A. C.] NYU, New York, NY USA. [Oza, A. M.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Xu, Y.] Merck & Co Inc, Clin Pharmacol, West Point, PA USA. [Song, Y.; Lam, R. L. H.] Merck & Co Inc, Biostat, N Wales, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-6349 J9 EJC SUPPL JI EJC Suppl. PD NOV PY 2010 VL 8 IS 7 BP 202 EP 202 PG 1 WC Oncology SC Oncology GA 735ZU UT WOS:000288460100639 ER PT J AU Swain, SM Jeong, JH Geyer, CE Costantino, JP Pajon, ER Fehrenbacher, L Atkins, JN Polikoff, J Vogel, VG Erban, JK Rastogi, P Livingston, RB Perez, EA Mamounas, EP Land, SR Ganz, PA Wolmark, N AF Swain, Sandra M. Jeong, Jong-Hyeon Geyer, Charles E., Jr. Costantino, Joseph P. Pajon, Eduardo R. Fehrenbacher, Louis Atkins, James N. Polikoff, Jonathan Vogel, Victor G. Erban, John K. Rastogi, Priya Livingston, Robert B. Perez, Edith A. Mamounas, Eleftherios P. Land, Stephanie R. Ganz, Patricia A. Wolmark, Norman TI Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material AB The effectiveness and superiority of sequential versus concurrent administration are unknown for regimens used in patients with operable, node-positive, early-stage breast cancer. There is evidence that the adjunctive use of ovarian ablation or suppression independent of chemotherapy may be associated with improved survival in premenopausal patients with hormone-receptor-positive breast cancer. The added benefit of ovarian suppression to chemotherapy outcomes in early-stage node-positive breast cancer is unclear. This randomized, multicenter, phase 3 trial compared the effect of sequential and concurrent regimens on overall survival and disease-free survival in patients with operable, node-positive, early-stage breast cancer. A total of 5351 patients were randomized to receive 1 of the following 3 regimens: (1) 4 cycles of doxorubicin plus cyclophosphamide followed by 4 cycles of docetaxel (the sequential-ACT regimen); (2) 4 cycles of doxorubicin plus docetaxel (the concurrent doxorubicin-docetaxel regimen); or (3) 4 cycles of doxorubicin plus cyclophosphamide plus docetaxel (the concurrent-ACT regimen). The primary aims of this trial were to determine whether the concurrent ACT regimen was more effective than the sequential ACT regimen and whether the doxorubicin-docetaxel regimen was as effective as the concurrent-ACT regimen. Secondary aims were to investigate the effect of amenorrhea on outcome end points of disease-free and overall survival. The patients were followed for up to 8 years. Treatment with sequential ACT was associated with a significant improvement in overall survival (8-year overall survival, 83%) compared with doxorubicin-docetaxel (overall survival, 79%); the hazard ratio (HR) was 0.83; P = 0.03. There was a nonsignificant improvement for concurrent ACT (overall survival, 79%; HR, 0.86; P = 0.09). With respect to disease-free survival, patients treated with sequential ACT (8-year disease-free survival, 74%) showed a significant reduction in the likelihood of disease recurrence, a second malignant condition, or death compared with either doxorubicin-docetaxel (disease-free survival, 69%; HR, 0.80; P = 0.001) or concurrent ACT (disease-free survival, 69%; HR, 0.83; P = 0.01). No difference was noted between the doxorubicin-docetaxel group and the concurrent-ACT group for either overall survival (HR, 0.96; P = 0.67) or disease-free survival (HR, 0.96; P = 0.58). There was improved overall and disease-free survival among women who had treatment-induced amenorrhea for 6 months or more, independent of the treatment and estrogen-receptor status. These findings show that the sequential administration of ACT is a superior treatment option for women with operable node-positive breast cancer to improve disease-free survival compared with doxorubicin-docetaxel or concurrent ACT, and to improve overall survival compared with doxorubicin-docetaxel. These data provide support for the added benefit of ovarian suppression induced by chemotherapy to improve survival, regardless of the regimen. C1 [Swain, Sandra M.; Geyer, Charles E., Jr.; Pajon, Eduardo R.; Fehrenbacher, Louis; Atkins, James N.; Polikoff, Jonathan; Vogel, Victor G.; Rastogi, Priya; Mamounas, Eleftherios P.; Land, Stephanie R.; Ganz, Patricia A.; Wolmark, Norman] Washington Hosp Ctr, Natl Surg Adjuvant Breast & Bowel Project NSABP, Washington, DC 20010 USA. [Swain, Sandra M.] Washington Hosp Ctr, Washington Canc Inst, Washington, DC 20010 USA. [Jeong, Jong-Hyeon; Costantino, Joseph P.; Land, Stephanie R.] Univ Pittsburgh, NSABP Biostat Ctr, Pittsburgh, PA USA. [Jeong, Jong-Hyeon; Costantino, Joseph P.; Land, Stephanie R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Geyer, Charles E., Jr.; Wolmark, Norman] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA. [Vogel, Victor G.; Rastogi, Priya] Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA USA. [Pajon, Eduardo R.] Colorado Canc Res Program, Denver, CO USA. [Fehrenbacher, Louis] Kaiser Permanente No Calif, Vallejo, CA USA. [Atkins, James N.] Clin Canc Oncol Program, SE Canc Control Consortium, Goldsboro, NC USA. [Polikoff, Jonathan] So Calif Kaiser Permanente, San Diego, CA USA. [Vogel, Victor G.] Amer Canc Soc, Atlanta, GA 30329 USA. [Erban, John K.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Erban, John K.] Harvard Univ, Sch Med, Boston, MA USA. [Erban, John K.] Eastern Cooperat Oncol Grp, Philadelphia, PA USA. [Livingston, Robert B.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA. [Livingston, Robert B.] SW Oncol Grp, Ann Arbor, MI USA. [Perez, Edith A.] Mayo Clin, Jacksonville, FL 32224 USA. [Perez, Edith A.] N Cent Canc Treatment Grp, Rochester, MN USA. [Mamounas, Eleftherios P.] Aultman Hlth Fdn, Canton, OH USA. [Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med & Publ Hlth, Los Angeles, CA 90024 USA. RP Swain, SM (reprint author), Washington Hosp Ctr, Natl Surg Adjuvant Breast & Bowel Project NSABP, Washington, DC 20010 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD NOV PY 2010 VL 65 IS 11 BP 710 EP 712 DI 10.1097/OGX.0b013e318202211d PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 730BE UT WOS:000288002900012 ER PT J AU Brockman, ML Maas, NS Skog, J Breakefield, XO Sena-Esteves, M AF Brockman, Marike L. Maas, Niek S. Skog, Johan Breakefield, Xandra O. Sena-Esteves, Miguel TI REVERSAL OF EFFECT OF U87 DERIVED MICRO-VESICLES ON BIOLOGICAL PROCESSES OF GLIOBLASTOMA MULTIFORME SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Maas, Niek S.] Univ Med Ctr Utrecht, Utrecht, Netherlands. [Skog, Johan; Breakefield, Xandra O.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sena-Esteves, Miguel] Univ Massachusetts, Sch Med, Amherst, MA 01003 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 15 EP 16 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400069 ER PT J AU Furnari, F Inda, M Bonavia, R Mukasa, A Narita, Y Sah, D Vandenberg, S Brennan, C Johns, T Bachoo, R Hadwiger, P Tan, P Tan, P DePinho, R Cavenee, W AF Furnari, Frank Inda, Maria-del-Mar Bonavia, Rudy Mukasa, Akitake Narita, Yoshitake Sah, Dinak Vandenberg, Scott Brennan, Cameron Johns, Terrance Bachoo, Robert Hadwiger, Philip Tan, Pamela Tan, Pamela DePinho, Ronald Cavenee, Webster TI TUMOR HETEROGENEITY IS AN ACTIVE PROCESS DRIVEN BY A MUTANT EGFR-INDUCED PARACRINE CIRCUIT IN GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Mukasa, Akitake] Univ Tokyo, Tokyo 1138654, Japan. [Narita, Yoshitake] Natl Canc Ctr Hosp, Kashiwa, Chiba, Japan. [Vandenberg, Scott] Univ Calif San Diego, La Jolla, CA 92093 USA. [Brennan, Cameron] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Johns, Terrance] Monash Inst Med Res, Clayton, Vic, Australia. [Bachoo, Robert] Univ Texas SW Med Ctr, Dallas, TX USA. [DePinho, Ronald] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 15 EP 15 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400066 ER PT J AU Narayanan, R Levin, BS Maeder, ML Joung, JK Nutt, CL Louis, DN AF Narayanan, Radhakrishnan Levin, Benjamin S. Maeder, Morgan L. Joung, J. K. Nutt, Catherine L. Louis, David N. TI A COMBINATORIAL ZINC-FINGER LIBRARY APPROACH TO EXPLORING TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Narayanan, Radhakrishnan; Levin, Benjamin S.; Maeder, Morgan L.; Joung, J. K.; Nutt, Catherine L.; Louis, David N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RI Nutt, Catherine/K-8794-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 18 EP 19 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400083 ER PT J AU Wykosky, J Mukasa, A Chin, L Cavenee, W Furnari, F AF Wykosky, Jill Mukasa, Akitake Chin, Lynda Cavenee, Webster Furnari, Frank TI RESISTANCE TO EGFR INHIBITION VIA THE EMERGENCE OF EGFRVIII-INDEPENDENT TUMOR GROWTH-PROMOTING MECHANISMS IN GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Wykosky, Jill; Cavenee, Webster; Furnari, Frank] Ludwig Inst Canc Res, New York, NY USA. [Mukasa, Akitake] Univ Tokyo, Tokyo 1138654, Japan. [Chin, Lynda] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 21 EP 21 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400096 ER PT J AU Iwamoto, F Lamborn, K Kuhn, J Wen, P Yung, WKA Gilbert, M Chang, S Lieberman, F Prados, M Fine, H AF Iwamoto, Fabio Lamborn, Kathleen Kuhn, John Wen, Patrick Yung, W. K. A. Gilbert, Mark Chang, Susan Lieberman, Frank Prados, Michael Fine, Howard TI PHASE II TRIAL OF HISTONE DEACETYLASE INHIBITOR ROMIDEPSIN FOR ADULTS WITH RECURRENT HIGH-GRADE GLIOMAS (NORTH AMERICAN BRAIN TUMOR CONSORTIUM STUDY 03-03) SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Iwamoto, Fabio; Fine, Howard] Natl Canc Inst, Bethesda, MD USA. [Lamborn, Kathleen; Chang, Susan; Prados, Michael] UCSF, San Francisco, CA USA. [Kuhn, John] Univ Texas San Antonio, San Antonio, TX USA. [Wen, Patrick] Dana Farber Canc Inst, Boston, MA USA. [Yung, W. K. A.; Gilbert, Mark] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Lieberman, Frank] Univ Pittsburgh, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 37 EP 38 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400164 ER PT J AU Lu-Emerson, C Norden, AD Drappatz, J Quant, EC Ciampa, AS Doherty, LM LaFrankie, DC Wen, PY AF Lu-Emerson, Christine Norden, Andrew D. Drappatz, Jan Quant, Eudocia C. Ciampa, Abigail S. Doherty, Lisa M. LaFrankie, Debra C. Wen, Patrick Y. TI RETROSPECTIVE STUDY OF DASATINIB IN RECURRENT HIGH-GRADE GLIOMA (HGG) PATIENTS WHO FAILED BEVACIZUMAB SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Lu-Emerson, Christine; Norden, Andrew D.; Drappatz, Jan; Quant, Eudocia C.; Ciampa, Abigail S.; Doherty, Lisa M.; LaFrankie, Debra C.; Wen, Patrick Y.] Dana Farber Canc Inst, Brigham & Womens Dept, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 38 EP 38 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400165 ER PT J AU Shonka, N Gilbert, M Yung, WKA Piao, YJ Liu, J Bekele, N Wen, P Chen, A Heymach, J de Groor, J AF Shonka, Nicole Gilbert, Mark Yung, W. K. Alfred Piao, Yuji Liu, Jun Bekele, Nebiyou Wen, Patrick Chen, Alice Heymach, John de Groor, John TI CYTOKINES PREDICT ON-TARGET TOXICITY FROM AFLIBERCEPT IN PATIENTS WITH RECURRENT GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Shonka, Nicole; Gilbert, Mark; Yung, W. K. Alfred; Piao, Yuji; Liu, Jun; Bekele, Nebiyou; Heymach, John; de Groor, John] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Wen, Patrick] Dana Farber Canc Inst, Boston, MA USA. [Chen, Alice] Natl Canc Inst, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 39 EP 39 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400170 ER PT J AU Bartolomeo, J Norden, AD Drappatz, J Ciampa, AS Doherty, LM LaFrankie, DC Ruland, S Quant, EC Beroukhim, R Wen, PY AF Bartolomeo, Julie Norden, Andrew D. Drappatz, Jan Ciampa, Abigail S. Doherty, Lisa M. LaFrankie, Debra C. Ruland, Sandra Quant, Eudocia C. Beroukhim, Rameen Wen, Patrick Y. TI SAFETY OF CONCURRENT BEVACIZUMAB THERAPY AND ANTICOAGULATION IN HIGH-GRADE GLIOMA PATIENTS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Bartolomeo, Julie; Norden, Andrew D.; Drappatz, Jan; Ciampa, Abigail S.; Doherty, Lisa M.; LaFrankie, Debra C.; Ruland, Sandra; Quant, Eudocia C.; Beroukhim, Rameen; Wen, Patrick Y.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 41 EP 41 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400179 ER PT J AU Hammond, SN Norden, AD Fisher, DC Wong, ET Cote, GM Ciampa, AS Doherty, LM Ruland, SF LaFrankie, DC Wen, PY Drappatz, J AF Hammond, Samantha N. Norden, Andrew D. Fisher, David C. Wong, Eric T. Cote, Gregory M. Ciampa, Abigail S. Doherty, Lisa M. Ruland, Sandra F. LaFrankie, Debra C. Wen, Patrick Y. Drappatz, Jan TI PEMETREXED AS SALVAGE THERAPY FOR CNS LYMPHOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Hammond, Samantha N.; Norden, Andrew D.; Fisher, David C.; Cote, Gregory M.; Ciampa, Abigail S.; Doherty, Lisa M.; Ruland, Sandra F.; LaFrankie, Debra C.; Wen, Patrick Y.; Drappatz, Jan] Dana Farber Canc Inst, Boston, MA USA. [Wong, Eric T.] Beth Israel Deaconess Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 52 EP 52 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400226 ER PT J AU Rauschkolb, PK Drappatz, J Batchelor, TT Meyer, LP Fadul, CE Lallana, EC AF Rauschkolb, Paula K. Drappatz, Jan Batchelor, Tracy T. Meyer, Louise P. Fadul, Camilo E. Lallana, Enrico C. TI PEMETREXED FOR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Rauschkolb, Paula K.; Meyer, Louise P.; Fadul, Camilo E.; Lallana, Enrico C.] Dartmouth Hitchcock Med Ctr, Lebanon, NH USA. [Drappatz, Jan] Dana Farber Canc Inst, Boston, MA USA. [Batchelor, Tracy T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 54 EP 54 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400236 ER PT J AU Schanker, BD Curry, WT AF Schanker, Benjamin D. Curry, William T., Jr. TI DETERMINATION OF NEGATIVE AND POSITIVE PERSONALITY CHANGES WITH BRAIN NEOPLASIA USING CLINICAL ASSESSMENTS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Schanker, Benjamin D.; Curry, William T., Jr.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Curry, William T., Jr.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 60 EP 60 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400262 ER PT J AU Marko, NF Quackenbush, J Weil, RJ AF Marko, Nicholas F. Quackenbush, John Weil, Robert J. TI WHY IS THERE A LACK OF CONSENSUS ON MOLECULAR SUBGROUPS OF GLIOBLASTOMA? UNDERSTANDING THE NATURE OF BIOLOGICAL AND STATISTICAL VARIABILITY IN GLIOBLASTOMA EXPRESSION DATA AND THEIR IMPLICATIONS FOR MOLECULAR TUMOR CLASSIFICATION SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Marko, Nicholas F.; Weil, Robert J.] Cleveland Clin, Cleveland, OH USA. [Quackenbush, John] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 66 EP 66 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400284 ER PT J AU Zinn, PO Kozono, D Kasper, EM Warnke, PC Chin, L Chen, CC AF Zinn, Pascal O. Kozono, David Kasper, Ekkehard M. Warnke, Peter C. Chin, Lynda Chen, Clark C. TI IN VITRO-DERIVED GENE SIGNATURES TO PREDICT SURVIVAL IN GLIOBLASTOMA PATIENTS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Zinn, Pascal O.; Kozono, David; Chin, Lynda; Chen, Clark C.] Dana Farber Canc Inst, Boston, MA USA. [Kasper, Ekkehard M.] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Warnke, Peter C.] Boston Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 66 EP 66 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400286 ER PT J AU Hammond, SN Norden, AD Drappatz, J Phuphanich, S Reardon, D Wong, ET Plotkin, SR Lesser, G Mintz, A Raizer, JJ Batchelor, TT Quant, EC Beroukhim, R Kaley, TJ Ciampa, A Doherty, L LaFrankie, D Ruland, S Smith, KH Wen, PY AF Hammond, Samantha N. Norden, Andrew D. Drappatz, Jan Phuphanich, Surasak Reardon, David Wong, Eric T. Plotkin, Scott R. Lesser, Glenn Mintz, Akiva Raizer, Jeffrey J. Batchelor, Tracy T. Quant, Eudocia C. Beroukhim, Rameen Kaley, Thomas J. Ciampa, Abigail Doherty, Lisa LaFrankie, Debra Ruland, Sandra Smith, Katrina H. Wen, Patrick Y. TI PHASE II STUDY OF MONTHLY PASIREOTIDE LAR (SOM230C) FOR RECURRENT OR PROGRESSIVE MENINGIOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Hammond, Samantha N.; Norden, Andrew D.; Drappatz, Jan; Quant, Eudocia C.; Beroukhim, Rameen; Ciampa, Abigail; Doherty, Lisa; LaFrankie, Debra; Ruland, Sandra; Smith, Katrina H.; Wen, Patrick Y.] Dana Farber Canc Inst, Boston, MA USA. [Phuphanich, Surasak] Cedars Sinai Med Ctr, Los Angeles, CA USA. [Reardon, David] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Wong, Eric T.] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Plotkin, Scott R.; Batchelor, Tracy T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Lesser, Glenn; Mintz, Akiva] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA. [Raizer, Jeffrey J.] Northwestern Univ, Ctr Canc, Evanston, IL 60208 USA. [Kaley, Thomas J.] Mem Sloan Kettering Canc Ctr, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 71 EP 71 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400305 ER PT J AU Norden, AD Lesser, G Hammond, SN Drappatz, J Fadul, CE Batchelor, TT Quant, EC Beroukhim, R Ciampa, A Doherty, L LaFrankie, D Ruland, S Bochacki, C Phan, P Faroh, E McNamara, B David, K Rosenfeld, MR Wen, PY AF Norden, Andrew D. Lesser, Glenn Hammond, Samantha N. Drappatz, Jan Fadul, Camilo E. Batchelor, Tracy T. Quant, Eudocia C. Beroukhim, Rameen Ciampa, Abigail Doherty, Lisa LaFrankie, Debra Ruland, Sandra Bochacki, Caelainn Phan, Phuong Faroh, Elizabeth McNamara, Brenna David, Karly Rosenfeld, Myrna R. Wen, Patrick Y. TI PHASE II STUDY OF DOSE-INTENSE TEMOZOLOMIDE IN RECURRENT GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Norden, Andrew D.; Hammond, Samantha N.; Drappatz, Jan; Quant, Eudocia C.; Beroukhim, Rameen; Ciampa, Abigail; Doherty, Lisa; LaFrankie, Debra; Ruland, Sandra; Bochacki, Caelainn; Phan, Phuong; Faroh, Elizabeth; McNamara, Brenna; David, Karly; Wen, Patrick Y.] Dana Farber Canc Inst, Boston, MA USA. [Lesser, Glenn] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA. [Fadul, Camilo E.] Dartmouth Hitchcock Norris Cotton Canc Ctr, Lebanon, NH USA. [Batchelor, Tracy T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Rosenfeld, Myrna R.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 71 EP 71 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400304 ER PT J AU Paugh, BS Qu, CX Zhang, JY Geyer, JR Chi, SS da Silva, NS Baker, J Gajjar, A Ellison, DW Broniscer, A Baker, SJ AF Paugh, Barbara S. Qu, Chunxu Zhang, Junyuan Geyer, J. Russell Chi, Susan da Silva, Nasjla Saba Baker, Justin Gajjar, Amar Ellison, David W. Broniscer, Alberto Baker, Suzanne J. TI GENOME-WIDE ANALYSES OF DIFFUSE INTRINSIC PONTINE GLIOMAS REVEAL KEY DIFFERENCES WITH SUPRATENTORIAL PEDIATRIC GLIOBLASTOMAS AND ADULT GLIOBLASTOMAS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Paugh, Barbara S.; Qu, Chunxu; Zhang, Junyuan; Baker, Justin; Gajjar, Amar; Ellison, David W.; Broniscer, Alberto; Baker, Suzanne J.] St Jude Childrens Hosp, Memphis, TN USA. [Geyer, J. Russell] Univ Washington, Seattle, WA 98195 USA. [Chi, Susan] Dana Farber Canc Inst, Boston, MA USA. [da Silva, Nasjla Saba] Univ Fed Sao Paulo, Sao Paulo, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 85 EP 85 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400362 ER PT J AU Tamura, K Wakimoto, H Rabkin, SD Martuza, RL Shah, K AF Tamura, Kaoru Wakimoto, Hiroaki Rabkin, Samuel D. Martuza, Robert L. Shah, Khalid TI TARGETING TRAIL-RESISTANT GLIOMA-INITIATING CELLS IN VIVO AND IN VITRO SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Tamura, Kaoru; Shah, Khalid] Harvard Univ, Sch Med, Mol Neurotherapy & Imaging Lab, Dept Radiol & Neurol,Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Wakimoto, Hiroaki; Rabkin, Samuel D.; Martuza, Robert L.] Harvard Univ, Sch Med, Mol Neurosurg Lab,Dept Neurosurg, Brain Tumor Res Ctr,Massachusetts Gen Hosp, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 87 EP 87 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400371 ER PT J AU Lucas, MR AF Lucas, Michele R. TI DIAGNOSIS TO DEATH: MEETING BRAIN CANCER PATIENT AND CAREGIVER EMOTIONAL NEEDS ALONG THE CONTINUUM OF DISEASE SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Lucas, Michele R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 99 EP 99 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400422 ER PT J AU Kozono, D Zinn, P Ng, K Chen, C AF Kozono, David Zinn, Pascal Ng, Kimberly Chen, Clark TI A PROTEASOME EXPRESSION SIGNATURE THAT PREDICTS RESISTANCE TO TEMOZOLOMIDE AND IONIZING RADIATION FOR PRONEURAL GLIOBLASTOMAS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Kozono, David; Zinn, Pascal; Ng, Kimberly; Chen, Clark] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 111 EP 111 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400473 ER PT J AU Kleijn, A Chen, JW Sun, PZ Buhrman, J Rabkin, SD Weissleder, R Martuza, RL Lamfers, ML Fulci, G AF Kleijn, Anne Chen, John W. Sun, Phillip Z. Buhrman, Jason Rabkin, Samuel D. Weissleder, Ralph Martuza, Robert L. Lamfers, Martine L. Fulci, Giulia TI MAGNETIC RESONANCE IMAGING OF VIRAL SPREAD AND INTRATUMORAL INFLAMMATION DURING ONCOLYTIC VIROTHERAPY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Kleijn, Anne; Lamfers, Martine L.] Erasmus MC, Rotterdam, Netherlands. [Chen, John W.; Sun, Phillip Z.; Buhrman, Jason; Rabkin, Samuel D.; Weissleder, Ralph; Martuza, Robert L.; Fulci, Giulia] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 116 EP 116 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400495 ER PT J AU Chi, AS Rheinbay, E Wakimoto, H Gillespie, S Kasif, S Rabkin, SD Martuza, RL Bernstein, BE AF Chi, Andrew S. Rheinbay, Esther Wakimoto, Hiroaki Gillespie, Shawn Kasif, Simon Rabkin, Samuel D. Martuza, Robert L. Bernstein, Bradley E. TI EPIGENOMIC ANALYSIS OF GLIOBLASTOMA STEM CELLS REVEALS AN ABERRANTLY ACTIVE NETWORK OF DEVELOPMENTAL REGULATORS CONTROLLED BY WNT SIGNALING SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Chi, Andrew S.; Rheinbay, Esther; Wakimoto, Hiroaki; Gillespie, Shawn; Rabkin, Samuel D.; Martuza, Robert L.; Bernstein, Bradley E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Kasif, Simon] Boston Univ, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 121 EP 122 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400516 ER PT J AU Wakimoto, H Kanai, R Curry, WT Yip, S Barnard, ZR Mohapatra, G Stetntner-Rachamimov, AO Martuza, RL Rabkin, SD AF Wakimoto, Hiroaki Kanai, Ryuichi Curry, William T. Yip, Stephen Barnard, Zachary R. Mohapatra, Gayatry Stetntner-Rachamimov, Anat O. Martuza, Robert L. Rabkin, Samuel D. TI GLIOBLASTOMA STEM CELLS DISPLAY INVASIVE OR LOCALIZED PHENOTYPES IN VIVO SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Wakimoto, Hiroaki; Kanai, Ryuichi; Curry, William T.; Barnard, Zachary R.; Mohapatra, Gayatry; Stetntner-Rachamimov, Anat O.; Martuza, Robert L.; Rabkin, Samuel D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yip, Stephen] BC Canc Agcy, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2010 VL 12 SU 4 BP 134 EP 134 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 691LX UT WOS:000285082400569 ER PT J AU Zhou, Y Manka, JT Rodriguez, AL Weaver, CD Days, EL Vinson, PN Jadhav, S Hermann, EJ Jones, CK Conn, PJ Lindsley, CW Stauffer, SR AF Zhou, Ya Manka, Jason T. Rodriguez, Alice L. Weaver, C. David Days, Emily L. Vinson, Paige N. Jadhav, Satyawan Hermann, Elizabeth J. Jones, Carrie K. Conn, P. Jeffrey Lindsley, Craig W. Stauffer, Shaun R. TI Discovery of N-Aryl Piperazines as Selective mGluR(5) Potentiators with Improved In Vivo Utility SO ACS MEDICINAL CHEMISTRY LETTERS LA English DT Article DE mGluR; potentiator; positive allosteric modulator; schizophrenia; hyperlocomotion ID POSITIVE ALLOSTERIC MODULATOR; GLUTAMATE-RECEPTOR SUBTYPE-5; ANTIPSYCHOTIC-LIKE; SCHIZOPHRENIA; SERIES; SAR AB This letter describes the discovery, structure-activity relationship, and in vitro and in vivo pharmacological profile of a novel non-MPEP-derived mGluR(5) positive allosteric modulator (PAM) based upon an N-aryl piperazine chemotype. This mGluR(5) chemotyper exhibits the ability to act as either a noncompetitive antagonist/negative allosteric modulator or a potentiator of the glutamate response, depending on the identity of the amide substituent, that is, a molecular switch". A rapidly optimized PAM, 10e (VU0364289), was shown to be potent and specific for the rat mGluR(5) receptor and subsequently demonstrated to be efficacious in a clinically relevant rodent model predictive of antipsychotic activity, thus providing the first example of a centrally active mGluR(5) PAM optimized from an HTS-derived mGluR(5) noncompetitive antagonist. C1 [Zhou, Ya; Manka, Jason T.; Rodriguez, Alice L.; Weaver, C. David; Vinson, Paige N.; Jadhav, Satyawan; Hermann, Elizabeth J.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. [Lindsley, Craig W.] Vanderbilt Univ, Med Ctr, Dept Chem, Nashville, TN 37232 USA. [Zhou, Ya; Manka, Jason T.; Rodriguez, Alice L.; Weaver, C. David; Days, Emily L.; Vinson, Paige N.; Jadhav, Satyawan; Hermann, Elizabeth J.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Med Ctr, Vanderbilt Program Drug Discovery, Nashville, TN 37232 USA. [Jones, Carrie K.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA. [Weaver, C. David; Days, Emily L.] Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA. RP Stauffer, SR (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. EM shaun.stauffer@vanderbilt.edu RI Conn, Peter/D-7848-2012; Zhou, Ya/F-1220-2013 FU NIH National Institute of Neurological Disorders and Stroke (NINDS) [5R01 NS031373-15]; National Institute of Mental Health (NIMH) [R01 MH073676-04] FX We thank the NIH National Institute of Neurological Disorders and Stroke (NINDS #5R01 NS031373-15) and the National Institute of Mental Health (NIMH #R01 MH073676-04) for support of this program. NR 25 TC 29 Z9 29 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1948-5875 J9 ACS MED CHEM LETT JI ACS Med. Chem. Lett. PD NOV PY 2010 VL 1 IS 8 BP 433 EP 438 DI 10.1021/ml100181a PG 6 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 680AS UT WOS:000284203100013 PM 23308336 ER PT J AU Chan, KE Hakim, R AF Chan, Kevin E. Hakim, Raymond TI Association of Digoxin With Mortality in ESRD: Does the Medical Evidence Still Apply When the Patient Is on Dialysis? SO DIALYSIS & TRANSPLANTATION LA English DT Editorial Material ID DISEASE; HEMODIALYSIS C1 [Chan, Kevin E.] Fresenius Med Care N Amer, Clin Outcomes Res & Med Analyt, Waltham, MA USA. [Chan, Kevin E.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. RP Chan, KE (reprint author), Fresenius Med Care N Amer, Clin Outcomes Res & Med Analyt, Waltham, MA USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0090-2934 J9 DIALYSIS TRANSPLANT JI Dial. Transplant. PD NOV PY 2010 VL 39 IS 11 BP 468 EP 469 DI 10.1002/dat.20501 PG 2 WC Engineering, Biomedical; Transplantation; Urology & Nephrology SC Engineering; Transplantation; Urology & Nephrology GA 678DA UT WOS:000284049700005 ER PT J AU Knudsen, AB Landsdorp-Vogelaar, I Rutter, CM Savarino, JE Van Ballegooijen, M Kuntz, KM Zauber, AG AF Knudsen, Amy B. Landsdorp-Vogelaar, Iris Rutter, Carolyn M. Savarino, James E. Van Ballegooijen, Marjolein Kuntz, Karen M. Zauber, Ann G. TI Re: Cost-Effectiveness of Computed Tomographic Colonography Screening for Colorectal Cancer in the Medicare Population Response SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Letter ID CT COLONOGRAPHY C1 [Knudsen, Amy B.] Massachusetts Gen Hosp, Dept Radiol, Inst Tech Assessment, Boston, MA 02114 USA. [Landsdorp-Vogelaar, Iris; Van Ballegooijen, Marjolein] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands. [Rutter, Carolyn M.; Savarino, James E.] Grp Hlth Res Inst, Seattle, WA USA. [Kuntz, Karen M.] Univ Minnesota, Sch Public Hlth, Div Hlth Policy & Management, Minneapolis, MN USA. [Zauber, Ann G.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA. RP Knudsen, AB (reprint author), Massachusetts Gen Hosp, Dept Radiol, Inst Tech Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. EM aknudsen@mgh-ita.org NR 5 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD NOV PY 2010 VL 102 IS 21 BP 1676 EP 1677 DI 10.1093/jnci/djq383 PG 2 WC Oncology SC Oncology GA 676PA UT WOS:000283923300013 ER PT J AU Debette, S Beiser, A Wang, TJ DeCarli, C Wolf, PA Fox, CS Seshadri, S AF Debette, Stephanie Beiser, Alexa Wang, Thomas J. DeCarli, Charles Wolf, Philip A. Fox, Caroline S. Seshadri, Sudha TI Visceral Obesity and Brain Volume Reply SO ANNALS OF NEUROLOGY LA English DT Letter C1 [Debette, Stephanie; Beiser, Alexa; Wang, Thomas J.; DeCarli, Charles; Wolf, Philip A.; Fox, Caroline S.; Seshadri, Sudha] NHLBI, Framingham Heart Study, Framingham, MA USA. [Debette, Stephanie; Beiser, Alexa; Wolf, Philip A.; Seshadri, Sudha] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Beiser, Alexa] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Wang, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. [DeCarli, Charles] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA. [Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol Metab & Diabet, Boston, MA 02115 USA. RP Debette, S (reprint author), NHLBI, Framingham Heart Study, Framingham, MA USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD NOV PY 2010 VL 68 IS 5 BP 771 EP 772 DI 10.1002/ana.22233 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 675HR UT WOS:000283819000032 ER PT J AU Prentice-Mott, H Toner, M Irimia, D AF Prentice-Mott, Harrison Toner, Mehmet Irimia, Daniel TI Microfluidic proportional flow controller SO JOURNAL OF MICROMECHANICS AND MICROENGINEERING LA English DT Article ID SOFT LITHOGRAPHY; VALVES; MEMBRANES; GRADIENTS; CIRCUITS; PUMPS AB Precise flow control in microfluidic chips is important for many biochemical assays and experiments at microscale. While several technologies for controlling fluid flow have been implemented either on- or off-chip, these can provide either high-speed or high-precision control, but seldom could accomplish both at the same time. Here we describe a new on- chip, pneumatically activated flow controller that allows for fast and precise control of the flow rate through a microfluidic channel. Experimental results show that the new proportional flow controllers exhibited a response time of approximately 250 ms, while our numerical simulations suggest that faster actuation down to approximately 50 ms could be achieved with alternative actuation schemes. C1 [Prentice-Mott, Harrison] Harvard Univ, Sch Engn & Appl Sci, Boston, MA 02129 USA. [Toner, Mehmet; Irimia, Daniel] Massachusetts Gen Hosp, BioMEMS Resource Ctr, Ctr Engn Med & Surg Serv, Shriners Hosp Children, Boston, MA 02129 USA. [Toner, Mehmet; Irimia, Daniel] Harvard Univ, Sch Med, Boston, MA 02129 USA. RP Prentice-Mott, H (reprint author), Harvard Univ, Sch Engn & Appl Sci, Boston, MA 02129 USA. EM dirimia@hms.harvard.edu OI Irimia, Daniel/0000-0001-7347-2082 FU National Institutes of Health [P41EB002503, R21AI076760] FX We thank Octavio Hurtado for valuable assistance with microfabrication, Dr Aman Russom for his assistance in performing the simulations and Dr Jagesh Shah for his help in producing this manuscript. This work was supported in part by the National Institutes of Health grants (P41EB002503 and R21AI076760). NR 22 TC 1 Z9 1 U1 0 U2 16 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0960-1317 J9 J MICROMECH MICROENG JI J. Micromech. Microeng. PD NOV PY 2010 VL 20 IS 11 AR 115020 DI 10.1088/0960-1317/20/11/115020 PG 8 WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Applied SC Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Physics GA 673VI UT WOS:000283691600021 ER PT J AU Schoessow, KA Gilbert, LM Jackson, ML AF Schoessow, Kimberly A. Gilbert, Leah M. Jackson, Mary Lou TI Low Vision Rehabilitation Intervention for People with Ring Scotomas SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS LA English DT Article ID RETINAL-PIGMENT EPITHELIUM; VISUAL-ACUITY LOSS; MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; CONTRAST SENSITIVITY; DISEASE; LIGHT; MICROPERIMETRY; FIXATION C1 [Schoessow, Kimberly A.; Gilbert, Leah M.; Jackson, Mary Lou] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Vis Rehabil Ctr, Boston, MA 02114 USA. RP Schoessow, KA (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Vis Rehabil Ctr, 243 Charles St, Boston, MA 02114 USA. EM kimberly_schoessow@meei.harvard.edu; leahgilbert@earthlink.net; marylou_jackson@meei.harvardedu NR 26 TC 1 Z9 1 U1 0 U2 0 PU AMER FOUNDATION BLIND PI NEW YORK PA J VISUAL IMPAIRMENT BLINDNESS 2 PENN PLAZA, SUITE 1102, NEW YORK, NY 10121 USA SN 0145-482X J9 J VISUAL IMPAIR BLIN JI J. Vis. Impair. Blind. PD NOV PY 2010 VL 104 IS 11 BP 704 EP 709 PG 6 WC Rehabilitation SC Rehabilitation GA 676FZ UT WOS:000283897700004 ER PT J AU Perkins, BA Ficociello, LH Krolewski, AS AF Perkins, Bruce A. Ficociello, Linda H. Krolewski, Andrzej S. TI Comments on 'In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria' Reply SO KIDNEY INTERNATIONAL LA English DT Letter C1 [Perkins, Bruce A.] Univ Toronto, Dept Endocrinol, Toronto, ON M5G 2C4, Canada. [Ficociello, Linda H.; Krolewski, Andrzej S.] Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA. RP Perkins, BA (reprint author), Univ Toronto, Dept Endocrinol, EN12-218,200 Elizabeth St, Toronto, ON M5G 2C4, Canada. EM bruce.perkins@uhn.on.ca NR 3 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD NOV PY 2010 VL 78 IS 10 BP 1049 EP 1049 DI 10.1038/ki.2010.289 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 672QB UT WOS:000283600700020 ER PT J AU Jablecki, CK Nuckols, TK Sandin, KJ Asch, SM AF Jablecki, Charles K. Nuckols, Teryl K. Sandin, Karl J. Asch, Steven M. TI CLINICAL QUALITY MEASURES FOR ELECTRODIAGNOSIS IN SUSPECTED CTS: COMMENTS REPLY SO MUSCLE & NERVE LA English DT Letter C1 [Jablecki, Charles K.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Nuckols, Teryl K.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Nuckols, Teryl K.; Asch, Steven M.] RAND Corp, Santa Monica, CA USA. [Sandin, Karl J.] Sister Kenny Rehabil Inst, Minneapolis, MN USA. [Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. RP Jablecki, CK (reprint author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD NOV PY 2010 VL 42 IS 5 BP 843 EP 844 DI 10.1002/21850 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 675JW UT WOS:000283827700029 ER PT J AU Timmons, SD Duhaime, AC Lee, SM AF Timmons, Shelly D. Duhaime, Ann-Christine Lee, Stefan M. TI Mild traumatic brain injury Introduction SO NEUROSURGICAL FOCUS LA English DT Editorial Material C1 [Timmons, Shelly D.] Geisinger Hlth Syst, Inst Neurosci, Dept Neurosurg, Danville, PA USA. [Duhaime, Ann-Christine] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Duhaime, Ann-Christine] Harvard Univ, Sch Med, Boston, MA USA. [Lee, Stefan M.] Univ So Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA USA. [Lee, Stefan M.] Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA USA. RP Timmons, SD (reprint author), Geisinger Hlth Syst, Inst Neurosci, Dept Neurosurg, Danville, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 1092-0684 J9 NEUROSURG FOCUS JI Neurosurg. Focus PD NOV PY 2010 VL 29 IS 5 AR 29 DI 10.3171/2010.11.FOCUS.Intro PG 1 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 675CE UT WOS:000283801900001 ER PT J AU Grudzen, CR Richardson, LD Morrison, M Cho, E Morrison, RS AF Grudzen, Corita R. Richardson, Lynne D. Morrison, Matthew Cho, Elizabeth Morrison, R. Sean TI Palliative Care Needs of Seriously Ill, Older Adults Presenting to the Emergency Department SO ACADEMIC EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT Annual Scientific Meeting of the Society-for-Academic-Emergency-Medicine CY JUN, 2010 CL Phoenix, AZ SP Soc Acad Emergency Med ID OF-LIFE QUESTIONNAIRE; COGNITIVE IMPAIRMENT; VALIDATION; MORTALITY; VALIDITY AB Objectives: The objective was to identify the palliative care needs of seriously ill, older adults in the emergency department (ED). Methods: The authors conducted a cross-sectional structured survey. A convenience sample of 50 functionally impaired adults 65 years or older with coexisting cancer, congestive heart failure, end-stage liver or renal disease, stroke, oxygen-dependent pulmonary disease, or dementia was recruited from an urban academic tertiary care ED. Face-to-face interviews were conducted using the Needs Near the End-of-Life Screening Tool (NEST), McGill Quality of Life Index (MQOL), and Edmonton Symptom Assessment Survey (ESAS) to assess 1) range and severity of symptoms, 2) goals of care, 3) psychological well-being, 4) health care utilization, 5) spirituality, 6) social connectedness, 7) financial burden, 8) the patient clinician relationship, and 9) overall quality of life (QOL). Results: Mean (+/- SD) age was 74.3 (+/- 6.5) years and cancer was the most common diagnosis. Mean (+/- SD) QOL on the MQOL was 3.6 (+/- 2.9). Over half of the patients exceeded intratest severity-of-needs cutoffs in four categories of the NEST: physical symptoms (47/50, 94%), finances (36/50, 72%), mental health (31/50, 62%), and access to care (29/50, 58%). The majority of patients reported moderate to severe fatigue, pain, dyspnea, and depression on the ESAS. Conclusions: Seriously ill, older adults in an urban ED have substantial palliative care needs. Future work should focus on the role of emergency medicine and the new specialty of palliative care in addressing these needs. C1 [Grudzen, Corita R.; Richardson, Lynne D.; Morrison, Matthew; Cho, Elizabeth] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA. [Grudzen, Corita R.; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Morrison, R. Sean] James J Peters VA Hosp, Bronx, NY USA. RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA. EM corita.grudzen@mssm.edu OI Grudzen, Corita/0000-0003-3039-8497 FU NIA NIH HHS [K24 AG022345] NR 21 TC 37 Z9 39 U1 3 U2 11 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD NOV PY 2010 VL 17 IS 11 BP 1253 EP 1257 DI 10.1111/j.1553-2712.2010.00907.x PG 5 WC Emergency Medicine SC Emergency Medicine GA 676UW UT WOS:000283945100019 PM 21175525 ER PT J AU Zinner, DE DesRoches, CM Bristol, SJ Clarridge, B Campbell, EG AF Zinner, Darren E. DesRoches, Catherine M. Bristol, Steffanie J. Clarridge, Brian Campbell, Eric G. TI Tightening Conflict-of-Interest Policies: The Impact of 2005 Ethics Rules at the NIH SO ACADEMIC MEDICINE LA English DT Article ID INDUSTRY; PARTICIPATION; SCIENTISTS AB Purpose To determine both the intended and unintended effects of the National Institutes of Health (NIH) 2005 ethics rules by examining changes in publishing rates and the frequency of external relationships among NIH scientists. Method After identifying eligible intramural scientists and administrators from institutes' Web pages and central directories, a mailed survey was administered to 900 NIH research faculty between October 2008 and January 2009 (response rate 70.1%). Results Eighty percent of respondents believed the NIH ethics rules were too restrictive. Whereas 45% of respondents believed the rules positively impacted the public's trust in the NIH, 77% believed the rules hindered the NIH's ability to complete its mission. Implementation of the ethics rules significantly decreased self-reported government-industry relationships among NIH faculty (from 51.8% to 33.2%, P < .01), including significant drops in consulting (33.1% to 7.8%, P < .01) and scientific advisory board membership (31.5% to 16.0%, P < .01), both of which may be allowed under the new regulations in restricted situations with increased oversight. The policy had limited impact on NIH faculty participation in nonindustrial professional service roles and had no detectable change in publishing behavior (5.29 articles per researcher per year from 2002-2005 versus 5.26 from 2005-2008, P = .88). Conclusions The NIH ethics rules accomplished much of what they were intended to do, limiting relationships with industry while maintaining NIH researchers' association with external scientific and professional organizations. However, the rules negatively affected personnel morale and the perceived progress of research. C1 [Zinner, Darren E.] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA 02454 USA. [DesRoches, Catherine M.; Campbell, Eric G.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Bristol, Steffanie J.] Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. [Clarridge, Brian] Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA. RP Zinner, DE (reprint author), Brandeis Univ, Heller Sch, Schneider Inst Hlth Policy, 415 S St MS 035, Waltham, MA 02454 USA. EM dzinner@brandeis.edu FU Office of Research Integrity through the National Institute of General Medical Sciences of the National Institutes of Health [5R01GM0844455-01]; Brandeis University FX This research was supported by a grant from Office of Research Integrity through the National Institute of General Medical Sciences of the National Institutes of Health (5R01GM0844455-01, PI Eric G. Campbell).; Dr. Zinner is partially supported by Brandeis University's Health Industry Forum, an independent policy consortium of major health care insurers, delivery systems, and biopharmaceutical and medical device firms. No other disclosures are reported. NR 15 TC 3 Z9 3 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD NOV PY 2010 VL 85 IS 11 BP 1685 EP 1691 DI 10.1097/ACM.0b013e3181f578b2 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 672LC UT WOS:000283583500025 PM 20852402 ER PT J AU Huffman, JC Petersen, T Baer, L Romeo, S Sutton-Skinner, K Fromson, JA Birnbaum, RJ AF Huffman, Jeff C. Petersen, Tim Baer, Lee Romeo, Sarah Sutton-Skinner, Kelly Fromson, John A. Birnbaum, Robert J. TI Outcomes Assessment in Psychiatric Postgraduate Medical Education: An Exploratory Study Using Clinical Case Vignettes SO ACADEMIC PSYCHIATRY LA English DT Article ID QUALITY; CARE C1 [Huffman, Jeff C.; Petersen, Tim; Baer, Lee; Romeo, Sarah; Sutton-Skinner, Kelly; Fromson, John A.; Birnbaum, Robert J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Huffman, Jeff C.; Petersen, Tim; Baer, Lee; Fromson, John A.; Birnbaum, Robert J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Huffman, JC (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St,Warren 1220C, Boston, MA 02114 USA. EM jhuffman@partners.org NR 10 TC 1 Z9 1 U1 0 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1042-9670 J9 ACAD PSYCHIATR JI Acad. Psych. PD NOV-DEC PY 2010 VL 34 IS 6 BP 445 EP 448 PG 4 WC Education & Educational Research; Psychiatry SC Education & Educational Research; Psychiatry GA 673GQ UT WOS:000283647900009 PM 21041469 ER PT J AU Donati, OF Burg, MC Desbiolles, L Karlo, C Stolzmann, P Bunck, A Baumueller, S Marincek, B Seifarth, H Alkadhi, H Leschka, S Maintz, D AF Donati, Olivio F. Burg, Matthias C. Desbiolles, Lotus Karlo, Christoph Stolzmann, Paul Bunck, Alexander Baumueller, Stephan Marincek, Borut Seifarth, Harald Alkadhi, Hatem Leschka, Sebastian Maintz, David TI High-Pitch 128-Slice Dual-Source CT for the Assessment of Coronary Stents in a Phantom Model SO ACADEMIC RADIOLOGY LA English DT Article DE Stent; computed tomography; high pitch; coronary artery disease; dual source ID PACLITAXEL-ELUTING STENT; IN-VITRO EVALUATION; BARE-METAL STENT; COMPUTED-TOMOGRAPHY; ARTERY-DISEASE; ANGIOGRAPHY; EXPERIENCE; PATENCY; RESTENOSIS; TRIAL AB Rationale and Objectives: To evaluate the quality of stent lumen delineation using dual-source computed tomography (DSCT) in the standard-pitch mode (SP) as compared to the high-pitch mode (HP) in a phantom study. Materials and Methods: Forty different coronary stents placed in plastic tubes filled with contrast agent were imaged with a second generation DSCT system in a SP (pitch 0.23) and HP (pitch 3.4) mode in orientations of 0, 450, and 90 relative to the z-axis. Two observers independently measured the in-stent lumen and the attenuation values in the center of the stents. The artificial lumen narrowing (ALN) was calculated using the measured in-stent lumen and the nominal diameter of the plastic tube. Results: lnterobserver correlation was excellent for in-stent lumen (0.86) and attenuation measurements (0.91). There was no significant difference neither for ALN (SP: 54.7-62.8%; HP: 55.8-64.0%) nor attenuation (SP: 356-395 Hounsfield units [HU]; HP: 352-384 HU) between SP and HP mode. For both modes, the orientation of the stent relative to the z-axis significantly affected ALN and attenuation (each P < .001). CT volume dose index was significantly lower using HP mode as compared to SP mode (P < .001). Conclusion: The HP mode in DSCT provides visualization of the coronary in-stent lumen comparable to that measured in SP mode while reducing applied radiation dose in a stationary phantom model. C1 [Donati, Olivio F.; Desbiolles, Lotus; Karlo, Christoph; Stolzmann, Paul; Baumueller, Stephan; Marincek, Borut; Alkadhi, Hatem; Leschka, Sebastian] Univ Zurich Hosp, Inst Diagnost Radiol, CH-8091 Zurich, Switzerland. [Burg, Matthias C.; Bunck, Alexander; Seifarth, Harald; Maintz, David] Univ Munster, Dept Clin Radiol, D-4400 Munster, Germany. [Stolzmann, Paul; Alkadhi, Hatem] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program, Boston, MA USA. RP Leschka, S (reprint author), Univ Zurich Hosp, Inst Diagnost Radiol, Raemistr 100, CH-8091 Zurich, Switzerland. EM sebastian.leschka@usz.ch RI Bunck, Alexander/M-6389-2014 FU Foundation Innovative Medizinische Forschung, University of Muenster [IMF BU 610901] FX From the Institute of Diagnostic Radiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland (O.F.D., L.D., C.K., P.S., S.B., B.M., H.A., S.L.); Department of Clinical Radiology, University of Muenster, Germany (M.C.B., A.B., H.S., D.M.); Cardiac MR PET CT Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA (P.S., H.A.). Received May 26, 2010; accepted June 14, 2010. Conflicts of interest: none. Matthias C. Burg was supported by grant IMF BU 610901 from the Foundation Innovative Medizinische Forschung, University of Muenster. Olivio F. Donati and Matthias C. Burg contributed equally to this publication. Address correspondence to: S.L. e-mail: sebastian.leschka@usz.ch NR 21 TC 7 Z9 8 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD NOV PY 2010 VL 17 IS 11 BP 1366 EP 1374 DI 10.1016/j.acra.2010.06.017 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 672TO UT WOS:000283610000007 PM 20801697 ER EF